PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
1718419-5	1991	In rifampicin-treated cells, metabolically labeled with [35S]methionine and induced by IPTG, the P68 kinase was the predominant labeled product.	Rifampin	3-13	KH RNA binding domain containing, signal transduction associated 1	Homo sapiens	97-100
2015817-6	1991	Onset of CYP3A6 gene expression occurred at day 30 of gestation and both transcription and mRNA accumulation were transplacentally inducible by rifampicin only shortly before birth, i.e. after treatment of the females between days 28 and 30 of gestation.	Rifampin	144-154	cytochrome P450 3A6	Oryctolagus cuniculus	9-15
1863618-11	1991	Over the entire outbreak period, the MRSA strain developed resistance to rifampin, imipenem-cilastatin and ciprofloxacin.	Rifampin	73-81	solute carrier family 9 member A6	Homo sapiens	37-41
2388264-12	1990	The rifampicin resistance of uvsW-repressed replication suggests that it involves either tertiary initiation or some novel mode of initiation.	Rifampin	4-14	UvsW helicase	Escherichia phage T4	29-33
1991139-9	1991	In contrast, the transport of a typical substrate of the bilirubin carrier (rifampicin), of amino acids (alpha-aminoisobutyric acid), long chain fatty acids (oleic acid) and cationic compounds (thiamin hydrochloride) was not inhibited by the same renin inhibitors.	Rifampin	76-86	renin	Homo sapiens	247-252
2013969-7	1991	Treatment of the mice with the new rifamycin derivatives or rifampicin (RFP: as a control drug) was performed by daily oral administration of 10 mg/kg of the drugs, starting at the 24th hour of infection and continuing until the 40th day of infection.	Rifampin	60-70	tripartite motif-containing 27	Mus musculus	72-75
2015817-8	1991	CYP3A6 gene expression was also induced by rifampicin in 1-week-old and 2-week-old animals.	Rifampin	43-53	cytochrome P450 3A6	Oryctolagus cuniculus	0-6
2015817-15	1991	It is concluded that (a) the onset of CYP3A6 gene expression in the fetus occurs at day 30 of gestation, (b) expression of this gene may be induced transplacentally by rifampicin, (c) CYP1A1, CYP1A2 and CYP3A6 gene expression is sharply activated at weaning, and (d) thyroid hormones appear not to be responsible for the pattern of developmental expression of these genes in the rabbit.	Rifampin	168-178	cytochrome P450 3A6	Oryctolagus cuniculus	38-44
2015817-15	1991	It is concluded that (a) the onset of CYP3A6 gene expression in the fetus occurs at day 30 of gestation, (b) expression of this gene may be induced transplacentally by rifampicin, (c) CYP1A1, CYP1A2 and CYP3A6 gene expression is sharply activated at weaning, and (d) thyroid hormones appear not to be responsible for the pattern of developmental expression of these genes in the rabbit.	Rifampin	168-178	cytochrome P450 1A2	Oryctolagus cuniculus	192-198
2015817-15	1991	It is concluded that (a) the onset of CYP3A6 gene expression in the fetus occurs at day 30 of gestation, (b) expression of this gene may be induced transplacentally by rifampicin, (c) CYP1A1, CYP1A2 and CYP3A6 gene expression is sharply activated at weaning, and (d) thyroid hormones appear not to be responsible for the pattern of developmental expression of these genes in the rabbit.	Rifampin	168-178	cytochrome P450 3A6	Oryctolagus cuniculus	203-209
2200675-1	1990	Hepatocytes from adult and newborn humans were put into primary culture and exposed to phenobarbital, 3-methylcholanthrene, or rifampicin, three well-known inducers of cytochrome P-450 in animals.	Rifampin	127-137	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	168-184
2200675-5	1990	Phenobarbital and rifampicin increased P-450 IIC8/9/10 mRNA transcripts and the corresponding protein, while 3-methylcholanthrene was ineffective.	Rifampin	18-28	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	39-54
1974199-5	1990	Only pretreatment of rabbits with rifampicin, which induces cytochrome P-450 form 3c (P-450IIIA6), significantly increased the microsomal hydroxylation of tolbutamide.	Rifampin	34-44	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-76
2103248-3	1990	We consider that the association of two antibiotics (rifampin, doxycycline or trimethoprim/sulfamethoxazole) are valid and should be administered until the symptoms disappear and the CSF becomes normal.	Rifampin	53-61	colony stimulating factor 2	Homo sapiens	183-186
2185231-7	1990	Rifampin challenge, end-labeling with [gamma-32P]ATP, and selective initiation with a dinucleotide all indicate that the decreased in vitro activity of the wild-type polymerase relative to that of the alc mutants was due to inhibition of elongation, not to any difference in initiation rates.	Rifampin	0-8	Alc inhibitor of host transcription	Escherichia phage T4	201-204
20702214-3	1990	Phenobarbital and rifampicin were found to increase the levels of P-450 IIC8, 9, 10 mRNA and protein while troleandomycin and 3-methylcholanthrene were ineffective.	Rifampin	18-28	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	66-79
33806634-6	2021	DDI model performance was evaluated by prediction of clinical studies with rifampicin (CYP2B6 and CYP2C19 inducer), fluvoxamine (CYP2C19 inhibitor) and voriconazole (CYP2B6 and CYP2C19 inhibitor).	Rifampin	75-85	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	87-93
33590212-8	2021	Additionally, while rifampin induced CYP3A4 in HepaRG-MPCCs and HepaRG-CCs, only HepaRG-MPCCs showed the dual omeprazole-mediated CYP1A2/3A4 induction as with PHHs.	Rifampin	20-28	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	37-43
33945104-8	2021	These results suggested that TIR8 exerts a protective role in IL-1beta-mediated EMT and potentially represents a new target for RIF treatment.	Rifampin	128-131	single Ig and TIR domain containing	Rattus norvegicus	29-33
33945104-8	2021	These results suggested that TIR8 exerts a protective role in IL-1beta-mediated EMT and potentially represents a new target for RIF treatment.	Rifampin	128-131	interleukin 1 alpha	Rattus norvegicus	62-70
29368402-0	2018	Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug-Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects.	Rifampin	28-38	solute carrier organic anion transporter family member 1A2	Homo sapiens	126-130
33232732-8	2021	The first pattern (amoxicillin-clavulanate, ceftriaxone) is characterised by high rate of UAP in every department, the second (cloxacillin, rifampin) by high rate of SAP in every department and the third (broad-spectrum beta-lactams) by heterogeneous distribution of SAP/UAP among departments.	Rifampin	140-148	SH2 domain containing 1A	Homo sapiens	166-169
33763207-2	2020	Drugs such as rifampicin and glibenclamide inhibit BSEP.	Rifampin	14-24	ATP binding cassette subfamily B member 11	Homo sapiens	51-55
29368402-3	2018	The parameters for cytochrome P450 (CYP) 3A and CYP2C9 induction by rifampicin were similarly optimized using clinical DDI data with midazolam and tolbutamide as probe substrates, respectively.	Rifampin	68-78	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	48-54
29368402-2	2018	Using in silico and in vitro parameters, and reported clinical pharmacokinetic data, rifampicin PBPK model was built and relevant parameters for saturable hepatic uptake and UDP-glucuronosyltransferase (UGT) auto-induction were optimized by fitting.	Rifampin	85-95	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	174-201
29368402-6	2018	Altogether, our constructed PBPK model of rifampicin demonstrates the robustness and utility in quantitatively predicting CYP3A/2C9 induction-mediated and/or OATP inhibition-mediated DDIs with victim drugs.	Rifampin	42-52	solute carrier organic anion transporter family member 1A2	Homo sapiens	158-162
29368402-2	2018	Using in silico and in vitro parameters, and reported clinical pharmacokinetic data, rifampicin PBPK model was built and relevant parameters for saturable hepatic uptake and UDP-glucuronosyltransferase (UGT) auto-induction were optimized by fitting.	Rifampin	85-95	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	203-206
29368402-3	2018	The parameters for cytochrome P450 (CYP) 3A and CYP2C9 induction by rifampicin were similarly optimized using clinical DDI data with midazolam and tolbutamide as probe substrates, respectively.	Rifampin	68-78	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	19-43
16847425-0	2006	Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin.	Rifampin	57-67	solute carrier organic anion transporter family member 1B1	Homo sapiens	10-17
18096695-5	2008	In this study, we showed that activation of PXR by genetic (using a constitutively activated PXR) or pharmacological (using PXR agonist rifampicin) means protected the PXR-overexpressing colon cancer HCT116 cells from deoxycholic acid-induced apoptosis.	Rifampin	136-146	nuclear receptor subfamily 1 group I member 2	Homo sapiens	44-47
18096695-9	2008	Treatment with rifampicin in colon cancer LS180 cells, a cell line known to express endogenous PXR, also inhibited apoptosis.	Rifampin	15-25	nuclear receptor subfamily 1 group I member 2	Homo sapiens	95-98
16847425-0	2006	Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin.	Rifampin	57-67	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	47-53
16847425-1	2006	Rifampicin (rifampin) is a potent inducer of cytochrome P450 (CYP) 3A4.	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	45-70
16847425-1	2006	Rifampicin (rifampin) is a potent inducer of cytochrome P450 (CYP) 3A4.	Rifampin	12-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	45-70
16847425-3	2006	The present study aimed to investigate the possible association of single nucleotide polymorphisms (SNP) in the SLCO1B1 gene encoding for OATP1B1 with the inducing effect of rifampicin on hepatic CYP3A4.	Rifampin	174-184	solute carrier organic anion transporter family member 1B1	Homo sapiens	112-119
16847425-3	2006	The present study aimed to investigate the possible association of single nucleotide polymorphisms (SNP) in the SLCO1B1 gene encoding for OATP1B1 with the inducing effect of rifampicin on hepatic CYP3A4.	Rifampin	174-184	solute carrier organic anion transporter family member 1B1	Homo sapiens	138-145
16847425-3	2006	The present study aimed to investigate the possible association of single nucleotide polymorphisms (SNP) in the SLCO1B1 gene encoding for OATP1B1 with the inducing effect of rifampicin on hepatic CYP3A4.	Rifampin	174-184	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	196-202
16847425-7	2006	A large intersubject variability existed in the induction of CYP3A4 by rifampicin, but no associations were observed between the variability in induction and any of the polymorphisms studied.	Rifampin	71-81	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	61-67
16847425-9	2006	However, the present study had sufficient power to detect only a considerably smaller rifampicin-induced increase in 4beta-hydroxycholesterol in carriers of the SLCO1B1 c.521C allele compared to subjects with the reference genotype.	Rifampin	86-96	solute carrier organic anion transporter family member 1B1	Homo sapiens	161-168
34949673-12	2022	Increased susceptibility to RTV-induced liver injury caused by the PXR activator rifampicin was attenuated by HNF4A-AS1 overexpression or HNF1A-AS1 knockdown.	Rifampin	81-91	nuclear receptor subfamily 1 group I member 2	Homo sapiens	67-70
34623637-8	2022	For the first time, it was possible to deploy plasma-derived sEV to study CYP3A4 induction beyond rifampicin, a more potent CYP3A4 inducer.	Rifampin	98-108	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	124-130
34689256-4	2022	We used 3D PHHs to assess time-dependent expression profiles of 12 prototypic PXR-controlled genes in the time course of 168 h of rifampicin treatment (1 or 10 microM).	Rifampin	130-140	nuclear receptor subfamily 1 group I member 2	Homo sapiens	78-81
34742755-7	2022	Immunofluorescent staining of centromere protein B with the micronuclei formed by BDE-47 in HepG2 cells pretreated with ethanol or rifampicin demonstrated selective formation of centromere-containing micronuclei.	Rifampin	131-141	centromere protein B	Homo sapiens	30-50
34949673-14	2022	Significance Statement HNF4A-AS1 and HNF1A-AS1, transcribed separately from neighboring antisense genes of the human transcription factor genes HNF4A and HNF1A, were identified as lncRNAs that can affect RTV-induced hepatotoxicity and susceptibility to RTV-induced hepatotoxicity caused by rifampicin exposure, mainly by affecting the expression of CY3A4 via alterations in PXR enrichment and histone modification status in the CYP3A4 promoter.	Rifampin	290-300	HNF4A antisense RNA 1	Homo sapiens	23-32
34949673-14	2022	Significance Statement HNF4A-AS1 and HNF1A-AS1, transcribed separately from neighboring antisense genes of the human transcription factor genes HNF4A and HNF1A, were identified as lncRNAs that can affect RTV-induced hepatotoxicity and susceptibility to RTV-induced hepatotoxicity caused by rifampicin exposure, mainly by affecting the expression of CY3A4 via alterations in PXR enrichment and histone modification status in the CYP3A4 promoter.	Rifampin	290-300	HNF1A antisense RNA 1	Homo sapiens	37-46
34949673-12	2022	Increased susceptibility to RTV-induced liver injury caused by the PXR activator rifampicin was attenuated by HNF4A-AS1 overexpression or HNF1A-AS1 knockdown.	Rifampin	81-91	HNF4A antisense RNA 1	Homo sapiens	110-119
34949673-14	2022	Significance Statement HNF4A-AS1 and HNF1A-AS1, transcribed separately from neighboring antisense genes of the human transcription factor genes HNF4A and HNF1A, were identified as lncRNAs that can affect RTV-induced hepatotoxicity and susceptibility to RTV-induced hepatotoxicity caused by rifampicin exposure, mainly by affecting the expression of CY3A4 via alterations in PXR enrichment and histone modification status in the CYP3A4 promoter.	Rifampin	290-300	hepatocyte nuclear factor 4 alpha	Homo sapiens	144-149
34949673-12	2022	Increased susceptibility to RTV-induced liver injury caused by the PXR activator rifampicin was attenuated by HNF4A-AS1 overexpression or HNF1A-AS1 knockdown.	Rifampin	81-91	HNF1A antisense RNA 1	Homo sapiens	138-147
34949673-14	2022	Significance Statement HNF4A-AS1 and HNF1A-AS1, transcribed separately from neighboring antisense genes of the human transcription factor genes HNF4A and HNF1A, were identified as lncRNAs that can affect RTV-induced hepatotoxicity and susceptibility to RTV-induced hepatotoxicity caused by rifampicin exposure, mainly by affecting the expression of CY3A4 via alterations in PXR enrichment and histone modification status in the CYP3A4 promoter.	Rifampin	290-300	HNF1 homeobox A	Homo sapiens	154-159
34966254-2	2021	Previously we demonstrated that oral or intranasal rifampicin improved the cognition of APP-, tau-, and alpha-synuclein-transgenic mice by reducing the amount of Abeta, tau, and alpha-synuclein oligomers in the brain.	Rifampin	51-61	synuclein, alpha	Mus musculus	104-119
34949673-14	2022	Significance Statement HNF4A-AS1 and HNF1A-AS1, transcribed separately from neighboring antisense genes of the human transcription factor genes HNF4A and HNF1A, were identified as lncRNAs that can affect RTV-induced hepatotoxicity and susceptibility to RTV-induced hepatotoxicity caused by rifampicin exposure, mainly by affecting the expression of CY3A4 via alterations in PXR enrichment and histone modification status in the CYP3A4 promoter.	Rifampin	290-300	nuclear receptor subfamily 1 group I member 2	Homo sapiens	374-377
34949673-14	2022	Significance Statement HNF4A-AS1 and HNF1A-AS1, transcribed separately from neighboring antisense genes of the human transcription factor genes HNF4A and HNF1A, were identified as lncRNAs that can affect RTV-induced hepatotoxicity and susceptibility to RTV-induced hepatotoxicity caused by rifampicin exposure, mainly by affecting the expression of CY3A4 via alterations in PXR enrichment and histone modification status in the CYP3A4 promoter.	Rifampin	290-300	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	428-434
34762904-9	2021	Furthermore, we found that CYP3A4 induction by rifampicin augmented NBP-induced cell toxicity and supplementing with GSH or NAC alleviated the oxidative stresses and reactive metabolites caused by 3-OH-NBP.	Rifampin	47-57	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	27-33
34888851-2	2022	Rifampin inhibits transporters including organic-anion-transporting polypeptide (OATP)1B and P-glycoprotein (P-gp), and induces enzymes and transporters including cytochrome P450 3A, UDP-glucuronosyltransferase (UGT)1A, and P-gp.	Rifampin	0-8	ATP binding cassette subfamily B member 1	Homo sapiens	93-107
34888851-2	2022	Rifampin inhibits transporters including organic-anion-transporting polypeptide (OATP)1B and P-glycoprotein (P-gp), and induces enzymes and transporters including cytochrome P450 3A, UDP-glucuronosyltransferase (UGT)1A, and P-gp.	Rifampin	0-8	ATP binding cassette subfamily B member 1	Homo sapiens	109-113
34888851-2	2022	Rifampin inhibits transporters including organic-anion-transporting polypeptide (OATP)1B and P-glycoprotein (P-gp), and induces enzymes and transporters including cytochrome P450 3A, UDP-glucuronosyltransferase (UGT)1A, and P-gp.	Rifampin	0-8	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	183-189
34888851-2	2022	Rifampin inhibits transporters including organic-anion-transporting polypeptide (OATP)1B and P-glycoprotein (P-gp), and induces enzymes and transporters including cytochrome P450 3A, UDP-glucuronosyltransferase (UGT)1A, and P-gp.	Rifampin	0-8	ATP binding cassette subfamily B member 1	Homo sapiens	224-228
34988253-1	2022	Clarithromycin (CYP inhibitor) can be used instead of azithromycin for nontuberculous mycobacteria therapy in patients requiring CYP substrates to mitigate rifampin"s CYP induction.	Rifampin	156-164	peptidylprolyl isomerase G	Homo sapiens	129-132
34988253-1	2022	Clarithromycin (CYP inhibitor) can be used instead of azithromycin for nontuberculous mycobacteria therapy in patients requiring CYP substrates to mitigate rifampin"s CYP induction.	Rifampin	156-164	peptidylprolyl isomerase G	Homo sapiens	167-170
34966254-2	2021	Previously we demonstrated that oral or intranasal rifampicin improved the cognition of APP-, tau-, and alpha-synuclein-transgenic mice by reducing the amount of Abeta, tau, and alpha-synuclein oligomers in the brain.	Rifampin	51-61	amyloid beta (A4) precursor protein	Mus musculus	162-167
34966254-2	2021	Previously we demonstrated that oral or intranasal rifampicin improved the cognition of APP-, tau-, and alpha-synuclein-transgenic mice by reducing the amount of Abeta, tau, and alpha-synuclein oligomers in the brain.	Rifampin	51-61	synuclein, alpha	Mus musculus	178-193
34966254-5	2021	Compared with rifampicin and resveratrol alone, the combinatorial medicine significantly improved mouse cognition, reduced amyloid oligomer accumulation, and recovered synaptophysin levels in the hippocampus.	Rifampin	14-24	synaptophysin	Mus musculus	168-181
34966254-7	2021	Notably, resveratrol alone and the combinatorial medicine, but not rifampicin alone, enhanced the levels of brain-derived neurotrophic factor (BDNF) and its precursor, pro-BDNF, in the hippocampus.	Rifampin	67-77	brain derived neurotrophic factor	Mus musculus	108-141
34966254-7	2021	Notably, resveratrol alone and the combinatorial medicine, but not rifampicin alone, enhanced the levels of brain-derived neurotrophic factor (BDNF) and its precursor, pro-BDNF, in the hippocampus.	Rifampin	67-77	brain derived neurotrophic factor	Mus musculus	143-147
34694920-2	2021	Mutation analysis was done by sequencing the rpoB gene encoding RNA polymerase beta-subunit of the rifampicin-resistant mutants.	Rifampin	99-109	rpoB	Deinococcus radiodurans R1	45-49
34871095-8	2021	MALDI MS imaging analysis of clofazimine, pyrazinamide and rifampicin revealed a drug-specific distribution within different lesion types including cellular granulomas, developing in BALB/c wild-type mice, and necrotic granulomas of BALB/c IL-13tg animals, emphasizing the necessity of pre-clinical models reflecting human pathology.	Rifampin	59-69	interleukin 13	Mus musculus	240-245
34562427-1	2021	Post-exposure prophylaxis (PEP) with single-dose rifampicin (SDR) reduces the risk of developing leprosy among contacts of leprosy patients.	Rifampin	49-59	prolyl endopeptidase	Homo sapiens	27-30
34872459-11	2021	Patients with tuberculosis with older age and genetic polymorphism of CYP3A4, CYP2C9, and CYP2C19 who received long-term rifampicin treatment were more likely to have antituberculosis drug-induced liver injury.	Rifampin	121-131	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	70-76
34872459-11	2021	Patients with tuberculosis with older age and genetic polymorphism of CYP3A4, CYP2C9, and CYP2C19 who received long-term rifampicin treatment were more likely to have antituberculosis drug-induced liver injury.	Rifampin	121-131	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	78-84
34872459-11	2021	Patients with tuberculosis with older age and genetic polymorphism of CYP3A4, CYP2C9, and CYP2C19 who received long-term rifampicin treatment were more likely to have antituberculosis drug-induced liver injury.	Rifampin	121-131	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	90-97
34729944-1	2021	Rifampicin induces both P-glycoprotein (P-gp) and cytochrome P450 3A4 (CYP3A4) through regulating common nuclear receptors (e.g., pregnane X receptor).	Rifampin	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	24-38
34729944-1	2021	Rifampicin induces both P-glycoprotein (P-gp) and cytochrome P450 3A4 (CYP3A4) through regulating common nuclear receptors (e.g., pregnane X receptor).	Rifampin	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	40-44
34729944-1	2021	Rifampicin induces both P-glycoprotein (P-gp) and cytochrome P450 3A4 (CYP3A4) through regulating common nuclear receptors (e.g., pregnane X receptor).	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	50-69
34729944-1	2021	Rifampicin induces both P-glycoprotein (P-gp) and cytochrome P450 3A4 (CYP3A4) through regulating common nuclear receptors (e.g., pregnane X receptor).	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	71-77
34729944-1	2021	Rifampicin induces both P-glycoprotein (P-gp) and cytochrome P450 3A4 (CYP3A4) through regulating common nuclear receptors (e.g., pregnane X receptor).	Rifampin	0-10	nuclear receptor subfamily 1 group I member 2	Homo sapiens	130-149
34729944-4	2021	In this study, we used a PBPK modeling approach for the assessment of DDIs between rifampicin and 12 drugs: three sensitive P-gp substrates, seven P-gp-CYP3A4 dual substrates, and two P-gp-CYP3A4 dual substrates and inhibitors.	Rifampin	83-93	ATP binding cassette subfamily B member 1	Homo sapiens	124-128
34729944-4	2021	In this study, we used a PBPK modeling approach for the assessment of DDIs between rifampicin and 12 drugs: three sensitive P-gp substrates, seven P-gp-CYP3A4 dual substrates, and two P-gp-CYP3A4 dual substrates and inhibitors.	Rifampin	83-93	ATP binding cassette subfamily B member 1	Homo sapiens	147-151
34729944-4	2021	In this study, we used a PBPK modeling approach for the assessment of DDIs between rifampicin and 12 drugs: three sensitive P-gp substrates, seven P-gp-CYP3A4 dual substrates, and two P-gp-CYP3A4 dual substrates and inhibitors.	Rifampin	83-93	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	152-158
34729944-4	2021	In this study, we used a PBPK modeling approach for the assessment of DDIs between rifampicin and 12 drugs: three sensitive P-gp substrates, seven P-gp-CYP3A4 dual substrates, and two P-gp-CYP3A4 dual substrates and inhibitors.	Rifampin	83-93	ATP binding cassette subfamily B member 1	Homo sapiens	184-188
34729944-4	2021	In this study, we used a PBPK modeling approach for the assessment of DDIs between rifampicin and 12 drugs: three sensitive P-gp substrates, seven P-gp-CYP3A4 dual substrates, and two P-gp-CYP3A4 dual substrates and inhibitors.	Rifampin	83-93	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	189-195
34729944-5	2021	A 3.5-fold increase of intestinal P-gp abundance was incorporated in the PBPK models to account for rifampicin-mediated P-gp induction at steady state.	Rifampin	100-110	ATP binding cassette subfamily B member 1	Homo sapiens	34-38
34729944-5	2021	A 3.5-fold increase of intestinal P-gp abundance was incorporated in the PBPK models to account for rifampicin-mediated P-gp induction at steady state.	Rifampin	100-110	ATP binding cassette subfamily B member 1	Homo sapiens	120-124
34282472-2	2021	Two drug-drug interaction studies, one with acid-reducing agents, esomeprazole (proton pump inhibitor (PPI)) and ranitidine (histamine-2 (H2) antagonist), and the other with potent CYP3A-modulating agents, itraconazole (CYP3A inhibitor) and rifampin (CYP3A inducer), were performed.	Rifampin	241-249	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	251-256
34722780-5	2021	Moreover, IFI44L was significantly upregulated, and it restricted the intracellular survival of M. tuberculosis H37Rv strains at 72 h after rifampicin treatment.	Rifampin	140-150	interferon induced protein 44 like	Homo sapiens	10-16
34529779-0	2021	Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial.	Rifampin	41-51	ras homolog family member F, filopodia associated	Homo sapiens	82-85
34278601-16	2021	Most PHSF patients have UGT1A1 deficiency, which may be the target of rifampicin.	Rifampin	70-80	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	24-30
34664792-3	2021	Phenotyping studies indicated cytochrome P450 (CYP) 3A are the major CYP isoform responsible for zanubrutinib metabolism, which was confirmed by a clinical DDI study with itraconazole and rifampin.	Rifampin	188-196	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	30-54
34686228-0	2021	Impact of the bacillary load on the accuracy of rifampicin resistance results by Xpert  MTB/RIF.	Rifampin	48-58	ras homolog family member F, filopodia associated	Homo sapiens	92-95
34722780-6	2021	Individuals with cutaneous tuberculosis (CTB) were found to have significantly higher IFI44L expression after 6 months of rifampicin therapy than after only 1 month.	Rifampin	122-132	interferon induced protein 44 like	Homo sapiens	86-92
34691435-0	2021	The role of C-Reactive protein as an inflammatory marker to predict prolonged QTc interval in rifampicin-resistant tuberculosis patients: A case-control study.	Rifampin	94-104	C-reactive protein	Homo sapiens	12-30
34491807-6	2021	Through microcalorimetric measurements, adjunctive rifampicin resulted in decreased metabolic activity and extended lag phase for all clinical GAS strains tested (p<0.05).	Rifampin	51-61	gastrin	Homo sapiens	143-146
34491807-7	2021	In addition, a case report is presented of adjunctive rifampicin treatment in an NSTI case with persistent GAS tissue infection.	Rifampin	54-64	gastrin	Homo sapiens	107-110
34491807-8	2021	Conclusion: The findings of this study demonstrate that adjunctive rifampicin enhances clearance of GAS biofilm in an in vitro tissue infection model.	Rifampin	67-77	gastrin	Homo sapiens	100-103
34691435-1	2021	Background: long-term use of anti-tuberculosis drugs (ATD) increases the risk of QTc prolongation, while C-reactive protein (CRP) can be used as an inflammatory marker of Mycobacterium tuberculosis infection.Objective: correlation of CRP on the QTc interval in Rifampicin-resistant tuberculosis (RR-TB) patients with the short regimen.	Rifampin	261-271	C-reactive protein	Homo sapiens	105-123
34691435-1	2021	Background: long-term use of anti-tuberculosis drugs (ATD) increases the risk of QTc prolongation, while C-reactive protein (CRP) can be used as an inflammatory marker of Mycobacterium tuberculosis infection.Objective: correlation of CRP on the QTc interval in Rifampicin-resistant tuberculosis (RR-TB) patients with the short regimen.	Rifampin	261-271	C-reactive protein	Homo sapiens	125-128
34691435-1	2021	Background: long-term use of anti-tuberculosis drugs (ATD) increases the risk of QTc prolongation, while C-reactive protein (CRP) can be used as an inflammatory marker of Mycobacterium tuberculosis infection.Objective: correlation of CRP on the QTc interval in Rifampicin-resistant tuberculosis (RR-TB) patients with the short regimen.	Rifampin	261-271	C-reactive protein	Homo sapiens	234-237
34273250-9	2021	Other than a simulated ~60% exposure reduction with strong CYP3A/2C inducers such as rifampin, other DDI liabilities were minimal and considered not clinically relevant.	Rifampin	85-93	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	59-66
34619012-6	2021	Furthermore, when (14 C)epyrifenacil was administered with OATP inhibitors, the liver/plasma ratio of S-3100-CA was significantly decreased by rifampicin, an Oatp1a1/Oatp1a4 inhibitor in mice, but not by digoxin, an Oatp1a4-specific inhibitor.	Rifampin	143-153	solute carrier organic anion transporter family member 1A2	Homo sapiens	59-63
34619012-6	2021	Furthermore, when (14 C)epyrifenacil was administered with OATP inhibitors, the liver/plasma ratio of S-3100-CA was significantly decreased by rifampicin, an Oatp1a1/Oatp1a4 inhibitor in mice, but not by digoxin, an Oatp1a4-specific inhibitor.	Rifampin	143-153	solute carrier organic anion transporter family, member 1a1	Mus musculus	158-165
34619012-6	2021	Furthermore, when (14 C)epyrifenacil was administered with OATP inhibitors, the liver/plasma ratio of S-3100-CA was significantly decreased by rifampicin, an Oatp1a1/Oatp1a4 inhibitor in mice, but not by digoxin, an Oatp1a4-specific inhibitor.	Rifampin	143-153	solute carrier organic anion transporter family, member 1a4	Mus musculus	166-173
34581255-0	2022	Treatment of spinal tuberculosis in rabbits using bovine serum albumin nanoparticles loaded with isoniazid and rifampicin.	Rifampin	111-121	albumin	Oryctolagus cuniculus	57-70
34581255-1	2022	OBJECTIVE: To evaluate the clinical efficacy of bovine serum albumin nanoparticles loaded with isoniazid and rifampicin (INH-RFP-BSA-NPs) in the treatment of spinal tuberculosis in rabbits.	Rifampin	109-119	albumin	Oryctolagus cuniculus	55-68
34498807-2	2022	Three drug-drug interactions studies were conducted in healthy subjects to evaluate the effect of P-glycoprotein (P-gp) modulation (Study 1: P-gp inhibition by itraconazole; Study 2: P-gp induction by rifampin) on filgotinib pharmacokinetics and the potential of filgotinib to impact exposure of metformin, an organic cation transporter (OCT) 2 and multidrug and toxin extrusion (MATE) 1/2K substrate (Study 3).	Rifampin	201-209	ATP binding cassette subfamily B member 1	Homo sapiens	183-187
34145979-6	2021	Based on these results, the strong CYP3A inhibitor itraconazole and inducer rifampin significantly influenced the PK of mobocertinib and its active metabolites.	Rifampin	76-84	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	35-40
34518943-5	2021	However, CYP inhibitory effect of INH gets masked by opposite enzyme-inducing effect of rifampicin, when used in combination.	Rifampin	88-98	peptidylprolyl isomerase G	Homo sapiens	9-12
34171773-7	2021	ECg and EGCg also strongly inhibited AADAC-mediated rifampicin hydrolase activity in human liver microsomes with IC50 values of 2.2 +- 1.4 and 1.7 +- 0.4 muM, respectively, whereas it weakly inhibited p-nitrophenyl acetate hydrolase activity, which is catalyzed by AADAC, CES1, and CES2.	Rifampin	52-62	arylacetamide deacetylase	Homo sapiens	37-42
34485328-1	2021	Background: The Xpert Mycobacterium tuberculosis/rifampin (MTB/RIF) assay has shown good diagnostic efficacy in brushing and biopsy tissue samples from patients with tracheobronchial tuberculosis (TBTB).	Rifampin	49-57	ras homolog family member F, filopodia associated	Homo sapiens	63-66
34447304-6	2021	We used the PBMCs collected from three healthy control participants with no known history of adverse drug reaction and two patients with a rifampicin-associated drug reaction with eosinophilia and systemic symptoms (DRESS), confirmed on IFN-gamma ELISpot assay.	Rifampin	139-149	interferon gamma	Homo sapiens	237-246
34447304-8	2021	Results: In a human immunodeficiency virus (HIV) negative and a positive rifampicin-associated DRESS with positive ex vivo IFN-gamma ELISpot assay, use of 10- and 100-fold Cmax drug concentrations decreased spot forming units/million cells by 32-100%, and this corresponded to cell cytotoxicity of more than 40 and 20% using an LDH assay and 7-AAD cell viability staining, respectively.	Rifampin	73-83	interferon gamma	Homo sapiens	123-132
34446483-3	2021	Post-exposure prophylaxis with single-dose rifampicin (SDR-PEP) reduces the risk of developing leprosy when administered to screened contacts of patients.	Rifampin	43-53	caveolae associated protein 2	Homo sapiens	55-58
34446483-3	2021	Post-exposure prophylaxis with single-dose rifampicin (SDR-PEP) reduces the risk of developing leprosy when administered to screened contacts of patients.	Rifampin	43-53	prolyl endopeptidase	Homo sapiens	59-62
34445158-0	2021	Nasal Rifampicin Improves Cognition in a Mouse Model of Dementia with Lewy Bodies by Reducing alpha-Synuclein Oligomers.	Rifampin	6-16	synuclein, alpha	Mus musculus	94-109
34445158-3	2021	Previously, we demonstrated that in APP- and tau-transgenic mice, oral or intranasal rifampicin reduced brain Abeta and tau oligomers and improved mouse cognition.	Rifampin	85-95	amyloid beta (A4) precursor protein	Mus musculus	110-115
34445158-5	2021	Rifampicin was intranasally administered to 6-month-old A53T-mutant alpha-synuclein-transgenic mice at 0.1 mg/day for 1 month.	Rifampin	0-10	synuclein, alpha	Mus musculus	68-83
34445158-9	2021	Intranasal rifampicin significantly reduced the levels of (pSer129) alpha-synuclein in the hippocampus and alpha-synuclein oligomers in the visual cortex and hippocampus.	Rifampin	11-21	synuclein, alpha	Mus musculus	68-83
34445158-9	2021	Intranasal rifampicin significantly reduced the levels of (pSer129) alpha-synuclein in the hippocampus and alpha-synuclein oligomers in the visual cortex and hippocampus.	Rifampin	11-21	synuclein, alpha	Mus musculus	107-122
34444675-7	2021	Rifampicin is a well-known human PXR ligand that has been used to treat intractable pruritus in severe cholestasis.	Rifampin	0-10	nuclear receptor subfamily 1 group I member 2	Homo sapiens	33-36
34386782-4	2021	We recruited patients with sputum Xpert MTB/RIF-positive rifampicin-susceptible pulmonary tuberculosis.	Rifampin	57-67	ras homolog family member F, filopodia associated	Homo sapiens	44-47
34267345-0	2022	Itraconazole and rifampicin, as CYP3A modulators but not P-gp modulators, affect the pharmacokinetics of almonertinib and active metabolite HAS-719 in healthy volunteers.	Rifampin	17-27	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	32-37
34302035-8	2021	The MP-evolved strains showed cross-resistance to rifampicin and clarithromycin owing to the acquisition of a mutation in the intergenic region of the Rv2864c ortholog, which encodes a penicillin-binding protein, at an early stage.	Rifampin	50-60	penicillin-binding lipoprotein	Mycobacterium tuberculosis H37Rv	151-158
34267345-3	2022	In this study, we investigated the effects of CYP3A inhibitor itraconazole and CYP3A inducer rifampicin on the pharmacokinetics of almonertinib and HAS-719 in 64 healthy volunteers.	Rifampin	93-103	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	79-84
34267345-7	2022	Co-administration of rifampicin in Beagle dogs reduced the fecal recovery of almonertinib and HAS-719, and markedly increased the levels of metabolites derived from further metabolism of HAS-719, which was consistent with human plasma data, suggesting that although rifampicin was also a potent inducer of P-gp, the pharmacokinetic alternation of HAS-719 was mainly due to its further metabolism but not excretion changes.	Rifampin	21-31	phosphoglycolate phosphatase	Homo sapiens	306-310
34267345-7	2022	Co-administration of rifampicin in Beagle dogs reduced the fecal recovery of almonertinib and HAS-719, and markedly increased the levels of metabolites derived from further metabolism of HAS-719, which was consistent with human plasma data, suggesting that although rifampicin was also a potent inducer of P-gp, the pharmacokinetic alternation of HAS-719 was mainly due to its further metabolism but not excretion changes.	Rifampin	266-276	phosphoglycolate phosphatase	Homo sapiens	306-310
34217369-0	2021	Hepatoprotective activity of melittin on isoniazid- and rifampicin-induced liver injuries in male albino rats.	Rifampin	56-66	melittin	Apis mellifera	29-37
34217369-1	2021	BACKGROUND: The present study investigated the ameliorative effect of melittin, a major polypeptide in the venom of honeybee (Apis mellifera), on isoniazid-(INH) and rifampicin-(RIF) induced hepatotoxicity in male albino rats.	Rifampin	166-176	melittin	Apis mellifera	70-78
34217369-1	2021	BACKGROUND: The present study investigated the ameliorative effect of melittin, a major polypeptide in the venom of honeybee (Apis mellifera), on isoniazid-(INH) and rifampicin-(RIF) induced hepatotoxicity in male albino rats.	Rifampin	178-181	melittin	Apis mellifera	70-78
34143391-8	2021	The simulations of CYP inducers predicted that the strongest interaction would occur with rifampin, with the AUC decreasing to 0.36 of the control value, whereas the simulations of CYP inhibitors predicted that the greatest effect would occur with fluconazole, with a 1.43-fold increase in AUC.	Rifampin	90-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-22
34177592-0	2021	Rifampicin Induces Gene, Protein, and Activity of P-Glycoprotein (ABCB1) in Human Precision-Cut Intestinal Slices.	Rifampin	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	50-64
34267886-3	2021	Subsequent assay of this library led to the identification of a series of potent hPXR agonists, showing better efficacy than that of typical hPXR agonist, rifampicin.	Rifampin	155-165	nuclear receptor subfamily 1 group I member 2	Homo sapiens	81-85
34267886-3	2021	Subsequent assay of this library led to the identification of a series of potent hPXR agonists, showing better efficacy than that of typical hPXR agonist, rifampicin.	Rifampin	155-165	nuclear receptor subfamily 1 group I member 2	Homo sapiens	141-145
34177592-0	2021	Rifampicin Induces Gene, Protein, and Activity of P-Glycoprotein (ABCB1) in Human Precision-Cut Intestinal Slices.	Rifampin	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	66-71
34177592-7	2021	Rifampicin significantly increased gene expression, protein levels, and efflux activity of ABCB1.	Rifampin	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	91-96
34154362-12	2021	CONCLUSIONS: Our meta-analysis has uncovered an association between CYP2E1 RsaI/PstI polymorphisms and ATDILI, especially among patients who receive a four-drug (INH + RIF + PZA + EMB) or three-drug (INH + RIF + PZA) anti-TB treatment regimen.	Rifampin	206-209	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	68-74
34154362-12	2021	CONCLUSIONS: Our meta-analysis has uncovered an association between CYP2E1 RsaI/PstI polymorphisms and ATDILI, especially among patients who receive a four-drug (INH + RIF + PZA + EMB) or three-drug (INH + RIF + PZA) anti-TB treatment regimen.	Rifampin	206-209	serine peptidase inhibitor Kazal type 1	Homo sapiens	80-84
34458006-3	2021	Combined administrations of 2-allyl-2-isopropylacetamide and rifampicin in rabbits halved hepatic PPOX activity, resulting in increased accumulation of a potentially neurotoxic heme precursor, lipid peroxidation, inflammation, and hepatocyte cytoplasmic stress.	Rifampin	61-71	protoporphyrinogen oxidase	Oryctolagus cuniculus	98-102
34223120-0	2021	TPR1, a novel rifampicin derivative, demonstrates efficacy alone and in combination with doxycycline against the NIAID Category A priority pathogen Francisella tularensis.	Rifampin	14-24	tetratricopeptide repeat domain 1	Mus musculus	0-4
34069974-7	2021	In addition, we showed that the expression of MDR1 and CYP3A4 genes increased synergistically after 24 h of rifampicin and MK-4 co-treatment.	Rifampin	108-118	ATP binding cassette subfamily B member 1	Homo sapiens	46-50
34069974-7	2021	In addition, we showed that the expression of MDR1 and CYP3A4 genes increased synergistically after 24 h of rifampicin and MK-4 co-treatment.	Rifampin	108-118	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	55-61
34223120-2	2021	Methods: We utilized a systematic analysis of antibacterial potency, extent of dissemination by analysis of bacterial burden in a secondary vital organ, and survival rates to assess the efficacy of a novel rifampicin derivative, TPR1.	Rifampin	206-216	tetratricopeptide repeat domain 1	Mus musculus	229-233
35460165-2	2022	This phase 1, open-label, randomized, two-way crossover study (NCT04121078) evaluated the effect of single-dose intravenous rifampin, a potent inhibitor of the organic anion transporting polypeptides (OATP) 1B1 and 1B3, on the pharmacokinetics and safety of trazpiroben in healthy adults.	Rifampin	124-132	solute carrier organic anion transporter family member 1B1	Homo sapiens	160-218
34345857-9	2021	For the CYP2B/C/D"s, phenobarbital and rifampicin caused increases in expression.	Rifampin	39-49	cytochrome P450 family 2 subfamily B member 7, pseudogene	Homo sapiens	8-13
34345857-11	2021	Both phenobarbital, rifampicin and omeprazole increased CYP3A expression in PHH and PPH.	Rifampin	20-30	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	56-61
35370222-1	2022	We encountered cases in which the anticoagulant effects of warfarin (CYP2C9 substrate) were reversibly attenuated by the concomitant administration of rifampicin or bosentan, which are potent pregnane X receptor (PXR) ligands.	Rifampin	151-161	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	69-75
35370222-1	2022	We encountered cases in which the anticoagulant effects of warfarin (CYP2C9 substrate) were reversibly attenuated by the concomitant administration of rifampicin or bosentan, which are potent pregnane X receptor (PXR) ligands.	Rifampin	151-161	nuclear receptor subfamily 1 group I member 2	Homo sapiens	192-211
35370222-1	2022	We encountered cases in which the anticoagulant effects of warfarin (CYP2C9 substrate) were reversibly attenuated by the concomitant administration of rifampicin or bosentan, which are potent pregnane X receptor (PXR) ligands.	Rifampin	151-161	nuclear receptor subfamily 1 group I member 2	Homo sapiens	213-216
35292967-7	2022	Correlation between AUCR of pitavastatin, and Cmax R or AUCR of CP-I were consistent between this study and our previous study using rifampicin as an OATP1B1/1B3 inhibitor.	Rifampin	133-143	solute carrier organic anion transporter family member 1B1	Homo sapiens	150-161
35460165-9	2022	This is also the first assessment of the utility of CPI and CPIII as endogenous biomarkers of OATP1B1/1B3 inhibition after a single intravenous dose of rifampin.	Rifampin	152-160	solute carrier organic anion transporter family member 1B1	Homo sapiens	94-105
35636769-7	2022	In contrast, multiple doses of 15 mg/kg rifampin (RIF), a pregnane X receptor (PXR) agonist, had no effect on hepatic OATP1B protein although it induced the intestinal P-gp and MR2 proteins by ~2-fold.	Rifampin	40-48	glycerol-3-phosphate phosphatase	Macaca fascicularis	168-172
35238961-8	2022	Rifampicin increased CYP2C19-mediated omeprazole metabolism.	Rifampin	0-10	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	21-28
35238961-10	2022	Both fluconazole and rifampicin altered CYP3A4 activity whereas no change of CYP2D6 activity was observed at all.	Rifampin	21-31	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	40-46
35636769-7	2022	In contrast, multiple doses of 15 mg/kg rifampin (RIF), a pregnane X receptor (PXR) agonist, had no effect on hepatic OATP1B protein although it induced the intestinal P-gp and MR2 proteins by ~2-fold.	Rifampin	50-53	glycerol-3-phosphate phosphatase	Macaca fascicularis	168-172
35616006-7	2022	The AUC of asciminib was marginally decreased by concomitant administration with the strong CYP3A inducer rifampicin (by ~13-15%) and the strong P-gp inhibitor quinidine (by ~13-16%).	Rifampin	106-116	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	92-97
35570332-0	2022	Robust PBPK Model of Rifampicin for Predicting Drug-Drug Interactions via P-gp Induction and Inhibition in Intestine, Liver, and Kidney.	Rifampin	21-31	ATP binding cassette subfamily B member 1	Homo sapiens	74-78
35579824-6	2022	The relative contributions of different cytochromes P450 (CYPs), mainly CYP3A4 and CYP2B6, involved in esketamine/noresketamine clearance was captured correctly in the IN-PBPK model using the DDI clinical studies of intranasal esketamine with clarithromycin and rifampicin and a published DDI study of oral esketamine with ticlopidine.	Rifampin	262-272	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	72-78
35570332-1	2022	P-glycoprotein (P-gp) is an efflux transporter that plays an important role in pharmacokinetics of its substrate, and P-gp activities can be altered by induction and inhibition effects of rifampicin.	Rifampin	188-198	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
35570332-1	2022	P-glycoprotein (P-gp) is an efflux transporter that plays an important role in pharmacokinetics of its substrate, and P-gp activities can be altered by induction and inhibition effects of rifampicin.	Rifampin	188-198	ATP binding cassette subfamily B member 1	Homo sapiens	16-20
35570332-1	2022	P-glycoprotein (P-gp) is an efflux transporter that plays an important role in pharmacokinetics of its substrate, and P-gp activities can be altered by induction and inhibition effects of rifampicin.	Rifampin	188-198	ATP binding cassette subfamily B member 1	Homo sapiens	118-122
35570332-2	2022	This study aimed to establish a physiologically based pharmacokinetic (PBPK) model of rifampicin to predict the P-gp-mediated drug-drug interactions (DDIs) and assess the DDI impact in the intestine, liver, and kidney.	Rifampin	86-96	ATP binding cassette subfamily B member 1	Homo sapiens	112-116
35570332-3	2022	The induction and inhibition parameters of rifampicin for P-gp were estimated using 2 of 7 DDI cases of rifampicin and digoxin and incorporated into our previously constructed PBPK model of rifampicin.	Rifampin	43-53	ATP binding cassette subfamily B member 1	Homo sapiens	58-62
35570332-3	2022	The induction and inhibition parameters of rifampicin for P-gp were estimated using 2 of 7 DDI cases of rifampicin and digoxin and incorporated into our previously constructed PBPK model of rifampicin.	Rifampin	104-114	ATP binding cassette subfamily B member 1	Homo sapiens	58-62
35570332-3	2022	The induction and inhibition parameters of rifampicin for P-gp were estimated using 2 of 7 DDI cases of rifampicin and digoxin and incorporated into our previously constructed PBPK model of rifampicin.	Rifampin	190-200	ATP binding cassette subfamily B member 1	Homo sapiens	58-62
35570332-5	2022	Based on the established PBPK model, following repeated dosing of 600 mg rifampicin, the deduced net effect was a ~3-fold induction in P-gp activities in the intestine, liver, and kidney.	Rifampin	73-83	ATP binding cassette subfamily B member 1	Homo sapiens	135-139
35570332-9	2022	These findings demonstrate that our rifampicin model can be applicable to quantitatively predict the net impact of P-gp induction and/or inhibition on diverse P-gp substrates and investigate the magnitude of DDIs in each tissue.	Rifampin	36-46	ATP binding cassette subfamily B member 1	Homo sapiens	115-119
35569070-0	2022	Long-term efficacy and safety of rifampin in the treatment of a patient carrying a CYP24A1 loss-of-function variant.	Rifampin	33-41	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	83-90
35570332-9	2022	These findings demonstrate that our rifampicin model can be applicable to quantitatively predict the net impact of P-gp induction and/or inhibition on diverse P-gp substrates and investigate the magnitude of DDIs in each tissue.	Rifampin	36-46	ATP binding cassette subfamily B member 1	Homo sapiens	159-163
35569070-2	2022	Rifampin is an antituberculosis drug that is a potent inducer of cytochrome P450 3 subfamily A member 4 (CYP3A4), involved in an alternative catabolic pathway of vitamin D.	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	65-103
35452411-7	2022	In 100% of rifampin-resistant isolates, mutations were found in the rifampin resistance-determining region (RRDR) of the rpoB, with S450L substitution being the most common, especially in MDRs (77.8%, 7/9).	Rifampin	11-19	DNA-directed RNA polymerase subunit beta	Mycobacterium tuberculosis H37Rv	121-125
35569070-2	2022	Rifampin is an antituberculosis drug that is a potent inducer of cytochrome P450 3 subfamily A member 4 (CYP3A4), involved in an alternative catabolic pathway of vitamin D.	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	105-111
35536601-8	2022	Activation of the nuclear receptors PXR and AHR was demonstrated via the induction of specific CYP isoenzymes by rifampicin, pregnenolone-16a-carbonitrile and beta-naphthoflavone.	Rifampin	113-123	nuclear receptor subfamily 1 group I member 2	Homo sapiens	36-39
35536601-8	2022	Activation of the nuclear receptors PXR and AHR was demonstrated via the induction of specific CYP isoenzymes by rifampicin, pregnenolone-16a-carbonitrile and beta-naphthoflavone.	Rifampin	113-123	aryl hydrocarbon receptor	Homo sapiens	44-47
35536601-8	2022	Activation of the nuclear receptors PXR and AHR was demonstrated via the induction of specific CYP isoenzymes by rifampicin, pregnenolone-16a-carbonitrile and beta-naphthoflavone.	Rifampin	113-123	peptidylprolyl isomerase G	Homo sapiens	95-98
35625816-0	2022	C9orf72 Hexanucleotide Repeat Expansion-Related Neuropathology Is Attenuated by Nasal Rifampicin in Mice.	Rifampin	86-96	C9orf72-SMCR8 complex subunit	Homo sapiens	0-7
35625816-5	2022	Rifampicin treatment reduced the formation of RNA foci and cytoplasmic inclusions containing DPRs or phosphorylated TDP-43, and furthermore, the levels of phosphorylated double-strand RNA-dependent protein kinase (PKR) that regulates repeat-associated non-ATG (RAN) translation.	Rifampin	0-10	TAR DNA binding protein	Mus musculus	116-122
35625816-5	2022	Rifampicin treatment reduced the formation of RNA foci and cytoplasmic inclusions containing DPRs or phosphorylated TDP-43, and furthermore, the levels of phosphorylated double-strand RNA-dependent protein kinase (PKR) that regulates repeat-associated non-ATG (RAN) translation.	Rifampin	0-10	eukaryotic translation initiation factor 2-alpha kinase 2	Mus musculus	214-217
35625816-5	2022	Rifampicin treatment reduced the formation of RNA foci and cytoplasmic inclusions containing DPRs or phosphorylated TDP-43, and furthermore, the levels of phosphorylated double-strand RNA-dependent protein kinase (PKR) that regulates repeat-associated non-ATG (RAN) translation.	Rifampin	0-10	RAN, member RAS oncogene family	Mus musculus	234-259
35625816-5	2022	Rifampicin treatment reduced the formation of RNA foci and cytoplasmic inclusions containing DPRs or phosphorylated TDP-43, and furthermore, the levels of phosphorylated double-strand RNA-dependent protein kinase (PKR) that regulates repeat-associated non-ATG (RAN) translation.	Rifampin	0-10	RAN, member RAS oncogene family	Mus musculus	261-264
35625816-7	2022	Our findings suggest a therapeutic potential of nasal rifampicin in the prevention of C9orf72-linked neurodegenerative disorders.	Rifampin	54-64	C9orf72-SMCR8 complex subunit	Homo sapiens	86-93
35506332-5	2022	The model under-predicted rifampin induction by 100% (approximate 6.7-fold decrease in AUC and approximate 2.6-fold decrease in Cmax in DDI study), presumably reflecting non-CYP3A4 mechanisms being impacted.	Rifampin	26-34	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	174-180
35428895-8	2022	Additionally, in the presence of strong or moderate CYP3A4 inducers, rifampicin and efavirenz, ipatasertib exposures were predicted to decrease by 86% and 74%, respectively.	Rifampin	69-79	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	52-58
35241487-1	2022	Cyclosporine A (CsA) and rifampin are potent inhibitors of organic anion transporting polypeptide (OATP) 1B1 and are widely used to assess the risk for drug-drug interactions.	Rifampin	25-33	solute carrier organic anion transporter family member 1B1	Homo sapiens	59-108
35241487-8	2022	Rifampin also displayed preincubation time-dependent inhibition of OATP1B1, albeit the extent of enhancement was only 2-fold.	Rifampin	0-8	solute carrier organic anion transporter family member 1B1	Homo sapiens	67-74
35435627-2	2022	Rifampicin (RIF) is a strong index CYP3A4 inducer.	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	35-41
35435627-2	2022	Rifampicin (RIF) is a strong index CYP3A4 inducer.	Rifampin	12-15	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	35-41
35510231-6	2022	Furthermore, although pretreatment with the CYP3A inducer rifampicin or the substitution of glucose with galactose in the growth media significantly augmented the loss of cell viability elicited by dronedarone and poyendarone, a lower loss of cell viability was consistently observed in poyendarone across all concentrations.	Rifampin	58-68	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	44-49
35455390-10	2022	Rifampicin effectively blocked both the Oatp-mediated influx and the Mrp2/3-related efflux of 99mTc-mebrofenin.	Rifampin	0-10	ATP binding cassette subfamily C member 2	Rattus norvegicus	69-75
35229613-2	2022	We showed previously that activation of pregnane X receptor (PXR) by rifampicin elevates 24-hour blood pressure (BP) and plasma 4beta-hydroxycholesterol (4betaHC), agonist for liver X receptor (LXR).	Rifampin	69-79	nuclear receptor subfamily 1 group I member 2	Homo sapiens	40-59
35229613-2	2022	We showed previously that activation of pregnane X receptor (PXR) by rifampicin elevates 24-hour blood pressure (BP) and plasma 4beta-hydroxycholesterol (4betaHC), agonist for liver X receptor (LXR).	Rifampin	69-79	nuclear receptor subfamily 1 group I member 2	Homo sapiens	61-64
35230741-6	2022	Consistent with the proposed metabolic pathway of belumosudil, the strong CYP3A4 inducer rifampicin significantly decreased exposure of belumosudil and KD025m2 and increased KD025m1 exposure.	Rifampin	89-99	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	74-80
35146537-7	2022	We also identified other variants which were associated with adverse effects in isoniazid and rifampicin (CYP2E1; hepatotoxicity).	Rifampin	94-104	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	106-112
35605912-3	2022	Then two clinical studies were performed to investigate the effects of itraconazole and rifampicin (potent CYP3A4/5 inhibitor and inducer, respectively) on the pharmacokinetics of youkenafil and its main metabolite, N-desethyl youkenafil (M1).	Rifampin	88-98	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	107-115
35229613-3	2022	Methods and Results In combined "PXR activation data set" (n=62) of 4 clinical trials, 1 week rifampicin dosing increased office systolic BP (SBP) by 3.1 mm Hg, DBP 1.8 mm Hg, and mean arterial pressure 2.2 mm Hg in comparison with placebo (P<0.01).	Rifampin	94-104	nuclear receptor subfamily 1 group I member 2	Homo sapiens	33-36
35165925-1	2022	AIMS: Clinical drug interaction studies with itraconazole and rifampicin demonstrated acalabrutinib is a sensitive substrate of CYP3A.	Rifampin	62-72	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	128-133
35452411-7	2022	In 100% of rifampin-resistant isolates, mutations were found in the rifampin resistance-determining region (RRDR) of the rpoB, with S450L substitution being the most common, especially in MDRs (77.8%, 7/9).	Rifampin	68-76	DNA-directed RNA polymerase subunit beta	Mycobacterium tuberculosis H37Rv	121-125
35045794-0	2022	4-Phenylbutyrate protects against rifampin-induced liver injury via regulating MRP2 ubiquitination through inhibiting endoplasmic reticulum stress.	Rifampin	34-42	ATP binding cassette subfamily C member 2	Homo sapiens	79-83
35544702-0	2022	Tanshinone IIA alleviate rifampicin-induced cholestasis by regulating the expression and function of bile salt export pump.	Rifampin	25-35	ATP binding cassette subfamily B member 11	Rattus norvegicus	101-122
35062050-13	2022	In the NAFLD model, Omeprazole maintained an expected induction of CYP1A1, however Phenytoin and Rifampicin showed elevated induction of CYP2B6 and CYP2C9 compared to healthy cultures.	Rifampin	97-107	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	148-154
35062050-12	2022	We then exposed the NAFLD model to the drug inducers rifampicin, Omeprazole, and Phenytoin as activators of transcription factors pregnane X receptor (PXR), aryl hydrocarbon receptor (AHR) and constitutive androstane receptor (CAR), respectively.	Rifampin	53-63	nuclear receptor subfamily 1 group I member 2	Homo sapiens	130-149
35062050-12	2022	We then exposed the NAFLD model to the drug inducers rifampicin, Omeprazole, and Phenytoin as activators of transcription factors pregnane X receptor (PXR), aryl hydrocarbon receptor (AHR) and constitutive androstane receptor (CAR), respectively.	Rifampin	53-63	nuclear receptor subfamily 1 group I member 2	Homo sapiens	151-154
35062050-12	2022	We then exposed the NAFLD model to the drug inducers rifampicin, Omeprazole, and Phenytoin as activators of transcription factors pregnane X receptor (PXR), aryl hydrocarbon receptor (AHR) and constitutive androstane receptor (CAR), respectively.	Rifampin	53-63	aryl hydrocarbon receptor	Homo sapiens	157-182
35062050-12	2022	We then exposed the NAFLD model to the drug inducers rifampicin, Omeprazole, and Phenytoin as activators of transcription factors pregnane X receptor (PXR), aryl hydrocarbon receptor (AHR) and constitutive androstane receptor (CAR), respectively.	Rifampin	53-63	aryl hydrocarbon receptor	Homo sapiens	184-187
35062050-12	2022	We then exposed the NAFLD model to the drug inducers rifampicin, Omeprazole, and Phenytoin as activators of transcription factors pregnane X receptor (PXR), aryl hydrocarbon receptor (AHR) and constitutive androstane receptor (CAR), respectively.	Rifampin	53-63	nuclear receptor subfamily 1 group I member 3	Homo sapiens	193-225
35062050-12	2022	We then exposed the NAFLD model to the drug inducers rifampicin, Omeprazole, and Phenytoin as activators of transcription factors pregnane X receptor (PXR), aryl hydrocarbon receptor (AHR) and constitutive androstane receptor (CAR), respectively.	Rifampin	53-63	nuclear receptor subfamily 1 group I member 3	Homo sapiens	227-230
35062050-13	2022	In the NAFLD model, Omeprazole maintained an expected induction of CYP1A1, however Phenytoin and Rifampicin showed elevated induction of CYP2B6 and CYP2C9 compared to healthy cultures.	Rifampin	97-107	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	137-143
34985190-0	2022	Two novel ATP8B1 mutations involved in progressive familial intrahepatic cholestasis type 1 that is ameliorated by rifampicin: a case report.	Rifampin	115-125	ATPase phospholipid transporting 8B1	Homo sapiens	10-16
34985190-0	2022	Two novel ATP8B1 mutations involved in progressive familial intrahepatic cholestasis type 1 that is ameliorated by rifampicin: a case report.	Rifampin	115-125	ATPase phospholipid transporting 8B1	Homo sapiens	51-91
35203506-0	2022	Nasal Rifampicin Halts the Progression of Tauopathy by Inhibiting Tau Oligomer Propagation in Alzheimer Brain Extract-Injected Mice.	Rifampin	6-16	microtubule associated protein tau	Homo sapiens	66-69
35203506-3	2022	We previously showed that intranasal rifampicin inhibits tau oligomer accumulation and improves cognition in tauopathy mice.	Rifampin	37-47	microtubule associated protein tau	Homo sapiens	57-60
35203506-8	2022	Rifampicin treatment inhibited the spreading of tau oligomers from the injection site to other brain regions and neurofibrillary tangle formation in the entorhinal cortex.	Rifampin	0-10	microtubule associated protein tau	Homo sapiens	48-51
35203506-10	2022	These results suggest that intranasal rifampicin could be a promising remedy that halts the progression of tauopathy by inhibiting tau oligomer propagation.	Rifampin	38-48	microtubule associated protein tau	Homo sapiens	131-134
35048417-6	2022	Analysis of cell culture medium of rifampicin treated HS explants revealed an anti-inflammatory effect of rifampicin that significantly inhibiting interleukin (IL)-1beta, IL-6, IL-8, IL-10, and tumour necrosis factor (TNF) -alpha production.	Rifampin	35-45	interleukin 1 alpha	Homo sapiens	147-169
35048417-6	2022	Analysis of cell culture medium of rifampicin treated HS explants revealed an anti-inflammatory effect of rifampicin that significantly inhibiting interleukin (IL)-1beta, IL-6, IL-8, IL-10, and tumour necrosis factor (TNF) -alpha production.	Rifampin	35-45	interleukin 6	Homo sapiens	171-175
35048417-6	2022	Analysis of cell culture medium of rifampicin treated HS explants revealed an anti-inflammatory effect of rifampicin that significantly inhibiting interleukin (IL)-1beta, IL-6, IL-8, IL-10, and tumour necrosis factor (TNF) -alpha production.	Rifampin	35-45	interleukin 10	Homo sapiens	183-188
35048417-6	2022	Analysis of cell culture medium of rifampicin treated HS explants revealed an anti-inflammatory effect of rifampicin that significantly inhibiting interleukin (IL)-1beta, IL-6, IL-8, IL-10, and tumour necrosis factor (TNF) -alpha production.	Rifampin	106-116	interleukin 1 alpha	Homo sapiens	147-169
35048417-6	2022	Analysis of cell culture medium of rifampicin treated HS explants revealed an anti-inflammatory effect of rifampicin that significantly inhibiting interleukin (IL)-1beta, IL-6, IL-8, IL-10, and tumour necrosis factor (TNF) -alpha production.	Rifampin	106-116	interleukin 6	Homo sapiens	171-175
35048417-6	2022	Analysis of cell culture medium of rifampicin treated HS explants revealed an anti-inflammatory effect of rifampicin that significantly inhibiting interleukin (IL)-1beta, IL-6, IL-8, IL-10, and tumour necrosis factor (TNF) -alpha production.	Rifampin	106-116	C-X-C motif chemokine ligand 8	Homo sapiens	177-181
35048417-6	2022	Analysis of cell culture medium of rifampicin treated HS explants revealed an anti-inflammatory effect of rifampicin that significantly inhibiting interleukin (IL)-1beta, IL-6, IL-8, IL-10, and tumour necrosis factor (TNF) -alpha production.	Rifampin	106-116	interleukin 10	Homo sapiens	183-188
35048417-6	2022	Analysis of cell culture medium of rifampicin treated HS explants revealed an anti-inflammatory effect of rifampicin that significantly inhibiting interleukin (IL)-1beta, IL-6, IL-8, IL-10, and tumour necrosis factor (TNF) -alpha production.	Rifampin	106-116	tumor necrosis factor	Homo sapiens	194-229
35048417-7	2022	Immunohistochemistry of the rifampicin-treated explants suggested a tendency for it to reduce the expression of TLR2 while not affecting the number of immune cells.	Rifampin	28-38	toll like receptor 2	Homo sapiens	112-116
2531681-2	1989	Seminal plasmin, which is known to be a stronger inhibitor than rifampicin binds at the same site as rifampicin to RNA polymerase.	Rifampin	64-74	plasminogen	Bos taurus	8-15
32795137-5	2022	In our study, we have investigated the role of these major tuberculosis drugs namely Rifampicin, Streptomycin, Isoniazid, Pyrazinamide, and Ethambutol on actin polymerization which are famously known to be a central player in the sarcomere region of the muscle in human body.	Rifampin	85-95	actin	Saccharomyces cerevisiae S288C	154-159
2531681-2	1989	Seminal plasmin, which is known to be a stronger inhibitor than rifampicin binds at the same site as rifampicin to RNA polymerase.	Rifampin	101-111	plasminogen	Bos taurus	8-15
2677927-5	1989	Against enterococci, all combinations showed a synergistic or additive effect, the most pronounced effect being demonstrated with rifampicin (FIC Index value around 0.3).	Rifampin	130-140	Fic	Escherichia coli	142-145
2590599-6	1989	Cortisol 6 beta-hydroxylase activity increased from 15 +/- 6 pmol min-1 mg-1 in organ donors (considered as "control subjects") to 87 +/- 31 pmol min-1 mg-1 in rifampicin treated patients.	Rifampin	160-170	CD59 molecule (CD59 blood group)	Homo sapiens	146-156
2777787-3	1989	In this report, we demonstrate that in immature rabbits, rifampicin activates the transcription of the Cyp3A6 gene which encodes P450IIIA6 (cytochrome P-450 3c).	Rifampin	57-67	cytochrome P450 3A6	Oryctolagus cuniculus	103-109
2777787-3	1989	In this report, we demonstrate that in immature rabbits, rifampicin activates the transcription of the Cyp3A6 gene which encodes P450IIIA6 (cytochrome P-450 3c).	Rifampin	57-67	cytochrome P450 3A6	Oryctolagus cuniculus	140-159
2806536-1	1989	In experiments of rats it was established that administration of isoniazid and rifampicin in equimolecular doses (50 and 250 mg/kg) for 14 days increased the activities of alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase in the serum, enhanced lipid peroxidation in hepatocytic membranes, caused significant disturbances of bile excretion.	Rifampin	79-89	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	198-224
2811375-0	1989	Plasma levels of estradiol, estrone, estrone sulfate and sex hormone binding globulin in patients receiving rifampicin.	Rifampin	108-118	sex hormone binding globulin	Homo sapiens	57-85
2811375-5	1989	In eight patients, from whom all tuberculostatic treatment except rifampicin had been withdrawn, plasma sex hormone binding globulin was found to be increased by 75% by rifampicin treatment.	Rifampin	66-76	sex hormone binding globulin	Homo sapiens	104-132
2811375-5	1989	In eight patients, from whom all tuberculostatic treatment except rifampicin had been withdrawn, plasma sex hormone binding globulin was found to be increased by 75% by rifampicin treatment.	Rifampin	169-179	sex hormone binding globulin	Homo sapiens	104-132
2682943-3	1989	Rifampin and perhaps nafcillin induce cytochrome P-450-dependent isoenzyme metabolism of cyclosporine.	Rifampin	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-54
2565211-2	1989	Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily.	Rifampin	39-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
16347898-5	1989	Rifampin-resistant strain D10 and 2-bromobutyrate mutant R were found to be deficient in only CoA-transferase, while several other mutants exhibited reduced butyraldehyde dehydrogenase and butanol dehydrogenase activities as well.	Rifampin	0-8	CA_C1423	Clostridium acetobutylicum ATCC 824	171-184
16347898-5	1989	Rifampin-resistant strain D10 and 2-bromobutyrate mutant R were found to be deficient in only CoA-transferase, while several other mutants exhibited reduced butyraldehyde dehydrogenase and butanol dehydrogenase activities as well.	Rifampin	0-8	CA_C1423	Clostridium acetobutylicum ATCC 824	197-210
2744145-2	1989	The use of GABA under induction of cytochrome P-450 of the liver by phenobarbital or rifampicin was not followed by immunodepression.	Rifampin	85-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-51
2565211-10	1989	Moreover, these monoxygenase activities and the hepatic level of P-450(CsA) were simultaneously increased in the liver of patients treated for 4 days with 600 mg of rifampicin per day.	Rifampin	165-175	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	65-75
2565211-12	1989	We conclude that P-450(CsA) is responsible for most (80%) of CsA oxidase activity in human liver, is encoded by gene P450IIIA3, as is NF oxidase, or a very closely related gene, and is strongly inducible by rifampicin pretreatment.	Rifampin	207-217	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	17-27
2792166-6	1989	In these 6 volunteers, intake of diltiazem (240 mg daily), concurrently with rifampicin for a week, significantly elevated theophylline half-life to 6.2 h as well as reduced its clearance to 1.03 ml.min-1.kg-1.	Rifampin	77-87	CD59 molecule (CD59 blood group)	Homo sapiens	199-204
3175736-3	1988	After cessation of rifampin and isoniazid, prothrombin time was maintained within the same range by a 50% reduction of warfarin doses, despite a twofold rise in the plasma warfarin concentration.	Rifampin	19-27	coagulation factor II, thrombin	Homo sapiens	43-54
2559042-3	1989	Nondirected and FMLP-directed migration was significantly (P less than 0.01) inhibited by rifamycin SV and rifampin at assay concentrations above 0.31 and 5.0 micrograms/ml respectively thus confirming the low dose rifamycin effect observed by others using human neutrophils.	Rifampin	107-115	formyl peptide receptor 1	Homo sapiens	16-20
3182866-5	1988	The antibiotic rifampicin induces cytochrome P-450 3c in rabbit liver microsomes, and the benzo(a)pyrene hydroxylase, estradiol 2-hydroxylase, and progesterone 6 beta-hydroxylase activities of these microsomes are stimulated by alpha-naphthoflavone.	Rifampin	15-25	cytochrome P450 3A6	Oryctolagus cuniculus	34-53
3412203-2	1988	Further evidence is given of by time rifampicin induction of beta-glucuronidase and beta-N acetylglucosaminidase and its possible relation to hepatitis and pancreatitis.	Rifampin	37-47	glucuronidase beta	Homo sapiens	61-79
3147199-2	1988	In fact, the antibacterial activity of SPA-S-565 against numerous Gram-positive cocci belonging to Staphylococcus and Streptococcus species as well as against 20 strains of Mycobacterium tuberculosis, was similar to that of rifampicin.	Rifampin	224-234	surfactant associated protein A1	Mus musculus	39-42
3412203-2	1988	Further evidence is given of by time rifampicin induction of beta-glucuronidase and beta-N acetylglucosaminidase and its possible relation to hepatitis and pancreatitis.	Rifampin	37-47	O-GlcNAcase	Homo sapiens	84-112
3367901-1	1988	Rifampicin induces cytochrome P-450 3c, progesterone 16 alpha- and 6 beta-hydroxylation, 17 beta-estradiol 2-hydroxylation, benzo[a] pyrene hydroxylation, and erythromycin N-demethylation in rabbit liver microsomes.	Rifampin	0-10	cytochrome P450 3A6	Oryctolagus cuniculus	19-38
3259880-2	1988	This study was undertaken into liver microsomal fractions prepared from untreated rabbits or animals treated with drugs known to specifically induce various cytochrome P-450 isozymes such as form LM2 by phenobarbital, LM4 and LM6 by 3-methylcholanthrene and beta-naphthoflavone, LM3a by ethyl alcohol and acetone, and LM3c by macrolide antibiotics (rifampicin, erythromycin and triacetyloleandomycin).	Rifampin	349-359	cytochrome P-450	Oryctolagus cuniculus	157-173
3665337-6	1987	Based on formation clearance values estimated for 6-, 7-, and 8-hydroxywarfarin, rifampin appears to increase the clearance of the parent drug by induction of the cytochrome P-450 isozyme(s) responsible for aromatic hydroxylation.	Rifampin	81-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	163-179
3335807-5	1988	However, an increase in adherence of 65% was observed for one strain, RP14 (ATCC 35981), with rifampin treatment.	Rifampin	94-102	TUB like protein 1	Homo sapiens	70-74
3573148-2	1987	Results of in vivo studies showed that the transcription of the Xp10 genome in Xp10-infected cells shifted from rifampin sensitivity to rifampin resistance.	Rifampin	112-120	xenotropic-MCF leukemia virus 51	Mus musculus	64-68
3608348-5	1987	Therefore rifampin preferentially affects norantipyrine or desmethyl- and 3-hydroxydiazepam metabolic formation, suggesting induction of different (iso)zymes of cytochrome P-450.	Rifampin	10-18	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	161-177
3573148-2	1987	Results of in vivo studies showed that the transcription of the Xp10 genome in Xp10-infected cells shifted from rifampin sensitivity to rifampin resistance.	Rifampin	112-120	xenotropic-MCF leukemia virus 51	Mus musculus	79-83
3573148-2	1987	Results of in vivo studies showed that the transcription of the Xp10 genome in Xp10-infected cells shifted from rifampin sensitivity to rifampin resistance.	Rifampin	136-144	xenotropic-MCF leukemia virus 51	Mus musculus	64-68
3573148-2	1987	Results of in vivo studies showed that the transcription of the Xp10 genome in Xp10-infected cells shifted from rifampin sensitivity to rifampin resistance.	Rifampin	136-144	xenotropic-MCF leukemia virus 51	Mus musculus	79-83
3091058-0	1986	Recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin in experimental murine tuberculosis.	Rifampin	65-75	interferon gamma	Mus musculus	12-28
3919717-0	1985	Isolation and partial characterization of a rifampicin induced rabbit liver microsomal cytochrome P-450.	Rifampin	44-54	cytochrome P-450	Oryctolagus cuniculus	87-103
3707122-11	1986	Reversal of the delayed-nodulation phenotype of HS111 through lectin pretreatment was prevented by chloramphenicol or rifampin.	Rifampin	118-126	LOW QUALITY PROTEIN: lectin	Glycine max	62-68
4074601-4	1985	Clearance of phenytoin in patients receiving only rifampicin increased from 46.7 ml min-1 +/- 20.6 ml min-1 to 97.8 ml min-1 +/- 33.4 ml min-1 (P less than 0.01), while clearance in patients on three drugs increased from 47.1 +/- 23.4 ml min-1 to 81.3 ml min-1 +/- 41.6 ml min-1 (P less than 0.01).	Rifampin	50-60	CD59 molecule (CD59 blood group)	Homo sapiens	84-89
4074601-4	1985	Clearance of phenytoin in patients receiving only rifampicin increased from 46.7 ml min-1 +/- 20.6 ml min-1 to 97.8 ml min-1 +/- 33.4 ml min-1 (P less than 0.01), while clearance in patients on three drugs increased from 47.1 +/- 23.4 ml min-1 to 81.3 ml min-1 +/- 41.6 ml min-1 (P less than 0.01).	Rifampin	50-60	CD59 molecule (CD59 blood group)	Homo sapiens	102-115
4074601-4	1985	Clearance of phenytoin in patients receiving only rifampicin increased from 46.7 ml min-1 +/- 20.6 ml min-1 to 97.8 ml min-1 +/- 33.4 ml min-1 (P less than 0.01), while clearance in patients on three drugs increased from 47.1 +/- 23.4 ml min-1 to 81.3 ml min-1 +/- 41.6 ml min-1 (P less than 0.01).	Rifampin	50-60	CD59 molecule (CD59 blood group)	Homo sapiens	102-107
4074601-4	1985	Clearance of phenytoin in patients receiving only rifampicin increased from 46.7 ml min-1 +/- 20.6 ml min-1 to 97.8 ml min-1 +/- 33.4 ml min-1 (P less than 0.01), while clearance in patients on three drugs increased from 47.1 +/- 23.4 ml min-1 to 81.3 ml min-1 +/- 41.6 ml min-1 (P less than 0.01).	Rifampin	50-60	CD59 molecule (CD59 blood group)	Homo sapiens	102-107
4074601-4	1985	Clearance of phenytoin in patients receiving only rifampicin increased from 46.7 ml min-1 +/- 20.6 ml min-1 to 97.8 ml min-1 +/- 33.4 ml min-1 (P less than 0.01), while clearance in patients on three drugs increased from 47.1 +/- 23.4 ml min-1 to 81.3 ml min-1 +/- 41.6 ml min-1 (P less than 0.01).	Rifampin	50-60	CD59 molecule (CD59 blood group)	Homo sapiens	102-107
4074601-4	1985	Clearance of phenytoin in patients receiving only rifampicin increased from 46.7 ml min-1 +/- 20.6 ml min-1 to 97.8 ml min-1 +/- 33.4 ml min-1 (P less than 0.01), while clearance in patients on three drugs increased from 47.1 +/- 23.4 ml min-1 to 81.3 ml min-1 +/- 41.6 ml min-1 (P less than 0.01).	Rifampin	50-60	CD59 molecule (CD59 blood group)	Homo sapiens	102-107
4074601-4	1985	Clearance of phenytoin in patients receiving only rifampicin increased from 46.7 ml min-1 +/- 20.6 ml min-1 to 97.8 ml min-1 +/- 33.4 ml min-1 (P less than 0.01), while clearance in patients on three drugs increased from 47.1 +/- 23.4 ml min-1 to 81.3 ml min-1 +/- 41.6 ml min-1 (P less than 0.01).	Rifampin	50-60	CD59 molecule (CD59 blood group)	Homo sapiens	102-107
3720370-2	1986	Short-course chemotherapy (SCC) for pulmonary tuberculosis for nine months with isoniazid (INH) and rifampin (RIF) is well established.	Rifampin	100-108	ras homolog family member F, filopodia associated	Homo sapiens	110-113
2581616-2	1985	We have reported that a protein newly synthesized in the presence of rifampin might be a product of the srnB gene required for stable RNA degradation (Ito, R. and Ohnishi, Y.	Rifampin	69-77	modulator of post-segregation killing protein SrnB	Escherichia coli	104-108
3161772-0	1985	Induction of rat liver bilirubin-conjugating enzymes and glutathione S-transferase by rifampicin.	Rifampin	86-96	hematopoietic prostaglandin D synthase	Rattus norvegicus	57-82
3161772-2	1985	Rifampicin induced bilirubin UDP-glucuronyltransferase, bilirubin UDP-glucosyltransferase, bilirubin UDP-xylosyltransferase and glutathione S-transferase activities, but did not induce mixed function oxidase activities.	Rifampin	0-10	hematopoietic prostaglandin D synthase	Rattus norvegicus	128-153
3161772-6	1985	Induction of bilirubin-conjugating enzymes and glutathione S-transferase by rifampicin in rats was different from that in humans, in which selective induction of mixed function oxidase is reported to occur.	Rifampin	76-86	hematopoietic prostaglandin D synthase	Rattus norvegicus	47-72
3882459-0	1985	Interaction of bovine seminalplasmin with Escherichia coli RNA polymerase in the presence of rifampicin.	Rifampin	93-103	caltrin	Bos taurus	22-36
3882459-3	1985	Rifampicin quenced the intrinsic fluorescence of RNA polymerase and seminalplasmin when excited at 280 nm.	Rifampin	0-10	caltrin	Bos taurus	68-82
3882459-4	1985	However, excess of seminalplasmin reversed the quenching of RNA polymerase fluorescence by rifampicin.	Rifampin	91-101	caltrin	Bos taurus	19-33
3882459-5	1985	Upon addition of rifampicin to the seminalplasmin-RNA polymerase complex, no change in fluorescence spectrum was observed.	Rifampin	17-27	caltrin	Bos taurus	35-49
3882459-6	1985	It appeared that although rifampicin could form complexes with RNA polymerase and seminalplasmin alone, no binding domain was available for rifampicin in the RNA polymerase-seminalplasmin complex.	Rifampin	26-36	caltrin	Bos taurus	82-96
3919717-1	1985	Rifampicin administration to New Zealand male rabbits increased the concentration of an LM3 form of cytochrome P-450 to up to 30% of the microsomal P-450 concentration.	Rifampin	0-10	cytochrome P-450	Oryctolagus cuniculus	100-116
6318656-2	1983	First, rifampin inhibited chemotaxis induced with FMLP but reversed the immobilization of PMLs that occurred at high FMLP concentrations.	Rifampin	7-15	formyl peptide receptor 1	Homo sapiens	50-54
6508979-5	1984	Rifampicin seems to induce preferentially the cytochrome P-450 (iso-) enzyme(s) involved in the demethylation of antipyrine to norantipyrine.	Rifampin	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-62
6466384-0	1984	Inductive and repressive effects of rifampicin on rabbit liver microsomal cytochrome P-450.	Rifampin	36-46	cytochrome P-450	Oryctolagus cuniculus	74-90
6466384-6	1984	The concomitant inductive/repressive effect of rifampicine on two cytochrome P-450 isoenzymes makes this drug a very atypical inducer, at least in the rabbit.	Rifampin	47-58	cytochrome P-450	Oryctolagus cuniculus	66-82
6318656-1	1983	Three independent experimental approaches support the hypothesis that rifampin competes for receptors on polymorphonuclear leukocytes (PMLs) with small peptide chemoattractants, e.g., N-formylmethionylleucylphenylalanine (FMLP), but not with serum-derived chemoattractants (C5a).	Rifampin	70-78	formyl peptide receptor 1	Homo sapiens	222-226
6318656-1	1983	Three independent experimental approaches support the hypothesis that rifampin competes for receptors on polymorphonuclear leukocytes (PMLs) with small peptide chemoattractants, e.g., N-formylmethionylleucylphenylalanine (FMLP), but not with serum-derived chemoattractants (C5a).	Rifampin	70-78	complement C5a receptor 1	Homo sapiens	274-277
6494651-5	1984	Not only the microsomal monooxygenase but also amidase was strongly induced by pretreatment with phenobarbital, 3-methylcholanthrene and rifampicin, respectively.	Rifampin	137-147	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	13-37
6639842-5	1983	Rifampicin (600 mg/day) caused a large increase in propranolol"s oral clearance (35.7 +/- 16.3 vs 96.1 +/- 26.9 ml min-1 kg-1, mean +/- s.d.	Rifampin	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	115-125
6318656-2	1983	First, rifampin inhibited chemotaxis induced with FMLP but reversed the immobilization of PMLs that occurred at high FMLP concentrations.	Rifampin	7-15	formyl peptide receptor 1	Homo sapiens	117-121
6318656-3	1983	Second, rifampin competed with radiolabeled FMLP for binding sites on PMLs and displaced already-bound radiolabeled FMLP.	Rifampin	8-16	formyl peptide receptor 1	Homo sapiens	116-120
6318656-4	1983	Third, rifampin blocked and reversed the bipolar shape changes induced in PMLs by FMLP.	Rifampin	7-15	formyl peptide receptor 1	Homo sapiens	82-86
6318656-7	1983	The evidence suggests, therefore, that rifampin is a ligand for FMLP-type receptors on PMLs.	Rifampin	39-47	formyl peptide receptor 1	Homo sapiens	64-68
6854335-0	1983	Non-competitive inhibition of hepatic and intestinal aryl hydrocarbon hydroxylase activities from rats by rifampin.	Rifampin	106-114	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	53-81
6357197-4	1983	Since the resistance to nuclease was not observed in the presence of rifampicin or by preincubation without UTP, both RNA chain initiation and elongation were considered to be essential for the manifestation of resistance.	Rifampin	69-79	nuclease	Escherichia coli	24-32
6222344-1	1983	In a 48-years old woman, intermittent rifampicin treatment induced an immunoallergic reaction with digestive disorders, haemolysis, acute renal failure and prolonged prothrombin time.	Rifampin	38-48	coagulation factor II, thrombin	Homo sapiens	166-177
6196945-3	1983	The effect of different inhibitors like actinomycin D, chloramphenicol, tetracycline, nitrofurantoin and rifampicin on histidase induction was also studied.	Rifampin	105-115	histidine ammonia-lyase	Homo sapiens	119-128
6854335-1	1983	Rifampin is a semisynthetic antibiotic which is known to alter hepatic cytochrome P-450 mediated drug metabolizing enzymes.	Rifampin	0-8	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	71-87
6854335-2	1983	Using benzo(a)pyrene as the substrate we have shown that rifampin acts as a non-competitive inhibitor of hepatic microsomal aryl hydrocarbon hydroxylase in vitro at or below 0.10 mM and that it is also a non-competitive inhibitor of intestinal aryl hydrocarbon hydroxylase at or below 0.075 mM.	Rifampin	57-65	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	124-152
6854335-2	1983	Using benzo(a)pyrene as the substrate we have shown that rifampin acts as a non-competitive inhibitor of hepatic microsomal aryl hydrocarbon hydroxylase in vitro at or below 0.10 mM and that it is also a non-competitive inhibitor of intestinal aryl hydrocarbon hydroxylase at or below 0.075 mM.	Rifampin	57-65	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	244-272
7039435-1	1982	Early phase hyperglycemia, associated with increased rates of insulin and C-peptide secretion after oral administration of 100 g glucose, was observed among patients with pulmonary tuberculosis who were taking rifampicin.	Rifampin	210-220	insulin	Homo sapiens	62-69
7154665-6	1982	Rifampicin treatment gives a variable enzyme induction of antipyrine metabolism, cytochrome P450 and aniline hydroxylase activity; aminopyrine N-demethylase activity is significantly inhibited.	Rifampin	0-10	cytochrome P-450	Oryctolagus cuniculus	81-156
6189376-1	1982	Alkaline phosphate, catalase and beta-galactosidase activities of Vibrio et tor were decreased after acquisition of resistance towards rifampicin.	Rifampin	135-145	catalase	Homo sapiens	20-28
6189376-1	1982	Alkaline phosphate, catalase and beta-galactosidase activities of Vibrio et tor were decreased after acquisition of resistance towards rifampicin.	Rifampin	135-145	galactosidase beta 1	Homo sapiens	33-51
6845400-2	1983	The maximal plasma concentrations (Cmax) and the elimination half-lives (t 1/2 beta) of RMP are 8.83 +/- 1.72 mg L-1 and 4.09 +/- 2.59 h, respectively.	Rifampin	88-91	interleukin 1 receptor like 1	Homo sapiens	73-83
7039435-1	1982	Early phase hyperglycemia, associated with increased rates of insulin and C-peptide secretion after oral administration of 100 g glucose, was observed among patients with pulmonary tuberculosis who were taking rifampicin.	Rifampin	210-220	insulin	Homo sapiens	74-83
7042603-7	1981	This trial revealed the satisfactory efficacy, good tolerability, and practicability of a supervised once-monthly 1200 mg single oral dose rifampin schedule as a component of combination regimes for the initial treatment of patients with lepromatous (LLs and LLp) leprosy.	Rifampin	139-147	LLP homolog, long-term synaptic facilitation factor	Homo sapiens	259-262
6277242-5	1982	It should be noted that the inhibitory effect of rifampicin on the activity of SDH, TP and AP was less pronounced than that of lincomycin.	Rifampin	49-59	aminoadipate-semialdehyde synthase	Mus musculus	79-82
7278139-1	1981	Lepromatous patients of "Introductory Rifampicin therapy" (Lepr.	Rifampin	38-48	leptin receptor	Homo sapiens	0-4
7416733-1	1980	The effect of semisynthetic antibiotics, such as ampicillin and rifampicin on activity of succinate dehydrogenase (SDH) in the liver and spleen of mice immunized with heated typhoid vaccine was studied.	Rifampin	64-74	aminoadipate-semialdehyde synthase	Mus musculus	90-113
7416733-1	1980	The effect of semisynthetic antibiotics, such as ampicillin and rifampicin on activity of succinate dehydrogenase (SDH) in the liver and spleen of mice immunized with heated typhoid vaccine was studied.	Rifampin	64-74	aminoadipate-semialdehyde synthase	Mus musculus	115-118
6110213-0	1980	[The activity of transaminases (GOT and GPT), alkaline phosphatase and gamma-glutamyl transferases in the serum of patients treated with Rifampicin (author"s transl)].	Rifampin	137-147	glutamic--pyruvic transaminase	Homo sapiens	40-43
7389010-3	1980	PB, Rifa and PCN induced the aryl hydrocarbon hydroxylase (AHH) in the skin though to a lesser extent than MC.	Rifampin	4-8	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	29-57
7389010-3	1980	PB, Rifa and PCN induced the aryl hydrocarbon hydroxylase (AHH) in the skin though to a lesser extent than MC.	Rifampin	4-8	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	59-62
7359301-0	1980	Rifampin for CSF shunt infection.	Rifampin	0-8	colony stimulating factor 2	Homo sapiens	13-16
702642-6	1978	Results obtained from an addition of rifampin at the prereplicative cycle after infection indicated that mRNA from genes 43, rIIA, 46, 39, 52, and 63 are more stable in T4amC5 (gene 59) than in wild-type-infected cells.	Rifampin	37-45	protein kinase cAMP-dependent type I regulatory subunit alpha	Rattus norvegicus	125-129
6449961-1	1980	In mitomycin C-treated lambda lysogens, even though the rate of synthesis of RecA protein was greatly reduced by a low concentration of rifampicin (4 microgram/ml), induction of prophage lambda occurred readily as assessed by (i) cell lysis of the lysogens, (ii) production of progeny phage, and (iii) extensive cleavage of lambda repressor.	Rifampin	136-146	RAD51 recombinase	Homo sapiens	77-81
477551-3	1979	During and after treatment with rifampicin optimal levels of prothrombin time were difficult or even impossible to achieve in two of the three patients.	Rifampin	32-42	coagulation factor II, thrombin	Homo sapiens	61-72
6244557-4	1980	EGF also induced a perturbation of chromatin structure in GH3 cell nuclei that was detected by an increase (40%) in the number of rifampicin-resistant initiation sites for bacterial RNA polymerase.	Rifampin	130-140	epidermal growth factor	Rattus norvegicus	0-3
924280-0	1977	Effect of rifampicin on tryptophanase induction in normal and rifampicin-resistant Vibrio el tor.	Rifampin	10-20	tryptophan 2,3-dioxygenase	Homo sapiens	24-37
657879-4	1978	From the beginning of combination therapy with synergistic-acting substances (rifampicin + isoprodian (INH + PTH + DDS) the logarithms of the number of bacteria in the homogenates decreased, both during treatment period and during treatment-free observation period (Figs.	Rifampin	78-88	parathyroid hormone	Homo sapiens	109-112
856862-0	1977	Protein binding of rifampicin to bovine serum albumin as measured by gel filtration.	Rifampin	19-29	albumin	Homo sapiens	40-53
322700-0	1977	Treatment of TRIC infection of the eye with rifampicin or chloramphenicol.	Rifampin	44-54	MARVEL domain containing 2	Homo sapiens	13-17
930514-3	1977	Rifampicin induced solely lun mutation.	Rifampin	0-10	TOP1 binding arginine/serine rich protein, E3 ubiquitin ligase	Homo sapiens	26-29
140033-4	1977	Rifampicin seems to be a potent inducer of drug metabolism in humans and it causes a proliferation of the smooth endoplasmatic reticulum and an increase of cytochrome P450 content in the liver.	Rifampin	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	156-171
33307820-0	2021	Tanshinone IIA may alleviate rifampin-induced cholestasis by regulating the expression and function of NTCP.	Rifampin	29-37	solute carrier family 10 member 1	Rattus norvegicus	103-107
1100115-1	1975	The influence of temperature and KCl concentration on the formation of rifampicin-resistant preinitiation complexes by holo RNA polymerase has been compared for T4 DNA and Azotobacter phage A21 DNA.	Rifampin	71-81	immunoglobulin kappa variable 2-26 (pseudogene)	Homo sapiens	190-193
1100115-7	1975	Both holo and core RNA polymerases are able to form complexes with A21 DNA that are resistant to attack by rifampicin.	Rifampin	107-117	immunoglobulin kappa variable 2-26 (pseudogene)	Homo sapiens	67-70
775309-0	1976	A bacterial RNA polymerase mutant that renders lambda growth independent of the N and cro functions at 42 degrees C. We describe a bacterial RNA polymerase mutation, rif 501, which confers rifampicin resistance and thermosensitivity to E. coli K 12.	Rifampin	189-199	cro	Escherichia virus Lambda	86-89
1233229-5	1975	The acceleration of oestrogen hydroxylation by rifampicin was paralleled by an increase in microsomal cytochrome P-450, and also by microsomal reduction of rifampicin-quinone, a reactive metabolite of rifampicin.	Rifampin	47-57	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-118
4584805-0	1973	Conjugal deoxyribonucleic acid replication by Excherichia coli K-12: effect of chloramphenicol and rifampin.	Rifampin	99-107	keratin 12	Homo sapiens	63-67
33405191-3	2021	METHOD: P-gp modulation in rats was performed by using P-gp inducer (150 mg/kg rifampicin) and P-gp inhibitor (10 mg/kg cyclosporine A) for 14 days prior to be infected with Helicobacter pylori (H. pylori).	Rifampin	79-89	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	8-12
33405191-10	2021	The use of rifampicin to induce P-gp level was also shown to be effective in eradicating the H. pylori infection.	Rifampin	11-21	ATP binding cassette subfamily B member 1	Homo sapiens	32-36
33629115-5	2021	Rifampicin (RIF), a first line anti-TB drug, is a human specific activator of pregnane X receptor (PXR).	Rifampin	0-10	nuclear receptor subfamily 1 group I member 2	Homo sapiens	78-97
33674270-2	2021	In the current study, the hepatocyte nuclear factor 4 alpha (HNF4A) antisense RNA 1 (HNF4A-AS1), an antisense lncRNA of HNF4A, was found to be a negative regulator of the basal and rifampicin (RIF)-induced expression of nuclear receptors and downstream CYPs.	Rifampin	181-191	hepatocyte nuclear factor 4 alpha	Homo sapiens	26-59
33674270-2	2021	In the current study, the hepatocyte nuclear factor 4 alpha (HNF4A) antisense RNA 1 (HNF4A-AS1), an antisense lncRNA of HNF4A, was found to be a negative regulator of the basal and rifampicin (RIF)-induced expression of nuclear receptors and downstream CYPs.	Rifampin	181-191	hepatocyte nuclear factor 4 alpha	Homo sapiens	61-66
33674270-2	2021	In the current study, the hepatocyte nuclear factor 4 alpha (HNF4A) antisense RNA 1 (HNF4A-AS1), an antisense lncRNA of HNF4A, was found to be a negative regulator of the basal and rifampicin (RIF)-induced expression of nuclear receptors and downstream CYPs.	Rifampin	181-191	HNF4A antisense RNA 1	Homo sapiens	85-94
33674270-2	2021	In the current study, the hepatocyte nuclear factor 4 alpha (HNF4A) antisense RNA 1 (HNF4A-AS1), an antisense lncRNA of HNF4A, was found to be a negative regulator of the basal and rifampicin (RIF)-induced expression of nuclear receptors and downstream CYPs.	Rifampin	181-191	hepatocyte nuclear factor 4 alpha	Homo sapiens	85-90
33749522-0	2021	Rifampicin ameliorates lipopolysaccharide-induced cognitive and motor impairments via inhibition of the TLR4/MyD88/NF-kappaB signaling pathway in mice.	Rifampin	0-10	toll-like receptor 4	Mus musculus	104-108
33749522-0	2021	Rifampicin ameliorates lipopolysaccharide-induced cognitive and motor impairments via inhibition of the TLR4/MyD88/NF-kappaB signaling pathway in mice.	Rifampin	0-10	myeloid differentiation primary response gene 88	Mus musculus	109-114
33749522-0	2021	Rifampicin ameliorates lipopolysaccharide-induced cognitive and motor impairments via inhibition of the TLR4/MyD88/NF-kappaB signaling pathway in mice.	Rifampin	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	115-124
33749522-9	2021	Rifampicin suppressed the release of pro-inflammatory mediators, including tumor necrosis factor-alpha, interleukin-1beta, and prostaglandin E2 in the serum and nitric oxide (NO) in brain tissue, and cyclooxygenase-2 and inducible nitric oxide synthase levels.	Rifampin	0-10	tumor necrosis factor	Mus musculus	75-102
33749522-9	2021	Rifampicin suppressed the release of pro-inflammatory mediators, including tumor necrosis factor-alpha, interleukin-1beta, and prostaglandin E2 in the serum and nitric oxide (NO) in brain tissue, and cyclooxygenase-2 and inducible nitric oxide synthase levels.	Rifampin	0-10	interleukin 1 beta	Mus musculus	104-121
33749522-9	2021	Rifampicin suppressed the release of pro-inflammatory mediators, including tumor necrosis factor-alpha, interleukin-1beta, and prostaglandin E2 in the serum and nitric oxide (NO) in brain tissue, and cyclooxygenase-2 and inducible nitric oxide synthase levels.	Rifampin	0-10	prostaglandin-endoperoxide synthase 2	Mus musculus	200-216
33749522-9	2021	Rifampicin suppressed the release of pro-inflammatory mediators, including tumor necrosis factor-alpha, interleukin-1beta, and prostaglandin E2 in the serum and nitric oxide (NO) in brain tissue, and cyclooxygenase-2 and inducible nitric oxide synthase levels.	Rifampin	0-10	nitric oxide synthase 2, inducible	Mus musculus	221-252
34035488-6	2022	In addition, inconsistencies were observed between the protein expression and enzyme activities of CYP3A4 in cells induced by rifampin but not in groups treated with furmonertinib.	Rifampin	126-134	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	99-105
34035488-9	2022	The fold change in the CYP3A4 enzyme activity in the cells treated with rifampin was 5.22 +- 1.13, which was similar to that of 0.5 microM furmonertinib (3.79 +- 0.52).	Rifampin	72-80	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	23-29
33970450-7	2021	RESULTS: Based on the findings, Rifampicin and Letermovir appeared as the most promising drug showing a very good binding affinity with the main protease of SARS-CoV-2 and TNF-alpha, IL-6, and IL-1beta.	Rifampin	32-42	tumor necrosis factor	Homo sapiens	172-181
33970450-7	2021	RESULTS: Based on the findings, Rifampicin and Letermovir appeared as the most promising drug showing a very good binding affinity with the main protease of SARS-CoV-2 and TNF-alpha, IL-6, and IL-1beta.	Rifampin	32-42	interleukin 6	Homo sapiens	183-187
33970450-7	2021	RESULTS: Based on the findings, Rifampicin and Letermovir appeared as the most promising drug showing a very good binding affinity with the main protease of SARS-CoV-2 and TNF-alpha, IL-6, and IL-1beta.	Rifampin	32-42	interleukin 1 alpha	Homo sapiens	193-201
33963620-2	2021	Isavuconazole is metabolized by CYP3A4 and CYP3A5 and it has been shown that the CYP3A inducer rifampin reduces isavuconazole exposure.	Rifampin	95-103	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	32-38
33963620-2	2021	Isavuconazole is metabolized by CYP3A4 and CYP3A5 and it has been shown that the CYP3A inducer rifampin reduces isavuconazole exposure.	Rifampin	95-103	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	43-49
33963620-2	2021	Isavuconazole is metabolized by CYP3A4 and CYP3A5 and it has been shown that the CYP3A inducer rifampin reduces isavuconazole exposure.	Rifampin	95-103	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	32-37
33749522-11	2021	Rifampicin inhibited the activation of the toll-like receptor 4 (TLR4)/myeloid differentiation primary response 88 (MyD88)/nuclear factor kappa B (NF-kappaB) signaling pathway.	Rifampin	0-10	toll-like receptor 4	Mus musculus	43-63
33749522-11	2021	Rifampicin inhibited the activation of the toll-like receptor 4 (TLR4)/myeloid differentiation primary response 88 (MyD88)/nuclear factor kappa B (NF-kappaB) signaling pathway.	Rifampin	0-10	toll-like receptor 4	Mus musculus	65-69
33749522-11	2021	Rifampicin inhibited the activation of the toll-like receptor 4 (TLR4)/myeloid differentiation primary response 88 (MyD88)/nuclear factor kappa B (NF-kappaB) signaling pathway.	Rifampin	0-10	myeloid differentiation primary response gene 88	Mus musculus	116-121
33749522-11	2021	Rifampicin inhibited the activation of the toll-like receptor 4 (TLR4)/myeloid differentiation primary response 88 (MyD88)/nuclear factor kappa B (NF-kappaB) signaling pathway.	Rifampin	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	147-156
33749522-12	2021	Rifampicin downregulated TLR4 and MyD88 protein levels and inhibited NF-kappaB inhibitor alpha and NF-kappaB inhibitor kinase beta phosphorylation, thus reducing p65 nuclear transfer by inhibiting NF-kappaB signaling activation in LPS-treated mice.	Rifampin	0-10	toll-like receptor 4	Mus musculus	25-29
33749522-12	2021	Rifampicin downregulated TLR4 and MyD88 protein levels and inhibited NF-kappaB inhibitor alpha and NF-kappaB inhibitor kinase beta phosphorylation, thus reducing p65 nuclear transfer by inhibiting NF-kappaB signaling activation in LPS-treated mice.	Rifampin	0-10	myeloid differentiation primary response gene 88	Mus musculus	34-39
33749522-12	2021	Rifampicin downregulated TLR4 and MyD88 protein levels and inhibited NF-kappaB inhibitor alpha and NF-kappaB inhibitor kinase beta phosphorylation, thus reducing p65 nuclear transfer by inhibiting NF-kappaB signaling activation in LPS-treated mice.	Rifampin	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	69-94
33749522-12	2021	Rifampicin downregulated TLR4 and MyD88 protein levels and inhibited NF-kappaB inhibitor alpha and NF-kappaB inhibitor kinase beta phosphorylation, thus reducing p65 nuclear transfer by inhibiting NF-kappaB signaling activation in LPS-treated mice.	Rifampin	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	69-78
33749522-12	2021	Rifampicin downregulated TLR4 and MyD88 protein levels and inhibited NF-kappaB inhibitor alpha and NF-kappaB inhibitor kinase beta phosphorylation, thus reducing p65 nuclear transfer by inhibiting NF-kappaB signaling activation in LPS-treated mice.	Rifampin	0-10	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	162-165
33749522-12	2021	Rifampicin downregulated TLR4 and MyD88 protein levels and inhibited NF-kappaB inhibitor alpha and NF-kappaB inhibitor kinase beta phosphorylation, thus reducing p65 nuclear transfer by inhibiting NF-kappaB signaling activation in LPS-treated mice.	Rifampin	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	99-108
33749522-13	2021	CONCLUSION: Rifampicin protects against LPS-induced neuroinflammation and attenuates cognitive and motor impairments by inhibiting the TLR4/MyD88/NF-kappaB signaling pathway.	Rifampin	12-22	toll-like receptor 4	Mus musculus	135-139
33749522-13	2021	CONCLUSION: Rifampicin protects against LPS-induced neuroinflammation and attenuates cognitive and motor impairments by inhibiting the TLR4/MyD88/NF-kappaB signaling pathway.	Rifampin	12-22	myeloid differentiation primary response gene 88	Mus musculus	140-145
33749522-13	2021	CONCLUSION: Rifampicin protects against LPS-induced neuroinflammation and attenuates cognitive and motor impairments by inhibiting the TLR4/MyD88/NF-kappaB signaling pathway.	Rifampin	12-22	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	146-155
33629115-5	2021	Rifampicin (RIF), a first line anti-TB drug, is a human specific activator of pregnane X receptor (PXR).	Rifampin	0-10	nuclear receptor subfamily 1 group I member 2	Homo sapiens	99-102
33629115-5	2021	Rifampicin (RIF), a first line anti-TB drug, is a human specific activator of pregnane X receptor (PXR).	Rifampin	12-15	nuclear receptor subfamily 1 group I member 2	Homo sapiens	78-97
33629115-5	2021	Rifampicin (RIF), a first line anti-TB drug, is a human specific activator of pregnane X receptor (PXR).	Rifampin	12-15	nuclear receptor subfamily 1 group I member 2	Homo sapiens	99-102
33880760-1	2021	The objective of this study was to determine the effects of the OATP inhibitor rifampin on pharmacokinetic of Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1 compound fluvastatin.	Rifampin	79-87	solute carrier organic anion transporter family member 1A2	Homo sapiens	64-68
33907428-2	2021	We presented a case of a household contact of rifampicin-resistant TB revealing reactive IFN-gamma release assay with unsuspicious clinical and radiologic examinations.	Rifampin	46-56	interferon gamma	Homo sapiens	89-98
33759451-7	2021	Subsequently, the model was used to explore UGT1A1-related DDI risk with atazanavir and rifampicin along with the effect of enzyme genotype on raltegravir apparent clearance.	Rifampin	88-98	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	44-50
33937284-13	2021	Cirrhotic patients displayed higher concentrations of MOR agonist Leu-enkephalin and KOR agonist dynorphin A. Endogenous opioid levels remained largely unchanged after successful treatment with the potent anti-pruritic drugs rifampicin and bezafibrate.	Rifampin	225-235	opioid receptor mu 1	Homo sapiens	54-57
33851518-5	2022	Rifampicin treatment increased ALP activity and mRNA level of bone biomarker genes (ALP, MGP, OPN, and OPG).	Rifampin	0-10	secreted phosphoprotein 1	Homo sapiens	94-97
33851518-5	2022	Rifampicin treatment increased ALP activity and mRNA level of bone biomarker genes (ALP, MGP, OPN, and OPG).	Rifampin	0-10	basic transcription factor 3 pseudogene 11	Homo sapiens	103-106
33851518-9	2022	In conclusion, rifampicin treatment induces the bone form of ALP in the serum of healthy human volunteers.	Rifampin	15-25	alkaline phosphatase, placental	Homo sapiens	61-64
33863817-10	2021	Interestingly, with rifampin, in vivo CYP3A activity was approximately 4-fold higher than in vitro activity.	Rifampin	20-28	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	38-43
33851518-0	2022	Rifampicin induces the bone form of alkaline phosphatase in humans.	Rifampin	0-10	alkaline phosphatase, placental	Homo sapiens	36-56
33851518-2	2022	In our clinical trials on healthy volunteers to discover novel metabolic functions of PXR activation, we observed that rifampicin, a well-established ligand for human PXR, 600 mg daily for a week, increased the plasma alkaline phosphatase (ALP) significantly compared with the placebo.	Rifampin	119-129	nuclear receptor subfamily 1 group I member 2	Homo sapiens	86-89
33851518-2	2022	In our clinical trials on healthy volunteers to discover novel metabolic functions of PXR activation, we observed that rifampicin, a well-established ligand for human PXR, 600 mg daily for a week, increased the plasma alkaline phosphatase (ALP) significantly compared with the placebo.	Rifampin	119-129	nuclear receptor subfamily 1 group I member 2	Homo sapiens	167-170
33851518-2	2022	In our clinical trials on healthy volunteers to discover novel metabolic functions of PXR activation, we observed that rifampicin, a well-established ligand for human PXR, 600 mg daily for a week, increased the plasma alkaline phosphatase (ALP) significantly compared with the placebo.	Rifampin	119-129	alkaline phosphatase, placental	Homo sapiens	218-238
33851518-2	2022	In our clinical trials on healthy volunteers to discover novel metabolic functions of PXR activation, we observed that rifampicin, a well-established ligand for human PXR, 600 mg daily for a week, increased the plasma alkaline phosphatase (ALP) significantly compared with the placebo.	Rifampin	119-129	alkaline phosphatase, placental	Homo sapiens	240-243
33851518-5	2022	Rifampicin treatment increased ALP activity and mRNA level of bone biomarker genes (ALP, MGP, OPN, and OPG).	Rifampin	0-10	alkaline phosphatase, placental	Homo sapiens	31-34
33851518-5	2022	Rifampicin treatment increased ALP activity and mRNA level of bone biomarker genes (ALP, MGP, OPN, and OPG).	Rifampin	0-10	alkaline phosphatase, placental	Homo sapiens	84-87
33851518-5	2022	Rifampicin treatment increased ALP activity and mRNA level of bone biomarker genes (ALP, MGP, OPN, and OPG).	Rifampin	0-10	matrix Gla protein	Homo sapiens	89-92
33759451-8	2021	Simulations of pregnancy-related induction of UGT1A1 either exacerbated UGT1A1 induction by rifampicin or negated atazanavir UGT1A1 inhibition.	Rifampin	92-102	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	46-52
33759451-8	2021	Simulations of pregnancy-related induction of UGT1A1 either exacerbated UGT1A1 induction by rifampicin or negated atazanavir UGT1A1 inhibition.	Rifampin	92-102	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	72-78
33759451-8	2021	Simulations of pregnancy-related induction of UGT1A1 either exacerbated UGT1A1 induction by rifampicin or negated atazanavir UGT1A1 inhibition.	Rifampin	92-102	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	72-78
33790071-0	2021	Real-World Performance Assessment of Xpert MTB/RIF Assay for Detecting Pulmonary Tuberculosis and Rifampin Resistance in a Single Tertiary Care Hospital in Korea.	Rifampin	98-106	ras homolog family member F, filopodia associated	Homo sapiens	47-50
33446525-10	2021	Similar tendencies were observed in the other 4 substrates of AADAC; that is, p-nitrophenyl acetate, ketoconazole, phenacetin, and rifampicin.	Rifampin	131-141	arylacetamide deacetylase	Homo sapiens	62-67
33412187-0	2021	Rifampicin impairs adipogenesis by suppressing NRF2-ARE activity in mice fed a high-fat diet.	Rifampin	0-10	nuclear factor, erythroid derived 2, like 2	Mus musculus	47-51
33263786-6	2021	Furthermore, we showed that CYP1A1 and CYP1B1 were induced by beta-naphtoflavone in all three models, whereas CYP3A4 was induced by phenobarbital and rifampicin in HIOs, in the IEC-based model (although not statistically significant), but not in Caco-2 cells.	Rifampin	150-160	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	110-116
33355210-9	2021	Physiologically based pharmacokinetic (PBPK) models built upon two independent bottom-up approaches predicted elevation of E7766 plasma exposure when administered with Rifampicin, a clinical OATP inhibitor.	Rifampin	168-178	solute carrier organic anion transporter family member 1A2	Homo sapiens	191-195
33355212-7	2021	Rifampin induced CYP3A4; estimated EC50 and Emax were 3.75 microM and 8.96-fold, respectively for ileal organoids, and 1.40 microM and 11.3-fold, respectively, for colon organoids.	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	17-23
33355212-8	2021	Ileal, but not colon organoids exhibited nifedipine oxidase activity, which was induced by rifampin up to 14-fold.	Rifampin	91-99	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	41-59
33483427-7	2021	Impaired co-activator recruitment by nelfinavir, as compared to the full agonist rifampin, proved to be the underlying mechanism of both effects on PXR.	Rifampin	81-89	nuclear receptor subfamily 1 group I member 2	Homo sapiens	148-151
33483427-8	2021	Physiological relevance of nelfinavir-dependent modulation of PXR activity was investigated in respectively treated primary human hepatocytes, which showed differential induction of PXR target genes and antagonism of rifampin-induced ABCB1 and CYP3A4 gene expression.	Rifampin	217-225	nuclear receptor subfamily 1 group I member 2	Homo sapiens	62-65
33483427-8	2021	Physiological relevance of nelfinavir-dependent modulation of PXR activity was investigated in respectively treated primary human hepatocytes, which showed differential induction of PXR target genes and antagonism of rifampin-induced ABCB1 and CYP3A4 gene expression.	Rifampin	217-225	ATP binding cassette subfamily B member 1	Homo sapiens	234-239
33483427-8	2021	Physiological relevance of nelfinavir-dependent modulation of PXR activity was investigated in respectively treated primary human hepatocytes, which showed differential induction of PXR target genes and antagonism of rifampin-induced ABCB1 and CYP3A4 gene expression.	Rifampin	217-225	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	244-250
33616229-1	2021	BACKGROUND: Xpert MTB/RIF and Xpert MTB/RIF Ultra (Xpert Ultra) are World Health Organization (WHO)-recommended rapid tests that simultaneously detect tuberculosis and rifampicin resistance in people with signs and symptoms of tuberculosis.	Rifampin	168-178	ras homolog family member F, filopodia associated	Homo sapiens	40-43
33616229-30	2021	Rifampicin resistance detection Pooled sensitivity and specificity were 94.9% (88.9 to 97.9) and 99.1% (97.7 to 99.8) (5 studies, 921 participants; high-certainty evidence) for Xpert Ultra versus 95.3% (90.0 to 98.1) and 98.8% (97.2 to 99.6) (5 studies, 930 participants; high-certainty evidence) for Xpert MTB/RIF.	Rifampin	0-10	ras homolog family member F, filopodia associated	Homo sapiens	311-314
33547469-4	2021	As absorption of temsavir is not altered with increased gastric pH, patients may take acid suppressive agents such as famotidine during fostemsavir therapy.Temsavir is primarily metabolized through hydrolysis but also via cytochrome P-450 (CYP) oxidation; therefore, coadministration of fostemsavir with strong CYP3A inducers such as rifampin, carbamazepine, phenytoin, mitotane, enzalutamide, or St John"s wort is contraindicated because it may result in significantly lower temsavir exposure, which can ultimately impair virologic response.	Rifampin	334-342	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	222-238
33688304-0	2021	Antituberculosis Drugs (Rifampicin and Isoniazid) Induce Liver Injury by Regulating NLRP3 Inflammasomes.	Rifampin	24-34	NLR family, pyrin domain containing 3	Rattus norvegicus	84-89
33616229-33	2021	The number of people wrongly diagnosed with rifampicin resistance would be 8 with Xpert Ultra and 11 with Xpert MTB/RIF.	Rifampin	44-54	ras homolog family member F, filopodia associated	Homo sapiens	116-119
33617360-0	2021	Quercetin Modulates Nrf2 and NF-kappaB/TLR-4 Pathways to Protect against Isoniazid and Rifampicin Induced Hepatotoxicity in vivo.	Rifampin	87-97	toll-like receptor 4	Rattus norvegicus	39-44
33672438-5	2021	In addition, the modulation of CYP3A was reflected in the 1beta-OH-DCA/DCA UMR after the intake of rifampicin (induction ratio = 11.4, p < 0.01).	Rifampin	99-109	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-36
32705692-2	2021	We assessed the impact of RI and single dose oral rifampin (RIF) on the pharmacokinetics of CYP3A, OATP1B, P-gp, and BCRP substrates using a microdose cocktail and OATP1B endogenous biomarkers.	Rifampin	50-58	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	92-97
33583375-0	2021	Quality by Design Approach for Development and Optimization of Rifampicin Loaded Bovine Serum Albumin Nanoparticles and Characterization.	Rifampin	63-73	albumin	Mus musculus	88-101
33583375-1	2021	AIM: This study is focused on preparing rifampicin loaded bovine serum albumin nanoparticles (RIF BSA NPs) suitable for intravenous application using systematic quality by design (QbD) approach.	Rifampin	40-50	albumin	Mus musculus	65-78
33583375-5	2021	OBJECTIVES: The main objective of this study is optimizing particle size and entrapment efficiency of rifampicin loaded bovine serum albumin nanoparticles (RIF BSA NPs) and making it suitable for intravenous application using QbD approach.	Rifampin	102-112	albumin	Mus musculus	127-140
33538008-3	2021	We aimed to investigate relationship between genetic polymorphism of SLCO1B1 and rifampin exposure and its impact on clinical outcomes in Korean patients with active pulmonary TB.	Rifampin	81-89	solute carrier organic anion transporter family member 1B1	Homo sapiens	69-76
32705692-2	2021	We assessed the impact of RI and single dose oral rifampin (RIF) on the pharmacokinetics of CYP3A, OATP1B, P-gp, and BCRP substrates using a microdose cocktail and OATP1B endogenous biomarkers.	Rifampin	50-58	phosphoglycolate phosphatase	Homo sapiens	107-111
32705692-2	2021	We assessed the impact of RI and single dose oral rifampin (RIF) on the pharmacokinetics of CYP3A, OATP1B, P-gp, and BCRP substrates using a microdose cocktail and OATP1B endogenous biomarkers.	Rifampin	50-58	BCR pseudogene 1	Homo sapiens	117-121
32705692-2	2021	We assessed the impact of RI and single dose oral rifampin (RIF) on the pharmacokinetics of CYP3A, OATP1B, P-gp, and BCRP substrates using a microdose cocktail and OATP1B endogenous biomarkers.	Rifampin	60-63	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	92-97
32705692-2	2021	We assessed the impact of RI and single dose oral rifampin (RIF) on the pharmacokinetics of CYP3A, OATP1B, P-gp, and BCRP substrates using a microdose cocktail and OATP1B endogenous biomarkers.	Rifampin	60-63	phosphoglycolate phosphatase	Homo sapiens	107-111
32705692-2	2021	We assessed the impact of RI and single dose oral rifampin (RIF) on the pharmacokinetics of CYP3A, OATP1B, P-gp, and BCRP substrates using a microdose cocktail and OATP1B endogenous biomarkers.	Rifampin	60-63	BCR pseudogene 1	Homo sapiens	117-121
33130504-1	2021	The Xpert MTB/RIF assay is a molecular assay that has improved the detection of tuberculosis and rifampicin resistance.	Rifampin	97-107	ras homolog family member F, filopodia associated	Homo sapiens	14-17
33509114-1	2021	BACKGROUND: Xpert MTB/RIF (Xpert) has been recommended by WHO as the initial diagnostic test for TB and rifampicin-resistance detection.	Rifampin	104-114	ras homolog family member F, filopodia associated	Homo sapiens	22-25
32759993-0	2021	New paradigms of USP53 disease: normal GGT cholestasis, BRIC, cholangiopathy, and responsiveness to rifampicin.	Rifampin	100-110	ubiquitin specific peptidase 53	Homo sapiens	17-22
33155329-2	2021	Since rifampicin is a hepatic enzyme (CYP3A4) inducer, in a post-renal transplant recipient, the dose of calcineurin inhibitors needs to be up-regulated and frequently monitored.	Rifampin	6-16	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	38-44
33506323-4	2021	The aim of this study was to investigate the effects of rifampicin (a strong CYP3A4 inducer) on the pharmacokinetics of alflutinib and AST5902 in healthy volunteers, thus providing important information for drug-drug interaction evaluation and guiding clinical usage.	Rifampin	56-66	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	77-83
33506323-11	2021	Conclusions As a strong CYP3A4 inducer, rifampicin exerted significant effects on the pharmacokinetics of alflutinib and the total active ingredients (alflutinib and AST5902).	Rifampin	40-50	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	24-30
33542643-2	2021	Due to rifampin"s strong induction of CYP2C9, most cases could not attain the target international normalized ratio (INR) despite warfarin dose escalation.	Rifampin	7-15	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	38-44
33614819-0	2021	Low Cycle Threshold Value in Xpert MTB/RIF Assay May Herald False Detection of Tuberculosis and Rifampicin Resistance: A Study of Two Cases.	Rifampin	96-106	ras homolog family member F, filopodia associated	Homo sapiens	39-42
33614819-1	2021	We report 2 cases for whom Xpert MTB/RIF falsely signaled rifampicin-resistant tuberculosis, based on unusually low cycle threshold and 3 of 5 probes missing.	Rifampin	58-68	ras homolog family member F, filopodia associated	Homo sapiens	37-40
32460379-3	2021	Current data indicate that intestinal P-gp protein levels can be induced <=3-4 fold in humans primarily with pregnane X receptor (PXR) activators, and that this induction can decrease the systemic exposure of drugs with P-gp efflux-limited absorption (e.g., <=67% decrease in the exposure of total dabigatran following rifampin multiple oral dosing).	Rifampin	319-327	ATP binding cassette subfamily B member 1	Homo sapiens	38-42
33448348-37	2021	Xpert Ultra and Xpert MTB/RIF had similar sensitivity and specificity for rifampicin resistance.	Rifampin	74-84	ras homolog family member F, filopodia associated	Homo sapiens	26-29
33443639-1	2021	Diagnostic yield of an automated molecular test, Gene Xpert Mycobacterium tuberculosis/rifampicin (MTB/RIF), was evaluated in this study to simultaneously detect the MTB gene and resistance to rifampicin (RIF) on cytology samples acquired via endoscopic ultrasound (EUS)-guided fine-needle aspiration (FNAC) in suspected tubercular lymphadenitis.	Rifampin	87-97	metallothionein 1J, pseudogene	Homo sapiens	99-102
33443639-1	2021	Diagnostic yield of an automated molecular test, Gene Xpert Mycobacterium tuberculosis/rifampicin (MTB/RIF), was evaluated in this study to simultaneously detect the MTB gene and resistance to rifampicin (RIF) on cytology samples acquired via endoscopic ultrasound (EUS)-guided fine-needle aspiration (FNAC) in suspected tubercular lymphadenitis.	Rifampin	87-97	metallothionein 1J, pseudogene	Homo sapiens	166-169
33443639-1	2021	Diagnostic yield of an automated molecular test, Gene Xpert Mycobacterium tuberculosis/rifampicin (MTB/RIF), was evaluated in this study to simultaneously detect the MTB gene and resistance to rifampicin (RIF) on cytology samples acquired via endoscopic ultrasound (EUS)-guided fine-needle aspiration (FNAC) in suspected tubercular lymphadenitis.	Rifampin	193-203	metallothionein 1J, pseudogene	Homo sapiens	99-102
32460379-3	2021	Current data indicate that intestinal P-gp protein levels can be induced <=3-4 fold in humans primarily with pregnane X receptor (PXR) activators, and that this induction can decrease the systemic exposure of drugs with P-gp efflux-limited absorption (e.g., <=67% decrease in the exposure of total dabigatran following rifampin multiple oral dosing).	Rifampin	319-327	ATP binding cassette subfamily B member 1	Homo sapiens	220-224
33305020-6	2020	The GeneXpert Mtuberculosis/RIF assay is a novel molecular diagnostic method for rapid diagnosis of tuberculosis and rifampicin resistance in clinical specimens.	Rifampin	117-127	ras homolog family member F, filopodia associated	Homo sapiens	28-31
32990533-10	2021	Rifampin is reported to perpetrate drug interactions by inducing CYP3A or inhibiting OATP1B; it is also reported to be a victim of drug interactions, due to the dual inhibition of CYP3A4 and OATP1B by indinavir.	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	65-70
32990533-10	2021	Rifampin is reported to perpetrate drug interactions by inducing CYP3A or inhibiting OATP1B; it is also reported to be a victim of drug interactions, due to the dual inhibition of CYP3A4 and OATP1B by indinavir.	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	180-186
32806986-5	2021	With the introduction of Xpert MTB/RIF and more recently Xpert Ultra, this has changed TB diagnostics by providing a rapid accessible platform to diagnose TB and identify rifampicin resistance within 2 hours.	Rifampin	171-181	ras homolog family member F, filopodia associated	Homo sapiens	35-38
33159914-6	2021	The doubly transfected MDCKII cells were also used to kinetically analyze the inhibitory effects of rifampicin on BSEP and NTCP.	Rifampin	100-110	ATP binding cassette subfamily B member 11	Homo sapiens	114-118
33139294-7	2020	CSF penetration of rifampicin was relatively poor and increased with increasing protein levels in CSF, a marker of CSF inflammation.	Rifampin	19-29	colony stimulating factor 2	Homo sapiens	0-3
33139294-7	2020	CSF penetration of rifampicin was relatively poor and increased with increasing protein levels in CSF, a marker of CSF inflammation.	Rifampin	19-29	colony stimulating factor 2	Homo sapiens	98-101
33322603-5	2020	Whole-mount in situ hybridization revealed cyp2y3, 2r1, and 3a65 transcripts in larvae at 55 hpf after exposure to rifampicin, phenobarbital, or 2,3,7,8-tetrachlorodibenzo-p-dioxin from 30 hpf onward.	Rifampin	115-125	cytochrome P450, family 2, subfamily Y, polypeptide 3	Danio rerio	43-49
33317678-0	2020	Systematic rifampicin resistance errors with Xpert  MTB/RIF Ultra: implications for regulation of genotypic assays.	Rifampin	11-21	ras homolog family member F, filopodia associated	Homo sapiens	56-59
33361721-8	2020	Xpert MTB/RIF was able to detect rifampicin resistance with a sensitivity and specificity of 87.5% and 98.9%, respectively.	Rifampin	33-43	ras homolog family member F, filopodia associated	Homo sapiens	10-13
33361721-13	2020	Xpert MTB/RIF can be employed in urban district health facilities not only to diagnose PTB in smear-positive patients, but also to detect rifampicin resistance with good sensitivity and specificity.	Rifampin	138-148	ras homolog family member F, filopodia associated	Homo sapiens	10-13
32415528-7	2020	The induction of neural cell death by duloxetine was not affected by classic cell death inhibitors but was promoted by the CYP inducer rifampicin.	Rifampin	135-145	cytochrome P450, family 21, subfamily a, polypeptide 1	Mus musculus	123-126
33127565-0	2021	Hepatocyte-derived MANF is protective for rifampicin-induced cholestatic hepatic injury via inhibiting ATF4-CHOP signal activation.	Rifampin	42-52	mesencephalic astrocyte-derived neurotrophic factor	Mus musculus	19-23
33127565-0	2021	Hepatocyte-derived MANF is protective for rifampicin-induced cholestatic hepatic injury via inhibiting ATF4-CHOP signal activation.	Rifampin	42-52	activating transcription factor 4	Mus musculus	103-107
33127565-0	2021	Hepatocyte-derived MANF is protective for rifampicin-induced cholestatic hepatic injury via inhibiting ATF4-CHOP signal activation.	Rifampin	42-52	DNA-damage inducible transcript 3	Mus musculus	108-112
33127565-2	2021	Here we found that mesencephalic astrocyte-derived neurotrophic factor (MANF), an endoplasmic reticulum (ER) stress inducible protein, is a protector in RFP-induced liver injury.	Rifampin	153-156	mesencephalic astrocyte-derived neurotrophic factor	Mus musculus	19-70
33127565-2	2021	Here we found that mesencephalic astrocyte-derived neurotrophic factor (MANF), an endoplasmic reticulum (ER) stress inducible protein, is a protector in RFP-induced liver injury.	Rifampin	153-156	mesencephalic astrocyte-derived neurotrophic factor	Mus musculus	72-76
33386800-4	2021	OBJECTIVE: Based on our previous findings that rifampicin possesses neuroprotective effects on improving cognitive function after neuroinflammation, we aimed to examine in this study whether rifampicin can inhibit Abeta accumulation by enhancing autophagy in a mouse model of lipopolysaccharide (LPS)-induced cognitive impairment.	Rifampin	191-201	amyloid beta (A4) precursor protein	Mus musculus	214-219
33386800-9	2021	Our results further demonstrated that rifampicin improved the neurological function by promoting autophagy through the inhibition of Akt/mTOR/p70S6K signaling pathway in the hippocampus of LPS-induced mice.	Rifampin	38-48	thymoma viral proto-oncogene 1	Mus musculus	133-136
33386800-9	2021	Our results further demonstrated that rifampicin improved the neurological function by promoting autophagy through the inhibition of Akt/mTOR/p70S6K signaling pathway in the hippocampus of LPS-induced mice.	Rifampin	38-48	mechanistic target of rapamycin kinase	Mus musculus	137-141
33386800-9	2021	Our results further demonstrated that rifampicin improved the neurological function by promoting autophagy through the inhibition of Akt/mTOR/p70S6K signaling pathway in the hippocampus of LPS-induced mice.	Rifampin	38-48	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	142-148
33386800-10	2021	CONCLUSION: Rifampicin ameliorates cognitive impairment by suppression of Abeta1-42 accumulation through inhibition of Akt/mTOR/p70S6K signaling and enhancement of autophagy in the hippocampus of LPS-induced mice.	Rifampin	12-22	thymoma viral proto-oncogene 1	Mus musculus	119-122
33386800-10	2021	CONCLUSION: Rifampicin ameliorates cognitive impairment by suppression of Abeta1-42 accumulation through inhibition of Akt/mTOR/p70S6K signaling and enhancement of autophagy in the hippocampus of LPS-induced mice.	Rifampin	12-22	mechanistic target of rapamycin kinase	Mus musculus	123-127
33386800-10	2021	CONCLUSION: Rifampicin ameliorates cognitive impairment by suppression of Abeta1-42 accumulation through inhibition of Akt/mTOR/p70S6K signaling and enhancement of autophagy in the hippocampus of LPS-induced mice.	Rifampin	12-22	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	128-134
33268331-6	2020	Importantly, both fresh and cryopreserved Definitive Endoderm and Hepatoblasts successfully differentiated to pure and functional hepatocytes with increased CYP3A4 activity in response to rifampicin and lipid accumulation upon fatty acid (FA) treatment.	Rifampin	188-198	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	157-163
33305020-16	2020	GeneXpert Mtuberculosis/RIF showed 2 cases of rifampicin resistance out of 67 cases.	Rifampin	46-56	ras homolog family member F, filopodia associated	Homo sapiens	24-27
32788213-2	2020	An anti-epileptic drug, phenobarbital (PB), activates CAR and its target CYP2B genes, while PXR is activated by drugs such as rifampicin and statins for the CYP3A genes.	Rifampin	126-136	nuclear receptor subfamily 1 group I member 2	Homo sapiens	92-95
32788213-2	2020	An anti-epileptic drug, phenobarbital (PB), activates CAR and its target CYP2B genes, while PXR is activated by drugs such as rifampicin and statins for the CYP3A genes.	Rifampin	126-136	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	157-162
33147218-0	2020	Frequency of MTB and rifampicin resistance MTB using Xpert-MTB/RIF assay among adult presumptive tuberculosis patients in Tigray, Northern Ethiopia: A cross sectional study.	Rifampin	21-31	metallothionein 1J, pseudogene	Homo sapiens	43-46
31665299-8	2020	Rifampicin CSF concentrations were described by a partition coefficient (5.5% [95%CI 4.4-6.4]) and half-life for distribution plasma to CSF (2.1 h [1.3-2.9]).	Rifampin	0-10	colony stimulating factor 2	Homo sapiens	11-14
31665299-8	2020	Rifampicin CSF concentrations were described by a partition coefficient (5.5% [95%CI 4.4-6.4]) and half-life for distribution plasma to CSF (2.1 h [1.3-2.9]).	Rifampin	0-10	colony stimulating factor 2	Homo sapiens	136-139
33147218-0	2020	Frequency of MTB and rifampicin resistance MTB using Xpert-MTB/RIF assay among adult presumptive tuberculosis patients in Tigray, Northern Ethiopia: A cross sectional study.	Rifampin	21-31	metallothionein 1J, pseudogene	Homo sapiens	43-46
33147218-2	2020	Data on rifampicin resistance MTB using Xpert- MTB/RIF assay in Ethiopia, particularly in the study area is limited.	Rifampin	8-18	metallothionein 1J, pseudogene	Homo sapiens	30-33
33147218-2	2020	Data on rifampicin resistance MTB using Xpert- MTB/RIF assay in Ethiopia, particularly in the study area is limited.	Rifampin	8-18	metallothionein 1J, pseudogene	Homo sapiens	47-50
33147218-3	2020	The aim of this study was to determine the frequency of MTB and rifampicin resistant-MTB among presumptive tuberculosis patients in Tigray, Northern Ethiopia.	Rifampin	64-74	metallothionein 1J, pseudogene	Homo sapiens	85-88
33147218-13	2020	Likewise, rifampicin resistant-MTB was more prevalent among relapse (p < 0.001) and failure cases (p = 0.025); while age group 30-39 years was significantly associated with lower frequency of rifampicin resistant-MTB (p = 0.008).	Rifampin	10-20	metallothionein 1J, pseudogene	Homo sapiens	31-34
33147218-13	2020	Likewise, rifampicin resistant-MTB was more prevalent among relapse (p < 0.001) and failure cases (p = 0.025); while age group 30-39 years was significantly associated with lower frequency of rifampicin resistant-MTB (p = 0.008).	Rifampin	10-20	metallothionein 1J, pseudogene	Homo sapiens	213-216
33147218-13	2020	Likewise, rifampicin resistant-MTB was more prevalent among relapse (p < 0.001) and failure cases (p = 0.025); while age group 30-39 years was significantly associated with lower frequency of rifampicin resistant-MTB (p = 0.008).	Rifampin	192-202	metallothionein 1J, pseudogene	Homo sapiens	31-34
33147218-13	2020	Likewise, rifampicin resistant-MTB was more prevalent among relapse (p < 0.001) and failure cases (p = 0.025); while age group 30-39 years was significantly associated with lower frequency of rifampicin resistant-MTB (p = 0.008).	Rifampin	192-202	metallothionein 1J, pseudogene	Homo sapiens	213-216
33147218-14	2020	CONCLUSION: Frequency of MTB among tuberculosis presumptive patients was low; however, the problem of rifampicin resistant-MTB among the tuberculosis confirmed patients was high.	Rifampin	102-112	metallothionein 1J, pseudogene	Homo sapiens	123-126
32779277-9	2020	While broadly inhibiting plastid transcription with rifampicin was also able to suppress cell death in fc2 mutants, specific reductions in plastid gene expression using other mutations was not always sufficient.	Rifampin	52-62	ferrochelatase 2	Arabidopsis thaliana	103-106
33030266-3	2020	Physiologically-based pharmacokinetic (PBPK) models for apixaban and rivaroxaban were developed to estimate the net effect of CYP3A induction, P-gp inhibition and P-gp induction by rifampicin.	Rifampin	181-191	ATP binding cassette subfamily B member 1	Homo sapiens	163-167
33187034-2	2020	Xpert MTB/ RIF assay is a fully automated cartridge-based real-time PCR to detect MTB and resistance to rifampicin within two hours using three specific primers and five unique molecular probes to target the rpoB gene.	Rifampin	104-114	ras homolog family member F, filopodia associated	Homo sapiens	11-14
32935287-7	2020	Rifampicin 600 mg/day resulted in ~ 90% reductions in both the Cmax (Day 10 GMR [90% CI], 0.14 [0.12-0.15]) and AUC (0.07 [0.06-0.07]) of balovaptan 10 mg/day.	Rifampin	0-10	colony stimulating factor 2 receptor subunit alpha	Homo sapiens	76-79
32978634-7	2020	Co-administration of the strong CYP3A4 inducer, rifampin, predicted a greater DDI effect on a single dose of ivosidenib than on multiple doses (AUC ratios 0.35 and 0.67, Cmax ratios 0.91 and 0.81, respectively).	Rifampin	48-56	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	32-38
32748370-9	2020	Significantly accelerated GR nuclear translocation was determined in EPI-ECs following treatment with GR modulators/ligands dexamethasone, rifampicin, or phenytoin.	Rifampin	139-149	nuclear receptor subfamily 3 group C member 1	Homo sapiens	26-28
32748370-9	2020	Significantly accelerated GR nuclear translocation was determined in EPI-ECs following treatment with GR modulators/ligands dexamethasone, rifampicin, or phenytoin.	Rifampin	139-149	nuclear receptor subfamily 3 group C member 1	Homo sapiens	102-104
33879905-1	2020	OBJECTIVE: To systematically review the diagnostic accuracy of Xpert  Mycobacterium tuberculosis/rifampicin (Xpert  MTB/RIF) for the detection of active tuberculosis (TB) and rifampicin-resistance TB in Chinese patients.	Rifampin	97-107	ras homolog family member F, filopodia associated	Homo sapiens	120-123
33879905-16	2020	CONCLUSION: Xpert  MTB/RIF has good sensitivity and specificity in detecting TB and rifampicin-resistant TB in Chinese people.	Rifampin	84-94	ras homolog family member F, filopodia associated	Homo sapiens	23-26
32320483-7	2020	Rifampicin requires solely PXR to induce CYP3A4 and CYP2B6, while phenobarbital-mediated induction of these CYPs did not show absolute dependency on either PXR or CAR suggesting its ability to switch nuclear receptor activation.	Rifampin	0-10	nuclear receptor subfamily 1 group I member 2	Homo sapiens	27-30
33060611-8	2020	HepaMN cells showed increased CYP3A4 expression after exposure to rifampicin, implying that their close resemblance to normal human hepatocytes makes them suitable for research applications including drug metabolism studies.	Rifampin	66-76	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	30-36
32235864-6	2020	Rifampin is a known strong CYP3A4 inducer and is recommended by the FDA as a positive control in the CYP3A4 induction assay.	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	27-33
32235864-6	2020	Rifampin is a known strong CYP3A4 inducer and is recommended by the FDA as a positive control in the CYP3A4 induction assay.	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	101-107
32250463-1	2020	AIMS: To investigate the effects of the strong cytochrome P450 (CYP) 3A inhibitor itraconazole and the strong CYP3A inducer rifampicin on the pharmacokinetics (PK) of single-dose esaxerenone, a non-steroidal mineralocorticoid receptor blocker, in healthy Japanese subjects.	Rifampin	124-134	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	110-115
32857315-11	2020	Rifampin reduced the AUC for CC112273 and CC1084037, primarily via CYP2C8 induction, by approximately 60% and 55%, respectively.	Rifampin	0-8	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	67-73
32344455-8	2020	In conclusion, rifampin stimulates renin activity and has a hypertensive effect.	Rifampin	15-23	renin	Homo sapiens	35-40
32320483-7	2020	Rifampicin requires solely PXR to induce CYP3A4 and CYP2B6, while phenobarbital-mediated induction of these CYPs did not show absolute dependency on either PXR or CAR suggesting its ability to switch nuclear receptor activation.	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	41-47
32320483-7	2020	Rifampicin requires solely PXR to induce CYP3A4 and CYP2B6, while phenobarbital-mediated induction of these CYPs did not show absolute dependency on either PXR or CAR suggesting its ability to switch nuclear receptor activation.	Rifampin	0-10	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	52-58
32344455-0	2020	Pregnane X receptor activator rifampin increases blood pressure and stimulates plasma renin activity.	Rifampin	30-38	nuclear receptor subfamily 1 group I member 2	Homo sapiens	0-19
32344455-0	2020	Pregnane X receptor activator rifampin increases blood pressure and stimulates plasma renin activity.	Rifampin	30-38	renin	Homo sapiens	86-91
32344455-1	2020	We conducted a clinical trial with 22 healthy volunteers to investigate the effects of pregnane X receptor (PXR) agonist rifampin on blood pressure (BP).	Rifampin	121-129	nuclear receptor subfamily 1 group I member 2	Homo sapiens	108-111
32719071-3	2020	This study investigated the in vivo effects of the common inducer rifampin (RIF) on the activity and expression of cynomolgus monkey OATP1B1 and OATP1B3 transporters, which are structurally and functionally similar their human OATP1B counterparts.	Rifampin	66-74	solute carrier organic anion transporter family member 1B1	Homo sapiens	133-140
32275771-0	2020	The effects of weak and strong CYP3A induction by rifampicin on the pharmacokinetics of five progestins and ethinylestradiol compared to midazolam.	Rifampin	50-60	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-36
32275771-3	2020	Rifampicin was used to induce CYP3A.	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	30-35
32719071-3	2020	This study investigated the in vivo effects of the common inducer rifampin (RIF) on the activity and expression of cynomolgus monkey OATP1B1 and OATP1B3 transporters, which are structurally and functionally similar their human OATP1B counterparts.	Rifampin	66-74	solute carrier organic anion transporter family member 1B3	Homo sapiens	145-152
32719071-3	2020	This study investigated the in vivo effects of the common inducer rifampin (RIF) on the activity and expression of cynomolgus monkey OATP1B1 and OATP1B3 transporters, which are structurally and functionally similar their human OATP1B counterparts.	Rifampin	76-79	solute carrier organic anion transporter family member 1B1	Homo sapiens	133-140
32719071-3	2020	This study investigated the in vivo effects of the common inducer rifampin (RIF) on the activity and expression of cynomolgus monkey OATP1B1 and OATP1B3 transporters, which are structurally and functionally similar their human OATP1B counterparts.	Rifampin	76-79	solute carrier organic anion transporter family member 1B3	Homo sapiens	145-152
32719071-9	2020	Rifampin treatment showed 2.0- to 3.3-fold increases in P-gp, BCRP, and MRP2 expression in the small intestine.	Rifampin	0-8	glycerol-3-phosphate phosphatase	Macaca fascicularis	56-60
32690641-0	2020	Rifampicin transport by OATP1B1 variants.	Rifampin	0-10	solute carrier organic anion transporter family member 1B1	Homo sapiens	24-31
32029904-6	2020	Using this system, we validated the association of hypermethylation of CYP2D6 and CYP2E1 with rifampin-induced DILI.	Rifampin	94-102	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	71-77
32029904-6	2020	Using this system, we validated the association of hypermethylation of CYP2D6 and CYP2E1 with rifampin-induced DILI.	Rifampin	94-102	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	82-88
32029904-7	2020	Our results revealed that, following treatment of HepaRG cells with rifampin, the methylation levels of CYP2D6 and CYP2E1 were inversely proportional to cell viability and glutathione content, and directly proportional to caspase 3/7 activity.	Rifampin	68-76	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	104-110
32029904-7	2020	Our results revealed that, following treatment of HepaRG cells with rifampin, the methylation levels of CYP2D6 and CYP2E1 were inversely proportional to cell viability and glutathione content, and directly proportional to caspase 3/7 activity.	Rifampin	68-76	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	115-121
32029904-7	2020	Our results revealed that, following treatment of HepaRG cells with rifampin, the methylation levels of CYP2D6 and CYP2E1 were inversely proportional to cell viability and glutathione content, and directly proportional to caspase 3/7 activity.	Rifampin	68-76	caspase 3	Homo sapiens	222-231
33061879-4	2020	Hepatotoxicity is the most commonly reported ADR in patients treated with anti-tubercular drugs such as isoniazid, rifampicin and pyrazinamide.	Rifampin	115-125	aldo-keto reductase family 1 member B	Homo sapiens	45-48
33117645-2	2020	Xpert MTB/RIF was positive after his second rifampicin-susceptible TB treatment.	Rifampin	44-54	ras homolog family member F, filopodia associated	Homo sapiens	10-13
32690641-1	2020	Single nucleotide polymorphisms in the OATP1B1 transporter have been suggested to partially explain the large interindividual variation in rifampicin exposure.	Rifampin	139-149	solute carrier organic anion transporter family member 1B1	Homo sapiens	39-46
32100958-4	2020	SLCO1B1 rs4149056 was associated with reduction in rifampin exposure, which has implications for dosing this important anti-tuberculosis therapy.	Rifampin	51-59	solute carrier organic anion transporter family member 1B1	Homo sapiens	0-7
33041817-8	2020	Activation of PXR and CAR in cells treated with 6-(4-chlorophenyl)-imidazo (2,1-b) thiazole-5-carbaldehyde (CITCO) and rifampicin (Rif) resulted in the enhancement of CYP450 isoforms, UGT1A1, PXR, and CAR.	Rifampin	119-129	nuclear receptor subfamily 1 group I member 2	Homo sapiens	14-17
33041817-8	2020	Activation of PXR and CAR in cells treated with 6-(4-chlorophenyl)-imidazo (2,1-b) thiazole-5-carbaldehyde (CITCO) and rifampicin (Rif) resulted in the enhancement of CYP450 isoforms, UGT1A1, PXR, and CAR.	Rifampin	119-129	nuclear receptor subfamily 1 group I member 3	Homo sapiens	22-25
33041817-8	2020	Activation of PXR and CAR in cells treated with 6-(4-chlorophenyl)-imidazo (2,1-b) thiazole-5-carbaldehyde (CITCO) and rifampicin (Rif) resulted in the enhancement of CYP450 isoforms, UGT1A1, PXR, and CAR.	Rifampin	131-134	nuclear receptor subfamily 1 group I member 2	Homo sapiens	14-17
33041817-8	2020	Activation of PXR and CAR in cells treated with 6-(4-chlorophenyl)-imidazo (2,1-b) thiazole-5-carbaldehyde (CITCO) and rifampicin (Rif) resulted in the enhancement of CYP450 isoforms, UGT1A1, PXR, and CAR.	Rifampin	131-134	nuclear receptor subfamily 1 group I member 3	Homo sapiens	22-25
32936818-0	2020	Post-exposure prophylaxis (PEP) efficacy of rifampin, rifapentine, moxifloxacin, minocycline, and clarithromycin in a susceptible-subclinical model of leprosy.	Rifampin	44-52	prolyl endopeptidase	Mus musculus	27-30
32557601-3	2020	Ritonavir (a strong CYP3A inhibitor) increased ribociclib 400 mg single-dose AUC by 3.2-fold, whereas rifampin (a strong CYP3A inducer) decreased ribociclib AUC by 89% in healthy volunteers (HV).	Rifampin	102-110	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	121-126
32166864-0	2020	Effect of rifampin-mediated OATP1B1 and OATP1B3 transporter inhibition on the pharmacokinetics of the P2Y12 receptor antagonist selatogrel.	Rifampin	10-18	solute carrier organic anion transporter family member 1B1	Homo sapiens	28-35
32166864-0	2020	Effect of rifampin-mediated OATP1B1 and OATP1B3 transporter inhibition on the pharmacokinetics of the P2Y12 receptor antagonist selatogrel.	Rifampin	10-18	purinergic receptor P2Y12	Homo sapiens	102-107
32166864-3	2020	Therefore, the study aim was to investigate the effect of rifampin-mediated OATP1B1 and OATP1B3 inhibition on the pharmacokinetics (PK) of selatogrel.	Rifampin	58-66	solute carrier organic anion transporter family member 1B1	Homo sapiens	76-83
32824985-8	2020	Previously, mutation of the intracellular domain of TLR2 has demonstrated its role in determining the susceptibility to LL, though LL was successfully treated using a combination of DDS with rifampicin and clofazimine.	Rifampin	191-201	toll like receptor 2	Homo sapiens	52-56
32387752-3	2020	Rifampicin and isoniazid co-therapy targets porphyrin biosynthesis via PXR and results in hepatic protoporphyrin IX accumulation and subsequent liver injury.	Rifampin	0-10	nuclear receptor subfamily 1 group I member 2	Homo sapiens	71-74
31900032-3	2020	Values for the effective permeability and the intrinsic clearance of hepatic uptake by organic anion transporting polypeptide (OATP) 1B1 were optimized in a simulator platform.This PBPK model was subsequently validated using reported maximum pemafibrate plasma concentration and area under the curve values in reported interaction studies in healthy subjects co-administered with rifampicin.For subjects with Child-Pugh A and B liver cirrhosis, the intrinsic clearance of hepatic uptake of pemafibrate by OATP1B1 were modeled using 53% and 31% of that of healthy subjects, respectively.	Rifampin	380-390	solute carrier organic anion transporter family member 1B1	Homo sapiens	87-136
32387752-2	2020	Pregnane X receptor (PXR, encoded by the NR1I2 gene) is a ligand-dependent transcription factor, and rifampicin is a human PXR-specific activator.	Rifampin	101-111	nuclear receptor subfamily 1 group I member 2	Homo sapiens	123-126
32918434-6	2020	We postulate that rifampicin has attenuated the therapeutic effect of amlodipine via potent induction of hepatic CYP3A4 but the failure to control the blood pressure even with medications unrelated to cytochrome P450 pathways raises the spectre of an additional interaction.	Rifampin	18-28	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	113-119
32853411-25	2020	Xpert MTB/RIF was accurate for detection of rifampicin resistance.	Rifampin	44-54	ras homolog family member F, filopodia associated	Homo sapiens	10-13
32750059-2	2020	Following a recent WHO guideline, the Indian National Leprosy Programme is introducing post-exposure prophylaxis with single-dose rifampicin (SDR-PEP) in all high-endemic districts of the country.	Rifampin	130-140	caveolae associated protein 2	Homo sapiens	142-145
32750059-2	2020	Following a recent WHO guideline, the Indian National Leprosy Programme is introducing post-exposure prophylaxis with single-dose rifampicin (SDR-PEP) in all high-endemic districts of the country.	Rifampin	130-140	progestagen associated endometrial protein	Homo sapiens	146-149
32492461-6	2020	These data suggested that rifampin increases TG and TC levels in the liver may be related to activate HMGCR, CYP7A1, PXR and FXR, theses toxic actions of rifampin were alleviated by pyrazinamide may be due to inhibite the activity of CYP7A1, PXR and FAS, and increasing the LPL protein expression and activity.	Rifampin	26-34	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	102-107
32492461-6	2020	These data suggested that rifampin increases TG and TC levels in the liver may be related to activate HMGCR, CYP7A1, PXR and FXR, theses toxic actions of rifampin were alleviated by pyrazinamide may be due to inhibite the activity of CYP7A1, PXR and FAS, and increasing the LPL protein expression and activity.	Rifampin	26-34	cytochrome P450, family 7, subfamily a, polypeptide 1	Mus musculus	109-115
32492461-0	2020	Pyrazinamide alleviates rifampin-induced steatohepatitis in mice by regulating the activities of cholesterol-activated 7alpha-hydroxylase and lipoprotein lipase.	Rifampin	24-32	lipoprotein lipase	Mus musculus	142-160
32492461-3	2020	The results showed that rifampin significantly increased transaminases, TBIL and TBA levels in serum, increased TG, TC content, HMGCR and CYP7A1 protein, CYP7A1, FGFR4, PXR, FAS and FXR mRNA expression, but decreased the level of SREBP-1c mRNA and induced severe steatohepatitis and hepatocyte necrosis in liver in mice.	Rifampin	24-32	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	128-133
32492461-6	2020	These data suggested that rifampin increases TG and TC levels in the liver may be related to activate HMGCR, CYP7A1, PXR and FXR, theses toxic actions of rifampin were alleviated by pyrazinamide may be due to inhibite the activity of CYP7A1, PXR and FAS, and increasing the LPL protein expression and activity.	Rifampin	26-34	nuclear receptor subfamily 1, group I, member 2	Mus musculus	117-120
32492461-3	2020	The results showed that rifampin significantly increased transaminases, TBIL and TBA levels in serum, increased TG, TC content, HMGCR and CYP7A1 protein, CYP7A1, FGFR4, PXR, FAS and FXR mRNA expression, but decreased the level of SREBP-1c mRNA and induced severe steatohepatitis and hepatocyte necrosis in liver in mice.	Rifampin	24-32	cytochrome P450, family 7, subfamily a, polypeptide 1	Mus musculus	138-144
32492461-3	2020	The results showed that rifampin significantly increased transaminases, TBIL and TBA levels in serum, increased TG, TC content, HMGCR and CYP7A1 protein, CYP7A1, FGFR4, PXR, FAS and FXR mRNA expression, but decreased the level of SREBP-1c mRNA and induced severe steatohepatitis and hepatocyte necrosis in liver in mice.	Rifampin	24-32	cytochrome P450, family 7, subfamily a, polypeptide 1	Mus musculus	154-160
32492461-6	2020	These data suggested that rifampin increases TG and TC levels in the liver may be related to activate HMGCR, CYP7A1, PXR and FXR, theses toxic actions of rifampin were alleviated by pyrazinamide may be due to inhibite the activity of CYP7A1, PXR and FAS, and increasing the LPL protein expression and activity.	Rifampin	26-34	nuclear receptor subfamily 1, group H, member 4	Mus musculus	125-128
32492461-3	2020	The results showed that rifampin significantly increased transaminases, TBIL and TBA levels in serum, increased TG, TC content, HMGCR and CYP7A1 protein, CYP7A1, FGFR4, PXR, FAS and FXR mRNA expression, but decreased the level of SREBP-1c mRNA and induced severe steatohepatitis and hepatocyte necrosis in liver in mice.	Rifampin	24-32	fibroblast growth factor receptor 4	Mus musculus	162-167
32492461-6	2020	These data suggested that rifampin increases TG and TC levels in the liver may be related to activate HMGCR, CYP7A1, PXR and FXR, theses toxic actions of rifampin were alleviated by pyrazinamide may be due to inhibite the activity of CYP7A1, PXR and FAS, and increasing the LPL protein expression and activity.	Rifampin	26-34	cytochrome P450, family 7, subfamily a, polypeptide 1	Mus musculus	234-240
32492461-3	2020	The results showed that rifampin significantly increased transaminases, TBIL and TBA levels in serum, increased TG, TC content, HMGCR and CYP7A1 protein, CYP7A1, FGFR4, PXR, FAS and FXR mRNA expression, but decreased the level of SREBP-1c mRNA and induced severe steatohepatitis and hepatocyte necrosis in liver in mice.	Rifampin	24-32	nuclear receptor subfamily 1, group I, member 2	Mus musculus	169-172
32492461-3	2020	The results showed that rifampin significantly increased transaminases, TBIL and TBA levels in serum, increased TG, TC content, HMGCR and CYP7A1 protein, CYP7A1, FGFR4, PXR, FAS and FXR mRNA expression, but decreased the level of SREBP-1c mRNA and induced severe steatohepatitis and hepatocyte necrosis in liver in mice.	Rifampin	24-32	nuclear receptor subfamily 1, group H, member 4	Mus musculus	182-185
32492461-6	2020	These data suggested that rifampin increases TG and TC levels in the liver may be related to activate HMGCR, CYP7A1, PXR and FXR, theses toxic actions of rifampin were alleviated by pyrazinamide may be due to inhibite the activity of CYP7A1, PXR and FAS, and increasing the LPL protein expression and activity.	Rifampin	26-34	nuclear receptor subfamily 1, group I, member 2	Mus musculus	242-245
32492461-6	2020	These data suggested that rifampin increases TG and TC levels in the liver may be related to activate HMGCR, CYP7A1, PXR and FXR, theses toxic actions of rifampin were alleviated by pyrazinamide may be due to inhibite the activity of CYP7A1, PXR and FAS, and increasing the LPL protein expression and activity.	Rifampin	26-34	lipoprotein lipase	Mus musculus	274-277
32492461-3	2020	The results showed that rifampin significantly increased transaminases, TBIL and TBA levels in serum, increased TG, TC content, HMGCR and CYP7A1 protein, CYP7A1, FGFR4, PXR, FAS and FXR mRNA expression, but decreased the level of SREBP-1c mRNA and induced severe steatohepatitis and hepatocyte necrosis in liver in mice.	Rifampin	24-32	sterol regulatory element binding transcription factor 1	Mus musculus	230-238
32492461-6	2020	These data suggested that rifampin increases TG and TC levels in the liver may be related to activate HMGCR, CYP7A1, PXR and FXR, theses toxic actions of rifampin were alleviated by pyrazinamide may be due to inhibite the activity of CYP7A1, PXR and FAS, and increasing the LPL protein expression and activity.	Rifampin	154-162	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	102-107
32492461-6	2020	These data suggested that rifampin increases TG and TC levels in the liver may be related to activate HMGCR, CYP7A1, PXR and FXR, theses toxic actions of rifampin were alleviated by pyrazinamide may be due to inhibite the activity of CYP7A1, PXR and FAS, and increasing the LPL protein expression and activity.	Rifampin	154-162	cytochrome P450, family 7, subfamily a, polypeptide 1	Mus musculus	109-115
32492461-6	2020	These data suggested that rifampin increases TG and TC levels in the liver may be related to activate HMGCR, CYP7A1, PXR and FXR, theses toxic actions of rifampin were alleviated by pyrazinamide may be due to inhibite the activity of CYP7A1, PXR and FAS, and increasing the LPL protein expression and activity.	Rifampin	154-162	nuclear receptor subfamily 1, group I, member 2	Mus musculus	117-120
32492461-6	2020	These data suggested that rifampin increases TG and TC levels in the liver may be related to activate HMGCR, CYP7A1, PXR and FXR, theses toxic actions of rifampin were alleviated by pyrazinamide may be due to inhibite the activity of CYP7A1, PXR and FAS, and increasing the LPL protein expression and activity.	Rifampin	154-162	nuclear receptor subfamily 1, group H, member 4	Mus musculus	125-128
32492461-6	2020	These data suggested that rifampin increases TG and TC levels in the liver may be related to activate HMGCR, CYP7A1, PXR and FXR, theses toxic actions of rifampin were alleviated by pyrazinamide may be due to inhibite the activity of CYP7A1, PXR and FAS, and increasing the LPL protein expression and activity.	Rifampin	154-162	cytochrome P450, family 7, subfamily a, polypeptide 1	Mus musculus	234-240
32492461-6	2020	These data suggested that rifampin increases TG and TC levels in the liver may be related to activate HMGCR, CYP7A1, PXR and FXR, theses toxic actions of rifampin were alleviated by pyrazinamide may be due to inhibite the activity of CYP7A1, PXR and FAS, and increasing the LPL protein expression and activity.	Rifampin	154-162	nuclear receptor subfamily 1, group I, member 2	Mus musculus	242-245
32492461-6	2020	These data suggested that rifampin increases TG and TC levels in the liver may be related to activate HMGCR, CYP7A1, PXR and FXR, theses toxic actions of rifampin were alleviated by pyrazinamide may be due to inhibite the activity of CYP7A1, PXR and FAS, and increasing the LPL protein expression and activity.	Rifampin	154-162	lipoprotein lipase	Mus musculus	274-277
32521634-5	2020	In this narrative review, we aim to identify literature that has explored the influence of single nucleotide polymorphisms (SNPs) of genes encoding drug transporters and their transcriptional regulators (SLCO1B1, ABCB1, PXR and CAR), metabolizing enzymes (CES1, CES2 and AADAC) and VDR and its pathway regulators (VDR, CYP27B1 and CYP24A1) on plasma RF concentrations in TB patients on antitubercular therapy.	Rifampin	350-352	solute carrier organic anion transporter family member 1B1	Homo sapiens	204-211
32474202-9	2020	The HbA1c<7% group had a lower risk of developing rifampicin resistance, isoniazid resistance and MDR, with odd ratios (ORs) of 1.904 (p=0.001), 2.896 (p<0.001) and 3.228 (p<0.001), respectively.	Rifampin	50-60	hemoglobin subunit alpha 1	Homo sapiens	4-8
32660103-0	2020	Toxicoproteomic Profiling of hPXR Transgenic Mice Treated with Rifampicin and Isoniazid.	Rifampin	63-73	nuclear receptor subfamily 1 group I member 2	Homo sapiens	29-33
32350061-8	2020	Induction of CYP3A4 using 10 muM rifampicin was 12-fold for RNA, 8-fold for protein, and 3-fold for activity; for CYP1A2 with 50 muM omeprazole induction was 30-fold for RNA, 13-fold for protein, and 17-fold for activity; for CYP2B6 with 50 muM phenytoin induction was 23-fold for RNA, 2-fold for protein, and 5-fold for activity.	Rifampin	33-43	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	13-19
32574211-4	2020	We discovered an aminopyrimidine small molecule, 2062, that had no direct antimycobacterial activity, but synergized with rifampin to reduce bacterial burden in Mtb infected macrophages and mice and also dampened lung immunopathology.	Rifampin	122-130	non-SMC condensin II complex, subunit G2	Mus musculus	161-164
32361205-8	2020	Dose adjustment should be considered when brivaracetam is coadministered with the more potent CYP inducer, rifampin.	Rifampin	107-115	peptidylprolyl isomerase G	Homo sapiens	94-97
32002554-1	2020	BACKGROUND: Mutations in the genes inhA, katG, and rpoB confer resistance to anti-tuberculosis (TB) drugs isoniazid and rifampin.	Rifampin	120-128	inhibin subunit alpha	Homo sapiens	35-39
32521634-5	2020	In this narrative review, we aim to identify literature that has explored the influence of single nucleotide polymorphisms (SNPs) of genes encoding drug transporters and their transcriptional regulators (SLCO1B1, ABCB1, PXR and CAR), metabolizing enzymes (CES1, CES2 and AADAC) and VDR and its pathway regulators (VDR, CYP27B1 and CYP24A1) on plasma RF concentrations in TB patients on antitubercular therapy.	Rifampin	350-352	CXADR pseudogene 1	Homo sapiens	228-231
32440172-0	2020	Successful Treatment of a Multidrug-Resistant Tuberculosis Patient with a Negative Xpert MTB/RIF Test for Rifampicin-Resistant Tuberculosis in Guizhou Province of China: A Case Report.	Rifampin	106-116	ras homolog family member F, filopodia associated	Homo sapiens	93-96
32052379-9	2020	Rifampin is the most potent P-gp inducer, resulting in an average reduction in substrate exposure ranging between 20 and 67%.	Rifampin	0-8	ATP binding cassette subfamily B member 1	Homo sapiens	28-32
32538031-10	2020	Thirty samples (8.5%) were detected as rifampicin resistance by Xpert MTB/RIF assay.	Rifampin	39-49	ras homolog family member F, filopodia associated	Homo sapiens	74-77
32538031-12	2020	Xpert MTB/RIF assay is the most rapid, sensitive, and specific method for microbiological confirmation and rifampicin resistance detection in pediatric tuberculosis.	Rifampin	107-117	ras homolog family member F, filopodia associated	Homo sapiens	10-13
32303457-3	2020	Omeprazole and rifampicin respectively induced CYP1A1 and CYP3A8 mRNAs, while phenobarbital induced CYP2C43, CYP2C75, and CYP3A8, and slightly induced CYP2B6.	Rifampin	15-25	cytochrome P450 family 1 subfamily A member 1	Macaca fascicularis	47-53
32303457-3	2020	Omeprazole and rifampicin respectively induced CYP1A1 and CYP3A8 mRNAs, while phenobarbital induced CYP2C43, CYP2C75, and CYP3A8, and slightly induced CYP2B6.	Rifampin	15-25	cytochrome P450 family 3 subfamily A member 4	Macaca fascicularis	58-64
32303457-3	2020	Omeprazole and rifampicin respectively induced CYP1A1 and CYP3A8 mRNAs, while phenobarbital induced CYP2C43, CYP2C75, and CYP3A8, and slightly induced CYP2B6.	Rifampin	15-25	cytochrome P450 family 2 subfamily C member 19	Macaca fascicularis	109-116
32303457-3	2020	Omeprazole and rifampicin respectively induced CYP1A1 and CYP3A8 mRNAs, while phenobarbital induced CYP2C43, CYP2C75, and CYP3A8, and slightly induced CYP2B6.	Rifampin	15-25	cytochrome P450 family 3 subfamily A member 4	Macaca fascicularis	122-128
32303457-3	2020	Omeprazole and rifampicin respectively induced CYP1A1 and CYP3A8 mRNAs, while phenobarbital induced CYP2C43, CYP2C75, and CYP3A8, and slightly induced CYP2B6.	Rifampin	15-25	cytochrome P450 family 2 subfamily B member 6	Macaca fascicularis	151-157
32303457-4	2020	The nuclear receptors AHR, PXR, and CAR mRNA levels, which were activated by omeprazole, rifampicin, and phenobarbital, respectively, tended to decrease via exposure to inducers despite the increase in CYP mRNA levels.	Rifampin	89-99	aryl hydrocarbon receptor	Macaca fascicularis	22-25
32303457-4	2020	The nuclear receptors AHR, PXR, and CAR mRNA levels, which were activated by omeprazole, rifampicin, and phenobarbital, respectively, tended to decrease via exposure to inducers despite the increase in CYP mRNA levels.	Rifampin	89-99	nuclear receptor subfamily 1 group I member 3	Macaca fascicularis	36-39
31733411-2	2020	OBJECTIVE: Rifampicin resistant (RR) tuberculosis (TB) on X-pert MTB/Rif is assumed a surrogate for MDR TB.	Rifampin	11-21	metallothionein 1J, pseudogene	Homo sapiens	65-68
32440172-1	2020	The Xpert MTB/RIF (Xpert) assay recommended by the World Health Organization (WHO) can be used to simultaneously detect Mycobacterium tuberculosis complex (MTBC) and rifampicin (RIF) resistance associated mutations.	Rifampin	166-176	ras homolog family member F, filopodia associated	Homo sapiens	14-17
32267374-1	2020	The aim was to analyze the acceptability of chemoprophylaxis with single-dose rifampicin (PEP) in contacts, index leprosy cases, and health professionals and related factors that can influence adherence.	Rifampin	78-88	prolyl endopeptidase	Homo sapiens	90-93
32291610-8	2020	Further, the model was able to accurately predict the impact of a strong CYP3A inducer (rifampicin) and inhibitor (ketoconazole) on bortezomib exposure.	Rifampin	88-98	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	73-78
31884012-3	2020	In hiPSC-IECs, gene expression levels of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) are enhanced by rifampicin and 1,25-dihydroxyvitamin D3.	Rifampin	112-122	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	41-60
31956998-5	2020	Rifampin 15mg/kg increased plasma and CSF exposures compared to 10mg/kg: day 14 plasma AUC0-24 increased from 48.2h mg/L (range 18.2-93.8) to 82.5h mg/L (range 8.7-161.0) and CSF AUC0-24 from 3.5h mg/L (range 1.2-9.6) to 6.0h mg/L (range 0.7-15.1).	Rifampin	0-8	colony stimulating factor 2	Homo sapiens	38-41
31956998-5	2020	Rifampin 15mg/kg increased plasma and CSF exposures compared to 10mg/kg: day 14 plasma AUC0-24 increased from 48.2h mg/L (range 18.2-93.8) to 82.5h mg/L (range 8.7-161.0) and CSF AUC0-24 from 3.5h mg/L (range 1.2-9.6) to 6.0h mg/L (range 0.7-15.1).	Rifampin	0-8	colony stimulating factor 2	Homo sapiens	175-178
31770456-2	2020	This open-label, two-arm, drug-drug interaction Phase 1 study in patients with advanced solid tumors assessed the effect of a P-gp inhibitor (itraconazole) and a P-gp inducer (rifampin) on the pharmacokinetics of a single dose of talazoparib.	Rifampin	176-184	ATP binding cassette subfamily B member 1	Homo sapiens	162-166
32553308-0	2020	Prevalence of p-glycoprotein (PGP) expression, function and its effect on efficacy of rifampicin in patients with lymph node tuberculosis.	Rifampin	86-96	ATP binding cassette subfamily B member 1	Homo sapiens	14-28
32553308-0	2020	Prevalence of p-glycoprotein (PGP) expression, function and its effect on efficacy of rifampicin in patients with lymph node tuberculosis.	Rifampin	86-96	ATP binding cassette subfamily B member 1	Homo sapiens	30-33
32553308-3	2020	In this study we aim to study the prevalence of PGP expression and function and its relationship with serum concentrations of Rifampicin in consecutive patients with lymph node tuberculosis.	Rifampin	126-136	ATP binding cassette subfamily B member 1	Homo sapiens	48-51
32553308-6	2020	The mean net PGP expression expressed as percent and relative fluorescence indices (RFI) of PGP expression and function respectively was compared at baseline at 2 months and was also correlated with serum rifampicin levels.	Rifampin	205-215	ATP binding cassette subfamily B member 1	Homo sapiens	13-16
32553308-10	2020	CONCLUSIONS: Overexpression of PGP is common in patients with lymph node tuberculosis and leads to lower concentrations of Rifampicin in blood which subsequently may give rise to development of drug resistance.	Rifampin	123-133	ATP binding cassette subfamily B member 1	Homo sapiens	31-34
31884012-3	2020	In hiPSC-IECs, gene expression levels of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) are enhanced by rifampicin and 1,25-dihydroxyvitamin D3.	Rifampin	112-122	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	62-68
31884012-3	2020	In hiPSC-IECs, gene expression levels of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) are enhanced by rifampicin and 1,25-dihydroxyvitamin D3.	Rifampin	112-122	ATP binding cassette subfamily B member 1	Homo sapiens	74-88
31884012-3	2020	In hiPSC-IECs, gene expression levels of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) are enhanced by rifampicin and 1,25-dihydroxyvitamin D3.	Rifampin	112-122	ATP binding cassette subfamily B member 1	Homo sapiens	90-94
31368836-5	2020	Rifampicin (OATP inhibitor) for OATP1B3-HEK293 cells and prazosin for OCT1-HEK293 cells could inhibit the uptake of jatrorrhizine with the IC50 of 5.49 +- 1.05 and 2.77 +- 0.72 muM, respectively.The above data indicate that hepatic uptake of jatrorrhizine is involved in both OATP and OCT, which may have important roles in jatrorrhizine liver disposition and potential drug-drug interactions.	Rifampin	0-10	solute carrier organic anion transporter family member 1A2	Homo sapiens	12-16
31368836-5	2020	Rifampicin (OATP inhibitor) for OATP1B3-HEK293 cells and prazosin for OCT1-HEK293 cells could inhibit the uptake of jatrorrhizine with the IC50 of 5.49 +- 1.05 and 2.77 +- 0.72 muM, respectively.The above data indicate that hepatic uptake of jatrorrhizine is involved in both OATP and OCT, which may have important roles in jatrorrhizine liver disposition and potential drug-drug interactions.	Rifampin	0-10	solute carrier organic anion transporter family member 1A2	Homo sapiens	32-36
32292343-4	2020	We measured oxysterols in serum of volunteers dosed with PXR agonist rifampicin 600 mg/day versus placebo for a week and analyzed the expression of cholesterol transporters in mononuclear cells.	Rifampin	69-79	nuclear receptor subfamily 1 group I member 2	Homo sapiens	57-60
32376574-8	2020	The PXR target gene MDR1 also increased significantly in the rifampicin- and SR12813-treated cells compared with the control cells (P=0.020 and 0.01, respectively).	Rifampin	61-71	nuclear receptor subfamily 1 group I member 2	Homo sapiens	4-7
32376574-8	2020	The PXR target gene MDR1 also increased significantly in the rifampicin- and SR12813-treated cells compared with the control cells (P=0.020 and 0.01, respectively).	Rifampin	61-71	ATP binding cassette subfamily B member 1	Homo sapiens	20-24
32376574-10	2020	The protein level of PDCD4 increased significantly in both rifampicin (t= 2.779, P=0.025) group and VP- PXR group (t=3.066, P=0.012).	Rifampin	59-69	programmed cell death 4	Homo sapiens	21-26
32376574-6	2020	RESULTS: The expressions of PDCD5 and PDCD6 mRNA did not differ significantly between rifampicin-treated and the control cells, while PDCD4 mRNA expression increased (t=4.209, P=0.008) and PDCD2 mRNA decreased significantly (t=-2.875, P=0.017) in rifampicin-treated cells.	Rifampin	86-96	programmed cell death 2	Homo sapiens	189-194
32106230-7	2020	In addition, an increase in PXR expression levels was observed in both hepatic cell lines and iPSC derived hepatocytes upon rifampicin treatment, whereas a reproducible increase in PXR expression was not achieved in PHHs.	Rifampin	124-134	nuclear receptor subfamily 1 group I member 2	Homo sapiens	28-31
32265867-5	2020	Deletion of greA results in growth retardation and poor survival in response to adverse stress, besides rendering M. tuberculosis more susceptible to vancomycin and rifampicin.	Rifampin	165-175	transcription elongation factor GreA	Mycobacterium tuberculosis H37Rv	12-16
31605489-7	2020	Simvastatin, fluvastatin and pravastatin showed the most favorable therapeutic index, and enhanced the anti-tubercular activity of the first-line drugs isoniazid, rifampin and pyrazinamide in THP-1 cells.	Rifampin	163-171	GLI family zinc finger 2	Homo sapiens	192-197
31877331-5	2020	This priming effect persisted up to 48 h. Mechanistically, DMSO pretreatment reduced H4K12 acetylation and therefore enhanced the subsequent rifampicin stimulated histone H4R3 methylation on the regulatory region of PXR target gene CYP3A4.	Rifampin	141-151	nuclear receptor subfamily 1 group I member 2	Homo sapiens	216-219
31877331-5	2020	This priming effect persisted up to 48 h. Mechanistically, DMSO pretreatment reduced H4K12 acetylation and therefore enhanced the subsequent rifampicin stimulated histone H4R3 methylation on the regulatory region of PXR target gene CYP3A4.	Rifampin	141-151	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	232-238
32233619-0	2020	Effect of Xpert MTB/RIF on the treatment of multi-drug-resistant or rifampicin-resistant tuberculosis screened out from re-treatment pulmonary tuberculosis patients, a prospective cohort study.	Rifampin	68-78	ras homolog family member F, filopodia associated	Homo sapiens	20-23
32233619-2	2020	The Xpert MTB/RIF assay possesses high efficacy for the evaluation of rifampicin resistance.	Rifampin	70-80	ras homolog family member F, filopodia associated	Homo sapiens	14-17
31879282-12	2020	Although disparate sets of tissue biopsy (atorvastatin and carbamazepine) and in vitro hepatocyte (phenobarbital, chenodeoxycholate, and amprenavir) data present OATP messenger RNA induction (>=2-fold) by agents beyond RIF, the clinical relevance of such data needs to be determined.	Rifampin	219-222	solute carrier organic anion transporter family member 1A2	Homo sapiens	162-166
31648047-5	2020	We found that rifampicin pretreatment suppressed the gene expression of IL-1beta and IL-6 via inhibiting activation of JNK after rotenone induction, but the anti-inflammatory effect of rifampicin was reversed by chloroquine.	Rifampin	14-24	interleukin 1 alpha	Homo sapiens	72-80
31648047-5	2020	We found that rifampicin pretreatment suppressed the gene expression of IL-1beta and IL-6 via inhibiting activation of JNK after rotenone induction, but the anti-inflammatory effect of rifampicin was reversed by chloroquine.	Rifampin	14-24	interleukin 6	Homo sapiens	85-89
31648047-5	2020	We found that rifampicin pretreatment suppressed the gene expression of IL-1beta and IL-6 via inhibiting activation of JNK after rotenone induction, but the anti-inflammatory effect of rifampicin was reversed by chloroquine.	Rifampin	14-24	mitogen-activated protein kinase 8	Homo sapiens	119-122
31648047-6	2020	Moreover, rifampicin pretreatment not only improved the ratio of LC3-II/LC3-I in rotenone-treated cells, but also increased autolysosomes and decreased autophagosomes in RFP-GFP-LC3B transfected HM cells exposed to rotenone, thus indicating rifampicin improves autophagy flux in rotenone-treated HM cells.	Rifampin	10-20	tripartite motif containing 27	Homo sapiens	170-173
31648047-6	2020	Moreover, rifampicin pretreatment not only improved the ratio of LC3-II/LC3-I in rotenone-treated cells, but also increased autolysosomes and decreased autophagosomes in RFP-GFP-LC3B transfected HM cells exposed to rotenone, thus indicating rifampicin improves autophagy flux in rotenone-treated HM cells.	Rifampin	10-20	microtubule associated protein 1 light chain 3 beta	Homo sapiens	178-182
31648047-7	2020	Finally, we verified rifampicin pretreatment enhanced ATP6V0A1 expression when compared to that exposed to rotenone alone.	Rifampin	21-31	ATPase H+ transporting V0 subunit a1	Homo sapiens	54-62
31648047-8	2020	ATP6V0A1 knockdown inhibited the effect of rifampicin on maintaining lysosome acidification and autophagosome-lysosome fusion in rotenone-treated microglia.	Rifampin	43-53	ATPase H+ transporting V0 subunit a1	Homo sapiens	0-8
31648047-9	2020	Taken together, our results indicated that rifampicin attenuates rotenone-induced microglia inflammation partially via elevating ATP6V0A1.	Rifampin	43-53	ATPase H+ transporting V0 subunit a1	Homo sapiens	129-137
31863284-2	2020	METHODS: This phase 1, open-label, two-period, crossover study estimated the effect of oral rifampin (a strong CYP3A inducer) on the pharmacokinetics and safety of oral lorlatinib (NCT02804399).	Rifampin	92-100	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	111-116
31901518-4	2020	Here, we demonstrate that in the context of therapy, the AhR binds several TB drugs, including front line drugs rifampicin (RIF) and rifabutin (RFB), resulting in altered host defense and drug metabolism.	Rifampin	112-122	aryl hydrocarbon receptor	Homo sapiens	57-60
31901518-4	2020	Here, we demonstrate that in the context of therapy, the AhR binds several TB drugs, including front line drugs rifampicin (RIF) and rifabutin (RFB), resulting in altered host defense and drug metabolism.	Rifampin	124-127	aryl hydrocarbon receptor	Homo sapiens	57-60
32123755-1	2020	Rationale: Previously treated persons with bacteriologically confirmed pulmonary tuberculosis (BC-PTB) have increased risk of developing multi-drug resistant or rifampicin resistant tuberculosis (MDR/RR-TB).	Rifampin	161-171	polypyrimidine tract binding protein 1	Homo sapiens	98-101
31993042-0	2019	Linezolid and Rifampicin Combination to Combat cfr-Positive Multidrug-Resistant MRSA in Murine Models of Bacteremia and Skin and Skin Structure Infection.	Rifampin	14-24	solute carrier family 9 member A6	Homo sapiens	80-84
31993325-6	2020	Co-administration of eliglustat with oral doses of rifampin reduced eliglustat exposure by >85% due to induction of CYP3A4/P-gp by rifampin, while a single intravenous dose of rifampin had no effect on eliglustat, confirming that eliglustat is not an OATP substrate.	Rifampin	51-59	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	116-122
31993325-6	2020	Co-administration of eliglustat with oral doses of rifampin reduced eliglustat exposure by >85% due to induction of CYP3A4/P-gp by rifampin, while a single intravenous dose of rifampin had no effect on eliglustat, confirming that eliglustat is not an OATP substrate.	Rifampin	51-59	ATP binding cassette subfamily B member 1	Homo sapiens	123-127
31993325-6	2020	Co-administration of eliglustat with oral doses of rifampin reduced eliglustat exposure by >85% due to induction of CYP3A4/P-gp by rifampin, while a single intravenous dose of rifampin had no effect on eliglustat, confirming that eliglustat is not an OATP substrate.	Rifampin	131-139	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	116-122
31993325-6	2020	Co-administration of eliglustat with oral doses of rifampin reduced eliglustat exposure by >85% due to induction of CYP3A4/P-gp by rifampin, while a single intravenous dose of rifampin had no effect on eliglustat, confirming that eliglustat is not an OATP substrate.	Rifampin	131-139	ATP binding cassette subfamily B member 1	Homo sapiens	123-127
31993325-6	2020	Co-administration of eliglustat with oral doses of rifampin reduced eliglustat exposure by >85% due to induction of CYP3A4/P-gp by rifampin, while a single intravenous dose of rifampin had no effect on eliglustat, confirming that eliglustat is not an OATP substrate.	Rifampin	131-139	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	116-122
31993325-6	2020	Co-administration of eliglustat with oral doses of rifampin reduced eliglustat exposure by >85% due to induction of CYP3A4/P-gp by rifampin, while a single intravenous dose of rifampin had no effect on eliglustat, confirming that eliglustat is not an OATP substrate.	Rifampin	131-139	ATP binding cassette subfamily B member 1	Homo sapiens	123-127
32019201-1	2020	The purpose of this study is to analyze the polyphenolic rich extract of Crocus sativus L. petals (CSP) in modulating liver oxidative stress and inflammatory response status against rifampicin isoniazid (INH-RIF) drug-induced liver injury.	Rifampin	182-202	DnaJ heat shock protein family (Hsp40) member C5	Rattus norvegicus	99-102
31993042-8	2019	Altogether, these data suggest that the use of linezolid in combination with rifampicin poses a viable therapeutic alternative for bacteremia and SSSI caused by cfr-positive multidrug resistant MRSA.	Rifampin	77-87	solute carrier family 9 member A6	Homo sapiens	194-198
31678598-0	2020	Rifampicin activates AMPK and alleviates oxidative stress in the liver as mediated with Nrf2 signaling.	Rifampin	0-10	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	21-25
31678598-0	2020	Rifampicin activates AMPK and alleviates oxidative stress in the liver as mediated with Nrf2 signaling.	Rifampin	0-10	NFE2 like bZIP transcription factor 2	Homo sapiens	88-92
31678598-4	2020	In vivo, oral administration of rifampicin (100 or 200 mg/kg) attenuated elevation of serum alanine aminotransferase (ALT) and aspartate transaminase (AST), serum liver injury markers, against APAP treatment and, histologically, ameliorated tissue damage.	Rifampin	32-42	glutamic--pyruvic transaminase	Homo sapiens	92-116
31678598-4	2020	In vivo, oral administration of rifampicin (100 or 200 mg/kg) attenuated elevation of serum alanine aminotransferase (ALT) and aspartate transaminase (AST), serum liver injury markers, against APAP treatment and, histologically, ameliorated tissue damage.	Rifampin	32-42	solute carrier family 17 member 5	Homo sapiens	127-149
31678598-4	2020	In vivo, oral administration of rifampicin (100 or 200 mg/kg) attenuated elevation of serum alanine aminotransferase (ALT) and aspartate transaminase (AST), serum liver injury markers, against APAP treatment and, histologically, ameliorated tissue damage.	Rifampin	32-42	solute carrier family 17 member 5	Homo sapiens	151-154
31678598-7	2020	Further, we explored whether rifampicin treatment enhanced phosphorylation of AMP-activated protein kinase (AMPK) by activation of liver kinase B1 (LKB1), the upstream kinase of AMPKalpha.	Rifampin	29-39	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	78-106
31678598-7	2020	Further, we explored whether rifampicin treatment enhanced phosphorylation of AMP-activated protein kinase (AMPK) by activation of liver kinase B1 (LKB1), the upstream kinase of AMPKalpha.	Rifampin	29-39	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	108-112
31678598-7	2020	Further, we explored whether rifampicin treatment enhanced phosphorylation of AMP-activated protein kinase (AMPK) by activation of liver kinase B1 (LKB1), the upstream kinase of AMPKalpha.	Rifampin	29-39	serine/threonine kinase 11	Homo sapiens	131-146
31678598-7	2020	Further, we explored whether rifampicin treatment enhanced phosphorylation of AMP-activated protein kinase (AMPK) by activation of liver kinase B1 (LKB1), the upstream kinase of AMPKalpha.	Rifampin	29-39	serine/threonine kinase 11	Homo sapiens	148-152
31678598-9	2020	Moreover, we confirmed a reversed cell protective effect of rifampicin under compound C (an AMPK inhibitor) treatment.	Rifampin	60-70	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	92-96
31678598-10	2020	Overall, our data demonstrate that rifampicin effectively protects the liver against cellular oxidative stress through AMPKalpha and Nrf2 pathway.	Rifampin	35-45	NFE2 like bZIP transcription factor 2	Homo sapiens	133-137
31316180-0	2020	Rifampicin induces clathrin-dependent endocytosis and ubiquitin-proteasome degradation of MRP2 via oxidative stress-activated PKC-ERK/JNK/p38 and PI3K signaling pathways in HepG2 cells.	Rifampin	0-10	ATP binding cassette subfamily C member 2	Homo sapiens	90-94
31998607-9	2020	Importantly, we observed significant upregulation of miR-18a-5p expression 6 h after treatment with the PXR ligand rifampicin, which indicates a putative mechanism underlying NR1I2 negative feed-back regulation in hepatic cells.	Rifampin	115-125	nuclear receptor subfamily 1, group I, member 2	Mus musculus	104-107
31316180-0	2020	Rifampicin induces clathrin-dependent endocytosis and ubiquitin-proteasome degradation of MRP2 via oxidative stress-activated PKC-ERK/JNK/p38 and PI3K signaling pathways in HepG2 cells.	Rifampin	0-10	mitogen-activated protein kinase 1	Homo sapiens	138-141
31316180-2	2020	In this study, we investigated the effects of rifampicin (RFP) on the membrane expression of multidrug resistance-associated protein 2 (MRP2) and the relationship between oxidative stress and RFP-induced endocytosis of MRP2 in HepG2 cells.	Rifampin	46-56	ATP binding cassette subfamily C member 2	Homo sapiens	93-134
31316180-2	2020	In this study, we investigated the effects of rifampicin (RFP) on the membrane expression of multidrug resistance-associated protein 2 (MRP2) and the relationship between oxidative stress and RFP-induced endocytosis of MRP2 in HepG2 cells.	Rifampin	46-56	ATP binding cassette subfamily C member 2	Homo sapiens	136-140
31571363-12	2020	Finally, in vivo, Nrf2 played an important role in RFP-induced liver injury (more serious liver injury in Nrf2-/- mice), and TAN IIA prevented it.	Rifampin	51-54	nuclear factor, erythroid derived 2, like 2	Mus musculus	18-22
31604032-0	2020	Rifampicin, Not Vitamin E, Suppresses Parenteral Nutrition Associated Liver Disease Development through Pregnane X Receptor Pathway in Piglets.	Rifampin	0-10	nuclear receptor subfamily 1 group I member 2	Homo sapiens	104-123
31432507-3	2020	Most importantly, we found that YPAC allows PHHs to retain enzymatic activities of CYP1A2, CYP2B6, and CYP3A4 even after 40 days of culture, and that inducibility of CYP3A4 activity in response to the prototypical inducers rifampicin and phenobarbital is also maintained.	Rifampin	223-233	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	166-172
32407272-2	2020	Rifampicin is a nonselective inducer of P-glycoprotein (P-gp) and CYP enzymes such as CYP3A4 and others.	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	86-92
31571363-0	2020	Tanshinone IIA prevents rifampicin-induced liver injury by regulating BSEP/NTCP expression via epigenetic activation of NRF2.	Rifampin	24-34	ATP binding cassette subfamily B member 11	Homo sapiens	70-74
31571363-0	2020	Tanshinone IIA prevents rifampicin-induced liver injury by regulating BSEP/NTCP expression via epigenetic activation of NRF2.	Rifampin	24-34	solute carrier family 10 member 1	Homo sapiens	75-79
31571363-12	2020	Finally, in vivo, Nrf2 played an important role in RFP-induced liver injury (more serious liver injury in Nrf2-/- mice), and TAN IIA prevented it.	Rifampin	51-54	nuclear factor, erythroid derived 2, like 2	Mus musculus	106-110
31571363-0	2020	Tanshinone IIA prevents rifampicin-induced liver injury by regulating BSEP/NTCP expression via epigenetic activation of NRF2.	Rifampin	24-34	NFE2 like bZIP transcription factor 2	Homo sapiens	120-124
31571363-14	2020	Pharmacological activation of NRF2 by TAN IIA may be beneficial for RFP-induced liver injury.	Rifampin	68-71	NFE2 like bZIP transcription factor 2	Homo sapiens	30-34
31247120-7	2019	Furthermore, we applied a CRISPR/Cas9-mediated methylation modifiable cell model and demonstrated that four CpGs in or near the gene region of AK2, SLC8A2, and PSTPIP2 affected the cellular response to rifampicin treatment.	Rifampin	202-212	adenylate kinase 2	Homo sapiens	143-146
31856744-13	2019	Rifampicin resistance rate found by GeneXpert MTB/RIF was 0.84%.	Rifampin	0-10	ras homolog family member F, filopodia associated	Homo sapiens	50-53
31856744-14	2019	Comparison of Rifampicin resistance obtained by GeneXpert MTB/RIF and Genotype MTBDRplus, showed 100% agreement between the two techniques for studied samples.	Rifampin	14-24	ras homolog family member F, filopodia associated	Homo sapiens	62-65
31805862-3	2019	Post-exposure prophylaxis (PEP) with a single dose of Rifampicin (SDR) has conditionally been recommended by the World Health Organization (WHO), based on a randomized-controlled-trial in Bangladesh.	Rifampin	54-64	prolyl endopeptidase	Homo sapiens	27-30
31129789-0	2019	Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole.	Rifampin	191-201	solute carrier organic anion transporter family member 1B1	Homo sapiens	82-89
31129789-0	2019	Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole.	Rifampin	191-201	solute carrier organic anion transporter family member 1B1	Homo sapiens	91-98
31247120-7	2019	Furthermore, we applied a CRISPR/Cas9-mediated methylation modifiable cell model and demonstrated that four CpGs in or near the gene region of AK2, SLC8A2, and PSTPIP2 affected the cellular response to rifampicin treatment.	Rifampin	202-212	solute carrier family 8 member A2	Homo sapiens	148-154
31247120-7	2019	Furthermore, we applied a CRISPR/Cas9-mediated methylation modifiable cell model and demonstrated that four CpGs in or near the gene region of AK2, SLC8A2, and PSTPIP2 affected the cellular response to rifampicin treatment.	Rifampin	202-212	proline-serine-threonine phosphatase interacting protein 2	Homo sapiens	160-167
31388941-12	2019	Conversely, strong CYP3A inducers, such as rifampin, are contraindicated with doravirine owing to a significant reduction in exposure with potential for impaired virological efficacy.	Rifampin	43-51	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	19-24
31582395-3	2019	Three-day treatment of RIF significantly induced CYP3A4 (~60-fold induction), but not CYP1A2 and CYP2D6 genes.	Rifampin	23-26	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	49-55
31571146-4	2019	A phase I drug-interaction study in healthy volunteers evaluated the impact of co-administering rifampicin [CYP3A4 and P-glycoprotein (P-gp) inducer] and itraconazole [CYP3A4, P-gp and breast cancer resistance protein (BCRP) inhibitor] on the pharmacokinetics of darolutamide.	Rifampin	96-106	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	108-114
31686406-2	2019	Concomitant use of rifampicin, an inducer of these enzymes, with FXa-DOACs, has been shown to decrease FXa-DOAC concentrations in healthy subjects.	Rifampin	19-29	coagulation factor X	Homo sapiens	65-68
31686406-2	2019	Concomitant use of rifampicin, an inducer of these enzymes, with FXa-DOACs, has been shown to decrease FXa-DOAC concentrations in healthy subjects.	Rifampin	19-29	coagulation factor X	Homo sapiens	103-106
31571146-4	2019	A phase I drug-interaction study in healthy volunteers evaluated the impact of co-administering rifampicin [CYP3A4 and P-glycoprotein (P-gp) inducer] and itraconazole [CYP3A4, P-gp and breast cancer resistance protein (BCRP) inhibitor] on the pharmacokinetics of darolutamide.	Rifampin	96-106	ATP binding cassette subfamily B member 1	Homo sapiens	135-139
31582395-9	2019	To investigate in vivo OATP induction, RIF (18 mg/kg per day) was orally dosed to cynomolgus monkeys for 7 days.	Rifampin	39-42	solute carrier organic anion transporter family member 1A2	Homo sapiens	23-27
31172535-7	2019	Avadomide exposures when coadministered with the CYP3A inducer rifampin were 62.83% and 88.17% of that when administered alone, for AUC0-inf and Cmax , respectively.	Rifampin	63-71	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	49-54
31976003-10	2019	Additionally, sesamin reduced valproate- and rifampin-induced LXRalpha and pregnane X receptor (PXR) transactivation.	Rifampin	45-53	nuclear receptor subfamily 1 group H member 3	Homo sapiens	62-70
31976003-10	2019	Additionally, sesamin reduced valproate- and rifampin-induced LXRalpha and pregnane X receptor (PXR) transactivation.	Rifampin	45-53	nuclear receptor subfamily 1 group I member 2	Homo sapiens	75-94
31976003-10	2019	Additionally, sesamin reduced valproate- and rifampin-induced LXRalpha and pregnane X receptor (PXR) transactivation.	Rifampin	45-53	nuclear receptor subfamily 1 group I member 2	Homo sapiens	96-99
31676845-7	2019	We also demonstrated that matured Huh7s can be used for drug induction studies, where CYP3A4, CYP1A2, CYP2C9, and CYP2C19 inductions were achieved following rifampicin treatment.	Rifampin	157-167	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	86-92
31754620-3	2019	Rifampicin-resistant TB (RR-TB) or multidrug-resistant TB (MDR-TB) was diagnosed upon the detection of rifampicin resistance by Xpert MTB/RIF or resistance to rifampicin and isoniazid by phenotypic drug susceptibility testing (DST).	Rifampin	0-10	ras homolog family member F, filopodia associated	Homo sapiens	138-141
31420941-2	2019	We previously constructed a physiologically-based pharmacokinetic (PBPK) model of rifampicin accounting for the components for the induction of cytochrome P450 (CYP) 3A/CYP2C9 and the inhibition of organic anion transporting polypeptide 1B (OATP1B).	Rifampin	82-92	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	144-168
31420941-2	2019	We previously constructed a physiologically-based pharmacokinetic (PBPK) model of rifampicin accounting for the components for the induction of cytochrome P450 (CYP) 3A/CYP2C9 and the inhibition of organic anion transporting polypeptide 1B (OATP1B).	Rifampin	82-92	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	169-175
31420941-3	2019	This study aimed to expand and verify the PBPK model for rifampicin by incorporating additional components for the induction of OATP1B and CYP2C8 and the inhibition of multidrug resistance protein 2.	Rifampin	57-67	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	139-145
31455676-4	2019	Oral administration of the human PXR activator rifampicin increased hepatic expression of CYP3A4 mRNA and triazolam (TRZ) 1"- and 4-hydroxylation activities, CYP3A probe activities, in the liver and intestine microsomes of hCYP3A-MAC/hPXR mice.	Rifampin	47-57	nuclear receptor subfamily 1 group I member 2	Homo sapiens	33-36
31455676-4	2019	Oral administration of the human PXR activator rifampicin increased hepatic expression of CYP3A4 mRNA and triazolam (TRZ) 1"- and 4-hydroxylation activities, CYP3A probe activities, in the liver and intestine microsomes of hCYP3A-MAC/hPXR mice.	Rifampin	47-57	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	90-96
31455676-4	2019	Oral administration of the human PXR activator rifampicin increased hepatic expression of CYP3A4 mRNA and triazolam (TRZ) 1"- and 4-hydroxylation activities, CYP3A probe activities, in the liver and intestine microsomes of hCYP3A-MAC/hPXR mice.	Rifampin	47-57	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	90-95
31455676-4	2019	Oral administration of the human PXR activator rifampicin increased hepatic expression of CYP3A4 mRNA and triazolam (TRZ) 1"- and 4-hydroxylation activities, CYP3A probe activities, in the liver and intestine microsomes of hCYP3A-MAC/hPXR mice.	Rifampin	47-57	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	223-229
31455676-5	2019	The plasma concentration of TRZ after oral dosing was significantly decreased by rifampicin treatment in hCYP3A-MAC/hPXR mice but not in hCYP3A-MAC mice.	Rifampin	81-91	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	105-111
31455676-6	2019	In addition, mass spectrometry imaging analysis showed that rifampicin treatment increased the formation of hydroxy TRZ in the intestine of hCYP3A-MAC/hPXR mice after oral dosing of TRZ.	Rifampin	60-70	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	140-146
31455676-7	2019	The plasma concentration of 1"- and 4-hydroxy TRZ in portal blood was also increased by rifampicin treatment in hCYP3A-MAC/hPXR mice.	Rifampin	88-98	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	112-118
31445882-0	2019	MicroRNAs hsa-miR-495-3p and hsa-miR-486-5p suppress basal and rifampicin-induced expression of human sulfotransferase 2A1 (SULT2A1) by facilitating mRNA degradation.	Rifampin	63-73	sulfotransferase family 2A member 1	Homo sapiens	102-122
31445882-0	2019	MicroRNAs hsa-miR-495-3p and hsa-miR-486-5p suppress basal and rifampicin-induced expression of human sulfotransferase 2A1 (SULT2A1) by facilitating mRNA degradation.	Rifampin	63-73	sulfotransferase family 2A member 1	Homo sapiens	124-131
31445882-8	2019	Furthermore, gain- and loss-of-function assays demonstrated that hsa-miR-486-5p and hsa-miR-495-3p negatively modulate basal and rifampicin-induced expression of SULT2A1 in HepG2 cells by decreasing mRNA stability.	Rifampin	129-139	sulfotransferase family 2A, dehydroepiandrosterone (DHEA)-preferring, member 1	Mus musculus	162-169
31090092-7	2019	5-HMT fractional clearance by CYP3A and CYP2D6 was verified from clinical DDI studies with a potent CYP3A4 inhibitor (ketoconazole) and inducer (rifampicin) in CYP2D6 extensive and poor metabolizers and with a moderate CYP3A inhibitor (fluconazole) in healthy volunteers.	Rifampin	145-155	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	30-35
31090092-7	2019	5-HMT fractional clearance by CYP3A and CYP2D6 was verified from clinical DDI studies with a potent CYP3A4 inhibitor (ketoconazole) and inducer (rifampicin) in CYP2D6 extensive and poor metabolizers and with a moderate CYP3A inhibitor (fluconazole) in healthy volunteers.	Rifampin	145-155	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	40-46
31090092-7	2019	5-HMT fractional clearance by CYP3A and CYP2D6 was verified from clinical DDI studies with a potent CYP3A4 inhibitor (ketoconazole) and inducer (rifampicin) in CYP2D6 extensive and poor metabolizers and with a moderate CYP3A inhibitor (fluconazole) in healthy volunteers.	Rifampin	145-155	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	160-166
31455676-11	2019	Expression of CYP3A4 and metabolism of triazolam, a typical CYP3A substrate, in the liver of CYP3A/PXR-humanized mice were enhanced in response to rifampicin, a typical human PXR activator.	Rifampin	147-157	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	14-20
31455676-11	2019	Expression of CYP3A4 and metabolism of triazolam, a typical CYP3A substrate, in the liver of CYP3A/PXR-humanized mice were enhanced in response to rifampicin, a typical human PXR activator.	Rifampin	147-157	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	14-19
31455676-11	2019	Expression of CYP3A4 and metabolism of triazolam, a typical CYP3A substrate, in the liver of CYP3A/PXR-humanized mice were enhanced in response to rifampicin, a typical human PXR activator.	Rifampin	147-157	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	60-65
31455676-11	2019	Expression of CYP3A4 and metabolism of triazolam, a typical CYP3A substrate, in the liver of CYP3A/PXR-humanized mice were enhanced in response to rifampicin, a typical human PXR activator.	Rifampin	147-157	nuclear receptor subfamily 1, group I, member 2	Mus musculus	99-102
31455676-11	2019	Expression of CYP3A4 and metabolism of triazolam, a typical CYP3A substrate, in the liver of CYP3A/PXR-humanized mice were enhanced in response to rifampicin, a typical human PXR activator.	Rifampin	147-157	nuclear receptor subfamily 1 group I member 2	Homo sapiens	175-178
31676845-7	2019	We also demonstrated that matured Huh7s can be used for drug induction studies, where CYP3A4, CYP1A2, CYP2C9, and CYP2C19 inductions were achieved following rifampicin treatment.	Rifampin	157-167	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	94-100
31676845-7	2019	We also demonstrated that matured Huh7s can be used for drug induction studies, where CYP3A4, CYP1A2, CYP2C9, and CYP2C19 inductions were achieved following rifampicin treatment.	Rifampin	157-167	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	102-108
31676845-7	2019	We also demonstrated that matured Huh7s can be used for drug induction studies, where CYP3A4, CYP1A2, CYP2C9, and CYP2C19 inductions were achieved following rifampicin treatment.	Rifampin	157-167	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	114-121
31581194-6	2019	PXR, activated by rifampicin, is rate-limiting for mucosal NF-kappaB activation in IBD.	Rifampin	18-28	nuclear receptor subfamily 1 group I member 2	Homo sapiens	0-3
31581123-8	2019	The tuberculostatic drug rifampicin is a CYP3A4 inducer, increasing the metabolism of hydrocortisone.	Rifampin	25-35	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	41-47
31581194-6	2019	PXR, activated by rifampicin, is rate-limiting for mucosal NF-kappaB activation in IBD.	Rifampin	18-28	nuclear factor kappa B subunit 1	Homo sapiens	59-68
30991038-0	2019	Rifampin Induces Expression of P-glycoprotein on the THP1 Cell-Derived Macrophages, Causing Decrease Intramacrophage Concentration of Prothionamide.	Rifampin	0-8	ATP binding cassette subfamily B member 1	Homo sapiens	31-45
31526233-6	2019	On the other hand, treatment of HepaRG cells with RMP resulted in a significant increase in mRNA expression for CYP2B6 (6.68-fold, p = 0.007) and CYP3A4 (111.96-fold, p = 0.001), whereas NR1I3 expression decreased (0.46-fold, p = 0.033).	Rifampin	50-53	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	112-118
31526233-6	2019	On the other hand, treatment of HepaRG cells with RMP resulted in a significant increase in mRNA expression for CYP2B6 (6.68-fold, p = 0.007) and CYP3A4 (111.96-fold, p = 0.001), whereas NR1I3 expression decreased (0.46-fold, p = 0.033).	Rifampin	50-53	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	146-152
31526233-6	2019	On the other hand, treatment of HepaRG cells with RMP resulted in a significant increase in mRNA expression for CYP2B6 (6.68-fold, p = 0.007) and CYP3A4 (111.96-fold, p = 0.001), whereas NR1I3 expression decreased (0.46-fold, p = 0.033).	Rifampin	50-53	nuclear receptor subfamily 1 group I member 3	Homo sapiens	187-192
30759187-0	2019	Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study.	Rifampin	86-96	metallothionein 1J, pseudogene	Homo sapiens	67-70
31361500-3	2019	Rifampin significantly induced the transcription of ABCB1 and ABCC2 and protein abundance of P-gp but not of MRP2.	Rifampin	0-8	ATP binding cassette subfamily B member 1	Homo sapiens	52-57
31361500-3	2019	Rifampin significantly induced the transcription of ABCB1 and ABCC2 and protein abundance of P-gp but not of MRP2.	Rifampin	0-8	ATP binding cassette subfamily C member 2	Homo sapiens	62-67
31361500-3	2019	Rifampin significantly induced the transcription of ABCB1 and ABCC2 and protein abundance of P-gp but not of MRP2.	Rifampin	0-8	ATP binding cassette subfamily B member 1	Homo sapiens	93-97
31361500-3	2019	Rifampin significantly induced the transcription of ABCB1 and ABCC2 and protein abundance of P-gp but not of MRP2.	Rifampin	0-8	ATP binding cassette subfamily C member 2	Homo sapiens	109-113
31119275-11	2019	Rifampicin co-administration showed the largest impact on CL/F.	Rifampin	0-10	crooked neck pre-mRNA splicing factor 1	Homo sapiens	58-62
31569378-4	2019	Validation of RGs was performed by an expression analysis of CYP3A4 and CYP1A2 on rifampicin and beta-naphthoflavone induction, respectively.	Rifampin	82-92	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	61-67
31569378-4	2019	Validation of RGs was performed by an expression analysis of CYP3A4 and CYP1A2 on rifampicin and beta-naphthoflavone induction, respectively.	Rifampin	82-92	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	72-78
31527775-6	2019	Uptake of NP-59 into HEK293 cells expressing organic anion transporting polypeptide (OATP)1B1 and OATP1B3 was significantly higher than that into mock cells and was inhibited by rifampicin.	Rifampin	178-188	solute carrier organic anion transporter family member 1B1	Homo sapiens	85-93
31527775-6	2019	Uptake of NP-59 into HEK293 cells expressing organic anion transporting polypeptide (OATP)1B1 and OATP1B3 was significantly higher than that into mock cells and was inhibited by rifampicin.	Rifampin	178-188	solute carrier organic anion transporter family member 1B3	Homo sapiens	98-105
31361500-0	2019	Transcriptional and Post-Transcriptional Regulation of Duodenal P-Glycoprotein and MRP2 in Healthy Human Subjects after Chronic Treatment with Rifampin and Carbamazepine.	Rifampin	143-151	ATP binding cassette subfamily B member 1	Homo sapiens	64-78
31361500-0	2019	Transcriptional and Post-Transcriptional Regulation of Duodenal P-Glycoprotein and MRP2 in Healthy Human Subjects after Chronic Treatment with Rifampin and Carbamazepine.	Rifampin	143-151	ATP binding cassette subfamily C member 2	Homo sapiens	83-87
31420942-0	2019	Physiologically-Based Pharmacokinetic Modeling Approach to Predict Rifampin-Mediated Intestinal P-Glycoprotein Induction.	Rifampin	67-75	ATP binding cassette subfamily B member 1	Homo sapiens	96-110
31420942-2	2019	This study aimed to predict effects of rifampin-mediated intestinal P-glycoprotein (Pgp) induction on pharmacokinetics of Pgp substrates via PBPK modeling.	Rifampin	39-47	ATP binding cassette subfamily B member 1	Homo sapiens	68-82
31420942-2	2019	This study aimed to predict effects of rifampin-mediated intestinal P-glycoprotein (Pgp) induction on pharmacokinetics of Pgp substrates via PBPK modeling.	Rifampin	39-47	ATP binding cassette subfamily B member 1	Homo sapiens	84-87
31420942-2	2019	This study aimed to predict effects of rifampin-mediated intestinal P-glycoprotein (Pgp) induction on pharmacokinetics of Pgp substrates via PBPK modeling.	Rifampin	39-47	ATP binding cassette subfamily B member 1	Homo sapiens	122-125
31420942-5	2019	Next, we predicted rifampin-mediated fold increases in intestinal Pgp abundances to reasonably recover clinically observed DDI results.	Rifampin	19-27	ATP binding cassette subfamily B member 1	Homo sapiens	66-69
31420942-6	2019	The modeling results suggested that threefold to fourfold increases in intestinal Pgp abundances could sufficiently reproduce the DDI results of these Pgp substrates with rifampin.	Rifampin	171-179	ATP binding cassette subfamily B member 1	Homo sapiens	82-85
31420942-6	2019	The modeling results suggested that threefold to fourfold increases in intestinal Pgp abundances could sufficiently reproduce the DDI results of these Pgp substrates with rifampin.	Rifampin	171-179	ATP binding cassette subfamily B member 1	Homo sapiens	151-154
30991038-9	2019	Further studies would be necessary to know the influence of RIF-induced P-gp induction on the treatment outcome of patients with TB.	Rifampin	60-63	phosphoglycolate phosphatase	Homo sapiens	72-76
31656654-12	2019	Conclusions: Coadministration of rifampicin and clarithromycin may increase CYP3A enzymatic activity.	Rifampin	33-43	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	76-81
30991038-0	2019	Rifampin Induces Expression of P-glycoprotein on the THP1 Cell-Derived Macrophages, Causing Decrease Intramacrophage Concentration of Prothionamide.	Rifampin	0-8	GLI family zinc finger 2	Homo sapiens	53-57
30991038-3	2019	The present study determined the effect of RIF on MDR1 gene (P-glycoprotein, P-gp) expression in THP1 macrophages and analyzed the intracellular concentration of the anti-TB drug prothionamide in the presence of RIF.	Rifampin	43-46	ATP binding cassette subfamily B member 1	Homo sapiens	50-54
30991038-3	2019	The present study determined the effect of RIF on MDR1 gene (P-glycoprotein, P-gp) expression in THP1 macrophages and analyzed the intracellular concentration of the anti-TB drug prothionamide in the presence of RIF.	Rifampin	43-46	ATP binding cassette subfamily B member 1	Homo sapiens	61-75
31656654-0	2019	Effect of rifampicin and clarithromycin on the CYP3A activity in patients with Mycobacterium avium complex.	Rifampin	10-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	47-52
31656654-3	2019	The cytochrome P450 (CYP) enzyme inducer, rifampicin, and the CYP inhibitor, clarithromycin, have clinical activity against MAC and key drugs in the treatment of MAC infection.	Rifampin	42-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
30991038-3	2019	The present study determined the effect of RIF on MDR1 gene (P-glycoprotein, P-gp) expression in THP1 macrophages and analyzed the intracellular concentration of the anti-TB drug prothionamide in the presence of RIF.	Rifampin	43-46	phosphoglycolate phosphatase	Homo sapiens	77-81
30991038-3	2019	The present study determined the effect of RIF on MDR1 gene (P-glycoprotein, P-gp) expression in THP1 macrophages and analyzed the intracellular concentration of the anti-TB drug prothionamide in the presence of RIF.	Rifampin	43-46	GLI family zinc finger 2	Homo sapiens	97-101
31404338-0	2019	Xpert MTB/RIF performance to diagnose tuberculosis and rifampicin resistance in a reference centre in southern Brazil.	Rifampin	55-65	ras homolog family member F, filopodia associated	Homo sapiens	10-13
31382894-0	2019	Xpert MTB/RIF assay for the diagnosis of rifampicin resistance in different regions: a meta-analysis.	Rifampin	41-51	ras homolog family member F, filopodia associated	Homo sapiens	10-13
31382894-1	2019	BACKGROUND: To estimate the diagnostic accuracy of Xpert MTB/RIF for rifampicin resistance in different regions, a meta-analysis was carried out.	Rifampin	69-79	ras homolog family member F, filopodia associated	Homo sapiens	61-64
31382894-5	2019	The pooled sensitivity, specificity and AUC of Xpert MTB/RIF for rifampicin resistance detection were 0.93 (95% CI 0.90-0.95), 0.98 (95% CI 0.96-0.98) and 0.99 (95% CI 0.97-0.99), respectively.	Rifampin	65-75	ras homolog family member F, filopodia associated	Homo sapiens	57-60
31382894-8	2019	CONCLUSIONS: The diagnostic accuracy of Xpert MTB/RIF for rifampicin resistance detection was excellent.	Rifampin	58-68	ras homolog family member F, filopodia associated	Homo sapiens	50-53
31404338-2	2019	Xpert MTB/RIF has been implemented in many countries to reduce the time to TB diagnosis and to rapidly detect rifampicin resistance.	Rifampin	110-120	metallothionein 1J, pseudogene	Homo sapiens	6-9
31404338-2	2019	Xpert MTB/RIF has been implemented in many countries to reduce the time to TB diagnosis and to rapidly detect rifampicin resistance.	Rifampin	110-120	ras homolog family member F, filopodia associated	Homo sapiens	10-13
31404338-3	2019	The study aimed to describe and evaluate Xpert MTB/RIF performance in diagnosing pulmonary TB and rifampicin resistance in a tertiary healthcare facility in Brazil.	Rifampin	98-108	metallothionein 1J, pseudogene	Homo sapiens	47-50
31404338-3	2019	The study aimed to describe and evaluate Xpert MTB/RIF performance in diagnosing pulmonary TB and rifampicin resistance in a tertiary healthcare facility in Brazil.	Rifampin	98-108	ras homolog family member F, filopodia associated	Homo sapiens	51-54
31349736-0	2019	Rifampicin and Its Derivative Rifampicin Quinone Reduce Microglial Inflammatory Responses and Neurodegeneration Induced In Vitro by alpha-Synuclein Fibrillary Aggregates.	Rifampin	0-10	synuclein alpha	Homo sapiens	132-147
30570831-3	2019	This phase 1, open-label, multicenter study evaluated the effect of rifampicin, a CYP3A4 inducer, on the pharmacokinetics of single-dose vemurafenib in 27 patients with BRAFV600 mutation-positive metastatic malignancy.	Rifampin	68-78	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	82-88
30583052-10	2019	Xpert MTB/RIF in addition detected rifampicin resistance in 13 patients, in perfect agreement with results from the line probe assay.	Rifampin	35-45	ras homolog family member F, filopodia associated	Homo sapiens	10-13
31349736-3	2019	Pretreatments with Rif and RifQ reduced the secretion of prototypical inflammatory cytokines (TNF- , IL-6) and the burst of oxidative stress in microglial cells activated with alphaS fibrillary aggregates.	Rifampin	19-22	tumor necrosis factor	Homo sapiens	94-97
31349736-3	2019	Pretreatments with Rif and RifQ reduced the secretion of prototypical inflammatory cytokines (TNF- , IL-6) and the burst of oxidative stress in microglial cells activated with alphaS fibrillary aggregates.	Rifampin	19-22	interleukin 6	Homo sapiens	101-105
31332230-8	2019	Treatment of spheroids with rifampicin increased CYP3A4 activity, demonstrating the metabolic capacity of HepaRG spheroids.	Rifampin	28-38	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	49-55
31262885-6	2019	Rifampicin, a PXR agonist, reduced the accumulation of CDDP and suppressed growth inhibition and caspase-3 activation in HepG2 after CDDP exposure.	Rifampin	0-10	nuclear receptor subfamily 1 group I member 2	Homo sapiens	14-17
30903956-8	2019	The developed sensor possessed a high sensitivity toward rifampicin with a detection limit of 0.16 muM and excellent specificity, as compared to rifabutin and rifapentine.	Rifampin	57-67	latexin	Homo sapiens	99-102
31334131-6	2019	This compound also synergized with rifampicin and azithromycin at sub-micromolar concentrations (0.25-0.5 muM), thereby inducing susceptibility to these antibiotics at clinically relevant concentrations in clinical MDR isolates.	Rifampin	35-45	latexin	Homo sapiens	106-109
31262885-6	2019	Rifampicin, a PXR agonist, reduced the accumulation of CDDP and suppressed growth inhibition and caspase-3 activation in HepG2 after CDDP exposure.	Rifampin	0-10	caspase 3	Homo sapiens	97-106
31260434-10	2019	Polymyxins are useful in the treatment of patients infected with Klebsiella pneumoniae NDM (New Delhi metallo-beta-lactamase), where the effectiveness of therapy is greater when colistin is used together with carbapenem or rifampicin or tigecycline.	Rifampin	223-233	NDM-1	Klebsiella pneumoniae	92-124
30975793-4	2019	Data implied rifamycin SV (20 microM) inhibits three OATPs, while rifampicin (5 microM) inhibits OATP1B1/1B3 only.	Rifampin	66-76	solute carrier organic anion transporter family member 1B1	Homo sapiens	97-108
31032736-0	2019	Peppermint (Mentha piperita L.) extract effectively inhibits cytochrome P450 3A4 (CYP3A4) mRNA induction in rifampicin-treated HepG2 cells.	Rifampin	108-118	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	82-88
31032736-2	2019	Therefore, here, we examined the suppressive effects of the extracts from seven edible herbs on the induction of CYP3A4 gene expression in rifampicin-treated HepG2 cells.	Rifampin	139-149	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	113-119
31032736-5	2019	It suppressed the induction of CYP3A4 mRNA expression by rifampicin in a dose-dependent manner.	Rifampin	57-67	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-37
31032736-7	2019	These findings demonstrate that pheophorbide a suppresses the induction of CYP3A4 mRNA expression in rifampicin-treated HepG2 cells.	Rifampin	101-111	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-81
30907428-0	2019	KITTEN following CAT on the long-term use of rifampicin in hidradenitis suppurativa and effectiveness of oral contraceptives.	Rifampin	45-55	catalase	Homo sapiens	17-20
31173647-19	2019	AUTHORS" CONCLUSIONS: We found Xpert MTB/RIF to be sensitive and specific for diagnosing PTB and rifampicin resistance, consistent with findings reported previously.	Rifampin	97-107	ras homolog family member F, filopodia associated	Homo sapiens	41-44
31218462-0	2019	Guidance for Rifampin and Midazolam Dosing Protocols To Study Intestinal and Hepatic Cytochrome P450 (CYP) 3A4 Induction and De-induction.	Rifampin	13-21	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	85-110
31218462-3	2019	To collate published data regarding induction of CYP3A4 expression by rifampin and identify an optimal protocol to study DDIs using physiologically based pharmacokinetic (PBPK) modelling.	Rifampin	70-78	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	49-55
31218462-4	2019	The University of Washington Drug Interaction Database was searched for published data regarding induction of CYP3A4 by rifampin.	Rifampin	120-128	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	110-116
31218462-5	2019	A verified PBPK model was used to define the optimal dose, duration, timing and route of administration of rifampin and midazolam to assess induction of intestinal and hepatic CYP3A4 by rifampin.	Rifampin	186-194	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	176-182
31218462-9	2019	Intestinal CYP3A4 expression returned to baseline in > 90% of participants within 7 days of rifampin cessation, whereas induction of hepatic CYP3A4 persisted for greater than 7 days in > 50% of participants.	Rifampin	92-100	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	11-17
31047967-7	2019	Contribution of both CYP3A and P-GP induction in intestine and liver by rifampicin to pharmacokinetic profiles of victim drugs was investigated.	Rifampin	72-82	phosphoglycolate phosphatase	Homo sapiens	31-35
31047967-11	2019	DDIs of rifampicin with CYP3A or P-GP substrates following oral versus intravenous administration to human were successfully predicted using the developed semi-PBPK model.	Rifampin	8-18	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	24-29
31047967-11	2019	DDIs of rifampicin with CYP3A or P-GP substrates following oral versus intravenous administration to human were successfully predicted using the developed semi-PBPK model.	Rifampin	8-18	phosphoglycolate phosphatase	Homo sapiens	33-37
31047967-0	2019	Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P-glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover.	Rifampin	54-64	ATP binding cassette subfamily B member 1	Homo sapiens	127-141
31047967-2	2019	We aimed to establish a semi-physiologically based pharmacokinetic (semi-PBPK) model involving both enzyme and transporter turnover to simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 (CYP) 3A4/P-glycoprotein (P-GP) in human.	Rifampin	189-199	ATP binding cassette subfamily B member 1	Homo sapiens	269-283
31047967-2	2019	We aimed to establish a semi-physiologically based pharmacokinetic (semi-PBPK) model involving both enzyme and transporter turnover to simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 (CYP) 3A4/P-glycoprotein (P-GP) in human.	Rifampin	189-199	phosphoglycolate phosphatase	Homo sapiens	285-289
31047967-3	2019	Rifampicin was chosen as the CYP3A /P-GP inducer.	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	29-34
31047967-3	2019	Rifampicin was chosen as the CYP3A /P-GP inducer.	Rifampin	0-10	phosphoglycolate phosphatase	Homo sapiens	36-40
30964656-11	2019	Baicalein, curcumin, and rifampicin showed concentration-dependent inhibition of the alpha-synuclein aggregation and the IC50 (the concentration of the compound at which the maxiumum intensity was reduced by one-half) were calculated.	Rifampin	25-35	synuclein alpha	Homo sapiens	85-100
31122209-13	2019	The number of live colonies colonized by the two mutants in the duckling brain and trachea were lower than that of the parental strain within 24 h. CONCLUSIONS: Mutations of rpoB gene in R. anatipestifer mediate rifampin resistance and result in fitness costs.	Rifampin	212-220	DNA-directed RNA polymerase subunit beta	Riemerella anatipestifer ATCC 11845 = DSM 15868	174-178
31005730-7	2019	Including the blaNDM-1 gene, in total 13 resistance genes were identified in E. cloacae EC32 conferring resistance to beta-lactams, rifampicin, phenicols, fosfomycin, macrolides, quinolones, sulfonamides and tetracycline.	Rifampin	132-142	metallo-beta-lactamase NDM-1	Enterobacter cloacae	14-22
31145690-7	2019	The estimated AUC ratios of ruxolitinib by co-administration of the moderate CYP3A4 inhibitor erythromycin (500 mg) and the strong CYP3A4 inducer rifampicin (600 mg) were within a 20% error compared with the clinically observed values.	Rifampin	146-156	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	131-137
30888624-7	2019	After a 14-day washout, 600 mg of rifampin (rifampicin), a strong CYP3A4 inducer, as well as an inducer of UGT enzymes and a weak inducer of CYP1A2, was administered once daily on days 15-21.	Rifampin	34-42	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	66-72
30748026-3	2019	Multiple studies in humans have shown that 4beta-OHC can qualitatively differentiate among weak, moderate, and potent CYP3A induction when an inducer, typically rifampin, is administered for up to 2 weeks.	Rifampin	161-169	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	118-123
30762305-0	2019	Physiologically-Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam.	Rifampin	149-159	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	49-55
30755272-4	2019	A recent rifampicin exposure 1 week earlier had resulted in a massive rise of CRP levels without organ manifestations.	Rifampin	9-19	C-reactive protein	Homo sapiens	78-81
31206055-2	2019	As a result of the Global Fund, some facilities in the country have access to improved diagnostics, including Xpert MTB/RIF testing, of particular use in diagnosing those at risk of drug resistance, in the form of rifampicin-resistant (RR) TB.	Rifampin	214-224	ras homolog family member F, filopodia associated	Homo sapiens	120-123
30944818-0	2019	Mitochondrial Damage and Drp1 Overexpression in Rifampicin- and Isoniazid-induced Liver Injury Cell Model.	Rifampin	48-58	dynamin 1 like	Homo sapiens	25-29
30682622-10	2019	Among tested xenobiotics tributyltin chloride and rifampicin non-enzymatically bound Gstr1 enzyme (the calculated Ki values are 0.26 muM and 65 muM, respectively) and inhibited its activity, showing that these compounds are reversible noncompetitive inhibitors of zebrafish Gstr1.	Rifampin	50-60	glutathione S-transferase rho	Danio rerio	85-90
30682622-10	2019	Among tested xenobiotics tributyltin chloride and rifampicin non-enzymatically bound Gstr1 enzyme (the calculated Ki values are 0.26 muM and 65 muM, respectively) and inhibited its activity, showing that these compounds are reversible noncompetitive inhibitors of zebrafish Gstr1.	Rifampin	50-60	glutathione S-transferase rho	Danio rerio	274-279
30602592-7	2019	Moreover, the rifampicin-induced expression of P450s was also affected by HNF1alpha and HNF1alpha-AS1.	Rifampin	14-24	HNF1 homeobox A	Homo sapiens	74-83
30602592-7	2019	Moreover, the rifampicin-induced expression of P450s was also affected by HNF1alpha and HNF1alpha-AS1.	Rifampin	14-24	HNF1 homeobox A	Homo sapiens	88-97
30602592-7	2019	Moreover, the rifampicin-induced expression of P450s was also affected by HNF1alpha and HNF1alpha-AS1.	Rifampin	14-24	prostaglandin D2 receptor	Homo sapiens	98-101
30622215-0	2019	Belinostat, at Its Clinically Relevant Concentrations, Inhibits Rifampicin-Induced CYP3A4 and MDR1 Gene Expression.	Rifampin	64-74	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	83-89
30622215-0	2019	Belinostat, at Its Clinically Relevant Concentrations, Inhibits Rifampicin-Induced CYP3A4 and MDR1 Gene Expression.	Rifampin	64-74	ATP binding cassette subfamily B member 1	Homo sapiens	94-98
30622215-8	2019	BEL repressed rifampicin-induced gene expression of CYP3A4 and multidrug resistance protein 1, as well as their respective protein activities.	Rifampin	14-24	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	52-58
30622215-8	2019	BEL repressed rifampicin-induced gene expression of CYP3A4 and multidrug resistance protein 1, as well as their respective protein activities.	Rifampin	14-24	ATP binding cassette subfamily B member 1	Homo sapiens	63-93
31039134-3	2019	Both rifampicin and efavirenz are activators of the pregnane X receptor (PXR), a transcription factor with significant inter-species differences in ligand-dependent activation.	Rifampin	5-15	nuclear receptor subfamily 1 group I member 2	Homo sapiens	52-71
31039134-3	2019	Both rifampicin and efavirenz are activators of the pregnane X receptor (PXR), a transcription factor with significant inter-species differences in ligand-dependent activation.	Rifampin	5-15	nuclear receptor subfamily 1 group I member 2	Homo sapiens	73-76
30987227-11	2019	When MA5 was screened for antibiotic resistance, broad resistance against penicillin, streptomycin, tetracycline, ampicillin, rifampicin, and erythromycin was found; this correlated with the presence of multiple gene determinants for antibiotic resistance within the whole genome sequence of MA5.	Rifampin	126-136	PNMA family member 3	Homo sapiens	5-8
30902567-7	2019	Rifampicin increased omeprazole metabolism in all subjects irrespective of genotype, which suggested that CYP2C19 enzymatic activity was induced by rifampicin administration for all genotypes.	Rifampin	0-10	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	106-113
30902567-7	2019	Rifampicin increased omeprazole metabolism in all subjects irrespective of genotype, which suggested that CYP2C19 enzymatic activity was induced by rifampicin administration for all genotypes.	Rifampin	148-158	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	106-113
31084692-1	2019	BACKGROUND: Xpert MTB/RIF assay rapidly diagnoses rifampicin resistance, enabling early initiation of second-line tuberculosis (TB) treatment.	Rifampin	50-60	ras homolog family member F, filopodia associated	Homo sapiens	22-25
30949526-0	2019	Surveillance of Rifampicin Resistance With GeneXpert MTB/RIF in the National Reference Laboratory for Tuberculosis at the Institut Pasteur in Bangui, 2015-2017.	Rifampin	16-26	ras homolog family member F, filopodia associated	Homo sapiens	57-60
30949526-2	2019	Surveillance of resistance to rifampicin with GeneXpert MTB/RIF was instituted in the National TB Reference Laboratory in 2015.	Rifampin	30-40	ras homolog family member F, filopodia associated	Homo sapiens	60-63
30342195-17	2019	To further investigate the regulatory mechanisms, we found that ginsenosides enhanced the rifampicin-induced pregnane X receptor (PXR) transactivation of the CYP3A4 promoter.	Rifampin	90-100	nuclear receptor subfamily 1 group I member 2	Homo sapiens	109-128
30758392-9	2019	However, rifampicin-treated patients had higher CD4 counts and more frequently undetectable HIV viral load by the end of treatment (67% versus 18%, p &lt; 0.001) compared to rifabutin-treated patients, even when only ART-experienced patients were evaluated (66,6% versus 36,3%, p = 0.039).	Rifampin	9-19	CD4 molecule	Homo sapiens	48-51
30496848-1	2019	INTRODUCTION: Xpert MTB/RIF is recommended for the simultaneous detection of tuberculosis (TB) and rifampicin resistance directly from sputum specimens.	Rifampin	99-109	ras homolog family member F, filopodia associated	Homo sapiens	24-27
32032019-0	2019	Rifampicin resistant tuberculosis in presumptive pulmonary tuberculosis cases in Dubti Hospital, Afar, Ethiopia.	Rifampin	0-10	aldo-keto reductase family 7 member A2	Homo sapiens	97-101
30227201-0	2019	Inhibitory kinetics and mechanism of rifampicin on alpha-glucosidase: Insights from spectroscopic and molecular docking analyses.	Rifampin	37-47	sucrase-isomaltase	Homo sapiens	51-68
30227201-2	2019	In this study, the inhibitory effect and mechanism of rifampicin on alpha-glucosidase were investigated by multispectroscopic methods along with molecular docking technique.	Rifampin	54-64	sucrase-isomaltase	Homo sapiens	68-85
30227201-3	2019	The results showed that rifampicin inhibited alpha-glucosidase activity prominently (IC50 = 135 +- 1.2 muM) in a reversible and competitive-type manner.	Rifampin	24-34	sucrase-isomaltase	Homo sapiens	45-62
30227201-4	2019	The fluorescence intensity of alpha-glucosidase was quenched by rifampicin through forming rifampicin-alpha-glucosidase complex in a static procedure.	Rifampin	64-74	sucrase-isomaltase	Homo sapiens	30-47
30227201-4	2019	The fluorescence intensity of alpha-glucosidase was quenched by rifampicin through forming rifampicin-alpha-glucosidase complex in a static procedure.	Rifampin	64-74	sucrase-isomaltase	Homo sapiens	102-119
30227201-7	2019	Moreover, it was found that the binding of rifampicin to alpha-glucosidase could alter the conformation of the enzyme to make it steady, and the binding distance was estimated to be 1.02 nm.	Rifampin	43-53	sucrase-isomaltase	Homo sapiens	57-74
29405807-8	2019	Atorvastatin and rifampicin could inhibit the uptake of deoxyschizandrin and schizandrin B mediated by OATP1B1.	Rifampin	17-27	solute carrier organic anion transporter family member 1B1	Homo sapiens	103-110
30342195-17	2019	To further investigate the regulatory mechanisms, we found that ginsenosides enhanced the rifampicin-induced pregnane X receptor (PXR) transactivation of the CYP3A4 promoter.	Rifampin	90-100	nuclear receptor subfamily 1 group I member 2	Homo sapiens	130-133
30342195-17	2019	To further investigate the regulatory mechanisms, we found that ginsenosides enhanced the rifampicin-induced pregnane X receptor (PXR) transactivation of the CYP3A4 promoter.	Rifampin	90-100	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	158-164
30342195-18	2019	Treatment of hPXR-over-expressed cells with ginsenosides increased the rifampicin-inducible expression of CYP3A4 in a concentration-dependent manner.	Rifampin	71-81	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	106-112
30555014-6	2019	RESULTS: Intoxication with RIF and INH markedly reduced the hematological indices and elevated the biochemical enzyme markers (AST, ALT and ALP, P &lt; 0.001) and lipid profile (P &lt; 0.001), while antioxidant biomarkers were significantly (P &lt; 0.01) depressed and MDA was elevated.	Rifampin	27-30	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	127-130
30503582-7	2019	In addition, treatment with 3-methylcholanthrene, phenobarbital, and rifampin led to the induction of cytochrome P-450 (cyp) 1a1 and cyp1a2, cyp2b10, cyp3a11.	Rifampin	69-77	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	102-128
30503582-7	2019	In addition, treatment with 3-methylcholanthrene, phenobarbital, and rifampin led to the induction of cytochrome P-450 (cyp) 1a1 and cyp1a2, cyp2b10, cyp3a11.	Rifampin	69-77	cytochrome P450, family 1, subfamily a, polypeptide 2	Mus musculus	133-139
30503582-7	2019	In addition, treatment with 3-methylcholanthrene, phenobarbital, and rifampin led to the induction of cytochrome P-450 (cyp) 1a1 and cyp1a2, cyp2b10, cyp3a11.	Rifampin	69-77	cytochrome P450, family 2, subfamily b, polypeptide 10	Mus musculus	141-148
30503582-7	2019	In addition, treatment with 3-methylcholanthrene, phenobarbital, and rifampin led to the induction of cytochrome P-450 (cyp) 1a1 and cyp1a2, cyp2b10, cyp3a11.	Rifampin	69-77	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	150-157
30340248-5	2019	Mean (95% confidence interval) exosome-derived CYP3A4 protein expression pre- and post-rifampicin dosing was 0.24 (0.2-0.28) and 0.42 (0.21-0.65) ng ml-1 exosome concentrate.	Rifampin	87-97	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	47-53
30340248-6	2019	Mean (95% confidence interval) exosome CYP3A4 mRNA expression pre- and post-rifampicin dosing was 6.0 (1.1-32.7) and 48.3 (11.3-104) x 10-11 2-DeltaDeltaCt , respectively.	Rifampin	76-86	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	39-45
30804707-5	2019	The protective roles of rifaximin and rifampicin partly depend on promoting pregnane X receptor (PXR) expression.	Rifampin	38-48	nuclear receptor subfamily 1 group I member 2	Homo sapiens	76-95
30804707-5	2019	The protective roles of rifaximin and rifampicin partly depend on promoting pregnane X receptor (PXR) expression.	Rifampin	38-48	nuclear receptor subfamily 1 group I member 2	Homo sapiens	97-100
31366871-0	2019	Changes in Bile Acid Concentrations after Administration of Ketoconazole or Rifampicin to Chimeric Mice with Humanized Liver.	Rifampin	76-86	glucosidase beta 2	Mus musculus	11-20
31366871-5	2019	Administration of a single dose of ketoconazole or rifampicin, known to potentially cause cholestasis by inhibiting BSEP, did not result in elevated levels of alkaline phosphatase (ALP), which are known hepatic biomarkers.	Rifampin	51-61	ATP-binding cassette, sub-family B (MDR/TAP), member 11	Mus musculus	116-120
31366871-8	2019	The mRNA levels of bile acid-related genes were also altered after treatment with ketoconazole or rifampicin.	Rifampin	98-108	glucosidase beta 2	Mus musculus	19-28
31228606-8	2019	Moreover, the drug-drug interaction and drug-food interaction could be observed by using our human iPS-IECM in the presence of an inducer and inhibitor of CYP3A4, i.e., rifampicin and grape fruit juice, respectively.	Rifampin	169-179	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	155-161
30539784-8	2019	In line with this, rifampicin decreased the number of apoptotic cells in the corpus callosum thereby diminishing the expression of cleaved caspase-3 and Bax, as well as increasing Bcl-2.	Rifampin	19-29	BCL2-associated X protein	Mus musculus	153-156
30539784-8	2019	In line with this, rifampicin decreased the number of apoptotic cells in the corpus callosum thereby diminishing the expression of cleaved caspase-3 and Bax, as well as increasing Bcl-2.	Rifampin	19-29	B cell leukemia/lymphoma 2	Mus musculus	180-185
30539784-9	2019	Moreover, rifampicin significantly lowered the levels of interleukin-6, interleukin-1beta, caspase-12 activity, heme oxygenase-1(HO-1), nitric oxide (NO), and malondialdehyde (MDA) in mice treated with cuprizone.	Rifampin	10-20	interleukin 6	Mus musculus	57-70
30539784-9	2019	Moreover, rifampicin significantly lowered the levels of interleukin-6, interleukin-1beta, caspase-12 activity, heme oxygenase-1(HO-1), nitric oxide (NO), and malondialdehyde (MDA) in mice treated with cuprizone.	Rifampin	10-20	interleukin 1 beta	Mus musculus	72-89
30539784-9	2019	Moreover, rifampicin significantly lowered the levels of interleukin-6, interleukin-1beta, caspase-12 activity, heme oxygenase-1(HO-1), nitric oxide (NO), and malondialdehyde (MDA) in mice treated with cuprizone.	Rifampin	10-20	heme oxygenase 1	Mus musculus	112-128
30539784-10	2019	Conversely, the activity of glutathione peroxidase (GPx) and the level of ferric reducing ability of plasma (FRAP) were increased in response to the treatment with rifampicin.	Rifampin	164-174	mechanistic target of rapamycin kinase	Mus musculus	109-113
30797272-2	2019	OBJECTIVE: To determine the common mutations responsible for rifampicin resistance in TB cases detected by Xpert MTB/RIF assay.	Rifampin	61-71	ras homolog family member F, filopodia associated	Homo sapiens	117-120
30797272-10	2019	CONCLUSION: Xpert MTB/RIF assay uses various combinations of probe to detect MTB along with rifampicin resistance and is a valuable diagnostic tool.	Rifampin	92-102	ras homolog family member F, filopodia associated	Homo sapiens	22-25
30775278-1	2018	Setting: Myanmar"s National Tuberculosis Programme (NTP) uses the Xpert  MTB/RIF assay to diagnose rifampicin (RMP) resistance in sputum smear-positive (Sm+) pulmonary tuberculosis (TB) patients.	Rifampin	99-109	metallothionein 1J, pseudogene	Homo sapiens	73-76
29503005-11	2019	As rifampin loosely binds to Dacron ESGs by weak intermolecular forces, a rifampin-coated ESG would need to be inserted in a timely fashion to treat the diseased aorta and to deliver its antibiotic affect.	Rifampin	3-11	TLE family member 2, transcriptional corepressor	Homo sapiens	36-39
30775278-1	2018	Setting: Myanmar"s National Tuberculosis Programme (NTP) uses the Xpert  MTB/RIF assay to diagnose rifampicin (RMP) resistance in sputum smear-positive (Sm+) pulmonary tuberculosis (TB) patients.	Rifampin	99-109	ras homolog family member F, filopodia associated	Homo sapiens	77-80
30775278-1	2018	Setting: Myanmar"s National Tuberculosis Programme (NTP) uses the Xpert  MTB/RIF assay to diagnose rifampicin (RMP) resistance in sputum smear-positive (Sm+) pulmonary tuberculosis (TB) patients.	Rifampin	111-114	metallothionein 1J, pseudogene	Homo sapiens	73-76
30775278-1	2018	Setting: Myanmar"s National Tuberculosis Programme (NTP) uses the Xpert  MTB/RIF assay to diagnose rifampicin (RMP) resistance in sputum smear-positive (Sm+) pulmonary tuberculosis (TB) patients.	Rifampin	111-114	ras homolog family member F, filopodia associated	Homo sapiens	77-80
30171692-0	2018	CYP3A4-mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1-mediated effects on bilirubin glucuronidation in humans.	Rifampin	27-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
30325673-4	2018	This study aimed to develop a nanoemulsion (NE) containing rifampicin (RIF-NE) and evaluate its in vitro antimycobacterial activity using Resazurin Microtiter Assay against three Mycobacterium tuberculosis strains: two susceptible and a multidrug-resistant.	Rifampin	59-69	alpha fetoprotein regulation 2, inducibility	Mus musculus	71-74
30558670-1	2018	BACKGROUND: In 2011, South Africa improved its ability to test for rifampicin-resistant TB (RR-TB) by introducing GeneXpert MTB/RIF.	Rifampin	67-77	ras homolog family member F, filopodia associated	Homo sapiens	128-131
30171692-1	2018	AIMS: The primary aim of the present study was to quantify the effects of rifampicin, a strong cytochrome P450 (CYP) 3A4 inducer, on the pharmacokinetics of the new selective progesterone receptor modulator, vilaprisan.	Rifampin	74-84	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	95-120
30171692-1	2018	AIMS: The primary aim of the present study was to quantify the effects of rifampicin, a strong cytochrome P450 (CYP) 3A4 inducer, on the pharmacokinetics of the new selective progesterone receptor modulator, vilaprisan.	Rifampin	74-84	progesterone receptor	Homo sapiens	175-196
29700814-3	2018	The MTP model predicted rifampicin biomarker response observed in 1) a hollow-fiber infection model, 2) a murine study to determine pharmacokinetic/pharmacodynamic indices, and 3) several clinical phase IIa early bactericidal activity (EBA) studies.	Rifampin	24-34	ATPase, class II, type 9A	Mus musculus	203-206
29569712-1	2018	Rifampin demonstrated dose-dependent relative induction between cytochrome P (CYP)3A and P-glycoprotein (P-gp), organic anion transporting polypeptides (OATPs), or CYP2C9; P-gp, OATP, and CYP2C9 induction was one drug-drug interaction (DDI) category lower than that observed for CYP3A across a wide range of pregnane X receptor (PXR) agonism.	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	64-84
29569712-1	2018	Rifampin demonstrated dose-dependent relative induction between cytochrome P (CYP)3A and P-glycoprotein (P-gp), organic anion transporting polypeptides (OATPs), or CYP2C9; P-gp, OATP, and CYP2C9 induction was one drug-drug interaction (DDI) category lower than that observed for CYP3A across a wide range of pregnane X receptor (PXR) agonism.	Rifampin	0-8	ATP binding cassette subfamily B member 1	Homo sapiens	89-103
29569712-1	2018	Rifampin demonstrated dose-dependent relative induction between cytochrome P (CYP)3A and P-glycoprotein (P-gp), organic anion transporting polypeptides (OATPs), or CYP2C9; P-gp, OATP, and CYP2C9 induction was one drug-drug interaction (DDI) category lower than that observed for CYP3A across a wide range of pregnane X receptor (PXR) agonism.	Rifampin	0-8	ATP binding cassette subfamily B member 1	Homo sapiens	105-109
29569712-1	2018	Rifampin demonstrated dose-dependent relative induction between cytochrome P (CYP)3A and P-glycoprotein (P-gp), organic anion transporting polypeptides (OATPs), or CYP2C9; P-gp, OATP, and CYP2C9 induction was one drug-drug interaction (DDI) category lower than that observed for CYP3A across a wide range of pregnane X receptor (PXR) agonism.	Rifampin	0-8	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	164-170
29569712-1	2018	Rifampin demonstrated dose-dependent relative induction between cytochrome P (CYP)3A and P-glycoprotein (P-gp), organic anion transporting polypeptides (OATPs), or CYP2C9; P-gp, OATP, and CYP2C9 induction was one drug-drug interaction (DDI) category lower than that observed for CYP3A across a wide range of pregnane X receptor (PXR) agonism.	Rifampin	0-8	ATP binding cassette subfamily B member 1	Homo sapiens	172-176
30340067-10	2018	The method was successfully used for the determination of 4beta-OHC and 4alpha-OHC concentrations in clinical plasma and serum samples collected before and after treatment with a known CYP3A4 inducer rifampicin.	Rifampin	200-210	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	185-191
29569712-1	2018	Rifampin demonstrated dose-dependent relative induction between cytochrome P (CYP)3A and P-glycoprotein (P-gp), organic anion transporting polypeptides (OATPs), or CYP2C9; P-gp, OATP, and CYP2C9 induction was one drug-drug interaction (DDI) category lower than that observed for CYP3A across a wide range of pregnane X receptor (PXR) agonism.	Rifampin	0-8	solute carrier organic anion transporter family member 1A2	Homo sapiens	153-157
29569712-1	2018	Rifampin demonstrated dose-dependent relative induction between cytochrome P (CYP)3A and P-glycoprotein (P-gp), organic anion transporting polypeptides (OATPs), or CYP2C9; P-gp, OATP, and CYP2C9 induction was one drug-drug interaction (DDI) category lower than that observed for CYP3A across a wide range of pregnane X receptor (PXR) agonism.	Rifampin	0-8	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	188-194
29569712-1	2018	Rifampin demonstrated dose-dependent relative induction between cytochrome P (CYP)3A and P-glycoprotein (P-gp), organic anion transporting polypeptides (OATPs), or CYP2C9; P-gp, OATP, and CYP2C9 induction was one drug-drug interaction (DDI) category lower than that observed for CYP3A across a wide range of pregnane X receptor (PXR) agonism.	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	279-284
29569712-1	2018	Rifampin demonstrated dose-dependent relative induction between cytochrome P (CYP)3A and P-glycoprotein (P-gp), organic anion transporting polypeptides (OATPs), or CYP2C9; P-gp, OATP, and CYP2C9 induction was one drug-drug interaction (DDI) category lower than that observed for CYP3A across a wide range of pregnane X receptor (PXR) agonism.	Rifampin	0-8	nuclear receptor subfamily 1 group I member 2	Homo sapiens	308-327
29569712-1	2018	Rifampin demonstrated dose-dependent relative induction between cytochrome P (CYP)3A and P-glycoprotein (P-gp), organic anion transporting polypeptides (OATPs), or CYP2C9; P-gp, OATP, and CYP2C9 induction was one drug-drug interaction (DDI) category lower than that observed for CYP3A across a wide range of pregnane X receptor (PXR) agonism.	Rifampin	0-8	nuclear receptor subfamily 1 group I member 2	Homo sapiens	329-332
29569723-2	2018	The objective of this study was to establish relative induction relationships between CYP3A and drug transporters (P-glycoprotein (P-gp), organic anion transporting polypeptide (OATP), and breast cancer resistance protein (BCRP)) or other P450s (CYP2C9 and CYP1A2) using ascending doses of the prototypical pregnane xenobiotic receptor (PXR) agonist, rifampin, to elicit weak, moderate, and strong PXR agonism.	Rifampin	351-359	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	86-91
29569723-2	2018	The objective of this study was to establish relative induction relationships between CYP3A and drug transporters (P-glycoprotein (P-gp), organic anion transporting polypeptide (OATP), and breast cancer resistance protein (BCRP)) or other P450s (CYP2C9 and CYP1A2) using ascending doses of the prototypical pregnane xenobiotic receptor (PXR) agonist, rifampin, to elicit weak, moderate, and strong PXR agonism.	Rifampin	351-359	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	189-221
29569723-2	2018	The objective of this study was to establish relative induction relationships between CYP3A and drug transporters (P-glycoprotein (P-gp), organic anion transporting polypeptide (OATP), and breast cancer resistance protein (BCRP)) or other P450s (CYP2C9 and CYP1A2) using ascending doses of the prototypical pregnane xenobiotic receptor (PXR) agonist, rifampin, to elicit weak, moderate, and strong PXR agonism.	Rifampin	351-359	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	223-227
30105453-1	2018	PURPOSE: To assess the potential pharmacokinetic (PK) interactions between siponimod and rifampin, a strong CYP3A4/moderate CYP2C9 inducer, in healthy subjects.	Rifampin	89-97	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	108-114
30105453-1	2018	PURPOSE: To assess the potential pharmacokinetic (PK) interactions between siponimod and rifampin, a strong CYP3A4/moderate CYP2C9 inducer, in healthy subjects.	Rifampin	89-97	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	124-130
30105453-14	2018	CONCLUSIONS: The study findings suggest that in the presence of rifampin, a strong CYP3A4/moderate CYP2C9 inducer, siponimod showed significant decrease in Cmax,ss (45%) and AUCtau,ss (57%) in healthy subjects.	Rifampin	64-72	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	83-89
30105453-14	2018	CONCLUSIONS: The study findings suggest that in the presence of rifampin, a strong CYP3A4/moderate CYP2C9 inducer, siponimod showed significant decrease in Cmax,ss (45%) and AUCtau,ss (57%) in healthy subjects.	Rifampin	64-72	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	99-105
31720410-13	2019	Three of the 31 Xpert MTB/RIF positive patients were detected as resistance to rifampicin (RR).	Rifampin	79-89	ras homolog family member F, filopodia associated	Homo sapiens	26-29
30178313-3	2018	Xpert MTB/RIF (Mycobacterium tuberculosis/Rifampicin) is increasingly used in many countries as the initial diagnostic test for TB.	Rifampin	42-52	ras homolog family member F, filopodia associated	Homo sapiens	10-13
30179260-6	2018	In the clinical setting, exposure to nilotinib was significantly reduced by the induction of CYP3A4 with rifampicin and significantly increased by the inhibition of CYP3A with ketoconazole.	Rifampin	105-115	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	93-99
30179260-6	2018	In the clinical setting, exposure to nilotinib was significantly reduced by the induction of CYP3A4 with rifampicin and significantly increased by the inhibition of CYP3A with ketoconazole.	Rifampin	105-115	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	93-98
30382126-7	2018	Co-treatment of HepaRG cells by the cAMP analog Sp-5,6-DCl-cBIMPS and the reference PXR agonist rifampicin reproduced the polarizing effects of FSK.	Rifampin	96-106	nuclear receptor subfamily 1 group I member 2	Homo sapiens	84-87
30175555-2	2018	The in vivo inhibition constants of rifampicin used as initial input parameters for OATP1Bs (Ki,u,OATP1Bs ) and multidrug resistance-associated protein two-mediated biliary excretion were estimated as 0.23 and 0.87 muM, respectively, from previous reports.	Rifampin	36-46	ornithine aminotransferase pseudogene 1	Homo sapiens	84-89
30175555-2	2018	The in vivo inhibition constants of rifampicin used as initial input parameters for OATP1Bs (Ki,u,OATP1Bs ) and multidrug resistance-associated protein two-mediated biliary excretion were estimated as 0.23 and 0.87 muM, respectively, from previous reports.	Rifampin	36-46	ATP binding cassette subfamily C member 3	Homo sapiens	112-151
29095659-0	2018	Indirect activation of pregnane X receptor in the induction of hepatic CYP3A11 by high-dose rifampicin in mice.	Rifampin	92-102	nuclear receptor subfamily 1, group I, member 2	Mus musculus	23-42
29095659-0	2018	Indirect activation of pregnane X receptor in the induction of hepatic CYP3A11 by high-dose rifampicin in mice.	Rifampin	92-102	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	71-78
29095659-1	2018	Rifampicin (RIF), a typical ligand of human pregnane X receptor (PXR), powerfully induces the expression of cytochrome P450 3A4 (CYP3A4) in humans.	Rifampin	0-10	nuclear receptor subfamily 1 group I member 2	Homo sapiens	44-63
29095659-1	2018	Rifampicin (RIF), a typical ligand of human pregnane X receptor (PXR), powerfully induces the expression of cytochrome P450 3A4 (CYP3A4) in humans.	Rifampin	0-10	nuclear receptor subfamily 1 group I member 2	Homo sapiens	65-68
29095659-1	2018	Rifampicin (RIF), a typical ligand of human pregnane X receptor (PXR), powerfully induces the expression of cytochrome P450 3A4 (CYP3A4) in humans.	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	108-127
29095659-1	2018	Rifampicin (RIF), a typical ligand of human pregnane X receptor (PXR), powerfully induces the expression of cytochrome P450 3A4 (CYP3A4) in humans.	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	129-135
29095659-1	2018	Rifampicin (RIF), a typical ligand of human pregnane X receptor (PXR), powerfully induces the expression of cytochrome P450 3A4 (CYP3A4) in humans.	Rifampin	12-15	nuclear receptor subfamily 1 group I member 2	Homo sapiens	44-63
29095659-1	2018	Rifampicin (RIF), a typical ligand of human pregnane X receptor (PXR), powerfully induces the expression of cytochrome P450 3A4 (CYP3A4) in humans.	Rifampin	12-15	nuclear receptor subfamily 1 group I member 2	Homo sapiens	65-68
29095659-1	2018	Rifampicin (RIF), a typical ligand of human pregnane X receptor (PXR), powerfully induces the expression of cytochrome P450 3A4 (CYP3A4) in humans.	Rifampin	12-15	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	108-127
29095659-1	2018	Rifampicin (RIF), a typical ligand of human pregnane X receptor (PXR), powerfully induces the expression of cytochrome P450 3A4 (CYP3A4) in humans.	Rifampin	12-15	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	129-135
29095659-2	2018	Although it is thought that RIF is not a ligand of rodent PXR, treatment with high-dose RIF (e.g. more than 20 mg/kg) increases the expression of CYP3A in the mouse liver.	Rifampin	88-91	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	146-151
29095659-6	2018	In addition, high-dose RIF stimulated nuclear accumulation of mPXR in the mouse liver, and geldanamycin and okadaic acid attenuated the induction of Cyp3a11 and other PXR-target genes in primary hepatocytes, suggesting that high-dose RIF triggers nuclear translocation of mPXR.	Rifampin	23-26	nuclear receptor subfamily 1, group I, member 2	Mus musculus	62-66
29095659-6	2018	In addition, high-dose RIF stimulated nuclear accumulation of mPXR in the mouse liver, and geldanamycin and okadaic acid attenuated the induction of Cyp3a11 and other PXR-target genes in primary hepatocytes, suggesting that high-dose RIF triggers nuclear translocation of mPXR.	Rifampin	23-26	nuclear receptor subfamily 1, group I, member 2	Mus musculus	63-66
29095659-6	2018	In addition, high-dose RIF stimulated nuclear accumulation of mPXR in the mouse liver, and geldanamycin and okadaic acid attenuated the induction of Cyp3a11 and other PXR-target genes in primary hepatocytes, suggesting that high-dose RIF triggers nuclear translocation of mPXR.	Rifampin	23-26	nuclear receptor subfamily 1, group I, member 2	Mus musculus	272-276
29095659-6	2018	In addition, high-dose RIF stimulated nuclear accumulation of mPXR in the mouse liver, and geldanamycin and okadaic acid attenuated the induction of Cyp3a11 and other PXR-target genes in primary hepatocytes, suggesting that high-dose RIF triggers nuclear translocation of mPXR.	Rifampin	234-237	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	149-156
30283337-6	2018	Furthermore, the toxicity was increased in CYP3A4-induced PHH by rifampicin, and CYP3A4 over-expressed (OE) HepG2 and L02 cells.	Rifampin	65-75	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	43-49
30351048-14	2018	Furthermore, it reduced valproate- and rifampin-induced LXRalpha- and pregnane X receptor-mediated lipogenesis, respectively, which indicates its potential benefit in treating drug-induced hepatic steatosis.	Rifampin	39-47	nuclear receptor subfamily 1 group H member 3	Homo sapiens	56-64
30351048-14	2018	Furthermore, it reduced valproate- and rifampin-induced LXRalpha- and pregnane X receptor-mediated lipogenesis, respectively, which indicates its potential benefit in treating drug-induced hepatic steatosis.	Rifampin	39-47	nuclear receptor subfamily 1 group I member 2	Homo sapiens	70-89
30091221-0	2018	PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin.	Rifampin	70-80	phosphoglycolate phosphatase	Homo sapiens	27-31
30180590-5	2018	To assess if the prototypical OATP inhibitor rifampicin can inhibit liver uptake of [11C]erlotinib in vivo, we performed [11C]erlotinib PET scans in six healthy volunteers without and with intravenous pretreatment with rifampicin (600 mg).	Rifampin	45-55	solute carrier organic anion transporter family member 1A2	Homo sapiens	30-34
30180590-10	2018	Furthermore, our data suggest that a standard clinical dose of rifampicin may exert in vivo a moderate inhibitory effect on hepatic OATP2B1.	Rifampin	63-73	solute carrier organic anion transporter family member 2B1	Homo sapiens	132-139
29908302-3	2018	Rifampicin, a PXR-activating agent, elicits a similar effect as PXR+ cells.	Rifampin	0-10	nuclear receptor subfamily 1 group I member 2	Homo sapiens	14-17
29908302-3	2018	Rifampicin, a PXR-activating agent, elicits a similar effect as PXR+ cells.	Rifampin	0-10	nuclear receptor subfamily 1 group I member 2	Homo sapiens	64-67
30195730-11	2018	Rifampicin pretreatment attenuated SE-induced neuroinflammation and decreased the hippocampal expression of interleukin-1beta, tumor necrosis factor-alpha, nuclear factor kappa-B, and cyclooxygenase-2.	Rifampin	0-10	interleukin 1 beta	Rattus norvegicus	108-178
30195730-11	2018	Rifampicin pretreatment attenuated SE-induced neuroinflammation and decreased the hippocampal expression of interleukin-1beta, tumor necrosis factor-alpha, nuclear factor kappa-B, and cyclooxygenase-2.	Rifampin	0-10	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	184-200
30195730-12	2018	Moreover, rifampicin mitigated SE-induced neuronal apoptosis as indicated by fewer positive cytochrome c immunostained cells and lower caspase-3 activity in the hippocampus.	Rifampin	10-20	caspase 3	Rattus norvegicus	135-144
30170758-3	2018	Rifampin induces UGT1A9, UGT2B7, CYP3A4, and CYP3A5.	Rifampin	0-8	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	17-23
30025298-1	2018	Rifampicin (RIF) and clindamycin phosphate (CDM) are the main drugs currently used in combination to treat severe infectious diseases in hair follicles.	Rifampin	0-10	ras homolog family member F, filopodia associated	Homo sapiens	12-15
29243231-2	2018	Plasma and urine CPI data in the presence/absence of rifampicin were modeled to describe CPI synthesis, elimination clearances, and obtain rifampicin in vivo OATP Ki.	Rifampin	139-149	solute carrier organic anion transporter family member 1A2	Homo sapiens	158-162
29243231-5	2018	Estimated rifampicin in vivo unbound OATP Ki (0.13 muM) using CPI data was 2-fold lower relative to rosuvastatin.	Rifampin	10-20	solute carrier organic anion transporter family member 1A2	Homo sapiens	37-41
30170758-3	2018	Rifampin induces UGT1A9, UGT2B7, CYP3A4, and CYP3A5.	Rifampin	0-8	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	25-31
30170758-3	2018	Rifampin induces UGT1A9, UGT2B7, CYP3A4, and CYP3A5.	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	33-39
30170758-3	2018	Rifampin induces UGT1A9, UGT2B7, CYP3A4, and CYP3A5.	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	45-51
30148542-0	2018	Xpert  MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance.	Rifampin	57-67	ras homolog family member F, filopodia associated	Homo sapiens	11-14
30148542-3	2018	Xpert  MTB/RIF (Xpert) is a World Health Organization (WHO)-recommended, rapid, automated, nucleic acid amplification assay that is used widely for simultaneous detection of Mycobacterium tuberculosis complex and rifampicin resistance in sputum specimens.	Rifampin	213-223	ras homolog family member F, filopodia associated	Homo sapiens	11-14
30087611-1	2018	Metoprolol is used for phenotyping of cytochrome P450 (CYP) 2D6, a CYP isoform considered not to be inducible by inducers of the CYP2C, CYP2B, and CYP3A families such as rifampicin.	Rifampin	170-180	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	38-63
29742964-9	2018	In addition, in the organoids generated, cytochrome P450 3A8 (CYP3A8) activity was inhibited by the specific inhibitor ketoconazole and was induced by rifampicin.	Rifampin	151-161	cytochrome P450 family 3 subfamily A member 4	Macaca fascicularis	41-60
29742964-9	2018	In addition, in the organoids generated, cytochrome P450 3A8 (CYP3A8) activity was inhibited by the specific inhibitor ketoconazole and was induced by rifampicin.	Rifampin	151-161	cytochrome P450 family 3 subfamily A member 4	Macaca fascicularis	62-68
30068608-7	2018	This interaction is the target of rifampicin, which prevents A17 binding, explaining the inhibition of viral morphogenesis.	Rifampin	34-44	immunoglobulin kappa variable 2-30	Homo sapiens	61-64
30087611-2	2018	While assessing CYP2D6 activity under basal conditions and after pre-treatment with rifampicin in vivo, we surprisingly observed a drop in the metoprolol/alpha-OH-metoprolol clearance ratio, suggesting CYP2D6 induction.	Rifampin	84-94	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	16-22
30087611-2	2018	While assessing CYP2D6 activity under basal conditions and after pre-treatment with rifampicin in vivo, we surprisingly observed a drop in the metoprolol/alpha-OH-metoprolol clearance ratio, suggesting CYP2D6 induction.	Rifampin	84-94	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	202-208
30087611-9	2018	CYP3A4, 2B6, and 2C9, which are inducible by rifampicin, contribute to alpha-hydroxylation, O-demethylation, and N-dealkylation of metoprolol.	Rifampin	45-55	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-11
28685622-8	2018	TaqMan  gene expression analysis of human hepatocytes treated with PF-06282999 and the prototypical PXR agonist rifampin demonstrated increases in mRNA for CYP3A4 and related CYPs that are regulated by PXR.	Rifampin	112-120	nuclear receptor subfamily 1 group I member 2	Homo sapiens	100-103
30094330-1	2018	Introduction: Oral rifampicin has been shown to significantly reduce amyloid beta (Abeta) and tau pathologies in mice.	Rifampin	19-29	histocompatibility 2, class II antigen A, beta 1	Mus musculus	83-88
29666154-8	2018	The ft values were then used for evaluating in vitro-in vivo correlations of hepatic uptake inhibition with OATP inhibitors rifampicin and cyclosporine.	Rifampin	124-134	solute carrier organic anion transporter family member 1A2	Homo sapiens	108-112
29940951-9	2018	Compared with drug susceptibility testing (DST), the pooled accordance rate of Xpert MTB/RIF in detecting rifampicin-susceptible cases and rifampicin-resistant cases was 99% (95% CI: 95-104%, I2 = 8.7%) and 94% (95% CI: 86-102%), respectively.	Rifampin	106-116	metallothionein 1J, pseudogene	Homo sapiens	85-88
29940951-9	2018	Compared with drug susceptibility testing (DST), the pooled accordance rate of Xpert MTB/RIF in detecting rifampicin-susceptible cases and rifampicin-resistant cases was 99% (95% CI: 95-104%, I2 = 8.7%) and 94% (95% CI: 86-102%), respectively.	Rifampin	106-116	ras homolog family member F, filopodia associated	Homo sapiens	89-92
28685622-8	2018	TaqMan  gene expression analysis of human hepatocytes treated with PF-06282999 and the prototypical PXR agonist rifampin demonstrated increases in mRNA for CYP3A4 and related CYPs that are regulated by PXR.	Rifampin	112-120	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	156-162
28685622-8	2018	TaqMan  gene expression analysis of human hepatocytes treated with PF-06282999 and the prototypical PXR agonist rifampin demonstrated increases in mRNA for CYP3A4 and related CYPs that are regulated by PXR.	Rifampin	112-120	nuclear receptor subfamily 1 group I member 2	Homo sapiens	202-205
28686070-0	2018	Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19.	Rifampin	21-31	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-93
29343610-5	2018	CYP2J2 has been shown to be resistant to induction by canonical CYP inducers such as phenytoin and rifampin.	Rifampin	99-107	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
29412463-4	2018	This study enrolled 64 healthy subjects to evaluate the effect of cyclosporine, a P-gp, BCRP, and OATP1B1/1B3 inhibitor; rifampin, a strong CYP3A4 and P-gp inducer; efavirenz, a moderate CYP3A4 inducer; and cobicistat, a potent CYP3A inhibitor, on presatovir pharmacokinetics.	Rifampin	121-129	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	140-146
29412463-4	2018	This study enrolled 64 healthy subjects to evaluate the effect of cyclosporine, a P-gp, BCRP, and OATP1B1/1B3 inhibitor; rifampin, a strong CYP3A4 and P-gp inducer; efavirenz, a moderate CYP3A4 inducer; and cobicistat, a potent CYP3A inhibitor, on presatovir pharmacokinetics.	Rifampin	121-129	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	187-193
29440451-2	2018	The goal of this research was to establish PXR-/CAR-/AhR-specific drug-metabolizing enzyme (DME) and transporter gene expression signatures in sandwich-cultured cryopreserved human hepatocytes using selective activators of PXR (rifampin), CAR (CITCO), and AhR (omeprazole).	Rifampin	228-236	nuclear receptor subfamily 1 group I member 2	Homo sapiens	43-46
29440451-2	2018	The goal of this research was to establish PXR-/CAR-/AhR-specific drug-metabolizing enzyme (DME) and transporter gene expression signatures in sandwich-cultured cryopreserved human hepatocytes using selective activators of PXR (rifampin), CAR (CITCO), and AhR (omeprazole).	Rifampin	228-236	nuclear receptor subfamily 1 group I member 3	Homo sapiens	48-51
29440451-2	2018	The goal of this research was to establish PXR-/CAR-/AhR-specific drug-metabolizing enzyme (DME) and transporter gene expression signatures in sandwich-cultured cryopreserved human hepatocytes using selective activators of PXR (rifampin), CAR (CITCO), and AhR (omeprazole).	Rifampin	228-236	aryl hydrocarbon receptor	Homo sapiens	53-56
29440451-2	2018	The goal of this research was to establish PXR-/CAR-/AhR-specific drug-metabolizing enzyme (DME) and transporter gene expression signatures in sandwich-cultured cryopreserved human hepatocytes using selective activators of PXR (rifampin), CAR (CITCO), and AhR (omeprazole).	Rifampin	228-236	nuclear receptor subfamily 1 group I member 2	Homo sapiens	223-226
29469947-6	2018	The inducers omeprazole, phenobarbital and rifampicin increased the levels of CYP1A2, 2B6 and 3A4 mRNAs by 110-fold, 12.5-fold and 5.4-fold, respectively, at day 2, compared with control human hepatocytes.	Rifampin	43-53	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	78-84
29872095-6	2018	GM-CSF neutralization compromised the bacterial control under sub-optimal isoniazid/rifampicin treatment in TNFalpha-deficient mice, leading to exacerbated lung inflammation with necrotic granulomatous structures and high numbers of intracellular M. tuberculosis bacilli.	Rifampin	84-94	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	0-6
29867823-6	2018	In vitro, colistin plus rifampin was synergistic against all the strains at 24 h. In vivo, compared to the controls, rifampin alone reduced tissue bacterial concentrations against VIM-1 and OXA-48 plus CTX-M-15 strains; CMS plus rifampin reduced tissue bacterial concentrations of these two CP-Kp and of the KPC-3 strain.	Rifampin	24-32	OXA-48	Klebsiella pneumoniae	190-196
29867823-6	2018	In vitro, colistin plus rifampin was synergistic against all the strains at 24 h. In vivo, compared to the controls, rifampin alone reduced tissue bacterial concentrations against VIM-1 and OXA-48 plus CTX-M-15 strains; CMS plus rifampin reduced tissue bacterial concentrations of these two CP-Kp and of the KPC-3 strain.	Rifampin	24-32	cystin 1	Mus musculus	291-296
29867823-6	2018	In vitro, colistin plus rifampin was synergistic against all the strains at 24 h. In vivo, compared to the controls, rifampin alone reduced tissue bacterial concentrations against VIM-1 and OXA-48 plus CTX-M-15 strains; CMS plus rifampin reduced tissue bacterial concentrations of these two CP-Kp and of the KPC-3 strain.	Rifampin	24-32	KPC-3	Klebsiella pneumoniae	308-313
29867823-6	2018	In vitro, colistin plus rifampin was synergistic against all the strains at 24 h. In vivo, compared to the controls, rifampin alone reduced tissue bacterial concentrations against VIM-1 and OXA-48 plus CTX-M-15 strains; CMS plus rifampin reduced tissue bacterial concentrations of these two CP-Kp and of the KPC-3 strain.	Rifampin	117-125	OXA-48	Klebsiella pneumoniae	190-196
29867823-6	2018	In vitro, colistin plus rifampin was synergistic against all the strains at 24 h. In vivo, compared to the controls, rifampin alone reduced tissue bacterial concentrations against VIM-1 and OXA-48 plus CTX-M-15 strains; CMS plus rifampin reduced tissue bacterial concentrations of these two CP-Kp and of the KPC-3 strain.	Rifampin	117-125	cystin 1	Mus musculus	291-296
29867823-6	2018	In vitro, colistin plus rifampin was synergistic against all the strains at 24 h. In vivo, compared to the controls, rifampin alone reduced tissue bacterial concentrations against VIM-1 and OXA-48 plus CTX-M-15 strains; CMS plus rifampin reduced tissue bacterial concentrations of these two CP-Kp and of the KPC-3 strain.	Rifampin	117-125	KPC-3	Klebsiella pneumoniae	308-313
29867823-6	2018	In vitro, colistin plus rifampin was synergistic against all the strains at 24 h. In vivo, compared to the controls, rifampin alone reduced tissue bacterial concentrations against VIM-1 and OXA-48 plus CTX-M-15 strains; CMS plus rifampin reduced tissue bacterial concentrations of these two CP-Kp and of the KPC-3 strain.	Rifampin	117-125	OXA-48	Klebsiella pneumoniae	190-196
29867823-6	2018	In vitro, colistin plus rifampin was synergistic against all the strains at 24 h. In vivo, compared to the controls, rifampin alone reduced tissue bacterial concentrations against VIM-1 and OXA-48 plus CTX-M-15 strains; CMS plus rifampin reduced tissue bacterial concentrations of these two CP-Kp and of the KPC-3 strain.	Rifampin	117-125	cystin 1	Mus musculus	291-296
29867823-6	2018	In vitro, colistin plus rifampin was synergistic against all the strains at 24 h. In vivo, compared to the controls, rifampin alone reduced tissue bacterial concentrations against VIM-1 and OXA-48 plus CTX-M-15 strains; CMS plus rifampin reduced tissue bacterial concentrations of these two CP-Kp and of the KPC-3 strain.	Rifampin	117-125	KPC-3	Klebsiella pneumoniae	308-313
29867823-7	2018	Rifampin and the combination increased the survival against the KPC-3 strain; in the pneumonia model, the combination also improved the survival.	Rifampin	0-8	KPC-3	Klebsiella pneumoniae	64-69
29488691-0	2018	Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer.	Rifampin	56-64	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	68-87
29488691-2	2018	Because it is a substrate of the cytochrome P450 system, specifically CYP3A4/5, ivacaftor is subject to significant drug-drug interactions, including due to commonly used antimicrobials such as rifampin.	Rifampin	194-202	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	70-76
29356861-12	2018	The compounds differentially antagonised the induction of PXR-regulated genes by rifampicin in primary human hepatocytes.	Rifampin	81-91	nuclear receptor subfamily 1 group I member 2	Homo sapiens	58-61
29031874-8	2018	Rifampicin, a potent CYP3A4 inducer, is the first-line treatment of cholestatic pruritus.	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	21-27
29440179-8	2018	Human liver carcinoma cells (HepG2) were transfected with CYP3A4 luciferase and PXR plasmids, followed by treatment with JNK inhibitor (SP600125; SP) and PXR activators rifampicin (RIF) or hyperforin.	Rifampin	169-179	nuclear receptor subfamily 1 group I member 2	Homo sapiens	154-157
29343610-5	2018	CYP2J2 has been shown to be resistant to induction by canonical CYP inducers such as phenytoin and rifampin.	Rifampin	99-107	peptidylprolyl isomerase G	Homo sapiens	0-3
29470228-3	2018	The long half-life of amiodarone and its active metabolite in combination with the late onset and offset of cytochrome P4503A (CYP3A4) induction by rifampicin makes this a challenging drug-drug interaction to cope with in clinical practice.	Rifampin	148-158	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	127-133
29635947-9	2018	Rifampicin significantly increases plasma concentrations of both enantiomers through inhibition of OATP1B3, whereas enantioselectivity of fexofenadine uptake by OATP1B3-expressing cells has not been observed.	Rifampin	0-10	solute carrier organic anion transporter family member 1B3	Homo sapiens	99-106
29143479-1	2018	Rifampin (RIF) is a bactericidal antibiotic drug and potent inducer of hepatic and intestinal cytochrome P-450 (CYP-450) enzyme systems.	Rifampin	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-110
29143479-1	2018	Rifampin (RIF) is a bactericidal antibiotic drug and potent inducer of hepatic and intestinal cytochrome P-450 (CYP-450) enzyme systems.	Rifampin	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-119
29143479-1	2018	Rifampin (RIF) is a bactericidal antibiotic drug and potent inducer of hepatic and intestinal cytochrome P-450 (CYP-450) enzyme systems.	Rifampin	10-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-110
29143479-1	2018	Rifampin (RIF) is a bactericidal antibiotic drug and potent inducer of hepatic and intestinal cytochrome P-450 (CYP-450) enzyme systems.	Rifampin	10-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-119
29393813-20	2018	Further consideration should be given to the use of rifampin in the treatment of CSF shunt infection.	Rifampin	52-60	colony stimulating factor 2	Homo sapiens	81-84
29435803-0	2018	Rifampicin Prevents SH-SY5Y Cells from Rotenone-Induced Apoptosis via the PI3K/Akt/GSK-3beta/CREB Signaling Pathway.	Rifampin	0-10	AKT serine/threonine kinase 1	Homo sapiens	79-82
29435803-0	2018	Rifampicin Prevents SH-SY5Y Cells from Rotenone-Induced Apoptosis via the PI3K/Akt/GSK-3beta/CREB Signaling Pathway.	Rifampin	0-10	glycogen synthase kinase 3 beta	Homo sapiens	83-92
29435803-0	2018	Rifampicin Prevents SH-SY5Y Cells from Rotenone-Induced Apoptosis via the PI3K/Akt/GSK-3beta/CREB Signaling Pathway.	Rifampin	0-10	cAMP responsive element binding protein 1	Homo sapiens	93-97
29435803-3	2018	This study aims to investigate whether rifampicin protects rotenone-lesioned SH-SY5Y cells via regulating PI3K/Akt/GSK-3beta/CREB pathway.	Rifampin	39-49	AKT serine/threonine kinase 1	Homo sapiens	111-114
29435803-3	2018	This study aims to investigate whether rifampicin protects rotenone-lesioned SH-SY5Y cells via regulating PI3K/Akt/GSK-3beta/CREB pathway.	Rifampin	39-49	glycogen synthase kinase 3 beta	Homo sapiens	115-124
29435803-3	2018	This study aims to investigate whether rifampicin protects rotenone-lesioned SH-SY5Y cells via regulating PI3K/Akt/GSK-3beta/CREB pathway.	Rifampin	39-49	cAMP responsive element binding protein 1	Homo sapiens	125-129
29098603-5	2018	The model was validated using clinical PK data for co-administration of GXR with ketoconazole (strong CYP3A4 inhibitor) or rifampicin (strong CYP3A4 inducer).	Rifampin	123-133	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	142-148
29437631-5	2018	The adjuvant potency of C12-PRP was apparent by its ability to reduce the MIC of minocycline and rifampin below their interpretative susceptibility breakpoints against MDR/XDR P. aeruginosa An attempt to optimize C12-PRP through peptidomimetic modification was performed by replacing all l- to d-amino acids.	Rifampin	97-105	prion protein	Homo sapiens	28-31
29437631-6	2018	C12-PRP demonstrated that it was amenable to optimization, since synergism with minocycline and rifampin were retained.	Rifampin	96-104	prion protein	Homo sapiens	4-7
29435803-8	2018	Both the cell viability and the expression of phospho-CREB in cells pretreated with rifampicin were higher than those of cells exposed to rotenone alone.	Rifampin	84-94	cAMP responsive element binding protein 1	Homo sapiens	54-58
29435803-9	2018	Moreover, pretreatment of SH-SY5Y cells with rifampicin enhanced phosphorylation of Akt and suppressed activity of GSK-3beta.	Rifampin	45-55	AKT serine/threonine kinase 1	Homo sapiens	84-87
29435803-9	2018	Moreover, pretreatment of SH-SY5Y cells with rifampicin enhanced phosphorylation of Akt and suppressed activity of GSK-3beta.	Rifampin	45-55	glycogen synthase kinase 3 beta	Homo sapiens	115-124
29435803-10	2018	The addition of LY294002, a PI3K inhibitor, could suppress phosphorylation of Akt and CREB and activate GSK-3beta, resulting in abolishment of neuroprotective effects of rifampicin on cells exposed to rotenone.	Rifampin	170-180	glycogen synthase kinase 3 beta	Homo sapiens	104-113
29435803-11	2018	Rifampicin provides neuroprotection against dopaminergic degeneration, partially via the PI3K/Akt/GSK-3beta/CREB signaling pathway.	Rifampin	0-10	AKT serine/threonine kinase 1	Homo sapiens	94-97
29435803-11	2018	Rifampicin provides neuroprotection against dopaminergic degeneration, partially via the PI3K/Akt/GSK-3beta/CREB signaling pathway.	Rifampin	0-10	glycogen synthase kinase 3 beta	Homo sapiens	98-107
29435803-11	2018	Rifampicin provides neuroprotection against dopaminergic degeneration, partially via the PI3K/Akt/GSK-3beta/CREB signaling pathway.	Rifampin	0-10	cAMP responsive element binding protein 1	Homo sapiens	108-112
29437631-3	2018	SPRLPs were further evaluated for their potential to serve as adjuvants in combination with existing antibiotics to enhance antibacterial activity against drug-resistant Pseudomonas aeruginosa Out of 16 prepared SPRLPs, C12-PRP was found to significantly potentiate the antibiotics minocycline and rifampin against multidrug- and extensively drug-resistant (MDR/XDR) P. aeruginosa clinical isolates.	Rifampin	298-306	prion protein	Homo sapiens	224-227
29610665-8	2018	Physiologically based pharmacokinetic modeling (PBPK) was used to simulate the clinical consequences of rifampin induction of CYP3A4- and UGT1A4-mediated midazolam metabolism.	Rifampin	104-112	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	126-132
29610665-8	2018	Physiologically based pharmacokinetic modeling (PBPK) was used to simulate the clinical consequences of rifampin induction of CYP3A4- and UGT1A4-mediated midazolam metabolism.	Rifampin	104-112	UDP glucuronosyltransferase family 1 member A4	Homo sapiens	138-144
29285606-9	2018	Regarding phase II metabolism, UGT2B7, 1A8 and 1A3 showed highest activity in glucuronidation of tamoxifen bisphenol and metabolite E. Anti-estrogenic metabolites (Z)-4-hydroxytamoxifen, (Z)-endoxifen and (Z)-norendoxifen inhibited the activity of CYP2C enzymes while tamoxifen bisphenol consistently induced CYPs similar to rifampicin and phenobarbital.	Rifampin	325-335	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	31-37
29593688-10	2018	Rifampicin resistance reported by Xpert MTB/RIF slightly deviated from that by phenotypic antibiotic susceptibility testing and requires further study with a larger sample size.	Rifampin	0-10	ras homolog family member F, filopodia associated	Homo sapiens	44-47
29358328-7	2018	Of note, M. tuberculosis infection and rifampicin exposure synergistically modulated macrophage drug-efflux transporters in vitro We also found that the xenobiotic nuclear receptor pregnane X receptor (PXR) modulates macrophage drug-efflux transporter expression and activity, which compromised the anti-TB efficacy of rifampicin.	Rifampin	39-49	nuclear receptor subfamily 1, group I, member 2	Mus musculus	202-205
29358328-7	2018	Of note, M. tuberculosis infection and rifampicin exposure synergistically modulated macrophage drug-efflux transporters in vitro We also found that the xenobiotic nuclear receptor pregnane X receptor (PXR) modulates macrophage drug-efflux transporter expression and activity, which compromised the anti-TB efficacy of rifampicin.	Rifampin	319-329	nuclear receptor subfamily 1, group I, member 2	Mus musculus	202-205
29358328-8	2018	We further validated this finding in a TB mouse model in which use of the PXR antagonist ketoconazole rescued rifampicin anti-TB activity.	Rifampin	110-120	nuclear receptor subfamily 1, group I, member 2	Mus musculus	74-77
29358328-9	2018	We conclude that PXR activation in macrophages compromises the efficacy of the anti-TB drug rifampicin.	Rifampin	92-102	nuclear receptor subfamily 1, group I, member 2	Mus musculus	17-20
28800141-3	2018	This multiarm phase 1 study (Clinicaltrials.gov identifier: NCT01454076) investigated the effect of the strong CYP3A inhibitors ketoconazole and clarithromycin and the strong CYP3A inducer rifampin on the pharmacokinetics of ixazomib.	Rifampin	189-197	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	175-180
29315976-2	2018	Here we summarize the underlying mechanisms of the neuroprotective and pro-cognitive effects of rifampicin that are mediated by its anti-inflammatory, anti-tau, anti-amyloid, and cholinergic effects.	Rifampin	96-106	microtubule associated protein tau	Homo sapiens	156-159
29440136-3	2018	Rifampicin is a common inducer of CYP3A4.	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	34-40
28967981-6	2018	In summary, a strong CYP3A4 inducer (rifampin) had a strong effect (>5-fold) on the clinical pharmacokinetics of apatinib, whereas a strong CYP3A inhibitor (itraconazole 100 mg once a day) had a weak effect (1.25- to 2-fold).	Rifampin	37-45	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	21-27
28967981-6	2018	In summary, a strong CYP3A4 inducer (rifampin) had a strong effect (>5-fold) on the clinical pharmacokinetics of apatinib, whereas a strong CYP3A inhibitor (itraconazole 100 mg once a day) had a weak effect (1.25- to 2-fold).	Rifampin	37-45	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	21-26
29263072-0	2018	Effect of Genetic Variation of NAT2 on Isoniazid and SLCO1B1 and CES2 on Rifampin Pharmacokinetics in Ghanaian Children with Tuberculosis.	Rifampin	73-81	N-acetyltransferase 2	Homo sapiens	31-35
29263072-0	2018	Effect of Genetic Variation of NAT2 on Isoniazid and SLCO1B1 and CES2 on Rifampin Pharmacokinetics in Ghanaian Children with Tuberculosis.	Rifampin	73-81	carboxylesterase 2	Homo sapiens	65-69
29636933-2	2018	Reduction in calcineurin inhibitor levels in organ transplant recipients due to enhanced metabolism from interaction with rifampin can predispose these individuals to develop IRIS during the treatment of tuberculosis and mimic sepsis.	Rifampin	122-130	calcineurin binding protein 1	Homo sapiens	13-34
30347615-5	2018	METHODS: CYP1A2 and CYP3A4 were induced by omeprazole and rifampicin, respectively.	Rifampin	58-68	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	9-15
29191818-5	2018	To analyze the contribution of Cyp3a11 to the protection of atherosclerosis development, Cyp3a11 was induced by Rifampicin (RIF) in ApoE KO and het mice.	Rifampin	112-122	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	89-96
29191818-5	2018	To analyze the contribution of Cyp3a11 to the protection of atherosclerosis development, Cyp3a11 was induced by Rifampicin (RIF) in ApoE KO and het mice.	Rifampin	112-122	apolipoprotein E	Mus musculus	132-136
29191818-5	2018	To analyze the contribution of Cyp3a11 to the protection of atherosclerosis development, Cyp3a11 was induced by Rifampicin (RIF) in ApoE KO and het mice.	Rifampin	124-127	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	89-96
29191818-5	2018	To analyze the contribution of Cyp3a11 to the protection of atherosclerosis development, Cyp3a11 was induced by Rifampicin (RIF) in ApoE KO and het mice.	Rifampin	124-127	apolipoprotein E	Mus musculus	132-136
29357810-5	2018	mRNA expression levels and enzyme activities of CYP1A2, CYP2B6, and CYP3A in HepaRG cells treated with prototypical inducers of each CYP isoform [omeprazole (OME) for CYP1A2, phenobarbital (PB) for CYP2B6, and rifampicin (RIF) for CYP3A] were evaluated.	Rifampin	210-220	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	48-54
29357810-5	2018	mRNA expression levels and enzyme activities of CYP1A2, CYP2B6, and CYP3A in HepaRG cells treated with prototypical inducers of each CYP isoform [omeprazole (OME) for CYP1A2, phenobarbital (PB) for CYP2B6, and rifampicin (RIF) for CYP3A] were evaluated.	Rifampin	210-220	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	68-73
29357810-5	2018	mRNA expression levels and enzyme activities of CYP1A2, CYP2B6, and CYP3A in HepaRG cells treated with prototypical inducers of each CYP isoform [omeprazole (OME) for CYP1A2, phenobarbital (PB) for CYP2B6, and rifampicin (RIF) for CYP3A] were evaluated.	Rifampin	210-220	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-51
29357810-5	2018	mRNA expression levels and enzyme activities of CYP1A2, CYP2B6, and CYP3A in HepaRG cells treated with prototypical inducers of each CYP isoform [omeprazole (OME) for CYP1A2, phenobarbital (PB) for CYP2B6, and rifampicin (RIF) for CYP3A] were evaluated.	Rifampin	222-225	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	48-54
29357810-5	2018	mRNA expression levels and enzyme activities of CYP1A2, CYP2B6, and CYP3A in HepaRG cells treated with prototypical inducers of each CYP isoform [omeprazole (OME) for CYP1A2, phenobarbital (PB) for CYP2B6, and rifampicin (RIF) for CYP3A] were evaluated.	Rifampin	222-225	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	68-73
29357810-5	2018	mRNA expression levels and enzyme activities of CYP1A2, CYP2B6, and CYP3A in HepaRG cells treated with prototypical inducers of each CYP isoform [omeprazole (OME) for CYP1A2, phenobarbital (PB) for CYP2B6, and rifampicin (RIF) for CYP3A] were evaluated.	Rifampin	222-225	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-51
28833380-8	2018	Food effects, comedication with itraconazole [a cytochrome P450 (CYP) 3A4 inhibitor], fluconazole (a CYP2C19 inhibitor) and rifampicin (a CYP3A4 inducer) and formulation effects were incorporated into the base model a priori.	Rifampin	124-134	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	138-144
30347615-5	2018	METHODS: CYP1A2 and CYP3A4 were induced by omeprazole and rifampicin, respectively.	Rifampin	58-68	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	20-26
28715853-2	2017	The present study evaluated the possible pharmacokinetic interactions of selexipag with gemfibrozil, a strong CYP2C8 inhibitor, and rifampicin, an inducer of CYP2C8.	Rifampin	132-142	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	158-164
29226732-10	2018	Further studies are needed in order to provide definitive recommendations of pharmacogenetic-based individualization: however lower isoniazid doses in NAT2 slow acetylators and higher rifampicin doses in individuals with SLCO1B1 loss of function genes are promising strategies.	Rifampin	184-194	solute carrier organic anion transporter family member 1B1	Homo sapiens	221-228
28946447-0	2018	Influence of the ultrasound-assisted synthesis of Cu-BTC metal-organic frameworks nanoparticles on uptake and release properties of rifampicin.	Rifampin	132-142	betacellulin	Homo sapiens	53-56
28946447-1	2018	In this work, we study uptake and release properties of rifampicin (denoted henceforth as Rif) from ultrasound-assisted synthesis Cu-BTC nanoparticles in comparison with bulk Cu-BTC and activated carbon.	Rifampin	56-66	betacellulin	Homo sapiens	133-136
28946447-1	2018	In this work, we study uptake and release properties of rifampicin (denoted henceforth as Rif) from ultrasound-assisted synthesis Cu-BTC nanoparticles in comparison with bulk Cu-BTC and activated carbon.	Rifampin	90-93	betacellulin	Homo sapiens	133-136
29076107-10	2017	CONCLUSION: These findings confirm that amenamevir (as a cytochrome P450 3A4 substrate) can interact with ketoconazole or rifampicin, and (as a cytochrome P450 3A4 inducer) can interact with midazolam; however, no interaction between amenamevir and (S)-warfarin was observed, indicating that amenamevir is not an inducer of cytochrome P450 2C9.	Rifampin	122-132	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	57-76
29157826-6	2017	RESULTS: Transient transfection assays showed that UA effectively attenuated CYP3A4 and CYP2B6 promoter activities mediated by rifampin (RIF, human PXR agonist) and CITCO (human CAR agonist).	Rifampin	127-135	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	88-94
29157826-6	2017	RESULTS: Transient transfection assays showed that UA effectively attenuated CYP3A4 and CYP2B6 promoter activities mediated by rifampin (RIF, human PXR agonist) and CITCO (human CAR agonist).	Rifampin	137-140	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	77-83
29157826-6	2017	RESULTS: Transient transfection assays showed that UA effectively attenuated CYP3A4 and CYP2B6 promoter activities mediated by rifampin (RIF, human PXR agonist) and CITCO (human CAR agonist).	Rifampin	137-140	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	88-94
28912253-6	2017	The model was then applied to predict the drug interaction with the strong CYP3A4 inducer rifampin (RIF) and the sensitive CYP3A4 substrate midazolam (MDZ) in lieu of clinical trials.	Rifampin	90-98	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-81
28912253-6	2017	The model was then applied to predict the drug interaction with the strong CYP3A4 inducer rifampin (RIF) and the sensitive CYP3A4 substrate midazolam (MDZ) in lieu of clinical trials.	Rifampin	100-103	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-81
28986232-5	2017	Here, we demonstrate that rifampicin pretreatment alleviated rotenone induced release of IL-1beta and IL-6, and its effects were suppressed when autophagy was inhibited by chloroquine.	Rifampin	26-36	interleukin 1 beta	Mus musculus	89-97
28986232-5	2017	Here, we demonstrate that rifampicin pretreatment alleviated rotenone induced release of IL-1beta and IL-6, and its effects were suppressed when autophagy was inhibited by chloroquine.	Rifampin	26-36	interleukin 6	Mus musculus	102-106
29157826-0	2017	Modulation of pregnane X receptor (PXR) and constitutive androstane receptor (CAR) activation by ursolic acid (UA) attenuates rifampin-isoniazid cytotoxicity.	Rifampin	126-134	nuclear receptor subfamily 1 group I member 3	Homo sapiens	44-76
29157826-0	2017	Modulation of pregnane X receptor (PXR) and constitutive androstane receptor (CAR) activation by ursolic acid (UA) attenuates rifampin-isoniazid cytotoxicity.	Rifampin	126-134	nuclear receptor subfamily 1 group I member 3	Homo sapiens	78-81
29157826-6	2017	RESULTS: Transient transfection assays showed that UA effectively attenuated CYP3A4 and CYP2B6 promoter activities mediated by rifampin (RIF, human PXR agonist) and CITCO (human CAR agonist).	Rifampin	127-135	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	77-83
28688954-0	2017	Rifampicin-induced injury in HepG2 cells is alleviated by TUDCA via increasing bile acid transporters expression and enhancing the Nrf2-mediated adaptive response.	Rifampin	0-10	NFE2 like bZIP transcription factor 2	Homo sapiens	131-135
29081091-8	2017	Serum immunoglobulin E (IgE) and interleukin-4 (IL-4) levels were also ameliorated in mice treated with rifampicin.	Rifampin	104-114	interleukin 4	Mus musculus	33-46
29081091-8	2017	Serum immunoglobulin E (IgE) and interleukin-4 (IL-4) levels were also ameliorated in mice treated with rifampicin.	Rifampin	104-114	interleukin 4	Mus musculus	48-52
29081091-10	2017	Rifampicin suppressed the release of beta-hexosaminidase and histamine from human mast cell (HMC)-1 cultures stimulated with compound 48/80.	Rifampin	0-10	O-GlcNAcase	Homo sapiens	37-56
29081091-11	2017	Treatment with rifampicin also inhibited secretion of inflammatory mediators, such tumor necrosis factor-alpha (TNF-alpha) and prostaglandin D2 (PGD2), in mast cells activated by compound 48/80.	Rifampin	15-25	tumor necrosis factor	Mus musculus	83-110
29081091-11	2017	Treatment with rifampicin also inhibited secretion of inflammatory mediators, such tumor necrosis factor-alpha (TNF-alpha) and prostaglandin D2 (PGD2), in mast cells activated by compound 48/80.	Rifampin	15-25	tumor necrosis factor	Mus musculus	112-121
29081091-11	2017	Treatment with rifampicin also inhibited secretion of inflammatory mediators, such tumor necrosis factor-alpha (TNF-alpha) and prostaglandin D2 (PGD2), in mast cells activated by compound 48/80.	Rifampin	15-25	prostaglandin D2 synthase (brain)	Mus musculus	127-143
29081091-12	2017	The mRNA expression of cyclooxygenase 2 (COX-2) was reduced in the cells treated with rifampicin in a concentration-dependent manner.	Rifampin	86-96	prostaglandin-endoperoxide synthase 2	Mus musculus	23-39
29081091-12	2017	The mRNA expression of cyclooxygenase 2 (COX-2) was reduced in the cells treated with rifampicin in a concentration-dependent manner.	Rifampin	86-96	prostaglandin-endoperoxide synthase 2	Mus musculus	41-46
29061956-3	2017	Rifampin is a strong inducer of several drug-metabolizing enzymes, including CYP3A.	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	77-82
28870519-7	2017	Rifampicin reduced the late increase of alphaSyn oligomers in sigma1R-/- mice.	Rifampin	0-10	synuclein, alpha	Mus musculus	40-48
28870519-7	2017	Rifampicin reduced the late increase of alphaSyn oligomers in sigma1R-/- mice.	Rifampin	0-10	sigma non-opioid intracellular receptor 1	Mus musculus	62-69
28870519-8	2017	Rifampicin or salubrinal could reduce the loss of dopaminergic neurons in sigma1R-/- mice and improved their motor coordination.	Rifampin	0-10	sigma non-opioid intracellular receptor 1	Mus musculus	74-81
29093504-1	2017	Xpert MTB/RIF (Xpert) is a widely-used test for tuberculosis (TB) and rifampicin-resistance.	Rifampin	70-80	ras homolog family member F, filopodia associated	Homo sapiens	10-13
29061956-4	2017	Hence, rifampin-induced CYP3A activity may decrease the effect of oxycodone.	Rifampin	7-15	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	24-29
28982166-9	2017	Among these patients, only six (54.5%) were found to have rifampin-resistant isolates in period 2, with no significant infectious events.	Rifampin	58-66	period circadian regulator 2	Homo sapiens	89-97
28945086-4	2017	OA attenuated the promoter activities, expressions, and enzyme catalytic activities of CYP3A4 and CYP2B6 mediated by rifampin (RIF) and CITCO.	Rifampin	117-125	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	98-104
28945086-4	2017	OA attenuated the promoter activities, expressions, and enzyme catalytic activities of CYP3A4 and CYP2B6 mediated by rifampin (RIF) and CITCO.	Rifampin	127-130	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	98-104
28407303-2	2017	Rifampicin, an antitubercular agent, is one of the most potent inducers of hepatic and intestinal CYP3A4 thus increasing dihydropyridine metabolism.	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	98-104
28856417-6	2017	Although at higher concentration, HBD-1 (x 2 MIC) and Pep-B (x 2 MIC) led to decrease in in vitro dormant mycobacterial load as compared to rifampicin (x 25 MIC) and isoniazid (x 16 MIC).	Rifampin	140-150	defensin beta 1	Homo sapiens	34-39
28856417-6	2017	Although at higher concentration, HBD-1 (x 2 MIC) and Pep-B (x 2 MIC) led to decrease in in vitro dormant mycobacterial load as compared to rifampicin (x 25 MIC) and isoniazid (x 16 MIC).	Rifampin	140-150	peptidase B	Homo sapiens	54-59
29171455-3	2017	Corresponding of CYP2E1 polymorphism in TB patients with the level of isoniazid and rifampicin as well as for the outcome and toxicity development during inpatient TB treatment.	Rifampin	84-94	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	17-23
29171455-8	2017	RESULTS: The concentration of rifampicin 6 h after its intake was 17.6% higher in carriers of slow metabolizer (SM) CYP2E1 genotype than in patients with rapid metabolizer (RM) genotype that proved a participation of hepatic enzyme CYP2E1 in metabolism of rifampicin.	Rifampin	30-40	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	116-122
29171455-8	2017	RESULTS: The concentration of rifampicin 6 h after its intake was 17.6% higher in carriers of slow metabolizer (SM) CYP2E1 genotype than in patients with rapid metabolizer (RM) genotype that proved a participation of hepatic enzyme CYP2E1 in metabolism of rifampicin.	Rifampin	30-40	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	232-238
28942083-4	2017	Treatment with rifampicin, a ligand of PXR, translocated PXR from the cytoplasm to nucleus and increased expression levels of CYP3A4 mRNA in HepG2 cells cultured by the hanging drop method.	Rifampin	15-25	nuclear receptor subfamily 1 group I member 2	Homo sapiens	39-42
28942083-4	2017	Treatment with rifampicin, a ligand of PXR, translocated PXR from the cytoplasm to nucleus and increased expression levels of CYP3A4 mRNA in HepG2 cells cultured by the hanging drop method.	Rifampin	15-25	nuclear receptor subfamily 1 group I member 2	Homo sapiens	57-60
28942083-4	2017	Treatment with rifampicin, a ligand of PXR, translocated PXR from the cytoplasm to nucleus and increased expression levels of CYP3A4 mRNA in HepG2 cells cultured by the hanging drop method.	Rifampin	15-25	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	126-132
28663285-6	2017	Rifabutin and rifampicin also inhibited several human UGTs including UGT1A4.	Rifampin	14-24	UDP glucuronosyltransferase family 1 member A4	Homo sapiens	69-75
29022528-8	2017	GeneXpert MTB/RIF also detected all 4 multidrug-resistant TB cases and an additional 2 rifampicin-resistant cases in culture-negative samples.	Rifampin	87-97	ras homolog family member F, filopodia associated	Homo sapiens	14-17
28836817-6	2017	The main spa type in this study was spa t030 with frequency as high as 75.5% from intensive care unit (ICU) of the hospitals and high rate of resistance to rifampicin (53%) was found in MRSA isolates.	Rifampin	156-166	surfactant protein A2	Homo sapiens	9-12
28414110-0	2017	Rifampicin as a novel tyrosinase inhibitor: Inhibitory activity and mechanism.	Rifampin	0-10	tyrosinase	Homo sapiens	22-32
28414110-1	2017	In this study, the inhibitory effect and mechanism of rifampicin on the activity of tyrosinase were investigated for developing a novel tyrosinase inhibitor.	Rifampin	54-64	tyrosinase	Homo sapiens	84-94
28414110-1	2017	In this study, the inhibitory effect and mechanism of rifampicin on the activity of tyrosinase were investigated for developing a novel tyrosinase inhibitor.	Rifampin	54-64	tyrosinase	Homo sapiens	136-146
28414110-4	2017	The results obtained from intrinsic fluorescence quenching indicated that rifampicin could interact with tyrosinase.	Rifampin	74-84	tyrosinase	Homo sapiens	105-115
28414110-6	2017	Moreover, the ANS-binding fluorescence analysis suggested that rifampicin binding to tyrosinase changed the polarity of the hydrophobic regions.	Rifampin	63-73	tyrosinase	Homo sapiens	85-95
28414110-9	2017	This work identified a novel tyrosinase inhibitor and potentially contributed to the usage of rifampicin as a potential hyperpigmentation drug.	Rifampin	94-104	tyrosinase	Homo sapiens	29-39
28065764-4	2017	Rifampicin and SR12813 significantly upregulated P-gp expression (1.5-fold and 1.9-fold, respectively) compared to control, as assessed by the ICW protocol.	Rifampin	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	49-53
27848009-1	2017	This study investigated the effects of rifampicin-modulated P-glycoprotein (P-gp) and cytochrome P450 (CYP450) activity on the development of steroid-induced osteonecrosis of the femoral head.	Rifampin	39-49	ATP-dependent translocase ABCB1	Oryctolagus cuniculus	60-74
27848009-1	2017	This study investigated the effects of rifampicin-modulated P-glycoprotein (P-gp) and cytochrome P450 (CYP450) activity on the development of steroid-induced osteonecrosis of the femoral head.	Rifampin	39-49	ATP-dependent translocase ABCB1	Oryctolagus cuniculus	76-80
27848009-1	2017	This study investigated the effects of rifampicin-modulated P-glycoprotein (P-gp) and cytochrome P450 (CYP450) activity on the development of steroid-induced osteonecrosis of the femoral head.	Rifampin	39-49	cytochrome P-450	Oryctolagus cuniculus	103-109
27848009-8	2017	P-gp activity of mesenchymal stem cells in rifampicin-implanted femoral head was significantly higher than that in the blank control.	Rifampin	43-53	ATP-dependent translocase ABCB1	Oryctolagus cuniculus	0-4
27848009-12	2017	P-gp activity locally enhanced by rifampicin decreases the intracellular steroid concentration, but rifampicin does not have significant effects on peripheral P-gp and hepatic CYP450.	Rifampin	34-44	ATP-dependent translocase ABCB1	Oryctolagus cuniculus	0-4
28716462-6	2017	Xpert MTB/RIF and Hain line probe assays identified rpoB and inhA mutations consistent with rifampicin and intermediate isoniazid resistance, and a further possible mutation conferring fluoroquinolone resistance.	Rifampin	92-102	inhibin subunit alpha	Homo sapiens	61-65
28546421-7	2017	Conversely, PXR knockdown abrogated the suppressive effect of rifampicin on NLRP3 inflammasome activation.	Rifampin	62-72	nuclear receptor subfamily 1 group I member 2	Homo sapiens	12-15
28495568-4	2017	DDIs with rifampicin and itraconazole were simulated using in vivo Rdif (ratio of diffusional uptake to active uptake) and beta (the fraction of the sum of intrinsic clearances for metabolism and biliary excretion in all possible itineraries of intracellular drugs including basolateral efflux) estimated by static analyses based on the extended clearance concept, in vivo inhibition constant (Ki) for hepatic OATPs reported previously, and in vivo Ki for CYP3A determined from DDI data with midazolam and itraconazole.	Rifampin	10-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	456-461
28535976-6	2017	Epigallocatechin gallate, cyclosporin A, rifampicin, and telmisartan inhibited cilostazol uptake in OATP1B1/1B3-HEK293 cells with Ki values close to their clinical plasma concentration, which suggested possible drug-drug interactions in humans via OATP1B1/1B3.	Rifampin	41-51	solute carrier organic anion transporter family member 1B1	Homo sapiens	100-107
28535976-6	2017	Epigallocatechin gallate, cyclosporin A, rifampicin, and telmisartan inhibited cilostazol uptake in OATP1B1/1B3-HEK293 cells with Ki values close to their clinical plasma concentration, which suggested possible drug-drug interactions in humans via OATP1B1/1B3.	Rifampin	41-51	solute carrier organic anion transporter family member 1B1	Homo sapiens	248-255
28817905-0	2017	Re: CYP3A4 Induction by Rifampin: An Alternative Pathway for Vitamin D Inactivation in Patients with CYP24A1 Mutations.	Rifampin	24-32	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	4-10
28817905-0	2017	Re: CYP3A4 Induction by Rifampin: An Alternative Pathway for Vitamin D Inactivation in Patients with CYP24A1 Mutations.	Rifampin	24-32	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	101-108
28546421-6	2017	In addition, PXR agonists (rifampicin and SR12813) or overexpression of a constitutively active PXR markedly suppressed the NLRP3 inflammasome activation.	Rifampin	27-37	nuclear receptor subfamily 1 group I member 2	Homo sapiens	13-16
28546421-6	2017	In addition, PXR agonists (rifampicin and SR12813) or overexpression of a constitutively active PXR markedly suppressed the NLRP3 inflammasome activation.	Rifampin	27-37	NLR family pyrin domain containing 3	Homo sapiens	124-129
28546421-7	2017	Conversely, PXR knockdown abrogated the suppressive effect of rifampicin on NLRP3 inflammasome activation.	Rifampin	62-72	NLR family pyrin domain containing 3	Homo sapiens	76-81
28546104-0	2017	Development of a paediatric physiologically based pharmacokinetic model to assess the impact of drug-drug interactions in tuberculosis co-infected malaria subjects: A case study with artemether-lumefantrine and the CYP3A4-inducer rifampicin.	Rifampin	230-240	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	215-221
28546104-4	2017	The concomitant treatment of AL with tuberculosis chemotherapy, which includes the CYP3A4 inducer rifampicin, increases the risk of parasite recrudescence and malaria treatment failure.	Rifampin	98-108	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	83-89
28789699-4	2017	We describe a case of severe poisoning with fixed drug combination of isoniazid and rifampicin successfully managed with oral pyridoxine at national hospital of Sri Lanka.	Rifampin	84-94	sorcin	Homo sapiens	161-164
28819225-5	2017	In contrast, P450/ABC transporter induction with rifampicin markedly impaired ivermectin absorption.	Rifampin	49-59	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	13-17
28213941-11	2017	An increase in cediranib dose may be needed for cediranib coadministered with strong uridine glucuronosyl transferase/P-glycoprotein inducers such as rifampicin.	Rifampin	150-160	ATP binding cassette subfamily B member 1	Homo sapiens	118-132
29187929-9	2017	Finally, GeneXpert MTB/RIF test detected rifampicin resistance in 20.8%.	Rifampin	41-51	ras homolog family member F, filopodia associated	Homo sapiens	23-26
28571685-0	2017	Activation of the aryl hydrocarbon receptor decreases rifampicin-induced CYP3A4 expression in primary human hepatocytes and HepaRG.	Rifampin	54-64	aryl hydrocarbon receptor	Homo sapiens	18-43
28571685-0	2017	Activation of the aryl hydrocarbon receptor decreases rifampicin-induced CYP3A4 expression in primary human hepatocytes and HepaRG.	Rifampin	54-64	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	73-79
28571685-6	2017	We also investigated whether knockdown of AhR using siRNA affected the basal expression of PXR and CYP3A4 and induction of CYP3A4 by rifampicin, TCDD and 3MI.	Rifampin	133-143	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	123-129
28571685-8	2017	Moreover, in both HepaRG and PHHs, AhR activation decreased rifampicin-induced expression of CYP3A4 mRNA.	Rifampin	60-70	aryl hydrocarbon receptor	Homo sapiens	35-38
28571685-8	2017	Moreover, in both HepaRG and PHHs, AhR activation decreased rifampicin-induced expression of CYP3A4 mRNA.	Rifampin	60-70	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	93-99
28571685-9	2017	Knock-down of AhR in PHHs increased both basal and rifampicin-induced expression of CYP3A4 mRNA.	Rifampin	51-61	aryl hydrocarbon receptor	Homo sapiens	14-17
28571685-9	2017	Knock-down of AhR in PHHs increased both basal and rifampicin-induced expression of CYP3A4 mRNA.	Rifampin	51-61	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	84-90
27858342-7	2017	Further analysis demonstrated that OATP1B1 inhibition by rifampin or cyclosporine in the existing inhibitor models needs to be approximately tenfold stronger to recapitulate the observed DDI with these two inhibitors.	Rifampin	57-65	solute carrier organic anion transporter family member 1B1	Homo sapiens	35-42
28576766-4	2017	All probes were determined in samples from a single study that examined their behavior and their association with rosuvastatin (RSV) pharmacokinetics after administration of an OATP inhibitor rifampin (RIF) in healthy subjects.	Rifampin	192-200	solute carrier organic anion transporter family member 1A2	Homo sapiens	177-181
27815731-11	2017	Rosuvastatin, BSP, rifampin, and glycyrrhizic acid all exhibited a certain extent inhibitory effect on the transport of OPD in OATP1B1*1a-HEK293T cells.	Rifampin	19-27	solute carrier organic anion transporter family member 1B1	Homo sapiens	127-134
27858342-8	2017	CONCLUSION: Through quantitative assessment of the effect of OATP1B1 genetic polymorphism and inhibitors of transporters and metabolizing enyzmes via PBPK modeling, we confirmed the importance of OATP1B1 in the disposition of these two statins, and explored potential causes for under-prediction of the inhibitory effect of rifampin and cyclosporine.	Rifampin	324-332	solute carrier organic anion transporter family member 1B1	Homo sapiens	61-68
27858342-8	2017	CONCLUSION: Through quantitative assessment of the effect of OATP1B1 genetic polymorphism and inhibitors of transporters and metabolizing enyzmes via PBPK modeling, we confirmed the importance of OATP1B1 in the disposition of these two statins, and explored potential causes for under-prediction of the inhibitory effect of rifampin and cyclosporine.	Rifampin	324-332	solute carrier organic anion transporter family member 1B1	Homo sapiens	196-203
28371445-4	2017	We found that SG transport by OATP1B1 or murine Oatp1b2 was effectively inhibited by rifampin, and that this agent can significantly increase plasma levels of SG in wildtype mice, but not in Oatp1b2-deficient animals.	Rifampin	85-93	solute carrier organic anion transporter family, member 1b2	Mus musculus	48-55
28546420-0	2017	Alterations of Histone Modifications Contribute to Pregnane X Receptor-Mediated Induction of CYP3A4 by Rifampicin.	Rifampin	103-113	nuclear receptor subfamily 1 group I member 2	Homo sapiens	51-70
28546420-0	2017	Alterations of Histone Modifications Contribute to Pregnane X Receptor-Mediated Induction of CYP3A4 by Rifampicin.	Rifampin	103-113	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	93-99
28546420-3	2017	This study aims to explore the role of histone modifications in rifampicin-induced expression of CYP3A4 in LS174T cells.	Rifampin	64-74	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	97-103
28546420-4	2017	We found that the induction of CYP3A4 mRNA (4- to 15-fold) by rifampicin in LS174T cells was associated with increased levels of histone H3 lysine 4 trimethylation (H3K4me3, above 1.8-fold) and H3 acetylation (above 2-fold) and a decreased level of histone H3 lysine 27 trimethylation (H3K27me3, about 50%) in the CYP3A4 promoter.	Rifampin	62-72	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-37
28546420-4	2017	We found that the induction of CYP3A4 mRNA (4- to 15-fold) by rifampicin in LS174T cells was associated with increased levels of histone H3 lysine 4 trimethylation (H3K4me3, above 1.8-fold) and H3 acetylation (above 2-fold) and a decreased level of histone H3 lysine 27 trimethylation (H3K27me3, about 50%) in the CYP3A4 promoter.	Rifampin	62-72	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	314-320
28546420-5	2017	Rifampicin enhanced recruitment to the CYP3A4 promoter of nuclear receptor coactivator 6 (NCOA6, above 3-fold) and histone acetyltransferase p300 (p300, above 1.6-fold).	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	39-45
28546420-5	2017	Rifampicin enhanced recruitment to the CYP3A4 promoter of nuclear receptor coactivator 6 (NCOA6, above 3-fold) and histone acetyltransferase p300 (p300, above 1.6-fold).	Rifampin	0-10	nuclear receptor coactivator 6	Homo sapiens	58-88
28546420-5	2017	Rifampicin enhanced recruitment to the CYP3A4 promoter of nuclear receptor coactivator 6 (NCOA6, above 3-fold) and histone acetyltransferase p300 (p300, above 1.6-fold).	Rifampin	0-10	nuclear receptor coactivator 6	Homo sapiens	90-95
28546420-5	2017	Rifampicin enhanced recruitment to the CYP3A4 promoter of nuclear receptor coactivator 6 (NCOA6, above 3-fold) and histone acetyltransferase p300 (p300, above 1.6-fold).	Rifampin	0-10	E1A binding protein p300	Homo sapiens	115-145
28546420-7	2017	Knockdown of pregnane X receptor (PXR) expression not only suppressed the recruitment of NCOA6 and p300 but also abolished the changes caused by rifampicin in H3K4me3, H3K27me3, and H3 acetylation levels in the CYP3A4 promoter.	Rifampin	145-155	nuclear receptor subfamily 1 group I member 2	Homo sapiens	13-32
28546420-7	2017	Knockdown of pregnane X receptor (PXR) expression not only suppressed the recruitment of NCOA6 and p300 but also abolished the changes caused by rifampicin in H3K4me3, H3K27me3, and H3 acetylation levels in the CYP3A4 promoter.	Rifampin	145-155	nuclear receptor subfamily 1 group I member 2	Homo sapiens	34-37
28546420-8	2017	Moreover, rifampicin treatment enhanced the nuclear accumulation and interactions between PXR and NCOA6/p300.	Rifampin	10-20	nuclear receptor subfamily 1 group I member 2	Homo sapiens	90-93
28546420-8	2017	Moreover, rifampicin treatment enhanced the nuclear accumulation and interactions between PXR and NCOA6/p300.	Rifampin	10-20	nuclear receptor coactivator 6	Homo sapiens	98-103
28546420-8	2017	Moreover, rifampicin treatment enhanced the nuclear accumulation and interactions between PXR and NCOA6/p300.	Rifampin	10-20	E1A binding protein p300	Homo sapiens	104-108
28546420-9	2017	In conclusion, we show that the alterations of histone modifications contribute to the PXR-mediated induction of CYP3A4 by rifampicin.	Rifampin	123-133	nuclear receptor subfamily 1 group I member 2	Homo sapiens	87-90
28546420-9	2017	In conclusion, we show that the alterations of histone modifications contribute to the PXR-mediated induction of CYP3A4 by rifampicin.	Rifampin	123-133	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	113-119
28484975-3	2017	Rifampicin (OATP inhibitor; 600 mg, p.o.)	Rifampin	0-10	solute carrier organic anion transporter family member 1A2	Homo sapiens	12-16
28403028-4	2017	RECENT FINDINGS: Dose adjustments of standard dose efavirenz are not necessary with rifampicin, because auto-induction of CYP2B6 by efavirenz counteracts the induction of rifampicin.	Rifampin	171-181	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	122-128
28403028-5	2017	However, patients with extensive metabolizer CYP2B6 genotypes have lower efavirenz concentrations and may have less auto-induction of CYP2B6; the additive inducing effects of rifampicin on CYP2B6 could result in clinically significant reductions of efavirenz concentrations.	Rifampin	175-185	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	45-51
28373111-0	2017	Pretreatment With Rifampicin and Tyrosine Kinase Inhibitor Dasatinib Potentiates the Inhibitory Effects Toward OATP1B1- and OATP1B3-Mediated Transport.	Rifampin	18-28	solute carrier organic anion transporter family member 1B1	Homo sapiens	111-118
28373111-0	2017	Pretreatment With Rifampicin and Tyrosine Kinase Inhibitor Dasatinib Potentiates the Inhibitory Effects Toward OATP1B1- and OATP1B3-Mediated Transport.	Rifampin	18-28	solute carrier organic anion transporter family member 1B3	Homo sapiens	124-131
28373111-1	2017	Present studies determined the effects of pretreatment with rifampicin, an organic anion-transporting polypeptide (OATP) inhibitor, and the tyrosine kinase inhibitor dasatinib on OATP1B1- and OATP1B3-mediated transport, and evaluated the OATP-mediated drug-drug interaction potential of dasatinib using the static R-value and dynamic physiologically based pharmacokinetic models.	Rifampin	60-70	solute carrier organic anion transporter family member 1B1	Homo sapiens	179-186
28373111-1	2017	Present studies determined the effects of pretreatment with rifampicin, an organic anion-transporting polypeptide (OATP) inhibitor, and the tyrosine kinase inhibitor dasatinib on OATP1B1- and OATP1B3-mediated transport, and evaluated the OATP-mediated drug-drug interaction potential of dasatinib using the static R-value and dynamic physiologically based pharmacokinetic models.	Rifampin	60-70	solute carrier organic anion transporter family member 1B3	Homo sapiens	192-199
28373111-1	2017	Present studies determined the effects of pretreatment with rifampicin, an organic anion-transporting polypeptide (OATP) inhibitor, and the tyrosine kinase inhibitor dasatinib on OATP1B1- and OATP1B3-mediated transport, and evaluated the OATP-mediated drug-drug interaction potential of dasatinib using the static R-value and dynamic physiologically based pharmacokinetic models.	Rifampin	60-70	solute carrier organic anion transporter family member 1A2	Homo sapiens	179-183
28373111-2	2017	Rifampicin and dasatinib pretreatment significantly decreased OATP1B1- and OATP1B3-mediated transport.	Rifampin	0-10	solute carrier organic anion transporter family member 1B1	Homo sapiens	62-69
28373111-2	2017	Rifampicin and dasatinib pretreatment significantly decreased OATP1B1- and OATP1B3-mediated transport.	Rifampin	0-10	solute carrier organic anion transporter family member 1B3	Homo sapiens	75-82
28373111-4	2017	Present studies revealed that estrone-3-sulfate is a less-sensitive OATP1B1 substrate than estradiol-17beta-glucuronide in assessing rifampicin pretreatment effects.	Rifampin	133-143	solute carrier organic anion transporter family member 1B1	Homo sapiens	68-75
28373111-5	2017	Pretreatment with rifampicin and dasatinib reduced the inhibition constant (Ki) values against OATP1B1 by 3 and 2.1 fold and against OATP1B3 by 2.4 and 2.1 fold, respectively.	Rifampin	18-28	solute carrier organic anion transporter family member 1B1	Homo sapiens	95-102
28373111-5	2017	Pretreatment with rifampicin and dasatinib reduced the inhibition constant (Ki) values against OATP1B1 by 3 and 2.1 fold and against OATP1B3 by 2.4 and 2.1 fold, respectively.	Rifampin	18-28	solute carrier organic anion transporter family member 1B3	Homo sapiens	133-140
28373111-9	2017	In summary, we report novel findings that pretreatment with rifampicin and dasatinib potentiates the inhibitory effects toward OATP1B1 and OATP1B3 without affecting plasma membrane levels of the transporters.	Rifampin	60-70	solute carrier organic anion transporter family member 1B1	Homo sapiens	127-134
28373111-9	2017	In summary, we report novel findings that pretreatment with rifampicin and dasatinib potentiates the inhibitory effects toward OATP1B1 and OATP1B3 without affecting plasma membrane levels of the transporters.	Rifampin	60-70	solute carrier organic anion transporter family member 1B3	Homo sapiens	139-146
28671602-10	2017	In the KEGG pathway enrichment-based clustering analysis, the peroxisome proliferator-activated receptor-gamma (PPARgamma) signaling pathway, cytochrome P450, glutathione metabolism, chemical carcinogenesis, and related proteins increased dose-dependently in rifampicin-treated livers.	Rifampin	259-269	peroxisome proliferator activated receptor gamma	Mus musculus	62-110
27784136-7	2017	Furthermore the Lnt mutant showed 64 fold and 16 fold increase in susceptibility to rifampicin and ciprofloxacin respectively.	Rifampin	84-94	apolipoprotein N-acyltransferase	Neisseria meningitidis MC58	16-19
28621455-0	2017	Addition of Rifampicin to Bolton Broth to Inhibit Extended-Spectrum beta-Lactamase-Producing Escherichia coli for the Detection of Campylobacter.	Rifampin	12-22	beta-lactamase	Escherichia coli	68-82
28199520-2	2017	: Xpert MTB/RIF (Xpert) detects rifampicin-resistant tuberculosis (RR-tuberculosis), enabling physicians to rapidly initiate a World Health Organization-recommended 5-drug regimen while awaiting second-line drug-susceptibility test (DST) results.	Rifampin	32-42	ras homolog family member F, filopodia associated	Homo sapiens	12-15
28904673-3	2017	The rpoB and katG genes molecular markers are used for detecting rifampicin and isoniazid resistance respectively.	Rifampin	65-75	DNA-directed RNA polymerase subunit beta	Mycobacterium tuberculosis H37Rv	4-8
28408657-0	2017	Negative Regulation of Human Pregnane X Receptor by MicroRNA-18a-5p: Evidence for Suppression of MicroRNA-18a-5p Expression by Rifampin and Rilpivirine.	Rifampin	127-135	nuclear receptor subfamily 1 group I member 2	Homo sapiens	29-48
28408657-8	2017	The decrease in hPXR expression by the miR-18a-5p mimic was associated with a reduction in the extent of hPXR target gene (CYP3A4) induction by rifampin and rilpivirine.	Rifampin	144-152	nuclear receptor subfamily 1 group I member 2	Homo sapiens	16-20
28408657-8	2017	The decrease in hPXR expression by the miR-18a-5p mimic was associated with a reduction in the extent of hPXR target gene (CYP3A4) induction by rifampin and rilpivirine.	Rifampin	144-152	nuclear receptor subfamily 1 group I member 2	Homo sapiens	105-109
28408657-8	2017	The decrease in hPXR expression by the miR-18a-5p mimic was associated with a reduction in the extent of hPXR target gene (CYP3A4) induction by rifampin and rilpivirine.	Rifampin	144-152	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	123-129
28408657-10	2017	In conclusion, miR-18a-5p is a negative regulator of hPXR expression and the hPXR agonists rifampin and rilpivirine are chemical suppressors of miR-18a-5p expression.	Rifampin	91-99	nuclear receptor subfamily 1 group I member 2	Homo sapiens	77-81
28173639-0	2017	Bosentan and Rifampin Interactions Modulate Influx Transporter and Cytochrome P450 Expression and Activities in Primary Human Hepatocytes.	Rifampin	13-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-82
28336091-4	2017	Further research showed that the CYP inducers omeprazole, ethanol, and rifampicin inhibited cell viability, in particular, ethanol, a CYP2E1 inducer, induced ROS generation, lipid peroxidation, and apoptosis in HepG2 cells treated with MC-LR.	Rifampin	71-81	peptidylprolyl isomerase G	Homo sapiens	33-36
28336091-4	2017	Further research showed that the CYP inducers omeprazole, ethanol, and rifampicin inhibited cell viability, in particular, ethanol, a CYP2E1 inducer, induced ROS generation, lipid peroxidation, and apoptosis in HepG2 cells treated with MC-LR.	Rifampin	71-81	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	134-140
28594304-1	2017	AIM: We retrospectively evaluate the pharmacogenetic role of single nucleotide polymorphisms involved in rifampicin transport (SLCO1B1, MDR1 and PXR genes) and vitamin D (VDR, CYP24A1 and CYP27B1 genes) metabolism and activity on drug plasma and intracellular concentrations.	Rifampin	105-115	solute carrier organic anion transporter family member 1B1	Homo sapiens	127-134
28594304-1	2017	AIM: We retrospectively evaluate the pharmacogenetic role of single nucleotide polymorphisms involved in rifampicin transport (SLCO1B1, MDR1 and PXR genes) and vitamin D (VDR, CYP24A1 and CYP27B1 genes) metabolism and activity on drug plasma and intracellular concentrations.	Rifampin	105-115	nuclear receptor subfamily 1 group I member 2	Homo sapiens	145-148
28475796-13	2017	Discordant rifampicin susceptibility results of Xpert MTB/RIF and mycobacteria growth indicator tube (MGIT) were confirmed by using rpoB gene sequencing, which raised the sensitivity of Xpert MTB/RIF in detecting rifampicin resistance to 93.8%.	Rifampin	11-21	metallothionein 1J, pseudogene	Homo sapiens	54-57
28475796-13	2017	Discordant rifampicin susceptibility results of Xpert MTB/RIF and mycobacteria growth indicator tube (MGIT) were confirmed by using rpoB gene sequencing, which raised the sensitivity of Xpert MTB/RIF in detecting rifampicin resistance to 93.8%.	Rifampin	11-21	metallothionein 1J, pseudogene	Homo sapiens	192-195
28475796-13	2017	Discordant rifampicin susceptibility results of Xpert MTB/RIF and mycobacteria growth indicator tube (MGIT) were confirmed by using rpoB gene sequencing, which raised the sensitivity of Xpert MTB/RIF in detecting rifampicin resistance to 93.8%.	Rifampin	213-223	metallothionein 1J, pseudogene	Homo sapiens	192-195
28475796-14	2017	Conclusions: Xpert MTB/RIF is an effective tool in diagnosing PTB but will be more cost-effective for sputum-negative patients and in settings with high prevalence of rifampicin resistance.	Rifampin	167-177	metallothionein 1J, pseudogene	Homo sapiens	19-22
28575098-7	2017	Pretreatment of rifampin (10 mumol/L), the agonist of PXR alleviated the TBA secretion induced by estradiol (500 nmol/L, 48 h).	Rifampin	16-24	nuclear receptor subfamily 1 group I member 2	Homo sapiens	54-57
28575098-9	2017	Both of miR-148a-siRNA and rifampin (10 mumol/L) inhibited the upregulated effect of estradiol on MRP3 expression.	Rifampin	27-35	ATP binding cassette subfamily C member 3	Homo sapiens	98-102
28259787-6	2017	Rifampicin activated hPXR as expected, but not cPXR.	Rifampin	0-10	nuclear receptor subfamily 1 group I member 2	Homo sapiens	21-25
28173639-3	2017	In this study, the effects of bosentan and rifampin on the expression and activities of organic anion-transporting peptide (OATP) and cytochrome P450 (CYP450) 2C9 and CYP3A4 were investigated in vitro.	Rifampin	43-51	solute carrier organic anion transporter family member 1A2	Homo sapiens	88-122
28173639-3	2017	In this study, the effects of bosentan and rifampin on the expression and activities of organic anion-transporting peptide (OATP) and cytochrome P450 (CYP450) 2C9 and CYP3A4 were investigated in vitro.	Rifampin	43-51	solute carrier organic anion transporter family member 1A2	Homo sapiens	124-128
28173639-3	2017	In this study, the effects of bosentan and rifampin on the expression and activities of organic anion-transporting peptide (OATP) and cytochrome P450 (CYP450) 2C9 and CYP3A4 were investigated in vitro.	Rifampin	43-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	134-149
28173639-3	2017	In this study, the effects of bosentan and rifampin on the expression and activities of organic anion-transporting peptide (OATP) and cytochrome P450 (CYP450) 2C9 and CYP3A4 were investigated in vitro.	Rifampin	43-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-157
28173639-3	2017	In this study, the effects of bosentan and rifampin on the expression and activities of organic anion-transporting peptide (OATP) and cytochrome P450 (CYP450) 2C9 and CYP3A4 were investigated in vitro.	Rifampin	43-51	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	167-173
28173639-4	2017	HEK293 cells and primary human hepatocytes overexpressing the target genes were treated with bosentan and various concentrations of rifampin, which decreased the uptake activities of OATP transporters in a dose-dependent manner.	Rifampin	132-140	solute carrier organic anion transporter family member 1A2	Homo sapiens	183-187
28173639-5	2017	In primary human hepatocytes, CYP2C9 and CYP3A4 gene expression and activities decreased upon treatment with 20 muM bosentan+200 muM rifampin.	Rifampin	133-141	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	30-36
28173639-5	2017	In primary human hepatocytes, CYP2C9 and CYP3A4 gene expression and activities decreased upon treatment with 20 muM bosentan+200 muM rifampin.	Rifampin	133-141	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	41-47
28173639-7	2017	These results confirm rifampin- and bosentan-induced interactions between OATP transporters and CYP450.	Rifampin	22-30	solute carrier organic anion transporter family member 1A2	Homo sapiens	74-78
28173639-7	2017	These results confirm rifampin- and bosentan-induced interactions between OATP transporters and CYP450.	Rifampin	22-30	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-102
28254951-3	2017	At the highest tested concentration of 300 muM, PF-06282999 caused maximal induction in CYP3A4 mRNA and enzyme activity ranging from 56% to 86% and 47% t0 72%, respectively, of rifampicin response across the three hepatocyte donor pools.	Rifampin	177-187	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	88-94
27545757-5	2017	Studies NP28990 and NP29042 enrolled 17 and 24 healthy subjects, respectively, and investigated potent CYP3A inhibition with posaconazole and potent CYP3A induction through rifampin, respectively, on the single oral dose pharmacokinetics (PK) of alectinib.	Rifampin	173-181	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	149-154
28157069-0	2017	Delayed de-induction of CYP2C9 compared to CYP3A after discontinuation of rifampicin: Report of two cases : .	Rifampin	74-84	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	24-30
28157069-1	2017	OBJECTIVE: Timely dose reduction of concomitant medications is important after withdrawal of rifampicin, a CYP inducer.	Rifampin	93-103	peptidylprolyl isomerase G	Homo sapiens	107-110
28157069-3	2017	To clarify the time courses of deinduction of CYP2C9 and -CYP3A activities after rifampicin withdrawal, we monitored these enzyme activities in 2 patients over time after discontinuing rifampicin.	Rifampin	81-91	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	46-52
28157069-3	2017	To clarify the time courses of deinduction of CYP2C9 and -CYP3A activities after rifampicin withdrawal, we monitored these enzyme activities in 2 patients over time after discontinuing rifampicin.	Rifampin	81-91	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	58-63
28157069-3	2017	To clarify the time courses of deinduction of CYP2C9 and -CYP3A activities after rifampicin withdrawal, we monitored these enzyme activities in 2 patients over time after discontinuing rifampicin.	Rifampin	185-195	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	46-52
28157069-5	2017	Warfarin doses were increased due to rifampicin-induced CYP activity.	Rifampin	37-47	peptidylprolyl isomerase G	Homo sapiens	56-59
28157069-9	2017	CONCLUSION: Our findings suggest that a uniform dose reduction protocol for drugs metabolized by different CYP isoforms may be unsafe after rifampicin withdrawal.	Rifampin	140-150	peptidylprolyl isomerase G	Homo sapiens	107-110
28329820-5	2017	In HepaRG cells, cytotoxicity started at 20 and 100 microM for posaconazole and ketoconazole, respectively, and was slightly accentuated by cytochrome P450 3A4 induction with rifampicin and 1A2 with 3-methylcholantrene.	Rifampin	175-185	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	140-159
28025853-12	2017	CONCLUSIONS/CLINICAL IMPORTANCE: Oral rifampicin combined with topical antimicrobials can be considered an effective therapeutic option for canine superficial and deep pyoderma caused by rifampicin-susceptible multidrug-resistant MRS. Liver enzyme induction might be the most important cause of ALT and ALP increase associated with rifampicin therapy in dogs.	Rifampin	38-48	alkaline phosphatase, biomineralization associated	Canis lupus familiaris	303-306
28025853-12	2017	CONCLUSIONS/CLINICAL IMPORTANCE: Oral rifampicin combined with topical antimicrobials can be considered an effective therapeutic option for canine superficial and deep pyoderma caused by rifampicin-susceptible multidrug-resistant MRS. Liver enzyme induction might be the most important cause of ALT and ALP increase associated with rifampicin therapy in dogs.	Rifampin	187-197	alkaline phosphatase, biomineralization associated	Canis lupus familiaris	303-306
28025853-12	2017	CONCLUSIONS/CLINICAL IMPORTANCE: Oral rifampicin combined with topical antimicrobials can be considered an effective therapeutic option for canine superficial and deep pyoderma caused by rifampicin-susceptible multidrug-resistant MRS. Liver enzyme induction might be the most important cause of ALT and ALP increase associated with rifampicin therapy in dogs.	Rifampin	187-197	alkaline phosphatase, biomineralization associated	Canis lupus familiaris	303-306
28215634-8	2017	We have confirmed that the hepatocyte-like cells prepared by our methods were able to increase gene expression of cytochrome P450 enzymes upon encountering rifampicin, phenobarbital, or omeprazole.	Rifampin	156-166	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-129
28263460-3	2017	Asunaprevir plasma concentrations are markedly increased by single-dose rifampin (an OATP inhibitor) and in subjects with moderate to severe hepatic impairment.	Rifampin	72-80	solute carrier organic anion transporter family member 1A2	Homo sapiens	85-89
28253382-0	2017	Kinetic and thermodynamic study of bovine serum albumin interaction with rifampicin using surface plasmon resonance and molecular docking methods.	Rifampin	73-83	albumin	Homo sapiens	42-55
28077325-0	2017	Role of 14-3-3 sigma in over-expression of P-gp by rifampin and paclitaxel stimulation through interaction with PXR.	Rifampin	51-59	stratifin	Homo sapiens	8-20
28077325-0	2017	Role of 14-3-3 sigma in over-expression of P-gp by rifampin and paclitaxel stimulation through interaction with PXR.	Rifampin	51-59	ATP binding cassette subfamily B member 1	Homo sapiens	43-47
28077325-1	2017	In this study, we presented the role of 14-3-3sigma to activate CK2-Hsp90beta-PXR-MDR1 pathway on rifampin and paclitaxel treated LS174T cells and in vivo LS174T cell-xenografted nude mouse model.	Rifampin	98-106	stratifin	Homo sapiens	40-51
28077325-1	2017	In this study, we presented the role of 14-3-3sigma to activate CK2-Hsp90beta-PXR-MDR1 pathway on rifampin and paclitaxel treated LS174T cells and in vivo LS174T cell-xenografted nude mouse model.	Rifampin	98-106	heat shock protein 90 alpha family class B member 1	Homo sapiens	68-77
28077325-1	2017	In this study, we presented the role of 14-3-3sigma to activate CK2-Hsp90beta-PXR-MDR1 pathway on rifampin and paclitaxel treated LS174T cells and in vivo LS174T cell-xenografted nude mouse model.	Rifampin	98-106	nuclear receptor subfamily 1 group I member 2	Homo sapiens	78-81
28077325-1	2017	In this study, we presented the role of 14-3-3sigma to activate CK2-Hsp90beta-PXR-MDR1 pathway on rifampin and paclitaxel treated LS174T cells and in vivo LS174T cell-xenografted nude mouse model.	Rifampin	98-106	ATP binding cassette subfamily B member 1	Homo sapiens	82-86
28077325-2	2017	Following several in vitro and in vivo experiments, rifampin and paclitaxel were found to be stimulated the CK2-Hsp90beta-PXR-MDR1 pathway.	Rifampin	52-60	heat shock protein 90 alpha family class B member 1	Homo sapiens	112-121
28077325-2	2017	Following several in vitro and in vivo experiments, rifampin and paclitaxel were found to be stimulated the CK2-Hsp90beta-PXR-MDR1 pathway.	Rifampin	52-60	nuclear receptor subfamily 1 group I member 2	Homo sapiens	122-125
28077325-2	2017	Following several in vitro and in vivo experiments, rifampin and paclitaxel were found to be stimulated the CK2-Hsp90beta-PXR-MDR1 pathway.	Rifampin	52-60	ATP binding cassette subfamily B member 1	Homo sapiens	126-130
28077325-4	2017	We constructed FLAG-PXR-LS174T stable cell lines and discovered 22 proteins that interacted with PXR on rifampin treatment.	Rifampin	104-112	nuclear receptor subfamily 1 group I member 2	Homo sapiens	20-23
28077325-4	2017	We constructed FLAG-PXR-LS174T stable cell lines and discovered 22 proteins that interacted with PXR on rifampin treatment.	Rifampin	104-112	nuclear receptor subfamily 1 group I member 2	Homo sapiens	97-100
28077325-7	2017	On the other hand, PXR was found to be localized in nucleus after rifampin and paclitaxel treatment by using cell fractionation assay.	Rifampin	66-74	nuclear receptor subfamily 1 group I member 2	Homo sapiens	19-22
28077325-10	2017	P-gp overexpression was induced only when 14-3-3sigma transfected LS174T cells were treated with rifampin and paclitaxel, whereas 14-3-3sigma inhibition by nonpeptidic inhibitor, BV02 and 14-3-3sigma siRNA reduced rifampin induced PXR and P-gp expression.	Rifampin	97-105	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
28077325-10	2017	P-gp overexpression was induced only when 14-3-3sigma transfected LS174T cells were treated with rifampin and paclitaxel, whereas 14-3-3sigma inhibition by nonpeptidic inhibitor, BV02 and 14-3-3sigma siRNA reduced rifampin induced PXR and P-gp expression.	Rifampin	97-105	stratifin	Homo sapiens	42-53
29359155-0	2017	The Feasibility of Xpert MTB/RIF Testing to Detect Rifampicin Resistance among Childhood Tuberculosis for Prevalence Surveys in Northern China.	Rifampin	51-61	ras homolog family member F, filopodia associated	Homo sapiens	29-32
29359155-3	2017	The goal of this work was to generate prevalence data regarding rifampicin- (RIF-) resistant childhood TB in northern China and to test the feasibility of Xpert for surveying pediatric TB drug resistance prevalence.	Rifampin	64-74	ras homolog family member F, filopodia associated	Homo sapiens	77-80
27273461-0	2017	Pharmacokinetic Evaluation of CYP3A4-Mediated Drug-Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults.	Rifampin	91-99	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	30-36
27273461-2	2017	Coadministration of oral isavuconazole (100 mg once daily) with oral rifampin (600 mg once daily; CYP3A4 inducer) decreased isavuconazole area under the concentration-time curve (AUCtau ) during a dosing interval by 90% and maximum concentration (Cmax ) by 75%.	Rifampin	69-77	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	98-104
28317812-3	2017	The new polymerase chain reaction-based XpertMTB/Rif (Cepheid Inc., CA, USA), which detects Mycobacterium tuberculosis and rifampicin resistance, was introduced in Cross River State in 2014.	Rifampin	123-133	ras homolog family member F, filopodia associated	Homo sapiens	49-52
27321774-1	2017	This open-label 2-period study assessed the effect of multiple-dose administration of rifampin, a strong cytochrome P450 3A (CYP3A) and P-glycoprotein inducer, on the pharmacokinetics of odanacatib, a cathepsin K inhibitor.	Rifampin	86-94	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	105-123
27321774-1	2017	This open-label 2-period study assessed the effect of multiple-dose administration of rifampin, a strong cytochrome P450 3A (CYP3A) and P-glycoprotein inducer, on the pharmacokinetics of odanacatib, a cathepsin K inhibitor.	Rifampin	86-94	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	125-130
27321774-1	2017	This open-label 2-period study assessed the effect of multiple-dose administration of rifampin, a strong cytochrome P450 3A (CYP3A) and P-glycoprotein inducer, on the pharmacokinetics of odanacatib, a cathepsin K inhibitor.	Rifampin	86-94	cathepsin K	Homo sapiens	201-212
28496040-6	2017	Thalidomide significantly induced P450 3A4/5, 2B6, and pregnane X receptor (PXR) mRNA levels 2 to 3-fold, but rifampicin only enhanced P450 3A5 and PXR mRNA under the modified media conditions.	Rifampin	110-120	nuclear receptor subfamily 1 group I member 2	Homo sapiens	148-151
27774592-5	2016	Furthermore, rifampicin dramatically reduced the disruption of blood-brain barrier integrity, down-regulated serum concentration of IL-6 and IL-17A, inhibited pathological Th17 cell differentiation, and modulated the expression of p-STAT3 and p-p65.	Rifampin	13-23	interleukin 6	Mus musculus	132-136
27774592-5	2016	Furthermore, rifampicin dramatically reduced the disruption of blood-brain barrier integrity, down-regulated serum concentration of IL-6 and IL-17A, inhibited pathological Th17 cell differentiation, and modulated the expression of p-STAT3 and p-p65.	Rifampin	13-23	interleukin 17A	Mus musculus	141-147
27774592-5	2016	Furthermore, rifampicin dramatically reduced the disruption of blood-brain barrier integrity, down-regulated serum concentration of IL-6 and IL-17A, inhibited pathological Th17 cell differentiation, and modulated the expression of p-STAT3 and p-p65.	Rifampin	13-23	lymphocyte cytosolic protein 1	Mus musculus	243-248
27774592-6	2016	These results suggest that rifampicin is effective for attenuating the clinical severity of EAE mice, which may be related to its inhibitive ability in differentiation of Th17 cell and secretion of its key effector molecule IL-17A via regulation of excessive activation of the key signaling molecules of JAK/STAT pathway.	Rifampin	27-37	interleukin 17A	Mus musculus	224-230
27965540-0	2016	Rifampicin Attenuated Global Cerebral Ischemia Injury via Activating the Nuclear Factor Erythroid 2-Related Factor Pathway.	Rifampin	0-10	nuclear factor, erythroid 2	Rattus norvegicus	73-99
27965540-4	2016	In this study, we examined whether rifampicin exhibits beneficial effects mediated by the Nrf2 pathway after global cerebral ischemia (GCI).	Rifampin	35-45	NFE2 like bZIP transcription factor 2	Rattus norvegicus	90-94
27965540-11	2016	In addition, rifampicin significantly elevated the nuclear expression of Nrf2, Nrf2 downstream anti-oxidant protein, HO-1 compared with the control group, and it simultaneously downregulated the expression of COX-2 in the hippocampus on day 3 after ischemia-reperfusion.	Rifampin	13-23	NFE2 like bZIP transcription factor 2	Rattus norvegicus	73-77
27965540-11	2016	In addition, rifampicin significantly elevated the nuclear expression of Nrf2, Nrf2 downstream anti-oxidant protein, HO-1 compared with the control group, and it simultaneously downregulated the expression of COX-2 in the hippocampus on day 3 after ischemia-reperfusion.	Rifampin	13-23	NFE2 like bZIP transcription factor 2	Rattus norvegicus	79-83
27965540-11	2016	In addition, rifampicin significantly elevated the nuclear expression of Nrf2, Nrf2 downstream anti-oxidant protein, HO-1 compared with the control group, and it simultaneously downregulated the expression of COX-2 in the hippocampus on day 3 after ischemia-reperfusion.	Rifampin	13-23	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	209-214
27965540-12	2016	Interestingly, the forenamed effects of rifampicin were abolished by pretreatment with brusatol, a specific inhibitor of Nrf2 activation.	Rifampin	40-50	NFE2 like bZIP transcription factor 2	Rattus norvegicus	121-125
27965540-13	2016	Conclusions: Rifampicin exerts neuroprotective effects against global cerebral ischemia, which may be attributed to activation of the Nrf2 pathway.	Rifampin	13-23	NFE2 like bZIP transcription factor 2	Rattus norvegicus	134-138
27856484-3	2016	Large-scale clinical trials with single dose rifampicin (SDR) given as post-exposure prophylaxis (PEP) to contacts of newly diagnosed patients with leprosy have shown a 50-60% reduction of the risk of developing leprosy over the following 2 years.	Rifampin	45-55	prolyl endopeptidase	Homo sapiens	98-101
27603548-3	2016	In the present study, the effects of cyclosporine A and rifampicin on recombinant cynomolgus monkey OATP-mediated pitavastatin uptake were investigated in pre- and simultaneous incubation systems.	Rifampin	56-66	solute carrier organic anion transporter family member 1A2	Homo sapiens	100-104
27538915-0	2016	Rifampin-Mediated Induction of Tamoxifen Metabolism in a Humanized PXR-CAR-CYP3A4/3A7-CYP2D6 Mouse Model.	Rifampin	0-8	nuclear receptor subfamily 1 group I member 2	Homo sapiens	67-70
27538915-0	2016	Rifampin-Mediated Induction of Tamoxifen Metabolism in a Humanized PXR-CAR-CYP3A4/3A7-CYP2D6 Mouse Model.	Rifampin	0-8	nuclear receptor subfamily 1, group I, member 3	Mus musculus	71-74
27538915-0	2016	Rifampin-Mediated Induction of Tamoxifen Metabolism in a Humanized PXR-CAR-CYP3A4/3A7-CYP2D6 Mouse Model.	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-81
27538915-0	2016	Rifampin-Mediated Induction of Tamoxifen Metabolism in a Humanized PXR-CAR-CYP3A4/3A7-CYP2D6 Mouse Model.	Rifampin	0-8	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	86-92
27538915-3	2016	In humans, tamoxifen is metabolized primarily by CYP3A4 and CYP2D6, and multiple-day treatment with rifampin decreased tamoxifen exposure by 6.2-fold.	Rifampin	100-108	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	49-55
27538915-3	2016	In humans, tamoxifen is metabolized primarily by CYP3A4 and CYP2D6, and multiple-day treatment with rifampin decreased tamoxifen exposure by 6.2-fold.	Rifampin	100-108	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	60-66
27538915-6	2016	In the humanized PXR-CAR (hPXR-CAR) model, rifampin decreased AUC0-8 of tamoxifen and its metabolites by approximately 2-fold.	Rifampin	43-51	nuclear receptor subfamily 1 group I member 2	Homo sapiens	17-20
27538915-6	2016	In the humanized PXR-CAR (hPXR-CAR) model, rifampin decreased AUC0-8 of tamoxifen and its metabolites by approximately 2-fold.	Rifampin	43-51	nuclear receptor subfamily 1, group I, member 3	Mus musculus	21-24
27538915-6	2016	In the humanized PXR-CAR (hPXR-CAR) model, rifampin decreased AUC0-8 of tamoxifen and its metabolites by approximately 2-fold.	Rifampin	43-51	nuclear receptor subfamily 1, group I, member 3	Mus musculus	31-34
27538915-8	2016	In vitro kinetics determined in microsomes prepared from livers of the Tg-composite animals showed that, although Km values were not different between vehicle- and rifampin-treated groups, rifampin increased the Vmax for the CYP3A4-mediated pathways.	Rifampin	189-197	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	225-231
27538915-9	2016	These data demonstrate that, although the hPXR-CAR model is responsive to rifampin, the extent of the clinical rifampin-tamoxifen interaction is better represented by the Tg-composite model.	Rifampin	74-82	nuclear receptor subfamily 1, group I, member 3	Mus musculus	47-50
27494923-0	2016	Molecular basis of rifampicin resistance in multiresistant porcine livestock-associated MRSA.	Rifampin	19-29	solute carrier family 9 member A6	Homo sapiens	88-92
27565568-11	2016	Finally, the validated assay was applied to measure 4-hydroxycholesterol and cholesterol in serum samples of clinical studies in humans and foals that could verify induction of hepatic CYP3A4 (human) and CYP3A89 (foals) after premedication with the known enzyme inducer rifampicin.	Rifampin	270-280	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	185-191
27745744-13	2016	IMPLICATIONS: Exposure to olaparib was significantly increased when co-administered with the potent CYP3A4 inhibitor itraconazole, and significantly decreased when co-administered with the potent CYP3A4 inducer rifampin, compared with olaparib alone.	Rifampin	211-219	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	196-202
27567379-1	2016	Pregnane X receptor (PXR) is involved in the transactivation of ABCB1 gene by rifampicin (RIF).	Rifampin	78-88	nuclear receptor subfamily 1 group I member 2	Homo sapiens	0-19
27567379-1	2016	Pregnane X receptor (PXR) is involved in the transactivation of ABCB1 gene by rifampicin (RIF).	Rifampin	78-88	nuclear receptor subfamily 1 group I member 2	Homo sapiens	21-24
27567379-1	2016	Pregnane X receptor (PXR) is involved in the transactivation of ABCB1 gene by rifampicin (RIF).	Rifampin	78-88	ATP binding cassette subfamily B member 1	Homo sapiens	64-69
27567379-1	2016	Pregnane X receptor (PXR) is involved in the transactivation of ABCB1 gene by rifampicin (RIF).	Rifampin	90-93	nuclear receptor subfamily 1 group I member 2	Homo sapiens	0-19
27567379-1	2016	Pregnane X receptor (PXR) is involved in the transactivation of ABCB1 gene by rifampicin (RIF).	Rifampin	90-93	nuclear receptor subfamily 1 group I member 2	Homo sapiens	21-24
27567379-1	2016	Pregnane X receptor (PXR) is involved in the transactivation of ABCB1 gene by rifampicin (RIF).	Rifampin	90-93	ATP binding cassette subfamily B member 1	Homo sapiens	64-69
26320398-11	2016	Compared with vancomycin-susceptible S. aureus, hVISA and VISA isolates were less susceptible to ciprofloxacin, clindamycin, daptomycin, gentamicin, rifampin, and trimethoprim/sulfamethoxazole, and are thus, more likely to have SCCmec II or III element.	Rifampin	149-157	mitochondrial antiviral signaling protein	Homo sapiens	48-53
27458223-2	2016	Three studies were conducted to evaluate the potential drug-drug interactions between delamanid and antiretroviral drugs, including ritonavir, a strong inhibitor of CYP3A4, and selected anti-TB drugs, including rifampin, a strong inducer of cytochrome P450 (CYP) isozymes.	Rifampin	211-219	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	241-256
27713827-4	2016	The selective PXR agonist rifampicin, a selective CAR activator, 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime (CITCO), and dual activators of CAR and PXR including phenobarbital (PB) were analyzed.	Rifampin	26-36	nuclear receptor subfamily 1 group I member 2	Homo sapiens	14-17
27041449-6	2016	Rifampicin and St. John"s wort, the prototypical human PXR agonists, impair glucose tolerance in healthy volunteers.	Rifampin	0-10	nuclear receptor subfamily 1 group I member 2	Homo sapiens	55-58
26724677-8	2016	Furthermore, catalytic activities of cytochrome P450 3A4 were modified by omeprazole and rifampicin in the 3D-cultured HepaRG spheroids.	Rifampin	89-99	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	37-56
27795624-2	2016	Rifampicin, a first-line antitubercular therapy (ATT) drug, is a potent inducer of hepatic cytochrome P450 (CYP).	Rifampin	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	91-106
27795624-2	2016	Rifampicin, a first-line antitubercular therapy (ATT) drug, is a potent inducer of hepatic cytochrome P450 (CYP).	Rifampin	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	108-111
27795624-3	2016	There is potential for pharmacokinetic interaction between rifampicin and anti-hypertensives that are CYP substrates: amlodipine and metoprolol.	Rifampin	59-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-105
27510251-1	2016	OBJECTIVE: To determine the effect of SLCO1B1 gene polymorphisms (rs11045819, rs4149032 and rs4149033) on rifampicin (RMP) concentrations in adult tuberculosis (TB) patients from south India.	Rifampin	106-116	solute carrier organic anion transporter family member 1B1	Homo sapiens	38-45
27510251-1	2016	OBJECTIVE: To determine the effect of SLCO1B1 gene polymorphisms (rs11045819, rs4149032 and rs4149033) on rifampicin (RMP) concentrations in adult tuberculosis (TB) patients from south India.	Rifampin	118-121	solute carrier organic anion transporter family member 1B1	Homo sapiens	38-45
27631193-2	2016	SLCO1B1 genetic variation is associated, for example, with highly variable rifampicin exposure, thus influencing the cornerstone antituberculosis therapy, especially in sub-Saharan Africa where it is a key therapeutic modality.	Rifampin	75-85	solute carrier organic anion transporter family member 1B1	Homo sapiens	0-7
27631194-7	2016	Well-characterized haplotypes, *5 (RS4149056C) and *15 (RS4149056T), have been associated with a strikingly reduced uptake of multiple OATP1B1 substrates, including estrone-3-sulfate, estradiol-17beta-d-glucuronide, atorvastatin, cerivastatin, pravastatin, and rifampicin.	Rifampin	261-271	solute carrier organic anion transporter family member 1B1	Homo sapiens	135-142
27557147-3	2016	Rifampin induces gene expression, at least in part, by activating the pregnane X receptor (PXR), which induces gene expression; however, the impact of rifampin on global gene regulation has not been examined under the molecular network frameworks.	Rifampin	0-8	nuclear receptor subfamily 1 group I member 2	Homo sapiens	70-89
27557147-3	2016	Rifampin induces gene expression, at least in part, by activating the pregnane X receptor (PXR), which induces gene expression; however, the impact of rifampin on global gene regulation has not been examined under the molecular network frameworks.	Rifampin	0-8	nuclear receptor subfamily 1 group I member 2	Homo sapiens	91-94
27197997-6	2016	Activation of CAR and PXR in cells treated with a high dose of CITCO [6-(4-chlorophenyl)-imidazo(2,1-b)thiazole-5-carbaldehyde] or cotreated with rifampicin and tetracycline resulted in synergistic enhancement of CYP3A4, but not CYP2B6, CYP2C9, or UGT1A1, mRNA expression in HepTR/hCAR/hPXR cells.	Rifampin	146-156	nuclear receptor subfamily 1 group I member 3	Homo sapiens	14-17
27197997-6	2016	Activation of CAR and PXR in cells treated with a high dose of CITCO [6-(4-chlorophenyl)-imidazo(2,1-b)thiazole-5-carbaldehyde] or cotreated with rifampicin and tetracycline resulted in synergistic enhancement of CYP3A4, but not CYP2B6, CYP2C9, or UGT1A1, mRNA expression in HepTR/hCAR/hPXR cells.	Rifampin	146-156	nuclear receptor subfamily 1 group I member 2	Homo sapiens	22-25
27105861-0	2016	Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin.	Rifampin	117-125	androgen receptor	Homo sapiens	51-68
27155371-7	2016	Relevant drugs described to up-regulate intestinal MRP2 via PXR are rifampicin, spironolactone and carbamazepine, among others.	Rifampin	68-78	ATP binding cassette subfamily C member 2	Homo sapiens	51-55
27155371-7	2016	Relevant drugs described to up-regulate intestinal MRP2 via PXR are rifampicin, spironolactone and carbamazepine, among others.	Rifampin	68-78	nuclear receptor subfamily 1 group I member 2	Homo sapiens	60-63
27358806-0	2016	Diagnosis and treatment of TB patients with rifampicin resistance detected using Xpert( ) MTB/RIF in Zimbabwe.	Rifampin	44-54	ras homolog family member F, filopodia associated	Homo sapiens	94-97
27358806-1	2016	SETTING: In Zimbabwe, there are concerns about the management of tuberculosis (TB) patients with rifampicin (RMP) resistance diagnosed using Xpert( ) MTB/RIF.	Rifampin	97-107	ras homolog family member F, filopodia associated	Homo sapiens	154-157
27358806-1	2016	SETTING: In Zimbabwe, there are concerns about the management of tuberculosis (TB) patients with rifampicin (RMP) resistance diagnosed using Xpert( ) MTB/RIF.	Rifampin	109-112	ras homolog family member F, filopodia associated	Homo sapiens	154-157
27297123-8	2016	The competitive inhibitor of NQO1 dicoumarol synergized with rifampin to promote intracellular killing of mycobacteria.	Rifampin	61-69	NAD(P)H quinone dehydrogenase 1	Homo sapiens	29-33
27098526-1	2016	Since many drugs are cytochrome P450 (CYP)-3A4 substrates, it has become common practice to assess drug-drug interaction (DDI) potential with a CYP3A4 inhibitor (ketoconazole) or inducer (rifampicin) in early drug development.	Rifampin	188-198	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	144-150
27098526-5	2016	We hypothesized that DDIs between anticancer drugs and rifampicin were primarily driven by CYP3A4 induction.	Rifampin	55-65	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	91-97
27098526-9	2016	Given the complexity and paradoxical effects arising with DDIs with rifampicin, the continued preference for rifampicin as CYP3A4 inducer needs immediate re-appraisal.	Rifampin	109-119	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	123-129
28302396-12	2017	The SAS co-precipitation process using a mixture of ethyl acetate/dimethyl sulfoxide demonstrates that this strategy can be successful for controlling rifampicin delivery.	Rifampin	151-161	tetraspanin 31	Homo sapiens	4-7
27918128-4	2017	It was found that Mul A significantly suppressed PXR-mediated P-gp luciferase activity induced by rifampicin (Rif).	Rifampin	98-108	nuclear receptor subfamily 1 group I member 2	Homo sapiens	49-52
27918128-4	2017	It was found that Mul A significantly suppressed PXR-mediated P-gp luciferase activity induced by rifampicin (Rif).	Rifampin	98-108	ATP binding cassette subfamily B member 1	Homo sapiens	62-66
27918128-4	2017	It was found that Mul A significantly suppressed PXR-mediated P-gp luciferase activity induced by rifampicin (Rif).	Rifampin	110-113	nuclear receptor subfamily 1 group I member 2	Homo sapiens	49-52
27918128-4	2017	It was found that Mul A significantly suppressed PXR-mediated P-gp luciferase activity induced by rifampicin (Rif).	Rifampin	110-113	ATP binding cassette subfamily B member 1	Homo sapiens	62-66
28324001-0	2017	CYP3A4 Induction by Rifampin: An Alternative Pathway for Vitamin D Inactivation in Patients With CYP24A1 Mutations.	Rifampin	20-28	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
28324001-0	2017	CYP3A4 Induction by Rifampin: An Alternative Pathway for Vitamin D Inactivation in Patients With CYP24A1 Mutations.	Rifampin	20-28	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	97-104
28324001-5	2017	Objective: Our goal was to determine if rifampin, a potent inducer of CYP3A4, can normalize mineral metabolism in patients with IIH due to mutations in CYP24A1.	Rifampin	40-48	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	70-76
28324001-5	2017	Objective: Our goal was to determine if rifampin, a potent inducer of CYP3A4, can normalize mineral metabolism in patients with IIH due to mutations in CYP24A1.	Rifampin	40-48	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	152-159
28324001-10	2017	Conclusion: These observations suggest that rifampin-induced overexpression of CYP3A4 provides an alternative pathway for inactivation of vitamin D metabolites in patients who lack CYP24A1 function.	Rifampin	44-52	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	79-85
28324001-10	2017	Conclusion: These observations suggest that rifampin-induced overexpression of CYP3A4 provides an alternative pathway for inactivation of vitamin D metabolites in patients who lack CYP24A1 function.	Rifampin	44-52	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	181-188
28345929-6	2017	As an assessment of CYP3A4 induction, following rifampin pretreatment to PXR-CAR-3A4/3A7Hep/Int mice, an 8% decrease in vandetanib mean AUC was observed; 39-52% reduction in AUC were observed for dasatinib, ibrutinib, regorafenib, and sorafenib compared to vehicle treated mice.	Rifampin	48-56	nuclear receptor subfamily 1, group I, member 2	Mus musculus	73-76
28879160-1	2017	BACKGROUND: Xpert  MTB/RIF is a molecular test for the detection of Mycobacterium tuberculosis and rifampicin resistance.	Rifampin	99-109	ras homolog family member F, filopodia associated	Homo sapiens	23-26
28879160-10	2017	Xpert MTB/RIF correctly identified 185/186 (99.5%) rifampicin-sensitive and 2/2 (100%) rifampicin-resistant M. tuberculosis strains.	Rifampin	51-61	ras homolog family member F, filopodia associated	Homo sapiens	10-13
28879160-10	2017	Xpert MTB/RIF correctly identified 185/186 (99.5%) rifampicin-sensitive and 2/2 (100%) rifampicin-resistant M. tuberculosis strains.	Rifampin	87-97	ras homolog family member F, filopodia associated	Homo sapiens	10-13
28879160-11	2017	Mutations were not detected by sequencing in one isolate which was rifampicin resistant on Xpert MTB/RIF but sensitive on MTBDRplus.	Rifampin	67-77	ras homolog family member F, filopodia associated	Homo sapiens	101-104
28132806-0	2017	Rifampicin pre-treatment inhibits the toxicity of rotenone-induced PC12 cells by enhancing sumoylation modification of alpha-synuclein.	Rifampin	0-10	synuclein alpha	Rattus norvegicus	119-134
28132806-1	2017	Our previous research revealed that rifampicin could protect PC12 (pheochromocytoma 12) cells from rotenone-induced cytotoxicity by reversing the aggregation of alpha-synuclein.	Rifampin	36-46	synuclein alpha	Rattus norvegicus	161-176
28132806-3	2017	Here, we investigated whether rifampicin could stabilize alpha-synuclein and prevent rotenone-induced PC12 cells from undergoing apoptosis by enhancing SUMOylation of alpha-synuclein.	Rifampin	30-40	synuclein alpha	Rattus norvegicus	57-72
28132806-3	2017	Here, we investigated whether rifampicin could stabilize alpha-synuclein and prevent rotenone-induced PC12 cells from undergoing apoptosis by enhancing SUMOylation of alpha-synuclein.	Rifampin	30-40	synuclein alpha	Rattus norvegicus	167-182
28132806-8	2017	Treatment with 150 mumol/L rifampicin, increased the expressions of SUMO1 and SUMO2/3 in cells by 1.5 times compared with the control group; meanwhile, the cell viability of rotenone-induced cells increased from 20 to 80% (P &lt; 0.05).	Rifampin	27-37	small ubiquitin-like modifier 1	Rattus norvegicus	68-73
28132806-8	2017	Treatment with 150 mumol/L rifampicin, increased the expressions of SUMO1 and SUMO2/3 in cells by 1.5 times compared with the control group; meanwhile, the cell viability of rotenone-induced cells increased from 20 to 80% (P &lt; 0.05).	Rifampin	27-37	small ubiquitin-like modifier 2	Rattus norvegicus	78-83
28132806-10	2017	SUMOylation of alpha-synuclein was more significant in rifampicin-treated cells and Ubc9 upregulated cells.	Rifampin	55-65	synuclein alpha	Rattus norvegicus	15-30
28132806-12	2017	In conclusion, rifampicin might reduce the cytotoxicity of rotenone-induced PC12 cells by promoting SUMOylation of alpha-synuclein.	Rifampin	15-25	synuclein alpha	Rattus norvegicus	115-130
28469522-2	2017	In vivo chemical inhibition of P-gp and Oatp was achieved using elacridar and rifampicin, respectively.	Rifampin	78-88	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	31-35
27174018-2	2017	Plasma concentrations of curcumin-O-glucuronide (COG) and curcumin-O-sulfate (COS) significantly increased after Sprague-Dawley rats dealt with the Oatp inhibitor rifampicin, with the Cmax ascending 2.9 and 6.7 times, and the AUC0-  ascending 4.4 and 10.8 times, respectively.	Rifampin	163-173	solute carrier organic anion transporter family member 1A2	Homo sapiens	148-152
28108285-0	2017	Rifampin suppresses osteoclastogenesis and titanium particle-induced osteolysis via modulating RANKL signaling pathways.	Rifampin	0-8	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	95-100
28108285-13	2017	Further investigation revealed that rifampin inhibited osteoclast formation by specifically abrogating RANKL-induced p38 and NF-kappaB signaling.	Rifampin	36-44	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	103-108
28108285-13	2017	Further investigation revealed that rifampin inhibited osteoclast formation by specifically abrogating RANKL-induced p38 and NF-kappaB signaling.	Rifampin	36-44	AHA1, activator of heat shock protein ATPase 1	Mus musculus	117-120
27373553-10	2017	Furthermore, we isolated isoniazid/rifampicin-specific T cells from patients, which consisted primarily of CD4+ T cells.	Rifampin	35-45	CD4 molecule	Homo sapiens	107-110
27373553-11	2017	Drug-specific CD4+ T cells proliferated and secreted IFN-gamma/granzyme B when stimulated with isoniazid or rifampicin, respectively.	Rifampin	108-118	CD4 molecule	Homo sapiens	14-17
27373553-11	2017	Drug-specific CD4+ T cells proliferated and secreted IFN-gamma/granzyme B when stimulated with isoniazid or rifampicin, respectively.	Rifampin	108-118	interferon gamma	Homo sapiens	53-62
27373553-11	2017	Drug-specific CD4+ T cells proliferated and secreted IFN-gamma/granzyme B when stimulated with isoniazid or rifampicin, respectively.	Rifampin	108-118	granzyme B	Homo sapiens	63-73
28077325-10	2017	P-gp overexpression was induced only when 14-3-3sigma transfected LS174T cells were treated with rifampin and paclitaxel, whereas 14-3-3sigma inhibition by nonpeptidic inhibitor, BV02 and 14-3-3sigma siRNA reduced rifampin induced PXR and P-gp expression.	Rifampin	214-222	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
28077325-12	2017	This data indicates that 14-3-3sigma contributes to P-gp overexpression through interaction with PXR with rifampin and paclitaxel treatment.	Rifampin	106-114	stratifin	Homo sapiens	25-36
28077325-12	2017	This data indicates that 14-3-3sigma contributes to P-gp overexpression through interaction with PXR with rifampin and paclitaxel treatment.	Rifampin	106-114	ATP binding cassette subfamily B member 1	Homo sapiens	52-56
28077325-12	2017	This data indicates that 14-3-3sigma contributes to P-gp overexpression through interaction with PXR with rifampin and paclitaxel treatment.	Rifampin	106-114	nuclear receptor subfamily 1 group I member 2	Homo sapiens	97-100
28952270-4	2017	The results showed that RIF can significantly induce CYP1A2 and CYP2B enzyme activity, and inhibit CYP3A enzyme activity.	Rifampin	24-27	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	53-59
28952270-4	2017	The results showed that RIF can significantly induce CYP1A2 and CYP2B enzyme activity, and inhibit CYP3A enzyme activity.	Rifampin	24-27	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	99-104
27693756-10	2017	These results indicate that NQO1 and CPR play an important role in redox cycle of RIF-Q and may thus contribute to RIF-induced adverse reactions.	Rifampin	82-86	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	28-32
27693756-10	2017	These results indicate that NQO1 and CPR play an important role in redox cycle of RIF-Q and may thus contribute to RIF-induced adverse reactions.	Rifampin	82-86	cytochrome p450 oxidoreductase	Rattus norvegicus	37-40
28674261-5	2017	After 2 d exposure of hepatocyte spheroids to omeprazole, phenobarbital and rifampicin (typical inducers of CYP1A2, 2B6 and 3A4, respectively), CYP1A2, 2B6 and 3A4 mRNA expression levels were significantly increased.	Rifampin	76-86	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	108-114
27637290-10	2017	Especially, the down-regulation of hepatic Cyp3a11 suggests that undesirable pharmacokinetic alternations of drugs especially Cyp3a11 substrates like rifampicin might occur in phase with cholecystectomy.	Rifampin	150-160	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	43-50
27637290-10	2017	Especially, the down-regulation of hepatic Cyp3a11 suggests that undesirable pharmacokinetic alternations of drugs especially Cyp3a11 substrates like rifampicin might occur in phase with cholecystectomy.	Rifampin	150-160	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	126-133
27967330-6	2017	Overexpression of miR-628-3p and miR-641 showed significant decrease of CYP3A4 mRNA level as well as CYP3A4 induction by rifampin.	Rifampin	121-129	microRNA 641	Homo sapiens	33-40
27967330-6	2017	Overexpression of miR-628-3p and miR-641 showed significant decrease of CYP3A4 mRNA level as well as CYP3A4 induction by rifampin.	Rifampin	121-129	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	101-107
27967330-7	2017	CONCLUSION: miR-628-3p and miR-641 could directly target CYP3A4 and are negatively regulated in CYP3A4 induction by rifampin.	Rifampin	116-124	microRNA 641	Homo sapiens	27-34
27967330-7	2017	CONCLUSION: miR-628-3p and miR-641 could directly target CYP3A4 and are negatively regulated in CYP3A4 induction by rifampin.	Rifampin	116-124	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	57-63
27967330-7	2017	CONCLUSION: miR-628-3p and miR-641 could directly target CYP3A4 and are negatively regulated in CYP3A4 induction by rifampin.	Rifampin	116-124	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	96-102
27898714-3	2016	SAB management was optimized with formal bedside infectious disease specialist consultation in 88%, deep infection foci diagnosed in 77% and adjunctive rifampicin therapy given to 61% of patients.	Rifampin	152-162	SH3 domain binding protein 5	Homo sapiens	0-3
27917125-6	2016	After treatment with 20 muM rifampicin, mRNA increased 3- to 50-fold for all CYPs except CYP1A2 and 2D6 for HepaRG and 3D-PHH, 4-fold (CYP2B6) and 17-fold (CYP3A4) for 2D-PHH and four-fold (CYP3A4) for HepG2.	Rifampin	28-38	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	89-95
27917125-6	2016	After treatment with 20 muM rifampicin, mRNA increased 3- to 50-fold for all CYPs except CYP1A2 and 2D6 for HepaRG and 3D-PHH, 4-fold (CYP2B6) and 17-fold (CYP3A4) for 2D-PHH and four-fold (CYP3A4) for HepG2.	Rifampin	28-38	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	135-141
27917125-6	2016	After treatment with 20 muM rifampicin, mRNA increased 3- to 50-fold for all CYPs except CYP1A2 and 2D6 for HepaRG and 3D-PHH, 4-fold (CYP2B6) and 17-fold (CYP3A4) for 2D-PHH and four-fold (CYP3A4) for HepG2.	Rifampin	28-38	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	156-162
27917125-6	2016	After treatment with 20 muM rifampicin, mRNA increased 3- to 50-fold for all CYPs except CYP1A2 and 2D6 for HepaRG and 3D-PHH, 4-fold (CYP2B6) and 17-fold (CYP3A4) for 2D-PHH and four-fold (CYP3A4) for HepG2.	Rifampin	28-38	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	190-196
27806127-0	2016	Rifampicin-Induced Hepatic Lipid Accumulation: Association with Up-Regulation of Peroxisome Proliferator-Activated Receptor gamma in Mouse Liver.	Rifampin	0-10	peroxisome proliferator activated receptor gamma	Mus musculus	81-129
27806127-7	2016	Moreover, mRNA levels of Fas, Acc and Scd-1, several key genes for fatty acid synthesis, were elevated in rifampicin-treated mice.	Rifampin	106-116	anterior capsular cataract	Mus musculus	30-33
27806127-7	2016	Moreover, mRNA levels of Fas, Acc and Scd-1, several key genes for fatty acid synthesis, were elevated in rifampicin-treated mice.	Rifampin	106-116	stearoyl-Coenzyme A desaturase 1	Mus musculus	38-43
27806127-10	2016	Instead, hepatic PXR was rapidly activated in rifampicin-treated mice.	Rifampin	46-56	nuclear receptor subfamily 1, group I, member 2	Mus musculus	17-20
27806127-13	2016	The increased uptake of fatty acids from circulation into liver might be partially attributed to rifampicin-induced up-regulation of PPARgamma and its target genes.	Rifampin	97-107	peroxisome proliferator activated receptor gamma	Mus musculus	133-142
27550354-2	2016	Ciprofloxacin, linezolid, para-aminosalicylic acid (PAS), and rifampin were observed to have strong inhibitory effects, with the concentrations for a 50% inhibitory effect (IC50s) being 35.1, 31.1, 37.6, and 48.1 muM, respectively, for OAT1 and &gt;100, 21.9, 24.6, and 30.2 muM, respectively, for OAT3.	Rifampin	62-70	latexin	Homo sapiens	213-216
27550354-2	2016	Ciprofloxacin, linezolid, para-aminosalicylic acid (PAS), and rifampin were observed to have strong inhibitory effects, with the concentrations for a 50% inhibitory effect (IC50s) being 35.1, 31.1, 37.6, and 48.1 muM, respectively, for OAT1 and &gt;100, 21.9, 24.6, and 30.2 muM, respectively, for OAT3.	Rifampin	62-70	solute carrier family 22 member 6	Homo sapiens	236-240
27550354-2	2016	Ciprofloxacin, linezolid, para-aminosalicylic acid (PAS), and rifampin were observed to have strong inhibitory effects, with the concentrations for a 50% inhibitory effect (IC50s) being 35.1, 31.1, 37.6, and 48.1 muM, respectively, for OAT1 and &gt;100, 21.9, 24.6, and 30.2 muM, respectively, for OAT3.	Rifampin	62-70	latexin	Homo sapiens	275-278
27550354-2	2016	Ciprofloxacin, linezolid, para-aminosalicylic acid (PAS), and rifampin were observed to have strong inhibitory effects, with the concentrations for a 50% inhibitory effect (IC50s) being 35.1, 31.1, 37.6, and 48.1 muM, respectively, for OAT1 and &gt;100, 21.9, 24.6, and 30.2 muM, respectively, for OAT3.	Rifampin	62-70	solute carrier family 22 member 8	Homo sapiens	298-302
27208659-0	2016	A rifampicin-resistant (rpoB) mutation in Pseudomonas protegens Pf-5 strain leads to improved antifungal activity and elevated production of secondary metabolites.	Rifampin	2-12	rpoB	Pseudomonas protegens Pf-5	24-28
27470132-0	2016	Rifampicin-induced injury in L02 cells is alleviated by 4-PBA via inhibition of the PERK-ATF4-CHOP pathway.	Rifampin	0-10	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	84-88
27470132-0	2016	Rifampicin-induced injury in L02 cells is alleviated by 4-PBA via inhibition of the PERK-ATF4-CHOP pathway.	Rifampin	0-10	activating transcription factor 4	Homo sapiens	89-93
27470132-0	2016	Rifampicin-induced injury in L02 cells is alleviated by 4-PBA via inhibition of the PERK-ATF4-CHOP pathway.	Rifampin	0-10	DNA damage inducible transcript 3	Homo sapiens	94-98
27118859-0	2016	Potential pharmacokinetic effect of rifampicin on enrofloxacin in broilers: Roles of P-glycoprotein and BCRP induction by rifampicin.	Rifampin	122-132	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	104-108
27118859-2	2016	It has been shown that rifampicin is the typical inducer of P-gp in rodents by activating the nuclear receptor.	Rifampin	23-33	phosphoglycolate phosphatase	Homo sapiens	60-64
27118859-4	2016	This study explored the effect of rifampicin on mRNA expression of Abcb1, Abcg2, CYP3A37, CXR as well as its effect on the pharmacokinetics of enrofloxacin in broilers.	Rifampin	34-44	ATP binding cassette subfamily B member 1	Homo sapiens	67-72
27118859-4	2016	This study explored the effect of rifampicin on mRNA expression of Abcb1, Abcg2, CYP3A37, CXR as well as its effect on the pharmacokinetics of enrofloxacin in broilers.	Rifampin	34-44	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	74-79
27118859-5	2016	The mRNA levels of Abcb1, Abcg2, CYP3A37, and CXR were significantly increased in the liver (except Abcg2), kidney, jejunum, and ileum (P &lt; 0.05) but not significantly changed in the duodenum (P &gt; 0.05) after treated with rifampicin.	Rifampin	228-238	ATP binding cassette subfamily B member 1	Homo sapiens	19-24
27118859-10	2016	Our study shows that rifampicin up-regulated the small intestinal level of P-gp and BCRP and suggests that P-gp and BCRP are key factors that affected pharmacokinetic behavior of orally administered enrofloxacin by limiting its absorption from the intestine in broilers.	Rifampin	21-31	phosphoglycolate phosphatase	Homo sapiens	75-79
27118859-10	2016	Our study shows that rifampicin up-regulated the small intestinal level of P-gp and BCRP and suggests that P-gp and BCRP are key factors that affected pharmacokinetic behavior of orally administered enrofloxacin by limiting its absorption from the intestine in broilers.	Rifampin	21-31	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	84-88
27118859-10	2016	Our study shows that rifampicin up-regulated the small intestinal level of P-gp and BCRP and suggests that P-gp and BCRP are key factors that affected pharmacokinetic behavior of orally administered enrofloxacin by limiting its absorption from the intestine in broilers.	Rifampin	21-31	phosphoglycolate phosphatase	Homo sapiens	107-111
27118859-10	2016	Our study shows that rifampicin up-regulated the small intestinal level of P-gp and BCRP and suggests that P-gp and BCRP are key factors that affected pharmacokinetic behavior of orally administered enrofloxacin by limiting its absorption from the intestine in broilers.	Rifampin	21-31	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	116-120
27311985-8	2016	Transfection of HepaRG cells with hsa-miR-25-3p mimics inhibited expression of the endogenous CYP2B6 gene and it also decreased rifampicin-dependent induction of CYP2B6 at the mRNA and protein levels.	Rifampin	128-138	microRNA 25	Homo sapiens	34-44
27311985-8	2016	Transfection of HepaRG cells with hsa-miR-25-3p mimics inhibited expression of the endogenous CYP2B6 gene and it also decreased rifampicin-dependent induction of CYP2B6 at the mRNA and protein levels.	Rifampin	128-138	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	162-168
26678015-6	2016	The exposure of naloxegol was affected substantially by ketoconazole, diltiazem, and rifampin, suggesting that it is a sensitive in vivo substrate of CYP3A4.	Rifampin	85-93	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	150-156
27638038-1	2016	Compared with smear microscopy, the Xpert MTB/RIF assay (Xpert), with superior accuracy and capacity to diagnose rifampicin resistance, has advanced TB diagnostic capability.	Rifampin	113-123	ras homolog family member F, filopodia associated	Homo sapiens	46-49
27062377-8	2016	In subgroup analyses of the RsaI/PstI polymorphism, significant results were found in East Asians, patients who used isoniazid + rifampicin + pyrazinamide + ethambutol and patients with twice the upper limit of normal as the minimum standard for defining ATDH.	Rifampin	129-139	serine peptidase inhibitor Kazal type 1	Homo sapiens	33-37
27169677-0	2016	Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNFalpha biologic for ulcerative colitis: a case report.	Rifampin	100-108	tumor necrosis factor	Homo sapiens	140-148
26920453-7	2016	KEY RESULTS: OCT1 mRNA in human hepatocytes was down-regulated along with reduced [(3) H]MPP(+) accumulation in differentiated HepaRG cells after treatment with rifampicin.	Rifampin	161-171	solute carrier family 22 member 1	Homo sapiens	13-17
27020329-0	2016	Rifampicin is a candidate preventive medicine against amyloid-beta and tau oligomers.	Rifampin	0-10	amyloid beta precursor protein	Homo sapiens	54-66
27020329-6	2016	Among these compounds, rifampicin, a well-known antibiotic, showed the strongest activities against the accumulation and toxicity (i.e. cytochrome c release from mitochondria) of intracellular amyloid-beta oligomers.	Rifampin	23-33	amyloid beta precursor protein	Homo sapiens	193-205
27020329-7	2016	Under cell-free conditions, rifampicin inhibited oligomer formation of amyloid-beta, tau, and alpha-synuclein, indicating its broad spectrum.	Rifampin	28-38	amyloid beta precursor protein	Homo sapiens	71-83
26920453-8	2016	Rifampicin and hyperforin as well as the constitutively active PXR mutant T248D suppressed activity of the 1.8 kb OCT1 promoter construct in gene reporter assays.	Rifampin	0-10	solute carrier family 22 member 1	Homo sapiens	114-118
27020329-7	2016	Under cell-free conditions, rifampicin inhibited oligomer formation of amyloid-beta, tau, and alpha-synuclein, indicating its broad spectrum.	Rifampin	28-38	synuclein, alpha	Mus musculus	94-109
27020329-8	2016	The inhibitory effects of rifampicin against amyloid-beta and tau oligomers were evaluated in APPOSK mice (amyloid-beta oligomer model), Tg2576 mice (Alzheimer"s disease model), and tau609 mice (tauopathy model).	Rifampin	26-36	amyloid beta precursor protein	Homo sapiens	45-57
26839383-1	2016	BACKGROUND: The Xpert MTB/RIF (Xpert) assay is a rapid nucleic acid amplification test widely used in settings of high tuberculosis prevalence to detect tuberculosis as well asrpoBmutations associated with rifampin resistance.	Rifampin	206-214	metallothionein 1J, pseudogene	Homo sapiens	22-25
27020329-9	2016	When orally administered to 17-month-old APPOSK mice at 0.5 and 1 mg/day for 1 month, rifampicin reduced the accumulation of amyloid-beta oligomers as well as tau hyperphosphorylation, synapse loss, and microglial activation in a dose-dependent manner.	Rifampin	86-96	amyloid beta precursor protein	Homo sapiens	125-137
27020329-11	2016	Rifampicin also inhibited cytochrome c release from the mitochondria and caspase 3 activation in the hippocampus.	Rifampin	0-10	caspase 3	Mus musculus	73-82
27020329-12	2016	In 13-month-old Tg2576 mice, oral rifampicin at 0.5 mg/day for 1 month decreased amyloid-beta oligomer accumulation, tau hyperphosphorylation, synapse loss, and microglial activation, but not amyloid deposition.	Rifampin	34-44	amyloid beta precursor protein	Homo sapiens	81-93
27020329-14	2016	In addition, rifampicin decreased the level of p62/sequestosome-1 in the brain without affecting the increased levels of LC3 (microtubule-associated protein light chain 3) conversion, suggesting the restoration of autophagy-lysosomal function.	Rifampin	13-23	sequestosome 1	Mus musculus	47-50
27020329-14	2016	In addition, rifampicin decreased the level of p62/sequestosome-1 in the brain without affecting the increased levels of LC3 (microtubule-associated protein light chain 3) conversion, suggesting the restoration of autophagy-lysosomal function.	Rifampin	13-23	sequestosome 1	Mus musculus	51-65
26966071-7	2016	Treatment with dexamethasone, phenobarbital, rifampicin, or 1alpha,25-dihydroxyvitamin D3 resulted in 5.8-fold, 13.4-fold, 9.8-fold, or 95.0-fold induction of CYP3A4 expression relative to that in the untreated controls, respectively.	Rifampin	45-55	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	159-165
27199754-11	2016	The effects of rifampin on four uptake drug transporters (SLCO1B3, SLC47A1, SLC29A1, SLC22A9) were negatively correlated with the rifampin effects on specific microRNA expression (SLCO1B3/miR-92a, SLC47A1/miR-95, SLC29A1/miR-30d#, and SLC22A9/miR-20; r &lt; -0.79; p &lt; 0.05).	Rifampin	15-23	solute carrier organic anion transporter family member 1B3	Homo sapiens	58-65
27199754-11	2016	The effects of rifampin on four uptake drug transporters (SLCO1B3, SLC47A1, SLC29A1, SLC22A9) were negatively correlated with the rifampin effects on specific microRNA expression (SLCO1B3/miR-92a, SLC47A1/miR-95, SLC29A1/miR-30d#, and SLC22A9/miR-20; r &lt; -0.79; p &lt; 0.05).	Rifampin	15-23	solute carrier family 47 member 1	Homo sapiens	67-74
27199754-11	2016	The effects of rifampin on four uptake drug transporters (SLCO1B3, SLC47A1, SLC29A1, SLC22A9) were negatively correlated with the rifampin effects on specific microRNA expression (SLCO1B3/miR-92a, SLC47A1/miR-95, SLC29A1/miR-30d#, and SLC22A9/miR-20; r &lt; -0.79; p &lt; 0.05).	Rifampin	15-23	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	76-83
27199754-11	2016	The effects of rifampin on four uptake drug transporters (SLCO1B3, SLC47A1, SLC29A1, SLC22A9) were negatively correlated with the rifampin effects on specific microRNA expression (SLCO1B3/miR-92a, SLC47A1/miR-95, SLC29A1/miR-30d#, and SLC22A9/miR-20; r &lt; -0.79; p &lt; 0.05).	Rifampin	15-23	solute carrier family 22 member 9	Homo sapiens	85-92
27199754-11	2016	The effects of rifampin on four uptake drug transporters (SLCO1B3, SLC47A1, SLC29A1, SLC22A9) were negatively correlated with the rifampin effects on specific microRNA expression (SLCO1B3/miR-92a, SLC47A1/miR-95, SLC29A1/miR-30d#, and SLC22A9/miR-20; r &lt; -0.79; p &lt; 0.05).	Rifampin	15-23	solute carrier organic anion transporter family member 1B3	Homo sapiens	180-187
27199754-11	2016	The effects of rifampin on four uptake drug transporters (SLCO1B3, SLC47A1, SLC29A1, SLC22A9) were negatively correlated with the rifampin effects on specific microRNA expression (SLCO1B3/miR-92a, SLC47A1/miR-95, SLC29A1/miR-30d#, and SLC22A9/miR-20; r &lt; -0.79; p &lt; 0.05).	Rifampin	15-23	solute carrier family 47 member 1	Homo sapiens	197-204
27199754-11	2016	The effects of rifampin on four uptake drug transporters (SLCO1B3, SLC47A1, SLC29A1, SLC22A9) were negatively correlated with the rifampin effects on specific microRNA expression (SLCO1B3/miR-92a, SLC47A1/miR-95, SLC29A1/miR-30d#, and SLC22A9/miR-20; r &lt; -0.79; p &lt; 0.05).	Rifampin	15-23	microRNA 95	Homo sapiens	205-211
27199754-11	2016	The effects of rifampin on four uptake drug transporters (SLCO1B3, SLC47A1, SLC29A1, SLC22A9) were negatively correlated with the rifampin effects on specific microRNA expression (SLCO1B3/miR-92a, SLC47A1/miR-95, SLC29A1/miR-30d#, and SLC22A9/miR-20; r &lt; -0.79; p &lt; 0.05).	Rifampin	15-23	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	213-220
27199754-11	2016	The effects of rifampin on four uptake drug transporters (SLCO1B3, SLC47A1, SLC29A1, SLC22A9) were negatively correlated with the rifampin effects on specific microRNA expression (SLCO1B3/miR-92a, SLC47A1/miR-95, SLC29A1/miR-30d#, and SLC22A9/miR-20; r &lt; -0.79; p &lt; 0.05).	Rifampin	15-23	microRNA 30d	Homo sapiens	221-228
27199754-11	2016	The effects of rifampin on four uptake drug transporters (SLCO1B3, SLC47A1, SLC29A1, SLC22A9) were negatively correlated with the rifampin effects on specific microRNA expression (SLCO1B3/miR-92a, SLC47A1/miR-95, SLC29A1/miR-30d#, and SLC22A9/miR-20; r &lt; -0.79; p &lt; 0.05).	Rifampin	15-23	solute carrier family 22 member 9	Homo sapiens	235-242
27199754-11	2016	The effects of rifampin on four uptake drug transporters (SLCO1B3, SLC47A1, SLC29A1, SLC22A9) were negatively correlated with the rifampin effects on specific microRNA expression (SLCO1B3/miR-92a, SLC47A1/miR-95, SLC29A1/miR-30d#, and SLC22A9/miR-20; r &lt; -0.79; p &lt; 0.05).	Rifampin	15-23	microRNA 20a	Homo sapiens	243-249
27199754-11	2016	The effects of rifampin on four uptake drug transporters (SLCO1B3, SLC47A1, SLC29A1, SLC22A9) were negatively correlated with the rifampin effects on specific microRNA expression (SLCO1B3/miR-92a, SLC47A1/miR-95, SLC29A1/miR-30d#, and SLC22A9/miR-20; r &lt; -0.79; p &lt; 0.05).	Rifampin	130-138	solute carrier organic anion transporter family member 1B3	Homo sapiens	58-65
27199754-11	2016	The effects of rifampin on four uptake drug transporters (SLCO1B3, SLC47A1, SLC29A1, SLC22A9) were negatively correlated with the rifampin effects on specific microRNA expression (SLCO1B3/miR-92a, SLC47A1/miR-95, SLC29A1/miR-30d#, and SLC22A9/miR-20; r &lt; -0.79; p &lt; 0.05).	Rifampin	130-138	solute carrier family 47 member 1	Homo sapiens	67-74
27199754-11	2016	The effects of rifampin on four uptake drug transporters (SLCO1B3, SLC47A1, SLC29A1, SLC22A9) were negatively correlated with the rifampin effects on specific microRNA expression (SLCO1B3/miR-92a, SLC47A1/miR-95, SLC29A1/miR-30d#, and SLC22A9/miR-20; r &lt; -0.79; p &lt; 0.05).	Rifampin	130-138	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	76-83
27199754-11	2016	The effects of rifampin on four uptake drug transporters (SLCO1B3, SLC47A1, SLC29A1, SLC22A9) were negatively correlated with the rifampin effects on specific microRNA expression (SLCO1B3/miR-92a, SLC47A1/miR-95, SLC29A1/miR-30d#, and SLC22A9/miR-20; r &lt; -0.79; p &lt; 0.05).	Rifampin	130-138	solute carrier family 22 member 9	Homo sapiens	85-92
27199754-11	2016	The effects of rifampin on four uptake drug transporters (SLCO1B3, SLC47A1, SLC29A1, SLC22A9) were negatively correlated with the rifampin effects on specific microRNA expression (SLCO1B3/miR-92a, SLC47A1/miR-95, SLC29A1/miR-30d#, and SLC22A9/miR-20; r &lt; -0.79; p &lt; 0.05).	Rifampin	130-138	solute carrier organic anion transporter family member 1B3	Homo sapiens	180-187
27199754-11	2016	The effects of rifampin on four uptake drug transporters (SLCO1B3, SLC47A1, SLC29A1, SLC22A9) were negatively correlated with the rifampin effects on specific microRNA expression (SLCO1B3/miR-92a, SLC47A1/miR-95, SLC29A1/miR-30d#, and SLC22A9/miR-20; r &lt; -0.79; p &lt; 0.05).	Rifampin	130-138	solute carrier family 47 member 1	Homo sapiens	197-204
27199754-11	2016	The effects of rifampin on four uptake drug transporters (SLCO1B3, SLC47A1, SLC29A1, SLC22A9) were negatively correlated with the rifampin effects on specific microRNA expression (SLCO1B3/miR-92a, SLC47A1/miR-95, SLC29A1/miR-30d#, and SLC22A9/miR-20; r &lt; -0.79; p &lt; 0.05).	Rifampin	130-138	microRNA 95	Homo sapiens	205-211
27199754-11	2016	The effects of rifampin on four uptake drug transporters (SLCO1B3, SLC47A1, SLC29A1, SLC22A9) were negatively correlated with the rifampin effects on specific microRNA expression (SLCO1B3/miR-92a, SLC47A1/miR-95, SLC29A1/miR-30d#, and SLC22A9/miR-20; r &lt; -0.79; p &lt; 0.05).	Rifampin	130-138	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	213-220
27199754-11	2016	The effects of rifampin on four uptake drug transporters (SLCO1B3, SLC47A1, SLC29A1, SLC22A9) were negatively correlated with the rifampin effects on specific microRNA expression (SLCO1B3/miR-92a, SLC47A1/miR-95, SLC29A1/miR-30d#, and SLC22A9/miR-20; r &lt; -0.79; p &lt; 0.05).	Rifampin	130-138	microRNA 30d	Homo sapiens	221-228
27199754-11	2016	The effects of rifampin on four uptake drug transporters (SLCO1B3, SLC47A1, SLC29A1, SLC22A9) were negatively correlated with the rifampin effects on specific microRNA expression (SLCO1B3/miR-92a, SLC47A1/miR-95, SLC29A1/miR-30d#, and SLC22A9/miR-20; r &lt; -0.79; p &lt; 0.05).	Rifampin	130-138	solute carrier family 22 member 9	Homo sapiens	235-242
27199754-11	2016	The effects of rifampin on four uptake drug transporters (SLCO1B3, SLC47A1, SLC29A1, SLC22A9) were negatively correlated with the rifampin effects on specific microRNA expression (SLCO1B3/miR-92a, SLC47A1/miR-95, SLC29A1/miR-30d#, and SLC22A9/miR-20; r &lt; -0.79; p &lt; 0.05).	Rifampin	130-138	microRNA 20a	Homo sapiens	243-249
27045425-0	2016	CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population.	Rifampin	60-70	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	0-6
26749408-2	2016	The effects of rifampin, a strong inducer of CYP3A4 and P-glycoprotein, on the pharmacokinetics of oral and intravenous apixaban were evaluated in an open-label, randomized, sequential crossover study.	Rifampin	15-23	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	45-51
26749408-2	2016	The effects of rifampin, a strong inducer of CYP3A4 and P-glycoprotein, on the pharmacokinetics of oral and intravenous apixaban were evaluated in an open-label, randomized, sequential crossover study.	Rifampin	15-23	ATP binding cassette subfamily B member 1	Homo sapiens	56-70
27478623-7	2016	Furthermore, these mouse strains showed a significantly different response to rifampicin treatment with regard to Abeta clearance and effect on brain level of its clearance-related proteins.	Rifampin	78-88	amyloid beta (A4) precursor protein	Mus musculus	114-119
26889608-6	2016	Our finding that in Latvia, time to treatment initiation was decreased for MDR TB cases that were rifampin-resistant TB by XpertMTB/RIF has implications for the use of this test in other settings with a high burden of MDR TB in which rifampin resistance is highly predictive of MDR TB.	Rifampin	98-106	ras homolog family member F, filopodia associated	Homo sapiens	132-135
26810651-9	2016	After adjusting for age and weight, rifampin exposures for the two formulations used differed inCmax(geometric mean ratio [GMR],2.55; 95% confidence interval [CI], 1.47 to 4.41;P= 0.001) and AUC0-8(GMR, 2.52; 95% CI, 1.34 to 4.73;P= 0.005).	Rifampin	36-44	colony stimulating factor 2 receptor subunit alpha	Homo sapiens	123-126
26810651-9	2016	After adjusting for age and weight, rifampin exposures for the two formulations used differed inCmax(geometric mean ratio [GMR],2.55; 95% confidence interval [CI], 1.47 to 4.41;P= 0.001) and AUC0-8(GMR, 2.52; 95% CI, 1.34 to 4.73;P= 0.005).	Rifampin	36-44	colony stimulating factor 2 receptor subunit alpha	Homo sapiens	198-201
27627555-3	2016	MATERIAL AND METHODS: In in vitro experiments, everted parts of rat small intestines were used to evaluate the effects of verapamil (a P-gp inhibitor) and rifampicin (a P-gp inducer) on the intestinal absorption of cyclosporine and tacrolimus.	Rifampin	155-165	phosphoglycolate phosphatase	Rattus norvegicus	169-173
26808255-13	2016	In conclusion, the major undesired influence of RIF on oral absorption and pulmonary distribution of CLA is associated with induction of intestinal P-gp.	Rifampin	48-51	phosphoglycolate phosphatase	Equus caballus	148-152
26385839-5	2016	It performed well in recovering the observed effect of the CYP3A4 inhibitors ketoconazole and cyclosporine, and the CYP3A4 inducer rifampicin, as well as in predicting interactions with S-warfarin and sildenafil.	Rifampin	131-141	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	116-122
26739683-0	2016	Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies.	Rifampin	79-89	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	64-70
26616219-10	2016	Atorvastatin and rifampicin significantly inhibited glucose uptake and down-regulated GLUT2 and GCK expressions.	Rifampin	17-27	solute carrier family 2 member 2	Rattus norvegicus	86-91
26259716-5	2016	The interplay between hepatic uptake and CYP3A4 metabolism was verified by simulations with rifampicin, a potent CYP3A4 inducer and OATP1B1/3 inhibitor, and maintenance doses of cyclosporine.	Rifampin	92-102	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	41-47
26259716-5	2016	The interplay between hepatic uptake and CYP3A4 metabolism was verified by simulations with rifampicin, a potent CYP3A4 inducer and OATP1B1/3 inhibitor, and maintenance doses of cyclosporine.	Rifampin	92-102	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	113-119
26782648-0	2016	SUMOylation of pregnane X receptor suppresses rifampicin-induced CYP3A4 and P-gp expression and activity in LS174T cells.	Rifampin	46-56	nuclear receptor subfamily 1 group I member 2	Homo sapiens	15-34
26782648-0	2016	SUMOylation of pregnane X receptor suppresses rifampicin-induced CYP3A4 and P-gp expression and activity in LS174T cells.	Rifampin	46-56	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	65-71
26782648-0	2016	SUMOylation of pregnane X receptor suppresses rifampicin-induced CYP3A4 and P-gp expression and activity in LS174T cells.	Rifampin	46-56	ATP binding cassette subfamily B member 1	Homo sapiens	76-80
26782648-5	2016	Our results revealed that rifampicin-induced PXR transactivation of the CYP3A4 and P-gp promoter was suppressed by SUMOylation of PXR in reporter gene assay.	Rifampin	26-36	nuclear receptor subfamily 1 group I member 2	Homo sapiens	45-48
26782648-5	2016	Our results revealed that rifampicin-induced PXR transactivation of the CYP3A4 and P-gp promoter was suppressed by SUMOylation of PXR in reporter gene assay.	Rifampin	26-36	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	72-78
26782648-5	2016	Our results revealed that rifampicin-induced PXR transactivation of the CYP3A4 and P-gp promoter was suppressed by SUMOylation of PXR in reporter gene assay.	Rifampin	26-36	ATP binding cassette subfamily B member 1	Homo sapiens	83-87
26782648-5	2016	Our results revealed that rifampicin-induced PXR transactivation of the CYP3A4 and P-gp promoter was suppressed by SUMOylation of PXR in reporter gene assay.	Rifampin	26-36	nuclear receptor subfamily 1 group I member 2	Homo sapiens	130-133
26782648-7	2016	Moreover, CYP3A4 enzymatic assay and Rho123 intracellular assay revealed that rifampicin-induced CYP3A4 and P-gp activity was also suppressed by SUMOylated PXR.	Rifampin	78-88	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	10-16
26782648-7	2016	Moreover, CYP3A4 enzymatic assay and Rho123 intracellular assay revealed that rifampicin-induced CYP3A4 and P-gp activity was also suppressed by SUMOylated PXR.	Rifampin	78-88	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	97-103
26782648-7	2016	Moreover, CYP3A4 enzymatic assay and Rho123 intracellular assay revealed that rifampicin-induced CYP3A4 and P-gp activity was also suppressed by SUMOylated PXR.	Rifampin	78-88	ATP binding cassette subfamily B member 1	Homo sapiens	108-112
26782648-7	2016	Moreover, CYP3A4 enzymatic assay and Rho123 intracellular assay revealed that rifampicin-induced CYP3A4 and P-gp activity was also suppressed by SUMOylated PXR.	Rifampin	78-88	nuclear receptor subfamily 1 group I member 2	Homo sapiens	156-159
26782648-8	2016	Our data collectively indicated for the first time that SUMOylation of PXR exerts suppressive effect on rifampicin-induced expression and activity of CYP3A4 and P-gp, which suggest that alteration in the SUMOylation status of PXR will be expected to affect the CYP3A4 mediated drug metabolism and P-gp mediated drug transport.	Rifampin	104-114	nuclear receptor subfamily 1 group I member 2	Homo sapiens	71-74
26782648-8	2016	Our data collectively indicated for the first time that SUMOylation of PXR exerts suppressive effect on rifampicin-induced expression and activity of CYP3A4 and P-gp, which suggest that alteration in the SUMOylation status of PXR will be expected to affect the CYP3A4 mediated drug metabolism and P-gp mediated drug transport.	Rifampin	104-114	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	150-156
26782648-8	2016	Our data collectively indicated for the first time that SUMOylation of PXR exerts suppressive effect on rifampicin-induced expression and activity of CYP3A4 and P-gp, which suggest that alteration in the SUMOylation status of PXR will be expected to affect the CYP3A4 mediated drug metabolism and P-gp mediated drug transport.	Rifampin	104-114	ATP binding cassette subfamily B member 1	Homo sapiens	161-165
26782648-8	2016	Our data collectively indicated for the first time that SUMOylation of PXR exerts suppressive effect on rifampicin-induced expression and activity of CYP3A4 and P-gp, which suggest that alteration in the SUMOylation status of PXR will be expected to affect the CYP3A4 mediated drug metabolism and P-gp mediated drug transport.	Rifampin	104-114	nuclear receptor subfamily 1 group I member 2	Homo sapiens	226-229
26782648-8	2016	Our data collectively indicated for the first time that SUMOylation of PXR exerts suppressive effect on rifampicin-induced expression and activity of CYP3A4 and P-gp, which suggest that alteration in the SUMOylation status of PXR will be expected to affect the CYP3A4 mediated drug metabolism and P-gp mediated drug transport.	Rifampin	104-114	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	261-267
26616219-3	2016	Rifampicin/PCN served as PXR activator control.	Rifampin	0-10	nuclear receptor subfamily 1, group I, member 2	Rattus norvegicus	25-28
26854345-2	2016	The objective of this study was to investigate the patterns of C-reactive protein (CRP), haptoglobin (Hp), ferritin and paraoxonase-1 (PON-1) during treatment of dogs with acute CME with rifampicin.	Rifampin	187-197	paraoxonase 1	Canis lupus familiaris	135-140
26658225-5	2016	The EC50 of rifampin for CYP3A4 and CYP2C9 was up to 10-fold lower in HepatoPac than the monocultures.	Rifampin	12-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	25-31
26658225-5	2016	The EC50 of rifampin for CYP3A4 and CYP2C9 was up to 10-fold lower in HepatoPac than the monocultures.	Rifampin	12-20	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	36-42
26782648-8	2016	Our data collectively indicated for the first time that SUMOylation of PXR exerts suppressive effect on rifampicin-induced expression and activity of CYP3A4 and P-gp, which suggest that alteration in the SUMOylation status of PXR will be expected to affect the CYP3A4 mediated drug metabolism and P-gp mediated drug transport.	Rifampin	104-114	ATP binding cassette subfamily B member 1	Homo sapiens	297-301
26684581-9	2016	Furthermore, uptake of compound 2 was inhibited by two inhibitors of OATP1B1*1a and OATP1B3: rifampicin and ritonavir.	Rifampin	93-103	solute carrier organic anion transporter family member 1B1	Homo sapiens	69-76
26684581-9	2016	Furthermore, uptake of compound 2 was inhibited by two inhibitors of OATP1B1*1a and OATP1B3: rifampicin and ritonavir.	Rifampin	93-103	solute carrier organic anion transporter family member 1B3	Homo sapiens	84-91
26616219-10	2016	Atorvastatin and rifampicin significantly inhibited glucose uptake and down-regulated GLUT2 and GCK expressions.	Rifampin	17-27	glucokinase	Rattus norvegicus	96-99
26616219-12	2016	Ketoconazole and resveratrol attenuated the impaired glucose utilization by atorvastatin and rifampicin in both parental and overexpressed PXR cells.	Rifampin	93-103	nuclear receptor subfamily 1, group I, member 2	Rattus norvegicus	139-142
26616219-13	2016	PXR knockdown significantly up-regulated GLUT2 and GCK proteins and abolished the decreased glucose consumption and uptake by atorvastatin and rifampicin.	Rifampin	143-153	nuclear receptor subfamily 1, group I, member 2	Rattus norvegicus	0-3
26319954-0	2016	Rifampicin Induces Bicarbonate-Rich Choleresis in Rats: Involvement of Anion Exchanger 2.	Rifampin	0-10	solute carrier family 4 member 2	Rattus norvegicus	71-88
26549688-6	2016	RT-PCR analysis showed that PXR SUMOylation in presence of rifampicin also enhances the endogenous expression levels of key PXR-regulated genes like CYP3A4, CYP2C9, MDR1 and UGT1A1.	Rifampin	59-69	nuclear receptor subfamily 1 group I member 2	Homo sapiens	28-31
26549688-6	2016	RT-PCR analysis showed that PXR SUMOylation in presence of rifampicin also enhances the endogenous expression levels of key PXR-regulated genes like CYP3A4, CYP2C9, MDR1 and UGT1A1.	Rifampin	59-69	nuclear receptor subfamily 1 group I member 2	Homo sapiens	124-127
26549688-6	2016	RT-PCR analysis showed that PXR SUMOylation in presence of rifampicin also enhances the endogenous expression levels of key PXR-regulated genes like CYP3A4, CYP2C9, MDR1 and UGT1A1.	Rifampin	59-69	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	157-163
26549688-6	2016	RT-PCR analysis showed that PXR SUMOylation in presence of rifampicin also enhances the endogenous expression levels of key PXR-regulated genes like CYP3A4, CYP2C9, MDR1 and UGT1A1.	Rifampin	59-69	ATP binding cassette subfamily B member 1	Homo sapiens	165-169
26549688-6	2016	RT-PCR analysis showed that PXR SUMOylation in presence of rifampicin also enhances the endogenous expression levels of key PXR-regulated genes like CYP3A4, CYP2C9, MDR1 and UGT1A1.	Rifampin	59-69	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	174-180
26759747-2	2016	Rifampin is a widely used antimicrobial that has major interactions with several medications including warfarin due to its strong P-glycoprotein and liver enzyme inducer activity especially on CYP2C9, CYP3A4, CYP1A2 and CYP2C19.	Rifampin	0-8	ATP binding cassette subfamily B member 1	Homo sapiens	130-144
26759747-2	2016	Rifampin is a widely used antimicrobial that has major interactions with several medications including warfarin due to its strong P-glycoprotein and liver enzyme inducer activity especially on CYP2C9, CYP3A4, CYP1A2 and CYP2C19.	Rifampin	0-8	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	193-199
26759747-2	2016	Rifampin is a widely used antimicrobial that has major interactions with several medications including warfarin due to its strong P-glycoprotein and liver enzyme inducer activity especially on CYP2C9, CYP3A4, CYP1A2 and CYP2C19.	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	201-207
26759747-2	2016	Rifampin is a widely used antimicrobial that has major interactions with several medications including warfarin due to its strong P-glycoprotein and liver enzyme inducer activity especially on CYP2C9, CYP3A4, CYP1A2 and CYP2C19.	Rifampin	0-8	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	209-215
26759747-2	2016	Rifampin is a widely used antimicrobial that has major interactions with several medications including warfarin due to its strong P-glycoprotein and liver enzyme inducer activity especially on CYP2C9, CYP3A4, CYP1A2 and CYP2C19.	Rifampin	0-8	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	220-227
25921553-0	2016	Rifampicin-dependent antibodies target glycoprotein IIb/IIIa and cause clearance of human platelets in NOD/SCID mice.	Rifampin	0-10	atrophin 1	Homo sapiens	103-106
26319954-11	2016	After rifampicin treatment, the expression level of anion exchanger 2 (AE2) increased, while the location of hepatic transporters did not change.	Rifampin	6-16	solute carrier family 4 member 2	Rattus norvegicus	52-69
26534988-6	2016	Treatment with pifithrin-mu and transfection with anti-CHIP small-interfering RNA reduced the levels of CYP3A4 mRNA induced by rifampicin, suggesting the contribution of Hsp70 and CHIP to the transactivation of hPXR.	Rifampin	127-137	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	104-110
26452722-10	2016	Rifampin-mediated CYP3A4 induction increased midazolam clearance by 73%, while CYP3A4 inhibition with ritonavir decreased midazolam clearance by 79%.	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	18-24
26319954-11	2016	After rifampicin treatment, the expression level of anion exchanger 2 (AE2) increased, while the location of hepatic transporters did not change.	Rifampin	6-16	solute carrier family 4 member 2	Rattus norvegicus	71-74
26534988-6	2016	Treatment with pifithrin-mu and transfection with anti-CHIP small-interfering RNA reduced the levels of CYP3A4 mRNA induced by rifampicin, suggesting the contribution of Hsp70 and CHIP to the transactivation of hPXR.	Rifampin	127-137	heat shock protein family A (Hsp70) member 4	Homo sapiens	170-175
26319954-13	2016	CONCLUSIONS: These results indicate that the increase in bile flow induced by rifampicin is mainly due to increased HCO3 (-) excretion mediated by increased AE2 protein expression and activity.	Rifampin	78-88	solute carrier family 4 member 2	Rattus norvegicus	157-160
26534988-6	2016	Treatment with pifithrin-mu and transfection with anti-CHIP small-interfering RNA reduced the levels of CYP3A4 mRNA induced by rifampicin, suggesting the contribution of Hsp70 and CHIP to the transactivation of hPXR.	Rifampin	127-137	nuclear receptor subfamily 1 group I member 2	Homo sapiens	211-215
26987268-0	2016	Monoammonium glycyrrhizinate protects rifampicin- and isoniazid-induced hepatotoxicity via regulating the expression of transporter Mrp2, Ntcp, and Oatp1a4 in liver.	Rifampin	38-48	ATP binding cassette subfamily C member 2	Rattus norvegicus	132-136
26910068-0	2016	In Vitro Approaches to Study Regulation of Hepatic Cytochrome P450 (CYP) 3A Expression by Paclitaxel and Rifampicin.	Rifampin	105-115	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	51-75
26910068-10	2016	The cells were then treated with the pro-inflammatory cytokine, TNFalpha, followed by the prototype CYP3A inducer rifampicin.	Rifampin	114-124	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	100-105
26910068-11	2016	It is well established that rifampicin activates PXR, leading to CYP3A4 induction.	Rifampin	28-38	nuclear receptor subfamily 1 group I member 2	Homo sapiens	49-52
26910068-11	2016	It is well established that rifampicin activates PXR, leading to CYP3A4 induction.	Rifampin	28-38	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	65-71
26910068-12	2016	We found that induction of CYP3A4-luciferase activity by rifampicin was significantly attenuated by TNFalpha.	Rifampin	57-67	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	27-33
26910068-12	2016	We found that induction of CYP3A4-luciferase activity by rifampicin was significantly attenuated by TNFalpha.	Rifampin	57-67	tumor necrosis factor	Homo sapiens	100-108
26636619-2	2015	Covalently linking unacylated tridecaptin A1 (H-TriA1) to rifampicin, vancomycin, and erythromycin enhanced their activity in vitro but not by the same magnitude as coadministration of the peptide and these antibiotics.	Rifampin	58-68	T cell receptor induced activation 1	Mus musculus	48-53
26434531-9	2015	Treatments with Dexamethasone (GR ligand), Rifampicin (PXR ligand) and TCDD (AhR ligand) increased the mRNA levels of PON1 at 24 and 48 h. We showed that the activation of GR by Dexamethasone results in PON1 gene induction accompanied by an increase in activity levels.	Rifampin	43-53	nuclear receptor subfamily 1 group I member 2	Homo sapiens	55-58
26434531-9	2015	Treatments with Dexamethasone (GR ligand), Rifampicin (PXR ligand) and TCDD (AhR ligand) increased the mRNA levels of PON1 at 24 and 48 h. We showed that the activation of GR by Dexamethasone results in PON1 gene induction accompanied by an increase in activity levels.	Rifampin	43-53	paraoxonase 1	Homo sapiens	118-122
26434531-9	2015	Treatments with Dexamethasone (GR ligand), Rifampicin (PXR ligand) and TCDD (AhR ligand) increased the mRNA levels of PON1 at 24 and 48 h. We showed that the activation of GR by Dexamethasone results in PON1 gene induction accompanied by an increase in activity levels.	Rifampin	43-53	paraoxonase 1	Homo sapiens	203-207
26559489-6	2015	In addition, CYP3A4 expression in the hiPS-ELCs was induced by treatment with 1, 25-dihydroxyvitamin D3 or rifampicin, which are known to induce CYP3A4 expression, indicating that the hiPS-ELCs have CYP3A4 induction potency.	Rifampin	107-117	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	13-19
26474710-6	2015	Using HEK293 cells overexpressing OATP1B1 or OATP1B3, we estimated IC50 values for both rifampicin (0.9 or 0.3 muM) and telmisartan (6.7 or 7.9 muM) in inhibiting OATP-mediated MTX uptake in vitro.	Rifampin	88-98	solute carrier organic anion transporter family member 1B1	Homo sapiens	34-41
26474710-6	2015	Using HEK293 cells overexpressing OATP1B1 or OATP1B3, we estimated IC50 values for both rifampicin (0.9 or 0.3 muM) and telmisartan (6.7 or 7.9 muM) in inhibiting OATP-mediated MTX uptake in vitro.	Rifampin	88-98	solute carrier organic anion transporter family member 1B3	Homo sapiens	45-52
26474710-6	2015	Using HEK293 cells overexpressing OATP1B1 or OATP1B3, we estimated IC50 values for both rifampicin (0.9 or 0.3 muM) and telmisartan (6.7 or 7.9 muM) in inhibiting OATP-mediated MTX uptake in vitro.	Rifampin	88-98	solute carrier organic anion transporter family member 1A2	Homo sapiens	34-38
26474710-7	2015	Using wild-type, Oatp1a/1b-/-, and OATP1B1- or OATP1B3-humanized transgenic mice, we found that rifampicin inhibits hepatic uptake of MTX mediated by the mouse Oatp1a/1b and human OATP1B1 and OATP1B3 transporters at clinically relevant concentrations.	Rifampin	96-106	solute carrier organic anion transporter family member 1B1	Homo sapiens	35-42
26474710-7	2015	Using wild-type, Oatp1a/1b-/-, and OATP1B1- or OATP1B3-humanized transgenic mice, we found that rifampicin inhibits hepatic uptake of MTX mediated by the mouse Oatp1a/1b and human OATP1B1 and OATP1B3 transporters at clinically relevant concentrations.	Rifampin	96-106	solute carrier organic anion transporter family member 1B3	Homo sapiens	47-54
26474710-7	2015	Using wild-type, Oatp1a/1b-/-, and OATP1B1- or OATP1B3-humanized transgenic mice, we found that rifampicin inhibits hepatic uptake of MTX mediated by the mouse Oatp1a/1b and human OATP1B1 and OATP1B3 transporters at clinically relevant concentrations.	Rifampin	96-106	solute carrier organic anion transporter family member 1B1	Homo sapiens	180-187
26474710-7	2015	Using wild-type, Oatp1a/1b-/-, and OATP1B1- or OATP1B3-humanized transgenic mice, we found that rifampicin inhibits hepatic uptake of MTX mediated by the mouse Oatp1a/1b and human OATP1B1 and OATP1B3 transporters at clinically relevant concentrations.	Rifampin	96-106	solute carrier organic anion transporter family member 1B3	Homo sapiens	192-199
26381275-6	2015	Co-administration of a single 250-mg crizotinib dose with the strong CYP3A inducer rifampin caused an 82 % decrease in crizotinib AUC0-inf.	Rifampin	83-91	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	69-74
26614197-2	2015	OBJECTIVE: To document the impact of identifying rifampicin (RMP) resistance using Xpert( ) MTB/RIF on time to diagnosis and time to treatment, and evaluate its performance under programmatic conditions.	Rifampin	49-59	ras homolog family member F, filopodia associated	Homo sapiens	96-99
26559489-6	2015	In addition, CYP3A4 expression in the hiPS-ELCs was induced by treatment with 1, 25-dihydroxyvitamin D3 or rifampicin, which are known to induce CYP3A4 expression, indicating that the hiPS-ELCs have CYP3A4 induction potency.	Rifampin	107-117	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	145-151
26559489-6	2015	In addition, CYP3A4 expression in the hiPS-ELCs was induced by treatment with 1, 25-dihydroxyvitamin D3 or rifampicin, which are known to induce CYP3A4 expression, indicating that the hiPS-ELCs have CYP3A4 induction potency.	Rifampin	107-117	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	145-151
26232425-1	2015	Upon treatment with the pregnane X receptor (PXR) activator rifampicin (RIF), human hepatocellular carcinoma HepG2-derived ShP51 cells that stably express PXR showed epithelial-mesenchymal transition (EMT)-like morphological changes and migration.	Rifampin	60-70	nuclear receptor subfamily 1 group I member 2	Homo sapiens	24-43
26374116-10	2015	In addition, the levels of IL-10 and IL-6 were significantly elevated in the INH + RIF-induced rats treated with CoQ10.	Rifampin	83-86	interleukin 10	Rattus norvegicus	27-32
26374116-10	2015	In addition, the levels of IL-10 and IL-6 were significantly elevated in the INH + RIF-induced rats treated with CoQ10.	Rifampin	83-86	interleukin 6	Rattus norvegicus	37-41
26459536-0	2015	Evaluation of Xpert( ) MTB/RIF assay: diagnosis and treatment outcomes in rifampicin-resistant tuberculosis.	Rifampin	74-84	ras homolog family member F, filopodia associated	Homo sapiens	27-30
26459536-1	2015	SETTING: The Xpert( ) MTB/RIF assay is endorsed by the World Health Organization for the detection of rifampicin (RMP) resistant tuberculosis (TB).	Rifampin	102-112	ras homolog family member F, filopodia associated	Homo sapiens	26-29
26819743-1	2015	BACKGROUND: Concomitant use of clarithromycin (CAM) and rifampicin (RFP) for the treatment of pulmonary Mycobacterium avium complex (MAC) disease affects the systemic concentrations of both drugs due to CYP3A4-related interactions.	Rifampin	56-66	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	203-209
26819743-1	2015	BACKGROUND: Concomitant use of clarithromycin (CAM) and rifampicin (RFP) for the treatment of pulmonary Mycobacterium avium complex (MAC) disease affects the systemic concentrations of both drugs due to CYP3A4-related interactions.	Rifampin	68-71	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	203-209
26354948-9	2015	Rifampin treatment induced systemic CYP3A metabolism of (11)C-verapamil; however, it reduced the ER by 6%.	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	36-41
26482301-3	2016	Nonlinear mixed-effects modeling found that influential covariates for the pharmacokinetics were weight, sex, and a 30% increased bioavailability among heterozygous carriers of SLCO1B1 rs1104581 (previously associated with low rifampin concentrations).	Rifampin	227-235	solute carrier organic anion transporter family member 1B1	Homo sapiens	177-184
26086368-0	2015	Rifampicin attenuates rotenone-induced inflammation via suppressing NLRP3 inflammasome activation in microglia.	Rifampin	0-10	NLR family, pyrin domain containing 3	Mus musculus	68-73
26086368-6	2015	Results demonstrated that rifampicin pretreatment significantly reduced rotenone-induced cytotoxicity and gene expression of IL-1beta in BV2 microglia.	Rifampin	26-36	interleukin 1 beta	Mus musculus	125-133
26086368-7	2015	Moreover, western blot analysis verified that rifampicin pretreatment suppressed NLRP3 inflammasome activation via inhibiting caspase-1 cleavage and protein expression of NLRP3.	Rifampin	46-56	NLR family, pyrin domain containing 3	Mus musculus	81-86
26086368-7	2015	Moreover, western blot analysis verified that rifampicin pretreatment suppressed NLRP3 inflammasome activation via inhibiting caspase-1 cleavage and protein expression of NLRP3.	Rifampin	46-56	caspase 1	Mus musculus	126-135
26086368-7	2015	Moreover, western blot analysis verified that rifampicin pretreatment suppressed NLRP3 inflammasome activation via inhibiting caspase-1 cleavage and protein expression of NLRP3.	Rifampin	46-56	NLR family, pyrin domain containing 3	Mus musculus	171-176
26086368-10	2015	Taken together, our data indicate that rifampicin pretreatment inhibits maturation of IL-1beta and neuroinflammation induced by rotenone via attenuating NLRP3 inflammasome activation.	Rifampin	39-49	interleukin 1 beta	Mus musculus	86-94
26086368-10	2015	Taken together, our data indicate that rifampicin pretreatment inhibits maturation of IL-1beta and neuroinflammation induced by rotenone via attenuating NLRP3 inflammasome activation.	Rifampin	39-49	NLR family, pyrin domain containing 3	Mus musculus	153-158
26182937-0	2015	Role of Specificity Protein 1, Hepatocyte Nuclear Factor 1alpha, and Pregnane X Receptor in the Basal and Rifampicin-Induced Transcriptional Regulation of Porcine Cytochrome P450 3A46.	Rifampin	106-116	Sp1 transcription factor	Homo sapiens	8-29
26182937-0	2015	Role of Specificity Protein 1, Hepatocyte Nuclear Factor 1alpha, and Pregnane X Receptor in the Basal and Rifampicin-Induced Transcriptional Regulation of Porcine Cytochrome P450 3A46.	Rifampin	106-116	HNF1 homeobox A	Homo sapiens	31-63
26182937-0	2015	Role of Specificity Protein 1, Hepatocyte Nuclear Factor 1alpha, and Pregnane X Receptor in the Basal and Rifampicin-Induced Transcriptional Regulation of Porcine Cytochrome P450 3A46.	Rifampin	106-116	nuclear receptor subfamily 1 group I member 2	Homo sapiens	69-88
26516577-7	2015	In addition, PXR (rifampicin) and CAR-selective (carbamazepine and phenytoin) inducers of CYP3A4 and CYP2B6 induction, respectively, were demonstrated.	Rifampin	18-28	nuclear receptor subfamily 1 group I member 2	Homo sapiens	13-16
26516577-7	2015	In addition, PXR (rifampicin) and CAR-selective (carbamazepine and phenytoin) inducers of CYP3A4 and CYP2B6 induction, respectively, were demonstrated.	Rifampin	18-28	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	90-96
26516577-7	2015	In addition, PXR (rifampicin) and CAR-selective (carbamazepine and phenytoin) inducers of CYP3A4 and CYP2B6 induction, respectively, were demonstrated.	Rifampin	18-28	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	101-107
26232425-1	2015	Upon treatment with the pregnane X receptor (PXR) activator rifampicin (RIF), human hepatocellular carcinoma HepG2-derived ShP51 cells that stably express PXR showed epithelial-mesenchymal transition (EMT)-like morphological changes and migration.	Rifampin	60-70	nuclear receptor subfamily 1 group I member 2	Homo sapiens	45-48
26232425-1	2015	Upon treatment with the pregnane X receptor (PXR) activator rifampicin (RIF), human hepatocellular carcinoma HepG2-derived ShP51 cells that stably express PXR showed epithelial-mesenchymal transition (EMT)-like morphological changes and migration.	Rifampin	60-70	nuclear receptor subfamily 1 group I member 2	Homo sapiens	155-158
26232425-1	2015	Upon treatment with the pregnane X receptor (PXR) activator rifampicin (RIF), human hepatocellular carcinoma HepG2-derived ShP51 cells that stably express PXR showed epithelial-mesenchymal transition (EMT)-like morphological changes and migration.	Rifampin	72-75	nuclear receptor subfamily 1 group I member 2	Homo sapiens	24-43
26232425-1	2015	Upon treatment with the pregnane X receptor (PXR) activator rifampicin (RIF), human hepatocellular carcinoma HepG2-derived ShP51 cells that stably express PXR showed epithelial-mesenchymal transition (EMT)-like morphological changes and migration.	Rifampin	72-75	nuclear receptor subfamily 1 group I member 2	Homo sapiens	45-48
26232425-1	2015	Upon treatment with the pregnane X receptor (PXR) activator rifampicin (RIF), human hepatocellular carcinoma HepG2-derived ShP51 cells that stably express PXR showed epithelial-mesenchymal transition (EMT)-like morphological changes and migration.	Rifampin	72-75	nuclear receptor subfamily 1 group I member 2	Homo sapiens	155-158
26232425-7	2015	Subsequently, small interfering RNA knockdown of HNF4alpha connected PXR-mediated gene regulation with the PXR-induced cellular responses, showing that the knockdown resulted in the upregulation of IGFBP1 and EMT-like morphological changes without RIF treatment.	Rifampin	248-251	hepatocyte nuclear factor 4 alpha	Homo sapiens	49-58
26232425-7	2015	Subsequently, small interfering RNA knockdown of HNF4alpha connected PXR-mediated gene regulation with the PXR-induced cellular responses, showing that the knockdown resulted in the upregulation of IGFBP1 and EMT-like morphological changes without RIF treatment.	Rifampin	248-251	nuclear receptor subfamily 1 group I member 2	Homo sapiens	69-72
26232425-7	2015	Subsequently, small interfering RNA knockdown of HNF4alpha connected PXR-mediated gene regulation with the PXR-induced cellular responses, showing that the knockdown resulted in the upregulation of IGFBP1 and EMT-like morphological changes without RIF treatment.	Rifampin	248-251	nuclear receptor subfamily 1 group I member 2	Homo sapiens	107-110
27137144-2	2015	This open-label, nonrandomized, fixed-order crossover study evaluated the effect of multiple oral doses of rifampin, a strong CYP3A4 inducer, on the pharmacokinetics of ponatinib (45 mg, single dose).	Rifampin	107-115	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	126-132
26757559-4	2015	The results showed that SENP1 could remarkably reduce the rifampicin (RIF)-induced MDR1 reporter activity and mRNA level in hPXR over expressed HepG2 and LS174T cells (P &lt; 0.05), whereas adding SENP1m restored the RIF-induced increases (P &lt; 0.05).	Rifampin	58-68	SUMO specific peptidase 1	Homo sapiens	24-29
25776278-8	2015	However, positive controls (50 microM omeprazole and 25 microM rifampin) caused the anticipated CYP induction, but the highest concentration of SIPI5357 (5 microM; 10 times plasma Cmax ) had a minimal effect on CYP1A2 and CYP3A4 mRNA levels in freshly isolated human hepatocytes, suggesting that SIPI5357 is not an inducer of these enzymes.	Rifampin	63-71	peptidylprolyl isomerase G	Homo sapiens	96-99
26757559-4	2015	The results showed that SENP1 could remarkably reduce the rifampicin (RIF)-induced MDR1 reporter activity and mRNA level in hPXR over expressed HepG2 and LS174T cells (P &lt; 0.05), whereas adding SENP1m restored the RIF-induced increases (P &lt; 0.05).	Rifampin	58-68	ATP binding cassette subfamily B member 1	Homo sapiens	83-87
26757559-4	2015	The results showed that SENP1 could remarkably reduce the rifampicin (RIF)-induced MDR1 reporter activity and mRNA level in hPXR over expressed HepG2 and LS174T cells (P &lt; 0.05), whereas adding SENP1m restored the RIF-induced increases (P &lt; 0.05).	Rifampin	58-68	nuclear receptor subfamily 1 group I member 2	Homo sapiens	124-128
26757559-4	2015	The results showed that SENP1 could remarkably reduce the rifampicin (RIF)-induced MDR1 reporter activity and mRNA level in hPXR over expressed HepG2 and LS174T cells (P &lt; 0.05), whereas adding SENP1m restored the RIF-induced increases (P &lt; 0.05).	Rifampin	58-68	SUMO specific peptidase 1	Homo sapiens	197-202
26757559-4	2015	The results showed that SENP1 could remarkably reduce the rifampicin (RIF)-induced MDR1 reporter activity and mRNA level in hPXR over expressed HepG2 and LS174T cells (P &lt; 0.05), whereas adding SENP1m restored the RIF-induced increases (P &lt; 0.05).	Rifampin	70-73	SUMO specific peptidase 1	Homo sapiens	24-29
26757559-4	2015	The results showed that SENP1 could remarkably reduce the rifampicin (RIF)-induced MDR1 reporter activity and mRNA level in hPXR over expressed HepG2 and LS174T cells (P &lt; 0.05), whereas adding SENP1m restored the RIF-induced increases (P &lt; 0.05).	Rifampin	70-73	ATP binding cassette subfamily B member 1	Homo sapiens	83-87
26757559-4	2015	The results showed that SENP1 could remarkably reduce the rifampicin (RIF)-induced MDR1 reporter activity and mRNA level in hPXR over expressed HepG2 and LS174T cells (P &lt; 0.05), whereas adding SENP1m restored the RIF-induced increases (P &lt; 0.05).	Rifampin	70-73	nuclear receptor subfamily 1 group I member 2	Homo sapiens	124-128
26757559-4	2015	The results showed that SENP1 could remarkably reduce the rifampicin (RIF)-induced MDR1 reporter activity and mRNA level in hPXR over expressed HepG2 and LS174T cells (P &lt; 0.05), whereas adding SENP1m restored the RIF-induced increases (P &lt; 0.05).	Rifampin	70-73	SUMO specific peptidase 1	Homo sapiens	197-202
26757559-4	2015	The results showed that SENP1 could remarkably reduce the rifampicin (RIF)-induced MDR1 reporter activity and mRNA level in hPXR over expressed HepG2 and LS174T cells (P &lt; 0.05), whereas adding SENP1m restored the RIF-induced increases (P &lt; 0.05).	Rifampin	217-220	SUMO specific peptidase 1	Homo sapiens	24-29
26306393-0	2015	Rifampin use in acute community-acquired meningitis in intensive care units: the French retrospective cohort ACAM-ICU study.	Rifampin	0-8	CXADR like membrane protein	Homo sapiens	109-113
25862466-5	2015	When 5 mug/ml hBD3-CBD was combined with antibiotics, it decreased the MIC50 and MIC90 of tetracycline, rifampicin, and streptomycin against clinical P. aeruginosa isolates.	Rifampin	104-114	defensin beta 103B	Homo sapiens	14-18
26067842-2	2015	Rifampin (RMP) and ethambutol (ETB), two anti-tubercular agents, are substrates of P-gp.	Rifampin	0-8	ATP binding cassette subfamily B member 1	Homo sapiens	83-87
26067842-2	2015	Rifampin (RMP) and ethambutol (ETB), two anti-tubercular agents, are substrates of P-gp.	Rifampin	10-13	ATP binding cassette subfamily B member 1	Homo sapiens	83-87
26067842-4	2015	Genotype/allele frequencies in C1236T, G2677T/A and C3435T SNPs of ABCB1 were obtained from 99 tuberculosis patients susceptible or resistant to RMP and ETB (NoRER or RER).	Rifampin	145-148	ATP binding cassette subfamily B member 1	Homo sapiens	67-72
26067842-7	2015	The present study suggests the 2677G&gt;A allele of ABCB1 could be associated with simultaneous resistance to RMP and ETB in pulmonary tuberculosis patients.	Rifampin	110-113	ATP binding cassette subfamily B member 1	Homo sapiens	52-57
25995454-0	2015	Casein Kinase 2 (CK2)-mediated Phosphorylation of Hsp90beta as a Novel Mechanism of Rifampin-induced MDR1 Expression.	Rifampin	84-92	heat shock protein 90 alpha family class B member 1	Homo sapiens	50-59
26181578-1	2015	BACKGROUND: Xpert MTB/RIF (Xpert) was piloted in Kazakhstan to detect tuberculosis (TB) and rifampicin resistance (RR-)TB among individuals at risk of multidrug-resistant (MDR-) TB.	Rifampin	92-102	ras homolog family member F, filopodia associated	Homo sapiens	22-25
25760671-9	2015	Rifampin caused a substantial decrease in idelalisib (58% and 75%, Cmax and AUCinf , respectively) and GS-563117 exposures, indicating an enhanced contribution of CYP3A to idelalisib metabolism under a strongly induced state.	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	163-168
26214306-4	2015	Intracellular and secreted proteomes from activated THP-1 cells infected with the Mtb H37Rv strain (MOI = 1) and treated with isoniazid and rifampicin for 1 day (infection stage) and 5 days (clearance stage) were analyzed.	Rifampin	140-150	GLI family zinc finger 2	Homo sapiens	52-57
25995454-0	2015	Casein Kinase 2 (CK2)-mediated Phosphorylation of Hsp90beta as a Novel Mechanism of Rifampin-induced MDR1 Expression.	Rifampin	84-92	ATP binding cassette subfamily B member 1	Homo sapiens	101-105
25720500-0	2015	Rifampicin reduces advanced glycation end products and activates DAF-16 to increase lifespan in Caenorhabditis elegans.	Rifampin	0-10	Fork-head domain-containing protein;Forkhead box protein O	Caenorhabditis elegans	65-71
26068927-2	2015	The effect of rifampin-induced induction of P-gp and CYP3A4/5 on transport and metabolism of edoxaban through the CYP3A4/5 pathway was investigated in a single-dose edoxaban study.	Rifampin	14-22	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	53-59
26068927-2	2015	The effect of rifampin-induced induction of P-gp and CYP3A4/5 on transport and metabolism of edoxaban through the CYP3A4/5 pathway was investigated in a single-dose edoxaban study.	Rifampin	14-22	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	114-120
26075722-1	2015	BACKGROUND: In March 2012, the Xpert MTB/RIF assay (Xpert) was introduced in three provincial public hospitals in Indonesia as a novel diagnostic to detect tuberculosis and rifampicin resistance among high risk individuals.	Rifampin	173-183	ras homolog family member F, filopodia associated	Homo sapiens	41-44
25808545-6	2015	Differentiated cells produce albumin and apolipoprotein B100 at levels equivalent to primary human hepatocytes, while demonstrating an 8-fold induction of CYP450 activity in response to aryl hydrocarbon receptor (AhR) agonist omeprazole and a 10-fold induction in response to PXR agonist rifampicin.	Rifampin	288-298	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-161
25808545-6	2015	Differentiated cells produce albumin and apolipoprotein B100 at levels equivalent to primary human hepatocytes, while demonstrating an 8-fold induction of CYP450 activity in response to aryl hydrocarbon receptor (AhR) agonist omeprazole and a 10-fold induction in response to PXR agonist rifampicin.	Rifampin	288-298	aryl hydrocarbon receptor	Homo sapiens	186-211
25808545-6	2015	Differentiated cells produce albumin and apolipoprotein B100 at levels equivalent to primary human hepatocytes, while demonstrating an 8-fold induction of CYP450 activity in response to aryl hydrocarbon receptor (AhR) agonist omeprazole and a 10-fold induction in response to PXR agonist rifampicin.	Rifampin	288-298	aryl hydrocarbon receptor	Homo sapiens	213-216
25720500-7	2015	For its effect on longevity, rifampicin requires DAF-18 (nematode PTEN) as well as JNK-1 and activates DAF-16, the FOXO homolog.	Rifampin	29-39	Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase daf-18	Caenorhabditis elegans	49-55
25720500-7	2015	For its effect on longevity, rifampicin requires DAF-18 (nematode PTEN) as well as JNK-1 and activates DAF-16, the FOXO homolog.	Rifampin	29-39	Stress-activated protein kinase jnk-1	Caenorhabditis elegans	83-88
25720500-7	2015	For its effect on longevity, rifampicin requires DAF-18 (nematode PTEN) as well as JNK-1 and activates DAF-16, the FOXO homolog.	Rifampin	29-39	Fork-head domain-containing protein;Forkhead box protein O	Caenorhabditis elegans	103-109
25720500-10	2015	Together, our data suggest that the dual ability to reduce glycation in vivo and activate prolongevity processes through DAF-16 makes RIF and RSV effective lifespan-extending interventions.	Rifampin	134-137	Fork-head domain-containing protein;Forkhead box protein O	Caenorhabditis elegans	121-127
25443889-8	2015	Quantifying victim DDI potential was also demonstrated using fmCYP3A estimates from ketoconazole clinical DDI studies to predict the magnitude of interaction on co-administration with the CYP3A inducer, rifampicin (1.6-3.3 fold error).	Rifampin	203-213	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	63-68
25835148-0	2015	Expression of hepatic cytochrome P450s and UDP-glucuronosyltransferases in PXR and CAR double humanized mice treated with rifampicin.	Rifampin	122-132	nuclear receptor subfamily 1, group I, member 2	Mus musculus	75-78
25715734-1	2015	Arylacetamide deacetylase (AADAC), a microsomal serine esterase, hydrolyzes drugs, such as flutamide, phenacetin and rifampicin.	Rifampin	117-127	arylacetamide deacetylase	Homo sapiens	0-25
25715734-1	2015	Arylacetamide deacetylase (AADAC), a microsomal serine esterase, hydrolyzes drugs, such as flutamide, phenacetin and rifampicin.	Rifampin	117-127	arylacetamide deacetylase	Homo sapiens	27-32
25797167-9	2015	Prescribers should be vigilant against combination prescription of NOACs with strong inhibitors (such as ketoconazole) or inducers of P-gp and/or CYP3A4 (such as rifampicin).	Rifampin	162-172	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	146-152
26017968-9	2015	CONCLUSIONS: The Xpert MTB/RIF assay was reliable for the detection of rifampicin resistant MTBC strains directly from sputum samples of patients undergoing first-line treatment for two months, being more trustworthy than the simple presence of acid-fast bacilli in the smear.	Rifampin	71-81	metallothionein 1J, pseudogene	Homo sapiens	23-26
25407545-5	2015	In the biodistribution study, both RFP-Man-NLCs and RFP-NLCs, compared with the commercially available rifampicin solution, displayed superior lung-targeting ability.	Rifampin	103-113	tripartite motif containing 27	Homo sapiens	35-38
25996389-8	2015	Compared with the baseline strategy of selective drug-susceptibility testing only for PTB cases at high risk of drug-resistant TB, Xpert MTB/RIF implementation increased rifampicin resistant TB case detection by over fivefold.	Rifampin	170-180	ras homolog family member F, filopodia associated	Homo sapiens	141-144
25996389-10	2015	Positive predictive value (PPV) of rifampicin resistance detected by Xpert MTB/RIF was 94.7% (CI 91.3-98.1), in comparison to conventional DST.	Rifampin	35-45	ras homolog family member F, filopodia associated	Homo sapiens	79-82
25996389-11	2015	CONCLUSION: Introduction of Xpert MTB/RIF as initial diagnostic test for TB in public health facilities significantly increased case-notification rates of all bacteriologically confirmed TB by 39% and rifampicin-resistant TB case notification by fivefold.	Rifampin	201-211	ras homolog family member F, filopodia associated	Homo sapiens	38-41
25865846-5	2015	In in vivo studies, following the oral administration of a P-gp substrate drug, rifampicin, along with compound , the Cmax and AUC0-  of rifampicin was enhanced by 31% and 46%, respectively.	Rifampin	80-90	ATP binding cassette subfamily B member 1	Homo sapiens	59-63
25865846-5	2015	In in vivo studies, following the oral administration of a P-gp substrate drug, rifampicin, along with compound , the Cmax and AUC0-  of rifampicin was enhanced by 31% and 46%, respectively.	Rifampin	137-147	ATP binding cassette subfamily B member 1	Homo sapiens	59-63
25407545-5	2015	In the biodistribution study, both RFP-Man-NLCs and RFP-NLCs, compared with the commercially available rifampicin solution, displayed superior lung-targeting ability.	Rifampin	103-113	tripartite motif containing 27	Homo sapiens	52-55
25407545-8	2015	CONCLUSIONS: RFP-Man-NLCs provided an alternative strategy for selectively delivering rifampicin to alveolar macrophages.	Rifampin	86-96	tripartite motif containing 27	Homo sapiens	13-16
25915745-1	2015	INTRODUCTION: The impact on treatment outcomes of XpertMTB/RIF, a molecular-based test that provides rapid diagnosis of tuberculosis (TB) and rifampicin resistance with high accuracy, has not been reported despite its adoption in a few countries.	Rifampin	142-152	ras homolog family member F, filopodia associated	Homo sapiens	59-62
25907584-4	2015	We found that both ppk mutants shared most of the phenotypic changes and interestingly many of them related to susceptibility toward numerous and different type of antibiotics such as Ciprofloxacin, Chloramphenicol and Rifampicin.	Rifampin	219-229	polyphosphate kinase	Pseudomonas aeruginosa PAO1	19-22
25989893-5	2015	Rifampicin (RIF), a typical OATP inhibitor, inhibited this uptake, indicating the involvement of OATP in DHEAS uptake.	Rifampin	0-10	sulfotransferase family 2A member 1	Homo sapiens	105-110
25581390-3	2015	In rats administered 20 and 80 mg/kg rifampicin, the plasma levels of bilirubin glucuronides were elevated, gradually decreased, and almost returned to the baseline level at 24 hours after administration without an elevation of alanine aminotransferase (ALT) and aspartate aminotransferase (AST).	Rifampin	37-47	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	263-289
25581390-3	2015	In rats administered 20 and 80 mg/kg rifampicin, the plasma levels of bilirubin glucuronides were elevated, gradually decreased, and almost returned to the baseline level at 24 hours after administration without an elevation of alanine aminotransferase (ALT) and aspartate aminotransferase (AST).	Rifampin	37-47	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	291-294
25989893-5	2015	Rifampicin (RIF), a typical OATP inhibitor, inhibited this uptake, indicating the involvement of OATP in DHEAS uptake.	Rifampin	12-15	sulfotransferase family 2A member 1	Homo sapiens	105-110
25989893-6	2015	In in vivo experiments, the area under the plasma concentration-time curve (AUC) and maximum plasma concentration (Cmax) of DHEAS were significantly increased following administration of RIF 10 mg/kg, although the extent of this increase was lower than that observed with the test-statins used in this study.	Rifampin	187-190	sulfotransferase family 2A member 1	Homo sapiens	124-129
24905729-2	2015	We characterized patients with severe persistent hepatocellular secretory failure (PHSF) and treated them with the pregnane X receptor (PXR) agonist, rifampicin.	Rifampin	150-160	nuclear receptor subfamily 1 group I member 2	Homo sapiens	115-134
25535219-4	2015	Rifampicin and rifapentine, two anti-TB drugs now being optimized to shorten TB treatment duration, are potent inducers of CYP3A4.	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	123-129
26167828-0	2015	[Rifampicin-resistant Mycobacterium bovis BCG strain isolated from an infant with NEMO mutation].	Rifampin	1-11	inhibitor of nuclear factor kappa B kinase regulatory subunit gamma	Homo sapiens	82-86
26167828-2	2015	In this report, a rifampicin-resistant M.bovis BCG strain isolated from an infant with NEMO defect was presented.	Rifampin	18-28	inhibitor of nuclear factor kappa B kinase regulatory subunit gamma	Homo sapiens	87-91
25628225-4	2015	The prototypical PXR activator rifampicin markedly induced the mRNA and protein expression of SLC13A5 in human primary hepatocytes.	Rifampin	31-41	nuclear receptor subfamily 1 group I member 2	Homo sapiens	17-20
25628225-4	2015	The prototypical PXR activator rifampicin markedly induced the mRNA and protein expression of SLC13A5 in human primary hepatocytes.	Rifampin	31-41	solute carrier family 13 member 5	Homo sapiens	94-101
24905729-2	2015	We characterized patients with severe persistent hepatocellular secretory failure (PHSF) and treated them with the pregnane X receptor (PXR) agonist, rifampicin.	Rifampin	150-160	nuclear receptor subfamily 1 group I member 2	Homo sapiens	136-139
24905729-3	2015	We also studied the effect of rifampicin on PXR-dependent expression of genes involved in biotransformation and secretion in vitro.	Rifampin	30-40	nuclear receptor subfamily 1 group I member 2	Homo sapiens	44-47
24905729-11	2015	In vitro, rifampicin PXR-dependently upregulated biotransformation phase 1 (CYP3A4), phase 2 (UGT1A1) and phase 3 (MRP2) enzymes/carriers as well as the basolateral bile salt exporter OSTbeta.	Rifampin	10-20	nuclear receptor subfamily 1 group I member 2	Homo sapiens	21-24
24905729-11	2015	In vitro, rifampicin PXR-dependently upregulated biotransformation phase 1 (CYP3A4), phase 2 (UGT1A1) and phase 3 (MRP2) enzymes/carriers as well as the basolateral bile salt exporter OSTbeta.	Rifampin	10-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	76-82
24905729-11	2015	In vitro, rifampicin PXR-dependently upregulated biotransformation phase 1 (CYP3A4), phase 2 (UGT1A1) and phase 3 (MRP2) enzymes/carriers as well as the basolateral bile salt exporter OSTbeta.	Rifampin	10-20	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	94-100
24905729-11	2015	In vitro, rifampicin PXR-dependently upregulated biotransformation phase 1 (CYP3A4), phase 2 (UGT1A1) and phase 3 (MRP2) enzymes/carriers as well as the basolateral bile salt exporter OSTbeta.	Rifampin	10-20	ATP binding cassette subfamily C member 2	Homo sapiens	115-119
25712654-2	2015	It is considered a strong constitutive androstane receptor activator, however both CBZ and its main metabolite CBZ 10, 11-epoxide have been reported to be pregnane X receptor (PXR) activators whose maximal efficacy and potency are comparable with the human PXR ligand rifampicin.	Rifampin	268-278	nuclear receptor subfamily 1 group I member 2	Homo sapiens	176-179
24905729-11	2015	In vitro, rifampicin PXR-dependently upregulated biotransformation phase 1 (CYP3A4), phase 2 (UGT1A1) and phase 3 (MRP2) enzymes/carriers as well as the basolateral bile salt exporter OSTbeta.	Rifampin	10-20	solute carrier family 51 subunit beta	Homo sapiens	184-191
24905729-14	2015	PXR-dependent induction of CYP3A4, UGT1A1, MRP2 and OSTbeta could contribute to the anticholestatic effect of rifampicin in PHSF.	Rifampin	110-120	nuclear receptor subfamily 1 group I member 2	Homo sapiens	0-3
24905729-14	2015	PXR-dependent induction of CYP3A4, UGT1A1, MRP2 and OSTbeta could contribute to the anticholestatic effect of rifampicin in PHSF.	Rifampin	110-120	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	27-33
24905729-14	2015	PXR-dependent induction of CYP3A4, UGT1A1, MRP2 and OSTbeta could contribute to the anticholestatic effect of rifampicin in PHSF.	Rifampin	110-120	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	35-41
24905729-14	2015	PXR-dependent induction of CYP3A4, UGT1A1, MRP2 and OSTbeta could contribute to the anticholestatic effect of rifampicin in PHSF.	Rifampin	110-120	ATP binding cassette subfamily C member 2	Homo sapiens	43-47
24905729-14	2015	PXR-dependent induction of CYP3A4, UGT1A1, MRP2 and OSTbeta could contribute to the anticholestatic effect of rifampicin in PHSF.	Rifampin	110-120	solute carrier family 51 subunit beta	Homo sapiens	52-59
25545714-1	2015	The present study has been designed to investigate the potential of rifampicin [Pregnane X receptors (PXR) agonist] in experimental dementia.	Rifampin	68-78	nuclear receptor subfamily 1, group I, member 2	Rattus norvegicus	80-100
25586052-10	2015	Conversely, the CYP3A inducer rifampicin enhanced AR nuclear localization.	Rifampin	30-40	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	16-21
25586052-10	2015	Conversely, the CYP3A inducer rifampicin enhanced AR nuclear localization.	Rifampin	30-40	androgen receptor	Mus musculus	50-52
25545714-9	2015	Rifampicin-treated AlCl3-rats exhibited significant attenuation in memory deficits, biochemical parameters like AChE activity (33+-1.4), TBARS level (4.1+-1.0), nitrite level (64+-2.6), MPO activity (3.6+-1.0) and GSH level (53+-2.4) along with improved histopathological alterations and locomotor activity when compared with AlCl3-treated rats (p&lt;0.05).	Rifampin	0-10	acetylcholinesterase	Rattus norvegicus	112-116
25545714-1	2015	The present study has been designed to investigate the potential of rifampicin [Pregnane X receptors (PXR) agonist] in experimental dementia.	Rifampin	68-78	nuclear receptor subfamily 1, group I, member 2	Rattus norvegicus	102-105
25545714-9	2015	Rifampicin-treated AlCl3-rats exhibited significant attenuation in memory deficits, biochemical parameters like AChE activity (33+-1.4), TBARS level (4.1+-1.0), nitrite level (64+-2.6), MPO activity (3.6+-1.0) and GSH level (53+-2.4) along with improved histopathological alterations and locomotor activity when compared with AlCl3-treated rats (p&lt;0.05).	Rifampin	0-10	myeloperoxidase	Rattus norvegicus	186-189
25749104-5	2015	We hypothesized that genes induced by SXR in chondrocytes have a protective effect on articular cartilage and identified Fam20a (family with sequence similarity 20a) as an SXR-dependent gene induced by the known SXR ligands, rifampicin and vitamin K2.	Rifampin	225-235	FAM20A, golgi associated secretory pathway pseudokinase	Mus musculus	121-127
25545714-10	2015	Combined administration of ketoconazole (a PXR antagonist) and rifampicin to AlCl3-treated animals reversed the rifampicin-induced protective effects.	Rifampin	112-122	nuclear receptor subfamily 1, group I, member 2	Rattus norvegicus	43-46
25749104-5	2015	We hypothesized that genes induced by SXR in chondrocytes have a protective effect on articular cartilage and identified Fam20a (family with sequence similarity 20a) as an SXR-dependent gene induced by the known SXR ligands, rifampicin and vitamin K2.	Rifampin	225-235	nuclear receptor subfamily 1, group I, member 2	Mus musculus	172-175
25749104-5	2015	We hypothesized that genes induced by SXR in chondrocytes have a protective effect on articular cartilage and identified Fam20a (family with sequence similarity 20a) as an SXR-dependent gene induced by the known SXR ligands, rifampicin and vitamin K2.	Rifampin	225-235	nuclear receptor subfamily 1, group I, member 2	Mus musculus	38-41
25749104-5	2015	We hypothesized that genes induced by SXR in chondrocytes have a protective effect on articular cartilage and identified Fam20a (family with sequence similarity 20a) as an SXR-dependent gene induced by the known SXR ligands, rifampicin and vitamin K2.	Rifampin	225-235	nuclear receptor subfamily 1, group I, member 2	Mus musculus	172-175
25803093-2	2015	This study assessed the safety, tolerability, and pharmacokinetics of bosutinib when coadministered with the CYP3A4 inducer rifampin in 24 healthy men.	Rifampin	124-132	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	109-115
27128217-4	2015	The purpose of these studies was to evaluate the effect of ketoconazole, a potent inhibitor of CYP3A4, and rifampin, a potent inducer of CYP3A4, on the pharmacokinetics of tivozanib.	Rifampin	107-115	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	137-143
27128217-8	2015	However, coadministration of tivozanib with rifampin caused a significant decrease in the area under the curve from 0 to infinity and half-life and an increase in clearance of tivozanib, which suggest increased clearance via the enhanced CYP3A4-mediated metabolism of tivozanib.	Rifampin	44-52	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	238-244
25809761-3	2015	Progress has been made in clinic-based detection tools with the introduction of Xpert MTB/RIF, a nucleic acid amplification test that combines sample processing and analysis in a single instrument to provide a diagnostic result and detection of resistance to rifampicin in under 2h.	Rifampin	259-269	ras homolog family member F, filopodia associated	Homo sapiens	90-93
25418376-9	2015	By using telmisartan (a non-specific OATP inhibitor) and rifampicin, OATP2B1 was demonstrated to account for &lt;20% of hepatic HMME uptake.	Rifampin	57-67	solute carrier organic anion transporter family member 2B1	Homo sapiens	69-76
25658091-8	2015	Upfront Xpert MTB/RIF testing of presumptive PTB and DR-TB cases resulted in diagnosis of 73 (9.5%, CI 7.6-11.8) and 16 (11.2%, CI 6.7-17.1) rifampicin resistance cases, respectively.	Rifampin	141-151	ras homolog family member F, filopodia associated	Homo sapiens	18-21
25733917-4	2015	As a substrate of CYP 3A4, dolutegravir is affected by rifampin, efavirenz, tipranavir/ritonavir, fosamprenavir/ritonavir, and dose increase is required.	Rifampin	55-63	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	18-25
25479155-6	2015	RESULTS: Administration of both rifampicin and BCG-LPS elicited hepatic damage reflected in significantly (p&lt;0.01) increased serum marker enzymes AST, ALT, ALP, GGT, LDH and decreased total proteins, increased MDA and NO formation in liver homogenate.	Rifampin	32-42	PDZ and LIM domain 3	Rattus norvegicus	159-162
25670521-4	2015	In vitro reevaluation at therapeutically relevant low-nanomolar concentrations of unbound ASV showed active, saturable human hepatocyte uptake (Km = 0.685 muM) and rifampin-reversible transport by OATP1B1 and OATP2B1, but not OATP1B3.	Rifampin	164-172	solute carrier organic anion transporter family member 1B1	Homo sapiens	197-204
25407255-2	2015	Canagliflozin exposures may be affected by coadministration of drugs that induce (e.g., rifampin for UGT) or inhibit (e.g. probenecid for UGT; cyclosporine A for P-gp) these pathways.	Rifampin	88-96	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	101-104
25670521-3	2015	Although no significant OATP transport of ASV was observed in vitro at standard micromolar assay concentrations, clinical coadministration of ASV with a single dose of the OATP inhibitor rifampin gave large, variable increases in ASV plasma Cmax (21-fold mean) and AUCinf (15-fold mean), consistent with reduced hepatic uptake.	Rifampin	187-195	solute carrier organic anion transporter family member 1A2	Homo sapiens	24-28
25670521-3	2015	Although no significant OATP transport of ASV was observed in vitro at standard micromolar assay concentrations, clinical coadministration of ASV with a single dose of the OATP inhibitor rifampin gave large, variable increases in ASV plasma Cmax (21-fold mean) and AUCinf (15-fold mean), consistent with reduced hepatic uptake.	Rifampin	187-195	solute carrier organic anion transporter family member 1A2	Homo sapiens	172-176
25263393-10	2015	Therefore, the interactive mechanism of multidose rifampicin may occur through a combination of OATP and P-gp transporters, thereby altering the pharmacokinetics of fexofenadine enantiomers.	Rifampin	50-60	ATP binding cassette subfamily B member 1	Homo sapiens	105-109
25598834-2	2015	RAL should be double-dosed to 800 mg semi-daily in situation of rifampicin co-medication, because RAL is more rapidly metabolized due to rifampicin-induced Uridine-5"-diphosph- gluronosyl-transferase (UGT1A1).	Rifampin	64-74	RAS like proto-oncogene A	Homo sapiens	0-3
25653502-4	2015	The increased uptake of catalposide via the OAT3, OATP1B1, and OATP1B3 transporters was decreased to basal levels in the presence of representative inhibitors such as probenecid, furosemide, and cimetidine (for OAT3) and cyclosporin A, gemfibrozil, and rifampin (for OATP1B1 and OATP1B3).	Rifampin	253-261	solute carrier family 22 member 8	Homo sapiens	44-48
25653502-4	2015	The increased uptake of catalposide via the OAT3, OATP1B1, and OATP1B3 transporters was decreased to basal levels in the presence of representative inhibitors such as probenecid, furosemide, and cimetidine (for OAT3) and cyclosporin A, gemfibrozil, and rifampin (for OATP1B1 and OATP1B3).	Rifampin	253-261	solute carrier organic anion transporter family member 1B3	Homo sapiens	63-70
25263393-1	2015	WHAT IS KNOWN AND OBJECTIVE: Rifampicin is a potent inducer of P-glycoprotein (P-gp) and inhibitor of organic anion-transporting polypeptides (OATPs), with fexofenadine acting as a substrate for both mechanisms.	Rifampin	29-39	ATP binding cassette subfamily B member 1	Homo sapiens	63-77
25263393-1	2015	WHAT IS KNOWN AND OBJECTIVE: Rifampicin is a potent inducer of P-glycoprotein (P-gp) and inhibitor of organic anion-transporting polypeptides (OATPs), with fexofenadine acting as a substrate for both mechanisms.	Rifampin	29-39	ATP binding cassette subfamily B member 1	Homo sapiens	79-83
25263393-2	2015	Simultaneous administration of single- or multiple-dose rifampicin 600 mg significantly increases the concentrations of fexofenadine enantiomers by inhibiting OATP transporters.	Rifampin	56-66	solute carrier organic anion transporter family member 1A2	Homo sapiens	159-163
25263393-8	2015	These results indicated that multiple doses of rifampicin 450 mg may be sufficient to inhibit the renal influx transporter and OATP-mediated hepatic uptake of both enantiomers.	Rifampin	47-57	solute carrier organic anion transporter family member 1A2	Homo sapiens	127-131
25263393-9	2015	Moreover, these effects may be greater than the P-gp-inductive effects of rifampicin.	Rifampin	74-84	ATP binding cassette subfamily B member 1	Homo sapiens	48-52
25263393-10	2015	Therefore, the interactive mechanism of multidose rifampicin may occur through a combination of OATP and P-gp transporters, thereby altering the pharmacokinetics of fexofenadine enantiomers.	Rifampin	50-60	solute carrier organic anion transporter family member 1A2	Homo sapiens	96-100
25648393-14	2015	Imipenem/meropenem/rifampicin in combination with polymyxin B demonstrated consistent bactericidal effect against 49 bla OXA-23-harbouring XDR A. baumannii clinical isolates, suggesting a role of combination therapy in the treatment of these infections.	Rifampin	19-29	class D beta-lactamase OXA-23	Acinetobacter baumannii	121-127
25598834-2	2015	RAL should be double-dosed to 800 mg semi-daily in situation of rifampicin co-medication, because RAL is more rapidly metabolized due to rifampicin-induced Uridine-5"-diphosph- gluronosyl-transferase (UGT1A1).	Rifampin	137-147	RAS like proto-oncogene A	Homo sapiens	0-3
25598834-2	2015	RAL should be double-dosed to 800 mg semi-daily in situation of rifampicin co-medication, because RAL is more rapidly metabolized due to rifampicin-induced Uridine-5"-diphosph- gluronosyl-transferase (UGT1A1).	Rifampin	137-147	RAS like proto-oncogene A	Homo sapiens	98-101
25598834-2	2015	RAL should be double-dosed to 800 mg semi-daily in situation of rifampicin co-medication, because RAL is more rapidly metabolized due to rifampicin-induced Uridine-5"-diphosph- gluronosyl-transferase (UGT1A1).	Rifampin	137-147	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	201-207
25598834-3	2015	Recently, it was speculated that chewed RAL might lead to increased absorption, which might compensate the inductive effect of rifampicin-rapid metabolized RAL, as part of cost-saving effects in countries with high-tuberculosis prevalence and less economic power.	Rifampin	127-137	RAS like proto-oncogene A	Homo sapiens	156-159
25069801-5	2015	Protective effects of AITC on rifampin-induced cytotoxicity were observed, and transient transfection assays showed that AITC was able to effectively attenuate the agonist effects of rifampin and CITCO on human PXR and CAR activity, respectively.	Rifampin	183-191	nuclear receptor subfamily 1 group I member 2	Homo sapiens	211-214
26168679-4	2015	The highest levels of the MRSA resistance were stated against ciprofloxacin--92%(MIC50 32 mcg/ml), gentamicin--85% (MIC50 128 mcg/ml), erythromycin--54% (MIC50 32-mcg/ml) and clindainycin - 45% (MIC50 0.03 mcg/ml), as well as against rifampicin--38% (MIC50 0.06 mcg/ml).	Rifampin	234-244	solute carrier family 9 member A6	Homo sapiens	26-30
26094899-2	2015	Rifampicin, rifabutin, and thioacetazone inhibited one CYP reaction.	Rifampin	0-10	peptidylprolyl isomerase G	Homo sapiens	55-58
26574146-12	2015	Unlike CYP1 and 3 and other CYP2 members, CYP2D6 is resistant to typical inducers such as rifampin, phenobarbital and dexamethasone.	Rifampin	90-98	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	42-48
27128001-2	2015	Hence, the potential for drug-drug interactions when alisporivir is co-administered with CYP3A4 and/or P-gp inhibitors such as ketoconazole, azithromycin and CYP3A4 inducers such as rifampin were evaluated in three separate clinical studies.	Rifampin	182-190	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	158-164
27128001-5	2015	Rifampin (a CYP3A4 inducer) caused an approximate 90% reduction in alisporivir Cmax and AUC and a fourfold reduction in alisporivir terminal elimination half-life.	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	12-18
26405974-2	2015	Previous studies have shown that rifampin can indirectly influence drug deposition through the regulation of molecular interactions of miRNA, PXR and other genes.	Rifampin	33-41	nuclear receptor subfamily 1 group I member 2	Homo sapiens	142-145
24464437-10	2015	A short course treatment with isoniazid and rifampin provided efficacy, good tolerability and good completion rate in patients with rheumatic conditions proposed for anti-TNF therapy.	Rifampin	44-52	tumor necrosis factor	Homo sapiens	171-174
25351763-3	2015	The predominant role of OATPs was further supported by a dramatic inhibition of flavopiridol uptake in the presence of the OATP substrate rifampicin.	Rifampin	138-148	solute carrier organic anion transporter family member 1A2	Homo sapiens	24-28
25600204-2	2015	To evaluate time-dependent cytochrome P450 induction precisely, induction of CYP1A2, CYP2B6, and CYP3A4 mRNA was confirmed (&gt;2-fold) by the treatment with omeprazole, phenobarbital, and rifampicin, respectively, for 24 or 48 h on day 3 from the start of culture.	Rifampin	189-199	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	77-83
25600204-2	2015	To evaluate time-dependent cytochrome P450 induction precisely, induction of CYP1A2, CYP2B6, and CYP3A4 mRNA was confirmed (&gt;2-fold) by the treatment with omeprazole, phenobarbital, and rifampicin, respectively, for 24 or 48 h on day 3 from the start of culture.	Rifampin	189-199	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	85-91
25209610-2	2015	The aim of this study was to assess the non-inferiority of a combination of trimethoprim/sulfamethoxazole plus rifampicin versus linezolid alone for the treatment of MRSA infection.	Rifampin	111-121	solute carrier family 9 member A6	Homo sapiens	166-170
25209610-13	2015	CONCLUSIONS: Compared with linezolid, trimethoprim/sulfamethoxazole and rifampicin seems to be non-inferior in the treatment of MRSA infection.	Rifampin	72-82	solute carrier family 9 member A6	Homo sapiens	128-132
24934663-8	2015	A combination of rifampin and clarithromycin released from the polymer film provided &gt;99.9% kill of an MRSA inoculate for up to 72 h. CONCLUSION: Results showed that combining multiple drugs in copolymer films with unique surface properties, initial hydrophilicity and increase in roughness, can be an effective way to prevent biofilm formation.	Rifampin	17-25	solute carrier family 9 member A6	Homo sapiens	106-110
26506671-4	2015	MATERIAL AND METHODS: The specific zone mutations in rpoB, katG and inhA gene for rifampicin and isoniazid were investigated with molecular methods in 198 recently isolated unique strains from patients diagnosed with pulmonary tuberculosis.	Rifampin	82-92	inhibin subunit alpha	Homo sapiens	68-72
25761590-8	2015	Inhibitors of MRP2, (MK571 and rifampicin) and co-incubation with kaempferol (10 muM), increased transfer from the apical to the basolateral side by three to five fold.	Rifampin	31-41	ATP binding cassette subfamily C member 2	Homo sapiens	14-18
25886055-0	2015	The inhibition of hepatic bile acids transporters Ntcp and Bsep is involved in the pathogenesis of isoniazid/rifampicin-induced hepatotoxicity.	Rifampin	109-119	solute carrier family 10 (sodium/bile acid cotransporter family), member 1	Mus musculus	50-54
25886055-0	2015	The inhibition of hepatic bile acids transporters Ntcp and Bsep is involved in the pathogenesis of isoniazid/rifampicin-induced hepatotoxicity.	Rifampin	109-119	ATP-binding cassette, sub-family B (MDR/TAP), member 11	Mus musculus	59-63
25625052-0	2014	Verapamil and rifampin effect on p-glycoprotein expression in hepatocellular carcinoma.	Rifampin	14-22	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	33-47
26068524-5	2015	Our studies indicated that berberine uptake was significantly suppressed by rifampicin, cyclosporine A and glycyrrhizic acid, which act as specific inhibitors of different Oatp isoforms (Oatp1a1, Oatp1a4 and Oatp1b2) in rat hepatocytes.	Rifampin	76-86	solute carrier organic anion transporter family member 1A2	Homo sapiens	172-176
25096076-1	2014	OBJECTIVES: To assess the effect of the major efavirenz metabolizing enzyme (CYP2B6) genotype and the effects of rifampicin co-treatment on induction of CYP3A by efavirenz.	Rifampin	113-123	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	153-158
25047139-12	2014	WHAT IS NEW AND CONCLUSION: Co-administration navitoclax with rifampin moderately decreased navitoclax AUC, which could be partly due to the induction effect of rifampin on CYP3A4.	Rifampin	62-70	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	173-179
25047139-12	2014	WHAT IS NEW AND CONCLUSION: Co-administration navitoclax with rifampin moderately decreased navitoclax AUC, which could be partly due to the induction effect of rifampin on CYP3A4.	Rifampin	161-169	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	173-179
25302422-0	2014	Protective effects of resveratrol on hepatotoxicity induced by isoniazid and rifampicin via SIRT1 modulation.	Rifampin	77-87	sirtuin 1	Mus musculus	92-97
25302422-8	2014	The results presented herein show that 1 was able to largely prevent the hepatotoxicity induced by isoniazid and rifampicin in mice, mainly by modulating SIRT1 mRNA expression.	Rifampin	113-123	sirtuin 1	Mus musculus	154-159
25008118-6	2014	The model predicted an alisporivir AUC increase by 9.4-fold and a decrease by 86% when alisporivir was co-administrated with ketoconazole (CYP3A4 inhibitor) or rifampin (CYP3A4 inducer), respectively.	Rifampin	160-168	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	170-176
26521872-4	2015	We found that flutamide, phenacetin, rifamycins (rifampicin, rifabutin, and rifapentine), and indiplon are hydrolyzed by arylacetamide deacetylase (AADAC), which is highly expressed in human liver and gastrointestinal tissues.	Rifampin	49-59	arylacetamide deacetylase	Homo sapiens	148-153
25395048-1	2014	BACKGROUND: The Xpert MTB/RIF assay (Xpert assay; Cepheid, Sunnyvale, CA) is becoming the test of choice for the rapid diagnosis of tuberculosis and rifampin (RIF) resistance.	Rifampin	149-157	ras homolog family member F, filopodia associated	Homo sapiens	16-29
24962564-9	2014	However, the effect of CYP3A4 induction by rifampicin on apremilast clearance is much more pronounced than that of CYP3A4 inhibition by ketoconazole.	Rifampin	43-53	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	23-29
25625052-3	2014	OBJECTIVES: The aim of this study was to elucidate the effect of potent carcinogen nitrosamine with and without verapamil and rifampin drugs on P-gp expression at the mRNA level in HCC.	Rifampin	126-134	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	144-148
25625052-8	2014	Rifampin administrated group had a decreased level of the mdr1a mRNA compared to the control group (P &lt;= 0.006).	Rifampin	0-8	ATP binding cassette subfamily B member 1A	Rattus norvegicus	58-63
25625052-11	2014	CONCLUSIONS: Verapamil and rifampin were found specific and effective against P-gp expression in HCC.	Rifampin	27-35	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	78-82
25022720-8	2014	RESULTS: Single-dose rifampicin (P-gp inhibition) increased area under the plasma concentration-time curve from time zero to infinity (AUC0- ) of free and total lenvatinib by 32 and 31 %, respectively.	Rifampin	21-31	ATP binding cassette subfamily B member 1	Homo sapiens	33-37
25145495-7	2014	Additionally, using a chequerboard assay, we have shown that hepcidin has an antagonistic effect in combination with the antibiotics rifampicin and tetracycline against Staphylococcus aureus, Pseudomonas aeruginosa and Streptococcus pyogenes, evidenced by a fractional inhibitory concentration index (FICI) &gt; 4.	Rifampin	133-143	hepcidin antimicrobial peptide	Homo sapiens	61-69
24617605-8	2014	In vitro studies showed that rifampicin was an inhibitor of OATP1B1 and OATP1B3, breast cancer resistance protein and multidrug resistance protein 2, but not of organic anion transporter 3.	Rifampin	29-39	solute carrier organic anion transporter family member 1B1	Homo sapiens	60-67
24617605-8	2014	In vitro studies showed that rifampicin was an inhibitor of OATP1B1 and OATP1B3, breast cancer resistance protein and multidrug resistance protein 2, but not of organic anion transporter 3.	Rifampin	29-39	solute carrier organic anion transporter family member 1B3	Homo sapiens	72-79
25070100-9	2014	In human hepatocytes, ketoconazole dose dependently inhibited the formation of N(+)-glucuronides (50% inhibitory concentration [IC50], 1.5 muM), while rifampin induced the mRNA level of UGT1A9 by 28% and the activity of UGT1A9 by 53%.	Rifampin	151-159	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	186-192
25070100-9	2014	In human hepatocytes, ketoconazole dose dependently inhibited the formation of N(+)-glucuronides (50% inhibitory concentration [IC50], 1.5 muM), while rifampin induced the mRNA level of UGT1A9 by 28% and the activity of UGT1A9 by 53%.	Rifampin	151-159	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	220-226
25074870-4	2014	The amount of the unphosphorylated wild-type yellow fluorescent protein-hPXR fusion protein but not the T290A mutant increased on Phos-tag gels in response to stimulations with rifampicin and cyclin-dependent kinase 2 inhibitor roscovitine, and a marked increase was observed in the unphosphorylated levels of the T290A mutant in nontreated cells.	Rifampin	177-187	nuclear receptor subfamily 1 group I member 2	Homo sapiens	72-76
25074870-8	2014	After the rifampicin and roscovitine stimulations, PP1 was recruited to the wild-type hPXR but not the T290A mutant.	Rifampin	10-20	neuropeptide Y receptor Y4	Homo sapiens	51-54
25074870-8	2014	After the rifampicin and roscovitine stimulations, PP1 was recruited to the wild-type hPXR but not the T290A mutant.	Rifampin	10-20	nuclear receptor subfamily 1 group I member 2	Homo sapiens	86-90
25119251-0	2014	Rifampicin improves neuronal apoptosis in LPS-stimulated co-cultured BV2 cells through inhibition of the TLR-4 pathway.	Rifampin	0-10	toll-like receptor 4	Mus musculus	42-45
25119251-0	2014	Rifampicin improves neuronal apoptosis in LPS-stimulated co-cultured BV2 cells through inhibition of the TLR-4 pathway.	Rifampin	0-10	toll-like receptor 4	Mus musculus	105-110
25119251-3	2014	Our previous study showed that rifampicin inhibits the production of lipopolysaccharide (LPS)-induced pro-inflammatory mediators and improves neuron survival in inflammation; however, the mechanism through which rifampicin inhibits microglial inflammation and its neuroprotective effects are not completely understood.	Rifampin	31-41	toll-like receptor 4	Mus musculus	89-92
25119251-3	2014	Our previous study showed that rifampicin inhibits the production of lipopolysaccharide (LPS)-induced pro-inflammatory mediators and improves neuron survival in inflammation; however, the mechanism through which rifampicin inhibits microglial inflammation and its neuroprotective effects are not completely understood.	Rifampin	212-222	toll-like receptor 4	Mus musculus	89-92
25119251-4	2014	In this study, we examined the effects of rifampicin on morphological changes induced by LPS in murine microglial BV2 cells.	Rifampin	42-52	toll-like receptor 4	Mus musculus	89-92
25119251-5	2014	Then we investigated, in BV2 microglia, the effects of rifampicin on two signaling pathway componentss stimulated by LPS, the Toll-like receptor-4 (TLR-4) and the nuclear factor-kappaB (NF-kappaB).	Rifampin	55-65	toll-like receptor 4	Mus musculus	117-120
25119251-5	2014	Then we investigated, in BV2 microglia, the effects of rifampicin on two signaling pathway componentss stimulated by LPS, the Toll-like receptor-4 (TLR-4) and the nuclear factor-kappaB (NF-kappaB).	Rifampin	55-65	toll-like receptor 4	Mus musculus	126-146
25119251-7	2014	Rifampicin inhibited LPS-stimulated expression of the TLR-4 gene.	Rifampin	0-10	toll-like receptor 4	Mus musculus	21-24
25119251-7	2014	Rifampicin inhibited LPS-stimulated expression of the TLR-4 gene.	Rifampin	0-10	toll-like receptor 4	Mus musculus	54-59
25119251-8	2014	When neurons were co-cultured with LPS-stimulated BV2 microglia, pre-treatment with rifampicin increased neuronal viability and reduced the number of apoptotic cells.	Rifampin	84-94	toll-like receptor 4	Mus musculus	35-38
25022720-9	2014	Multiple-dose rifampicin (simultaneous P-gp and CYP3A4 induction) decreased lenvatinib AUC0-  (total: 18 %; free: 9 %).	Rifampin	14-24	ATP binding cassette subfamily B member 1	Homo sapiens	39-43
25022720-9	2014	Multiple-dose rifampicin (simultaneous P-gp and CYP3A4 induction) decreased lenvatinib AUC0-  (total: 18 %; free: 9 %).	Rifampin	14-24	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	48-54
24890593-6	2014	Respiratory epithelial cell-derived MMP-3 was suppressed by moxifloxacin, rifampicin, and azithromycin in a dose-dependent manner.	Rifampin	74-84	matrix metallopeptidase 3	Homo sapiens	36-41
24996840-1	2014	We aimed to analyze the efficacy and safety of high doses of daptomycin (10 mg/kg/d) plus rifampin (D10 + R) for prosthetic joint infection (PJI).	Rifampin	90-98	CHRNA7 (exons 5-10) and FAM7A (exons A-E) fusion	Homo sapiens	100-103
25361020-3	2014	Xpert MTB/RIF allows for the rapid diagnosis of Mycobacterium tuberculosis and identification of rifampicin susceptibility.	Rifampin	97-107	ras homolog family member F, filopodia associated	Homo sapiens	10-13
25141173-7	2014	Lansoprazole dose-dependently activated pregnane X receptor PXR in gene reporter assays, and slightly modulated rifampicin-inducible PXR activity, with similar potency for each enantiomer.	Rifampin	112-122	nuclear receptor subfamily 1 group I member 2	Homo sapiens	133-136
25141173-8	2014	Omeprazole dose-dependently activated PXR and inhibited rifampicin-inducible PXR activity.	Rifampin	56-66	nuclear receptor subfamily 1 group I member 2	Homo sapiens	77-80
25158258-6	2014	In addition, increased rifampicin concentrations inhibited the formation of calcium nodules, OPN/BGP, and COL1A1 in osteoblasts after 28 days of induction.	Rifampin	23-33	secreted phosphoprotein 1	Homo sapiens	93-96
25158258-6	2014	In addition, increased rifampicin concentrations inhibited the formation of calcium nodules, OPN/BGP, and COL1A1 in osteoblasts after 28 days of induction.	Rifampin	23-33	bone gamma-carboxyglutamate protein	Homo sapiens	97-100
25158258-6	2014	In addition, increased rifampicin concentrations inhibited the formation of calcium nodules, OPN/BGP, and COL1A1 in osteoblasts after 28 days of induction.	Rifampin	23-33	collagen type I alpha 1 chain	Homo sapiens	106-112
25140877-10	2014	Upfront Xpert MTB/RIF testing of presumptive PTB and presumptive DR-TB cases resulted in diagnosis of 79 and 12 rifampicin resistance cases, respectively.	Rifampin	112-122	ras homolog family member F, filopodia associated	Homo sapiens	18-21
25140877-12	2014	CONCLUSION: Upfront access to Xpert MTB/RIF testing in pediatric presumptive PTB cases was associated with a two-fold increase in bacteriologically-confirmed PTB, and increased detection of rifampicin-resistant TB cases under routine operational conditions across India.	Rifampin	190-200	ras homolog family member F, filopodia associated	Homo sapiens	40-43
25129689-1	2014	BACKGROUND: An algorithm instituted following Xpert MTB/RIF (Xpert) introduction in South Africa advocates for treating all Xpert rifampicin resistant patients as MDR-TB cases while awaiting confirmation by phenotypic or genotypic drug susceptibility testing.	Rifampin	130-140	ras homolog family member F, filopodia associated	Homo sapiens	56-59
25116663-9	2014	Polymorphism frequency in the SLCO1B1 (rs4149032) drug transporter gene was high (0.76) and was associated with low median rifampicin C2.5 hr, 3.7 (2.8-5.0) microg/mL in the heterozygous and 3.4 (2.7-4.7) microg/mL in the homozygous variant carriers.	Rifampin	123-133	solute carrier organic anion transporter family member 1B1	Homo sapiens	30-37
25116663-13	2014	CONCLUSION: Approximated peak rifampicin concentrations were well below the recommended target range of 8 to 24 microg/mL in this patient population with its high frequency of the SLCO1B1 (rs4149032) polymorphism.	Rifampin	30-40	solute carrier organic anion transporter family member 1B1	Homo sapiens	180-187
24839948-0	2014	Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin.	Rifampin	116-126	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	43-49
24839948-11	2014	CONCLUSIONS: Both 6betaCR and 4betaHC levels showed a good dynamic response range upon strong CYP3A4 induction with rifampicin.	Rifampin	116-126	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	94-100
24752503-4	2014	Here, we present a simple suspension culture of aggregates of ES cell-derived hepatocytes that compared to conventional monolayer adherent culture significantly increases induction of CYP 1A2 by omeprazole and 3A4 by rifampicin.	Rifampin	217-227	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	184-191
24820076-4	2014	In vitro studies were conducted to determine whether one or more of the antituberculosis drugs (rifampin, isoniazid, pyrazinamide, or ethambutol) potently inhibit efavirenz 8-hydroxylation by CYP2B6 or efavirenz 7-hydroxylation by CYP2A6, the main mechanisms of efavirenz clearance.	Rifampin	96-104	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	192-198
24820076-4	2014	In vitro studies were conducted to determine whether one or more of the antituberculosis drugs (rifampin, isoniazid, pyrazinamide, or ethambutol) potently inhibit efavirenz 8-hydroxylation by CYP2B6 or efavirenz 7-hydroxylation by CYP2A6, the main mechanisms of efavirenz clearance.	Rifampin	96-104	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	231-237
24627312-6	2014	RESULTS: The anthracycline Antibiotic 301A(1) was isolated from the fermentation broth of a strain of Streptomyces (WAC450); the molecule was shown to be highly synergistic with rifampicin (fractional inhibitory concentration index = 0.156) and moderately synergistic with linezolid (FIC index = 0.25) in both E. coli and Acinetobacter baumannii.	Rifampin	178-188	Fic	Escherichia coli	284-287
24446527-7	2014	Finally, adjunctive transferrin reduced the emergence of rifampin-resistant mutants of S. aureus in infected mice treated with rifampin.	Rifampin	57-65	transferrin	Homo sapiens	20-31
24446527-7	2014	Finally, adjunctive transferrin reduced the emergence of rifampin-resistant mutants of S. aureus in infected mice treated with rifampin.	Rifampin	127-135	transferrin	Homo sapiens	20-31
24725118-5	2014	A2 increased the mRNA expression of OATP1B3 (an organic anion-transporting polypeptide) and uptake of A2 was inhibited by rifampin (inhibitor of OATP1B3), which indicated that the transporter-mediated transport of A2 was mediated by OATP1B3.	Rifampin	122-130	solute carrier organic anion transporter family member 1B3	Homo sapiens	36-43
24725118-5	2014	A2 increased the mRNA expression of OATP1B3 (an organic anion-transporting polypeptide) and uptake of A2 was inhibited by rifampin (inhibitor of OATP1B3), which indicated that the transporter-mediated transport of A2 was mediated by OATP1B3.	Rifampin	122-130	solute carrier organic anion transporter family member 1B3	Homo sapiens	145-152
24725118-5	2014	A2 increased the mRNA expression of OATP1B3 (an organic anion-transporting polypeptide) and uptake of A2 was inhibited by rifampin (inhibitor of OATP1B3), which indicated that the transporter-mediated transport of A2 was mediated by OATP1B3.	Rifampin	122-130	solute carrier organic anion transporter family member 1B3	Homo sapiens	145-152
24742608-3	2014	Hepatic damage induced in Wistar rats by isoniazid and rifampicin resulted in significant alterations in biomarkers of liver function, namely, bilirubin, aspartate transaminase, alanine transaminase, alkaline phosphatase, and oxidative stress markers such as superoxide dismutase, catalase, glutathione, and thiobarbituric acid reactive substances.	Rifampin	55-65	catalase	Rattus norvegicus	281-289
24964282-1	2014	A Bayesian mechanism-based pharmacokinetic/pharmacodynamic model of cytochrome P450 3A4 (CYP3A4) activity was developed based on a clinical study of the effects of ketoconazole and rifampin on midazolam exposure and plasma 4beta-hydroxycholesterol (4betaHC) concentrations.	Rifampin	181-189	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	68-87
24880706-9	2014	The up-regulation of Th1 immunity by piperine can be synergistically combined with rifampicin to improve its therapeutic efficacy in immune-compromised TB patients.	Rifampin	83-93	negative elongation factor complex member C/D	Homo sapiens	21-24
24964282-1	2014	A Bayesian mechanism-based pharmacokinetic/pharmacodynamic model of cytochrome P450 3A4 (CYP3A4) activity was developed based on a clinical study of the effects of ketoconazole and rifampin on midazolam exposure and plasma 4beta-hydroxycholesterol (4betaHC) concentrations.	Rifampin	181-189	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	89-95
24641623-9	2014	Induction of UGT1A4 and UGT1A3 gene expression was also determined in human hepatocytes treated with pregnane X receptor/constitutive androstane receptor agonists, such as rifampin, carbamazepine, and phenobarbital.	Rifampin	172-180	UDP glucuronosyltransferase family 1 member A4	Homo sapiens	13-19
25420292-4	2014	The mutations that appear for Rifampicin are in region rpoB, for Isoniazid in region katG and inhA, for Ethambutol-embB, Quinolone-gyrA, Aminoglicozid and Cyclical Peptides-rrs.	Rifampin	30-40	inhibin subunit alpha	Homo sapiens	94-98
24530864-0	2014	Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration.	Rifampin	70-80	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	50-56
24530864-2	2014	Rifampicin (RIF) is a potent inducer of CYP3A4 and also acts as a competitive inhibitor which can partially mask the induction.	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	40-46
24530864-2	2014	Rifampicin (RIF) is a potent inducer of CYP3A4 and also acts as a competitive inhibitor which can partially mask the induction.	Rifampin	12-15	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	40-46
24777631-6	2014	Rifampicin is also an inducer of the uridine diphosphate glucuronosyltransferase (UGT) 1A1 enzymes and interferes with drugs, such as integrase inhibitors, that are metabolized by this metabolic pathway.	Rifampin	0-10	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	37-90
24641623-9	2014	Induction of UGT1A4 and UGT1A3 gene expression was also determined in human hepatocytes treated with pregnane X receptor/constitutive androstane receptor agonists, such as rifampin, carbamazepine, and phenobarbital.	Rifampin	172-180	UDP glucuronosyltransferase family 1 member A3	Homo sapiens	24-30
24486740-4	2014	Functionally, activation of human PXR by rifampicin or ectopic expression of constitutively-activated human VP-PXR inhibited cervical cell proliferation.	Rifampin	41-51	nuclear receptor subfamily 1 group I member 2	Homo sapiens	34-37
24553381-6	2014	In contrast, of the 8 hepatocyte lots treated with rifampicin, CYP2C8 and CYP2C9 mRNA were not induced in 5 and 2 hepatocyte lots, respectively, and CYP2C19 mRNA was not induced in any of the 8 hepatocyte lots tested.	Rifampin	51-61	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	63-69
24486481-9	2014	Stimulation of Caco-2 intestinal epithelial cells with rifaximin, rifampicin and SR12813, all potent agonists of the PXR, significantly increased wound closure.	Rifampin	66-76	nuclear receptor subfamily 1 group I member 2	Homo sapiens	117-120
24553381-5	2014	The results revealed that CYP1A2, CYP2B6, and CYP3A4 were induced (&gt;2.0-fold) by omeprazole, phenobarbital, and rifampicin, respectively, in all the hepatocyte lots tested at enzyme activity level (23 lots) and mRNA level (8 lots).	Rifampin	115-125	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	26-32
24553381-5	2014	The results revealed that CYP1A2, CYP2B6, and CYP3A4 were induced (&gt;2.0-fold) by omeprazole, phenobarbital, and rifampicin, respectively, in all the hepatocyte lots tested at enzyme activity level (23 lots) and mRNA level (8 lots).	Rifampin	115-125	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	34-40
24553381-5	2014	The results revealed that CYP1A2, CYP2B6, and CYP3A4 were induced (&gt;2.0-fold) by omeprazole, phenobarbital, and rifampicin, respectively, in all the hepatocyte lots tested at enzyme activity level (23 lots) and mRNA level (8 lots).	Rifampin	115-125	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	46-52
24595680-4	2014	Following multiple oral administration of rifampicin (a known CYP3A inducer) at 15 mg/kg/d in cynomolgus monkeys, the mean serum 4beta-hydroxycholesterol levels increased 4-fold from the baseline of 55.3 +- 21.7 to 221 +- 53.4 ng/ml.	Rifampin	42-52	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	62-67
24595680-8	2014	The serum exposure (area under the curve) of midazolam was markedly decreased by ~95%, confirming the induction of CYP3A catalytic activity by rifampicin treatment in monkeys.	Rifampin	143-153	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	115-120
24788541-10	2014	In addition, all the above expression levels in the transfected cell models could be further induced with additional treatment of Rifampicin, a specific inducer for CYP3A4.	Rifampin	130-140	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	165-171
24733486-7	2014	Furthermore, the CYP3A4 activity in the HNF1alpha-transfected cells could be induced by CYP3A4-specific inducer, rifampicin, and metabolized nifedipine in a dose-dependent manner.	Rifampin	113-123	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	17-23
24733486-7	2014	Furthermore, the CYP3A4 activity in the HNF1alpha-transfected cells could be induced by CYP3A4-specific inducer, rifampicin, and metabolized nifedipine in a dose-dependent manner.	Rifampin	113-123	HNF1 homeobox A	Homo sapiens	40-49
24733486-7	2014	Furthermore, the CYP3A4 activity in the HNF1alpha-transfected cells could be induced by CYP3A4-specific inducer, rifampicin, and metabolized nifedipine in a dose-dependent manner.	Rifampin	113-123	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	88-94
24420910-9	2014	However, drugs that could specifically interfere with the metabolic pathways of SGLT2 inhibitors [rifampicin, inhibitors or inducers of uridine diphosphate-glucuronosyltransferase (UGT)] may result in significant changes in the exposure of SGLT2 inhibitors, as shown for dapagliflozin and canagliflozin.	Rifampin	98-108	solute carrier family 5 member 2	Homo sapiens	80-85
24464802-7	2014	In a panel of 24 individual HLM samples, the indiplon hydrolase activities were significantly correlated with the hydrolase activities of flutamide, phenacetin, and rifampicin, which are known AADAC substrates.	Rifampin	165-175	oxysterol binding protein 2	Homo sapiens	28-31
24464802-7	2014	In a panel of 24 individual HLM samples, the indiplon hydrolase activities were significantly correlated with the hydrolase activities of flutamide, phenacetin, and rifampicin, which are known AADAC substrates.	Rifampin	165-175	arylacetamide deacetylase	Homo sapiens	193-198
24420910-9	2014	However, drugs that could specifically interfere with the metabolic pathways of SGLT2 inhibitors [rifampicin, inhibitors or inducers of uridine diphosphate-glucuronosyltransferase (UGT)] may result in significant changes in the exposure of SGLT2 inhibitors, as shown for dapagliflozin and canagliflozin.	Rifampin	98-108	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	136-179
24420910-9	2014	However, drugs that could specifically interfere with the metabolic pathways of SGLT2 inhibitors [rifampicin, inhibitors or inducers of uridine diphosphate-glucuronosyltransferase (UGT)] may result in significant changes in the exposure of SGLT2 inhibitors, as shown for dapagliflozin and canagliflozin.	Rifampin	98-108	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	181-184
24420910-9	2014	However, drugs that could specifically interfere with the metabolic pathways of SGLT2 inhibitors [rifampicin, inhibitors or inducers of uridine diphosphate-glucuronosyltransferase (UGT)] may result in significant changes in the exposure of SGLT2 inhibitors, as shown for dapagliflozin and canagliflozin.	Rifampin	98-108	solute carrier family 5 member 2	Homo sapiens	240-245
24638036-0	2014	Rifampicin protects PC12 cells from rotenone-induced cytotoxicity by activating GRP78 via PERK-eIF2alpha-ATF4 pathway.	Rifampin	0-10	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	80-85
24447252-0	2014	In vitro activity of rifampicin alone and in combination with imipenem against multidrug-resistant Acinetobacter baumannii harboring the blaOXA-72 resistance gene.	Rifampin	21-31	carbapenem-hydrolyzing oxacillinase	Acinetobacter baumannii	137-146
24638036-0	2014	Rifampicin protects PC12 cells from rotenone-induced cytotoxicity by activating GRP78 via PERK-eIF2alpha-ATF4 pathway.	Rifampin	0-10	eukaryotic translation initiation factor 2A	Rattus norvegicus	95-104
24638036-0	2014	Rifampicin protects PC12 cells from rotenone-induced cytotoxicity by activating GRP78 via PERK-eIF2alpha-ATF4 pathway.	Rifampin	0-10	activating transcription factor 4	Rattus norvegicus	105-109
24638036-4	2014	In this study, using the comprehensive proteomic analysis, we identified that the 78 kDa glucose-regulated protein (GRP78), a hallmark of the unfolded protein response (UPR), was upregulated in rifampicin-treated PC12 cells.	Rifampin	194-204	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	82-114
24638036-4	2014	In this study, using the comprehensive proteomic analysis, we identified that the 78 kDa glucose-regulated protein (GRP78), a hallmark of the unfolded protein response (UPR), was upregulated in rifampicin-treated PC12 cells.	Rifampin	194-204	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	116-121
24638036-6	2014	GRP78 functions cytoprotectively in stressed cells, therefore, we hypothesized that GRP78 mediated rifampicin-induced neuroprotection.	Rifampin	99-109	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	0-5
24638036-6	2014	GRP78 functions cytoprotectively in stressed cells, therefore, we hypothesized that GRP78 mediated rifampicin-induced neuroprotection.	Rifampin	99-109	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	84-89
24638036-7	2014	Using RNA interference, we found that GRP78 gene knockdown significantly attenuated the neuroprotective effects of rifampicin.	Rifampin	115-125	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	38-43
24638036-9	2014	Our results showed that PERK, eukaryotic initiation factor 2alpha (eIF2alpha), and activating transcription factor 4 (ATF4) were activated in rifampicin-treated PC12 cells.	Rifampin	142-152	eukaryotic translation initiation factor 2A	Rattus norvegicus	67-76
24638036-9	2014	Our results showed that PERK, eukaryotic initiation factor 2alpha (eIF2alpha), and activating transcription factor 4 (ATF4) were activated in rifampicin-treated PC12 cells.	Rifampin	142-152	activating transcription factor 4	Rattus norvegicus	83-116
24638036-9	2014	Our results showed that PERK, eukaryotic initiation factor 2alpha (eIF2alpha), and activating transcription factor 4 (ATF4) were activated in rifampicin-treated PC12 cells.	Rifampin	142-152	activating transcription factor 4	Rattus norvegicus	118-122
24638036-12	2014	Taken together, our data suggested that rifampicin induced GRP78 via the PERK-eIF2alpha-ATF4 pathway to protect neurons against rotenone-induced cell damage.	Rifampin	40-50	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	59-64
24638036-12	2014	Taken together, our data suggested that rifampicin induced GRP78 via the PERK-eIF2alpha-ATF4 pathway to protect neurons against rotenone-induced cell damage.	Rifampin	40-50	activating transcription factor 4	Rattus norvegicus	73-92
24474302-0	2014	The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects.	Rifampin	14-24	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	41-47
24411494-2	2014	High expression of ABCB1 induced by forskolin (FSK) and rifampicin (RIF) in the bovine blastocysts reportedly improves the cellular quality.	Rifampin	56-66	LOW QUALITY PROTEIN: multidrug resistance protein 1	Bos taurus	19-24
24411494-2	2014	High expression of ABCB1 induced by forskolin (FSK) and rifampicin (RIF) in the bovine blastocysts reportedly improves the cellular quality.	Rifampin	68-71	LOW QUALITY PROTEIN: multidrug resistance protein 1	Bos taurus	19-24
24411494-3	2014	In the present study, interferon-alpha, similar to FSK and RIF, was highly potent in inducing the expression of ABCB1 in the bovine blastocysts but did not exhibit an additive effect with FSK and RIF.	Rifampin	59-62	LOW QUALITY PROTEIN: multidrug resistance protein 1	Bos taurus	112-117
24474302-3	2014	Two phase I studies were conducted in healthy male subjects to evaluate the effect of pre- or co-administered rifampicin, a CYP3A4 inducer, on the pharmacokinetics of erlotinib.	Rifampin	110-120	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	124-130
24335393-6	2014	SULT1C2 protein content was strongly increased by 1,25(OH)2D3 treatment and moderately increased by GW3965, GW4064, and rifampicin.	Rifampin	120-130	sulfotransferase family 1C member 4	Homo sapiens	0-7
24399452-2	2014	As afatinib is a substrate for the P-glycoprotein (P-gp) pump transporter the three studies presented here investigated the pharmacokinetics of afatinib in the presence of a potent inhibitor (ritonavir) or inducer [rifampicin (rifampin)] of P-gp.	Rifampin	215-225	ATP binding cassette subfamily B member 1	Homo sapiens	51-55
24399452-2	2014	As afatinib is a substrate for the P-glycoprotein (P-gp) pump transporter the three studies presented here investigated the pharmacokinetics of afatinib in the presence of a potent inhibitor (ritonavir) or inducer [rifampicin (rifampin)] of P-gp.	Rifampin	227-235	ATP binding cassette subfamily B member 1	Homo sapiens	51-55
24259679-5	2014	Here we investigated five synthetic TRPC6-activating phloroglucinol derivatives and four TRPC6-nonactivating compounds compared with hyperforin and rifampicin for their potential to activate PXR in silico and in vitro.	Rifampin	148-158	nuclear receptor subfamily 1 group I member 2	Homo sapiens	191-194
24259679-8	2014	Hyperforin and rifampicin treatment of primary human hepatocytes resulted in highly correlated induction of PXR target genes, whereas treatment with the phloroglucinol derivatives elicited moderate gene expression changes that were only weakly correlated with those of rifampicin and hyperforin treatment.	Rifampin	15-25	nuclear receptor subfamily 1 group I member 2	Homo sapiens	108-111
24831405-0	2014	Lymphadenitis caused by infection with an isoniazid- and rifampin-resistant strain of Mycobacterium bovis BCG in an infant with IFN-gamma/IL-12 pathway defect.	Rifampin	57-65	interferon gamma	Homo sapiens	128-137
24259679-7	2014	Hyperforin and rifampicin treatment of HepG2 cells cotransfected with human PXR expression vector and a CYP3A4 promoter-reporter construct resulted in potent PXR-dependent induction, whereas all TRPC6-activating compounds failed to show any PXR activation or to antagonize rifampicin-mediated CYP3A4 promoter induction.	Rifampin	15-25	nuclear receptor subfamily 1 group I member 2	Homo sapiens	76-79
24259679-7	2014	Hyperforin and rifampicin treatment of HepG2 cells cotransfected with human PXR expression vector and a CYP3A4 promoter-reporter construct resulted in potent PXR-dependent induction, whereas all TRPC6-activating compounds failed to show any PXR activation or to antagonize rifampicin-mediated CYP3A4 promoter induction.	Rifampin	15-25	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	104-110
24259679-7	2014	Hyperforin and rifampicin treatment of HepG2 cells cotransfected with human PXR expression vector and a CYP3A4 promoter-reporter construct resulted in potent PXR-dependent induction, whereas all TRPC6-activating compounds failed to show any PXR activation or to antagonize rifampicin-mediated CYP3A4 promoter induction.	Rifampin	15-25	nuclear receptor subfamily 1 group I member 2	Homo sapiens	158-161
24259679-7	2014	Hyperforin and rifampicin treatment of HepG2 cells cotransfected with human PXR expression vector and a CYP3A4 promoter-reporter construct resulted in potent PXR-dependent induction, whereas all TRPC6-activating compounds failed to show any PXR activation or to antagonize rifampicin-mediated CYP3A4 promoter induction.	Rifampin	15-25	transient receptor potential cation channel subfamily C member 6	Homo sapiens	195-200
24259679-7	2014	Hyperforin and rifampicin treatment of HepG2 cells cotransfected with human PXR expression vector and a CYP3A4 promoter-reporter construct resulted in potent PXR-dependent induction, whereas all TRPC6-activating compounds failed to show any PXR activation or to antagonize rifampicin-mediated CYP3A4 promoter induction.	Rifampin	15-25	nuclear receptor subfamily 1 group I member 2	Homo sapiens	158-161
24259679-7	2014	Hyperforin and rifampicin treatment of HepG2 cells cotransfected with human PXR expression vector and a CYP3A4 promoter-reporter construct resulted in potent PXR-dependent induction, whereas all TRPC6-activating compounds failed to show any PXR activation or to antagonize rifampicin-mediated CYP3A4 promoter induction.	Rifampin	15-25	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	293-299
24259679-7	2014	Hyperforin and rifampicin treatment of HepG2 cells cotransfected with human PXR expression vector and a CYP3A4 promoter-reporter construct resulted in potent PXR-dependent induction, whereas all TRPC6-activating compounds failed to show any PXR activation or to antagonize rifampicin-mediated CYP3A4 promoter induction.	Rifampin	273-283	nuclear receptor subfamily 1 group I member 2	Homo sapiens	76-79
24259679-7	2014	Hyperforin and rifampicin treatment of HepG2 cells cotransfected with human PXR expression vector and a CYP3A4 promoter-reporter construct resulted in potent PXR-dependent induction, whereas all TRPC6-activating compounds failed to show any PXR activation or to antagonize rifampicin-mediated CYP3A4 promoter induction.	Rifampin	273-283	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	104-110
24586675-1	2014	BACKGROUND: Xpert MTB/RIF is an automated cartridge-based nucleic acid amplification test that has demonstrated its potential to detect tuberculosis and rifampicin resistance with high accuracy.	Rifampin	153-163	ras homolog family member F, filopodia associated	Homo sapiens	22-25
24420746-10	2014	Solute carrier organic anion transporter family member 1B1 (SLCO1B1) c.388A G and SLCO1B1 c.463C A polymorphisms jointly had significant effect on rifampin Cmax (R(2)  = 0.75).	Rifampin	147-155	solute carrier organic anion transporter family member 1B1	Homo sapiens	60-67
24420746-10	2014	Solute carrier organic anion transporter family member 1B1 (SLCO1B1) c.388A G and SLCO1B1 c.463C A polymorphisms jointly had significant effect on rifampin Cmax (R(2)  = 0.75).	Rifampin	147-155	solute carrier organic anion transporter family member 1B1	Homo sapiens	82-89
24710854-13	2014	The expression of Cyp2b10 was increased 35-fold by phenobarbital, and Cyp3a11 was increased 4.5-fold by rifampin.	Rifampin	104-112	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	70-77
24710854-15	2014	Both phenobarbital and rifampin increased Ugt1a1, Ugt1a6, Ugt1a9, and icariin but did not show any suppressive effects on the Ugt1 family genes.	Rifampin	23-31	UDP glucuronosyltransferase 1 family, polypeptide A1	Mus musculus	42-48
24710854-15	2014	Both phenobarbital and rifampin increased Ugt1a1, Ugt1a6, Ugt1a9, and icariin but did not show any suppressive effects on the Ugt1 family genes.	Rifampin	23-31	UDP glucuronosyltransferase 1 family, polypeptide A6A	Mus musculus	50-56
24710854-15	2014	Both phenobarbital and rifampin increased Ugt1a1, Ugt1a6, Ugt1a9, and icariin but did not show any suppressive effects on the Ugt1 family genes.	Rifampin	23-31	UDP glucuronosyltransferase 1 family, polypeptide A9	Mus musculus	58-64
24710854-15	2014	Both phenobarbital and rifampin increased Ugt1a1, Ugt1a6, Ugt1a9, and icariin but did not show any suppressive effects on the Ugt1 family genes.	Rifampin	23-31	UDP glucuronosyltransferase 1 family, polypeptide A2	Mus musculus	42-46
24507091-2	2014	In a mouse model of multiple system atrophy, rifampicin inhibited formation of alpha-synuclein fibrils, the neuropathological hallmark of the disease.	Rifampin	45-55	synuclein, alpha	Mus musculus	79-94
23990572-0	2014	Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia.	Rifampin	29-39	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	108-114
24316028-4	2014	There was a significant difference between CYP1A2 -739T/G and T/T genotypes when patients were treated with EFV-containing therapy combined with rifampicin-based TB treatment, but not when EFV-containing therapy was alone.	Rifampin	145-155	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	43-49
24316028-5	2014	CYP2B6 516T/T genotype was associated with high EFV levels compared to other CYP2B6 516G&gt;T genotypes in the presence and in the absence of rifampicin-based TB treatment.	Rifampin	142-152	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	0-6
24316028-6	2014	Predictive factors of EFV plasma levels in the presence of rifampicin-based TB treatment were CYP2A6 1093G&gt;A, CYP2B6 516G&gt;T, and CYP2B6 983T&gt;C accounting for 27%, 43%, and 29% of the total variance in EFV levels, respectively.	Rifampin	59-69	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	94-100
23990572-0	2014	Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia.	Rifampin	29-39	N-acetyltransferase 2	Homo sapiens	119-123
24448973-2	2014	Xpert  MTB/RIF assay is an automated test that can detect both TB and rifampicin resistance, generally within two hours after starting the test, with minimal hands-on technical time.	Rifampin	70-80	ras homolog family member F, filopodia associated	Homo sapiens	11-14
24092658-9	2014	Mutations of rpoB and fusA following the use of rifampicin and fusidic acid were identified in the second step of evolution, which corresponded to the development of dual resistance to rifampicin and fusidic acid and the conversion of hVISA to VISA.	Rifampin	48-58	mitochondrial antiviral signaling protein	Homo sapiens	235-240
24092658-9	2014	Mutations of rpoB and fusA following the use of rifampicin and fusidic acid were identified in the second step of evolution, which corresponded to the development of dual resistance to rifampicin and fusidic acid and the conversion of hVISA to VISA.	Rifampin	48-58	mitochondrial antiviral signaling protein	Homo sapiens	236-240
24092658-9	2014	Mutations of rpoB and fusA following the use of rifampicin and fusidic acid were identified in the second step of evolution, which corresponded to the development of dual resistance to rifampicin and fusidic acid and the conversion of hVISA to VISA.	Rifampin	185-195	mitochondrial antiviral signaling protein	Homo sapiens	235-240
24092658-9	2014	Mutations of rpoB and fusA following the use of rifampicin and fusidic acid were identified in the second step of evolution, which corresponded to the development of dual resistance to rifampicin and fusidic acid and the conversion of hVISA to VISA.	Rifampin	185-195	mitochondrial antiviral signaling protein	Homo sapiens	236-240
24448973-23	2014	Rifampicin resistance For rifampicin resistance detection, Xpert  MTB/RIF pooled sensitivity was 95% (95% CrI 90% to 97%; 17 studies, 555 rifampicin resistance positives) and pooled specificity was 98% (95% CrI 97% to 99%; 24 studies, 2411 rifampicin resistance negatives).	Rifampin	0-10	ras homolog family member F, filopodia associated	Homo sapiens	70-73
24448973-25	2014	Where 5% of those with symptoms are rifampicin resistant, Xpert  MTB/RIF would correctly identify 48 individuals as rifampicin resistant and miss three cases and correctly identify 931 individuals as rifampicin susceptible and misclassify 19 individuals as resistant.	Rifampin	36-46	ras homolog family member F, filopodia associated	Homo sapiens	69-72
24448973-25	2014	Where 5% of those with symptoms are rifampicin resistant, Xpert  MTB/RIF would correctly identify 48 individuals as rifampicin resistant and miss three cases and correctly identify 931 individuals as rifampicin susceptible and misclassify 19 individuals as resistant.	Rifampin	116-126	ras homolog family member F, filopodia associated	Homo sapiens	69-72
24448973-25	2014	Where 5% of those with symptoms are rifampicin resistant, Xpert  MTB/RIF would correctly identify 48 individuals as rifampicin resistant and miss three cases and correctly identify 931 individuals as rifampicin susceptible and misclassify 19 individuals as resistant.	Rifampin	116-126	ras homolog family member F, filopodia associated	Homo sapiens	69-72
24448973-30	2014	For rifampicin resistance detection, Xpert  MTB/RIF provides accurate results and can allow rapid initiation of MDR-TB treatment, pending results from conventional culture and DST.	Rifampin	4-14	ras homolog family member F, filopodia associated	Homo sapiens	48-51
24191259-5	2014	Differentiated HepaRG cells were pretreated with dexamethasone (100 muM) or the prototypical CYP3A4 inducer rifampicin (4 muM) for 72 hours, followed by incubation with lapatinib (0-100 muM) for 24 hours.	Rifampin	108-118	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	93-99
24204015-7	2014	Rifampicin treatment of two different samples of human primary hepatocytes revealed that PXR induces G6Pase in the presence of high levels of SGK2, whereas PXR represses G6Pase in its absence.	Rifampin	0-10	nuclear receptor subfamily 1 group I member 2	Homo sapiens	156-159
24558228-6	2014	The modulations of ABCB1 and ABCC1 expressions were analyzed after ex vivo treatment of human skin with rifampicin and dexamethasone.	Rifampin	104-114	ATP binding cassette subfamily B member 1	Homo sapiens	19-24
24674673-8	2014	Multiple factors may affect CYP3A expression and activity, such as inducers like rifampicin, phenobarbital, 3-methylcholantrene, beta-naphtoflavone, and dexamethasone.	Rifampin	81-91	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	28-33
27128230-3	2014	This open-label, nonrandomized study investigated effects of CYP3A4 induction, by rifampin, on sirolimus pharmacokinetics.	Rifampin	82-90	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	61-67
24204015-7	2014	Rifampicin treatment of two different samples of human primary hepatocytes revealed that PXR induces G6Pase in the presence of high levels of SGK2, whereas PXR represses G6Pase in its absence.	Rifampin	0-10	glucose-6-phosphatase catalytic subunit 1	Homo sapiens	170-176
24204015-3	2014	Both SGK2 and G6Pase mRNAs were increased in rifampicin-treated HepG2 cells stably expressing human PXR.	Rifampin	45-55	serum/glucocorticoid regulated kinase 2	Homo sapiens	5-9
25335408-1	2014	The goal of this work was to study cytochrome-450 (CYP) 2C9 (CYP2C9) gene polymorphism in patients with tuberculosis (TB) and its meaning for development, progress, and outcome of TB, for the pharmacokinetics of the antituberculosis antibiotic rifampicin on the basis of the southern region of Ukraine.	Rifampin	244-254	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	35-59
24204015-3	2014	Both SGK2 and G6Pase mRNAs were increased in rifampicin-treated HepG2 cells stably expressing human PXR.	Rifampin	45-55	glucose-6-phosphatase catalytic subunit 1	Homo sapiens	14-20
24204015-3	2014	Both SGK2 and G6Pase mRNAs were increased in rifampicin-treated HepG2 cells stably expressing human PXR.	Rifampin	45-55	nuclear receptor subfamily 1 group I member 2	Homo sapiens	100-103
24204015-7	2014	Rifampicin treatment of two different samples of human primary hepatocytes revealed that PXR induces G6Pase in the presence of high levels of SGK2, whereas PXR represses G6Pase in its absence.	Rifampin	0-10	nuclear receptor subfamily 1 group I member 2	Homo sapiens	89-92
24204015-7	2014	Rifampicin treatment of two different samples of human primary hepatocytes revealed that PXR induces G6Pase in the presence of high levels of SGK2, whereas PXR represses G6Pase in its absence.	Rifampin	0-10	glucose-6-phosphatase catalytic subunit 1	Homo sapiens	101-107
24204015-7	2014	Rifampicin treatment of two different samples of human primary hepatocytes revealed that PXR induces G6Pase in the presence of high levels of SGK2, whereas PXR represses G6Pase in its absence.	Rifampin	0-10	serum/glucocorticoid regulated kinase 2	Homo sapiens	142-146
25341566-4	2014	Here, we showed that resveratrol (RES), a natural polyphenolic compound could significantly suppress the rifampicin-induced PXR transactivation of the CYP3A4 promoter.	Rifampin	105-115	nuclear receptor subfamily 1, group I, member 2	Mus musculus	124-127
25335408-1	2014	The goal of this work was to study cytochrome-450 (CYP) 2C9 (CYP2C9) gene polymorphism in patients with tuberculosis (TB) and its meaning for development, progress, and outcome of TB, for the pharmacokinetics of the antituberculosis antibiotic rifampicin on the basis of the southern region of Ukraine.	Rifampin	244-254	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	61-67
24362577-4	2013	The CYP1A1 and 1A2, and CYP3A4 mRNA expression levels increased significantly in the PXB-mouse livers with 20 mg/kg of 3-MC (Cmax, 12.2 ng/mL), and 10 mg/kg rifampicin (Cmax, 6.9 microg/mL), respectively.	Rifampin	157-167	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	4-18
24362577-6	2013	The CYP1A2 and CYP3A4 mRNA expression levels increased significantly with 50 ng/mL of 3-MC, and 5 mug/mL of rifampicin, respectively, which indicated that the sensitivities were similar between in vivo and in vitro studies.	Rifampin	108-118	cytochrome P450, family 1, subfamily a, polypeptide 2	Mus musculus	4-10
24085261-6	2013	RESULTS: Inhibition of CYP3A4 by ketoconazole increased midostaurin exposure more than tenfold, and induction of CYP3A4 by rifampicin decreased midostaurin exposure by more than tenfold.	Rifampin	123-133	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	113-119
24060875-0	2013	Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine.	Rifampin	100-108	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	48-67
24060875-1	2013	Rifampin is a potent inducer of cytochrome P450 (CYP) enzymes and transporters.	Rifampin	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-47
24060875-1	2013	Rifampin is a potent inducer of cytochrome P450 (CYP) enzymes and transporters.	Rifampin	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-52
24060875-4	2013	Rifampin and rifabutin significantly induced CYP3A4 (80-fold and 20-fold, respectively) in primary human hepatocytes.	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	45-51
24085261-8	2013	CONCLUSION: The pharmacokinetics of midostaurin and its metabolites was affected substantially by ketoconazole and rifampicin, suggesting that midostaurin is a sensitive CYP3A4 substrate.	Rifampin	115-125	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	170-176
23852652-8	2013	Strong CYP3A or CYP2C9 inducers (e.g. rifampicin) would be expected to decrease the exposure to ospemifene.	Rifampin	38-48	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	7-12
23770199-5	2013	In primary human hepatocytes, clopidogrel (10 and 100 muM) was cytotoxic only after cytochrome P450 (CYP) induction by rifampicin.	Rifampin	119-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	84-99
23770199-5	2013	In primary human hepatocytes, clopidogrel (10 and 100 muM) was cytotoxic only after cytochrome P450 (CYP) induction by rifampicin.	Rifampin	119-129	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	101-104
23916555-0	2013	PXR-ALAS1: a key regulatory pathway in liver toxicity induced by isoniazid-rifampicin antituberculosis treatment.	Rifampin	75-85	nuclear receptor subfamily 1 group I member 2	Homo sapiens	0-3
23916555-0	2013	PXR-ALAS1: a key regulatory pathway in liver toxicity induced by isoniazid-rifampicin antituberculosis treatment.	Rifampin	75-85	5'-aminolevulinate synthase 1	Homo sapiens	4-9
23974699-0	2013	Chronological effects of rifampicin discontinuation on cytochrome P450 activity in healthy Japanese volunteers, using the cocktail method.	Rifampin	25-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-70
23974699-5	2013	Seven-day rifampicin administration increased CYP2C19 and CYP3A enzyme activities.	Rifampin	10-20	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	46-53
23974699-5	2013	Seven-day rifampicin administration increased CYP2C19 and CYP3A enzyme activities.	Rifampin	10-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	58-63
23974699-6	2013	The induced CYP2C19 and CYP3A activities remained elevated at 4 days after rifampicin discontinuation and returned to baseline levels 8 days after rifampicin discontinuation.	Rifampin	75-85	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	12-19
23974699-6	2013	The induced CYP2C19 and CYP3A activities remained elevated at 4 days after rifampicin discontinuation and returned to baseline levels 8 days after rifampicin discontinuation.	Rifampin	75-85	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	24-29
23974699-6	2013	The induced CYP2C19 and CYP3A activities remained elevated at 4 days after rifampicin discontinuation and returned to baseline levels 8 days after rifampicin discontinuation.	Rifampin	147-157	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	12-19
23974699-6	2013	The induced CYP2C19 and CYP3A activities remained elevated at 4 days after rifampicin discontinuation and returned to baseline levels 8 days after rifampicin discontinuation.	Rifampin	147-157	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	24-29
23974699-7	2013	CYP1A2 and CYP2D6 enzyme activities showed no significant changes, and CYP2C9 enzyme activity was increased with rifampicin administration, with a tendency toward statistical significance.	Rifampin	113-123	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	71-77
23852652-8	2013	Strong CYP3A or CYP2C9 inducers (e.g. rifampicin) would be expected to decrease the exposure to ospemifene.	Rifampin	38-48	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	16-22
23852717-8	2013	LRP1- and P-gp-mediated 125I-Abeta40 biliary excretion was inducible and increased BEI% by 26% after rifampicin pretreatment.	Rifampin	101-111	LDL receptor related protein 1	Rattus norvegicus	0-4
23852717-8	2013	LRP1- and P-gp-mediated 125I-Abeta40 biliary excretion was inducible and increased BEI% by 26% after rifampicin pretreatment.	Rifampin	101-111	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	10-14
23258774-1	2013	Xpert MTB/RIF is a rapid test to diagnose tuberculosis (TB) and rifampicin-resistant TB.	Rifampin	64-74	ras homolog family member F, filopodia associated	Homo sapiens	10-13
23935064-4	2013	Rifampin induced the expression of 10 clinically important and 13 additional P450 genes and repressed the expression of 9 other P450 genes (P &lt; 0.05).	Rifampin	0-8	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	77-81
23935064-4	2013	Rifampin induced the expression of 10 clinically important and 13 additional P450 genes and repressed the expression of 9 other P450 genes (P &lt; 0.05).	Rifampin	0-8	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	128-132
23935064-6	2013	Several of these changes were highly negatively correlated with the rifampin-induced changes in the expression of their predicted target P450 mRNAs, supporting the possibility of miRNA-induced regulation of P450 mRNA expression.	Rifampin	68-76	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	137-141
23935064-6	2013	Several of these changes were highly negatively correlated with the rifampin-induced changes in the expression of their predicted target P450 mRNAs, supporting the possibility of miRNA-induced regulation of P450 mRNA expression.	Rifampin	68-76	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	207-211
23935064-9	2013	In conclusion, rifampin treatment alters miRNA expression patterns in human hepatocytes, and some of the changes were correlated with the rifampin-induced changes in expression of the P450 mRNAs they are predicted to target.	Rifampin	15-23	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	184-188
23935064-9	2013	In conclusion, rifampin treatment alters miRNA expression patterns in human hepatocytes, and some of the changes were correlated with the rifampin-induced changes in expression of the P450 mRNAs they are predicted to target.	Rifampin	138-146	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	184-188
23928187-5	2013	Here we report the virtual screening of ~25,000 natural product derivatives from the ZINC database using the Molecular Operating Environment docking software tool against the PXR-rifampicin complex X-ray crystal structure.	Rifampin	179-189	nuclear receptor subfamily 1 group I member 2	Homo sapiens	175-178
23073537-7	2013	Basal expression of CYP3A4 protein in HepG2-PGC-1alpha cells was increased but rifampicin-inducible expression of CYP3A4 protein was lowered in comparison with parent HepG2 cells.	Rifampin	79-89	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	114-120
23929936-3	2013	Cyclosporine A (CsA) and rifampicin (RIF), typical OATP inhibitors, inhibited active uptake of pitavastatin into monkey hepatocytes with half-maximal inhibitory concentration values comparable with those in human hepatocytes.	Rifampin	25-35	solute carrier organic anion transporter family member 1A2	Homo sapiens	51-55
23929936-3	2013	Cyclosporine A (CsA) and rifampicin (RIF), typical OATP inhibitors, inhibited active uptake of pitavastatin into monkey hepatocytes with half-maximal inhibitory concentration values comparable with those in human hepatocytes.	Rifampin	37-40	solute carrier organic anion transporter family member 1A2	Homo sapiens	51-55
24086247-0	2013	Modeling of rifampicin-induced CYP3A4 activation dynamics for the prediction of clinical drug-drug interactions from in vitro data.	Rifampin	12-22	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-37
24086247-3	2013	Rifampicin is a well-known CYP3A4 inducer, and is commonly used as a positive control for evaluating the CYP3A4 induction potential of test compounds.	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	27-33
24086247-3	2013	Rifampicin is a well-known CYP3A4 inducer, and is commonly used as a positive control for evaluating the CYP3A4 induction potential of test compounds.	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	105-111
24086247-4	2013	Herein, we report the compilation of in vitro induction data for CYP3A4 by rifampicin in human hepatocytes, and the transcription/translation model developed for this enzyme using an extended least squares method that can account for inherent inter-individual variability.	Rifampin	75-85	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	65-71
23764483-0	2013	Hepatocyte growth factor protects against isoniazid/rifampicin-induced oxidative liver damage.	Rifampin	52-62	hepatocyte growth factor	Mus musculus	0-24
23712732-7	2013	In human cryopreserved hepatocytes, JPH203 uptake was saturable and inhibited by rifampicin, a prototypical OATP inhibitor.	Rifampin	81-91	solute carrier organic anion transporter family member 1A2	Homo sapiens	108-112
23581556-9	2013	CYP3A12 and CYP2B11 induction after phenobarbital or rifampin treatment was robust in both cell types but stronger in S cells.	Rifampin	53-61	cytochrome P450 3A12	Canis lupus familiaris	0-7
23581556-9	2013	CYP3A12 and CYP2B11 induction after phenobarbital or rifampin treatment was robust in both cell types but stronger in S cells.	Rifampin	53-61	cytochrome P450 2B11	Canis lupus familiaris	12-19
23677771-14	2013	In the presence of ketoconazole, a strong CYP3A4/5 inhibitor, axitinib C max and AUC  increased by 1.5- and 2-fold, respectively, whereas co-administration of rifampin, a strong CYP3A4/5 inducer, resulted in a 71 and 79 % decrease in the C max and AUC , respectively.	Rifampin	159-167	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	178-184
23686764-6	2013	The predicted decrease in AUC and Cmax values of digoxin following administration of rifampicin because of P-gp induction was 1.57- (range: 1.42-1.77) and 1.62-fold (range: 1.53-1.70), which were reasonably consistent with observed values of 1.4- and 2.2-fold, respectively.	Rifampin	85-95	ATP binding cassette subfamily B member 1	Homo sapiens	107-111
23703021-1	2013	A prerequisite for the prediction of the magnitude of P-glycoprotein (P-gp)-mediated drug-drug interactions between digoxin and P-gp inhibitors (e.g. verapamil and its metabolite norverapamil) or P-gp inducers (e.g. rifampicin) is a predictive pharmacokinetic model for digoxin itself.	Rifampin	216-226	ATP binding cassette subfamily B member 1	Homo sapiens	54-68
23703021-1	2013	A prerequisite for the prediction of the magnitude of P-glycoprotein (P-gp)-mediated drug-drug interactions between digoxin and P-gp inhibitors (e.g. verapamil and its metabolite norverapamil) or P-gp inducers (e.g. rifampicin) is a predictive pharmacokinetic model for digoxin itself.	Rifampin	216-226	ATP binding cassette subfamily B member 1	Homo sapiens	70-74
23991219-0	2013	Development of novel rifampicin-derived P-glycoprotein activators/inducers.	Rifampin	21-31	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	40-54
23764483-4	2013	The present work was focused to address the antioxidant and antiapoptotic effects of HGF on isoniazid- and rifampicin-induced hepatotoxicity.	Rifampin	107-117	hepatocyte growth factor	Mus musculus	85-88
23764483-8	2013	Furthermore, inhibition of endogenous HGF with anti-HGF antibody (iv) enhanced the isoniazid- and rifampicin-induced oxidative stress damage and decreased the GSH content, aggravating liver damage.	Rifampin	98-108	hepatocyte growth factor	Mus musculus	38-41
23764483-8	2013	Furthermore, inhibition of endogenous HGF with anti-HGF antibody (iv) enhanced the isoniazid- and rifampicin-induced oxidative stress damage and decreased the GSH content, aggravating liver damage.	Rifampin	98-108	hepatocyte growth factor	Mus musculus	52-55
24101390-8	2013	In the present study, findings of the P-gp expression were inconclusive but regarding previous studies, it can be suggested that the beneficial effects of rifampicin and spironolactone may be partly due to their action as a P-gp ligand.	Rifampin	155-165	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	224-228
23674608-0	2013	Comparison of endogenous 4beta-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin.	Rifampin	100-110	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	80-86
23674608-5	2013	The CYP3A4 induction could be detected even at the lowest dose of rifampicin (10 mg) via the estimated midazolam clearance, the 4beta-hydroxycholesterol ratio (both P &lt; 0.01), and the 6beta-hydroxycortisol ratio (P &lt; 0.05).	Rifampin	66-76	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	4-10
23851904-0	2013	GC-MS-based quantitative signatures of cytochrome P450-mediated steroid oxidation induced by rifampicin.	Rifampin	93-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	39-54
23851904-4	2013	Twelve healthy subjects were orally administered 600 mg of rifampicin a day for 7 days, and their CYP enzyme activity was evaluated.	Rifampin	59-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-101
23851904-7	2013	Administration of the CYP3A4 inducer rifampicin produced distinct differences in CYP3A4 and CYP11B1, CYP19A1, HSD11B, and HSD17B, which were indicated by their heat map-visualized steroid signatures.	Rifampin	37-47	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	22-28
23851904-7	2013	Administration of the CYP3A4 inducer rifampicin produced distinct differences in CYP3A4 and CYP11B1, CYP19A1, HSD11B, and HSD17B, which were indicated by their heat map-visualized steroid signatures.	Rifampin	37-47	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	81-87
23851904-7	2013	Administration of the CYP3A4 inducer rifampicin produced distinct differences in CYP3A4 and CYP11B1, CYP19A1, HSD11B, and HSD17B, which were indicated by their heat map-visualized steroid signatures.	Rifampin	37-47	cytochrome P450 family 11 subfamily B member 1	Homo sapiens	92-99
23851904-7	2013	Administration of the CYP3A4 inducer rifampicin produced distinct differences in CYP3A4 and CYP11B1, CYP19A1, HSD11B, and HSD17B, which were indicated by their heat map-visualized steroid signatures.	Rifampin	37-47	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	101-108
23851904-7	2013	Administration of the CYP3A4 inducer rifampicin produced distinct differences in CYP3A4 and CYP11B1, CYP19A1, HSD11B, and HSD17B, which were indicated by their heat map-visualized steroid signatures.	Rifampin	37-47	hydroxysteroid 11-beta dehydrogenase 1	Homo sapiens	110-116
24180002-0	2013	Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype.	Rifampin	11-19	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	106-112
24180002-2	2013	However, rifampin, a key component of antituberculosis therapy, induces CYP2B6.	Rifampin	9-17	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	72-78
23670789-5	2013	The GMRs and 90% CIs for anacetrapib AUC0-  and Cmax were 1.25 (1.04, 1.51) and 1.43 (1.13, 1.82) for SD rifampin (Period 2/Period 1) and 0.35 (0.29, 0.42) and 0.26 (0.21, 0.32) for MD rifampin (Period 3/Period 1), respectively.	Rifampin	105-113	period circadian regulator 2	Homo sapiens	115-123
23685082-0	2013	Mechanisms of P-gp inhibition and effects on membrane fluidity of a new rifampicin derivative, 1,8-dibenzoyl-rifampicin.	Rifampin	72-82	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	14-18
23685082-1	2013	PURPOSE: To assess P-glycoprotein (P-gp)-modulation ability and the mechanisms of P-gp inhibition mediated by a new synthetic rifampicin derivative, 1,8-dibenzoyl-rifampicin (DiBenzRif), in an in vitro model of the blood-brain barrier (BBB), RBE4 cells, and in membrane mimetic models (liposomes).	Rifampin	126-136	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	82-86
23624173-3	2013	We previously identified zebrafish CYP3A65 as a CYP3A ortholog that is constitutively expressed in gastrointestinal tissues, and is upregulated by treatment with dexamethasone, rifampicin or tetrachlorodibenzo-p-dioxin (TCDD).	Rifampin	177-187	cytochrome P450, family 3, subfamily A, polypeptide 65	Danio rerio	35-42
23591749-1	2013	Isoniazid (INH) and rifampicin (RIF) are the first-line drugs for antituberculosis (anti-TB) chemotherapy.	Rifampin	20-30	alpha fetoprotein regulation 2, inducibility	Mus musculus	32-35
23180585-3	2013	Xpert MTB/RIF, a new assay employing automated nucleic acid amplification to detect Mycobacterium tuberculosis, as well as mutations that confer rifampicin resistance, holds the promise to largely overcome these operational challenges.	Rifampin	145-155	ras homolog family member F, filopodia associated	Homo sapiens	10-13
23377313-8	2013	In the subgroup analyses, the pooled results showed that GSTM1 null allele carriers had a significant association with ADIH risk in East Asians and the patients who used isoniazid (INH) + rifampicin (RMP) + pyrazinamide (PZA) + ethambutol (EMB), or + streptomycin (SM) (HRZES), but the opposite result was observed for patients using HR.	Rifampin	188-198	glutathione S-transferase mu 1	Homo sapiens	57-62
23377313-8	2013	In the subgroup analyses, the pooled results showed that GSTM1 null allele carriers had a significant association with ADIH risk in East Asians and the patients who used isoniazid (INH) + rifampicin (RMP) + pyrazinamide (PZA) + ethambutol (EMB), or + streptomycin (SM) (HRZES), but the opposite result was observed for patients using HR.	Rifampin	200-203	glutathione S-transferase mu 1	Homo sapiens	57-62
23874477-3	2013	In this study, we found that rifampicin, an agonist of human PXR, induced lipid accumulation in HepG2 cells.	Rifampin	29-39	nuclear receptor subfamily 1 group I member 2	Homo sapiens	61-64
23874477-6	2013	Treatment of HepG2 cells with rifampicin induced the expression of the free fatty acid transporter CD36 and ABCG1, as well as several lipogenic enzymes, including stearoyl-CoA desaturase-1 (SCD1), long chain free fatty acid elongase (FAE), and lecithin-cholesterol acyltransferase (LCAT), while the expression of acyl:cholesterol acetyltransferase(ACAT1) was not affected.	Rifampin	30-40	stearoyl-CoA desaturase	Homo sapiens	190-194
23874477-7	2013	Moreover, in PXR over-expressing HepG2 cells (HepG2-PXR), the SCD1 expression was significantly higher than in HepG2-Vector cells, even in the absence of rifampicin.	Rifampin	154-164	nuclear receptor subfamily 1 group I member 2	Homo sapiens	13-16
23874477-8	2013	Down-regulation of PXR by shRNA abolished the rifampicin-induced SCD1 gene expression in HepG2 cells.	Rifampin	46-56	nuclear receptor subfamily 1 group I member 2	Homo sapiens	19-22
23874477-8	2013	Down-regulation of PXR by shRNA abolished the rifampicin-induced SCD1 gene expression in HepG2 cells.	Rifampin	46-56	stearoyl-CoA desaturase	Homo sapiens	65-69
23701163-2	2013	Cytochrome P450 2E1 (CYP2E1) is thought to contribute to the synergistic effects of RIF and INH.	Rifampin	84-87	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	0-19
23701163-2	2013	Cytochrome P450 2E1 (CYP2E1) is thought to contribute to the synergistic effects of RIF and INH.	Rifampin	84-87	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	21-27
23701163-9	2013	RESULTS: Mannitol inhibited CYP2E1 activity by 54% in mice with INH/RIF-induced hepatotoxicity (p &lt; 0.005).	Rifampin	68-71	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	28-34
23670789-5	2013	The GMRs and 90% CIs for anacetrapib AUC0-  and Cmax were 1.25 (1.04, 1.51) and 1.43 (1.13, 1.82) for SD rifampin (Period 2/Period 1) and 0.35 (0.29, 0.42) and 0.26 (0.21, 0.32) for MD rifampin (Period 3/Period 1), respectively.	Rifampin	185-193	period circadian regulator 2	Homo sapiens	115-123
23558944-8	2013	In in situ liver perfusion model, the hepatic extraction ratio of MTC-220 was reduced to 40 % of control in the presence of rifampicin, an Oatps inhibitor, and the cumulative biliary excretion rates of MTC-220 were reduced to 52.9, 71.5 and 62.9 % of control when concomitant perfusion with probenecid, novobiocin and verapamil, the inhibitors of Mrp2, Bcrp and P-gp, respectively.	Rifampin	124-134	ATP binding cassette subfamily C member 2	Rattus norvegicus	347-351
23558944-8	2013	In in situ liver perfusion model, the hepatic extraction ratio of MTC-220 was reduced to 40 % of control in the presence of rifampicin, an Oatps inhibitor, and the cumulative biliary excretion rates of MTC-220 were reduced to 52.9, 71.5 and 62.9 % of control when concomitant perfusion with probenecid, novobiocin and verapamil, the inhibitors of Mrp2, Bcrp and P-gp, respectively.	Rifampin	124-134	phosphoglycolate phosphatase	Rattus norvegicus	362-366
23471941-0	2013	Relationship between CES2 genetic variations and rifampicin metabolism.	Rifampin	49-59	carboxylesterase 2	Homo sapiens	21-25
24089608-1	2013	Xpert MTB/RIF is an automated real-time polymerase chain reaction test for simultaneous detection of tuberculosis and rifampicin resistance.	Rifampin	118-128	ras homolog family member F, filopodia associated	Homo sapiens	10-13
24252529-5	2013	Coadministration of RPV with drugs that increase gastric pH, such as omeprazole, or those inducing CYP3A4, such as rifampicin, can significantly reduce RPV concentrations and is contraindicated.	Rifampin	115-125	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	99-105
23471941-11	2013	CONCLUSIONS: Variations in CES2, especially c.-2263A &gt; G in the promoter region, may alter rifampicin metabolism by affecting expression of the gene.	Rifampin	94-104	carboxylesterase 2	Homo sapiens	27-31
23479137-10	2013	Surprisingly, only in two cell lines, PXR activity was increased by the well-known inductor rifampicin.	Rifampin	92-102	nuclear receptor subfamily 1 group I member 2	Homo sapiens	38-41
23393219-0	2013	Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin.	Rifampin	199-209	solute carrier organic anion transporter family member 1B1	Homo sapiens	167-174
23396419-7	2013	(-)-Epigallocatechin gallate, cyclosporin A, rifampicin, and telmisartan inhibited transport of dioscin in OATP1B3-HEK293 cells.	Rifampin	45-55	solute carrier organic anion transporter family member 1B3	Homo sapiens	107-114
23562850-2	2013	We have previously shown that silencing mediator for retinoid and thyroid receptors (SMRT) interacts with SXR even in the presence of rifampicin on cytochrome P450 monooxygenase 3A4 (CYP3A4) promoter in HepG2 cells.	Rifampin	134-144	nuclear receptor corepressor 2	Homo sapiens	30-83
23562850-2	2013	We have previously shown that silencing mediator for retinoid and thyroid receptors (SMRT) interacts with SXR even in the presence of rifampicin on cytochrome P450 monooxygenase 3A4 (CYP3A4) promoter in HepG2 cells.	Rifampin	134-144	nuclear receptor corepressor 2	Homo sapiens	85-89
23562850-2	2013	We have previously shown that silencing mediator for retinoid and thyroid receptors (SMRT) interacts with SXR even in the presence of rifampicin on cytochrome P450 monooxygenase 3A4 (CYP3A4) promoter in HepG2 cells.	Rifampin	134-144	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	148-181
23562850-7	2013	KEY FINDINGS: SMRT, but not NCoR suppressed rifampicin-induced SXR-mediated transcription.	Rifampin	44-54	nuclear receptor corepressor 2	Homo sapiens	14-18
23562850-7	2013	KEY FINDINGS: SMRT, but not NCoR suppressed rifampicin-induced SXR-mediated transcription.	Rifampin	44-54	nuclear receptor subfamily 1 group I member 2	Homo sapiens	63-66
23562850-8	2013	The SXR-mediated MDR1 mRNA expression was augmented in the presence of rifampicin, whereas it suppressed the expression following the overexpression of SMRT.	Rifampin	71-81	nuclear receptor subfamily 1 group I member 2	Homo sapiens	4-7
23562850-8	2013	The SXR-mediated MDR1 mRNA expression was augmented in the presence of rifampicin, whereas it suppressed the expression following the overexpression of SMRT.	Rifampin	71-81	ATP binding cassette subfamily B member 1	Homo sapiens	17-21
23562850-9	2013	In mammalian one-hybrid assay, only SMRT but not NCoR interacted with SXR on MDR1 promoter in the presence of rifampicin.	Rifampin	110-120	nuclear receptor corepressor 2	Homo sapiens	36-40
23562850-9	2013	In mammalian one-hybrid assay, only SMRT but not NCoR interacted with SXR on MDR1 promoter in the presence of rifampicin.	Rifampin	110-120	nuclear receptor subfamily 1 group I member 2	Homo sapiens	70-73
23562850-9	2013	In mammalian one-hybrid assay, only SMRT but not NCoR interacted with SXR on MDR1 promoter in the presence of rifampicin.	Rifampin	110-120	ATP binding cassette subfamily B member 1	Homo sapiens	77-81
23475203-0	2013	Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy.	Rifampin	51-61	nuclear receptor subfamily 1 group I member 2	Homo sapiens	6-9
23212742-4	2013	With human hepatocytes, treatment with phenobarbital, hyperforin, carbamazepine, and rifampin significantly increased the levels of CYP3A4, but not CYP24A1 or CYP27B1 mRNA.	Rifampin	85-93	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	132-138
23212742-4	2013	With human hepatocytes, treatment with phenobarbital, hyperforin, carbamazepine, and rifampin significantly increased the levels of CYP3A4, but not CYP24A1 or CYP27B1 mRNA.	Rifampin	85-93	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	148-155
23212742-4	2013	With human hepatocytes, treatment with phenobarbital, hyperforin, carbamazepine, and rifampin significantly increased the levels of CYP3A4, but not CYP24A1 or CYP27B1 mRNA.	Rifampin	85-93	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	159-166
23395915-5	2013	To further confirm Pgp induction in rifampin treated mice, digoxin, a known substrate of Pgp, was administered to the rifampin pre-treated mice, and a significant drop in the digoxin exposure was observed compared to the control group.	Rifampin	36-44	phosphoglycolate phosphatase	Mus musculus	19-22
23395915-5	2013	To further confirm Pgp induction in rifampin treated mice, digoxin, a known substrate of Pgp, was administered to the rifampin pre-treated mice, and a significant drop in the digoxin exposure was observed compared to the control group.	Rifampin	118-126	phosphoglycolate phosphatase	Mus musculus	89-92
23395915-6	2013	Collectively, our results show that repeated administration of rifampin in mice leads to a reduction in oral exposure due to induction of Pgp-mediated efflux of rifampin, and not via induction of CYP3A isoforms.	Rifampin	63-71	phosphoglycolate phosphatase	Mus musculus	138-141
23395915-6	2013	Collectively, our results show that repeated administration of rifampin in mice leads to a reduction in oral exposure due to induction of Pgp-mediated efflux of rifampin, and not via induction of CYP3A isoforms.	Rifampin	161-169	phosphoglycolate phosphatase	Mus musculus	138-141
23238784-7	2013	The CYP3A4 activity could be induced 2-fold by rifampicin, whereas CYP2C9 activity remained equally high.	Rifampin	47-57	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	4-10
23493125-2	2013	The data show that electroporation of HaCaT cells in combination with rifampicin induces cytoskeleton disruption and increases permeability of cell monolayer due to cell-cell junctions" interruption, visualized by fluorescent imaging of E-cadherin and actin integrity.	Rifampin	70-80	cadherin 1	Homo sapiens	237-247
23143285-5	2013	Furthermore, correlation analysis revealed that the over-expression of both Rv1217c and Rv1218c resulted in the higher minimum inhibition concentrations (MICs) of rifampicin (RIF) (OR = 1.01, P &lt; 0.05 of Rv1217c; OR = 1.23, P &lt; 0.05 of Rv1218c), while the over-expression of Rv1218c only led to the higher MICs of isoniazid (INH) (OR = 1.17, P &lt; 0.05).	Rifampin	163-173	tetronasin ABC transporter integral membrane protein	Mycobacterium tuberculosis H37Rv	76-83
23143285-5	2013	Furthermore, correlation analysis revealed that the over-expression of both Rv1217c and Rv1218c resulted in the higher minimum inhibition concentrations (MICs) of rifampicin (RIF) (OR = 1.01, P &lt; 0.05 of Rv1217c; OR = 1.23, P &lt; 0.05 of Rv1218c), while the over-expression of Rv1218c only led to the higher MICs of isoniazid (INH) (OR = 1.17, P &lt; 0.05).	Rifampin	163-173	tetronasin ABC transporter ATP-binding protein	Mycobacterium tuberculosis H37Rv	88-95
23143285-5	2013	Furthermore, correlation analysis revealed that the over-expression of both Rv1217c and Rv1218c resulted in the higher minimum inhibition concentrations (MICs) of rifampicin (RIF) (OR = 1.01, P &lt; 0.05 of Rv1217c; OR = 1.23, P &lt; 0.05 of Rv1218c), while the over-expression of Rv1218c only led to the higher MICs of isoniazid (INH) (OR = 1.17, P &lt; 0.05).	Rifampin	163-173	tetronasin ABC transporter integral membrane protein	Mycobacterium tuberculosis H37Rv	207-214
23143285-5	2013	Furthermore, correlation analysis revealed that the over-expression of both Rv1217c and Rv1218c resulted in the higher minimum inhibition concentrations (MICs) of rifampicin (RIF) (OR = 1.01, P &lt; 0.05 of Rv1217c; OR = 1.23, P &lt; 0.05 of Rv1218c), while the over-expression of Rv1218c only led to the higher MICs of isoniazid (INH) (OR = 1.17, P &lt; 0.05).	Rifampin	163-173	tetronasin ABC transporter ATP-binding protein	Mycobacterium tuberculosis H37Rv	242-249
23143285-5	2013	Furthermore, correlation analysis revealed that the over-expression of both Rv1217c and Rv1218c resulted in the higher minimum inhibition concentrations (MICs) of rifampicin (RIF) (OR = 1.01, P &lt; 0.05 of Rv1217c; OR = 1.23, P &lt; 0.05 of Rv1218c), while the over-expression of Rv1218c only led to the higher MICs of isoniazid (INH) (OR = 1.17, P &lt; 0.05).	Rifampin	163-173	tetronasin ABC transporter ATP-binding protein	Mycobacterium tuberculosis H37Rv	242-249
23360470-6	2013	The P-gp inhibitor GF120918 increased the permeability for darunavir by 400% in rifampicin-treated mice, whereas this was only 56% in mice that were not treated, thus indicating P-gp induction by rifampicin.	Rifampin	80-90	phosphoglycolate phosphatase	Mus musculus	4-8
23360470-6	2013	The P-gp inhibitor GF120918 increased the permeability for darunavir by 400% in rifampicin-treated mice, whereas this was only 56% in mice that were not treated, thus indicating P-gp induction by rifampicin.	Rifampin	80-90	phosphoglycolate phosphatase	Mus musculus	178-182
23360470-6	2013	The P-gp inhibitor GF120918 increased the permeability for darunavir by 400% in rifampicin-treated mice, whereas this was only 56% in mice that were not treated, thus indicating P-gp induction by rifampicin.	Rifampin	196-206	phosphoglycolate phosphatase	Mus musculus	4-8
23360470-6	2013	The P-gp inhibitor GF120918 increased the permeability for darunavir by 400% in rifampicin-treated mice, whereas this was only 56% in mice that were not treated, thus indicating P-gp induction by rifampicin.	Rifampin	196-206	phosphoglycolate phosphatase	Mus musculus	178-182
23360470-8	2013	Quantitative Western blot analysis of the intestinal tissue showed that rifampicin treatment induced intestinal P-gp levels 4-fold, while CYP3A4 levels remained unchanged.	Rifampin	72-82	phosphoglycolate phosphatase	Mus musculus	112-116
23320515-0	2013	Global metabolomics and targeted steroid profiling reveal that rifampin, a strong human PXR activator, alters endogenous urinary steroid markers.	Rifampin	63-71	nuclear receptor subfamily 1 group I member 2	Homo sapiens	88-91
23255551-6	2013	Further study on other Oatp1a2 substrates showed that the high affinity component for E-3-S is responsible for the interaction with taurocholate, bromsulphthalein, and rifampicin and is sensitive to proton concentration change, whereas the low affinity binding site is only involved in the binding of the antitumor drug methotrexate and had no response to change of pH.	Rifampin	168-178	solute carrier organic anion transporter family member 1A2	Homo sapiens	23-30
23320515-2	2013	To identify endogenous biomarkers of PXR activation in humans, rifampin, a strong PXR activator, was administered to 12 healthy male subjects, and their urine was analyzed before and after rifampin administration.	Rifampin	63-71	nuclear receptor subfamily 1 group I member 2	Homo sapiens	37-40
23320515-2	2013	To identify endogenous biomarkers of PXR activation in humans, rifampin, a strong PXR activator, was administered to 12 healthy male subjects, and their urine was analyzed before and after rifampin administration.	Rifampin	63-71	nuclear receptor subfamily 1 group I member 2	Homo sapiens	82-85
23264496-5	2013	The PXR ligand rifampicin further increased the expression of CYP3A4, and siRNA-mediated knock-down of PXR in confluent cells resulted in decreased CYP3A4 expression.	Rifampin	15-25	nuclear receptor subfamily 1 group I member 2	Homo sapiens	4-7
23264496-5	2013	The PXR ligand rifampicin further increased the expression of CYP3A4, and siRNA-mediated knock-down of PXR in confluent cells resulted in decreased CYP3A4 expression.	Rifampin	15-25	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	62-68
22642697-9	2013	CONCLUSION: CYP3A inducers, rifampicin and efavirenz, can reduce telaprevir exposure to varying degrees based on their potency.	Rifampin	28-38	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	12-17
23071008-1	2013	Induction of the cytochrome P450 (CYP) family of enzymes by coadministered compounds can result in drug-drug interactions, as in the case of the coadministration of rifampicin with many CYP3A substrates, including midazolam.	Rifampin	165-175	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-32
22803519-2	2013	The aim of this study was to determine the effect of rifampicin, a CYP3A4 inducer, on the plasma pharmacokinetics of eribulin in patients with solid tumours.	Rifampin	53-63	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	67-73
23071008-1	2013	Induction of the cytochrome P450 (CYP) family of enzymes by coadministered compounds can result in drug-drug interactions, as in the case of the coadministration of rifampicin with many CYP3A substrates, including midazolam.	Rifampin	165-175	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	34-37
23071008-1	2013	Induction of the cytochrome P450 (CYP) family of enzymes by coadministered compounds can result in drug-drug interactions, as in the case of the coadministration of rifampicin with many CYP3A substrates, including midazolam.	Rifampin	165-175	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	186-191
23071008-7	2013	The E(max) and EC(50) values in two separate lots of hepatocytes for CYP3A induction by rifampicin in a 96-well format were similar when discrete probe was compared with the probe cocktail.	Rifampin	88-98	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	69-74
23440123-2	2013	We detected the C526T and C531T mutations in the rifampicin resistance-determining region (RRDR) of the rpoB gene with qPCR-HRM using plasmid-based controls.	Rifampin	49-59	DNA-directed RNA polymerase subunit beta	Mycobacterium tuberculosis H37Rv	104-108
22889553-0	2013	Expression and inducibility of CYP1A1, 1A2, 1B1 by beta-naphthoflavone and CYP2B22, CYP3As by rifampicin in heart regions and coronary arteries of pig.	Rifampin	94-104	cytochrome P450 family 1 subfamily A member 1	Sus scrofa	31-37
22889553-0	2013	Expression and inducibility of CYP1A1, 1A2, 1B1 by beta-naphthoflavone and CYP2B22, CYP3As by rifampicin in heart regions and coronary arteries of pig.	Rifampin	94-104	cytochrome P450 family 2 subfamily B member 6B	Sus scrofa	75-82
22889553-3	2013	The rifampicin treatment resulted in an induction of CYP2B22 and CYP3As, at the transcriptional, activity and protein level in liver but not in heart nor in the coronary arteries, despite the expression of CAR and PXR in the cardiac tissues.	Rifampin	4-14	cytochrome P450 family 2 subfamily B member 6B	Sus scrofa	53-60
22889553-3	2013	The rifampicin treatment resulted in an induction of CYP2B22 and CYP3As, at the transcriptional, activity and protein level in liver but not in heart nor in the coronary arteries, despite the expression of CAR and PXR in the cardiac tissues.	Rifampin	4-14	CXADR Ig-like cell adhesion molecule	Sus scrofa	206-209
22889553-3	2013	The rifampicin treatment resulted in an induction of CYP2B22 and CYP3As, at the transcriptional, activity and protein level in liver but not in heart nor in the coronary arteries, despite the expression of CAR and PXR in the cardiac tissues.	Rifampin	4-14	nuclear receptor subfamily 1 group I member 2	Sus scrofa	214-217
23160820-8	2013	Of importance, ectopic overexpression and silencing of endogenous RBCK1 in primary human hepatocytes resulted in a decrease and increase, respectively, in endogenous PXR protein levels and in the induction of PXR target genes by rifampicin.	Rifampin	229-239	RANBP2-type and C3HC4-type zinc finger containing 1	Homo sapiens	66-71
23374512-10	2013	RESULTS: The vancomycin-resistant isolate CP2 was found to be resistant to oxacillin, chloramphenicol, erythromycin, rifampicin, gentamicin, tetracycline and ciprofloxacin, as well.	Rifampin	117-127	ceruloplasmin	Homo sapiens	42-45
23339213-36	2013	Thirteen days later, the CSF culture became positive for Mycobacterium tuberculosis sensitive to streptomycin, isoniazid, ethambutol, rifampin, and pyrazinamide.	Rifampin	134-142	colony stimulating factor 2	Homo sapiens	25-28
23400746-4	2013	In vitro studies indicated that ketoconazole inhibited the uptake of fimasartan into cells expressing OATP1B1 with a K(i) of 107.7 microM, and rifampicin inhibited OAT1- and OATP1B1-mediated fimasartan transport with a K(i) of 212 microM and 12.2 microM, respectively.	Rifampin	143-153	solute carrier family 22 member 6	Homo sapiens	164-168
23273219-3	2013	beta-Amyloid aggregation results showed that all compounds exhibited remarkable Abeta fibril aggregation inhibition activity with a nearly similar potential as the reference compound rifampicin, which makes them promising anti-Alzheimer drug candidates.	Rifampin	183-193	amyloid beta precursor protein	Homo sapiens	80-85
23095030-13	2013	Isolates with a DNA profile compatible with the BI/NAP1/027 ribotype had, on the average, higher MICs of rifampin.	Rifampin	105-113	nucleosome assembly protein 1 like 1	Homo sapiens	51-55
23123212-5	2013	Xenobiotics like rifampicin and hyperforin activate PXR and induce Abcb1 expression.	Rifampin	17-27	nuclear receptor subfamily 1 group I member 2	Homo sapiens	52-55
23123212-5	2013	Xenobiotics like rifampicin and hyperforin activate PXR and induce Abcb1 expression.	Rifampin	17-27	ATP binding cassette subfamily B member 1	Homo sapiens	67-72
23123212-8	2013	For activation of the pregnane X receptor the ligands hyperforin and rifampicin were used.	Rifampin	69-79	nuclear receptor subfamily 1 group I member 2	Homo sapiens	22-41
23123212-12	2013	In conclusion our data prove PXR activation by rifampicin and hyperforin lead to an increased ABC-transporter expression and transport activity.	Rifampin	47-57	nuclear receptor subfamily 1 group I member 2	Homo sapiens	29-32
23123212-12	2013	In conclusion our data prove PXR activation by rifampicin and hyperforin lead to an increased ABC-transporter expression and transport activity.	Rifampin	47-57	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	94-109
23137910-8	2013	Cotreatment with the prototypical pregnane X receptor activator, rifampicin, significantly reversed decitabine-induced ABCC3 and SLCO2A1 expression.	Rifampin	65-75	nuclear receptor subfamily 1 group I member 2	Homo sapiens	34-53
23137910-8	2013	Cotreatment with the prototypical pregnane X receptor activator, rifampicin, significantly reversed decitabine-induced ABCC3 and SLCO2A1 expression.	Rifampin	65-75	ATP binding cassette subfamily C member 3	Homo sapiens	119-124
23137910-8	2013	Cotreatment with the prototypical pregnane X receptor activator, rifampicin, significantly reversed decitabine-induced ABCC3 and SLCO2A1 expression.	Rifampin	65-75	solute carrier organic anion transporter family member 2A1	Homo sapiens	129-136
24852442-6	2013	Rifampicin significantly inhibited the overexpression of TLR2, TLR4, CD14 and IL8Rs.	Rifampin	0-10	toll like receptor 2	Homo sapiens	57-61
24852442-6	2013	Rifampicin significantly inhibited the overexpression of TLR2, TLR4, CD14 and IL8Rs.	Rifampin	0-10	toll like receptor 4	Homo sapiens	63-67
24852442-6	2013	Rifampicin significantly inhibited the overexpression of TLR2, TLR4, CD14 and IL8Rs.	Rifampin	0-10	CD14 molecule	Homo sapiens	69-73
23115085-5	2013	Rifampicin inhibited the uptake of fexofenadine enantiomers by human hepatocytes via organic anion transporter (OAT) OATP1B3 and its basal-to-apical transport in Caco-2 cells, but not OAT3-mediated or multidrug and toxic compound extrusion 1 (MATE1)-mediated transport.	Rifampin	0-10	solute carrier organic anion transporter family member 1B3	Homo sapiens	117-124
23115085-5	2013	Rifampicin inhibited the uptake of fexofenadine enantiomers by human hepatocytes via organic anion transporter (OAT) OATP1B3 and its basal-to-apical transport in Caco-2 cells, but not OAT3-mediated or multidrug and toxic compound extrusion 1 (MATE1)-mediated transport.	Rifampin	0-10	solute carrier family 22 member 8	Homo sapiens	184-188
23115085-5	2013	Rifampicin inhibited the uptake of fexofenadine enantiomers by human hepatocytes via organic anion transporter (OAT) OATP1B3 and its basal-to-apical transport in Caco-2 cells, but not OAT3-mediated or multidrug and toxic compound extrusion 1 (MATE1)-mediated transport.	Rifampin	0-10	solute carrier family 47 member 1	Homo sapiens	243-248
23115085-7	2013	The rifampicin-sensitive uptake by hepatocytes was 1.6 times higher for R-fexofenadine, whereas the transport activities by OATP1B3, OAT3, MATE1, or P-glycoprotein were identical for both enantiomers.	Rifampin	4-14	solute carrier family 22 member 8	Homo sapiens	133-137
23115085-9	2013	In conclusion, rifampicin has multiple interaction sites with fexofenadine, all of which contribute to increasing the area under the curve of fexofenadine when they are given simultaneously, to surpass the effect of the induction of P-glycoprotein elicited by multiple doses.	Rifampin	15-25	ATP binding cassette subfamily B member 1	Homo sapiens	233-247
23400746-4	2013	In vitro studies indicated that ketoconazole inhibited the uptake of fimasartan into cells expressing OATP1B1 with a K(i) of 107.7 microM, and rifampicin inhibited OAT1- and OATP1B1-mediated fimasartan transport with a K(i) of 212 microM and 12.2 microM, respectively.	Rifampin	143-153	solute carrier organic anion transporter family member 1B1	Homo sapiens	174-181
23841924-3	2013	The metabolism and bioavailability of cyclosporin can be significantly and persistently influenced through induction of CYP3A4 caused by the concomitant use of rifampicin.	Rifampin	160-170	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	120-126
23600152-5	2013	The positive hPXR/hCAR activators rifampicin and CITCO were applied to make sure that the reporter gene model was successfully established.	Rifampin	34-44	CXADR Ig-like cell adhesion molecule	Homo sapiens	18-22
23164983-4	2013	When bovine embryos were cultured with forskolin and/or rifampicin, the ABCB1 level was significantly increased in blastocysts but embryo development was not significantly improved.	Rifampin	56-66	LOW QUALITY PROTEIN: multidrug resistance protein 1	Bos taurus	72-77
23402082-4	2012	Rifampicin, the most effective antipruritic agent in cholestatic itch, has been shown to reduce autotaxin transcription in vitro.	Rifampin	0-10	ectonucleotide pyrophosphatase/phosphodiesterase 2	Homo sapiens	96-105
23153560-5	2013	The potent PXR ligand - rifampicin (300mg/d) was given alone for 7days in arm 1, or in daily combination with 450mumol SFN (Broccoli Sprout extract) in arm 2; SFN was given alone in arm 3.	Rifampin	24-34	nuclear receptor subfamily 1 group I member 2	Homo sapiens	11-14
23153560-7	2013	Rifampicin alone decreased midazolam AUC by 70%, indicative of the expected increase in CYP3A4 activity.	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	88-94
22676424-3	2012	We examined the effect rifampicin, a well-known inducer of many cytochrome P450 (CYP) enzymes and transporters, on the pharmacokinetics of intravenous and oral S-ketamine in healthy volunteers.	Rifampin	23-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-79
22834478-6	2012	Whereas positive controls (100 microM omeprazole and 10 microM rifampin) caused the anticipated CYP induction, the highest concentration of mirabegron (10 microM; 37 times plasma C(max)) had minimal effect on CYP1A2 and CYP3A4/5 activity, and CYP1A2 and CYP3A4 mRNA levels in freshly isolated human hepatocytes, suggesting that mirabegron is not an inducer of these enzymes.	Rifampin	63-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-99
22676424-3	2012	We examined the effect rifampicin, a well-known inducer of many cytochrome P450 (CYP) enzymes and transporters, on the pharmacokinetics of intravenous and oral S-ketamine in healthy volunteers.	Rifampin	23-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-84
22250979-6	2012	When rifampicin was stopped, IDV/r was reduced to 400/100 mg BID.	Rifampin	5-15	BH3 interacting domain death agonist	Homo sapiens	61-64
22809809-7	2012	The compounds 3-methylcholanthrene (a CYP1A2 inducer), phenobarbital (a CYP2B6 inducer), and rifampicin (a CYP3A4/5 inducer) served as positive controls.	Rifampin	93-103	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	107-113
22473838-5	2012	Rifampicin (RMP) significantly reduced itch intensity and ATX activity in patients with pruritus not responding to bile salt sequestrants.	Rifampin	0-10	ectonucleotide pyrophosphatase/phosphodiesterase 2	Homo sapiens	58-61
22445438-14	2012	Coadministration of CYP3A4 modulators should be avoided where possible, and another type of contraception should be used when coadministration of CYP3A4 inducers like rifampicin is unavoidable.	Rifampin	167-177	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	146-152
22829544-5	2012	Although phosphomimetic mutations at Thr290 and Thr408 retained the PXR protein in cytoplasm and attenuated the induction of UGT1A1 expression by both roscovitine and rifampicin, a mutation at Ser350 specifically reduced the activity of PXR induced by roscovitine.	Rifampin	167-177	nuclear receptor subfamily 1 group I member 2	Homo sapiens	68-71
22829544-5	2012	Although phosphomimetic mutations at Thr290 and Thr408 retained the PXR protein in cytoplasm and attenuated the induction of UGT1A1 expression by both roscovitine and rifampicin, a mutation at Ser350 specifically reduced the activity of PXR induced by roscovitine.	Rifampin	167-177	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	125-131
22829544-5	2012	Although phosphomimetic mutations at Thr290 and Thr408 retained the PXR protein in cytoplasm and attenuated the induction of UGT1A1 expression by both roscovitine and rifampicin, a mutation at Ser350 specifically reduced the activity of PXR induced by roscovitine.	Rifampin	167-177	nuclear receptor subfamily 1 group I member 2	Homo sapiens	237-240
22473838-5	2012	Rifampicin (RMP) significantly reduced itch intensity and ATX activity in patients with pruritus not responding to bile salt sequestrants.	Rifampin	12-15	ectonucleotide pyrophosphatase/phosphodiesterase 2	Homo sapiens	58-61
22875972-8	2012	In contrast, when virion envelope formation was blocked at a later step by repression of A14 expression or by rifampin treatment, A11 colocalized with virion membrane proteins in the factories.	Rifampin	110-118	DXS435E	Homo sapiens	130-133
22733800-7	2012	Differentiating cells showed significant induction in the expression of CYP1A1, 2B6, 2E1, 3A4, AHR, CAR, PXR, and GSTP1-1 when exposed to rifampin, a known universal inducer of CYPs.	Rifampin	138-146	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	72-78
22638872-4	2012	DDI with OATP1B1 inhibitors, cyclosporine, gemfibrozil and rifampin, was also simulated using inhibition constant (Ki) values.	Rifampin	59-67	solute carrier organic anion transporter family member 1B1	Homo sapiens	9-16
22733800-7	2012	Differentiating cells showed significant induction in the expression of CYP1A1, 2B6, 2E1, 3A4, AHR, CAR, PXR, and GSTP1-1 when exposed to rifampin, a known universal inducer of CYPs.	Rifampin	138-146	aryl hydrocarbon receptor	Homo sapiens	95-98
22733800-7	2012	Differentiating cells showed significant induction in the expression of CYP1A1, 2B6, 2E1, 3A4, AHR, CAR, PXR, and GSTP1-1 when exposed to rifampin, a known universal inducer of CYPs.	Rifampin	138-146	nuclear receptor subfamily 1 group I member 3	Homo sapiens	100-103
22825545-6	2012	We demonstrated that higher concentrations of rifampicin (&gt;50 muM) change the expression of reference genes and thus may complicate and adulterate normalization of qRT-PCR data.	Rifampin	46-56	latexin	Homo sapiens	65-68
22733800-7	2012	Differentiating cells showed significant induction in the expression of CYP1A1, 2B6, 2E1, 3A4, AHR, CAR, PXR, and GSTP1-1 when exposed to rifampin, a known universal inducer of CYPs.	Rifampin	138-146	nuclear receptor subfamily 1 group I member 2	Homo sapiens	105-108
22733800-7	2012	Differentiating cells showed significant induction in the expression of CYP1A1, 2B6, 2E1, 3A4, AHR, CAR, PXR, and GSTP1-1 when exposed to rifampin, a known universal inducer of CYPs.	Rifampin	138-146	glutathione S-transferase pi 1	Homo sapiens	114-121
22727860-3	2012	Pretreatment with rifampin significantly decreased serum alanine transaminase (ALT) activities, aspartate transaminase (AST) activities and prevented severe liver necrosis following acetaminophen overdose.	Rifampin	18-26	glutamic pyruvic transaminase, soluble	Mus musculus	57-77
22847250-0	2012	Effect of pH, mucin and bovine serum on rifampicin permeability through Caco-2 cells.	Rifampin	40-50	LOC100508689	Homo sapiens	14-19
22727860-3	2012	Pretreatment with rifampin significantly decreased serum alanine transaminase (ALT) activities, aspartate transaminase (AST) activities and prevented severe liver necrosis following acetaminophen overdose.	Rifampin	18-26	glutamic pyruvic transaminase, soluble	Mus musculus	79-82
22727860-3	2012	Pretreatment with rifampin significantly decreased serum alanine transaminase (ALT) activities, aspartate transaminase (AST) activities and prevented severe liver necrosis following acetaminophen overdose.	Rifampin	18-26	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	96-118
22727860-3	2012	Pretreatment with rifampin significantly decreased serum alanine transaminase (ALT) activities, aspartate transaminase (AST) activities and prevented severe liver necrosis following acetaminophen overdose.	Rifampin	18-26	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	120-123
22664347-4	2012	Cells were exposed to a range of non-coplanar PCBs (99, 138, 153, 180 and 194), or the coplanar PCB77: Direct activation of PXR and CAR was measured using a mammalian receptor activation assay in human liver cells, with rifampicin and CITCO used as positive controls ligands for PXR and CAR, respectively; activation of target gene expression was examined using reporter gene plasmids for CYP3A4 and MDR1 transfected into liver, intestine and lung cell lines.	Rifampin	220-230	nuclear receptor subfamily 1 group I member 2	Homo sapiens	124-127
23015129-1	2012	This study investigated the therapeutic effects of interleukin (IL)-2 and granulocyte-macrophage colony-stimulating factor (GM-CSF) co-administrated with antibacterial agents isoniazid (INH) and rifampin (RIF) to treat a mouse model of tuberculosis (TB) infection.	Rifampin	195-203	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	124-130
23015129-1	2012	This study investigated the therapeutic effects of interleukin (IL)-2 and granulocyte-macrophage colony-stimulating factor (GM-CSF) co-administrated with antibacterial agents isoniazid (INH) and rifampin (RIF) to treat a mouse model of tuberculosis (TB) infection.	Rifampin	205-208	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	124-130
22525741-2	2012	Rifampicin has been reported to be an effective treatment of jaundice and pruritus in patients with BRIC.	Rifampin	0-10	ATPase phospholipid transporting 8B1	Homo sapiens	100-104
22525741-3	2012	Proposed mechanisms of effect for rifampicin include enhancement of multidrug-resistance protein 2 expression, activation of the enzymes of uridine diphosphate glucuronosyltransferase 1A1 and cytochrome P450 3A4, and stimulation of 6alpha-hydroxylation of bile acids.	Rifampin	34-44	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	192-211
22525741-4	2012	METHODS: To confirm the diagnosis of BRIC-1 and demonstrate the effect of rifampicin treatment on bile acid metabolism, we analyzed the patient"s ATP8B1 gene and bile acids in urine.	Rifampin	74-84	ATPase phospholipid transporting 8B1	Homo sapiens	146-152
22525741-5	2012	RESULTS: We detected 2 heterozygous mutations in the ATP8B1 gene, and increasing amounts of unusual bile acids such as 1beta-hydroxylated cholic acid, 2beta-hydroxylated cholic acid, 4beta-hydroxylated cholic acid, 6alpha-hydroxylated cholic acid, and hyocholic acid in urine during rifampicin treatment.	Rifampin	283-293	ATPase phospholipid transporting 8B1	Homo sapiens	53-59
22339773-3	2012	Thus, the aim of this study is to investigate maternal, placental and foetal Abcb1 expression and function in pregnant rats after induction with rifampicin, dexamethasone, St. John"s wort (SJW) or thyroxine.	Rifampin	145-155	ATP binding cassette subfamily B member 1A	Rattus norvegicus	77-82
22644021-11	2012	While rifampin plus ceftriaxone versus ceftriaxone also led to lower CSF inflammation (P &lt; 0.02 for IL-6 at 6 h), it had no significant effect on apoptosis and hearing capacity.	Rifampin	6-14	interleukin 6	Rattus norvegicus	103-107
22644026-10	2012	Lersivirine should not be coadministered with rifampin, which is a potent inducer of CYP3A4, UGT2B7, and P-glycoprotein activity and thus substantially lowers lersivirine exposure.	Rifampin	46-54	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	85-91
22644026-10	2012	Lersivirine should not be coadministered with rifampin, which is a potent inducer of CYP3A4, UGT2B7, and P-glycoprotein activity and thus substantially lowers lersivirine exposure.	Rifampin	46-54	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	93-99
22339773-9	2012	Rifampicin induced Abcb1 in all maternal and foetal organs.	Rifampin	0-10	ATP binding cassette subfamily B member 1A	Rattus norvegicus	19-24
22339773-12	2012	Although rifampicin regulates maternal and foetal Abcb1 expression, organ distribution of talinolol remains unchanged most likely caused by the known inhibitory effect of rifampicin on Abcb1 function.	Rifampin	9-19	ATP binding cassette subfamily B member 1A	Rattus norvegicus	50-55
22339773-12	2012	Although rifampicin regulates maternal and foetal Abcb1 expression, organ distribution of talinolol remains unchanged most likely caused by the known inhibitory effect of rifampicin on Abcb1 function.	Rifampin	171-181	ATP binding cassette subfamily B member 1A	Rattus norvegicus	185-190
22636321-7	2012	Oral rifampicin was effective in clearing infection and halting further progression of focal inflammation from infected IFN-gamma(-/-) mice, although some symptoms and swelling remained.	Rifampin	5-15	interferon gamma	Mus musculus	120-129
22562045-3	2012	Treatment with the hPXR agonist rifampin significantly increased CYP3A4 mRNA content and catalytic activity, but had no effect on CYP24A1 or TRPV6 mRNA content.	Rifampin	32-40	nuclear receptor subfamily 1 group I member 2	Homo sapiens	19-23
22562045-3	2012	Treatment with the hPXR agonist rifampin significantly increased CYP3A4 mRNA content and catalytic activity, but had no effect on CYP24A1 or TRPV6 mRNA content.	Rifampin	32-40	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	65-71
22562045-4	2012	Pre-treating cells with rifampin for 48h, prior to a 24h 1alpha,25(OH)(2)D(3) treatment phase, was associated with a subsequent 48% increase in the elimination of 1alpha,25(OH)(2)D(3) and a 35% reduction of peak TRPV6 mRNA.	Rifampin	24-32	transient receptor potential cation channel subfamily V member 6	Homo sapiens	212-217
22562045-5	2012	Introduction of the CYP3A4 inhibitor, 6",7"-dihydroxybergamottin, an active inhibitor in grapefruit juice, reversed the effects of rifampin on 1alpha,25(OH)(2)D(3) clearance and TRPV6 expression.	Rifampin	131-139	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	20-26
22562045-5	2012	Introduction of the CYP3A4 inhibitor, 6",7"-dihydroxybergamottin, an active inhibitor in grapefruit juice, reversed the effects of rifampin on 1alpha,25(OH)(2)D(3) clearance and TRPV6 expression.	Rifampin	131-139	transient receptor potential cation channel subfamily V member 6	Homo sapiens	178-183
22562045-6	2012	Over-expression of hPXR in LS180 cells greatly enhanced the CYP3A4 responsiveness to rifampin pretreatment, and elicited a greater relative suppression of TRPV6 expression and an increase in 1alpha,25(OH)(2)D(3) disappearance rate, compared to vector expressed cells, following hormone administration.	Rifampin	85-93	nuclear receptor subfamily 1 group I member 2	Homo sapiens	19-23
22562045-6	2012	Over-expression of hPXR in LS180 cells greatly enhanced the CYP3A4 responsiveness to rifampin pretreatment, and elicited a greater relative suppression of TRPV6 expression and an increase in 1alpha,25(OH)(2)D(3) disappearance rate, compared to vector expressed cells, following hormone administration.	Rifampin	85-93	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	60-66
22585454-10	2012	CONCLUSION: Chemoprophylaxis with isoniazid and rifampicin generally decreased IFN-gamma levels among tuberculosis contacts.	Rifampin	48-58	interferon gamma	Homo sapiens	79-88
23087510-2	2012	Rifampicin is a strong CYP enzyme inducer while isoniazid is a potent CYP inhibitor.	Rifampin	0-10	peptidylprolyl isomerase G	Homo sapiens	23-26
22617226-0	2012	Effects of CYP induction by rifampicin on tamoxifen exposure.	Rifampin	28-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	11-14
22617226-3	2012	We evaluated the effects of cytochrome P450 (CYP) induction by rifampicin on the exposure levels of tamoxifen and its metabolites and found that coadministration of rifampicin resulted in markedly reduced (up to 86%, P &lt;= 0.040) concentrations of tamoxifen and its metabolites.	Rifampin	63-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
22617226-3	2012	We evaluated the effects of cytochrome P450 (CYP) induction by rifampicin on the exposure levels of tamoxifen and its metabolites and found that coadministration of rifampicin resulted in markedly reduced (up to 86%, P &lt;= 0.040) concentrations of tamoxifen and its metabolites.	Rifampin	63-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-48
22617226-3	2012	We evaluated the effects of cytochrome P450 (CYP) induction by rifampicin on the exposure levels of tamoxifen and its metabolites and found that coadministration of rifampicin resulted in markedly reduced (up to 86%, P &lt;= 0.040) concentrations of tamoxifen and its metabolites.	Rifampin	165-175	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
22617226-3	2012	We evaluated the effects of cytochrome P450 (CYP) induction by rifampicin on the exposure levels of tamoxifen and its metabolites and found that coadministration of rifampicin resulted in markedly reduced (up to 86%, P &lt;= 0.040) concentrations of tamoxifen and its metabolites.	Rifampin	165-175	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-48
21602517-4	2012	Pretreatment with rifampin, a potent CYP3A4 inducer, decreased ruxolitinib AUC(0- ) by 71% while resulting in only a 10% decrease in the overall PD activity.	Rifampin	18-26	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	37-43
22620706-9	2012	RESULTS: Rifampicin treatment upregulated duodenal P-gp in dogs and significantly reduced the area under the plasma concentration-time curve of prednisolone.	Rifampin	9-19	PGP	Canis lupus familiaris	51-55
22562052-0	2012	SLCO1B1 *15 haplotype is associated with rifampin-induced liver injury.	Rifampin	41-49	solute carrier organic anion transporter family member 1B1	Homo sapiens	0-7
22562052-1	2012	The organic anion transporting polypeptide 1B1 (OATP1B1, encoded by SLCO1B1) plays an important role in the transport of endogenous and xenobiotic compounds, such as bile acids and rifampin.	Rifampin	181-189	solute carrier organic anion transporter family member 1B1	Homo sapiens	4-46
22562052-1	2012	The organic anion transporting polypeptide 1B1 (OATP1B1, encoded by SLCO1B1) plays an important role in the transport of endogenous and xenobiotic compounds, such as bile acids and rifampin.	Rifampin	181-189	solute carrier organic anion transporter family member 1B1	Homo sapiens	48-55
22562052-1	2012	The organic anion transporting polypeptide 1B1 (OATP1B1, encoded by SLCO1B1) plays an important role in the transport of endogenous and xenobiotic compounds, such as bile acids and rifampin.	Rifampin	181-189	solute carrier organic anion transporter family member 1B1	Homo sapiens	68-75
22562052-13	2012	These results suggest that the OATP1B1 *15 haplotype is an important predisposing factor for rifampin-induced liver injury.	Rifampin	93-101	solute carrier organic anion transporter family member 1B1	Homo sapiens	31-38
22559005-3	2012	Here we investigated the effects of exposure of carp (Cyprinus carpio) primary hepatocytes to the human PXR agonist rifampicin (RIF) on expression of target genes involved in phase I (cyp2k, cyp3a) and phase II (gstalpha, gstpi) drug metabolism and drug transporters mdr1 and mrp2.	Rifampin	116-126	nuclear receptor subfamily 1 group I member 2	Homo sapiens	104-107
22559005-3	2012	Here we investigated the effects of exposure of carp (Cyprinus carpio) primary hepatocytes to the human PXR agonist rifampicin (RIF) on expression of target genes involved in phase I (cyp2k, cyp3a) and phase II (gstalpha, gstpi) drug metabolism and drug transporters mdr1 and mrp2.	Rifampin	116-126	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	191-196
22559005-3	2012	Here we investigated the effects of exposure of carp (Cyprinus carpio) primary hepatocytes to the human PXR agonist rifampicin (RIF) on expression of target genes involved in phase I (cyp2k, cyp3a) and phase II (gstalpha, gstpi) drug metabolism and drug transporters mdr1 and mrp2.	Rifampin	116-126	ATP binding cassette subfamily B member 1	Homo sapiens	267-271
22559005-3	2012	Here we investigated the effects of exposure of carp (Cyprinus carpio) primary hepatocytes to the human PXR agonist rifampicin (RIF) on expression of target genes involved in phase I (cyp2k, cyp3a) and phase II (gstalpha, gstpi) drug metabolism and drug transporters mdr1 and mrp2.	Rifampin	116-126	ATP binding cassette subfamily C member 2	Homo sapiens	276-280
22559005-3	2012	Here we investigated the effects of exposure of carp (Cyprinus carpio) primary hepatocytes to the human PXR agonist rifampicin (RIF) on expression of target genes involved in phase I (cyp2k, cyp3a) and phase II (gstalpha, gstpi) drug metabolism and drug transporters mdr1 and mrp2.	Rifampin	128-131	nuclear receptor subfamily 1 group I member 2	Homo sapiens	104-107
22559005-3	2012	Here we investigated the effects of exposure of carp (Cyprinus carpio) primary hepatocytes to the human PXR agonist rifampicin (RIF) on expression of target genes involved in phase I (cyp2k, cyp3a) and phase II (gstalpha, gstpi) drug metabolism and drug transporters mdr1 and mrp2.	Rifampin	128-131	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	191-196
22559005-3	2012	Here we investigated the effects of exposure of carp (Cyprinus carpio) primary hepatocytes to the human PXR agonist rifampicin (RIF) on expression of target genes involved in phase I (cyp2k, cyp3a) and phase II (gstalpha, gstpi) drug metabolism and drug transporters mdr1 and mrp2.	Rifampin	128-131	ATP binding cassette subfamily B member 1	Homo sapiens	267-271
22559005-3	2012	Here we investigated the effects of exposure of carp (Cyprinus carpio) primary hepatocytes to the human PXR agonist rifampicin (RIF) on expression of target genes involved in phase I (cyp2k, cyp3a) and phase II (gstalpha, gstpi) drug metabolism and drug transporters mdr1 and mrp2.	Rifampin	128-131	ATP binding cassette subfamily C member 2	Homo sapiens	276-280
22534255-3	2012	OBJECTIVE: The effects of multiple oral doses of ketoconazole (a potent CYP3A4 inhibitor) and multiple oral doses of rifampicin (a potent CYP3A4 inducer) on the pharmacokinetic properties of a single oral dose of gemigliptin were evaluated in fasting healthy male Korean volunteers.	Rifampin	117-127	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	138-144
22499612-8	2012	Rifampicin (600 mg by mouth), a potent OATP inhibitor, significantly reduced the radioactivity excreted into the bile (by 44%) by inhibiting both uptake (by 45%) and subsequent canalicular efflux (by 62%).	Rifampin	0-10	solute carrier organic anion transporter family member 1A2	Homo sapiens	39-43
22314385-5	2012	Walrycin A was as efficient as the reference PXR agonist rifampicin to activate PXR in a transactivation assay at noncytotoxic concentrations.	Rifampin	57-67	nuclear receptor subfamily 1 group I member 2	Homo sapiens	45-48
22314385-5	2012	Walrycin A was as efficient as the reference PXR agonist rifampicin to activate PXR in a transactivation assay at noncytotoxic concentrations.	Rifampin	57-67	nuclear receptor subfamily 1 group I member 2	Homo sapiens	80-83
22207054-1	2012	Human arylacetamide deacetylase (AADAC) is a major esterase responsible for the hydrolysis of clinical drugs such as flutamide, phenacetin, and rifampicin.	Rifampin	144-154	arylacetamide deacetylase	Homo sapiens	6-31
22207054-1	2012	Human arylacetamide deacetylase (AADAC) is a major esterase responsible for the hydrolysis of clinical drugs such as flutamide, phenacetin, and rifampicin.	Rifampin	144-154	arylacetamide deacetylase	Homo sapiens	33-38
22664508-0	2012	Need to confirm isoniazid susceptibility in Xpert MTB/RIF rifampin susceptible cases.	Rifampin	58-66	ras homolog family member F, filopodia associated	Homo sapiens	54-57
22213739-6	2012	Between January 2006 and December 2008, LiPA saved 25.3 and 32.2 days for TB diagnosis and rifampicin resistance of smear-positive samples, respectively.	Rifampin	91-101	lipase A, lysosomal acid type	Homo sapiens	40-44
22126990-5	2012	We evaluated the inductive effect of rifampicin (RIF), a typical human PXR ligand, on the plasma exposure to the four P450 substrate drugs (triazolam/CYP3A4, pioglitazone/CYP2C8, (S)-warfarin/CYP2C9, and (S)-(-)-mephenytoin/CYP2C19) by cassette dosing in PXB mice.	Rifampin	37-47	nuclear receptor subfamily 1 group I member 2	Homo sapiens	71-74
22126990-5	2012	We evaluated the inductive effect of rifampicin (RIF), a typical human PXR ligand, on the plasma exposure to the four P450 substrate drugs (triazolam/CYP3A4, pioglitazone/CYP2C8, (S)-warfarin/CYP2C9, and (S)-(-)-mephenytoin/CYP2C19) by cassette dosing in PXB mice.	Rifampin	49-52	nuclear receptor subfamily 1 group I member 2	Homo sapiens	71-74
22253426-8	2012	Glucocorticoids, including dexamethasone, cortisol, corticosterone, and cortisone all induced the expression of CYP3A7 mRNA, whereas rifampicin, an activator of PXR and an inducer of CYP3A4 in adult liver, had no effect on CYP3A7 expression.	Rifampin	133-143	nuclear receptor subfamily 1, group I, member 2	Mus musculus	161-164
22253426-8	2012	Glucocorticoids, including dexamethasone, cortisol, corticosterone, and cortisone all induced the expression of CYP3A7 mRNA, whereas rifampicin, an activator of PXR and an inducer of CYP3A4 in adult liver, had no effect on CYP3A7 expression.	Rifampin	133-143	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	183-189
22253426-8	2012	Glucocorticoids, including dexamethasone, cortisol, corticosterone, and cortisone all induced the expression of CYP3A7 mRNA, whereas rifampicin, an activator of PXR and an inducer of CYP3A4 in adult liver, had no effect on CYP3A7 expression.	Rifampin	133-143	cytochrome P450 family 3 subfamily A member 7	Homo sapiens	223-229
22281341-7	2012	In the rifampicin group, increases in the expression of mRNA for TNF-alpha, IL-1beta, IL-6, IL-8, and lactoferrin were observed at 6 h postinfection and in the expression of mRNA for TLR2 but not for TLR4 at 12 h postinfection.	Rifampin	7-17	tumor necrosis factor	Bos taurus	65-74
22281341-7	2012	In the rifampicin group, increases in the expression of mRNA for TNF-alpha, IL-1beta, IL-6, IL-8, and lactoferrin were observed at 6 h postinfection and in the expression of mRNA for TLR2 but not for TLR4 at 12 h postinfection.	Rifampin	7-17	interleukin 1 beta	Bos taurus	76-84
22281341-7	2012	In the rifampicin group, increases in the expression of mRNA for TNF-alpha, IL-1beta, IL-6, IL-8, and lactoferrin were observed at 6 h postinfection and in the expression of mRNA for TLR2 but not for TLR4 at 12 h postinfection.	Rifampin	7-17	interferon beta-2	Bos taurus	86-90
22281341-7	2012	In the rifampicin group, increases in the expression of mRNA for TNF-alpha, IL-1beta, IL-6, IL-8, and lactoferrin were observed at 6 h postinfection and in the expression of mRNA for TLR2 but not for TLR4 at 12 h postinfection.	Rifampin	7-17	C-X-C motif chemokine ligand 8	Bos taurus	92-96
22281341-7	2012	In the rifampicin group, increases in the expression of mRNA for TNF-alpha, IL-1beta, IL-6, IL-8, and lactoferrin were observed at 6 h postinfection and in the expression of mRNA for TLR2 but not for TLR4 at 12 h postinfection.	Rifampin	7-17	lactotransferrin	Bos taurus	102-113
22281341-7	2012	In the rifampicin group, increases in the expression of mRNA for TNF-alpha, IL-1beta, IL-6, IL-8, and lactoferrin were observed at 6 h postinfection and in the expression of mRNA for TLR2 but not for TLR4 at 12 h postinfection.	Rifampin	7-17	toll like receptor 2	Bos taurus	183-187
22281341-7	2012	In the rifampicin group, increases in the expression of mRNA for TNF-alpha, IL-1beta, IL-6, IL-8, and lactoferrin were observed at 6 h postinfection and in the expression of mRNA for TLR2 but not for TLR4 at 12 h postinfection.	Rifampin	7-17	toll like receptor 4	Bos taurus	200-204
22178124-9	2012	Among them, bufalin and cinobufagin significantly promoted the CYP3A4 enzyme activity, mRNA and protein levels, with the maximal induction challenging or exceeding that of the induction by rifampicin, indicating that they might play a critical role in CYP3A4 enzyme-inducing effects of SBP.	Rifampin	189-199	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	63-69
22687401-3	2012	The induction of CALUX in HPL-A3 by hPXR activators, including rifampicin, occurred in time- and concentration-dependent fashions, whereas no such induction was observed using rat/mouse PXR activators, such as pregnenolone-16alpha-carbonitrile and dexamethasone.	Rifampin	63-73	galectin 1	Homo sapiens	26-29
22687401-3	2012	The induction of CALUX in HPL-A3 by hPXR activators, including rifampicin, occurred in time- and concentration-dependent fashions, whereas no such induction was observed using rat/mouse PXR activators, such as pregnenolone-16alpha-carbonitrile and dexamethasone.	Rifampin	63-73	nuclear receptor subfamily 1 group I member 2	Homo sapiens	36-40
22687401-3	2012	The induction of CALUX in HPL-A3 by hPXR activators, including rifampicin, occurred in time- and concentration-dependent fashions, whereas no such induction was observed using rat/mouse PXR activators, such as pregnenolone-16alpha-carbonitrile and dexamethasone.	Rifampin	63-73	nuclear receptor subfamily 1, group I, member 2	Mus musculus	37-40
22076448-6	2012	The CYP3A4 reporter activity enhanced by overexpression of human PXR was further increased by treatment with PAHs and TCDD as well as by treatment with rifampicin.	Rifampin	152-162	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	4-10
22076448-6	2012	The CYP3A4 reporter activity enhanced by overexpression of human PXR was further increased by treatment with PAHs and TCDD as well as by treatment with rifampicin.	Rifampin	152-162	nuclear receptor subfamily 1 group I member 2	Homo sapiens	65-68
22504320-3	2012	In this study, we have hypothesized that enhanced amyloid-beta (Abeta) clearance from the brain across the blood-brain barrier (BBB) of wild-type mice treated with rifampicin or caffeine is caused by both drugs potential to upregulate low-density lipoprotein receptor related protein-1 (LRP1) and/or P-glycoprotein (P-gp) at the BBB.	Rifampin	164-174	low density lipoprotein receptor-related protein 1	Mus musculus	235-285
22504320-3	2012	In this study, we have hypothesized that enhanced amyloid-beta (Abeta) clearance from the brain across the blood-brain barrier (BBB) of wild-type mice treated with rifampicin or caffeine is caused by both drugs potential to upregulate low-density lipoprotein receptor related protein-1 (LRP1) and/or P-glycoprotein (P-gp) at the BBB.	Rifampin	164-174	low density lipoprotein receptor-related protein 1	Mus musculus	287-291
22504320-3	2012	In this study, we have hypothesized that enhanced amyloid-beta (Abeta) clearance from the brain across the blood-brain barrier (BBB) of wild-type mice treated with rifampicin or caffeine is caused by both drugs potential to upregulate low-density lipoprotein receptor related protein-1 (LRP1) and/or P-glycoprotein (P-gp) at the BBB.	Rifampin	164-174	phosphoglycolate phosphatase	Mus musculus	300-314
22504320-3	2012	In this study, we have hypothesized that enhanced amyloid-beta (Abeta) clearance from the brain across the blood-brain barrier (BBB) of wild-type mice treated with rifampicin or caffeine is caused by both drugs potential to upregulate low-density lipoprotein receptor related protein-1 (LRP1) and/or P-glycoprotein (P-gp) at the BBB.	Rifampin	164-174	phosphoglycolate phosphatase	Mus musculus	316-320
22504320-4	2012	Expression studies of LRP1 and P-gp in brain endothelial cells and isolated mice brain microvessels following treatment with rifampicin or caffeine demonstrated both drugs as P-gp inducers, and only rifampicin as an LRP1 inducer.	Rifampin	125-135	low density lipoprotein receptor-related protein 1	Mus musculus	22-26
22504320-4	2012	Expression studies of LRP1 and P-gp in brain endothelial cells and isolated mice brain microvessels following treatment with rifampicin or caffeine demonstrated both drugs as P-gp inducers, and only rifampicin as an LRP1 inducer.	Rifampin	125-135	phosphoglycolate phosphatase	Mus musculus	31-35
22467028-8	2012	Quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis showed that the human-selective ligand, rifampicin induced Cyp3a11 and Carboxylesterase 6 (Ces6) mRNA expression in liver and intestine, whereas the murine-selective ligand, pregnenolone-16-carbonitrile did not.	Rifampin	119-129	carboxylesterase 4A	Homo sapiens	150-168
22467028-8	2012	Quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis showed that the human-selective ligand, rifampicin induced Cyp3a11 and Carboxylesterase 6 (Ces6) mRNA expression in liver and intestine, whereas the murine-selective ligand, pregnenolone-16-carbonitrile did not.	Rifampin	119-129	carboxylesterase 4A	Homo sapiens	170-174
22363234-0	2012	Fucoxanthin attenuates rifampin-induced cytochrome P450 3A4 (CYP3A4) and multiple drug resistance 1 (MDR1) gene expression through pregnane X receptor (PXR)-mediated pathways in human hepatoma HepG2 and colon adenocarcinoma LS174T cells.	Rifampin	23-31	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	40-59
22363234-0	2012	Fucoxanthin attenuates rifampin-induced cytochrome P450 3A4 (CYP3A4) and multiple drug resistance 1 (MDR1) gene expression through pregnane X receptor (PXR)-mediated pathways in human hepatoma HepG2 and colon adenocarcinoma LS174T cells.	Rifampin	23-31	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	61-67
22363234-0	2012	Fucoxanthin attenuates rifampin-induced cytochrome P450 3A4 (CYP3A4) and multiple drug resistance 1 (MDR1) gene expression through pregnane X receptor (PXR)-mediated pathways in human hepatoma HepG2 and colon adenocarcinoma LS174T cells.	Rifampin	23-31	ATP binding cassette subfamily B member 1	Homo sapiens	73-99
22363234-0	2012	Fucoxanthin attenuates rifampin-induced cytochrome P450 3A4 (CYP3A4) and multiple drug resistance 1 (MDR1) gene expression through pregnane X receptor (PXR)-mediated pathways in human hepatoma HepG2 and colon adenocarcinoma LS174T cells.	Rifampin	23-31	ATP binding cassette subfamily B member 1	Homo sapiens	101-105
22363234-0	2012	Fucoxanthin attenuates rifampin-induced cytochrome P450 3A4 (CYP3A4) and multiple drug resistance 1 (MDR1) gene expression through pregnane X receptor (PXR)-mediated pathways in human hepatoma HepG2 and colon adenocarcinoma LS174T cells.	Rifampin	23-31	nuclear receptor subfamily 1 group I member 2	Homo sapiens	131-150
22363234-0	2012	Fucoxanthin attenuates rifampin-induced cytochrome P450 3A4 (CYP3A4) and multiple drug resistance 1 (MDR1) gene expression through pregnane X receptor (PXR)-mediated pathways in human hepatoma HepG2 and colon adenocarcinoma LS174T cells.	Rifampin	23-31	nuclear receptor subfamily 1 group I member 2	Homo sapiens	152-155
21567510-1	2012	This article studied the possible effect of rifampicin (RIF), an inhibitor of organic anion transporting polypeptide (Oatp), on the pharmacokinetics of salvianolic acid B (SAB) in rats.	Rifampin	44-54	SH3-domain binding protein 5	Rattus norvegicus	172-175
21567510-1	2012	This article studied the possible effect of rifampicin (RIF), an inhibitor of organic anion transporting polypeptide (Oatp), on the pharmacokinetics of salvianolic acid B (SAB) in rats.	Rifampin	56-59	SH3-domain binding protein 5	Rattus norvegicus	172-175
21567510-5	2012	These results suggested that pretreatment with rifampicin prior to SAB administration could decrease significantly the total and bile elimination of SAB and alter its pharmacokinetic profiles.	Rifampin	47-57	SH3-domain binding protein 5	Rattus norvegicus	67-70
21567510-5	2012	These results suggested that pretreatment with rifampicin prior to SAB administration could decrease significantly the total and bile elimination of SAB and alter its pharmacokinetic profiles.	Rifampin	47-57	SH3-domain binding protein 5	Rattus norvegicus	149-152
21567510-6	2012	The influence of rifampicin on the pharmacokinetics of SAB may be attributed to the inhibition of Oatp-mediated influx.	Rifampin	17-27	SH3-domain binding protein 5	Rattus norvegicus	55-58
22970271-10	2012	For rifampicin resistance detection, sensitivity of MTB/RIF was 100% (95% CI 61.0-100.0) (6/6); specificity was 91.0% (95% CI 76.4-96.9) (30/33); the positive predictive value was 66.7% (95% CI 35.4-87.9) (6/9); and the negative predictive value was 100% (95% CI 88.7 -100.0) (30/30).	Rifampin	4-14	ras homolog family member F, filopodia associated	Homo sapiens	56-59
22629310-3	2012	In this study, using 2-dimensional gel electrophoresis (2-DE) and mass spectrometry (MS), we discovered that 26S protease regulatory subunit 7 (MSS1) was decreased in rifampicin-treated microglia.	Rifampin	167-177	proteasome 26S subunit, ATPase 2	Homo sapiens	109-142
22629310-3	2012	In this study, using 2-dimensional gel electrophoresis (2-DE) and mass spectrometry (MS), we discovered that 26S protease regulatory subunit 7 (MSS1) was decreased in rifampicin-treated microglia.	Rifampin	167-177	proteasome 26S subunit, ATPase 2	Homo sapiens	144-148
22629310-4	2012	Western blot analysis verified the downregulation of MSS1 expression by rifampicin.	Rifampin	72-82	proteasome 26S subunit, ATPase 2	Homo sapiens	53-57
22864345-4	2012	Phenyl analogue menaquinone-3 was as active as the known SXR ligand rifampicin.	Rifampin	68-78	nuclear receptor subfamily 1 group I member 2	Homo sapiens	57-60
21930886-5	2011	Rifampin significantly increased the secretion of interleukin 8 (IL-8) in both untreated cells (P &lt; 0.001) and cytokine-treated cells (P &lt; 0.006).	Rifampin	0-8	C-X-C motif chemokine ligand 8	Homo sapiens	50-63
21930886-5	2011	Rifampin significantly increased the secretion of interleukin 8 (IL-8) in both untreated cells (P &lt; 0.001) and cytokine-treated cells (P &lt; 0.006).	Rifampin	0-8	C-X-C motif chemokine ligand 8	Homo sapiens	65-69
21930886-6	2011	An array screening assay revealed that rifampin stimulated the production of IL-1beta and gamma interferon-induced protein-10 (IP-10) in untreated cells and increased the secretion of RANTES in cytokine-treated cells.	Rifampin	39-47	interleukin 1 beta	Homo sapiens	77-85
21930886-6	2011	An array screening assay revealed that rifampin stimulated the production of IL-1beta and gamma interferon-induced protein-10 (IP-10) in untreated cells and increased the secretion of RANTES in cytokine-treated cells.	Rifampin	39-47	C-X-C motif chemokine ligand 10	Homo sapiens	127-132
21930886-6	2011	An array screening assay revealed that rifampin stimulated the production of IL-1beta and gamma interferon-induced protein-10 (IP-10) in untreated cells and increased the secretion of RANTES in cytokine-treated cells.	Rifampin	39-47	C-C motif chemokine ligand 5	Homo sapiens	184-190
22005110-1	2011	Xpert   MTB/RIF offers new and important possibilities for the diagnosis of sputum smear-negative tuberculosis (TB) and/or rifampicin (RMP) resistance, and many are encouraging rapid and widespread implementation.	Rifampin	123-133	ras homolog family member F, filopodia associated	Homo sapiens	12-15
22005110-1	2011	Xpert   MTB/RIF offers new and important possibilities for the diagnosis of sputum smear-negative tuberculosis (TB) and/or rifampicin (RMP) resistance, and many are encouraging rapid and widespread implementation.	Rifampin	135-138	ras homolog family member F, filopodia associated	Homo sapiens	12-15
22115371-10	2011	In addition, rifampicin, a P-gp inducer, resulted in some limited reduction in Salmonella and Klebsiella attachment only.	Rifampin	13-23	ATP binding cassette subfamily B member 1	Homo sapiens	27-31
21871880-8	2011	Induction of CYP3A4 mRNA by rifampicin was about 1.5-2.5 fold (clones 2, 4, 6, 7) and it was not significantly different from CYP3A4 mRNA induction in parent HepG2.	Rifampin	28-38	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	13-19
21871880-9	2011	The basal expression of CYP3A4 protein was increased in all clones, but rifampicin-induced expression of CYP3A4 protein was in all clones lower than in parent HepG2.	Rifampin	72-82	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	105-111
21764778-2	2011	Given our finding that PXR activation by rifampicin (RIF) represses the estrogen sulfotransferase (SULT1E1) gene in human primary hepatocytes and hepatocellular carcinoma Huh7 cells, here we have investigated the molecular mechanism of this repression.	Rifampin	41-51	nuclear receptor subfamily 1 group I member 2	Homo sapiens	23-26
21764778-2	2011	Given our finding that PXR activation by rifampicin (RIF) represses the estrogen sulfotransferase (SULT1E1) gene in human primary hepatocytes and hepatocellular carcinoma Huh7 cells, here we have investigated the molecular mechanism of this repression.	Rifampin	41-51	sulfotransferase family 1E member 1	Homo sapiens	99-106
21764778-2	2011	Given our finding that PXR activation by rifampicin (RIF) represses the estrogen sulfotransferase (SULT1E1) gene in human primary hepatocytes and hepatocellular carcinoma Huh7 cells, here we have investigated the molecular mechanism of this repression.	Rifampin	53-56	nuclear receptor subfamily 1 group I member 2	Homo sapiens	23-26
21764778-2	2011	Given our finding that PXR activation by rifampicin (RIF) represses the estrogen sulfotransferase (SULT1E1) gene in human primary hepatocytes and hepatocellular carcinoma Huh7 cells, here we have investigated the molecular mechanism of this repression.	Rifampin	53-56	sulfotransferase family 1E member 1	Homo sapiens	99-106
22310326-10	2012	When rifampicin-treated primary human hepatocyte cultures were exposed to arsenite concentrations as low as 50 nM, CYP3A mRNA was decreased.	Rifampin	5-15	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	115-120
22205755-7	2012	Formation of 4beta,25(OH)(2)D(3) in primary human hepatocytes was induced by rifampin and inhibited by CYP3A4-specific inhibitors.	Rifampin	77-85	iodothyronine deiodinase 3	Homo sapiens	28-32
22205755-8	2012	Short-term treatment of healthy volunteers (n = 6) with rifampin selectively induced CYP3A4-dependent 4beta,25(OH)(2)D(3), but not CYP24A1-dependent 24R,25-dihydroxyvitamin D(3) formation, and altered systemic mineral homeostasis.	Rifampin	56-64	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	85-91
22205755-8	2012	Short-term treatment of healthy volunteers (n = 6) with rifampin selectively induced CYP3A4-dependent 4beta,25(OH)(2)D(3), but not CYP24A1-dependent 24R,25-dihydroxyvitamin D(3) formation, and altered systemic mineral homeostasis.	Rifampin	56-64	iodothyronine deiodinase 3	Homo sapiens	117-121
22205755-8	2012	Short-term treatment of healthy volunteers (n = 6) with rifampin selectively induced CYP3A4-dependent 4beta,25(OH)(2)D(3), but not CYP24A1-dependent 24R,25-dihydroxyvitamin D(3) formation, and altered systemic mineral homeostasis.	Rifampin	56-64	iodothyronine deiodinase 3	Homo sapiens	173-177
22229830-7	2012	CONCLUSIONS: Both rifampicin and plasmapheresis represent important therapeutic options of acute cholestatic attacks in patients with BRIC.	Rifampin	18-28	ATPase phospholipid transporting 8B1	Homo sapiens	134-138
22159698-6	2012	In the presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin as an inducer for CYP1A and rifampin as an inducer for CYP3A, As(III) decreased the enzymatic activity of the four P450s more than it decreased their mRNA or protein expression levels.	Rifampin	83-91	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	110-115
22236925-1	2012	A study was carried out to establish the relative contribution of human cytochrome P450 (CYP450) enzymes in the metabolism of rifampicin (RMP), rifapentine (RPT) and rifabutin (RFB).	Rifampin	126-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-87
22236925-1	2012	A study was carried out to establish the relative contribution of human cytochrome P450 (CYP450) enzymes in the metabolism of rifampicin (RMP), rifapentine (RPT) and rifabutin (RFB).	Rifampin	126-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-95
22236925-1	2012	A study was carried out to establish the relative contribution of human cytochrome P450 (CYP450) enzymes in the metabolism of rifampicin (RMP), rifapentine (RPT) and rifabutin (RFB).	Rifampin	138-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-87
22236925-1	2012	A study was carried out to establish the relative contribution of human cytochrome P450 (CYP450) enzymes in the metabolism of rifampicin (RMP), rifapentine (RPT) and rifabutin (RFB).	Rifampin	138-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	89-95
22291651-6	2012	In this study, we studied the effect of rifampicin, a prototype PXR ligand, on SHP mRNA, and protein expression in three primary human hepatocyte cultures.	Rifampin	40-50	nuclear receptor subfamily 0 group B member 2	Homo sapiens	79-82
22185585-0	2012	Rifampicin-independent interactions between the pregnane X receptor ligand binding domain and peptide fragments of coactivator and corepressor proteins.	Rifampin	0-10	nuclear receptor subfamily 1 group I member 2	Homo sapiens	48-67
22185585-4	2012	In this work, steady-state total internal reflection fluorescence microscopy (TIRFM) and total internal reflection with fluorescence recovery after photobleaching were used to measure the thermodynamics and kinetics of the interaction between the PXR ligand binding domain and a peptide fragment of the steroid receptor coactivator-1 (SRC-1) in the presence and absence of the established PXR agonist, rifampicin.	Rifampin	402-412	nuclear receptor subfamily 1 group I member 2	Homo sapiens	247-250
22185585-7	2012	An equilibrium dissociation constant of ~70 muM was obtained for SMRT in the presence and absence of rifampicin.	Rifampin	101-111	nuclear receptor corepressor 2	Homo sapiens	65-69
22333269-0	2012	Lower expression of HNF4alpha and PGC1alpha might impair rifampicin-mediated CYP3A4 induction under conditions where PXR is overexpressed in human fetal liver cells.	Rifampin	57-67	hepatocyte nuclear factor 4 alpha	Homo sapiens	20-29
22333269-0	2012	Lower expression of HNF4alpha and PGC1alpha might impair rifampicin-mediated CYP3A4 induction under conditions where PXR is overexpressed in human fetal liver cells.	Rifampin	57-67	PPARG coactivator 1 alpha	Homo sapiens	34-43
22333269-0	2012	Lower expression of HNF4alpha and PGC1alpha might impair rifampicin-mediated CYP3A4 induction under conditions where PXR is overexpressed in human fetal liver cells.	Rifampin	57-67	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	77-83
22333269-0	2012	Lower expression of HNF4alpha and PGC1alpha might impair rifampicin-mediated CYP3A4 induction under conditions where PXR is overexpressed in human fetal liver cells.	Rifampin	57-67	nuclear receptor subfamily 1 group I member 2	Homo sapiens	117-120
22333269-2	2012	CYP3A4 was induced by rifampicin (RIF), mifepristone (RU486), clotrimazole (CTZ), and dexamethasone (DEX) in HepG2 cells, while these PXR ligands with the exception of DEX did not induce CYP3A4 mRNA expression in HFL cells.	Rifampin	22-32	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
22333269-2	2012	CYP3A4 was induced by rifampicin (RIF), mifepristone (RU486), clotrimazole (CTZ), and dexamethasone (DEX) in HepG2 cells, while these PXR ligands with the exception of DEX did not induce CYP3A4 mRNA expression in HFL cells.	Rifampin	34-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
22333269-10	2012	These results suggested that lower expression of HNF4alpha and PGC1alpha may impair RIF-mediated CYP3A4 induction under conditions of PXR overexpression in HFL cells.	Rifampin	84-87	hepatocyte nuclear factor 4 alpha	Homo sapiens	49-58
22333269-10	2012	These results suggested that lower expression of HNF4alpha and PGC1alpha may impair RIF-mediated CYP3A4 induction under conditions of PXR overexpression in HFL cells.	Rifampin	84-87	PPARG coactivator 1 alpha	Homo sapiens	63-72
22333269-10	2012	These results suggested that lower expression of HNF4alpha and PGC1alpha may impair RIF-mediated CYP3A4 induction under conditions of PXR overexpression in HFL cells.	Rifampin	84-87	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	97-103
22333269-10	2012	These results suggested that lower expression of HNF4alpha and PGC1alpha may impair RIF-mediated CYP3A4 induction under conditions of PXR overexpression in HFL cells.	Rifampin	84-87	nuclear receptor subfamily 1 group I member 2	Homo sapiens	134-137
22504320-8	2012	In conclusion, our results demonstrated the upregulation of LRP1 and P-gp at the BBB by rifampicin and caffeine enhanced brain Abeta clearance, and this effect could explain, at least in part, the protective effect of rifampicin and caffeine against AD.	Rifampin	88-98	low density lipoprotein receptor-related protein 1	Mus musculus	60-64
22504320-8	2012	In conclusion, our results demonstrated the upregulation of LRP1 and P-gp at the BBB by rifampicin and caffeine enhanced brain Abeta clearance, and this effect could explain, at least in part, the protective effect of rifampicin and caffeine against AD.	Rifampin	88-98	phosphoglycolate phosphatase	Mus musculus	69-73
22504320-8	2012	In conclusion, our results demonstrated the upregulation of LRP1 and P-gp at the BBB by rifampicin and caffeine enhanced brain Abeta clearance, and this effect could explain, at least in part, the protective effect of rifampicin and caffeine against AD.	Rifampin	218-228	low density lipoprotein receptor-related protein 1	Mus musculus	60-64
22504320-8	2012	In conclusion, our results demonstrated the upregulation of LRP1 and P-gp at the BBB by rifampicin and caffeine enhanced brain Abeta clearance, and this effect could explain, at least in part, the protective effect of rifampicin and caffeine against AD.	Rifampin	218-228	phosphoglycolate phosphatase	Mus musculus	69-73
22007302-3	2012	Recently the WHO endorsed Xpert MTB/RIF, a highly sensitive, real-time PCR assay for Mycobacterium tuberculosis that simultaneously detects rifampicin resistance directly from sputum and provides results within 100 minutes.	Rifampin	140-150	ras homolog family member F, filopodia associated	Homo sapiens	36-39
22363234-3	2012	In this study, we determined whether fucoxanthin could overcome drug resistance through attenuation of rifampin-induced CYP3A4 and MDR1 gene expression by PXR-mediated pathways in HepG2 hepatoma cells.	Rifampin	103-111	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	120-126
22363234-3	2012	In this study, we determined whether fucoxanthin could overcome drug resistance through attenuation of rifampin-induced CYP3A4 and MDR1 gene expression by PXR-mediated pathways in HepG2 hepatoma cells.	Rifampin	103-111	ATP binding cassette subfamily B member 1	Homo sapiens	131-135
22363234-3	2012	In this study, we determined whether fucoxanthin could overcome drug resistance through attenuation of rifampin-induced CYP3A4 and MDR1 gene expression by PXR-mediated pathways in HepG2 hepatoma cells.	Rifampin	103-111	nuclear receptor subfamily 1 group I member 2	Homo sapiens	155-158
22363234-4	2012	We found that fucoxanthin (1-10 muM) significantly attenuated rifampin (20 muM)-induced CYP3A4, MDR1 mRNA and CYP3A4 protein expression at 24 h of incubation.	Rifampin	62-70	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	88-94
22363234-4	2012	We found that fucoxanthin (1-10 muM) significantly attenuated rifampin (20 muM)-induced CYP3A4, MDR1 mRNA and CYP3A4 protein expression at 24 h of incubation.	Rifampin	62-70	ATP binding cassette subfamily B member 1	Homo sapiens	96-100
22363234-4	2012	We found that fucoxanthin (1-10 muM) significantly attenuated rifampin (20 muM)-induced CYP3A4, MDR1 mRNA and CYP3A4 protein expression at 24 h of incubation.	Rifampin	62-70	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	110-116
22363234-8	2012	Thus, fucoxanthin can decrease rifampin-induced CYP3A4 and MDR1 expression through attenuation of PXR-mediated CYP3A4 promoter activation and interaction between PXR and co-activator.	Rifampin	31-39	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	48-54
22363234-8	2012	Thus, fucoxanthin can decrease rifampin-induced CYP3A4 and MDR1 expression through attenuation of PXR-mediated CYP3A4 promoter activation and interaction between PXR and co-activator.	Rifampin	31-39	ATP binding cassette subfamily B member 1	Homo sapiens	59-63
22363234-8	2012	Thus, fucoxanthin can decrease rifampin-induced CYP3A4 and MDR1 expression through attenuation of PXR-mediated CYP3A4 promoter activation and interaction between PXR and co-activator.	Rifampin	31-39	nuclear receptor subfamily 1 group I member 2	Homo sapiens	98-101
22363234-8	2012	Thus, fucoxanthin can decrease rifampin-induced CYP3A4 and MDR1 expression through attenuation of PXR-mediated CYP3A4 promoter activation and interaction between PXR and co-activator.	Rifampin	31-39	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	111-117
22363234-8	2012	Thus, fucoxanthin can decrease rifampin-induced CYP3A4 and MDR1 expression through attenuation of PXR-mediated CYP3A4 promoter activation and interaction between PXR and co-activator.	Rifampin	31-39	nuclear receptor subfamily 1 group I member 2	Homo sapiens	162-165
21998292-9	2012	Quantification of the transcripts by RNA-Seq and real time quantitative PCR revealed that the CYP3A4 transcript with shorter 3"-UTR was preferentially expressed in developed livers, differentiated hepatocytes, and in rifampicin- and phenobarbital-induced hepatocytes.	Rifampin	217-227	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	94-100
23185139-1	2012	BACKGROUND: The Xpert MTB/RIF test enables rapid detection of tuberculosis (TB) and rifampicin resistance.	Rifampin	84-94	metallothionein 1J, pseudogene	Homo sapiens	22-25
23185139-1	2012	BACKGROUND: The Xpert MTB/RIF test enables rapid detection of tuberculosis (TB) and rifampicin resistance.	Rifampin	84-94	ras homolog family member F, filopodia associated	Homo sapiens	26-29
23236531-5	2012	This study examined the effect of MDT components on host lipid metabolism in vitro, and the outcome of rifampicin, dapsone and clofazimine treatment on ADRP and HSL expression in THP-1 cells.	Rifampin	103-113	perilipin 2	Homo sapiens	152-156
23236531-5	2012	This study examined the effect of MDT components on host lipid metabolism in vitro, and the outcome of rifampicin, dapsone and clofazimine treatment on ADRP and HSL expression in THP-1 cells.	Rifampin	103-113	lipase E, hormone sensitive type	Homo sapiens	161-164
22629310-8	2012	Taken together, our findings suggested that rifampicin inhibited microglial inflammation by suppressing MSS1 protein production.	Rifampin	44-54	proteasome 26S subunit, ATPase 2	Homo sapiens	104-108
21856291-0	2011	Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine.	Rifampin	80-90	arylacetamide deacetylase	Homo sapiens	6-31
22087865-13	2011	Concomitant administration of bortezomib with strong CYP3A4 inducers such as rifampicin is not recommended, as it may result in a reduction of the clinical effect, whereas concomitant administration of weak CYP3A4 inducers such as dexamethasone does not affect the pharmacological profile of bortezomib.	Rifampin	77-87	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	53-59
21930825-3	2011	Statistically significant induction of CYP1A2 (2.1-, 2.9-, and 2.2-fold), CYP2B6 (1.8-, 2.4-, and 4-fold), and CYP2C9 (1.3-, 1.8-, and 2.6-fold) was observed after NFV, RTV, or RIF treatment, respectively (as expected, CYP2D6 was not induced).	Rifampin	177-180	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	39-45
21930825-3	2011	Statistically significant induction of CYP1A2 (2.1-, 2.9-, and 2.2-fold), CYP2B6 (1.8-, 2.4-, and 4-fold), and CYP2C9 (1.3-, 1.8-, and 2.6-fold) was observed after NFV, RTV, or RIF treatment, respectively (as expected, CYP2D6 was not induced).	Rifampin	177-180	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	74-80
21930825-3	2011	Statistically significant induction of CYP1A2 (2.1-, 2.9-, and 2.2-fold), CYP2B6 (1.8-, 2.4-, and 4-fold), and CYP2C9 (1.3-, 1.8-, and 2.6-fold) was observed after NFV, RTV, or RIF treatment, respectively (as expected, CYP2D6 was not induced).	Rifampin	177-180	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	111-117
20623161-4	2011	The patient received anti-tuberculosis therapy including rifampicin, a potent CYP3A4/5 inducer.	Rifampin	57-67	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	78-84
20623161-5	2011	After introduction of rifampicin-based treatment, the patient experienced tumour progression, leaving questionable the potential pharmacokinetic interaction between rifampicin and temsirolimus, a substrate for CYP3A4.	Rifampin	22-32	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	210-216
20623161-5	2011	After introduction of rifampicin-based treatment, the patient experienced tumour progression, leaving questionable the potential pharmacokinetic interaction between rifampicin and temsirolimus, a substrate for CYP3A4.	Rifampin	165-175	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	210-216
22100163-3	2011	In mice, the ABL family tyrosine kinase inhibitor, imatinib (Gleevec), when administered prophylactically or therapeutically, reduced both the number of granulomatous lesions and bacterial load in infected organs and was also effective against a rifampicin-resistant strain.	Rifampin	246-256	c-abl oncogene 1, non-receptor tyrosine kinase	Mus musculus	13-16
22139693-8	2011	These results showed that Labrasol and Pluronic F68 might inhibit the function of P-gp in the intestine, thereby increasing intestinal absorption and changing the pharmacokinetic parameters of rifampicin.	Rifampin	193-203	phosphoglycolate phosphatase	Rattus norvegicus	82-86
22000295-3	2011	METHODS: PXR-knockdown experiments using RNAi showed that the cell cycle phase arrest mediated by rifampicin based on activation of PXR.	Rifampin	98-108	nuclear receptor subfamily 1 group I member 2	Homo sapiens	9-12
22000295-3	2011	METHODS: PXR-knockdown experiments using RNAi showed that the cell cycle phase arrest mediated by rifampicin based on activation of PXR.	Rifampin	98-108	nuclear receptor subfamily 1 group I member 2	Homo sapiens	132-135
22000295-5	2011	Retinoid X receptor alpha (RXRalpha) expression level in cells is another key factor for cell cycle phase arrest mediated by rifampicin.	Rifampin	125-135	retinoid X receptor alpha	Homo sapiens	0-25
22000295-5	2011	Retinoid X receptor alpha (RXRalpha) expression level in cells is another key factor for cell cycle phase arrest mediated by rifampicin.	Rifampin	125-135	retinoid X receptor alpha	Homo sapiens	27-35
22000295-6	2011	Both over expression and lacking expression of RXRalpha in cell reduced the cell arrest efficiency mediated by rifampicin.	Rifampin	111-121	retinoid X receptor alpha	Homo sapiens	47-55
22000295-9	2011	Competitive bind of rifampicin-activated PXR with RXRalpha is one main reason to arrest cell cycle phase through inhibiting combination of RXRalpha with other partners.	Rifampin	20-30	nuclear receptor subfamily 1 group I member 2	Homo sapiens	41-44
22000295-9	2011	Competitive bind of rifampicin-activated PXR with RXRalpha is one main reason to arrest cell cycle phase through inhibiting combination of RXRalpha with other partners.	Rifampin	20-30	retinoid X receptor alpha	Homo sapiens	50-58
22000295-9	2011	Competitive bind of rifampicin-activated PXR with RXRalpha is one main reason to arrest cell cycle phase through inhibiting combination of RXRalpha with other partners.	Rifampin	20-30	retinoid X receptor alpha	Homo sapiens	139-147
22000295-10	2011	Rifampicin could promote cell growth rate when RXRalpha expressed more excessively than PXR in cells.	Rifampin	0-10	retinoid X receptor alpha	Homo sapiens	47-55
22000295-10	2011	Rifampicin could promote cell growth rate when RXRalpha expressed more excessively than PXR in cells.	Rifampin	0-10	nuclear receptor subfamily 1 group I member 2	Homo sapiens	88-91
21771933-1	2011	Rifampin is a potent inducer of CYP3A4 in vitro and precipitates numerous drug-drug interactions (DDIs) when coadministered with CYP3A4 substrates.	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	32-38
21771933-1	2011	Rifampin is a potent inducer of CYP3A4 in vitro and precipitates numerous drug-drug interactions (DDIs) when coadministered with CYP3A4 substrates.	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	129-135
22010421-6	2011	PXR-ligands include a wide variety of pharmaceutical agents, such as antiepileptic drugs, taxol, rifampicin, and human immunodeficiency virus protease inhibitors such as ritonavir and saquinavir.	Rifampin	97-107	nuclear receptor subfamily 1 group I member 2	Homo sapiens	0-3
22499612-9	2012	(15R)-(11)C-TIC is an in vitro substrate of OATP1B1 and OATP1B3, and clinically relevant concentrations of rifampicin inhibited uptake by OATP1B1 and OATP1B3.	Rifampin	107-117	solute carrier organic anion transporter family member 1B1	Homo sapiens	138-145
22499612-9	2012	(15R)-(11)C-TIC is an in vitro substrate of OATP1B1 and OATP1B3, and clinically relevant concentrations of rifampicin inhibited uptake by OATP1B1 and OATP1B3.	Rifampin	107-117	solute carrier organic anion transporter family member 1B3	Homo sapiens	150-157
21555117-7	2011	Moreover, rifampicin suppressed LPS-induced nuclear factor-kappa B activation by blocking the degradation of the inhibitor of the nuclear transcription factor NF-kappa B.	Rifampin	10-20	nuclear factor kappa B subunit 1	Homo sapiens	159-169
21709081-0	2011	The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications.	Rifampin	104-112	solute carrier organic anion transporter family member 1B1	Homo sapiens	4-11
21709081-3	2011	The objectives were to identify genetic polymorphisms of drug transporters and the transcriptional regulators pregnane X receptor (PXR) and constitutive androstane receptor (CAR) with an impact on rifampin pharmacokinetics in South Africans.	Rifampin	197-205	nuclear receptor subfamily 1 group I member 2	Homo sapiens	110-129
21709081-3	2011	The objectives were to identify genetic polymorphisms of drug transporters and the transcriptional regulators pregnane X receptor (PXR) and constitutive androstane receptor (CAR) with an impact on rifampin pharmacokinetics in South Africans.	Rifampin	197-205	nuclear receptor subfamily 1 group I member 2	Homo sapiens	131-134
21709081-3	2011	The objectives were to identify genetic polymorphisms of drug transporters and the transcriptional regulators pregnane X receptor (PXR) and constitutive androstane receptor (CAR) with an impact on rifampin pharmacokinetics in South Africans.	Rifampin	197-205	nuclear receptor subfamily 1 group I member 3	Homo sapiens	140-172
21709081-3	2011	The objectives were to identify genetic polymorphisms of drug transporters and the transcriptional regulators pregnane X receptor (PXR) and constitutive androstane receptor (CAR) with an impact on rifampin pharmacokinetics in South Africans.	Rifampin	197-205	nuclear receptor subfamily 1 group I member 3	Homo sapiens	174-177
21709081-11	2011	SLCO1B1 rs4149032 was present in most patients and was associated with substantially reduced rifampin exposure.	Rifampin	93-101	solute carrier organic anion transporter family member 1B1	Homo sapiens	0-7
21605667-6	2011	Presence of the known OATP inhibitor rifampicin (25 muM) significantly (p&lt;0.01) decreased the accumulation of estrone-3-sulfate and E(2)-17beta-G to 48% and 70% of the control value, respectively, while no significant effect on digoxin accumulation was observed.	Rifampin	37-47	solute carrier organic anion transporter family member 1A2	Homo sapiens	22-26
21651615-6	2011	Similar maximum % inhibition and area under the % inhibition-time effect curve over 24 h for DPP-4 activity were observed when saxagliptin was administered alone or with rifampicin.	Rifampin	170-180	dipeptidyl peptidase 4	Homo sapiens	93-98
21561094-4	2011	Phenyl analogue menaquinone-3 was as active as the known SXR ligand rifampicin.	Rifampin	68-78	nuclear receptor subfamily 1 group I member 2	Homo sapiens	57-60
21746940-9	2011	Furthermore, 3 (33%) of 10 independently isolated VISA strains established from the heterogeneous subpopulations of Mu3graR were found to possess rpoB mutations with or without an accompanying rifampin-resistance phenotype.	Rifampin	193-201	mitochondrial antiviral signaling protein	Homo sapiens	50-54
21958145-0	2011	Xpert  MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance.	Rifampin	122-132	ras homolog family member F, filopodia associated	Homo sapiens	11-14
21958145-3	2011	The Xpert( ) MTB/RIF assay is a rapid molecular assay that can be used close to the point of care by operators with minimal technical expertise, enabling diagnosis of TB and simultaneous assessment of rifampicin resistance to be completed within 2 h. Moreover, this can be accomplished using unprocessed sputum samples as well as clinical specimens from extrapulmonary sites.	Rifampin	201-211	ras homolog family member F, filopodia associated	Homo sapiens	17-20
21832258-5	2011	In the 96-well plate induction assay, the CYP3A4 inducers rifampin, phenobarbital, carbamazepine, phenytoin, troglitazone, rosiglitazone, and pioglitazone yielded dose-dependent induction of LIPA metabolism, whereas the CYP1A2 inducers omeprazole and 3-methylcholanthrene did not display any induction in the CYP3A4 activity.	Rifampin	58-66	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	42-48
21526375-6	2011	The beneficial properties of rifampicin were associated with an increase in DME and export bile acid systems (multidrug resistance-associated protein 4, MRP4, and bile acid export pump to bile duct, BSEP) expression, as well as a reduction in NTCP expression.	Rifampin	29-39	ATP binding cassette subfamily C member 4	Homo sapiens	110-151
21526375-6	2011	The beneficial properties of rifampicin were associated with an increase in DME and export bile acid systems (multidrug resistance-associated protein 4, MRP4, and bile acid export pump to bile duct, BSEP) expression, as well as a reduction in NTCP expression.	Rifampin	29-39	ATP binding cassette subfamily C member 4	Homo sapiens	153-157
21526375-6	2011	The beneficial properties of rifampicin were associated with an increase in DME and export bile acid systems (multidrug resistance-associated protein 4, MRP4, and bile acid export pump to bile duct, BSEP) expression, as well as a reduction in NTCP expression.	Rifampin	29-39	ATP binding cassette subfamily B member 11	Homo sapiens	199-203
21526375-6	2011	The beneficial properties of rifampicin were associated with an increase in DME and export bile acid systems (multidrug resistance-associated protein 4, MRP4, and bile acid export pump to bile duct, BSEP) expression, as well as a reduction in NTCP expression.	Rifampin	29-39	solute carrier family 10 member 1	Homo sapiens	243-247
21555507-6	2011	IL-6 suppressed induction of CYP1A2 enzyme activity by omeprazole and CYP3A4 enzyme activity by rifampicin but only at supraphysiological concentrations of IL-6.	Rifampin	96-106	interleukin 6	Homo sapiens	0-4
21555507-6	2011	IL-6 suppressed induction of CYP1A2 enzyme activity by omeprazole and CYP3A4 enzyme activity by rifampicin but only at supraphysiological concentrations of IL-6.	Rifampin	96-106	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	29-35
21555507-6	2011	IL-6 suppressed induction of CYP1A2 enzyme activity by omeprazole and CYP3A4 enzyme activity by rifampicin but only at supraphysiological concentrations of IL-6.	Rifampin	96-106	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	70-76
21540293-3	2011	We screened the expression of 377 human miRNAs in HepG2 cells after 48 h of treatment with 5 muM rifampicin [a pregnane X receptor (PXR) ligand] or vehicle using reverse transcription-polymerase chain reaction-based low-density arrays.	Rifampin	97-107	nuclear receptor subfamily 1 group I member 2	Homo sapiens	111-130
21540293-3	2011	We screened the expression of 377 human miRNAs in HepG2 cells after 48 h of treatment with 5 muM rifampicin [a pregnane X receptor (PXR) ligand] or vehicle using reverse transcription-polymerase chain reaction-based low-density arrays.	Rifampin	97-107	nuclear receptor subfamily 1 group I member 2	Homo sapiens	132-135
21466844-8	2011	At concentration of 1 ng/ml, trantinterol was about 3.6 +- 3.1% as effective as rifampin (CYP3A4/5 inducer).	Rifampin	80-88	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	90-96
21436404-6	2011	Ketoconazole treatment decreased the CYP3A4 activity by 69%, and rifampicin induced the CYP3A4- and CYP2B6-dependent activity 6-fold, which predicts well the magnitude of changes observed in vivo.	Rifampin	65-75	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	88-94
21436404-6	2011	Ketoconazole treatment decreased the CYP3A4 activity by 69%, and rifampicin induced the CYP3A4- and CYP2B6-dependent activity 6-fold, which predicts well the magnitude of changes observed in vivo.	Rifampin	65-75	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	100-106
21441468-1	2011	Rifampin and carbamazepine have been recommended in the U.S. Food and Drug Administration draft drug interaction guidance as CYP3A4 inducers for clinical drug-drug interaction (DDI) studies.	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	125-131
21441468-8	2011	Comparison of the maximal CYP3A4 induction potential among the three inducers indicated that rifampin is the most potent inducer and is the best choice for clinical CYP3A4 induction DDI studies.	Rifampin	93-101	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	26-32
21441468-8	2011	Comparison of the maximal CYP3A4 induction potential among the three inducers indicated that rifampin is the most potent inducer and is the best choice for clinical CYP3A4 induction DDI studies.	Rifampin	93-101	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	165-171
21441468-9	2011	Moreover, a near-maximal CYP3A4 DDI was predicted to result from administration of rifampin for approximately 7 days at 450 to 600 mg q.d.	Rifampin	83-91	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	25-31
21714930-3	2011	FINDINGS: Oxidative stress-acclimatized bacteria thrive in rifampicin by generating antibiotic-detoxifying nitric oxide (NO), which can be repressed by artesunate or an inhibitor of nitric oxide synthase (NOS).	Rifampin	59-69	nitric oxide synthase 2	Homo sapiens	182-203
21555117-6	2011	Our results showed that rifampicin inhibited the LPS-stimulated expression of inducible nitric oxide synthase, cyclooxygenase-2, tumor necrosis factor-alpha, and interleukin-1beta, as well as the production of nitric oxide and prostaglandin E2.	Rifampin	24-34	prostaglandin-endoperoxide synthase 2	Homo sapiens	111-127
21555117-6	2011	Our results showed that rifampicin inhibited the LPS-stimulated expression of inducible nitric oxide synthase, cyclooxygenase-2, tumor necrosis factor-alpha, and interleukin-1beta, as well as the production of nitric oxide and prostaglandin E2.	Rifampin	24-34	tumor necrosis factor	Homo sapiens	129-156
21555117-6	2011	Our results showed that rifampicin inhibited the LPS-stimulated expression of inducible nitric oxide synthase, cyclooxygenase-2, tumor necrosis factor-alpha, and interleukin-1beta, as well as the production of nitric oxide and prostaglandin E2.	Rifampin	24-34	interleukin 1 beta	Homo sapiens	162-179
21508826-10	2011	CONCLUSIONS: : A novel observation is the large effect of rifampicin on S-norketamine concentrations and indicates that rifampicin induces the elimination of S-ketamine"s metabolite, S-norketamine, probably via induction of the CYP3A4 and/or CYP2B6 enzymes.	Rifampin	120-130	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	228-234
21508826-10	2011	CONCLUSIONS: : A novel observation is the large effect of rifampicin on S-norketamine concentrations and indicates that rifampicin induces the elimination of S-ketamine"s metabolite, S-norketamine, probably via induction of the CYP3A4 and/or CYP2B6 enzymes.	Rifampin	120-130	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	242-248
21508826-4	2011	The aim of this study was to investigate the effect of CYP enzyme induction by rifampicin on the pharmacokinetics of S-ketamine and its major metabolite, S-norketamine, in healthy volunteers.	Rifampin	79-89	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-58
21430235-5	2011	Finally, budesonide, cyclosporine, and rifampin were identified as inhibitors of OATP1B1-, OATP1B3-, and OATP2B1-meditated mesalazine uptake.	Rifampin	39-47	solute carrier organic anion transporter family member 1B1	Homo sapiens	81-88
21297316-7	2011	Rifampicin and some HIV protease inhibitors are also OATP1B1 inhibitors.	Rifampin	0-10	solute carrier organic anion transporter family member 1B1	Homo sapiens	53-60
21297316-8	2011	Rifampicin is also an inducer of metabolic enzymes, and although its single coadministration produces an increase in the plasma concentration of the affected drugs, multiple coadministrations may result in reductions in the plasma concentrations of OATP1B1 and CYP3A4 bisubstrates.	Rifampin	0-10	solute carrier organic anion transporter family member 1B1	Homo sapiens	249-256
21297316-8	2011	Rifampicin is also an inducer of metabolic enzymes, and although its single coadministration produces an increase in the plasma concentration of the affected drugs, multiple coadministrations may result in reductions in the plasma concentrations of OATP1B1 and CYP3A4 bisubstrates.	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	261-267
21415249-6	2011	The ratios of IC50 values obtained from the biliary excretion index over the IC(50, QTLI) were 1.34, 1.94, and 1.94, but ratios over IC50 values in CDF uptake by Mrp2-expressing membrane vesicles varied more: 6.69, 3.07, and 2.43 for rifampicin, cyclosporine, and MK-571, respectively.	Rifampin	234-244	ATP binding cassette subfamily C member 2	Rattus norvegicus	162-166
21430235-5	2011	Finally, budesonide, cyclosporine, and rifampin were identified as inhibitors of OATP1B1-, OATP1B3-, and OATP2B1-meditated mesalazine uptake.	Rifampin	39-47	solute carrier organic anion transporter family member 1B3	Homo sapiens	91-98
21430235-5	2011	Finally, budesonide, cyclosporine, and rifampin were identified as inhibitors of OATP1B1-, OATP1B3-, and OATP2B1-meditated mesalazine uptake.	Rifampin	39-47	solute carrier organic anion transporter family member 2B1	Homo sapiens	105-112
20852006-2	2011	A prior investigation of raltegravir coadministered with rifampin demonstrated a decrease in plasma concentrations of raltegravir likely secondary to induction of UGT1A1, the enzyme primarily responsible for the metabolism of raltegravir.	Rifampin	57-65	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	163-169
21419764-5	2011	We show that serum alanine aminotransferase (ALT) and alkaline phosphatase (ALP) were significantly increased in mice treated with isoniazid plus rifampicin.	Rifampin	146-156	glutamic pyruvic transaminase, soluble	Mus musculus	19-43
21402137-3	2011	MDMA significantly inhibited hPXR-mediated CYP3A4-reporter gene expression induced by the human PXR activator rifampicin (IC50 1.26 +- 0.36 mM) or the therapeutic drugs paroxetine, fluoxetine, clozapine, diazepam and risperidone.	Rifampin	110-120	nuclear receptor subfamily 1 group I member 2	Homo sapiens	29-33
21402137-3	2011	MDMA significantly inhibited hPXR-mediated CYP3A4-reporter gene expression induced by the human PXR activator rifampicin (IC50 1.26 +- 0.36 mM) or the therapeutic drugs paroxetine, fluoxetine, clozapine, diazepam and risperidone.	Rifampin	110-120	nuclear receptor subfamily 1 group I member 2	Homo sapiens	30-33
21419764-5	2011	We show that serum alanine aminotransferase (ALT) and alkaline phosphatase (ALP) were significantly increased in mice treated with isoniazid plus rifampicin.	Rifampin	146-156	glutamic pyruvic transaminase, soluble	Mus musculus	45-48
21419764-7	2011	In addition, isoniazid plus rifampicin resulted in hepatic apoptosis, as determined by terminal dUTP nick-end labeling (TUNEL) staining and caspase-3 activation.	Rifampin	28-38	caspase 3	Mus musculus	140-149
21507477-10	2011	MTB/RIF test sensitivity for rifampicin resistance was 94 4% (236 of 250) and specificity was 98 3% (796 of 810).	Rifampin	29-39	ras homolog family member F, filopodia associated	Homo sapiens	4-7
21292004-2	2011	Constitutive and induced expressions of these enzymes are under the control of HNF4alpha and rifampicin activated PXR.	Rifampin	93-103	nuclear receptor subfamily 1 group I member 2	Homo sapiens	114-117
21292004-6	2011	NCOA6 enhances the synergistic activation of CYP2C9 and CYP3A4 promoter activity by PXR and HNF4alpha in the presence of rifampicin.	Rifampin	121-131	nuclear receptor coactivator 6	Homo sapiens	0-5
21292004-6	2011	NCOA6 enhances the synergistic activation of CYP2C9 and CYP3A4 promoter activity by PXR and HNF4alpha in the presence of rifampicin.	Rifampin	121-131	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	45-51
21292004-6	2011	NCOA6 enhances the synergistic activation of CYP2C9 and CYP3A4 promoter activity by PXR and HNF4alpha in the presence of rifampicin.	Rifampin	121-131	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	56-62
21210720-11	2011	Drug-induced cytochrome P450 gene expression was increased with rifampicin induction.	Rifampin	64-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-28
21111054-4	2011	METHODS: To evaluate the xenobiotic-mediated induction of hepatocellular gene expression, the prototypical inducers rifampicin (10 muM) and phenobarbital (1 mM) were used for CYP3A4, CITCO (1 muM) and artemisinin (50 muM) were used for CYP2B6, and 3-methylcholanthrene (1 muM) and omeprazole (50 muM) were utilized for induction of CYP1A2.	Rifampin	116-126	latexin	Homo sapiens	131-134
21111054-4	2011	METHODS: To evaluate the xenobiotic-mediated induction of hepatocellular gene expression, the prototypical inducers rifampicin (10 muM) and phenobarbital (1 mM) were used for CYP3A4, CITCO (1 muM) and artemisinin (50 muM) were used for CYP2B6, and 3-methylcholanthrene (1 muM) and omeprazole (50 muM) were utilized for induction of CYP1A2.	Rifampin	116-126	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	175-181
21111054-4	2011	METHODS: To evaluate the xenobiotic-mediated induction of hepatocellular gene expression, the prototypical inducers rifampicin (10 muM) and phenobarbital (1 mM) were used for CYP3A4, CITCO (1 muM) and artemisinin (50 muM) were used for CYP2B6, and 3-methylcholanthrene (1 muM) and omeprazole (50 muM) were utilized for induction of CYP1A2.	Rifampin	116-126	latexin	Homo sapiens	192-195
21111054-4	2011	METHODS: To evaluate the xenobiotic-mediated induction of hepatocellular gene expression, the prototypical inducers rifampicin (10 muM) and phenobarbital (1 mM) were used for CYP3A4, CITCO (1 muM) and artemisinin (50 muM) were used for CYP2B6, and 3-methylcholanthrene (1 muM) and omeprazole (50 muM) were utilized for induction of CYP1A2.	Rifampin	116-126	latexin	Homo sapiens	192-195
21111054-4	2011	METHODS: To evaluate the xenobiotic-mediated induction of hepatocellular gene expression, the prototypical inducers rifampicin (10 muM) and phenobarbital (1 mM) were used for CYP3A4, CITCO (1 muM) and artemisinin (50 muM) were used for CYP2B6, and 3-methylcholanthrene (1 muM) and omeprazole (50 muM) were utilized for induction of CYP1A2.	Rifampin	116-126	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	236-242
21111054-4	2011	METHODS: To evaluate the xenobiotic-mediated induction of hepatocellular gene expression, the prototypical inducers rifampicin (10 muM) and phenobarbital (1 mM) were used for CYP3A4, CITCO (1 muM) and artemisinin (50 muM) were used for CYP2B6, and 3-methylcholanthrene (1 muM) and omeprazole (50 muM) were utilized for induction of CYP1A2.	Rifampin	116-126	latexin	Homo sapiens	192-195
21111054-4	2011	METHODS: To evaluate the xenobiotic-mediated induction of hepatocellular gene expression, the prototypical inducers rifampicin (10 muM) and phenobarbital (1 mM) were used for CYP3A4, CITCO (1 muM) and artemisinin (50 muM) were used for CYP2B6, and 3-methylcholanthrene (1 muM) and omeprazole (50 muM) were utilized for induction of CYP1A2.	Rifampin	116-126	latexin	Homo sapiens	192-195
21111054-4	2011	METHODS: To evaluate the xenobiotic-mediated induction of hepatocellular gene expression, the prototypical inducers rifampicin (10 muM) and phenobarbital (1 mM) were used for CYP3A4, CITCO (1 muM) and artemisinin (50 muM) were used for CYP2B6, and 3-methylcholanthrene (1 muM) and omeprazole (50 muM) were utilized for induction of CYP1A2.	Rifampin	116-126	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	332-338
21482342-6	2011	Anti-TNF therapy was stopped even though the patient had received 3 months of prophylactic treatment with rifampicin and isoniazid before starting etanercept.	Rifampin	106-116	tumor necrosis factor	Homo sapiens	5-8
21456052-0	2011	Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug-drug interactions.	Rifampin	39-47	solute carrier family 22 member 6	Homo sapiens	51-55
21456052-0	2011	Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug-drug interactions.	Rifampin	39-47	solute carrier organic anion transporter family member 1B1	Homo sapiens	60-67
21456052-2	2011	To determine the underlying mechanisms of DDI, this study was performed to investigate the inhibitory effects of ketoconazole and rifampin on the functions of OAT1 and OATP1B1, and to evaluate the potential of ketoconazole and rifampin for DDI with substrate drugs for these transporters in a clinical setting.	Rifampin	130-138	solute carrier family 22 member 6	Homo sapiens	159-163
21456052-2	2011	To determine the underlying mechanisms of DDI, this study was performed to investigate the inhibitory effects of ketoconazole and rifampin on the functions of OAT1 and OATP1B1, and to evaluate the potential of ketoconazole and rifampin for DDI with substrate drugs for these transporters in a clinical setting.	Rifampin	130-138	solute carrier organic anion transporter family member 1B1	Homo sapiens	168-175
21456052-3	2011	Ketoconazole inhibited OATP1B1-mediated transport activity, while rifampin inhibited OAT1 and OATP1B1.	Rifampin	66-74	solute carrier family 22 member 6	Homo sapiens	85-89
21456052-3	2011	Ketoconazole inhibited OATP1B1-mediated transport activity, while rifampin inhibited OAT1 and OATP1B1.	Rifampin	66-74	solute carrier organic anion transporter family member 1B1	Homo sapiens	94-101
21395646-0	2011	In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype.	Rifampin	38-48	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	94-100
21395646-4	2011	The model was used to simulate the effects of rifampicin on efavirenz pharmacokinetics in 400 virtual patients, taking into account bodyweight and CYP2B6 phenotype.	Rifampin	46-56	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	147-153
19780977-0	2011	In vitro interactions between amphotericin B and other antifungal agents and rifampin against Fusarium spp.	Rifampin	77-85	histocompatibility minor 13	Homo sapiens	103-106
21205914-0	2011	Pharmacokinetic-pharmacodynamic modeling of rifampicin-mediated Cyp3a11 induction in steroid and xenobiotic X receptor humanized mice.	Rifampin	44-54	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	64-71
21205914-0	2011	Pharmacokinetic-pharmacodynamic modeling of rifampicin-mediated Cyp3a11 induction in steroid and xenobiotic X receptor humanized mice.	Rifampin	44-54	nuclear receptor subfamily 1, group I, member 2	Mus musculus	85-118
21205914-1	2011	The purpose of this study was to develop a mechanistic pharmacokinetic-pharmacodynamic (PK-PD) model to describe the effects of rifampicin on hepatic Cyp3a11 RNA, enzymatic activity, and triazolam pharmacokinetics.	Rifampin	128-138	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	150-157
21205914-2	2011	Rifampicin was administered to steroid and xenobiotic X receptor (SXR) humanized mice at 10 mg/kg p.o.	Rifampin	0-10	nuclear receptor subfamily 1, group I, member 2	Mus musculus	31-64
21205914-2	2011	Rifampicin was administered to steroid and xenobiotic X receptor (SXR) humanized mice at 10 mg/kg p.o.	Rifampin	0-10	nuclear receptor subfamily 1, group I, member 2	Mus musculus	66-69
21205914-6	2011	Elevations in Cyp3a11 RNA expression were observed 24 h after the first dose of rifampicin, reaching a maximum (~10 times baseline) after the third dose and were sustained until day 4 and began declining 48 h after the last rifampicin dose.	Rifampin	80-90	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	14-21
21205914-6	2011	Elevations in Cyp3a11 RNA expression were observed 24 h after the first dose of rifampicin, reaching a maximum (~10 times baseline) after the third dose and were sustained until day 4 and began declining 48 h after the last rifampicin dose.	Rifampin	224-234	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	14-21
21205914-9	2011	The final PK-PD model incorporated rifampicin liver concentration as the driving force for the time-delayed Cyp3a11 induction governed by in vitro potency estimates, which in turn regulated the turnover of enzyme activity.	Rifampin	35-45	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	108-115
21205914-10	2011	The PK-PD model was able to recapitulate the delayed induction of Cyp3a11 mRNA and enzymatic activity by rifampicin.	Rifampin	105-115	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	66-73
21270793-0	2011	Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants.	Rifampin	0-8	solute carrier family 22 member 1	Homo sapiens	73-77
20876786-0	2011	Effects of pregnane X receptor (NR1I2) and CYP2B6 genetic polymorphisms on the induction of bupropion hydroxylation by rifampin.	Rifampin	119-127	nuclear receptor subfamily 1 group I member 2	Homo sapiens	11-30
21150552-0	2011	Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy.	Rifampin	118-126	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	93-99
21150552-3	2011	Two-way analysis of variance revealed a significant interaction between CYP2B6 516G T polymorphism and rifampin-containing therapy, suggesting that efavirenz dose adjustment may need to be individualized on the basis of the patient"s genotype.	Rifampin	103-111	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	72-78
21191377-1	2011	We studied the time course for the reversal of rifampin"s effect on the pharmacokinetics of oral midazolam (a cytochrome P450 (CYP) 3A4 substrate) and digoxin (a P-glycoprotein (P-gp) substrate).	Rifampin	47-55	DNA segment, 3a4	Mus musculus	132-135
21191377-1	2011	We studied the time course for the reversal of rifampin"s effect on the pharmacokinetics of oral midazolam (a cytochrome P450 (CYP) 3A4 substrate) and digoxin (a P-glycoprotein (P-gp) substrate).	Rifampin	47-55	phosphoglycolate phosphatase	Mus musculus	162-176
21191377-1	2011	We studied the time course for the reversal of rifampin"s effect on the pharmacokinetics of oral midazolam (a cytochrome P450 (CYP) 3A4 substrate) and digoxin (a P-glycoprotein (P-gp) substrate).	Rifampin	47-55	phosphoglycolate phosphatase	Mus musculus	178-182
21191377-7	2011	However, rifampin did inhibit the P-gp-mediated transport of digoxin with a half-maximal inhibitory concentration (IC(50)) below anticipated gut lumen concentrations, suggesting that rifampin inhibits digoxin efflux from the enterocyte to the intestinal lumen.	Rifampin	9-17	phosphoglycolate phosphatase	Mus musculus	34-38
21191377-7	2011	However, rifampin did inhibit the P-gp-mediated transport of digoxin with a half-maximal inhibitory concentration (IC(50)) below anticipated gut lumen concentrations, suggesting that rifampin inhibits digoxin efflux from the enterocyte to the intestinal lumen.	Rifampin	183-191	phosphoglycolate phosphatase	Mus musculus	34-38
21372390-7	2011	Rifampicin and penicillin were transported by both OATP1B1 and OATP1B3.	Rifampin	0-10	solute carrier organic anion transporter family member 1B1	Homo sapiens	51-58
21372390-7	2011	Rifampicin and penicillin were transported by both OATP1B1 and OATP1B3.	Rifampin	0-10	solute carrier organic anion transporter family member 1B3	Homo sapiens	63-70
21410294-16	2011	CONCLUSIONS: Exposure to vandetanib, as assessed by AUC(504) in healthy subjects, was reduced by around 40% when a single dose was given in combination with the potent CYP3A4 inducer rifampicin.	Rifampin	183-193	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	168-174
20876786-0	2011	Effects of pregnane X receptor (NR1I2) and CYP2B6 genetic polymorphisms on the induction of bupropion hydroxylation by rifampin.	Rifampin	119-127	nuclear receptor subfamily 1 group I member 2	Homo sapiens	32-37
20876786-0	2011	Effects of pregnane X receptor (NR1I2) and CYP2B6 genetic polymorphisms on the induction of bupropion hydroxylation by rifampin.	Rifampin	119-127	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	43-49
20876786-1	2011	We investigated genetic polymorphisms in the pregnane X receptor (NR1I2) in Korean individuals (n = 83) and the effects of NR1I2 genotypes on rifampin-mediated induction of bupropion hydroxylation.	Rifampin	142-150	nuclear receptor subfamily 1 group I member 2	Homo sapiens	123-128
20876786-3	2011	The area under the time-concentration curve (AUC) ratio of hydroxybupropion to bupropion in CYP2B6*6 carriers was significantly lower than that in CYP2B6*6 noncarriers in both the basal and rifampin-induced states (p = 0.012).	Rifampin	190-198	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	92-98
20876786-7	2011	In conclusion, it is suggested the NR1I2 TGT genotype decreases the bupropion hydroxylation induced by treatment with rifampin, particularly in CYP2B6*6 carriers.	Rifampin	118-126	nuclear receptor subfamily 1 group I member 2	Homo sapiens	35-40
20876786-7	2011	In conclusion, it is suggested the NR1I2 TGT genotype decreases the bupropion hydroxylation induced by treatment with rifampin, particularly in CYP2B6*6 carriers.	Rifampin	118-126	queuine tRNA-ribosyltransferase catalytic subunit 1	Homo sapiens	41-44
20876786-7	2011	In conclusion, it is suggested the NR1I2 TGT genotype decreases the bupropion hydroxylation induced by treatment with rifampin, particularly in CYP2B6*6 carriers.	Rifampin	118-126	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	144-150
21047828-1	2011	BACKGROUND: rifampicin lowers nevirapine plasma concentrations by inducing cytochrome P450.	Rifampin	12-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-90
20702754-4	2011	In the induction study, administration of rifampin 600 mg once daily for 8 days significantly increased urinary 6beta-hydroxycortisol/ cortisol ratio, from a preinduction baseline of 5.8 +- 2.7 to 18.0 +- 10.2 after 8 days of rifampin treatment, confirming an inductive effect on CYP3A4.	Rifampin	42-50	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	280-286
21436605-5	2011	Furthermore, CYP3A4 protein levels were significantly increased by the addition of rifampicin and dexamethasone to the culture media, indicating that the induction potential was maintained.	Rifampin	83-93	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	13-19
21733412-10	2011	The rank order of these drugs potencies to up-regulate P-gp activity was as following: hyperforin &gt;&gt;&gt; dexamethasone ~ beta-estradiol &gt; caffeine &gt; rifampicin ~ pentylenetetrazole &gt; verapamil.	Rifampin	161-171	ATP binding cassette subfamily B member 1	Homo sapiens	55-59
21789183-8	2011	Our findings establish an endogenous cellular function for a mono-ADP-ribosyltransferase apart from its role in mediating Rifampin resistance.	Rifampin	122-130	ADP-ribosyltransferase 3 (inactive)	Homo sapiens	61-88
20583967-0	2010	A multi-endpoint evaluation of cytochrome P450 1A2, 2B6 and 3A4 induction response in human hepatocyte cultures after treatment with beta-naphthoflavone, phenobarbital and rifampicin.	Rifampin	172-182	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	31-50
20583967-3	2010	The concentration-dependent response and time-course for the induction of CYP1A2, CYP2B6 and CYP3A4 by inducing agents beta-naphthoflavone, phenobarbital and rifampicin, respectively were examined in two or more donors using multiple end-points (mRNA, enzyme activity and Western blot analysis).	Rifampin	158-168	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	74-80
20583967-3	2010	The concentration-dependent response and time-course for the induction of CYP1A2, CYP2B6 and CYP3A4 by inducing agents beta-naphthoflavone, phenobarbital and rifampicin, respectively were examined in two or more donors using multiple end-points (mRNA, enzyme activity and Western blot analysis).	Rifampin	158-168	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	82-88
20583967-3	2010	The concentration-dependent response and time-course for the induction of CYP1A2, CYP2B6 and CYP3A4 by inducing agents beta-naphthoflavone, phenobarbital and rifampicin, respectively were examined in two or more donors using multiple end-points (mRNA, enzyme activity and Western blot analysis).	Rifampin	158-168	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	93-99
20962047-6	2010	In human prostate cancer cells, treatment with the PXR agonist rifampicin (RIF) inhibited androgen-dependent proliferation of LAPC-4 cells but had little effect on the growth of the androgen-independent isogenic LA99 cells.	Rifampin	63-73	nuclear receptor subfamily 1 group I member 2	Homo sapiens	51-54
20837660-4	2010	The efficacy of MG132 was increased by inclusion of ketoconazole in the hepatocyte incubations and decreased by prior treatment of the cultures with the CYP3A inducers phenobarbital or rifampicin.	Rifampin	185-195	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	153-158
20861156-5	2010	In DPX2 cells, the PXR-driven 5.5- and 6.5-fold induction responses to omeprazole and 10 muM rifampicin were attenuated to 4- and 3.5-fold, respectively.	Rifampin	93-103	nuclear receptor subfamily 1 group I member 2	Homo sapiens	19-22
20962047-6	2010	In human prostate cancer cells, treatment with the PXR agonist rifampicin (RIF) inhibited androgen-dependent proliferation of LAPC-4 cells but had little effect on the growth of the androgen-independent isogenic LA99 cells.	Rifampin	75-78	nuclear receptor subfamily 1 group I member 2	Homo sapiens	51-54
20832446-7	2010	A number of genes were regulated in a cell type and species-specific manner after incubation with the prototypical PXR agonists rifampicin or dexamethasone, respectively.	Rifampin	128-138	nuclear receptor subfamily 1 group I member 2	Homo sapiens	115-118
21131707-5	2010	The patient was treated with 3 months therapy of Ethambutol and Rifampicin with good clinical response.The clinical presentation of the case is discussed with a review of the literature about current guidelines for prophylaxis and other preventive strategy for infection among patients receiving TNF antagonists.	Rifampin	64-74	tumor necrosis factor	Homo sapiens	296-299
20887388-9	2010	Steroid and xenobiotic receptor (SXR), which was recently identified as a receptor of VK2, was expressed on myeloid progenitors, and the SXR agonist rifampicin (RIF) also upregulated CD11b and CD14 expressions on myeloid progenitors.	Rifampin	149-159	nuclear receptor subfamily 1 group I member 2	Homo sapiens	33-36
20887388-9	2010	Steroid and xenobiotic receptor (SXR), which was recently identified as a receptor of VK2, was expressed on myeloid progenitors, and the SXR agonist rifampicin (RIF) also upregulated CD11b and CD14 expressions on myeloid progenitors.	Rifampin	149-159	nuclear receptor subfamily 1 group I member 2	Homo sapiens	137-140
20887388-9	2010	Steroid and xenobiotic receptor (SXR), which was recently identified as a receptor of VK2, was expressed on myeloid progenitors, and the SXR agonist rifampicin (RIF) also upregulated CD11b and CD14 expressions on myeloid progenitors.	Rifampin	149-159	integrin subunit alpha M	Homo sapiens	183-188
20887388-9	2010	Steroid and xenobiotic receptor (SXR), which was recently identified as a receptor of VK2, was expressed on myeloid progenitors, and the SXR agonist rifampicin (RIF) also upregulated CD11b and CD14 expressions on myeloid progenitors.	Rifampin	149-159	CD14 molecule	Homo sapiens	193-197
20887388-9	2010	Steroid and xenobiotic receptor (SXR), which was recently identified as a receptor of VK2, was expressed on myeloid progenitors, and the SXR agonist rifampicin (RIF) also upregulated CD11b and CD14 expressions on myeloid progenitors.	Rifampin	161-164	nuclear receptor subfamily 1 group I member 2	Homo sapiens	33-36
20887388-9	2010	Steroid and xenobiotic receptor (SXR), which was recently identified as a receptor of VK2, was expressed on myeloid progenitors, and the SXR agonist rifampicin (RIF) also upregulated CD11b and CD14 expressions on myeloid progenitors.	Rifampin	161-164	nuclear receptor subfamily 1 group I member 2	Homo sapiens	137-140
20887388-9	2010	Steroid and xenobiotic receptor (SXR), which was recently identified as a receptor of VK2, was expressed on myeloid progenitors, and the SXR agonist rifampicin (RIF) also upregulated CD11b and CD14 expressions on myeloid progenitors.	Rifampin	161-164	integrin subunit alpha M	Homo sapiens	183-188
20887388-9	2010	Steroid and xenobiotic receptor (SXR), which was recently identified as a receptor of VK2, was expressed on myeloid progenitors, and the SXR agonist rifampicin (RIF) also upregulated CD11b and CD14 expressions on myeloid progenitors.	Rifampin	161-164	CD14 molecule	Homo sapiens	193-197
20871212-3	2010	When human estrogen receptor (hERalpha) and SXR were exogenously expressed, treatment with either rifampicin or corticosterone promoted significantly the SXR-mediated transactivation of LXRE reporter gene in HepG2.	Rifampin	98-108	estrogen receptor 1	Homo sapiens	11-39
20871212-3	2010	When human estrogen receptor (hERalpha) and SXR were exogenously expressed, treatment with either rifampicin or corticosterone promoted significantly the SXR-mediated transactivation of LXRE reporter gene in HepG2.	Rifampin	98-108	nuclear receptor subfamily 1 group I member 2	Homo sapiens	44-47
20871212-3	2010	When human estrogen receptor (hERalpha) and SXR were exogenously expressed, treatment with either rifampicin or corticosterone promoted significantly the SXR-mediated transactivation of LXRE reporter gene in HepG2.	Rifampin	98-108	nuclear receptor subfamily 1 group I member 2	Homo sapiens	154-157
20699409-4	2010	Concentration-dependent CYP3A induction of rifampicin was reproducible with the EC(50) values of 0.36 +- 0.28 muM from four batches of human hepatocytes using the 96-well plate with TL Matrigel.	Rifampin	43-53	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	24-29
20699409-6	2010	Cotreatment of avasimibe or efavirenz with 10 muM rifampicin was found to reduce CYP3A activities induced by rifampicin at a lower rate than treatment with rifampicin alone, whereas treatment with phenobarbital and carbamazepine had no effect.	Rifampin	50-60	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	81-86
20699409-6	2010	Cotreatment of avasimibe or efavirenz with 10 muM rifampicin was found to reduce CYP3A activities induced by rifampicin at a lower rate than treatment with rifampicin alone, whereas treatment with phenobarbital and carbamazepine had no effect.	Rifampin	109-119	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	81-86
20699409-6	2010	Cotreatment of avasimibe or efavirenz with 10 muM rifampicin was found to reduce CYP3A activities induced by rifampicin at a lower rate than treatment with rifampicin alone, whereas treatment with phenobarbital and carbamazepine had no effect.	Rifampin	109-119	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	81-86
20699409-8	2010	The cotreatment assay of test compound with rifampicin allows us to exclude the false-negative results caused by the cytotoxicity and/or the mechanism-based inactivation, when the drug candidate"s ability for CYP3A induction is evaluating the enzyme activity.	Rifampin	44-54	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	209-214
20624464-4	2010	In this study we aimed to further characterize this cell line by focusing on the time dependence of P-gp expression, localization and function in the presence of rifampicin, a P-gp inducer.	Rifampin	162-172	ATP binding cassette subfamily B member 1	Homo sapiens	100-104
20719936-1	2010	Long-term treatment of patients with the macrolide antibiotic and prototypical activator of pregnane X receptor (PXR) rifampicin (Rif) inhibits the inflammatory response in liver.	Rifampin	118-128	nuclear receptor subfamily 1 group I member 2	Homo sapiens	92-111
20719936-1	2010	Long-term treatment of patients with the macrolide antibiotic and prototypical activator of pregnane X receptor (PXR) rifampicin (Rif) inhibits the inflammatory response in liver.	Rifampin	118-128	nuclear receptor subfamily 1 group I member 2	Homo sapiens	113-116
20719936-1	2010	Long-term treatment of patients with the macrolide antibiotic and prototypical activator of pregnane X receptor (PXR) rifampicin (Rif) inhibits the inflammatory response in liver.	Rifampin	130-133	nuclear receptor subfamily 1 group I member 2	Homo sapiens	92-111
20719936-1	2010	Long-term treatment of patients with the macrolide antibiotic and prototypical activator of pregnane X receptor (PXR) rifampicin (Rif) inhibits the inflammatory response in liver.	Rifampin	130-133	nuclear receptor subfamily 1 group I member 2	Homo sapiens	113-116
20624464-4	2010	In this study we aimed to further characterize this cell line by focusing on the time dependence of P-gp expression, localization and function in the presence of rifampicin, a P-gp inducer.	Rifampin	162-172	ATP binding cassette subfamily B member 1	Homo sapiens	176-180
20624464-5	2010	P-gp protein expression was increased in a time and dose dependent manner following exposure of cells to rifampicin (5-50 muM).	Rifampin	105-115	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
20624464-5	2010	P-gp protein expression was increased in a time and dose dependent manner following exposure of cells to rifampicin (5-50 muM).	Rifampin	105-115	latexin	Homo sapiens	122-125
20624464-6	2010	The induction of P-gp by rifampicin and its inhibition by ketoconazole (an inhibitor of PXR mediated P-gp induction) confirms the suitability of these cells for PXR induction studies.	Rifampin	25-35	ATP binding cassette subfamily B member 1	Homo sapiens	17-21
20624464-6	2010	The induction of P-gp by rifampicin and its inhibition by ketoconazole (an inhibitor of PXR mediated P-gp induction) confirms the suitability of these cells for PXR induction studies.	Rifampin	25-35	nuclear receptor subfamily 1 group I member 2	Homo sapiens	161-164
20945562-17	2004	The current treatment regime for drug-sensitive TB involves the use of rifampicin (RIF), INH, pyrazinamide (PZA), and ethambutol or streptomycin for two months, followed by four months of continued dosing with INH and RIF (11, 12).	Rifampin	71-81	ras homolog family member F, filopodia associated	Homo sapiens	83-86
20939914-0	2010	Protective effect of rifampicin and clindamycin impregnated devices against Staphylococcus spp.	Rifampin	21-31	histocompatibility minor 13	Homo sapiens	91-94
20599501-7	2010	Rifampicin, a model CYP3A4 inducer, significantly induced CYP3A4 mRNA in both types of cells.	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	20-26
20599501-7	2010	Rifampicin, a model CYP3A4 inducer, significantly induced CYP3A4 mRNA in both types of cells.	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	58-64
20599501-8	2010	The level of CYP3A4 protein in human hepatocytes was increased by Orlistat after 48h, while rifampicin strongly induced CYP3A4 protein level.	Rifampin	92-102	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	120-126
20540932-10	2010	Molecules known to interact with OATPs, including cyclosporin A, rifampicin, and glibenclamide, each demonstrated concentration-dependent inhibition of 8-FcA transport by OATP1B1 and OATP1B3.	Rifampin	65-75	solute carrier organic anion transporter family member 1B1	Homo sapiens	171-178
20540932-10	2010	Molecules known to interact with OATPs, including cyclosporin A, rifampicin, and glibenclamide, each demonstrated concentration-dependent inhibition of 8-FcA transport by OATP1B1 and OATP1B3.	Rifampin	65-75	solute carrier organic anion transporter family member 1B3	Homo sapiens	183-190
20660695-3	2010	In this study, we evaluated rifampin pharmacokinetics in relation to tuberculosis, geographic region, race, and single nucleotide polymorphisms of the human transporter genes SLCO1B1, SLCO1B3, and MDR1.	Rifampin	28-36	ATP binding cassette subfamily B member 1	Homo sapiens	197-201
20660695-3	2010	In this study, we evaluated rifampin pharmacokinetics in relation to tuberculosis, geographic region, race, and single nucleotide polymorphisms of the human transporter genes SLCO1B1, SLCO1B3, and MDR1.	Rifampin	28-36	solute carrier organic anion transporter family member 1B1	Homo sapiens	175-182
20660695-6	2010	However, in multivariable analyses, the rifampin AUC(0-24) was significantly affected by rifampin dosage (in mg/kg of body weight), polymorphisms in the SLCO1B1 gene, and the presence of tuberculosis by geographic region.	Rifampin	40-48	solute carrier organic anion transporter family member 1B1	Homo sapiens	153-160
20660695-11	2010	Lower rifampin exposure was associated with the polymorphism of the SLCO1B1 c.463C&gt;A gene.	Rifampin	6-14	solute carrier organic anion transporter family member 1B1	Homo sapiens	68-75
20827821-0	2004	(11)C-Labeled rifampicin Rifampicin (RIF) (or rifampin) is a rifamycin derivative with a clinically effective group of 4-methyl-1-piperazinaminyl.	Rifampin	14-24	ras homolog family member F, filopodia associated	Homo sapiens	37-40
20624854-5	2010	Cell-based promoter reporter assays demonstrated that CYP2B6 luciferase activity was synergistically enhanced in the presence of both -82T C mutation and rifampicin (RIF)-activated PXR.	Rifampin	154-164	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	54-60
20624854-5	2010	Cell-based promoter reporter assays demonstrated that CYP2B6 luciferase activity was synergistically enhanced in the presence of both -82T C mutation and rifampicin (RIF)-activated PXR.	Rifampin	154-164	nuclear receptor subfamily 1 group I member 2	Homo sapiens	181-184
20624854-5	2010	Cell-based promoter reporter assays demonstrated that CYP2B6 luciferase activity was synergistically enhanced in the presence of both -82T C mutation and rifampicin (RIF)-activated PXR.	Rifampin	166-169	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	54-60
20624854-5	2010	Cell-based promoter reporter assays demonstrated that CYP2B6 luciferase activity was synergistically enhanced in the presence of both -82T C mutation and rifampicin (RIF)-activated PXR.	Rifampin	166-169	nuclear receptor subfamily 1 group I member 2	Homo sapiens	181-184
20703222-1	2010	Based on in vitro rat and human hepatocyte uptake studies showing inhibition of warfarin uptake in the presence of the nonspecific organic anion-transporting polypeptide (OATP) inhibitor rifampin, a clinical study was conducted in 10 healthy volunteers to examine the in vivo relevance of OATP hepatic uptake on the pharmacokinetics of warfarin.	Rifampin	187-195	solute carrier organic anion transporter family member 1A2	Homo sapiens	131-169
20703222-1	2010	Based on in vitro rat and human hepatocyte uptake studies showing inhibition of warfarin uptake in the presence of the nonspecific organic anion-transporting polypeptide (OATP) inhibitor rifampin, a clinical study was conducted in 10 healthy volunteers to examine the in vivo relevance of OATP hepatic uptake on the pharmacokinetics of warfarin.	Rifampin	187-195	solute carrier organic anion transporter family member 1A2	Homo sapiens	171-175
20703222-1	2010	Based on in vitro rat and human hepatocyte uptake studies showing inhibition of warfarin uptake in the presence of the nonspecific organic anion-transporting polypeptide (OATP) inhibitor rifampin, a clinical study was conducted in 10 healthy volunteers to examine the in vivo relevance of OATP hepatic uptake on the pharmacokinetics of warfarin.	Rifampin	187-195	solute carrier organic anion transporter family member 1A2	Homo sapiens	289-293
20827821-0	2004	(11)C-Labeled rifampicin Rifampicin (RIF) (or rifampin) is a rifamycin derivative with a clinically effective group of 4-methyl-1-piperazinaminyl.	Rifampin	25-35	ras homolog family member F, filopodia associated	Homo sapiens	37-40
20827821-0	2004	(11)C-Labeled rifampicin Rifampicin (RIF) (or rifampin) is a rifamycin derivative with a clinically effective group of 4-methyl-1-piperazinaminyl.	Rifampin	46-54	ras homolog family member F, filopodia associated	Homo sapiens	37-40
20818746-7	2010	Upon activation of PXR by rifampicin, the messenger RNA levels of CYP3A4, CYP3A5, and CYP3A7 increased 49- to 213-fold versus HepG2 cells.	Rifampin	26-36	nuclear receptor subfamily 1 group I member 2	Homo sapiens	19-22
20690781-12	2010	Therefore, exposure to saxagliptin and its primary metabolite may be significantly modified when saxagliptin is coadministered with specific strong inhibitors (ketoconazole, diltiazem) or inducers (rifampicin) of CYP3A4/5 isoforms.	Rifampin	198-208	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	213-219
20504912-6	2010	CPT treatment resulted in delayed metabolism of nifedipine in human hepatocytes treated with rifampicin, suggesting a potential prevention of drug-drug interactions between CYP3A4 inducers and CYP3A4-metabolized drugs.	Rifampin	93-103	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	173-179
20504912-6	2010	CPT treatment resulted in delayed metabolism of nifedipine in human hepatocytes treated with rifampicin, suggesting a potential prevention of drug-drug interactions between CYP3A4 inducers and CYP3A4-metabolized drugs.	Rifampin	93-103	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	193-199
20818746-7	2010	Upon activation of PXR by rifampicin, the messenger RNA levels of CYP3A4, CYP3A5, and CYP3A7 increased 49- to 213-fold versus HepG2 cells.	Rifampin	26-36	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	66-72
20818746-7	2010	Upon activation of PXR by rifampicin, the messenger RNA levels of CYP3A4, CYP3A5, and CYP3A7 increased 49- to 213-fold versus HepG2 cells.	Rifampin	26-36	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	74-80
20818746-7	2010	Upon activation of PXR by rifampicin, the messenger RNA levels of CYP3A4, CYP3A5, and CYP3A7 increased 49- to 213-fold versus HepG2 cells.	Rifampin	26-36	cytochrome P450 family 3 subfamily A member 7	Homo sapiens	86-92
20818746-8	2010	According to reporter gene assays with different inducers, the highest increase in CYP3A4 promoter activity (131-fold) was observed upon induction with rifampicin.	Rifampin	152-162	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	83-89
20642445-5	2010	ABT also modulated CYP-inducing actions of CITCO and rifampin, the known inducers of CYP2B6 and CYP3A4.	Rifampin	53-61	peptidylprolyl isomerase G	Homo sapiens	19-22
20488228-0	2010	Lack of P-glycoprotein induction by rifampicin and phenobarbital in human lymphocytes.	Rifampin	36-46	ATP binding cassette subfamily B member 1	Homo sapiens	8-22
20488228-3	2010	Rifampicin and phenobarbital have been shown to induce P-gp in hepatic and intestinal cells through the activation of the nuclear receptors PXR and CAR.	Rifampin	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	55-59
20488228-3	2010	Rifampicin and phenobarbital have been shown to induce P-gp in hepatic and intestinal cells through the activation of the nuclear receptors PXR and CAR.	Rifampin	0-10	nuclear receptor subfamily 1 group I member 2	Homo sapiens	140-143
20488228-3	2010	Rifampicin and phenobarbital have been shown to induce P-gp in hepatic and intestinal cells through the activation of the nuclear receptors PXR and CAR.	Rifampin	0-10	CXADR pseudogene 1	Homo sapiens	148-151
20488228-12	2010	Therefore, P-gp induction by rifampicin and phenobarbital may play a negligible role in drug interactions occurring within lymphocytes.	Rifampin	29-39	ATP binding cassette subfamily B member 1	Homo sapiens	11-15
20642445-5	2010	ABT also modulated CYP-inducing actions of CITCO and rifampin, the known inducers of CYP2B6 and CYP3A4.	Rifampin	53-61	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	85-91
20642445-5	2010	ABT also modulated CYP-inducing actions of CITCO and rifampin, the known inducers of CYP2B6 and CYP3A4.	Rifampin	53-61	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	96-102
20492465-0	2010	Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel.	Rifampin	59-69	purinergic receptor P2Y12	Homo sapiens	87-92
20584229-4	2010	Regarding drug-drug interactions, dabigatran requires caution when used in combination with strong inhibitors or inducers of P-glycoprotein, such as amiodarone or rifampicin.	Rifampin	163-173	ATP binding cassette subfamily B member 1	Homo sapiens	125-139
20233841-6	2010	The CYP3A4 activity in confluent cells was also inducible by rifampicin.	Rifampin	61-71	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	4-10
20014428-2	2010	Extracellular sodium depletion or coincubation with the OATP/Oatp inhibitors rifampicin and digoxin revealed that about 35% of active CGamF accumulation was mediated by Ntcp/NTCP in rat and human hepatocytes, while the contribution of this sodium-dependent transporter reached 50-60% in dog and pig hepatocytes.	Rifampin	77-87	solute carrier organic anion transporter family member 1A2	Homo sapiens	56-60
20014428-2	2010	Extracellular sodium depletion or coincubation with the OATP/Oatp inhibitors rifampicin and digoxin revealed that about 35% of active CGamF accumulation was mediated by Ntcp/NTCP in rat and human hepatocytes, while the contribution of this sodium-dependent transporter reached 50-60% in dog and pig hepatocytes.	Rifampin	77-87	solute carrier organic anion transporter family member 1A2	Homo sapiens	61-65
20014428-2	2010	Extracellular sodium depletion or coincubation with the OATP/Oatp inhibitors rifampicin and digoxin revealed that about 35% of active CGamF accumulation was mediated by Ntcp/NTCP in rat and human hepatocytes, while the contribution of this sodium-dependent transporter reached 50-60% in dog and pig hepatocytes.	Rifampin	77-87	solute carrier family 10 member 1	Rattus norvegicus	169-173
20803980-7	2010	Anti-NTM chemotherapy consisting of rifampicin, ethambutol and clarithromycin was started in addition to anticancer chemotherapy, without severe side effects.	Rifampin	36-46	neurotrimin	Homo sapiens	5-8
20406852-5	2010	In comparison, the IC(50) values for rifampicin were 11.9 (OATP1B1), 1.4 (OATP1B3), and 80.5 muM (OATP2B1), respectively.	Rifampin	37-47	solute carrier organic anion transporter family member 1B1	Homo sapiens	59-66
20406852-5	2010	In comparison, the IC(50) values for rifampicin were 11.9 (OATP1B1), 1.4 (OATP1B3), and 80.5 muM (OATP2B1), respectively.	Rifampin	37-47	solute carrier organic anion transporter family member 1B3	Homo sapiens	74-81
20406852-5	2010	In comparison, the IC(50) values for rifampicin were 11.9 (OATP1B1), 1.4 (OATP1B3), and 80.5 muM (OATP2B1), respectively.	Rifampin	37-47	latexin	Homo sapiens	93-96
20406852-5	2010	In comparison, the IC(50) values for rifampicin were 11.9 (OATP1B1), 1.4 (OATP1B3), and 80.5 muM (OATP2B1), respectively.	Rifampin	37-47	solute carrier organic anion transporter family member 2B1	Homo sapiens	98-105
20179914-1	2010	PURPOSE: This study aimed to investigate the effect of rifampicin, an inducer of CYP3A4 and P-glycoprotein, on the pharmacokinetics and pharmacodynamics of aliskiren, a renin inhibitor used in the treatment of hypertension.	Rifampin	55-65	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	81-87
20179914-1	2010	PURPOSE: This study aimed to investigate the effect of rifampicin, an inducer of CYP3A4 and P-glycoprotein, on the pharmacokinetics and pharmacodynamics of aliskiren, a renin inhibitor used in the treatment of hypertension.	Rifampin	55-65	ATP binding cassette subfamily B member 1	Homo sapiens	92-106
20179914-1	2010	PURPOSE: This study aimed to investigate the effect of rifampicin, an inducer of CYP3A4 and P-glycoprotein, on the pharmacokinetics and pharmacodynamics of aliskiren, a renin inhibitor used in the treatment of hypertension.	Rifampin	55-65	renin	Homo sapiens	169-174
20179914-6	2010	Plasma renin activity 24 h after aliskiren intake was 61% higher during the rifampicin phase than during the placebo phase (P = 0.008).	Rifampin	76-86	renin	Homo sapiens	7-12
20179914-7	2010	CONCLUSIONS: Rifampicin considerably reduces the plasma concentrations and the renin-inhibiting effect of aliskiren by decreasing its oral bioavailability.	Rifampin	13-23	renin	Homo sapiens	79-84
20222094-9	2010	Most genes showing changes greater than 3-fold were known to be rifampicin-responsive, and this suggested a PXR-dependent mode of regulation.	Rifampin	64-74	nuclear receptor subfamily 1 group I member 2	Homo sapiens	108-111
22009927-14	2010	CONCLUSION: Rifampicin may decrease the risk of steroid-induced ONFH by enhancing P-gp activity, thus preventing steroid-induced BMSC adipogenesis.	Rifampin	12-22	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	82-86
20447852-0	2010	Pregnancy during TNFalpha antagonist therapy: beware the rifampin-oral contraceptive interaction.	Rifampin	57-65	tumor necrosis factor	Homo sapiens	17-25
20086032-7	2010	Mutational studies showed that the HNF4alpha sites are needed for up-regulation of the CYP2C8 and CYP2C9 promoters by rifampicin.	Rifampin	118-128	hepatocyte nuclear factor 4 alpha	Homo sapiens	35-44
20086032-7	2010	Mutational studies showed that the HNF4alpha sites are needed for up-regulation of the CYP2C8 and CYP2C9 promoters by rifampicin.	Rifampin	118-128	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	87-93
20086032-7	2010	Mutational studies showed that the HNF4alpha sites are needed for up-regulation of the CYP2C8 and CYP2C9 promoters by rifampicin.	Rifampin	118-128	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	98-104
20086032-8	2010	Furthermore, silencing of HNF4alpha abolished transactivation of the CYP2C8 and CYP2C9 promoters by rifampicin.	Rifampin	100-110	hepatocyte nuclear factor 4 alpha	Homo sapiens	26-35
20086032-8	2010	Furthermore, silencing of HNF4alpha abolished transactivation of the CYP2C8 and CYP2C9 promoters by rifampicin.	Rifampin	100-110	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	69-75
20086032-8	2010	Furthermore, silencing of HNF4alpha abolished transactivation of the CYP2C8 and CYP2C9 promoters by rifampicin.	Rifampin	100-110	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	80-86
20086032-10	2010	Quantitative polymerase chain reaction analysis demonstrated that silencing HNF4alpha reduced the constitutive expression of CYP2C8 (53%), CYP2C9 (55%), and CYP2C19 (43%) mRNAs and significantly decreased the magnitude of the rifampicin-mediated induction of CYP2C8 (6.6- versus 2.7-fold), CYP2C9 (3- versus 1.5-fold), and CYP2C19 (1.8- versus 1.1-fold).	Rifampin	226-236	hepatocyte nuclear factor 4 alpha	Homo sapiens	76-85
20086032-10	2010	Quantitative polymerase chain reaction analysis demonstrated that silencing HNF4alpha reduced the constitutive expression of CYP2C8 (53%), CYP2C9 (55%), and CYP2C19 (43%) mRNAs and significantly decreased the magnitude of the rifampicin-mediated induction of CYP2C8 (6.6- versus 2.7-fold), CYP2C9 (3- versus 1.5-fold), and CYP2C19 (1.8- versus 1.1-fold).	Rifampin	226-236	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	125-131
20086032-11	2010	These results provide clear evidence that HNF4alpha contributes to the constitutive expression of the human CYP2C genes and is also important for up-regulation by the PXR agonist rifampicin.	Rifampin	179-189	hepatocyte nuclear factor 4 alpha	Homo sapiens	42-51
20086032-11	2010	These results provide clear evidence that HNF4alpha contributes to the constitutive expression of the human CYP2C genes and is also important for up-regulation by the PXR agonist rifampicin.	Rifampin	179-189	nuclear receptor subfamily 1 group I member 2	Homo sapiens	167-170
20446914-4	2010	Rifampicin, CITCO and T1317 significantly enhanced interactions for human PXR, human CAR and human LXR, respectively.	Rifampin	0-10	nuclear receptor subfamily 1 group I member 2	Homo sapiens	74-77
20179914-0	2010	Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren.	Rifampin	0-10	renin	Homo sapiens	53-58
20446914-4	2010	Rifampicin, CITCO and T1317 significantly enhanced interactions for human PXR, human CAR and human LXR, respectively.	Rifampin	0-10	nuclear receptor subfamily 1 group I member 3	Homo sapiens	85-88
19844775-5	2010	After pig treatment with rifampicin, the mRNA expression of CYPs and transporters from brain regions did not appear to change, except CYP3A22 and 3A29 in cortex and hippocampus, CYP2B22 in meninges.	Rifampin	25-35	cytochrome P450 family 2 subfamily B member 6B	Sus scrofa	178-185
19844775-1	2010	The in vivo effect of rifampicin, a potent ligand of PXR, on gene expression of CYP2B22, 3A22, 3A29, 3A46, CAR, PXR and MDR1, MRP1, MRP2, LRP transporters in liver and cortex, cerebellum, midbrain, hippocampus, meninges and brain capillaries of pig was investigated.	Rifampin	22-32	nuclear receptor subfamily 1 group I member 2	Sus scrofa	53-56
19844775-1	2010	The in vivo effect of rifampicin, a potent ligand of PXR, on gene expression of CYP2B22, 3A22, 3A29, 3A46, CAR, PXR and MDR1, MRP1, MRP2, LRP transporters in liver and cortex, cerebellum, midbrain, hippocampus, meninges and brain capillaries of pig was investigated.	Rifampin	22-32	cytochrome P450 family 2 subfamily B member 6B	Sus scrofa	80-87
19844775-1	2010	The in vivo effect of rifampicin, a potent ligand of PXR, on gene expression of CYP2B22, 3A22, 3A29, 3A46, CAR, PXR and MDR1, MRP1, MRP2, LRP transporters in liver and cortex, cerebellum, midbrain, hippocampus, meninges and brain capillaries of pig was investigated.	Rifampin	22-32	CXADR Ig-like cell adhesion molecule	Sus scrofa	107-110
19844775-1	2010	The in vivo effect of rifampicin, a potent ligand of PXR, on gene expression of CYP2B22, 3A22, 3A29, 3A46, CAR, PXR and MDR1, MRP1, MRP2, LRP transporters in liver and cortex, cerebellum, midbrain, hippocampus, meninges and brain capillaries of pig was investigated.	Rifampin	22-32	nuclear receptor subfamily 1 group I member 2	Sus scrofa	112-115
19844775-1	2010	The in vivo effect of rifampicin, a potent ligand of PXR, on gene expression of CYP2B22, 3A22, 3A29, 3A46, CAR, PXR and MDR1, MRP1, MRP2, LRP transporters in liver and cortex, cerebellum, midbrain, hippocampus, meninges and brain capillaries of pig was investigated.	Rifampin	22-32	ATP-binding cassette, sub-family B (MDR/TAP), member 1	Sus scrofa	120-124
19844775-1	2010	The in vivo effect of rifampicin, a potent ligand of PXR, on gene expression of CYP2B22, 3A22, 3A29, 3A46, CAR, PXR and MDR1, MRP1, MRP2, LRP transporters in liver and cortex, cerebellum, midbrain, hippocampus, meninges and brain capillaries of pig was investigated.	Rifampin	22-32	LOW QUALITY PROTEIN: multidrug resistance-associated protein 6	Sus scrofa	126-130
19844775-1	2010	The in vivo effect of rifampicin, a potent ligand of PXR, on gene expression of CYP2B22, 3A22, 3A29, 3A46, CAR, PXR and MDR1, MRP1, MRP2, LRP transporters in liver and cortex, cerebellum, midbrain, hippocampus, meninges and brain capillaries of pig was investigated.	Rifampin	22-32	ATP binding cassette subfamily C member 2	Sus scrofa	132-136
19844775-5	2010	After pig treatment with rifampicin, the mRNA expression of CYPs and transporters from brain regions did not appear to change, except CYP3A22 and 3A29 in cortex and hippocampus, CYP2B22 in meninges.	Rifampin	25-35	cytochrome P450 family 3 subfamily A member 22	Sus scrofa	134-141
20079722-10	2010	Indeed, over-expression of PXR in HepG2 cells enhanced the steatogenic effect of hyperforin and rifampicin.	Rifampin	96-106	nuclear receptor subfamily 1 group I member 2	Homo sapiens	27-30
20338069-11	2010	This is the first report to demonstrate the effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine concentrations when co-administered with rifampicin in HIV/TB co-infected Thai adults.	Rifampin	158-168	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	55-61
20086032-0	2010	Hepatocyte nuclear factor 4{alpha} regulates rifampicin-mediated induction of CYP2C genes in primary cultures of human hepatocytes.	Rifampin	45-55	hepatocyte nuclear factor 4 alpha	Homo sapiens	0-33
20086032-0	2010	Hepatocyte nuclear factor 4{alpha} regulates rifampicin-mediated induction of CYP2C genes in primary cultures of human hepatocytes.	Rifampin	45-55	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	78-83
20086032-3	2010	In the present study, we used primary cultures of human hepatocytes to investigate the role of HNF4alpha in the pregnane X receptor (PXR)/rifampicin-mediated up-regulation of CYP2C8, CYP2C9, and CYP2C19 gene expression.	Rifampin	138-148	hepatocyte nuclear factor 4 alpha	Homo sapiens	95-104
20086032-3	2010	In the present study, we used primary cultures of human hepatocytes to investigate the role of HNF4alpha in the pregnane X receptor (PXR)/rifampicin-mediated up-regulation of CYP2C8, CYP2C9, and CYP2C19 gene expression.	Rifampin	138-148	nuclear receptor subfamily 1 group I member 2	Homo sapiens	112-131
20086032-3	2010	In the present study, we used primary cultures of human hepatocytes to investigate the role of HNF4alpha in the pregnane X receptor (PXR)/rifampicin-mediated up-regulation of CYP2C8, CYP2C9, and CYP2C19 gene expression.	Rifampin	138-148	nuclear receptor subfamily 1 group I member 2	Homo sapiens	133-136
20086032-3	2010	In the present study, we used primary cultures of human hepatocytes to investigate the role of HNF4alpha in the pregnane X receptor (PXR)/rifampicin-mediated up-regulation of CYP2C8, CYP2C9, and CYP2C19 gene expression.	Rifampin	138-148	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	175-181
20086032-3	2010	In the present study, we used primary cultures of human hepatocytes to investigate the role of HNF4alpha in the pregnane X receptor (PXR)/rifampicin-mediated up-regulation of CYP2C8, CYP2C9, and CYP2C19 gene expression.	Rifampin	138-148	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	183-189
20171174-6	2010	TRalpha1, TRbeta1, COUP-TFI, and COUP-TFII further demonstrated dose-dependent repression of PXR-mediated CYP3A4 enhancer/promoter reporter activity in transient transfection in the presence and absence of the PXR inducer rifampin, while VDR showed this effect only in the absence of treatment.	Rifampin	222-230	nuclear receptor subfamily 2 group F member 1	Homo sapiens	19-27
20171174-6	2010	TRalpha1, TRbeta1, COUP-TFI, and COUP-TFII further demonstrated dose-dependent repression of PXR-mediated CYP3A4 enhancer/promoter reporter activity in transient transfection in the presence and absence of the PXR inducer rifampin, while VDR showed this effect only in the absence of treatment.	Rifampin	222-230	nuclear receptor subfamily 2 group F member 2	Homo sapiens	33-42
20171174-6	2010	TRalpha1, TRbeta1, COUP-TFI, and COUP-TFII further demonstrated dose-dependent repression of PXR-mediated CYP3A4 enhancer/promoter reporter activity in transient transfection in the presence and absence of the PXR inducer rifampin, while VDR showed this effect only in the absence of treatment.	Rifampin	222-230	nuclear receptor subfamily 1 group I member 2	Homo sapiens	93-96
20171174-6	2010	TRalpha1, TRbeta1, COUP-TFI, and COUP-TFII further demonstrated dose-dependent repression of PXR-mediated CYP3A4 enhancer/promoter reporter activity in transient transfection in the presence and absence of the PXR inducer rifampin, while VDR showed this effect only in the absence of treatment.	Rifampin	222-230	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	106-112
20171174-6	2010	TRalpha1, TRbeta1, COUP-TFI, and COUP-TFII further demonstrated dose-dependent repression of PXR-mediated CYP3A4 enhancer/promoter reporter activity in transient transfection in the presence and absence of the PXR inducer rifampin, while VDR showed this effect only in the absence of treatment.	Rifampin	222-230	nuclear receptor subfamily 1 group I member 2	Homo sapiens	210-213
20171174-6	2010	TRalpha1, TRbeta1, COUP-TFI, and COUP-TFII further demonstrated dose-dependent repression of PXR-mediated CYP3A4 enhancer/promoter reporter activity in transient transfection in the presence and absence of the PXR inducer rifampin, while VDR showed this effect only in the absence of treatment.	Rifampin	222-230	vitamin D receptor	Homo sapiens	238-241
19879123-0	2010	Serial interferon-gamma release assays after rifampicin prophylaxis in a tuberculosis outbreak.	Rifampin	45-55	interferon gamma	Homo sapiens	7-23
19854261-5	2010	On the other hand, the model inducers, i.e. 2,3,7,8- tetrachlorodibenzo-p-dioxin (TCDD) and rifampicin, significantly increased the levels of CYP1A2 and CYP3A4 mRNAs in all cultures.	Rifampin	92-102	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	142-148
19854261-5	2010	On the other hand, the model inducers, i.e. 2,3,7,8- tetrachlorodibenzo-p-dioxin (TCDD) and rifampicin, significantly increased the levels of CYP1A2 and CYP3A4 mRNAs in all cultures.	Rifampin	92-102	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	153-159
20035846-5	2010	CYP3A was induced by EMD in human HepG2 cells exceeding the level induced by rifampicin, but was not induced in rat H4IIE cells.	Rifampin	77-87	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-5
20460758-9	2010	However, rifampicin the nuclear receptor steroid and xenobiotic receptor (SXR) ligand had no effect of IL-beta, suggesting that IL-1beta is involved in VK(2) dependent gamma-calboxylation but not SXR-activation.	Rifampin	9-19	nuclear receptor subfamily 1 group I member 2	Homo sapiens	74-77
20019244-2	2010	In the present study, we carefully analyzed mRNA expression and activity of the major P450s and their responsiveness to three prototypical inducers, phenobarbital, rifampicin, and omeprazole, in differentiated HepaRG cell cultures over a 4-week period after low and high seeding.	Rifampin	164-174	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	86-91
20019244-7	2010	Thus, CYP1A2, CYP2B6, and CYP3A4 were found to accurately respond to their respective prototypical inducers, i.e., omeprazole, phenobarbital, and rifampicin.	Rifampin	146-156	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	6-12
20019244-7	2010	Thus, CYP1A2, CYP2B6, and CYP3A4 were found to accurately respond to their respective prototypical inducers, i.e., omeprazole, phenobarbital, and rifampicin.	Rifampin	146-156	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	14-20
20019244-7	2010	Thus, CYP1A2, CYP2B6, and CYP3A4 were found to accurately respond to their respective prototypical inducers, i.e., omeprazole, phenobarbital, and rifampicin.	Rifampin	146-156	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	26-32
20034695-4	2010	Current evidence indicates that ursodeoxycholic acid (UDCA) can be effective in selected patients with PFIC3 (ABCB4 deficiency), while rifampicin reduces pruritus in patients with PFIC1 (ATP8B1 deficiency) and PFIC2 (ABCB11 deficiency), and might abort cholestatic episodes in BRIC (mild ATP8B1 or ABCB11 deficiency).	Rifampin	135-145	ATPase phospholipid transporting 8B1	Homo sapiens	187-193
20012942-2	2010	Since they interact with ABCB1, ABCC2, and organic anion transporting proteins (OATPs), which are localized to lung tissue, pulmonary concentration may be influenced by rifampicin (RIF), an inducer and modulator of efflux and uptake transporters.	Rifampin	169-179	ATP binding cassette subfamily B member 1	Canis lupus familiaris	25-30
20012942-2	2010	Since they interact with ABCB1, ABCC2, and organic anion transporting proteins (OATPs), which are localized to lung tissue, pulmonary concentration may be influenced by rifampicin (RIF), an inducer and modulator of efflux and uptake transporters.	Rifampin	169-179	ATP binding cassette subfamily C member 2	Canis lupus familiaris	32-37
20012942-2	2010	Since they interact with ABCB1, ABCC2, and organic anion transporting proteins (OATPs), which are localized to lung tissue, pulmonary concentration may be influenced by rifampicin (RIF), an inducer and modulator of efflux and uptake transporters.	Rifampin	181-184	ATP binding cassette subfamily B member 1	Canis lupus familiaris	25-30
20012942-2	2010	Since they interact with ABCB1, ABCC2, and organic anion transporting proteins (OATPs), which are localized to lung tissue, pulmonary concentration may be influenced by rifampicin (RIF), an inducer and modulator of efflux and uptake transporters.	Rifampin	181-184	ATP binding cassette subfamily C member 2	Canis lupus familiaris	32-37
19712670-7	2010	In contrast, eNR3A4 is involved only in the basal transactivation in intestinal cells and in the PXR-mediated rifampicin-induced transactivation of CYP3A4 in LS174T intestinal cells.	Rifampin	110-120	nuclear receptor subfamily 1 group I member 2	Homo sapiens	97-100
19712670-7	2010	In contrast, eNR3A4 is involved only in the basal transactivation in intestinal cells and in the PXR-mediated rifampicin-induced transactivation of CYP3A4 in LS174T intestinal cells.	Rifampin	110-120	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	148-154
19898817-10	2010	Exposure of fathead minnow (FHM) cells with the CYP3A inducer rifampicin leads to dose-dependent increase in putative CYP3A enzyme activity.	Rifampin	62-72	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	48-53
19898817-10	2010	Exposure of fathead minnow (FHM) cells with the CYP3A inducer rifampicin leads to dose-dependent increase in putative CYP3A enzyme activity.	Rifampin	62-72	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	118-123
20305320-1	2010	BACKGROUND: Induction of the hepatic and intestinal cytochrome P450-3A4 system and intestinal P-glycoprotein is an unavoidable consequence of rifampin administration which requires substantial increase in tacrolimus dose when given concurrently.	Rifampin	142-150	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	52-71
20305320-1	2010	BACKGROUND: Induction of the hepatic and intestinal cytochrome P450-3A4 system and intestinal P-glycoprotein is an unavoidable consequence of rifampin administration which requires substantial increase in tacrolimus dose when given concurrently.	Rifampin	142-150	ATP binding cassette subfamily B member 1	Homo sapiens	94-108
21265468-5	2010	Rifampicin and minocycline at 10-100 microg/ml significantly inhibited interleukin-2 production from mitogen- or superantigen-stimulated peripheral-blood mononuclear cells (p &lt; 0.025).	Rifampin	0-10	interleukin 2	Homo sapiens	71-84
20923245-3	2010	OBJECTIVE: To assess the effects of rifampicin (rifampin), a potent inducer of CYP3A4 and inhibitor of organic anion transporter polypeptides (OATPs), on the steady-state pharmacokinetics, safety and tolerability of ambrisentan.	Rifampin	36-46	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	79-85
20016271-2	2010	The in vitro effects of rifampicin to rapidly downregulate angiogenesis and mitogenesis-related genes in cultured endothelial cells are reminiscent of endostatin, one of the most well-studied angiogenesis inhibitors.	Rifampin	24-34	collagen type XVIII alpha 1 chain	Homo sapiens	151-161
20923245-15	2010	No dose adjustment of ambrisentan should be required when it is co-administered with rifampicin, a strong inducer of CYP3A4 activity and inhibitor of OATPs.	Rifampin	85-95	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	117-123
20923245-3	2010	OBJECTIVE: To assess the effects of rifampicin (rifampin), a potent inducer of CYP3A4 and inhibitor of organic anion transporter polypeptides (OATPs), on the steady-state pharmacokinetics, safety and tolerability of ambrisentan.	Rifampin	48-56	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	79-85
19833845-7	2010	Second, two known human CYP3A4 inducers, rifampicin and hyperforin, were tested in monkey and human primary hepatocytes for induction of CYP3A enzymes.	Rifampin	41-51	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	24-30
19833845-7	2010	Second, two known human CYP3A4 inducers, rifampicin and hyperforin, were tested in monkey and human primary hepatocytes for induction of CYP3A enzymes.	Rifampin	41-51	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	24-29
20212331-0	2010	Discovery of rifampicin as a new anti-glycating compound by matrix-assisted laser desorption/ionization mass spectrometry-based insulin glycation assay.	Rifampin	13-23	insulin	Homo sapiens	128-135
19915937-4	2010	Following exposure of PICM-19H cells to either 3-methylcholanthrene, rifampicin or phenobarbital, the induced activities of cytochrome P450 (CYP450) isozymes CYP-1A, -2, and-3A were assessed.	Rifampin	69-79	cytochrome P450 family 2 subfamily D member 6	Sus scrofa	124-139
20201776-4	2010	We determined the induction of CYP3A4 by EFV, RTV, ATV, EFV+RTV, EFV+ATV, EFV+RTV+ATV and rifampicin (RIF) employing primary human hepatocytes from 3 donors.	Rifampin	90-100	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-37
20201776-4	2010	We determined the induction of CYP3A4 by EFV, RTV, ATV, EFV+RTV, EFV+ATV, EFV+RTV+ATV and rifampicin (RIF) employing primary human hepatocytes from 3 donors.	Rifampin	102-105	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-37
20201776-8	2010	hPXR activation data in LS180 cells were consistent with the induction of transcripts and the estimated EC(50) values were 0.87 microM, 0.44 microM and 3.7 microM for RIF, RTV and EFV, respectively.	Rifampin	167-170	nuclear receptor subfamily 1 group I member 2	Homo sapiens	0-4
19915937-4	2010	Following exposure of PICM-19H cells to either 3-methylcholanthrene, rifampicin or phenobarbital, the induced activities of cytochrome P450 (CYP450) isozymes CYP-1A, -2, and-3A were assessed.	Rifampin	69-79	cytochrome P450 family 2 subfamily D member 6	Sus scrofa	141-147
19915937-7	2010	Rifampicin induction of CYP450 isozyme activities was confirmed by conversion of testosterone to 6beta-OH-, 2alpha-OH- and 2beta-OH-testosterone, as determined by mass spectrometry.	Rifampin	0-10	cytochrome P450 family 2 subfamily D member 6	Sus scrofa	24-30
19836313-8	2009	In addition, the ability of MUTYH and the variants to suppress mutations and complement for the absence of MutY in Escherichia coli was assessed using rifampicin resistance assays.	Rifampin	151-161	mutY DNA glycosylase	Homo sapiens	28-33
20392161-1	2010	Intranasal administration of lipid microspheres (LM) containing rifampicin (LM-RFP) exhibited the bacteriostatic effect against Mycobacterium tuberculosis H37Rv.	Rifampin	64-74	tripartite motif-containing 27	Mus musculus	79-82
20392161-2	2010	The efficacies of intranasal LM-RFP in lung were markedly higher in immunodeficient BALB/c nude mice (p &lt; 0.001), but not different in immunocompetent BALB/c mice (p = 1.000) compared to the results of oral rifampicin groups.	Rifampin	210-220	tripartite motif-containing 27	Mus musculus	32-35
20392161-4	2010	These results suggested that intranasal LM-RFP could improve the anti-tuberculosis activity in immunodeficient host and minimize drug interaction between rifampicin and nevirapine.	Rifampin	154-164	tripartite motif-containing 27	Mus musculus	43-46
20305954-10	2010	Results showed rifampicin alone to raise (p &lt; 0.05) liver function enzymes (Aspartate amino transferase [AST], Serum alanine amino transferase [ALT] and Total Bilirubin) when compared with controls.	Rifampin	15-25	solute carrier family 17 member 5	Homo sapiens	79-106
20305954-10	2010	Results showed rifampicin alone to raise (p &lt; 0.05) liver function enzymes (Aspartate amino transferase [AST], Serum alanine amino transferase [ALT] and Total Bilirubin) when compared with controls.	Rifampin	15-25	solute carrier family 17 member 5	Homo sapiens	108-111
20305954-10	2010	Results showed rifampicin alone to raise (p &lt; 0.05) liver function enzymes (Aspartate amino transferase [AST], Serum alanine amino transferase [ALT] and Total Bilirubin) when compared with controls.	Rifampin	15-25	glutamic--pyruvic transaminase	Homo sapiens	120-145
20305954-10	2010	Results showed rifampicin alone to raise (p &lt; 0.05) liver function enzymes (Aspartate amino transferase [AST], Serum alanine amino transferase [ALT] and Total Bilirubin) when compared with controls.	Rifampin	15-25	glutamic--pyruvic transaminase	Homo sapiens	147-150
20110038-3	2009	OBJECTIVE: The aim of this study was to investigate the effects of a potent inhibitor (ketoconazole) and inducer (rifampicin) of the CYP3A4 isozyme on the pharmacokinetics of mirodenafil to meet the regulatory requirements for the marketing of mirodenafil in Korea.	Rifampin	114-124	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	133-139
19451401-7	2009	LIPA metabolism in human hepatocytes was found to be induced by the treatment of human hepatocytes with the prototypical CYP3A4 inducers rifampin, carbamazepine, omeprazole, phenobarbital, and phenytoin but not by the CYP1A2 inducer 3-methylcholanthrene.	Rifampin	137-145	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	121-127
20054495-0	2009	Rifampicin Inhibits the LPS-induced Expression of Toll-like Receptor 2 via the Suppression of NF-kappaB DNA-binding Activity in RAW 264.7 Cells.	Rifampin	0-10	toll-like receptor 2	Mus musculus	50-70
20054495-3	2009	Therefore, we hypothesized that rifampicin may influence the TLR2 expression in LPS-activated RAW 264.7 cells.	Rifampin	32-42	toll-like receptor 2	Mus musculus	61-65
20054495-4	2009	In this study, we determined that rifampicin suppresses LPS-induced TLR2 mRNA expression.	Rifampin	34-44	toll-like receptor 2	Mus musculus	68-72
20054495-8	2009	However, rifampicin slightly inhibited the nuclear translocation of NF-kappaB p65.	Rifampin	9-19	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	78-81
20054495-9	2009	In addition, rifampicin increased physical interaction between pregnane X receptor, a receptor for rifampicin, and NF-kappaB p65, suggesting pregnane X receptor interferes with NF-kappaB binding to DNA.	Rifampin	13-23	nuclear receptor subfamily 1, group I, member 2	Mus musculus	63-82
20054495-9	2009	In addition, rifampicin increased physical interaction between pregnane X receptor, a receptor for rifampicin, and NF-kappaB p65, suggesting pregnane X receptor interferes with NF-kappaB binding to DNA.	Rifampin	13-23	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	125-128
20054495-9	2009	In addition, rifampicin increased physical interaction between pregnane X receptor, a receptor for rifampicin, and NF-kappaB p65, suggesting pregnane X receptor interferes with NF-kappaB binding to DNA.	Rifampin	13-23	nuclear receptor subfamily 1, group I, member 2	Mus musculus	141-160
20054495-9	2009	In addition, rifampicin increased physical interaction between pregnane X receptor, a receptor for rifampicin, and NF-kappaB p65, suggesting pregnane X receptor interferes with NF-kappaB binding to DNA.	Rifampin	99-109	nuclear receptor subfamily 1, group I, member 2	Mus musculus	63-82
20054495-9	2009	In addition, rifampicin increased physical interaction between pregnane X receptor, a receptor for rifampicin, and NF-kappaB p65, suggesting pregnane X receptor interferes with NF-kappaB binding to DNA.	Rifampin	99-109	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	125-128
20054495-9	2009	In addition, rifampicin increased physical interaction between pregnane X receptor, a receptor for rifampicin, and NF-kappaB p65, suggesting pregnane X receptor interferes with NF-kappaB binding to DNA.	Rifampin	99-109	nuclear receptor subfamily 1, group I, member 2	Mus musculus	141-160
20054495-10	2009	Taken together, our results demonstrate that rifampicin inhibits LPS-induced TLR2 expression, at least in part, via the suppression of NF-kappaB DNA-binding activity in RAW 264.7 cells.	Rifampin	45-55	toll-like receptor 2	Mus musculus	77-81
20054495-11	2009	Thus, the present results suggest that the rifampicin-mediated inhibition of TLR2 via the suppression of NF-kappaB DNA-binding activity may be a novel mechanism of the immune-suppressive effects of rifampicin.	Rifampin	43-53	toll-like receptor 2	Mus musculus	77-81
20054495-11	2009	Thus, the present results suggest that the rifampicin-mediated inhibition of TLR2 via the suppression of NF-kappaB DNA-binding activity may be a novel mechanism of the immune-suppressive effects of rifampicin.	Rifampin	198-208	toll-like receptor 2	Mus musculus	77-81
19686824-6	2009	The levels of CYP1A1, CYP1A2, CY2C9 and CYP3A4 mRNAs were not altered by Zolpidem, whereas model inducers dioxin and rifampicin significantly induced CYP1A and CYP2/3 gene expression, respectively.	Rifampin	117-127	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	14-20
19686824-6	2009	The levels of CYP1A1, CYP1A2, CY2C9 and CYP3A4 mRNAs were not altered by Zolpidem, whereas model inducers dioxin and rifampicin significantly induced CYP1A and CYP2/3 gene expression, respectively.	Rifampin	117-127	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	22-28
19686824-6	2009	The levels of CYP1A1, CYP1A2, CY2C9 and CYP3A4 mRNAs were not altered by Zolpidem, whereas model inducers dioxin and rifampicin significantly induced CYP1A and CYP2/3 gene expression, respectively.	Rifampin	117-127	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	40-46
19686824-6	2009	The levels of CYP1A1, CYP1A2, CY2C9 and CYP3A4 mRNAs were not altered by Zolpidem, whereas model inducers dioxin and rifampicin significantly induced CYP1A and CYP2/3 gene expression, respectively.	Rifampin	117-127	peptidylprolyl isomerase F	Homo sapiens	160-166
19577586-8	2009	The integrity of hepatocyte ZO-1 and occludin was altered by a seven-day administration of rifampicin.	Rifampin	91-101	tight junction protein 1	Mus musculus	28-32
19577586-8	2009	The integrity of hepatocyte ZO-1 and occludin was altered by a seven-day administration of rifampicin.	Rifampin	91-101	occludin	Mus musculus	37-45
19577586-10	2009	The expression of hepatic ZO-1 and ZO-2 mRNA was significantly decreased, beginning as early as 30 min and remaining a lower level 12 h after a single dose of rifampicin.	Rifampin	159-169	tight junction protein 1	Mus musculus	26-30
19577586-10	2009	The expression of hepatic ZO-1 and ZO-2 mRNA was significantly decreased, beginning as early as 30 min and remaining a lower level 12 h after a single dose of rifampicin.	Rifampin	159-169	tight junction protein 2	Mus musculus	35-39
19520773-5	2009	Real-time polymerase chain reaction analysis of human hepatocyte cultures revealed that MD induces the mRNA expression of CYP2B6, CYP3A4, UGT1A1, and multidrug resistance 1 in a concentration-related manner, with the maximal induction of CYP2B6 challenging that of the induction by rifampicin.	Rifampin	282-292	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	122-128
19520773-5	2009	Real-time polymerase chain reaction analysis of human hepatocyte cultures revealed that MD induces the mRNA expression of CYP2B6, CYP3A4, UGT1A1, and multidrug resistance 1 in a concentration-related manner, with the maximal induction of CYP2B6 challenging that of the induction by rifampicin.	Rifampin	282-292	ATP binding cassette subfamily B member 1	Homo sapiens	150-172
19460945-0	2009	Rifampicin-activated human pregnane X receptor and CYP3A4 induction enhance acetaminophen-induced toxicity.	Rifampin	0-10	nuclear receptor subfamily 1 group I member 2	Homo sapiens	27-46
19460945-3	2009	Human PXR activation and CYP3A4 induction enhanced APAP-induced hepatotoxicity as revealed by hepatic alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities elevated in serum, and hepatic necrosis after coadministration of rifampicin and APAP, compared with APAP administration alone.	Rifampin	247-257	nuclear receptor subfamily 1 group I member 2	Homo sapiens	6-9
19460945-3	2009	Human PXR activation and CYP3A4 induction enhanced APAP-induced hepatotoxicity as revealed by hepatic alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities elevated in serum, and hepatic necrosis after coadministration of rifampicin and APAP, compared with APAP administration alone.	Rifampin	247-257	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	25-31
19460945-6	2009	Moreover, mRNA analysis demonstrated that CYP3A4 and other PXR target genes were significantly induced by rifampicin treatment.	Rifampin	106-116	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	42-48
19460945-6	2009	Moreover, mRNA analysis demonstrated that CYP3A4 and other PXR target genes were significantly induced by rifampicin treatment.	Rifampin	106-116	nuclear receptor subfamily 1 group I member 2	Homo sapiens	59-62
19845431-7	2009	Using rifampicin as a reference standard, compounds with a C(ss,u)/RF value greater than 7.31 nmol l(-1) may induce CYP3A in vivo in humans.	Rifampin	6-16	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	116-121
19843061-9	2009	CONCLUSIONS: Co-administration of rifampicin and roflumilast led to a reduction in total PDE4 inhibitory activity of roflumilast by about 58%.	Rifampin	34-44	phosphodiesterase 4A	Homo sapiens	89-93
19593667-6	2009	The expressions of PXR, SP1, and MRP3 were markedly enhanced after rifampicin treatment.	Rifampin	67-77	nuclear receptor subfamily 1 group I member 2	Homo sapiens	19-22
19593667-6	2009	The expressions of PXR, SP1, and MRP3 were markedly enhanced after rifampicin treatment.	Rifampin	67-77	ATP binding cassette subfamily C member 3	Homo sapiens	33-37
19593667-8	2009	It also observed that PXR, activated by rifampicin or knocked down via short hairpin RNAs, could enhance or reduce cells resistance to the chemotherapeutic agents through 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay.	Rifampin	40-50	nuclear receptor subfamily 1 group I member 2	Homo sapiens	22-25
19703346-8	2009	Rifampicin (a potent inhibitor of organic anion transporting polypeptide (Oatp) 2), but not indometacin (a representative inhibitor of organic anion transporter (Oat) 2 and Oatp1) treatment, significantly inhibited the uptake of paclitaxel and TAX-2"-Et.	Rifampin	0-10	solute carrier organic anion transporter family, member 1a4	Rattus norvegicus	34-81
19703346-9	2009	We characterized the rifampicin-sensitive uptake of paclitaxel and TAX-2"-Et using rat hepatocytes treated with PCN, which dramatically enhances hepatic Oatp2 protein levels.	Rifampin	21-31	solute carrier organic anion transporter family, member 1a4	Rattus norvegicus	153-158
19364845-9	2009	In addition, daptomycin at a high dose (30 mg/kg) completely prevented the emergence of rifampin resistance in planktonic and adherent MRSA cells.	Rifampin	88-96	solute carrier family 9 member A6	Homo sapiens	135-139
19364845-10	2009	Daptomycin at a high dose, corresponding to 6 mg/kg in humans, in combination with rifampin showed the highest activity against planktonic and adherent MRSA.	Rifampin	83-91	solute carrier family 9 member A6	Homo sapiens	152-156
19364845-11	2009	Daptomycin plus rifampin is a promising treatment option for implant-associated MRSA infections.	Rifampin	16-24	solute carrier family 9 member A6	Homo sapiens	80-84
19432554-7	2009	Median rifampin and pyrazinamide levels differed significantly by HIV status and CD4 cell count category.	Rifampin	7-15	CD4 molecule	Homo sapiens	81-84
19374892-0	2009	Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T&gt;C polymorphism.	Rifampin	0-10	solute carrier organic anion transporter family member 1B1	Homo sapiens	68-75
19374892-1	2009	BACKGROUND: Both atorvastatin and rifampicin are substrates of OATP1B1 (organic anion transporting polypeptide 1B1) encoded by SLCO1B1 gene.	Rifampin	34-44	solute carrier organic anion transporter family member 1B1	Homo sapiens	63-70
19374892-1	2009	BACKGROUND: Both atorvastatin and rifampicin are substrates of OATP1B1 (organic anion transporting polypeptide 1B1) encoded by SLCO1B1 gene.	Rifampin	34-44	solute carrier organic anion transporter family member 1B1	Homo sapiens	72-114
19374892-1	2009	BACKGROUND: Both atorvastatin and rifampicin are substrates of OATP1B1 (organic anion transporting polypeptide 1B1) encoded by SLCO1B1 gene.	Rifampin	34-44	solute carrier organic anion transporter family member 1B1	Homo sapiens	127-134
19374892-2	2009	Rifampicin is a potent inhibitor of SLCO1B1 (IC50 1.5 umol/l) and SLCO1B1 521T&gt;C functional genetic polymorphism alters the kinetics of atorvastatin in vivo.	Rifampin	0-10	solute carrier organic anion transporter family member 1B1	Homo sapiens	36-43
19374892-3	2009	We hypothesize that rifampicin might influence atorvastatin kinetics in a SLCO1B1 polymorphism dependent manner.	Rifampin	20-30	solute carrier organic anion transporter family member 1B1	Homo sapiens	74-81
19374892-7	2009	RESULTS: Rifampicin increased atorvastatin plasma concentration in accordance with SLCO1B1 521T&gt;C genotype while the increasing percentage of AUC((0-48)) among c.521TT, c.521TC and c.521CC individuals were 833+/-245% vs 468+/-233% vs 330+/-223% (P=0.007).	Rifampin	9-19	solute carrier organic anion transporter family member 1B1	Homo sapiens	83-90
19374892-9	2009	CONCLUSIONS: These results suggested that rifampicin elevated the plasma concentration of atorvastatin depending on SLCO1B1 genotype and rifampicin pharmacokinetics were not altered by SLCO1B1 genotype.	Rifampin	42-52	solute carrier organic anion transporter family member 1B1	Homo sapiens	116-123
19369937-9	2009	But the difference in activity levels between the CYP2C9*1/*1 and *3/*3 genotypes before the administration of rifampin was sixfold.	Rifampin	111-119	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	50-56
19702536-3	2009	A variety of xenobiotics such as phenobarbital, rifampicin, and hyperforin have been shown to induce the transcriptional expression of CYP2C genes in primary human hepatocytes and to increase the metabolism of CYP2C substrates in vivo in man.	Rifampin	48-58	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	135-140
19702536-3	2009	A variety of xenobiotics such as phenobarbital, rifampicin, and hyperforin have been shown to induce the transcriptional expression of CYP2C genes in primary human hepatocytes and to increase the metabolism of CYP2C substrates in vivo in man.	Rifampin	48-58	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	210-215
19584503-0	2009	Characterization of RPO B gene for detection of rifampicin drug resistance by SSCP and sequence analysis.	Rifampin	48-58	DNA-directed RNA polymerase subunit beta	Mycobacterium tuberculosis H37Rv	20-25
19429255-7	2009	In agreement, pretreatment with selective CYP inducers, beta-naphthoflavone and rifampin, could increase the cytotoxicity of ginkgolic acid in HepG2 cells.	Rifampin	80-88	peptidylprolyl isomerase G	Homo sapiens	42-45
19464568-0	2009	Expression and inducibility of CYP1A1, 1A2, 1B1 by beta-naphthoflavone and CYP2B22, 3A22, 3A29, 3A46 by rifampicin in the respiratory and olfactory mucosa of pig.	Rifampin	104-114	cytochrome P450 family 1 subfamily A member 1	Sus scrofa	31-37
19457725-2	2009	Rifampicin is a CYP3A4 inducer while clarithromycin is known to inhibit CYP3A4.	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	16-22
19464568-0	2009	Expression and inducibility of CYP1A1, 1A2, 1B1 by beta-naphthoflavone and CYP2B22, 3A22, 3A29, 3A46 by rifampicin in the respiratory and olfactory mucosa of pig.	Rifampin	104-114	cytochrome P450 family 2 subfamily B member 6B	Sus scrofa	75-82
19464568-4	2009	The rifampicin treatment resulted in a transcriptional activation of CYP2B22 and CYP3As genes in liver but not in respiratory and olfactory mucosa.	Rifampin	4-14	cytochrome P450 family 2 subfamily B member 6B	Sus scrofa	69-76
19417618-4	2009	Their hypothesis was that rifampin enhances the CYP3A-mediated metabolism of oxycodone and attenuates its pharmacologic effect.	Rifampin	26-34	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	48-53
19371336-0	2009	Does CYP2E1 play a major role in the aggravation of isoniazid toxicity by rifampicin in human hepatocytes?	Rifampin	74-84	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	5-11
19371336-4	2009	The main conclusion was that the difference in cytochrome P450 2E1 (CYP2E1) induction by rifampicin between rat and human hepatocytes accounted for the difference in exacerbation of isoniazid hepatotoxicity by rifampicin.	Rifampin	89-99	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	47-66
19371336-4	2009	The main conclusion was that the difference in cytochrome P450 2E1 (CYP2E1) induction by rifampicin between rat and human hepatocytes accounted for the difference in exacerbation of isoniazid hepatotoxicity by rifampicin.	Rifampin	89-99	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	68-74
19371336-4	2009	The main conclusion was that the difference in cytochrome P450 2E1 (CYP2E1) induction by rifampicin between rat and human hepatocytes accounted for the difference in exacerbation of isoniazid hepatotoxicity by rifampicin.	Rifampin	210-220	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	47-66
19371336-4	2009	The main conclusion was that the difference in cytochrome P450 2E1 (CYP2E1) induction by rifampicin between rat and human hepatocytes accounted for the difference in exacerbation of isoniazid hepatotoxicity by rifampicin.	Rifampin	210-220	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	68-74
19371336-6	2009	The authors presented data showing that rifampicin enhanced 4-NP activity and CYP2E1 mRNA expression in human hepatocytes, but not in rat hepatocytes.	Rifampin	40-50	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	78-84
19371336-8	2009	Rifampicin is a strong inducer of human CYP3A; thus, the increase in 4-NP activity in human hepatocytes could be due to the induction of CYP3A.	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	40-45
19371336-8	2009	Rifampicin is a strong inducer of human CYP3A; thus, the increase in 4-NP activity in human hepatocytes could be due to the induction of CYP3A.	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	137-142
19371336-10	2009	Additionally, more experiments are needed to support the conclusion that rifampicin increased CYP2E1 mRNA expression in human hepatocytes because of the small sample size and the limitations of semi-quantitative RT-PCR.	Rifampin	73-83	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	94-100
19251824-5	2009	In HepG2 and LS180 cells stably transduced with PXR.1, PXR target genes (CYP3A4, MDR1, CYP2B6, and UGT1A1) were higher than mock-transduced cells in the absence of ligand and were further induced in the presence of rifampin.	Rifampin	215-223	peroxisomal biogenesis factor 5	Homo sapiens	48-53
19251824-5	2009	In HepG2 and LS180 cells stably transduced with PXR.1, PXR target genes (CYP3A4, MDR1, CYP2B6, and UGT1A1) were higher than mock-transduced cells in the absence of ligand and were further induced in the presence of rifampin.	Rifampin	215-223	nuclear receptor subfamily 1 group I member 2	Homo sapiens	48-51
19251824-5	2009	In HepG2 and LS180 cells stably transduced with PXR.1, PXR target genes (CYP3A4, MDR1, CYP2B6, and UGT1A1) were higher than mock-transduced cells in the absence of ligand and were further induced in the presence of rifampin.	Rifampin	215-223	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	73-79
19251824-5	2009	In HepG2 and LS180 cells stably transduced with PXR.1, PXR target genes (CYP3A4, MDR1, CYP2B6, and UGT1A1) were higher than mock-transduced cells in the absence of ligand and were further induced in the presence of rifampin.	Rifampin	215-223	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	99-105
19480548-7	2009	The effective CYP3A29 induction in liver was also detected by rifampin oral intubation.	Rifampin	62-70	cytochrome P450 family 3 subfamily A member 29	Sus scrofa	14-21
19074998-5	2009	Introduction of a mutation into either an alpha or beta half-site of CYP3A4 reporter genes almost completely diminished the rifampicin-induced transcription.	Rifampin	124-134	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	69-75
19223781-1	2009	SETTING: Rifampicin may reduce plasma efavirenz concentrations by inducing the expression of the cytochrome P450 2B6, which metabolizes efavirenz.	Rifampin	9-19	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	97-116
19144646-6	2009	The chromatin immunoprecipitation (ChIP) assay showed that PRMT1 was recruited to the regulatory region of the PXR target gene cytochrome P450 3A4 (CYP3A4), with a concomitant methylation of arginine 3 of histone H4, in response to the PXR agonist rifampicin.	Rifampin	248-258	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	148-154
19188390-8	2009	Moreover, rifampin, a known inducer of efflux transport proteins, upregulated the expression of P-glycoprotein in Calu-3 cells and enhanced MXF active transport.	Rifampin	10-18	ATP binding cassette subfamily B member 1	Homo sapiens	96-110
19381336-1	2009	OBJECTIVES: Rifampin is a potent inducer of the cytochrome P450 3A4 isoenzyme (CYP3A4) that metabolizes most protease inhibitor (PI) antiretrovirals.	Rifampin	12-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	48-77
19381336-1	2009	OBJECTIVES: Rifampin is a potent inducer of the cytochrome P450 3A4 isoenzyme (CYP3A4) that metabolizes most protease inhibitor (PI) antiretrovirals.	Rifampin	12-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	79-85
19199552-7	2009	Rifampin resistance emerged more frequently among hVISA isolates than among MRSA isolates (44% vs. 5.9%; P &lt; .001).	Rifampin	0-8	mitochondrial antiviral signaling protein	Homo sapiens	50-55
19199552-9	2009	CONCLUSIONS: hVISA bacteremia was significantly associated with prolonged bacteremia duration, greater rates of complications, and emergence of rifampin resistance, compared with MRSA bacteremia.	Rifampin	144-152	mitochondrial antiviral signaling protein	Homo sapiens	13-18
18855943-7	2009	Treatment of hCMEC/D3 cells for 72 hr with rifampin or SR12813 (two well-established hPXR ligands) or PIs (atazanavir or ritonavir) resulted in an increase in P-gp expression by 1.8-, 6-, and 2-fold, respectively, with no effect observed for MRP1 expression.	Rifampin	43-51	nuclear receptor subfamily 1 group I member 2	Homo sapiens	85-89
18855943-7	2009	Treatment of hCMEC/D3 cells for 72 hr with rifampin or SR12813 (two well-established hPXR ligands) or PIs (atazanavir or ritonavir) resulted in an increase in P-gp expression by 1.8-, 6-, and 2-fold, respectively, with no effect observed for MRP1 expression.	Rifampin	43-51	phosphoglycolate phosphatase	Homo sapiens	159-163
18855943-7	2009	Treatment of hCMEC/D3 cells for 72 hr with rifampin or SR12813 (two well-established hPXR ligands) or PIs (atazanavir or ritonavir) resulted in an increase in P-gp expression by 1.8-, 6-, and 2-fold, respectively, with no effect observed for MRP1 expression.	Rifampin	43-51	ATP binding cassette subfamily B member 1	Homo sapiens	242-246
19144646-6	2009	The chromatin immunoprecipitation (ChIP) assay showed that PRMT1 was recruited to the regulatory region of the PXR target gene cytochrome P450 3A4 (CYP3A4), with a concomitant methylation of arginine 3 of histone H4, in response to the PXR agonist rifampicin.	Rifampin	248-258	protein arginine methyltransferase 1	Homo sapiens	59-64
19144646-6	2009	The chromatin immunoprecipitation (ChIP) assay showed that PRMT1 was recruited to the regulatory region of the PXR target gene cytochrome P450 3A4 (CYP3A4), with a concomitant methylation of arginine 3 of histone H4, in response to the PXR agonist rifampicin.	Rifampin	248-258	nuclear receptor subfamily 1 group I member 2	Homo sapiens	111-114
19144646-6	2009	The chromatin immunoprecipitation (ChIP) assay showed that PRMT1 was recruited to the regulatory region of the PXR target gene cytochrome P450 3A4 (CYP3A4), with a concomitant methylation of arginine 3 of histone H4, in response to the PXR agonist rifampicin.	Rifampin	248-258	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	127-146
19114679-0	2009	Roles of NF-kappaB activation and peroxisome proliferator-activated receptor gamma inhibition in the effect of rifampin on inducible nitric oxide synthase transcription in human lung epithelial cells.	Rifampin	111-119	peroxisome proliferator activated receptor gamma	Homo sapiens	34-82
19114679-2	2009	Previous studies have found that rifampin increases inducible nitric oxide (NO) synthase (iNOS) expression and NO production.	Rifampin	33-41	nitric oxide synthase 2	Homo sapiens	90-94
19114679-5	2009	The addition of rifampin increased the iNOS level by 1.9 +/- 0.3-fold at a dose of 10 microg/ml (P &lt; 0.01) and by 4.0 +/- 0.3-fold at a dose of 50 microg/ml (P &lt; 0.001).	Rifampin	16-24	nitric oxide synthase 2	Homo sapiens	39-43
19114679-6	2009	Rifampin treatment also affected the transcription factors that regulate iNOS mRNA: there was an increased and prolonged degradation of the inhibitory subunit of NF-kappaB, a corresponding increase in the level of cytokine-induced DNA binding of NF-kappaB (2.1 +/- 0.2-fold), and a decrease in the level of expression of peroxisome proliferator-activated receptor gamma (PPARgamma).	Rifampin	0-8	nitric oxide synthase 2	Homo sapiens	73-77
19114679-6	2009	Rifampin treatment also affected the transcription factors that regulate iNOS mRNA: there was an increased and prolonged degradation of the inhibitory subunit of NF-kappaB, a corresponding increase in the level of cytokine-induced DNA binding of NF-kappaB (2.1 +/- 0.2-fold), and a decrease in the level of expression of peroxisome proliferator-activated receptor gamma (PPARgamma).	Rifampin	0-8	nuclear factor kappa B subunit 1	Homo sapiens	162-171
19114679-6	2009	Rifampin treatment also affected the transcription factors that regulate iNOS mRNA: there was an increased and prolonged degradation of the inhibitory subunit of NF-kappaB, a corresponding increase in the level of cytokine-induced DNA binding of NF-kappaB (2.1 +/- 0.2-fold), and a decrease in the level of expression of peroxisome proliferator-activated receptor gamma (PPARgamma).	Rifampin	0-8	nuclear factor kappa B subunit 1	Homo sapiens	246-255
19114679-6	2009	Rifampin treatment also affected the transcription factors that regulate iNOS mRNA: there was an increased and prolonged degradation of the inhibitory subunit of NF-kappaB, a corresponding increase in the level of cytokine-induced DNA binding of NF-kappaB (2.1 +/- 0.2-fold), and a decrease in the level of expression of peroxisome proliferator-activated receptor gamma (PPARgamma).	Rifampin	0-8	peroxisome proliferator activated receptor gamma	Homo sapiens	321-369
19114679-6	2009	Rifampin treatment also affected the transcription factors that regulate iNOS mRNA: there was an increased and prolonged degradation of the inhibitory subunit of NF-kappaB, a corresponding increase in the level of cytokine-induced DNA binding of NF-kappaB (2.1 +/- 0.2-fold), and a decrease in the level of expression of peroxisome proliferator-activated receptor gamma (PPARgamma).	Rifampin	0-8	peroxisome proliferator activated receptor gamma	Homo sapiens	371-380
19114679-11	2009	The increases in the levels of NF-kappaB activation and NO production probably contribute to the therapeutic effects of rifampin.	Rifampin	120-128	nuclear factor kappa B subunit 1	Homo sapiens	31-40
19114679-12	2009	However, given the role of NF-kappaB in upregulating many inflammatory genes and the roles of PPARgamma in downregulating inflammatory genes and in lipid and glucose metabolism, these findings have implications for potential adverse effects of rifampin in patients with chronic inflammatory diseases and glucose or lipid disorders.	Rifampin	244-252	peroxisome proliferator activated receptor gamma	Homo sapiens	94-103
19336894-3	2009	CYP1A1 and CYP3A8 mRNAs were significantly induced by 3-methylcholanthrene and rifampicin, respectively.	Rifampin	79-89	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	0-6
19074998-7	2009	HepG2-based transactivation assays with the reporter gene constructs with or without mutations in the PXR binding element(s) demonstrated that this DR4 motif is essential for the transcriptional activation not only by rifampicin but also by various human PXR activators.	Rifampin	218-228	nuclear receptor subfamily 1 group I member 2	Homo sapiens	102-105
19074998-7	2009	HepG2-based transactivation assays with the reporter gene constructs with or without mutations in the PXR binding element(s) demonstrated that this DR4 motif is essential for the transcriptional activation not only by rifampicin but also by various human PXR activators.	Rifampin	218-228	major histocompatibility complex, class II, DR beta 4	Homo sapiens	148-151
19206053-6	2009	Inducers of metabolism (rifampicin, carbamazepine, St. John"s Wort) also induce the expression of drug transporters like ABCB1.	Rifampin	24-34	ATP binding cassette subfamily B member 1	Homo sapiens	121-126
19147857-8	2009	To activate PXR, we used the PXR ligands, rifampicin, hyperforin, and pregnenolone-16alpha-carbonitrile (PCN), and measured abcb1 mRNA with quantitative polymerase chain reaction, P-glycoprotein expression with Western blotting, and P-glycoprotein transport activity with a calcein assay.	Rifampin	42-52	nuclear receptor subfamily 1 group I member 2	Homo sapiens	12-15
19147857-9	2009	We provide first proof of principle that the human PXR ligands, rifampicin and hyperforin, but not the rodent PXR ligand, PCN, activate pig PXR at the blood-brain barrier and induce mRNA, protein expression, and transport activity of P-glycoprotein.	Rifampin	64-74	nuclear receptor subfamily 1 group I member 2	Homo sapiens	51-54
19129222-1	2009	Chromatin immunoprecipitation (ChIP) studies were conducted in human hepatocytes treated with rifampicin in order to identify new pregnane-X receptor (PXR) target genes.	Rifampin	94-104	nuclear receptor subfamily 1 group I member 2	Homo sapiens	130-149
19129222-1	2009	Chromatin immunoprecipitation (ChIP) studies were conducted in human hepatocytes treated with rifampicin in order to identify new pregnane-X receptor (PXR) target genes.	Rifampin	94-104	nuclear receptor subfamily 1 group I member 2	Homo sapiens	151-154
19129222-4	2009	Of these, only CYP4F12 demonstrated increased binding in the presence of rifampicin.	Rifampin	73-83	cytochrome P450 family 4 subfamily F member 12	Homo sapiens	15-22
19129222-7	2009	Both PXR and the steroid receptor coactivator (SRC-1) were found to bind to PXREs in the absence of rifampicin, although binding was stronger after rifampicin treatment.	Rifampin	100-110	steroid receptor RNA activator 1	Homo sapiens	17-45
19129222-7	2009	Both PXR and the steroid receptor coactivator (SRC-1) were found to bind to PXREs in the absence of rifampicin, although binding was stronger after rifampicin treatment.	Rifampin	100-110	nuclear receptor coactivator 1	Homo sapiens	47-52
19129222-7	2009	Both PXR and the steroid receptor coactivator (SRC-1) were found to bind to PXREs in the absence of rifampicin, although binding was stronger after rifampicin treatment.	Rifampin	148-158	nuclear receptor subfamily 1 group I member 2	Homo sapiens	5-8
19129222-7	2009	Both PXR and the steroid receptor coactivator (SRC-1) were found to bind to PXREs in the absence of rifampicin, although binding was stronger after rifampicin treatment.	Rifampin	148-158	steroid receptor RNA activator 1	Homo sapiens	17-45
19129222-7	2009	Both PXR and the steroid receptor coactivator (SRC-1) were found to bind to PXREs in the absence of rifampicin, although binding was stronger after rifampicin treatment.	Rifampin	148-158	nuclear receptor coactivator 1	Homo sapiens	47-52
19129222-9	2009	In conclusion, our findings indicate that PXR is involved in the regulation of CYP4F12 and that PXR along with SRC1 binds to a broad range of promoters but that many of these are not inducible by rifampicin.	Rifampin	196-206	nuclear receptor coactivator 1	Homo sapiens	111-115
18606396-2	2009	Two major groups of ligand-activated nuclear receptors/xenosensors evolved: the Ah receptor (activated by aryl hydrocarbons and drugs such as omeprazole) and type 2 steroid receptors such as PXR and CAR, activated by drugs such as rifampicin, carbamazepin and phenytoin.	Rifampin	231-241	nuclear receptor subfamily 1 group I member 2	Homo sapiens	191-194
18606396-2	2009	Two major groups of ligand-activated nuclear receptors/xenosensors evolved: the Ah receptor (activated by aryl hydrocarbons and drugs such as omeprazole) and type 2 steroid receptors such as PXR and CAR, activated by drugs such as rifampicin, carbamazepin and phenytoin.	Rifampin	231-241	CXADR pseudogene 1	Homo sapiens	199-202
19013243-0	2009	Effects of rifampin on CYP2E1-dependent hepatotoxicity of isoniazid in rats.	Rifampin	11-19	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	23-29
18981260-5	2009	The degree of the PXR-mediated locking of SMRT depends on the relative concentration of vitamin D(3) to the human PXR activator rifampicin; SMRT increased its dissociation as this ratio increased.	Rifampin	128-138	nuclear receptor subfamily 1 group I member 2	Homo sapiens	18-21
18981260-5	2009	The degree of the PXR-mediated locking of SMRT depends on the relative concentration of vitamin D(3) to the human PXR activator rifampicin; SMRT increased its dissociation as this ratio increased.	Rifampin	128-138	nuclear receptor corepressor 2	Homo sapiens	42-46
18981260-5	2009	The degree of the PXR-mediated locking of SMRT depends on the relative concentration of vitamin D(3) to the human PXR activator rifampicin; SMRT increased its dissociation as this ratio increased.	Rifampin	128-138	nuclear receptor corepressor 2	Homo sapiens	140-144
19013243-11	2009	Rifampin co-administration significantly attenuated isoniazid-induced CYP2E1 levels (p&lt;0.01) and inhibition of mu GST (p&lt;0.01).	Rifampin	0-8	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	70-76
19228077-12	2009	For example, sorafenib exposure was reduced by an average 37% with concomitant administration of the CYP3A4 inducer rifampicin (rifampin); sorafenib concentrations may also be decreased by other CYP3A4 inducers.	Rifampin	116-126	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	101-107
19006545-4	2009	In the present study we aimed to determine the time course of the decrease in plasma 4beta-hydroxycholesterol after termination of induction of CYP3A4/5 by rifampicin.	Rifampin	156-166	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	144-150
19515014-10	2009	CYP2C9 is subject to induction by rifampin, phenobarbital, and dexamethasone, indicating the involvement of pregnane X receptor, constitutive androstane receptor and glucocorticoid receptor in the regulation of CYP2C9.	Rifampin	34-42	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	0-6
19515014-10	2009	CYP2C9 is subject to induction by rifampin, phenobarbital, and dexamethasone, indicating the involvement of pregnane X receptor, constitutive androstane receptor and glucocorticoid receptor in the regulation of CYP2C9.	Rifampin	34-42	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	211-217
19881256-3	2009	Positive controls for CYP1A2 and CYP3A4 used beta-naphthoflavone (beta-NF) and rifampicin (Rif), respectively.	Rifampin	79-89	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	22-28
19881256-3	2009	Positive controls for CYP1A2 and CYP3A4 used beta-naphthoflavone (beta-NF) and rifampicin (Rif), respectively.	Rifampin	91-94	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	22-28
19697859-1	2009	The effects of isoniazid and rifampicin on the peripheral mononuclear production of IL-2, IL-12, IL-10, IFN-gamma, and TGF-beta were evaluated in patients with infiltrative pulmonary tuberculosis.	Rifampin	29-39	interleukin 2	Homo sapiens	84-88
19697859-2	2009	Irrespective of the susceptibility of the causative agent to the essential antituberculous drugs, rifampicin was ascertained to initiate increased IL-2 secretion and to reduce the generation of IL-12, IFN-gamma and TGF-beta.	Rifampin	98-108	interleukin 2	Homo sapiens	147-151
19697859-2	2009	Irrespective of the susceptibility of the causative agent to the essential antituberculous drugs, rifampicin was ascertained to initiate increased IL-2 secretion and to reduce the generation of IL-12, IFN-gamma and TGF-beta.	Rifampin	98-108	interferon gamma	Homo sapiens	201-210
19697859-2	2009	Irrespective of the susceptibility of the causative agent to the essential antituberculous drugs, rifampicin was ascertained to initiate increased IL-2 secretion and to reduce the generation of IL-12, IFN-gamma and TGF-beta.	Rifampin	98-108	transforming growth factor beta 1	Homo sapiens	215-223
19704172-1	2009	BACKGROUND: Rifampicin induces expression of the cytochrome P450 isoenzyme 2B6 (CYP2B6), which metabolizes efavirenz.	Rifampin	12-22	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	49-78
19704172-1	2009	BACKGROUND: Rifampicin induces expression of the cytochrome P450 isoenzyme 2B6 (CYP2B6), which metabolizes efavirenz.	Rifampin	12-22	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	80-86
19601803-7	2009	CYP2D6 is largely uninducible by prototypical CYP inducers such as phenobarbital, rifampin and dexamethasone, but it is regulated by hepatocyte nuclear factor-4alpha, a nuclear receptor.	Rifampin	82-90	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
19601803-7	2009	CYP2D6 is largely uninducible by prototypical CYP inducers such as phenobarbital, rifampin and dexamethasone, but it is regulated by hepatocyte nuclear factor-4alpha, a nuclear receptor.	Rifampin	82-90	peptidylprolyl isomerase G	Homo sapiens	0-3
19601803-7	2009	CYP2D6 is largely uninducible by prototypical CYP inducers such as phenobarbital, rifampin and dexamethasone, but it is regulated by hepatocyte nuclear factor-4alpha, a nuclear receptor.	Rifampin	82-90	hepatocyte nuclear factor 4 alpha	Homo sapiens	133-165
19202563-3	2009	Clotrimazole, rifampin, ritonavir, phenytoin, and phenobarbital induced CYP2C9 consistent with previous findings for CYP3A4.	Rifampin	14-22	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	72-78
19202563-3	2009	Clotrimazole, rifampin, ritonavir, phenytoin, and phenobarbital induced CYP2C9 consistent with previous findings for CYP3A4.	Rifampin	14-22	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	117-123
19202563-6	2009	In 17 donors, rifampin increased mean basal CYP2C9 activity from 59 +/- 43 to 143 +/- 68 pmol/mg protein/min; fold induction ranged from 1.4- to 6.4-fold.	Rifampin	14-22	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	44-50
19077665-3	2009	It was recently reported that hepatocyte nuclear receptor 4alpha (HNF4alpha), a master regulator of several nuclear receptors, associates with PXR thus regulates the expression of CYP3A4 under rifampin treatment.	Rifampin	193-201	hepatocyte nuclear factor 4 alpha	Homo sapiens	41-75
19077665-3	2009	It was recently reported that hepatocyte nuclear receptor 4alpha (HNF4alpha), a master regulator of several nuclear receptors, associates with PXR thus regulates the expression of CYP3A4 under rifampin treatment.	Rifampin	193-201	nuclear receptor subfamily 1 group I member 2	Homo sapiens	143-146
19077665-3	2009	It was recently reported that hepatocyte nuclear receptor 4alpha (HNF4alpha), a master regulator of several nuclear receptors, associates with PXR thus regulates the expression of CYP3A4 under rifampin treatment.	Rifampin	193-201	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	180-186
19077665-4	2009	We therefore focused on the role of PXR-HNF4alpha interaction in the transcriptional regulation of CYP3A4 under rifampin-mediated ketoconazole inhibition.	Rifampin	112-120	nuclear receptor subfamily 1 group I member 2	Homo sapiens	36-39
19077665-4	2009	We therefore focused on the role of PXR-HNF4alpha interaction in the transcriptional regulation of CYP3A4 under rifampin-mediated ketoconazole inhibition.	Rifampin	112-120	hepatocyte nuclear factor 4 alpha	Homo sapiens	40-49
19077665-4	2009	We therefore focused on the role of PXR-HNF4alpha interaction in the transcriptional regulation of CYP3A4 under rifampin-mediated ketoconazole inhibition.	Rifampin	112-120	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	99-105
18799805-6	2008	In TgCYP3A4/hPXR mice, CYP3A4 was strongly induced by rifampicin, a human-specific PXR ligand, but not by pregnenolone 16alpha-carbonitrile, a rodent-specific PXR ligand.	Rifampin	54-64	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	5-11
18799805-6	2008	In TgCYP3A4/hPXR mice, CYP3A4 was strongly induced by rifampicin, a human-specific PXR ligand, but not by pregnenolone 16alpha-carbonitrile, a rodent-specific PXR ligand.	Rifampin	54-64	nuclear receptor subfamily 1 group I member 2	Homo sapiens	13-16
18799805-6	2008	In TgCYP3A4/hPXR mice, CYP3A4 was strongly induced by rifampicin, a human-specific PXR ligand, but not by pregnenolone 16alpha-carbonitrile, a rodent-specific PXR ligand.	Rifampin	54-64	nuclear receptor subfamily 1 group I member 2	Homo sapiens	83-86
19228077-12	2009	For example, sorafenib exposure was reduced by an average 37% with concomitant administration of the CYP3A4 inducer rifampicin (rifampin); sorafenib concentrations may also be decreased by other CYP3A4 inducers.	Rifampin	116-126	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	195-201
19228077-12	2009	For example, sorafenib exposure was reduced by an average 37% with concomitant administration of the CYP3A4 inducer rifampicin (rifampin); sorafenib concentrations may also be decreased by other CYP3A4 inducers.	Rifampin	128-136	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	101-107
19228077-12	2009	For example, sorafenib exposure was reduced by an average 37% with concomitant administration of the CYP3A4 inducer rifampicin (rifampin); sorafenib concentrations may also be decreased by other CYP3A4 inducers.	Rifampin	128-136	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	195-201
18989830-4	2008	CYP3A4 mRNA and activity were induced by the prototypical pregnane X receptor (PXR) ligands, rifampicin (E(max) = 36- and 6-fold, respectively, and EC(50) = 4 microM) and phenobarbital (E(max) = 12- and 4-fold, respectively, and EC(50) = 205 microM).	Rifampin	93-103	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
18989830-4	2008	CYP3A4 mRNA and activity were induced by the prototypical pregnane X receptor (PXR) ligands, rifampicin (E(max) = 36- and 6-fold, respectively, and EC(50) = 4 microM) and phenobarbital (E(max) = 12- and 4-fold, respectively, and EC(50) = 205 microM).	Rifampin	93-103	nuclear receptor subfamily 1 group I member 2	Homo sapiens	58-77
18989830-4	2008	CYP3A4 mRNA and activity were induced by the prototypical pregnane X receptor (PXR) ligands, rifampicin (E(max) = 36- and 6-fold, respectively, and EC(50) = 4 microM) and phenobarbital (E(max) = 12- and 4-fold, respectively, and EC(50) = 205 microM).	Rifampin	93-103	nuclear receptor subfamily 1 group I member 2	Homo sapiens	79-82
19010908-6	2008	Interestingly, treatment of breast cancer cells in vitro with the PXR agonist rifampin induced OATP1A2 expression in a time-dependent and concentration-dependent manner.	Rifampin	78-86	nuclear receptor subfamily 1 group I member 2	Homo sapiens	66-69
19010908-6	2008	Interestingly, treatment of breast cancer cells in vitro with the PXR agonist rifampin induced OATP1A2 expression in a time-dependent and concentration-dependent manner.	Rifampin	78-86	solute carrier organic anion transporter family member 1A2	Homo sapiens	95-102
19010908-8	2008	The rifampin response was abrogated after small interfering RNA targeting of PXR.	Rifampin	4-12	nuclear receptor subfamily 1 group I member 2	Homo sapiens	77-80
18981575-1	2008	This study investigated the changes in the mRNA levels of the ATP binding cassette (ABC) transporters multidrug resistance 1 (MDR1), multidrug resistance-associated protein 1 (MRP1), and multidrug resistance-associated protein 2 (MRP2) following exposure to the prototypical microsomal enzyme inducers rifampicin (Rif), dexamethasone (Dex), and omeprazole (Ome) in primary cultures of cryopreserved human and cynomolgus monkey hepatocytes.	Rifampin	302-312	ATP binding cassette subfamily B member 1	Homo sapiens	102-124
18981575-1	2008	This study investigated the changes in the mRNA levels of the ATP binding cassette (ABC) transporters multidrug resistance 1 (MDR1), multidrug resistance-associated protein 1 (MRP1), and multidrug resistance-associated protein 2 (MRP2) following exposure to the prototypical microsomal enzyme inducers rifampicin (Rif), dexamethasone (Dex), and omeprazole (Ome) in primary cultures of cryopreserved human and cynomolgus monkey hepatocytes.	Rifampin	302-312	ATP binding cassette subfamily C member 2	Homo sapiens	230-234
18981575-1	2008	This study investigated the changes in the mRNA levels of the ATP binding cassette (ABC) transporters multidrug resistance 1 (MDR1), multidrug resistance-associated protein 1 (MRP1), and multidrug resistance-associated protein 2 (MRP2) following exposure to the prototypical microsomal enzyme inducers rifampicin (Rif), dexamethasone (Dex), and omeprazole (Ome) in primary cultures of cryopreserved human and cynomolgus monkey hepatocytes.	Rifampin	314-317	ATP binding cassette subfamily B member 1	Homo sapiens	102-124
18981575-1	2008	This study investigated the changes in the mRNA levels of the ATP binding cassette (ABC) transporters multidrug resistance 1 (MDR1), multidrug resistance-associated protein 1 (MRP1), and multidrug resistance-associated protein 2 (MRP2) following exposure to the prototypical microsomal enzyme inducers rifampicin (Rif), dexamethasone (Dex), and omeprazole (Ome) in primary cultures of cryopreserved human and cynomolgus monkey hepatocytes.	Rifampin	314-317	ATP binding cassette subfamily C member 2	Homo sapiens	230-234
18658192-8	2008	In contrast, rifampicin concentrations above the MIC were required to exert sustained killing in CSF(CO(2)).	Rifampin	13-23	complement C2	Homo sapiens	97-107
18786598-0	2008	Expression and induction by rifampicin of CAR- and PXR-regulated CYP2B and CYP3A in liver, kidney and airways of pig.	Rifampin	28-38	CXADR Ig-like cell adhesion molecule	Sus scrofa	42-46
18786598-0	2008	Expression and induction by rifampicin of CAR- and PXR-regulated CYP2B and CYP3A in liver, kidney and airways of pig.	Rifampin	28-38	nuclear receptor subfamily 1 group I member 2	Sus scrofa	51-54
18786598-9	2008	Thus, it is likely that rifampicin induced CYP2B22 both in liver and kidney of pig, not via activation of CAR, but via PXR, through a cross-talk mechanism, as previously observed in human liver.	Rifampin	24-34	cytochrome P450 family 2 subfamily B member 6B	Sus scrofa	43-50
18786598-9	2008	Thus, it is likely that rifampicin induced CYP2B22 both in liver and kidney of pig, not via activation of CAR, but via PXR, through a cross-talk mechanism, as previously observed in human liver.	Rifampin	24-34	nuclear receptor subfamily 1 group I member 2	Sus scrofa	119-122
18959805-9	2008	She remains on her original cART regimen with an undetectable viral load and normal CD4 count (34%; 1398 x 106/l).The combination of rifampicin and azithromycin was well tolerated, simple to administer and effective.	Rifampin	133-143	CD4 molecule	Homo sapiens	84-87
18800312-5	2008	Reporter assays were used to evaluate the function of all known hPXR variants in response to the secondary bile acid lithocholic acid and therapeutic agents rifampicin, ursodeoxycholic acid and dexamethasone.	Rifampin	157-167	nuclear receptor subfamily 1 group I member 2	Homo sapiens	64-68
18647599-2	2008	The extent of CYP3A4 induction (measured as RIF ratio in comparison to rifampicin) and EC50 was obtained from the dose-response curve.	Rifampin	71-81	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	14-20
18712882-7	2008	However, the BDO-hAGT complex at Cys(150) exhibited stability for more than 1 h. The effect of hAGT and mutants on BDO-induced genotoxicity was studied in E. coli using the forward assay to rifampicin resistance.	Rifampin	190-200	angiotensinogen	Homo sapiens	17-21
18799805-9	2008	By using TgCYP3A4/hPXR mice, human PXR-CYP3A4-mediated rifampicin-protease inhibitor interactions were recapitulated, as the metabolic stability of amprenavir, nelfinavir, and saquinavir decreased 52, 53, and 99%, respectively, in the liver microsomes of TgCYP3A4/hPXR mice pretreated with rifampicin.	Rifampin	55-65	nuclear receptor subfamily 1, group I, member 2	Mus musculus	19-22
18799805-9	2008	By using TgCYP3A4/hPXR mice, human PXR-CYP3A4-mediated rifampicin-protease inhibitor interactions were recapitulated, as the metabolic stability of amprenavir, nelfinavir, and saquinavir decreased 52, 53, and 99%, respectively, in the liver microsomes of TgCYP3A4/hPXR mice pretreated with rifampicin.	Rifampin	55-65	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	11-17
18765524-10	2008	In mice harboring SKOV-3 xenografts, rifampicin (PXR agonist) induces cell proliferation and tumor growth.	Rifampin	37-47	nuclear receptor subfamily 1, group I, member 2	Mus musculus	49-52
18544536-4	2008	In agreement with previous reports, we found that rexinoids are weak activators of SXR, but we also found that they can antagonize SXR activation by the potent SXR agonist rifampicin.	Rifampin	172-182	nuclear receptor subfamily 1 group I member 2	Homo sapiens	131-134
18573861-9	2008	Metabolism of 17-OHPC was significantly greater in FHH treated with the CYP3A inducers, rifampin and phenobarbital.	Rifampin	88-96	calcium sensing receptor	Homo sapiens	51-54
18534776-1	2008	The protective effects of Ginkgoselect Phytosome (GBP) on Rifampicin (RMP) induced hepatotoxicity and the probable mechanism(s) involved in this protection were investigated in rats.	Rifampin	58-68	transmembrane protein 132A	Rattus norvegicus	50-53
18523138-10	2008	In LS180 human intestinal cells, rifampicin increased UGT2A3 mRNA by more than 4.5-fold compared with vehicle, whereas levels were not significantly affected by the arylhydrocarbon receptor ligand beta-naphthoflavone.	Rifampin	33-43	UDP glucuronosyltransferase family 2 member A3	Homo sapiens	54-60
18695506-0	2008	Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy.	Rifampin	0-10	synuclein, alpha	Mus musculus	19-34
18695506-4	2008	This study investigates the ability of the antibiotic rifampicin to reduce alpha-synuclein aggregation and the associated neurodegeneration in a transgenic mouse model of MSA.	Rifampin	54-64	synuclein, alpha	Mus musculus	75-90
18695506-5	2008	We report a reduction in monomeric and oligomeric alpha-synuclein and a reduction in phosphorylated alpha-synuclein (S129) upon rifampicin treatment.	Rifampin	128-138	synuclein, alpha	Mus musculus	100-115
18556442-8	2008	The in vivo results showed a differential effect of Oatp1b2 on hepatic uptake of the model compounds, indicating that Oatp1b2 plays a more significant role in the hepatobiliary disposition of rifampicin and lovastatin than the other compounds tested.	Rifampin	192-202	solute carrier organic anion transporter family, member 1b2	Mus musculus	52-59
18556442-8	2008	The in vivo results showed a differential effect of Oatp1b2 on hepatic uptake of the model compounds, indicating that Oatp1b2 plays a more significant role in the hepatobiliary disposition of rifampicin and lovastatin than the other compounds tested.	Rifampin	192-202	solute carrier organic anion transporter family, member 1b2	Mus musculus	118-125
18559486-9	2008	Stimulation with 3-methylcholanthrene and rifampicin markedly increased CYP1A1/2 or CYP3A4 activities, which could be selectively inhibited by nifedipine, verapamil, ketoconazole, and quercetin.	Rifampin	42-52	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	72-78
18559486-9	2008	Stimulation with 3-methylcholanthrene and rifampicin markedly increased CYP1A1/2 or CYP3A4 activities, which could be selectively inhibited by nifedipine, verapamil, ketoconazole, and quercetin.	Rifampin	42-52	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	84-90
18728241-6	2008	Our results indicate that CYP2B6 c.516TT genotype can be used to identify efavirenz poor metabolizers in patients co-treated with rifampin.	Rifampin	130-138	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	26-32
18544536-4	2008	In agreement with previous reports, we found that rexinoids are weak activators of SXR, but we also found that they can antagonize SXR activation by the potent SXR agonist rifampicin.	Rifampin	172-182	nuclear receptor subfamily 1 group I member 2	Homo sapiens	131-134
18544536-5	2008	This antagonism included suppression of rifampicin-induced expression of SXR target genes, as well as reduced binding of SXR/RXR to SXR response elements both in vivo and in vitro.	Rifampin	40-50	nuclear receptor subfamily 1 group I member 2	Homo sapiens	73-76
18544536-9	2008	We suggest that the ability of rexinoids to induce degradation of both SXR and RXR, in combination with competition for binding to SXR, can also explain why rexinoids antagonize the activation of SXR by drugs like rifampicin.	Rifampin	214-224	nuclear receptor subfamily 1 group I member 2	Homo sapiens	71-74
18544536-9	2008	We suggest that the ability of rexinoids to induce degradation of both SXR and RXR, in combination with competition for binding to SXR, can also explain why rexinoids antagonize the activation of SXR by drugs like rifampicin.	Rifampin	214-224	retinoid X receptor alpha	Homo sapiens	79-82
18544536-9	2008	We suggest that the ability of rexinoids to induce degradation of both SXR and RXR, in combination with competition for binding to SXR, can also explain why rexinoids antagonize the activation of SXR by drugs like rifampicin.	Rifampin	214-224	nuclear receptor subfamily 1 group I member 2	Homo sapiens	131-134
18544536-9	2008	We suggest that the ability of rexinoids to induce degradation of both SXR and RXR, in combination with competition for binding to SXR, can also explain why rexinoids antagonize the activation of SXR by drugs like rifampicin.	Rifampin	214-224	nuclear receptor subfamily 1 group I member 2	Homo sapiens	131-134
18490434-6	2008	Rifampin increased ERBTs in CYP3A5(*)1 carriers (4.68 versus 2.60%, P = 0.0008) and noncarriers (3.55 versus 2.11%, P = 0.0017), whereas dexamethasone increased ERBTs only in CYP3A5(*)1 noncarriers (3.03 versus 2.14%, P = 0.031).	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	175-181
18727801-5	2008	Extracellular (broth) and intracellular (THP-1 macrophages) activities of rifampicin, linezolid and fusidic acid at C(max), and of vancomycin, daptomycin, quinupristin-dalfopristin and oritavancin over a wide range of extracellular concentrations (with pharmacological modelling to determine E(max)), were measured at 24 h. Increases in vancomycin MICs correlated with increased drug binding, and decreased cell wall turnover and detergent-induced autolysis.	Rifampin	74-84	GLI family zinc finger 2	Homo sapiens	41-46
18505790-6	2008	CYP3A4 activity was significantly increased by rifampin (9.7-fold), nafcillin and dicloxacillin (5.9-fold), and weakly induced (2-fold) by tetracycline, sufisoxazole, troleandomycin, and clindamycin.	Rifampin	47-55	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
18413659-0	2008	Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin.	Rifampin	172-180	solute carrier organic anion transporter family, member 1b2	Mus musculus	74-81
19356089-0	2008	Quantitative relationship between rifampicin exposure and induction of Cyp3a11 in SXR humanized mice: extrapolation to human CYP3A4 induction potential.	Rifampin	34-44	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	71-78
19356089-0	2008	Quantitative relationship between rifampicin exposure and induction of Cyp3a11 in SXR humanized mice: extrapolation to human CYP3A4 induction potential.	Rifampin	34-44	transposition, Chr Y, Cattanach 1	Mus musculus	82-85
19356089-1	2008	The SXR humanized mouse model was used to quantitatively assess an in vivo induction response of the human PXR agonist, rifampicin.	Rifampin	120-130	transposition, Chr Y, Cattanach 1	Mus musculus	4-7
19356089-1	2008	The SXR humanized mouse model was used to quantitatively assess an in vivo induction response of the human PXR agonist, rifampicin.	Rifampin	120-130	nuclear receptor subfamily 1 group I member 2	Homo sapiens	107-110
19356089-2	2008	Three days of rifampicin treatment increased RNA expression and microsomal enzyme activity of CYP3A11, as well as significantly reduced triazolam plasma exposure.	Rifampin	14-24	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	94-101
18413659-8	2008	After a single intravenous dose of rifampin (1 mg/kg), a 1.7-fold increase in plasma area under the concentration-time curve (AUC) was observed, whereas the liver-to-plasma ratio was reduced by 5-fold, and nearly 8-fold when assessed at steady-state conditions after 24 h of continuous subcutaneous infusion in Slco1b2(-/-) mice.	Rifampin	35-43	solute carrier organic anion transporter family, member 1b2	Mus musculus	311-318
18509604-4	2008	RESULTS: MEB (80 pM) transport by OATP1B1 and OATP1B3 was inhibited by rifampicin (50 microM) to 10% and 4% of control, respectively.	Rifampin	71-81	solute carrier organic anion transporter family member 1B1	Homo sapiens	34-41
18509604-4	2008	RESULTS: MEB (80 pM) transport by OATP1B1 and OATP1B3 was inhibited by rifampicin (50 microM) to 10% and 4% of control, respectively.	Rifampin	71-81	solute carrier organic anion transporter family member 1B3	Homo sapiens	46-53
18601745-9	2008	RESULTS: Treatment of rats with INH+RIF or INH+RIF+PZA induced hepatotoxicity as evidenced by biochemical measurements: serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) activities and the levels of total bilirubin were elevated, and the levels of albumin and total protein were decreased in drugs-treated animals.	Rifampin	36-39	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	158-184
18691987-1	2008	BACKGROUND: Rifampicin (rifampin) has been reported to have drug-drug interaction with several 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors due to its ability to influence the function of cytochrome P450 enzymes or transporters.	Rifampin	12-22	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	95-142
18691987-1	2008	BACKGROUND: Rifampicin (rifampin) has been reported to have drug-drug interaction with several 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors due to its ability to influence the function of cytochrome P450 enzymes or transporters.	Rifampin	24-32	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	95-142
18457428-3	2008	Recent studies have highlighted the potential use of rifampicin as an inhibitor of amyloid formation by a variety of polypeptides; however, there are conflicting reports on its ability to inhibit amyloid formation by islet amyloid polypeptide (IAPP).	Rifampin	53-63	islet amyloid polypeptide	Homo sapiens	217-242
18457428-3	2008	Recent studies have highlighted the potential use of rifampicin as an inhibitor of amyloid formation by a variety of polypeptides; however, there are conflicting reports on its ability to inhibit amyloid formation by islet amyloid polypeptide (IAPP).	Rifampin	53-63	islet amyloid polypeptide	Homo sapiens	244-248
18457428-7	2008	However, the effects of oxidized and reduced rifampicin are similar, in that neither prevents amyloid formation by IAPP.	Rifampin	45-55	islet amyloid polypeptide	Homo sapiens	115-119
18332078-5	2008	By using an optimized induction assay for Fa2N-4 cells, CYP3A4 induction by rifampicin, the prototypical PXR activator, increased from 1.5- to 7-fold at the level of functional activity.	Rifampin	76-86	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	56-62
18332078-5	2008	By using an optimized induction assay for Fa2N-4 cells, CYP3A4 induction by rifampicin, the prototypical PXR activator, increased from 1.5- to 7-fold at the level of functional activity.	Rifampin	76-86	nuclear receptor subfamily 1 group I member 2	Homo sapiens	105-108
18332078-10	2008	The EC(50) value for rifampicin-mediated CYP3A4 induction was 10-fold higher than that in human hepatocytes.	Rifampin	21-31	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	41-47
18473749-9	2008	A small number of drugs such as rifampin, phenytoin and ritonavir are identified as inducers of CYP3A4.	Rifampin	32-40	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	96-102
18560033-15	2008	The biochip-based analysis of RIF and INH susceptibility provides fast (less than 24 hours) and accurate identification of the mutations in gene rpoB, katG, inhA, ahpC responsible for resistance to rifampin and isoniazid.	Rifampin	198-206	inhibin subunit alpha	Homo sapiens	157-161
18490434-6	2008	Rifampin increased ERBTs in CYP3A5(*)1 carriers (4.68 versus 2.60%, P = 0.0008) and noncarriers (3.55 versus 2.11%, P = 0.0017), whereas dexamethasone increased ERBTs only in CYP3A5(*)1 noncarriers (3.03 versus 2.14%, P = 0.031).	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	28-34
18492796-10	2008	performed a pharmacokinetic analysis with the human OATP1B1 and -1B3 substrates rifampicin and pravastatin and demonstrated a reduced liver-to-plasma ratio for these drugs in knockout compared with control mice, providing strong evidence that Oatp1b2 played an important role in the disposition of these drugs.	Rifampin	80-90	solute carrier organic anion transporter family member 1B1	Homo sapiens	52-68
18492796-10	2008	performed a pharmacokinetic analysis with the human OATP1B1 and -1B3 substrates rifampicin and pravastatin and demonstrated a reduced liver-to-plasma ratio for these drugs in knockout compared with control mice, providing strong evidence that Oatp1b2 played an important role in the disposition of these drugs.	Rifampin	80-90	solute carrier organic anion transporter family, member 1b2	Mus musculus	243-250
19468476-11	2008	Rifampicin has to be avoided in allograft recipients as it activates cytochrome-P450 enzymes and thereby decreases the therapeutic levels of cyclosporine and prednisolone.	Rifampin	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-84
18332086-5	2008	CYP3A4 activity (1"-hydroxymidazolam formation) was increased (2-fold) by rifampin (10 microM) but was reduced by the PIs (1.5- to 7-fold).	Rifampin	74-82	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
18332086-8	2008	Furthermore, in a PXR-knockdown stable LS180 cell line, induction of CYP3A4 and MDR1 mRNA after treatment with PIs and rifampin was significantly reduced (1.4- to 5-fold) compared with that in PXR nonsilenced cells.	Rifampin	119-127	nuclear receptor subfamily 1 group I member 2	Homo sapiens	18-21
18332086-8	2008	Furthermore, in a PXR-knockdown stable LS180 cell line, induction of CYP3A4 and MDR1 mRNA after treatment with PIs and rifampin was significantly reduced (1.4- to 5-fold) compared with that in PXR nonsilenced cells.	Rifampin	119-127	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	69-75
18332086-8	2008	Furthermore, in a PXR-knockdown stable LS180 cell line, induction of CYP3A4 and MDR1 mRNA after treatment with PIs and rifampin was significantly reduced (1.4- to 5-fold) compared with that in PXR nonsilenced cells.	Rifampin	119-127	ATP binding cassette subfamily B member 1	Homo sapiens	80-84
18332086-8	2008	Furthermore, in a PXR-knockdown stable LS180 cell line, induction of CYP3A4 and MDR1 mRNA after treatment with PIs and rifampin was significantly reduced (1.4- to 5-fold) compared with that in PXR nonsilenced cells.	Rifampin	119-127	nuclear receptor subfamily 1 group I member 2	Homo sapiens	193-196
18535361-6	2008	For example,the antibiotic rifampicin, one of the strongest inducers of the human gene CYP3A4, was the strongest inducer of the worm ortholog CYP13A7.	Rifampin	27-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	87-93
18332862-3	2008	The ability of rifampin, a known PXR agonist and digoxin, a model MDR1 substrate, to regulate MDR1 expression and transport activity has been tested, in these T84 cells.	Rifampin	15-23	ATP binding cassette subfamily B member 1	Homo sapiens	94-98
18332862-6	2008	KEY RESULTS: Rifampin exposure (10 microM, 72 hours) increased MDR1 transcript levels (3.4 fold), MDR1 total protein levels (4.4 fold), apical MDR1 protein (2.7 fold) and functional activity of MDR1 (1.2 fold).	Rifampin	13-21	ATP binding cassette subfamily B member 1	Homo sapiens	63-67
18332862-6	2008	KEY RESULTS: Rifampin exposure (10 microM, 72 hours) increased MDR1 transcript levels (3.4 fold), MDR1 total protein levels (4.4 fold), apical MDR1 protein (2.7 fold) and functional activity of MDR1 (1.2 fold).	Rifampin	13-21	ATP binding cassette subfamily B member 1	Homo sapiens	98-102
18332862-6	2008	KEY RESULTS: Rifampin exposure (10 microM, 72 hours) increased MDR1 transcript levels (3.4 fold), MDR1 total protein levels (4.4 fold), apical MDR1 protein (2.7 fold) and functional activity of MDR1 (1.2 fold).	Rifampin	13-21	ATP binding cassette subfamily B member 1	Homo sapiens	98-102
18332862-6	2008	KEY RESULTS: Rifampin exposure (10 microM, 72 hours) increased MDR1 transcript levels (3.4 fold), MDR1 total protein levels (4.4 fold), apical MDR1 protein (2.7 fold) and functional activity of MDR1 (1.2 fold).	Rifampin	13-21	ATP binding cassette subfamily B member 1	Homo sapiens	98-102
18332862-8	2008	Whereas PXR expression was increased by rifampin incubation (2 fold), digoxin reduced PXR expression (0.3 fold).	Rifampin	40-48	nuclear receptor subfamily 1 group I member 2	Homo sapiens	8-11
18413659-0	2008	Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin.	Rifampin	172-180	solute carrier organic anion transporter family, member 1b2	Mus musculus	82-89
18413659-7	2008	Pharmacological characterization was carried out using two prototypical substrates of human OATP1B1 and -1B3, rifampin and pravastatin.	Rifampin	110-118	solute carrier organic anion transporter family member 1B1	Homo sapiens	92-108
18321482-5	2008	They mediate transport of a variety of drugs including the pregnane X receptor ligands rifampicin and dexamethasone.	Rifampin	87-97	nuclear receptor subfamily 1 group I member 2	Homo sapiens	59-78
18328680-8	2008	Enzyme activity of CYP3A4, measured by testosterone metabolism, was increased after 24h by RIF.	Rifampin	91-94	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	19-25
18180276-8	2008	As a result, cyclosporin A and rifampicin were found to have the potential to interact with OATP1B3-mediated uptake at clinical concentrations.	Rifampin	31-41	solute carrier organic anion transporter family member 1B3	Homo sapiens	92-99
18094037-8	2008	In proximal jejunum, rifampicin (RIF) [pregnane X receptor (PXR) ligand] induced CYP3A4 (5.2-fold), CYP2B6 (2-fold), UGT1A6 (2.2-fold), and multidrug resistance-1 (MDR1)/ABCB1 mRNA (2.7-fold), whereas 6beta-hydroxytestosterone formation (CYP3A4) increased 2-fold.	Rifampin	21-31	nuclear receptor subfamily 1 group I member 2	Homo sapiens	39-58
18334920-0	2008	Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol.	Rifampin	64-74	ATP binding cassette subfamily C member 2	Homo sapiens	93-98
18334920-4	2008	Moreover, the effects of rifampicin-type induction (600 mg, 8 days) of duodenal ABCC2 were quantified in 22 participants with regard to genetic polymorphisms.	Rifampin	25-35	ATP binding cassette subfamily C member 2	Homo sapiens	80-85
18334920-9	2008	Intestinal ABCC2 mRNA and protein expression were upregulated by rifampicin treatment, a genetic influence could be detected in only four cases heterozygote for 3563T&gt;A or 4544G&gt;A.	Rifampin	65-75	ATP binding cassette subfamily C member 2	Homo sapiens	11-16
18096673-5	2008	A-792611 also attenuated the rifampin and ritonavir-mediated activation of the human pregnane X receptor (PXR) in luciferase reporter assays.	Rifampin	29-37	nuclear receptor subfamily 1 group I member 2	Homo sapiens	85-104
18096673-5	2008	A-792611 also attenuated the rifampin and ritonavir-mediated activation of the human pregnane X receptor (PXR) in luciferase reporter assays.	Rifampin	29-37	nuclear receptor subfamily 1 group I member 2	Homo sapiens	106-109
18094037-8	2008	In proximal jejunum, rifampicin (RIF) [pregnane X receptor (PXR) ligand] induced CYP3A4 (5.2-fold), CYP2B6 (2-fold), UGT1A6 (2.2-fold), and multidrug resistance-1 (MDR1)/ABCB1 mRNA (2.7-fold), whereas 6beta-hydroxytestosterone formation (CYP3A4) increased 2-fold.	Rifampin	21-31	nuclear receptor subfamily 1 group I member 2	Homo sapiens	60-63
18094037-8	2008	In proximal jejunum, rifampicin (RIF) [pregnane X receptor (PXR) ligand] induced CYP3A4 (5.2-fold), CYP2B6 (2-fold), UGT1A6 (2.2-fold), and multidrug resistance-1 (MDR1)/ABCB1 mRNA (2.7-fold), whereas 6beta-hydroxytestosterone formation (CYP3A4) increased 2-fold.	Rifampin	21-31	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	81-87
18094037-8	2008	In proximal jejunum, rifampicin (RIF) [pregnane X receptor (PXR) ligand] induced CYP3A4 (5.2-fold), CYP2B6 (2-fold), UGT1A6 (2.2-fold), and multidrug resistance-1 (MDR1)/ABCB1 mRNA (2.7-fold), whereas 6beta-hydroxytestosterone formation (CYP3A4) increased 2-fold.	Rifampin	21-31	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	100-106
18094037-8	2008	In proximal jejunum, rifampicin (RIF) [pregnane X receptor (PXR) ligand] induced CYP3A4 (5.2-fold), CYP2B6 (2-fold), UGT1A6 (2.2-fold), and multidrug resistance-1 (MDR1)/ABCB1 mRNA (2.7-fold), whereas 6beta-hydroxytestosterone formation (CYP3A4) increased 2-fold.	Rifampin	21-31	UDP glucuronosyltransferase family 1 member A6	Homo sapiens	117-123
18094037-8	2008	In proximal jejunum, rifampicin (RIF) [pregnane X receptor (PXR) ligand] induced CYP3A4 (5.2-fold), CYP2B6 (2-fold), UGT1A6 (2.2-fold), and multidrug resistance-1 (MDR1)/ABCB1 mRNA (2.7-fold), whereas 6beta-hydroxytestosterone formation (CYP3A4) increased 2-fold.	Rifampin	21-31	ATP binding cassette subfamily B member 1	Homo sapiens	140-162
18094037-8	2008	In proximal jejunum, rifampicin (RIF) [pregnane X receptor (PXR) ligand] induced CYP3A4 (5.2-fold), CYP2B6 (2-fold), UGT1A6 (2.2-fold), and multidrug resistance-1 (MDR1)/ABCB1 mRNA (2.7-fold), whereas 6beta-hydroxytestosterone formation (CYP3A4) increased 2-fold.	Rifampin	21-31	ATP binding cassette subfamily B member 1	Homo sapiens	164-168
18094037-8	2008	In proximal jejunum, rifampicin (RIF) [pregnane X receptor (PXR) ligand] induced CYP3A4 (5.2-fold), CYP2B6 (2-fold), UGT1A6 (2.2-fold), and multidrug resistance-1 (MDR1)/ABCB1 mRNA (2.7-fold), whereas 6beta-hydroxytestosterone formation (CYP3A4) increased 2-fold.	Rifampin	21-31	ATP binding cassette subfamily B member 1	Homo sapiens	170-175
18094037-8	2008	In proximal jejunum, rifampicin (RIF) [pregnane X receptor (PXR) ligand] induced CYP3A4 (5.2-fold), CYP2B6 (2-fold), UGT1A6 (2.2-fold), and multidrug resistance-1 (MDR1)/ABCB1 mRNA (2.7-fold), whereas 6beta-hydroxytestosterone formation (CYP3A4) increased 2-fold.	Rifampin	21-31	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	238-244
18094037-8	2008	In proximal jejunum, rifampicin (RIF) [pregnane X receptor (PXR) ligand] induced CYP3A4 (5.2-fold), CYP2B6 (2-fold), UGT1A6 (2.2-fold), and multidrug resistance-1 (MDR1)/ABCB1 mRNA (2.7-fold), whereas 6beta-hydroxytestosterone formation (CYP3A4) increased 2-fold.	Rifampin	33-36	nuclear receptor subfamily 1 group I member 2	Homo sapiens	39-58
18094037-8	2008	In proximal jejunum, rifampicin (RIF) [pregnane X receptor (PXR) ligand] induced CYP3A4 (5.2-fold), CYP2B6 (2-fold), UGT1A6 (2.2-fold), and multidrug resistance-1 (MDR1)/ABCB1 mRNA (2.7-fold), whereas 6beta-hydroxytestosterone formation (CYP3A4) increased 2-fold.	Rifampin	33-36	nuclear receptor subfamily 1 group I member 2	Homo sapiens	60-63
18379929-1	2008	The study demonstrated that lipid microspheres (LM) containing rifampicin (LM-RFP) could deliver the drug to alveolar macrophages in vitro and in vivo, and that intranasal administration to animals could achieve preferential accumulation in the lungs with less effect on the liver.	Rifampin	63-73	tripartite motif containing 27	Homo sapiens	78-81
18094037-8	2008	In proximal jejunum, rifampicin (RIF) [pregnane X receptor (PXR) ligand] induced CYP3A4 (5.2-fold), CYP2B6 (2-fold), UGT1A6 (2.2-fold), and multidrug resistance-1 (MDR1)/ABCB1 mRNA (2.7-fold), whereas 6beta-hydroxytestosterone formation (CYP3A4) increased 2-fold.	Rifampin	33-36	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	81-87
18094037-8	2008	In proximal jejunum, rifampicin (RIF) [pregnane X receptor (PXR) ligand] induced CYP3A4 (5.2-fold), CYP2B6 (2-fold), UGT1A6 (2.2-fold), and multidrug resistance-1 (MDR1)/ABCB1 mRNA (2.7-fold), whereas 6beta-hydroxytestosterone formation (CYP3A4) increased 2-fold.	Rifampin	33-36	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	100-106
18094037-8	2008	In proximal jejunum, rifampicin (RIF) [pregnane X receptor (PXR) ligand] induced CYP3A4 (5.2-fold), CYP2B6 (2-fold), UGT1A6 (2.2-fold), and multidrug resistance-1 (MDR1)/ABCB1 mRNA (2.7-fold), whereas 6beta-hydroxytestosterone formation (CYP3A4) increased 2-fold.	Rifampin	33-36	UDP glucuronosyltransferase family 1 member A6	Homo sapiens	117-123
18094037-8	2008	In proximal jejunum, rifampicin (RIF) [pregnane X receptor (PXR) ligand] induced CYP3A4 (5.2-fold), CYP2B6 (2-fold), UGT1A6 (2.2-fold), and multidrug resistance-1 (MDR1)/ABCB1 mRNA (2.7-fold), whereas 6beta-hydroxytestosterone formation (CYP3A4) increased 2-fold.	Rifampin	33-36	ATP binding cassette subfamily B member 1	Homo sapiens	140-162
18094037-8	2008	In proximal jejunum, rifampicin (RIF) [pregnane X receptor (PXR) ligand] induced CYP3A4 (5.2-fold), CYP2B6 (2-fold), UGT1A6 (2.2-fold), and multidrug resistance-1 (MDR1)/ABCB1 mRNA (2.7-fold), whereas 6beta-hydroxytestosterone formation (CYP3A4) increased 2-fold.	Rifampin	33-36	ATP binding cassette subfamily B member 1	Homo sapiens	164-168
18094037-8	2008	In proximal jejunum, rifampicin (RIF) [pregnane X receptor (PXR) ligand] induced CYP3A4 (5.2-fold), CYP2B6 (2-fold), UGT1A6 (2.2-fold), and multidrug resistance-1 (MDR1)/ABCB1 mRNA (2.7-fold), whereas 6beta-hydroxytestosterone formation (CYP3A4) increased 2-fold.	Rifampin	33-36	ATP binding cassette subfamily B member 1	Homo sapiens	170-175
18094037-8	2008	In proximal jejunum, rifampicin (RIF) [pregnane X receptor (PXR) ligand] induced CYP3A4 (5.2-fold), CYP2B6 (2-fold), UGT1A6 (2.2-fold), and multidrug resistance-1 (MDR1)/ABCB1 mRNA (2.7-fold), whereas 6beta-hydroxytestosterone formation (CYP3A4) increased 2-fold.	Rifampin	33-36	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	238-244
17760873-8	2008	Rifampicin, indomethacin and benzbromarone decreased 5,(6)-carboxy-2",7"-dichlorofluorescein transport by multidrug resistance-associated protein (Mrp)2 as visualized by confocal laser microscopy and in vesicular transport experiments.	Rifampin	0-10	ATP binding cassette subfamily C member 2	Rattus norvegicus	106-152
17760873-9	2008	Interestingly, rifampicin decreased the MRP3 activity in vesicular transport experiments using 17-beta-estradiol-17-beta-D-glucuronide as substrate, in contrast to that observed in bilirubin-glucuronide transport experiments.	Rifampin	15-25	ATP binding cassette subfamily C member 3	Rattus norvegicus	40-44
17998298-0	2008	Azole antimycotics differentially affect rifampicin-induced pregnane X receptor-mediated CYP3A4 gene expression.	Rifampin	41-51	nuclear receptor subfamily 1 group I member 2	Homo sapiens	60-79
21279172-3	2008	The concomitant use of either CYP3A4 inducer rifampicin or CYP3A4 inhibitor erythromycin may influence the results of MEGX test.	Rifampin	45-55	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	30-36
17998298-0	2008	Azole antimycotics differentially affect rifampicin-induced pregnane X receptor-mediated CYP3A4 gene expression.	Rifampin	41-51	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	89-95
17962516-8	2008	In addition to pregnenolone 16alpha-carbonitrile, several clinically relevant PXR ligands (rifampicin and dexamethasone) all increased ATRA metabolism both in vitro and in vivo, which was PXR-dependent, and up-regulation of Cyp3a was the major contributor.	Rifampin	91-101	nuclear receptor subfamily 1, group I, member 2	Mus musculus	78-81
18071298-5	2008	For demonstration of the differential effects of rifampicin on human and rat hepatocytes, induction by rifampicin of cytochrome P450 (CYP) 2E1, a major enzyme associated with isoniazid hepatotoxicity, was detected by 4-nitrocatechol formation and RT-PCR analysis.	Rifampin	49-59	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	117-142
18071298-5	2008	For demonstration of the differential effects of rifampicin on human and rat hepatocytes, induction by rifampicin of cytochrome P450 (CYP) 2E1, a major enzyme associated with isoniazid hepatotoxicity, was detected by 4-nitrocatechol formation and RT-PCR analysis.	Rifampin	103-113	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	117-142
18071298-9	2008	CONCLUSIONS AND IMPLICATIONS: The difference in induction of CYP 2E1 by rifampicin between rat and human hepatocytes accounted for the difference in exacerbation of isoniazid hepatocyte toxicity by rifampicin, with more significant toxicity in gel entrapment than in monolayer cultures.	Rifampin	72-82	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	61-68
18071298-9	2008	CONCLUSIONS AND IMPLICATIONS: The difference in induction of CYP 2E1 by rifampicin between rat and human hepatocytes accounted for the difference in exacerbation of isoniazid hepatocyte toxicity by rifampicin, with more significant toxicity in gel entrapment than in monolayer cultures.	Rifampin	198-208	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	61-68
17962516-8	2008	In addition to pregnenolone 16alpha-carbonitrile, several clinically relevant PXR ligands (rifampicin and dexamethasone) all increased ATRA metabolism both in vitro and in vivo, which was PXR-dependent, and up-regulation of Cyp3a was the major contributor.	Rifampin	91-101	nuclear receptor subfamily 1, group I, member 2	Mus musculus	188-191
17962516-8	2008	In addition to pregnenolone 16alpha-carbonitrile, several clinically relevant PXR ligands (rifampicin and dexamethasone) all increased ATRA metabolism both in vitro and in vivo, which was PXR-dependent, and up-regulation of Cyp3a was the major contributor.	Rifampin	91-101	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	224-229
18783297-9	2008	Using this equation, the ICCYP3A4 was calculated for seven inducers (bosentan, carbamazepine, efavirenz, phenytoin, pioglitazone, rifampicin [rifampin], and St John"s wort [hypericum]) on the basis of the reduction in the AUC of a coadministered standard substrate of CYP3A4, such as simvastatin, in ten DDI studies.	Rifampin	130-140	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	27-33
17764444-7	2008	Consistent with the hypothesis, fusion of the far module to the proximal promoter of CYP3A4 markedly increased rifampicin-induced reporter activity.	Rifampin	111-121	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	85-91
18783297-9	2008	Using this equation, the ICCYP3A4 was calculated for seven inducers (bosentan, carbamazepine, efavirenz, phenytoin, pioglitazone, rifampicin [rifampin], and St John"s wort [hypericum]) on the basis of the reduction in the AUC of a coadministered standard substrate of CYP3A4, such as simvastatin, in ten DDI studies.	Rifampin	142-150	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	27-33
18783297-17	2008	It was indicated that coadministration of rifampicin, phenytoin and carbamazepine may reduce plasma AUCs to less than half for a broad range of CYP3A4 substrate drugs, with CRCYP3A4 values greater than 0.13, 0.21 and 0.33, respectively.	Rifampin	42-52	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	144-150
17826359-3	2008	In the present study, we determined the in vivo and in vitro effects of typical mammalian CYP3A inducers (rifampicin, phenobarbital and dexamethasone) on CYP3A-related enzyme activities in a freshwater teleost, the grass carp (Ctenopharyngodon idellus).	Rifampin	106-116	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	90-95
17925385-3	2008	PXR single nucleotide polymorphisms (SNP) were then genotyped in donor human livers phenotyped for CYP3A4 and multidrug resistance protein 1 mRNA and primary human hepatocytes phenotyped for basal and rifampin-inducible CYP3A4 activity.	Rifampin	201-209	nuclear receptor subfamily 1 group I member 2	Homo sapiens	0-3
17826359-3	2008	In the present study, we determined the in vivo and in vitro effects of typical mammalian CYP3A inducers (rifampicin, phenobarbital and dexamethasone) on CYP3A-related enzyme activities in a freshwater teleost, the grass carp (Ctenopharyngodon idellus).	Rifampin	106-116	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	154-159
17826359-6	2008	Using erythromycin and testosterone as substrates, we demonstrated that CYP3A catalysis exhibited non-Michaelis-Menten kinetics in GCL cells, and that V(max)/K(m) values were significantly increased due to rifampicin-treatment.	Rifampin	206-216	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	72-77
18608530-4	2008	These results show that rifampicin inhibits rapamycin-induced autophagy, at least in part, via the suppression of PP2A activity.	Rifampin	24-34	protein phosphatase 2, regulatory subunit A, alpha	Mus musculus	114-118
18305373-3	2008	Rif, Dex, and Ome increased SULT2A1 mRNA level in both human and cynomolgus monkey hepatocytes in dose-dependent manner, but not SULT1A1 mRNA level.	Rifampin	0-3	sulfotransferase family 2A member 1	Homo sapiens	28-35
18305373-4	2008	Rif, Dex, and Ome increased the mRNA level of UGT1A1 in both human and cynomolgus monkey hepatocytes, Ome more potently in humans and Rif and Ome more potently in monkeys.	Rifampin	0-3	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	46-52
18305373-4	2008	Rif, Dex, and Ome increased the mRNA level of UGT1A1 in both human and cynomolgus monkey hepatocytes, Ome more potently in humans and Rif and Ome more potently in monkeys.	Rifampin	134-137	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	46-52
18031740-5	2008	Rifampicin significantly suppressed HUVEC tube formation and proliferation, and its effects appeared to be mediated at least in part through inhibition of extracellular signal-regulated kinase (ERK) 1/2 phosphorylation.	Rifampin	0-10	mitogen-activated protein kinase 3	Mus musculus	155-202
18031740-7	2008	Rifampicin was given subcutaneously at 20mg/kg once a day from immediately after hyperoxia (P12) to P16.	Rifampin	0-10	CDK2 (cyclin-dependent kinase 2)-associated protein 1	Mus musculus	92-95
18031740-7	2008	Rifampicin was given subcutaneously at 20mg/kg once a day from immediately after hyperoxia (P12) to P16.	Rifampin	0-10	cyclin dependent kinase inhibitor 2A	Mus musculus	100-103
18618311-4	2008	Mice treated with LPS alone showed markedly increased plasma levels of TNF, IL-1beta, IL-6, and IL-10, while mice pretreated with rifampicin showed significantly lower plasma levels of these cytokines compared to the LPS alone.	Rifampin	130-140	interleukin 1 beta	Mus musculus	76-84
18618311-4	2008	Mice treated with LPS alone showed markedly increased plasma levels of TNF, IL-1beta, IL-6, and IL-10, while mice pretreated with rifampicin showed significantly lower plasma levels of these cytokines compared to the LPS alone.	Rifampin	130-140	interleukin 6	Mus musculus	86-90
18618311-4	2008	Mice treated with LPS alone showed markedly increased plasma levels of TNF, IL-1beta, IL-6, and IL-10, while mice pretreated with rifampicin showed significantly lower plasma levels of these cytokines compared to the LPS alone.	Rifampin	130-140	interleukin 10	Mus musculus	96-101
18094221-0	2008	Effect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone.	Rifampin	10-18	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	34-39
17998298-4	2008	We investigated individual effects of the tested azoles as well as their action on rifampicin-induced PXR-mediated transactivation and expression of CYP3A4 in LS174T cell line and primary human hepatocytes, their interactions with PXR ligand-binding domain, and azole-mediated recruitment of SRC-1 to PXR.	Rifampin	83-93	nuclear receptor subfamily 1 group I member 2	Homo sapiens	102-105
17998298-4	2008	We investigated individual effects of the tested azoles as well as their action on rifampicin-induced PXR-mediated transactivation and expression of CYP3A4 in LS174T cell line and primary human hepatocytes, their interactions with PXR ligand-binding domain, and azole-mediated recruitment of SRC-1 to PXR.	Rifampin	83-93	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	149-155
17998298-4	2008	We investigated individual effects of the tested azoles as well as their action on rifampicin-induced PXR-mediated transactivation and expression of CYP3A4 in LS174T cell line and primary human hepatocytes, their interactions with PXR ligand-binding domain, and azole-mediated recruitment of SRC-1 to PXR.	Rifampin	83-93	nuclear receptor subfamily 1 group I member 2	Homo sapiens	231-234
17998298-4	2008	We investigated individual effects of the tested azoles as well as their action on rifampicin-induced PXR-mediated transactivation and expression of CYP3A4 in LS174T cell line and primary human hepatocytes, their interactions with PXR ligand-binding domain, and azole-mediated recruitment of SRC-1 to PXR.	Rifampin	83-93	nuclear receptor coactivator 1	Homo sapiens	292-297
17998298-4	2008	We investigated individual effects of the tested azoles as well as their action on rifampicin-induced PXR-mediated transactivation and expression of CYP3A4 in LS174T cell line and primary human hepatocytes, their interactions with PXR ligand-binding domain, and azole-mediated recruitment of SRC-1 to PXR.	Rifampin	83-93	nuclear receptor subfamily 1 group I member 2	Homo sapiens	231-234
17998298-5	2008	In addition, applying the pharmacodynamic approach and dose-response analysis, we aimed to describe the nature of potential interactions of tested azole antimycotics coadministered with a prototypical PXR ligand rifampicin in transactivation of CYP3A4 gene.	Rifampin	212-222	nuclear receptor subfamily 1 group I member 2	Homo sapiens	201-204
17998298-5	2008	In addition, applying the pharmacodynamic approach and dose-response analysis, we aimed to describe the nature of potential interactions of tested azole antimycotics coadministered with a prototypical PXR ligand rifampicin in transactivation of CYP3A4 gene.	Rifampin	212-222	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	245-251
17998298-6	2008	We describe additive and antagonistic interactions of partial and full agonists of PXR nuclear receptor in the therapeutic group of azole antimycotics in rifampicin-mediated transactivation of CYP3A4.	Rifampin	154-164	nuclear receptor subfamily 1 group I member 2	Homo sapiens	83-86
17998298-6	2008	We describe additive and antagonistic interactions of partial and full agonists of PXR nuclear receptor in the therapeutic group of azole antimycotics in rifampicin-mediated transactivation of CYP3A4.	Rifampin	154-164	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	193-199
18094221-0	2008	Effect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone.	Rifampin	10-18	ATP binding cassette subfamily B member 1	Homo sapiens	44-58
18094221-1	2008	The authors studied the effect of rifampin, a dual inducer of CYP3A and P-glycoprotein, on the pharmacokinetics and pharmacodynamics of risperidone in humans.	Rifampin	34-42	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	62-67
18094221-1	2008	The authors studied the effect of rifampin, a dual inducer of CYP3A and P-glycoprotein, on the pharmacokinetics and pharmacodynamics of risperidone in humans.	Rifampin	34-42	ATP binding cassette subfamily B member 1	Homo sapiens	72-86
18094221-8	2008	Thus, rifampin reduced the exposure to risperidone, probably because of a decrease in its bioavailability through the induction of CYP3A and probably P-glycoprotein.	Rifampin	6-14	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	131-136
18094221-8	2008	Thus, rifampin reduced the exposure to risperidone, probably because of a decrease in its bioavailability through the induction of CYP3A and probably P-glycoprotein.	Rifampin	6-14	ATP binding cassette subfamily B member 1	Homo sapiens	150-164
17978482-6	2007	In HFL cells, CYP3A4 and CYP3A7 mRNA expression levels were markedly up-regulated by dexamethasone (DEX), but not by rifampicin (RIF).	Rifampin	117-127	cytochrome P450 family 3 subfamily A member 7	Homo sapiens	25-31
17998298-7	2008	We show that oxiconazole is a highly efficacious activator of CYP3A4 transactivation, which could be antagonized by rifampicin in a competitive manner.	Rifampin	116-126	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	62-68
17998298-8	2008	In addition, we show that activation of the CYP3A4 promoter is a complex process, which is not exclusively determined by azole-PXR interactions, and we suggest that the ability of some azoles to affect recruitment of SRC-1 to PXR modulates their net effects in transactivation of CYP3A4 both in the absence or presence of rifampicin.	Rifampin	322-332	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	44-50
17998298-8	2008	In addition, we show that activation of the CYP3A4 promoter is a complex process, which is not exclusively determined by azole-PXR interactions, and we suggest that the ability of some azoles to affect recruitment of SRC-1 to PXR modulates their net effects in transactivation of CYP3A4 both in the absence or presence of rifampicin.	Rifampin	322-332	nuclear receptor coactivator 1	Homo sapiens	217-222
17936189-9	2007	Induction (rifampicin) or inhibition (ketoconazole) of alpha-tocopherol metabolism and overexpression of PXR showed that the increase in PXR-related CYP3A4 expression caused by alpha-tocopherol enhanced cell death in hepatocytes.	Rifampin	11-21	nuclear receptor subfamily 1 group I member 2	Homo sapiens	137-140
17936189-9	2007	Induction (rifampicin) or inhibition (ketoconazole) of alpha-tocopherol metabolism and overexpression of PXR showed that the increase in PXR-related CYP3A4 expression caused by alpha-tocopherol enhanced cell death in hepatocytes.	Rifampin	11-21	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	149-155
18314648-1	2007	INTRODUCTION: Steroid and Xenobiotic Receptor (SXR) has demonstrated its activation by numerous drugs, including cytochrome P450 potent inducers like rifampicina or cotrimazol.	Rifampin	150-161	nuclear receptor subfamily 1 group I member 2	Homo sapiens	14-45
18314648-1	2007	INTRODUCTION: Steroid and Xenobiotic Receptor (SXR) has demonstrated its activation by numerous drugs, including cytochrome P450 potent inducers like rifampicina or cotrimazol.	Rifampin	150-161	nuclear receptor subfamily 1 group I member 2	Homo sapiens	47-50
17635106-3	2007	Adenoviral-mediated expression of human PXR (hPXR) and its activation by rifampicin strongly repressed cAMP-dependent induction of the endogenous G6Pase gene in Huh7 cells.	Rifampin	73-83	nuclear receptor subfamily 1 group I member 2	Homo sapiens	40-43
17635106-3	2007	Adenoviral-mediated expression of human PXR (hPXR) and its activation by rifampicin strongly repressed cAMP-dependent induction of the endogenous G6Pase gene in Huh7 cells.	Rifampin	73-83	glucose-6-phosphatase catalytic subunit 1	Homo sapiens	146-152
17978482-8	2007	On the other hand, CYP3A4, CYP3A5, and CYP3A7 mRNA expression levels in HepG2 cells were increased from 2- to 3-fold by treatment with DEX and RIF.	Rifampin	143-146	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	19-25
17978482-8	2007	On the other hand, CYP3A4, CYP3A5, and CYP3A7 mRNA expression levels in HepG2 cells were increased from 2- to 3-fold by treatment with DEX and RIF.	Rifampin	143-146	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	27-33
17978482-8	2007	On the other hand, CYP3A4, CYP3A5, and CYP3A7 mRNA expression levels in HepG2 cells were increased from 2- to 3-fold by treatment with DEX and RIF.	Rifampin	143-146	cytochrome P450 family 3 subfamily A member 7	Homo sapiens	39-45
17686907-4	2007	Considering that cyclosporin A and rifampicin inhibit multiple uptake/efflux transporters, the interactions of CP-671,305 with major human hepatic drug transporters, multidrug resistance protein 1 (MDR1), multidrug resistance-associated protein 2 (MRP2), breast cancer resistant protein (BCRP), and organic anion-transporting polypeptide (OATPs) were evaluated in vitro.	Rifampin	35-45	ATP binding cassette subfamily B member 1	Homo sapiens	198-202
17686907-4	2007	Considering that cyclosporin A and rifampicin inhibit multiple uptake/efflux transporters, the interactions of CP-671,305 with major human hepatic drug transporters, multidrug resistance protein 1 (MDR1), multidrug resistance-associated protein 2 (MRP2), breast cancer resistant protein (BCRP), and organic anion-transporting polypeptide (OATPs) were evaluated in vitro.	Rifampin	35-45	ATP binding cassette subfamily C member 2	Homo sapiens	205-246
17686907-4	2007	Considering that cyclosporin A and rifampicin inhibit multiple uptake/efflux transporters, the interactions of CP-671,305 with major human hepatic drug transporters, multidrug resistance protein 1 (MDR1), multidrug resistance-associated protein 2 (MRP2), breast cancer resistant protein (BCRP), and organic anion-transporting polypeptide (OATPs) were evaluated in vitro.	Rifampin	35-45	ATP binding cassette subfamily C member 2	Homo sapiens	248-252
17687072-8	2007	The suppressive effect of rifampicin was diminished, whereas the activating effect was augmented, in HepG2 cells with RNA interference-mediated PXR knockdown.	Rifampin	26-36	nuclear receptor subfamily 1 group I member 2	Homo sapiens	144-147
17687072-9	2007	These results suggest that HNF4alpha plays a central role in the control of SULT2A1 transcription and that rifampicin-liganded PXR suppresses SULT2A1 expression by interfering with HNF4alpha activity.	Rifampin	107-117	nuclear receptor subfamily 1 group I member 2	Homo sapiens	127-130
17687072-0	2007	Positive and negative regulation of human hepatic hydroxysteroid sulfotransferase (SULT2A1) gene transcription by rifampicin: roles of hepatocyte nuclear factor 4alpha and pregnane X receptor.	Rifampin	114-124	sulfotransferase family 2A member 1	Homo sapiens	83-90
17687072-1	2007	The effects of rifampicin treatment on SULT2A1 mRNA expression were evaluated in 23 preparations of primary cultured human hepatocytes.	Rifampin	15-25	sulfotransferase family 2A member 1	Homo sapiens	39-46
17687072-9	2007	These results suggest that HNF4alpha plays a central role in the control of SULT2A1 transcription and that rifampicin-liganded PXR suppresses SULT2A1 expression by interfering with HNF4alpha activity.	Rifampin	107-117	sulfotransferase family 2A member 1	Homo sapiens	142-149
17687072-2	2007	In contrast to the consistently occurring induction of CYP3A4, a prototypical pregnane X receptor (PXR) target gene, rifampicin treatment increased SULT2A1 mRNA levels in 12 of the hepatocyte preparations, but it produced little change or even suppression in the others.	Rifampin	117-127	nuclear receptor subfamily 1 group I member 2	Homo sapiens	78-97
17687072-9	2007	These results suggest that HNF4alpha plays a central role in the control of SULT2A1 transcription and that rifampicin-liganded PXR suppresses SULT2A1 expression by interfering with HNF4alpha activity.	Rifampin	107-117	hepatocyte nuclear factor 4 alpha	Homo sapiens	181-190
17687072-2	2007	In contrast to the consistently occurring induction of CYP3A4, a prototypical pregnane X receptor (PXR) target gene, rifampicin treatment increased SULT2A1 mRNA levels in 12 of the hepatocyte preparations, but it produced little change or even suppression in the others.	Rifampin	117-127	nuclear receptor subfamily 1 group I member 2	Homo sapiens	99-102
17687072-2	2007	In contrast to the consistently occurring induction of CYP3A4, a prototypical pregnane X receptor (PXR) target gene, rifampicin treatment increased SULT2A1 mRNA levels in 12 of the hepatocyte preparations, but it produced little change or even suppression in the others.	Rifampin	117-127	sulfotransferase family 2A member 1	Homo sapiens	148-155
17687072-3	2007	Transient transfection of HepG2 cells with a series of reporter constructs implicated two SULT2A1 5"-flanking regions as containing rifampicin-responsive information.	Rifampin	132-142	sulfotransferase family 2A member 1	Homo sapiens	90-97
17687072-10	2007	By contrast, the rifampicin-inducible SULT2A1 expression that occurs in many human hepatocyte preparations seems to be mediated through a PXR-independent mechanism.	Rifampin	17-27	sulfotransferase family 2A member 1	Homo sapiens	38-45
17687072-6	2007	Cotransfection of HepG2 cells with pregnane X receptor (PXR) dose-dependently suppressed reporter expression from SULT2A1 constructs containing the HNF4 sites, and rifampicin treatment augmented the suppression.	Rifampin	164-174	nuclear receptor subfamily 1 group I member 2	Homo sapiens	35-54
17687072-10	2007	By contrast, the rifampicin-inducible SULT2A1 expression that occurs in many human hepatocyte preparations seems to be mediated through a PXR-independent mechanism.	Rifampin	17-27	nuclear receptor subfamily 1 group I member 2	Homo sapiens	138-141
17687072-7	2007	Rifampicin treatment concentration-dependently suppressed SULT2A1 reporter expression at the same concentrations that progressively induced expression from a PXR-responsive CYP3A4 reporter, whereas higher rifampicin concentrations reversed the SULT2A1 suppression.	Rifampin	0-10	sulfotransferase family 2A member 1	Homo sapiens	58-65
17687072-7	2007	Rifampicin treatment concentration-dependently suppressed SULT2A1 reporter expression at the same concentrations that progressively induced expression from a PXR-responsive CYP3A4 reporter, whereas higher rifampicin concentrations reversed the SULT2A1 suppression.	Rifampin	0-10	nuclear receptor subfamily 1 group I member 2	Homo sapiens	158-161
17687072-7	2007	Rifampicin treatment concentration-dependently suppressed SULT2A1 reporter expression at the same concentrations that progressively induced expression from a PXR-responsive CYP3A4 reporter, whereas higher rifampicin concentrations reversed the SULT2A1 suppression.	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	173-179
17687072-7	2007	Rifampicin treatment concentration-dependently suppressed SULT2A1 reporter expression at the same concentrations that progressively induced expression from a PXR-responsive CYP3A4 reporter, whereas higher rifampicin concentrations reversed the SULT2A1 suppression.	Rifampin	0-10	sulfotransferase family 2A member 1	Homo sapiens	244-251
17687072-7	2007	Rifampicin treatment concentration-dependently suppressed SULT2A1 reporter expression at the same concentrations that progressively induced expression from a PXR-responsive CYP3A4 reporter, whereas higher rifampicin concentrations reversed the SULT2A1 suppression.	Rifampin	205-215	sulfotransferase family 2A member 1	Homo sapiens	244-251
17696253-8	2007	Overexpression of PXR and its dimerization partner retinoid X receptor (RXR) and stimulation with LCA or the potent PXR ligand rifampicin leads to a significant induction of FGF19 promoter activity in intestinal cells.	Rifampin	127-137	nuclear receptor subfamily 1 group I member 2	Homo sapiens	18-21
18183335-7	2007	Targeting for rapid drug resistance detection, in hospitalized patients at "Servico de Pneumologia 2 do Hospital Pulido Valente", the test INNO-LIPA Rif.TB, to identify the rifampicin resistance as a marker of multi-drug resistance, was evaluated.	Rifampin	173-183	lipase A, lysosomal acid type	Homo sapiens	144-148
17639026-5	2007	The induction by rifampin of CYP3A activity was significantly correlated with its induction of CYP3A4 transcripts (r = 0.96, p &lt; 0.05) and CYP3A protein (r = 0.89, p &lt; 0.05).	Rifampin	17-25	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	95-100
17768708-1	2007	In neutral medium, rifamycin antibiotics such as rifapentin (RFPT), rifampicin (RFP), rifandin (RFD) and rifamycin SV (RFSV) can bind with human serum albumin (HSA) and bovine serum albumin (BSA) to form complexes, resulting in the quenching of the intrinsic fluorescence (lambda(ex)/lambda(em) = 285/355 nm) of the BSA and HSA.	Rifampin	68-78	albumin	Homo sapiens	145-158
17768708-1	2007	In neutral medium, rifamycin antibiotics such as rifapentin (RFPT), rifampicin (RFP), rifandin (RFD) and rifamycin SV (RFSV) can bind with human serum albumin (HSA) and bovine serum albumin (BSA) to form complexes, resulting in the quenching of the intrinsic fluorescence (lambda(ex)/lambda(em) = 285/355 nm) of the BSA and HSA.	Rifampin	68-78	albumin	Homo sapiens	176-189
17696253-8	2007	Overexpression of PXR and its dimerization partner retinoid X receptor (RXR) and stimulation with LCA or the potent PXR ligand rifampicin leads to a significant induction of FGF19 promoter activity in intestinal cells.	Rifampin	127-137	retinoid X receptor alpha	Homo sapiens	72-75
17696253-8	2007	Overexpression of PXR and its dimerization partner retinoid X receptor (RXR) and stimulation with LCA or the potent PXR ligand rifampicin leads to a significant induction of FGF19 promoter activity in intestinal cells.	Rifampin	127-137	nuclear receptor subfamily 1 group I member 2	Homo sapiens	116-119
17696253-8	2007	Overexpression of PXR and its dimerization partner retinoid X receptor (RXR) and stimulation with LCA or the potent PXR ligand rifampicin leads to a significant induction of FGF19 promoter activity in intestinal cells.	Rifampin	127-137	fibroblast growth factor 19	Homo sapiens	174-179
17496208-0	2007	Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil.	Rifampin	147-157	solute carrier organic anion transporter family member 1B1	Homo sapiens	33-40
17624828-3	2007	First, induction of cytochrome P-450 enzymes and P-glycoprotein by rifampin results in reduced concentrations of nonnucleoside reverse-transcriptase inhibitors and, particularly, protease inhibitors.	Rifampin	67-75	ATP binding cassette subfamily B member 1	Homo sapiens	49-63
17496208-5	2007	Bosentan uptake into Chinese hamster ovary cells expressing these OATP transporters was efficiently inhibited by cyclosporin A and rifampicin with IC(50) values significantly below their effective plasma concentrations in humans.	Rifampin	131-141	solute carrier organic anion transporter family member 1A2	Homo sapiens	66-70
17635174-13	2007	GSE occur frequently in patients receiving rifampicin for osteoarticular infection but without an association with rifampicin plasma concentrations.	Rifampin	43-53	CELIAC2	Homo sapiens	0-3
17553741-0	2007	Rifampicin-induced CYP3A4 activation in CTX patients cannot replace chenodeoxycholic acid treatment.	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	19-25
17553741-6	2007	Rifampicin (600 mg/day x 7 days), known to induce the PXR, and thereby to increase CYP3A activity, was used.	Rifampin	0-10	nuclear receptor subfamily 1 group I member 2	Homo sapiens	54-57
17553741-6	2007	Rifampicin (600 mg/day x 7 days), known to induce the PXR, and thereby to increase CYP3A activity, was used.	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	83-88
17553741-7	2007	The degree of CYP3A4 induction was assessed by comparing midazolam pharmacokinetics before and after rifampicin treatment.	Rifampin	101-111	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	14-20
17553741-9	2007	The results show that despite 60% increase in CYP3A4 activity following rifampicin treatment, there is no significant change in cholestanol levels.	Rifampin	72-82	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	46-52
17392393-11	2007	Furthermore, we suggest that VPA synergistically augments the effect of rifampicin in transactivation of CYP3A4 in primary human hepatocytes.	Rifampin	72-82	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	105-111
17510066-2	2007	Exposure to some xenobiotics, such as the antibiotic rifampicin, increases P-gp expression.	Rifampin	53-63	ATP binding cassette subfamily B member 1	Homo sapiens	75-79
17434476-7	2007	A significant augmentation in the expression and activity of CYP1A2 and CYP2E1 was observed following pyrogallol and rifampicin+pyrogallol treatment; however, rifampicin exhibited a significant induction of CYP2E1 only.	Rifampin	117-127	cytochrome P450, family 1, subfamily a, polypeptide 2	Mus musculus	61-67
17434476-7	2007	A significant augmentation in the expression and activity of CYP1A2 and CYP2E1 was observed following pyrogallol and rifampicin+pyrogallol treatment; however, rifampicin exhibited a significant induction of CYP2E1 only.	Rifampin	117-127	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	72-78
17434476-7	2007	A significant augmentation in the expression and activity of CYP1A2 and CYP2E1 was observed following pyrogallol and rifampicin+pyrogallol treatment; however, rifampicin exhibited a significant induction of CYP2E1 only.	Rifampin	159-169	cytochrome P450, family 1, subfamily a, polypeptide 2	Mus musculus	61-67
17434476-7	2007	A significant augmentation in the expression and activity of CYP1A2 and CYP2E1 was observed following pyrogallol and rifampicin+pyrogallol treatment; however, rifampicin exhibited a significant induction of CYP2E1 only.	Rifampin	159-169	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	72-78
17434476-7	2007	A significant augmentation in the expression and activity of CYP1A2 and CYP2E1 was observed following pyrogallol and rifampicin+pyrogallol treatment; however, rifampicin exhibited a significant induction of CYP2E1 only.	Rifampin	159-169	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	207-213
17434476-8	2007	Attenuation of glutathione-S-transferase, glutathione reductase and glutathione peroxidase activities and augmentation of lipid peroxidation were observed following rifampicin and/or pyrogallol treatment and a cumulative effect was seen when the two drugs were administered in combination.	Rifampin	165-175	hematopoietic prostaglandin D synthase	Mus musculus	15-40
17434476-8	2007	Attenuation of glutathione-S-transferase, glutathione reductase and glutathione peroxidase activities and augmentation of lipid peroxidation were observed following rifampicin and/or pyrogallol treatment and a cumulative effect was seen when the two drugs were administered in combination.	Rifampin	165-175	glutathione reductase	Mus musculus	42-63
17434476-9	2007	Silymarin restored the rifampicin- and/or pyrogallol-induced alterations in the expression and activity of CYP1A2 and CYP2E1, the activity of glutathione-S-transferase, glutathione reductase, and glutathione peroxidase, and lipid peroxidation.	Rifampin	23-33	cytochrome P450, family 1, subfamily a, polypeptide 2	Mus musculus	107-113
17434476-9	2007	Silymarin restored the rifampicin- and/or pyrogallol-induced alterations in the expression and activity of CYP1A2 and CYP2E1, the activity of glutathione-S-transferase, glutathione reductase, and glutathione peroxidase, and lipid peroxidation.	Rifampin	23-33	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	118-124
17434476-9	2007	Silymarin restored the rifampicin- and/or pyrogallol-induced alterations in the expression and activity of CYP1A2 and CYP2E1, the activity of glutathione-S-transferase, glutathione reductase, and glutathione peroxidase, and lipid peroxidation.	Rifampin	23-33	hematopoietic prostaglandin D synthase	Mus musculus	142-167
17434476-9	2007	Silymarin restored the rifampicin- and/or pyrogallol-induced alterations in the expression and activity of CYP1A2 and CYP2E1, the activity of glutathione-S-transferase, glutathione reductase, and glutathione peroxidase, and lipid peroxidation.	Rifampin	23-33	glutathione reductase	Mus musculus	169-190
17434476-10	2007	The results demonstrate the role of CYP1A2, CYP2E1, glutathione-S-transferase, glutathione reductase and glutathione peroxidase in rifampicin- and pyrogallol-induced hepatotoxicity and provide evidence for the involvement of silymarin in attenuation of drug-induced hepatotoxicity.	Rifampin	131-141	cytochrome P450, family 1, subfamily a, polypeptide 2	Mus musculus	36-42
17434476-10	2007	The results demonstrate the role of CYP1A2, CYP2E1, glutathione-S-transferase, glutathione reductase and glutathione peroxidase in rifampicin- and pyrogallol-induced hepatotoxicity and provide evidence for the involvement of silymarin in attenuation of drug-induced hepatotoxicity.	Rifampin	131-141	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	44-50
17434476-10	2007	The results demonstrate the role of CYP1A2, CYP2E1, glutathione-S-transferase, glutathione reductase and glutathione peroxidase in rifampicin- and pyrogallol-induced hepatotoxicity and provide evidence for the involvement of silymarin in attenuation of drug-induced hepatotoxicity.	Rifampin	131-141	hematopoietic prostaglandin D synthase	Mus musculus	52-77
17434476-10	2007	The results demonstrate the role of CYP1A2, CYP2E1, glutathione-S-transferase, glutathione reductase and glutathione peroxidase in rifampicin- and pyrogallol-induced hepatotoxicity and provide evidence for the involvement of silymarin in attenuation of drug-induced hepatotoxicity.	Rifampin	131-141	glutathione reductase	Mus musculus	79-100
17198732-11	2007	However, 11/14 (79%) MRSA patients who received rifampin combinations, other than vancomycin and rifampin simultaneously, were apparently cured.	Rifampin	48-56	solute carrier family 9 member A6	Homo sapiens	21-25
17639026-4	2007	At 10 microM, rifampin induced CYP3A4 transcripts, CYP3A protein, and activity by 23-, 12-, and 13-fold, respectively.	Rifampin	14-22	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-37
17639026-4	2007	At 10 microM, rifampin induced CYP3A4 transcripts, CYP3A protein, and activity by 23-, 12-, and 13-fold, respectively.	Rifampin	14-22	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-36
17639026-5	2007	The induction by rifampin of CYP3A activity was significantly correlated with its induction of CYP3A4 transcripts (r = 0.96, p &lt; 0.05) and CYP3A protein (r = 0.89, p &lt; 0.05).	Rifampin	17-25	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	29-34
17639026-5	2007	The induction by rifampin of CYP3A activity was significantly correlated with its induction of CYP3A4 transcripts (r = 0.96, p &lt; 0.05) and CYP3A protein (r = 0.89, p &lt; 0.05).	Rifampin	17-25	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	95-101
17361125-2	2007	This study examines whether presumed changes in CYP3A4 activity are in fact related to inhibition of an uptake organic anion transporter using rifampin and inhibition of the efflux hepatic P-glycoprotein transporter using lansoprazole.	Rifampin	143-151	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	48-54
17369605-7	2007	Using HEK293-OATP1B3 cells, the cytotoxicity was attenuated by substrates and inhibitors of OATP1B3, including bromosulfophthalein, rifampicin, and cyclosporin A.	Rifampin	132-142	solute carrier organic anion transporter family member 1B3	Homo sapiens	13-20
17369605-7	2007	Using HEK293-OATP1B3 cells, the cytotoxicity was attenuated by substrates and inhibitors of OATP1B3, including bromosulfophthalein, rifampicin, and cyclosporin A.	Rifampin	132-142	solute carrier organic anion transporter family member 1B3	Homo sapiens	92-99
17293382-5	2007	Surprisingly, pyributicarb was found to increase the CYP3A4 reporter activity at 0.1 to 1 microM more strongly than typical CYP3A4 inducer rifampicin.	Rifampin	139-149	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	124-130
17207564-8	2007	HepG2 CYP3A4 activity was unaffected by 48 h DEX pretreatment; therefore, studies were done in DPX-2 cells, a HepG2 derivative engineered to overexpress pregnane-X receptor (PXR) that exhibits rifampicin (RIF)-inducible endogenous CYP3A4.	Rifampin	193-203	nuclear receptor subfamily 1 group I member 2	Homo sapiens	153-172
17207564-10	2007	CYP3A4 activity of DPX-2 cells treated with RIF (10 microM, 48 h) was twice that of untreated cells, but RIF did not increase alachlor toxicity.	Rifampin	44-47	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
17429319-4	2007	Instead, as shown using a mammalian two-hybrid assay, it decreased the interaction of pregnane X receptor with steroid receptor coactivator-1 in the presence of rifampin, clotrimazole, paclitaxel, or nifedipine but not in their absence.	Rifampin	161-169	nuclear receptor subfamily 1 group I member 2	Homo sapiens	86-105
17429319-4	2007	Instead, as shown using a mammalian two-hybrid assay, it decreased the interaction of pregnane X receptor with steroid receptor coactivator-1 in the presence of rifampin, clotrimazole, paclitaxel, or nifedipine but not in their absence.	Rifampin	161-169	nuclear receptor coactivator 1	Homo sapiens	111-141
17429319-5	2007	Rifampin treatment markedly increased pregnane X receptor protein in the wild-type pregnane X receptor-transfected cells as shown by coimmunoprecipitation but not in Q158K pregnane X receptor-transfected cells.	Rifampin	0-8	nuclear receptor subfamily 1 group I member 2	Homo sapiens	38-57
17429319-5	2007	Rifampin treatment markedly increased pregnane X receptor protein in the wild-type pregnane X receptor-transfected cells as shown by coimmunoprecipitation but not in Q158K pregnane X receptor-transfected cells.	Rifampin	0-8	nuclear receptor subfamily 1 group I member 2	Homo sapiens	83-102
17429319-5	2007	Rifampin treatment markedly increased pregnane X receptor protein in the wild-type pregnane X receptor-transfected cells as shown by coimmunoprecipitation but not in Q158K pregnane X receptor-transfected cells.	Rifampin	0-8	nuclear receptor subfamily 1 group I member 2	Homo sapiens	83-102
17381666-0	2007	Rifampin, a cytochrome P450 3A inducer, decreases plasma concentrations of antipsychotic risperidone in healthy volunteers.	Rifampin	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-27
17381666-2	2007	Rifampin, a potent CYP3A inducer, has been known to markedly decrease plasma concentrations of various drugs, which are concomitantly administered during treatment.	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	19-24
17389551-1	2007	The effect of rifampin, a cytochrome P450 3A4 inducer, on the pharmacokinetics of atrasentan was assessed in 12 healthy male subjects in an open-label study.	Rifampin	14-22	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	26-45
17470658-11	2007	However; the Cox regression analysis showed that rifampin was the only independent predictor associated with a lower risk of thrombocytopenia (hazard ratio, 0.37; 95% confidence interval, 0.14 to 0.98; P = 0.045).	Rifampin	49-57	cytochrome c oxidase subunit 8A	Homo sapiens	13-16
17259447-13	2007	Changes in plasma R/S methadone ratios observed after rifampin or troleandomycin pretreatment in humans in vivo were successfully predicted by CYP2B6- but not CYP3A4-catalyzed methadone N-demethylation.	Rifampin	54-62	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	143-149
17093002-5	2007	Treatment of PXR-humanized mice with the PXR ligands mimicked the human response, since both hepatic and intestinal CYP3As were strongly induced by rifampicin, a human-specific PXR ligand, but not by pregnenolone 16alpha-carbonitrile, a rodent-specific PXR ligand.	Rifampin	148-158	nuclear receptor subfamily 1, group I, member 2	Mus musculus	13-16
17251982-7	2007	Rifampin potently inhibited the uptake of bosentan into cells expressing human OATP1B1 and -1B3.	Rifampin	0-8	solute carrier organic anion transporter family member 1B1	Homo sapiens	79-95
17280646-0	2007	Rifampicin protects PC12 cells against MPP+-induced apoptosis and inhibits the expression of an alpha-Synuclein multimer.	Rifampin	0-10	synuclein alpha	Rattus norvegicus	96-111
17280646-5	2007	The expression of the higher molecular mass alpha-Synuclein was increased by MPP(+) exposure, and its expression was inversely related to cell survival in the rifampicin-treated cells.	Rifampin	159-169	synuclein alpha	Rattus norvegicus	44-59
17280646-6	2007	Importantly, rifampicin suppressed apoptosis almost completely, without shifting the death cascade to necrosis, which is a problem that has been reported with caspase inhibitors of apoptosis (Hartmann, A., Troadec, J.D., Hunot, S., Kikly, K., Faucheux, B.A., Mouatt-Prigent, A., Ruberg, M. Agid, Y., Hirsch, E.C., 2001.	Rifampin	13-23	caspase 8	Rattus norvegicus	159-166
17280646-10	2007	These results suggest that rifampicin improves survival of catecholamine- and alpha-Synuclein-containing cells, which degenerate in Parkinson"s disease (PD), and thus may be therapeutic in this disease.	Rifampin	27-37	synuclein alpha	Rattus norvegicus	78-93
17088262-6	2007	A human PXR ligand, rifampicin, induced CYP27A1 mRNA expression in intestine cells but not in liver cells.	Rifampin	20-30	nuclear receptor subfamily 1 group I member 2	Homo sapiens	8-11
17088262-6	2007	A human PXR ligand, rifampicin, induced CYP27A1 mRNA expression in intestine cells but not in liver cells.	Rifampin	20-30	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	40-47
17093002-5	2007	Treatment of PXR-humanized mice with the PXR ligands mimicked the human response, since both hepatic and intestinal CYP3As were strongly induced by rifampicin, a human-specific PXR ligand, but not by pregnenolone 16alpha-carbonitrile, a rodent-specific PXR ligand.	Rifampin	148-158	nuclear receptor subfamily 1, group I, member 2	Mus musculus	41-44
17088262-7	2007	Rifampicin induced CYP27A1 gene transcription, increased intracellular 27-HOC levels, and induced ABCA1 and ABCG1 mRNA expression only in intestine cells.	Rifampin	0-10	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	19-26
17093002-5	2007	Treatment of PXR-humanized mice with the PXR ligands mimicked the human response, since both hepatic and intestinal CYP3As were strongly induced by rifampicin, a human-specific PXR ligand, but not by pregnenolone 16alpha-carbonitrile, a rodent-specific PXR ligand.	Rifampin	148-158	peptidylprolyl isomerase F	Homo sapiens	116-120
17088262-7	2007	Rifampicin induced CYP27A1 gene transcription, increased intracellular 27-HOC levels, and induced ABCA1 and ABCG1 mRNA expression only in intestine cells.	Rifampin	0-10	ATP binding cassette subfamily A member 1	Homo sapiens	98-103
17093002-5	2007	Treatment of PXR-humanized mice with the PXR ligands mimicked the human response, since both hepatic and intestinal CYP3As were strongly induced by rifampicin, a human-specific PXR ligand, but not by pregnenolone 16alpha-carbonitrile, a rodent-specific PXR ligand.	Rifampin	148-158	nuclear receptor subfamily 1 group I member 2	Homo sapiens	41-44
17088262-7	2007	Rifampicin induced CYP27A1 gene transcription, increased intracellular 27-HOC levels, and induced ABCA1 and ABCG1 mRNA expression only in intestine cells.	Rifampin	0-10	ATP binding cassette subfamily G member 1	Homo sapiens	108-113
17088262-9	2007	Chromatin immunoprecipitation assays revealed that rifampicin induced the PXR recruitment of steroid receptor coactivator 1 to CYP27A1 chromatin.	Rifampin	51-61	nuclear receptor subfamily 1 group I member 2	Homo sapiens	74-77
17093002-5	2007	Treatment of PXR-humanized mice with the PXR ligands mimicked the human response, since both hepatic and intestinal CYP3As were strongly induced by rifampicin, a human-specific PXR ligand, but not by pregnenolone 16alpha-carbonitrile, a rodent-specific PXR ligand.	Rifampin	148-158	nuclear receptor subfamily 1 group I member 2	Homo sapiens	41-44
17088262-9	2007	Chromatin immunoprecipitation assays revealed that rifampicin induced the PXR recruitment of steroid receptor coactivator 1 to CYP27A1 chromatin.	Rifampin	51-61	nuclear receptor coactivator 1	Homo sapiens	93-123
17088262-9	2007	Chromatin immunoprecipitation assays revealed that rifampicin induced the PXR recruitment of steroid receptor coactivator 1 to CYP27A1 chromatin.	Rifampin	51-61	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	127-134
17093002-6	2007	In rifampicin-pretreated PXR-humanized mice, an approximately 60% decrease was observed for both the maximal midazolam serum concentration (C(max)) and the area under the concentration-time curve, as a result of a 3-fold increase in midazolam 1"-hydroxylation.	Rifampin	3-13	nuclear receptor subfamily 1, group I, member 2	Mus musculus	25-28
17088262-11	2007	Rifampicin, 27-HOC, and a potent LXRalpha agonist, T0901317, induced ABCA1 and ABCG1 protein expression and stimulated cholesterol efflux from intestine cells to apolipoprotein A-I and HDL.	Rifampin	0-10	ATP binding cassette subfamily A member 1	Homo sapiens	69-74
17069749-6	2007	NDGA and RIF inhibited the binding of Abeta to GM1 liposomes by competitively binding to the membranes and/or direct interaction with Abeta in solution, thus at least partly preventing fibrils from forming.	Rifampin	9-12	amyloid beta precursor protein	Rattus norvegicus	38-43
17088262-11	2007	Rifampicin, 27-HOC, and a potent LXRalpha agonist, T0901317, induced ABCA1 and ABCG1 protein expression and stimulated cholesterol efflux from intestine cells to apolipoprotein A-I and HDL.	Rifampin	0-10	ATP binding cassette subfamily G member 1	Homo sapiens	79-84
17088262-11	2007	Rifampicin, 27-HOC, and a potent LXRalpha agonist, T0901317, induced ABCA1 and ABCG1 protein expression and stimulated cholesterol efflux from intestine cells to apolipoprotein A-I and HDL.	Rifampin	0-10	apolipoprotein A1	Homo sapiens	162-180
17108049-7	2007	In addition, BKRF3 was able to complement an E. coli ung mutant in rifampin and nalidixic acid resistance mutator assays.	Rifampin	67-75	uracil-DNA glycosylase	Human gammaherpesvirus 4	13-18
17108049-7	2007	In addition, BKRF3 was able to complement an E. coli ung mutant in rifampin and nalidixic acid resistance mutator assays.	Rifampin	67-75	uracil DNA glycosylase	Homo sapiens	53-56
17069749-6	2007	NDGA and RIF inhibited the binding of Abeta to GM1 liposomes by competitively binding to the membranes and/or direct interaction with Abeta in solution, thus at least partly preventing fibrils from forming.	Rifampin	9-12	amyloid beta precursor protein	Rattus norvegicus	134-139
17936928-10	2007	Since species differences exist in ligand specificity between human and mice, a PXR-humanized mouse (hPXR) was produced that responds to human PXR activators such as rifampicin but does not respond to the rodent activator pregnenalone 16alpha-carbonitrile.	Rifampin	166-176	nuclear receptor subfamily 1, group I, member 2	Mus musculus	80-83
17253885-4	2007	For some time it has been known that inducers of drug-metabolising enzymes (such as the CYP3A4 inducer rifampicin [rifampin]) can lead to breakthrough bleeding and contraceptive failure.	Rifampin	103-113	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	88-94
17253885-4	2007	For some time it has been known that inducers of drug-metabolising enzymes (such as the CYP3A4 inducer rifampicin [rifampin]) can lead to breakthrough bleeding and contraceptive failure.	Rifampin	115-123	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	88-94
17936928-10	2007	Since species differences exist in ligand specificity between human and mice, a PXR-humanized mouse (hPXR) was produced that responds to human PXR activators such as rifampicin but does not respond to the rodent activator pregnenalone 16alpha-carbonitrile.	Rifampin	166-176	nuclear receptor subfamily 1 group I member 2	Homo sapiens	102-105
17365992-2	2007	The aim of this study was to examine Pgp activity in relation to age, gender, medical treatment (rifampicin or ketoconazole) and the multidrug resistance (MDR1) gene single nucleotide polymorphisms (SNPs) G2677T and C3435T using the model drug digoxin.	Rifampin	97-107	ATP binding cassette subfamily B member 1	Homo sapiens	37-40
16973756-3	2007	Activation of PXR by genetic (transgene) or pharmacological (ligand, such as rifampicin) markedly increased plasma concentrations of corticosterone and aldosterone, the respective primary glucocorticoid and mineralocorticoid in rodents.	Rifampin	77-87	nuclear receptor subfamily 1, group I, member 2	Mus musculus	14-17
17365992-7	2007	RESULTS: Rifampicin treatment resulted in increased Pgp activity, duodenal MDR1 mRNA expression and Pgp detection compared with that in the control group (p&lt;0.05 for all), Pgp activity being associated with duodenal MDR1 mRNA level (p&lt;0.05).	Rifampin	9-19	ATP binding cassette subfamily B member 1	Homo sapiens	52-55
17365992-7	2007	RESULTS: Rifampicin treatment resulted in increased Pgp activity, duodenal MDR1 mRNA expression and Pgp detection compared with that in the control group (p&lt;0.05 for all), Pgp activity being associated with duodenal MDR1 mRNA level (p&lt;0.05).	Rifampin	9-19	ATP binding cassette subfamily B member 1	Homo sapiens	75-79
17365992-7	2007	RESULTS: Rifampicin treatment resulted in increased Pgp activity, duodenal MDR1 mRNA expression and Pgp detection compared with that in the control group (p&lt;0.05 for all), Pgp activity being associated with duodenal MDR1 mRNA level (p&lt;0.05).	Rifampin	9-19	ATP binding cassette subfamily B member 1	Homo sapiens	100-103
17365992-7	2007	RESULTS: Rifampicin treatment resulted in increased Pgp activity, duodenal MDR1 mRNA expression and Pgp detection compared with that in the control group (p&lt;0.05 for all), Pgp activity being associated with duodenal MDR1 mRNA level (p&lt;0.05).	Rifampin	9-19	ATP binding cassette subfamily B member 1	Homo sapiens	100-103
17365992-7	2007	RESULTS: Rifampicin treatment resulted in increased Pgp activity, duodenal MDR1 mRNA expression and Pgp detection compared with that in the control group (p&lt;0.05 for all), Pgp activity being associated with duodenal MDR1 mRNA level (p&lt;0.05).	Rifampin	9-19	ATP binding cassette subfamily B member 1	Homo sapiens	219-223
17365992-10	2007	CONCLUSIONS: Our data confirm that rifampicin increases Pgp activity, by increasing MDR1 mRNA and Pgp levels.	Rifampin	35-45	ATP binding cassette subfamily B member 1	Homo sapiens	56-59
17365992-10	2007	CONCLUSIONS: Our data confirm that rifampicin increases Pgp activity, by increasing MDR1 mRNA and Pgp levels.	Rifampin	35-45	ATP binding cassette subfamily B member 1	Homo sapiens	84-88
17365992-10	2007	CONCLUSIONS: Our data confirm that rifampicin increases Pgp activity, by increasing MDR1 mRNA and Pgp levels.	Rifampin	35-45	ATP binding cassette subfamily B member 1	Homo sapiens	98-101
17112804-11	2006	CONCLUSIONS: Coadministration of rifampin increases the maximum serum concentrations of ezetimibe but reduces its enterosystemic recycling, most likely by inhibition of the secretion of ezetimibe and its glucuronide via P-gp and MRP2.	Rifampin	33-41	ATP binding cassette subfamily B member 1	Homo sapiens	220-224
16849627-5	2006	Rifampicin prevents hIAPP amyloid fibril formation and has been proposed as a potential target for prevention of T2DM.	Rifampin	0-10	islet amyloid polypeptide	Homo sapiens	20-25
16849627-7	2006	We report that rifampicin (Acocella G. Clin Pharmacokinet 3: 108-127, 1978) prevents hIAPP fibril formation, but not formation of toxic hIAPP oligomers (Bates G. Lancet 361: 1642-1644, 2003), and does not protect beta-cells from apoptosis induced by either overexpression or application of hIAPP.	Rifampin	15-25	islet amyloid polypeptide	Homo sapiens	85-90
17220562-9	2006	CYP3A4 mRNA expression was increased significantly by rifampicin (Rif) exposure in human hepatocytes, whereas Rif-induced increases in CYP3A4 mRNA expression in chimeric mouse hepatocytes was seen for two of the three donors.	Rifampin	54-64	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
17220562-9	2006	CYP3A4 mRNA expression was increased significantly by rifampicin (Rif) exposure in human hepatocytes, whereas Rif-induced increases in CYP3A4 mRNA expression in chimeric mouse hepatocytes was seen for two of the three donors.	Rifampin	66-69	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
17220562-9	2006	CYP3A4 mRNA expression was increased significantly by rifampicin (Rif) exposure in human hepatocytes, whereas Rif-induced increases in CYP3A4 mRNA expression in chimeric mouse hepatocytes was seen for two of the three donors.	Rifampin	110-113	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	135-141
17112807-12	2006	CONCLUSION: This study demonstrates an interaction between mycophenolate mofetil and rifampin, which is a result of induction of MPA glucuronidation and possibly also rifampin-associated alterations in MRP2-mediated transport of MPAG and AcMPAG.	Rifampin	85-93	ATP binding cassette subfamily C member 2	Homo sapiens	202-206
17112807-12	2006	CONCLUSION: This study demonstrates an interaction between mycophenolate mofetil and rifampin, which is a result of induction of MPA glucuronidation and possibly also rifampin-associated alterations in MRP2-mediated transport of MPAG and AcMPAG.	Rifampin	167-175	ATP binding cassette subfamily C member 2	Homo sapiens	202-206
17112804-11	2006	CONCLUSIONS: Coadministration of rifampin increases the maximum serum concentrations of ezetimibe but reduces its enterosystemic recycling, most likely by inhibition of the secretion of ezetimibe and its glucuronide via P-gp and MRP2.	Rifampin	33-41	ATP binding cassette subfamily C member 2	Homo sapiens	229-233
16632523-2	2006	Rifampin, the classical activator of CYP3A4, binds to SXR directly.	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	37-43
16952291-0	2006	Identification of a novel 974C-->G nonsense mutation of the MRP2/ABCC2 gene in a patient with Dubin-Johnson syndrome and analysis of the effects of rifampicin and ursodeoxycholic acid on serum bilirubin and bile acids.	Rifampin	148-158	ATP binding cassette subfamily C member 2	Homo sapiens	60-64
16837569-4	2006	With a threshold corresponding to a 1.5-fold factor change in mRNA levels, observed in at least three of seven independent human hepatocyte cultures, efflux transporters such as MDR1, MRP2 and BCRP were up-regulated by PB, RIF, and OPZ, whereas MRP3 was induced by OPZ and RIF.	Rifampin	223-226	ATP binding cassette subfamily B member 1	Homo sapiens	178-182
16837569-4	2006	With a threshold corresponding to a 1.5-fold factor change in mRNA levels, observed in at least three of seven independent human hepatocyte cultures, efflux transporters such as MDR1, MRP2 and BCRP were up-regulated by PB, RIF, and OPZ, whereas MRP3 was induced by OPZ and RIF.	Rifampin	223-226	ATP binding cassette subfamily C member 2	Homo sapiens	184-188
16837569-4	2006	With a threshold corresponding to a 1.5-fold factor change in mRNA levels, observed in at least three of seven independent human hepatocyte cultures, efflux transporters such as MDR1, MRP2 and BCRP were up-regulated by PB, RIF, and OPZ, whereas MRP3 was induced by OPZ and RIF.	Rifampin	223-226	BCR pseudogene 1	Homo sapiens	193-197
16837569-4	2006	With a threshold corresponding to a 1.5-fold factor change in mRNA levels, observed in at least three of seven independent human hepatocyte cultures, efflux transporters such as MDR1, MRP2 and BCRP were up-regulated by PB, RIF, and OPZ, whereas MRP3 was induced by OPZ and RIF.	Rifampin	223-226	ATP binding cassette subfamily C member 3	Homo sapiens	245-249
16837569-4	2006	With a threshold corresponding to a 1.5-fold factor change in mRNA levels, observed in at least three of seven independent human hepatocyte cultures, efflux transporters such as MDR1, MRP2 and BCRP were up-regulated by PB, RIF, and OPZ, whereas MRP3 was induced by OPZ and RIF.	Rifampin	273-276	ATP binding cassette subfamily B member 1	Homo sapiens	178-182
16837569-4	2006	With a threshold corresponding to a 1.5-fold factor change in mRNA levels, observed in at least three of seven independent human hepatocyte cultures, efflux transporters such as MDR1, MRP2 and BCRP were up-regulated by PB, RIF, and OPZ, whereas MRP3 was induced by OPZ and RIF.	Rifampin	273-276	ATP binding cassette subfamily C member 2	Homo sapiens	184-188
16837569-4	2006	With a threshold corresponding to a 1.5-fold factor change in mRNA levels, observed in at least three of seven independent human hepatocyte cultures, efflux transporters such as MDR1, MRP2 and BCRP were up-regulated by PB, RIF, and OPZ, whereas MRP3 was induced by OPZ and RIF.	Rifampin	273-276	BCR pseudogene 1	Homo sapiens	193-197
16837569-4	2006	With a threshold corresponding to a 1.5-fold factor change in mRNA levels, observed in at least three of seven independent human hepatocyte cultures, efflux transporters such as MDR1, MRP2 and BCRP were up-regulated by PB, RIF, and OPZ, whereas MRP3 was induced by OPZ and RIF.	Rifampin	273-276	ATP binding cassette subfamily C member 3	Homo sapiens	245-249
16837625-5	2006	P-glycoprotein expression and transport activity in brain capillaries from transgenic mice was significantly increased when capillaries were exposed to the hPXR ligands, rifampin and hyperforin, in vitro and when the mice were dosed with rifampin in vivo.	Rifampin	170-178	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
16837625-5	2006	P-glycoprotein expression and transport activity in brain capillaries from transgenic mice was significantly increased when capillaries were exposed to the hPXR ligands, rifampin and hyperforin, in vitro and when the mice were dosed with rifampin in vivo.	Rifampin	170-178	nuclear receptor subfamily 1 group I member 2	Homo sapiens	156-160
16837625-5	2006	P-glycoprotein expression and transport activity in brain capillaries from transgenic mice was significantly increased when capillaries were exposed to the hPXR ligands, rifampin and hyperforin, in vitro and when the mice were dosed with rifampin in vivo.	Rifampin	238-246	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
16837625-5	2006	P-glycoprotein expression and transport activity in brain capillaries from transgenic mice was significantly increased when capillaries were exposed to the hPXR ligands, rifampin and hyperforin, in vitro and when the mice were dosed with rifampin in vivo.	Rifampin	238-246	nuclear receptor subfamily 1 group I member 2	Homo sapiens	156-160
16782766-2	2006	In monkey hepatocytes, rifampin markedly induced CYP3A64 mRNA (EC50 = 0.5 microM; Emax = 6-fold) and midazolam (MDZ) 1"-hydroxylase activity (EC50 = 0.2 microM; Emax = 2-fold).	Rifampin	23-31	cytochrome P450 3A64	Macaca mulatta	49-56
16782766-4	2006	Similar corresponding results also were obtained with human CYP3A4 in the presence of rifampin or compound A.	Rifampin	86-94	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	60-66
16842400-0	2006	Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements.	Rifampin	64-74	ATP binding cassette subfamily B member 1	Homo sapiens	13-27
16842400-4	2006	METHODS: Pgp expression was assessed by flow cytometry and real-time reverse transcriptase-polymerase chain reaction using lymphocytes from four healthy subjects after incubation with therapeutic concentrations of CBZ, using rifampicin as a positive control.	Rifampin	225-235	ATP binding cassette subfamily B member 1	Homo sapiens	9-12
16946557-3	2006	In primary cultures of human hepatocytes, mRNA levels of MDR and MRP1 were increased by about 1.5 fold and 1.3 fold, respectively, by exposure to Rif at 2 to 50 microM as compared with 0.1% DMSO-treated controls.	Rifampin	146-149	mutS homolog 3	Homo sapiens	65-69
16946557-4	2006	MRP2 mRNA levels in the same human hepatocytes were significantly increased by 1.2 to 1.8 fold by exposure to Rif at 50 microM as compared with controls.	Rifampin	110-113	ATP binding cassette subfamily C member 2	Homo sapiens	0-4
16822884-8	2006	Furthermore, the addition of rifampicin increased the gene expression of CYP3A4, which is similar with the activities of human liver cells.	Rifampin	29-39	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	73-79
16713641-5	2006	We used real time PCR to examine whether known and suspected CYP3A inducers (dexamethasone, metyrapone, rifampicin, and toxaphene) up-regulate steady state levels of hepatic CYP3A77 transcript to determine if induction patterns in female juvenile alligators are similar to those reported in other vertebrates and whether toxaphene, an organochlorine compound found in high concentrations in Lake Apopka alligators, induces this gene.	Rifampin	104-114	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	61-66
16606623-4	2006	To explore the SXR-mediated vitamin K2 signaling network in bone homeostasis, we identified genes up-regulated by both vitamin K2 and the prototypical SXR ligand, rifampicin, in osteoblastic cells using oligonucleotide microarray analysis and quantitative reverse transcription-PCR.	Rifampin	163-173	nuclear receptor subfamily 1 group I member 2	Homo sapiens	15-18
16606623-4	2006	To explore the SXR-mediated vitamin K2 signaling network in bone homeostasis, we identified genes up-regulated by both vitamin K2 and the prototypical SXR ligand, rifampicin, in osteoblastic cells using oligonucleotide microarray analysis and quantitative reverse transcription-PCR.	Rifampin	163-173	nuclear receptor subfamily 1 group I member 2	Homo sapiens	151-154
16620787-6	2006	Rifampin (10 microM) caused significant induction of ABCB1 (595+/-263%, p&lt;0.05) in LS174T cells but induction was absent in Caco-2 or A549 cells.	Rifampin	0-8	ATP binding cassette subfamily B member 1	Homo sapiens	53-58
16691293-7	2006	Moreover, 1,25(OH)2D3-induced CYP24 expression was enhanced in mice lacking the SXR ortholog pregnane X receptor, and treatment of humans with the SXR agonist rifampicin had no effect on intestinal CYP24 expression, despite demonstration of marked CYP3A4 induction.	Rifampin	159-169	nuclear receptor subfamily 1 group I member 2	Homo sapiens	147-150
16857725-3	2006	Rifampicin, phenobarbital, and 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime, which are activators of pregnane X receptor (PXR) and constitutive androstane receptor (CAR), induced CYP2A6 mRNA in human hepatocytes.	Rifampin	0-10	nuclear receptor subfamily 1 group I member 2	Homo sapiens	145-164
16857725-3	2006	Rifampicin, phenobarbital, and 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime, which are activators of pregnane X receptor (PXR) and constitutive androstane receptor (CAR), induced CYP2A6 mRNA in human hepatocytes.	Rifampin	0-10	nuclear receptor subfamily 1 group I member 2	Homo sapiens	166-169
16857725-3	2006	Rifampicin, phenobarbital, and 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime, which are activators of pregnane X receptor (PXR) and constitutive androstane receptor (CAR), induced CYP2A6 mRNA in human hepatocytes.	Rifampin	0-10	nuclear receptor subfamily 1 group I member 3	Homo sapiens	175-207
16857725-3	2006	Rifampicin, phenobarbital, and 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime, which are activators of pregnane X receptor (PXR) and constitutive androstane receptor (CAR), induced CYP2A6 mRNA in human hepatocytes.	Rifampin	0-10	nuclear receptor subfamily 1 group I member 3	Homo sapiens	209-212
16857725-3	2006	Rifampicin, phenobarbital, and 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime, which are activators of pregnane X receptor (PXR) and constitutive androstane receptor (CAR), induced CYP2A6 mRNA in human hepatocytes.	Rifampin	0-10	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	223-229
16760228-7	2006	The well known cholestatic drugs, rifampicin, rifamycin SV, glibenclamide, and cyclosporin A, reduced the basal-to-apical transport and the apical efflux clearance of taurocholate across NTCP- and BSEP-coexpressing cell monolayers.	Rifampin	34-44	solute carrier family 10 member 1	Homo sapiens	187-191
16760228-7	2006	The well known cholestatic drugs, rifampicin, rifamycin SV, glibenclamide, and cyclosporin A, reduced the basal-to-apical transport and the apical efflux clearance of taurocholate across NTCP- and BSEP-coexpressing cell monolayers.	Rifampin	34-44	ATP binding cassette subfamily B member 11	Homo sapiens	197-201
16849379-8	2006	In contrast, the combinations doxycycline/gentamicin and doxycycline/rifampicin were effective in the clearance of Rev 1 infection, but only the former improved significantly the therapeutic efficacy as compared with that of the antibiotics given alone.	Rifampin	69-79	REV1, DNA directed polymerase	Mus musculus	115-120
16831602-4	2006	RESULTS: The pregnane X receptor was expressed in primary cultures at the level of messenger RNA and protein and was activated by the ligand rifampicin as judged by increases in binding of proteins to the pregnane X receptor ER6 DNA response element and by increases in ER6-dependent reporter gene expression.	Rifampin	141-151	nuclear receptor subfamily 1 group I member 2	Homo sapiens	13-32
16831602-4	2006	RESULTS: The pregnane X receptor was expressed in primary cultures at the level of messenger RNA and protein and was activated by the ligand rifampicin as judged by increases in binding of proteins to the pregnane X receptor ER6 DNA response element and by increases in ER6-dependent reporter gene expression.	Rifampin	141-151	nuclear receptor subfamily 1 group I member 2	Homo sapiens	205-224
16831602-5	2006	Short-term treatment of hepatic stellate cells with rifampicin inhibited the expression of selected fibrosis-related genes (transforming growth factor beta1, alpha-smooth muscle actin), proliferation-related genes, and WNT signaling-associated genes.	Rifampin	52-62	transforming growth factor beta 1	Homo sapiens	124-156
16479312-7	2006	Rifampin and taurocholic acid (a substrate of OATP-C) reversed the increased toxicity of arsenate and arsenite seen in OATP-C-transfected cells.	Rifampin	0-8	solute carrier organic anion transporter family member 1B1	Homo sapiens	46-52
16479312-7	2006	Rifampin and taurocholic acid (a substrate of OATP-C) reversed the increased toxicity of arsenate and arsenite seen in OATP-C-transfected cells.	Rifampin	0-8	solute carrier organic anion transporter family member 1B1	Homo sapiens	119-125
16632523-2	2006	Rifampin, the classical activator of CYP3A4, binds to SXR directly.	Rifampin	0-8	nuclear receptor subfamily 1 group I member 2	Homo sapiens	54-57
16109480-6	2006	However, in highly differentiated primary human hepatocytes treated with rifampicin an agonist of the pregnane X receptor (PXR), omeprazole-sulphide behaves as an agonist of AhR.	Rifampin	73-83	nuclear receptor subfamily 1 group I member 2	Homo sapiens	102-121
16109480-6	2006	However, in highly differentiated primary human hepatocytes treated with rifampicin an agonist of the pregnane X receptor (PXR), omeprazole-sulphide behaves as an agonist of AhR.	Rifampin	73-83	nuclear receptor subfamily 1 group I member 2	Homo sapiens	123-126
16501008-6	2006	Induction response for CYP3A4 to 100 microM clevidipine was approximately 20% of that of the positive control inducer rifampicin.	Rifampin	118-128	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	23-29
16455805-0	2006	Rifampicin induction of CYP3A4 requires pregnane X receptor cross talk with hepatocyte nuclear factor 4alpha and coactivators, and suppression of small heterodimer partner gene expression.	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	24-30
16455805-0	2006	Rifampicin induction of CYP3A4 requires pregnane X receptor cross talk with hepatocyte nuclear factor 4alpha and coactivators, and suppression of small heterodimer partner gene expression.	Rifampin	0-10	nuclear receptor subfamily 1 group I member 2	Homo sapiens	40-59
16455805-0	2006	Rifampicin induction of CYP3A4 requires pregnane X receptor cross talk with hepatocyte nuclear factor 4alpha and coactivators, and suppression of small heterodimer partner gene expression.	Rifampin	0-10	hepatocyte nuclear factor 4 alpha	Homo sapiens	76-108
16455805-0	2006	Rifampicin induction of CYP3A4 requires pregnane X receptor cross talk with hepatocyte nuclear factor 4alpha and coactivators, and suppression of small heterodimer partner gene expression.	Rifampin	0-10	nuclear receptor subfamily 0 group B member 2	Homo sapiens	146-171
16455805-3	2006	Rifampicin dose dependently induced the CYP3A4 but inhibited small heterodimer partner (SHP) mRNA expression levels in primary human hepatocytes.	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	40-46
16455805-3	2006	Rifampicin dose dependently induced the CYP3A4 but inhibited small heterodimer partner (SHP) mRNA expression levels in primary human hepatocytes.	Rifampin	0-10	nuclear receptor subfamily 0 group B member 2	Homo sapiens	61-86
16455805-3	2006	Rifampicin dose dependently induced the CYP3A4 but inhibited small heterodimer partner (SHP) mRNA expression levels in primary human hepatocytes.	Rifampin	0-10	nuclear receptor subfamily 0 group B member 2	Homo sapiens	88-91
16455805-4	2006	Rifampicin strongly stimulated PXR and hepatocyte nuclear factor 4alpha (HNF4alpha) interaction, and CYP3A4 reporter activity, which was further stimulated by peroxisome proliferators-activated receptorgamma co-activator 1alpha (PGC-1alpha) and steroid receptor coactivator-1 (SRC-1) but inhibited by SHP.	Rifampin	0-10	nuclear receptor subfamily 1 group I member 2	Homo sapiens	31-34
16455805-4	2006	Rifampicin strongly stimulated PXR and hepatocyte nuclear factor 4alpha (HNF4alpha) interaction, and CYP3A4 reporter activity, which was further stimulated by peroxisome proliferators-activated receptorgamma co-activator 1alpha (PGC-1alpha) and steroid receptor coactivator-1 (SRC-1) but inhibited by SHP.	Rifampin	0-10	hepatocyte nuclear factor 4 alpha	Homo sapiens	39-71
16455805-4	2006	Rifampicin strongly stimulated PXR and hepatocyte nuclear factor 4alpha (HNF4alpha) interaction, and CYP3A4 reporter activity, which was further stimulated by peroxisome proliferators-activated receptorgamma co-activator 1alpha (PGC-1alpha) and steroid receptor coactivator-1 (SRC-1) but inhibited by SHP.	Rifampin	0-10	hepatocyte nuclear factor 4 alpha	Homo sapiens	73-82
16455805-4	2006	Rifampicin strongly stimulated PXR and hepatocyte nuclear factor 4alpha (HNF4alpha) interaction, and CYP3A4 reporter activity, which was further stimulated by peroxisome proliferators-activated receptorgamma co-activator 1alpha (PGC-1alpha) and steroid receptor coactivator-1 (SRC-1) but inhibited by SHP.	Rifampin	0-10	PPARG coactivator 1 alpha	Homo sapiens	229-239
16455805-4	2006	Rifampicin strongly stimulated PXR and hepatocyte nuclear factor 4alpha (HNF4alpha) interaction, and CYP3A4 reporter activity, which was further stimulated by peroxisome proliferators-activated receptorgamma co-activator 1alpha (PGC-1alpha) and steroid receptor coactivator-1 (SRC-1) but inhibited by SHP.	Rifampin	0-10	nuclear receptor coactivator 1	Homo sapiens	245-275
16455805-4	2006	Rifampicin strongly stimulated PXR and hepatocyte nuclear factor 4alpha (HNF4alpha) interaction, and CYP3A4 reporter activity, which was further stimulated by peroxisome proliferators-activated receptorgamma co-activator 1alpha (PGC-1alpha) and steroid receptor coactivator-1 (SRC-1) but inhibited by SHP.	Rifampin	0-10	nuclear receptor coactivator 1	Homo sapiens	277-282
16455805-4	2006	Rifampicin strongly stimulated PXR and hepatocyte nuclear factor 4alpha (HNF4alpha) interaction, and CYP3A4 reporter activity, which was further stimulated by peroxisome proliferators-activated receptorgamma co-activator 1alpha (PGC-1alpha) and steroid receptor coactivator-1 (SRC-1) but inhibited by SHP.	Rifampin	0-10	nuclear receptor subfamily 0 group B member 2	Homo sapiens	301-304
16455805-6	2006	Chromatin immunoprecipitation assays revealed that rifampicin-activated PXR recruited HNF4alpha and SRC-1 to the CYP3A4 chromatin.	Rifampin	51-61	nuclear receptor subfamily 1 group I member 2	Homo sapiens	72-75
16455805-6	2006	Chromatin immunoprecipitation assays revealed that rifampicin-activated PXR recruited HNF4alpha and SRC-1 to the CYP3A4 chromatin.	Rifampin	51-61	hepatocyte nuclear factor 4 alpha	Homo sapiens	86-95
16455805-6	2006	Chromatin immunoprecipitation assays revealed that rifampicin-activated PXR recruited HNF4alpha and SRC-1 to the CYP3A4 chromatin.	Rifampin	51-61	nuclear receptor coactivator 1	Homo sapiens	100-105
16455805-6	2006	Chromatin immunoprecipitation assays revealed that rifampicin-activated PXR recruited HNF4alpha and SRC-1 to the CYP3A4 chromatin.	Rifampin	51-61	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	113-119
16455805-9	2006	Upon activation by rifampicin, PXR inhibited SHP promoter activity.	Rifampin	19-29	nuclear receptor subfamily 1 group I member 2	Homo sapiens	31-34
16455805-9	2006	Upon activation by rifampicin, PXR inhibited SHP promoter activity.	Rifampin	19-29	nuclear receptor subfamily 0 group B member 2	Homo sapiens	45-48
16488578-5	2006	In addition, expression of canalicular transporters in HepaRG cells was found to be up-regulated by known inducers of transporters such as rifampicin, phenobarbital and chenodeoxycholate acting on P-glycoprotein, MRP2 and BSEP, respectively.	Rifampin	139-149	ATP binding cassette subfamily B member 1	Homo sapiens	197-211
16488578-5	2006	In addition, expression of canalicular transporters in HepaRG cells was found to be up-regulated by known inducers of transporters such as rifampicin, phenobarbital and chenodeoxycholate acting on P-glycoprotein, MRP2 and BSEP, respectively.	Rifampin	139-149	ATP binding cassette subfamily C member 2	Homo sapiens	213-217
16488578-5	2006	In addition, expression of canalicular transporters in HepaRG cells was found to be up-regulated by known inducers of transporters such as rifampicin, phenobarbital and chenodeoxycholate acting on P-glycoprotein, MRP2 and BSEP, respectively.	Rifampin	139-149	ATP binding cassette subfamily B member 11	Homo sapiens	222-226
16836137-0	2006	[Fluorescence spectroscopy study of human serum albumin quenched by rifampicin capsules].	Rifampin	68-78	albumin	Homo sapiens	42-55
16495352-9	2006	In conclusion, we have identified OATP1B3 as the human hepatic uptake transporter for amatoxins; moreover, substrates and inhibitors of OATP1B3, among others rifampicin, may be useful for the treatment of human amatoxin poisoning.	Rifampin	158-168	solute carrier organic anion transporter family member 1B3	Homo sapiens	34-41
16525793-2	2006	Substrates for members of the OATP family include bile salts, hormones, and steroid conjugates as well as drugs like the HMG-CoA-reductase inhibitors (statins), cardiac glycosides, anticancer agents like methotrexate, and antibiotics like rifampicin.	Rifampin	239-249	solute carrier organic anion transporter family member 1A2	Homo sapiens	30-34
16944591-6	2006	The results of sequence analysis were shown as: amomg 18 rifampin-resistant strains, only one has deletion in codons 513 and 514 of rpoB gene, which is a new report, the others have point mutation; among 12 rifampin- susceptible strains, 3 positive strains in SSCP occur gene mutations directly related to rifampin resistance.	Rifampin	57-65	DNA-directed RNA polymerase subunit beta	Mycobacterium tuberculosis H37Rv	132-136
16498570-6	2006	Losartan appears to be primarily a P-glycoprotein (P-gp) substrate, as previously reported, but MRP inhibitors such as MK-571 and rifampicin also affect the difference between apical to basolateral and basolateral to apical transport.	Rifampin	130-140	ATP binding cassette subfamily C member 1	Homo sapiens	96-99
16473453-11	2006	In conclusion, human hepatocytes cryopreserved on collagen gels show a clear induction of CYP3A4 by rifampicin, although the basal activities are reduced compared to non-frozen cells.	Rifampin	100-110	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	90-96
16513445-3	2006	This study evaluates the contribution of these factors to the disposition and cholesterol-lowering effect of ezetimibe before and after induction of UGT1A1, P-gp, and MRP2 with rifampin (INN, rifampicin).	Rifampin	177-185	ATP binding cassette subfamily C member 2	Homo sapiens	167-171
16513445-7	2006	RESULTS: Up-regulation of intestinal P-gp, MRP2, and UGT1A1 (but not of NPC1L1) by rifampin was associated with markedly decreased areas under the curve of ezetimibe and its glucuronide (116 +/- 78.1 ng.h/mL versus 49.9 +/- 31.0 ng.h/mL and 635 +/- 302 ng.h/mL versus 225 +/- 86.4 ng.h/mL, respectively; both P = .002) and increased intestinal clearances (2400 +/- 1560 mL/min versus 5500 +/- 4610 mL/min [P = .003] and 76.6 +/- 113 mL/min versus 316 +/- 457 mL/min [P = .010], respectively) and nearly abolished sterol-lowering effects.	Rifampin	83-91	ATP binding cassette subfamily B member 1	Homo sapiens	37-41
16513445-7	2006	RESULTS: Up-regulation of intestinal P-gp, MRP2, and UGT1A1 (but not of NPC1L1) by rifampin was associated with markedly decreased areas under the curve of ezetimibe and its glucuronide (116 +/- 78.1 ng.h/mL versus 49.9 +/- 31.0 ng.h/mL and 635 +/- 302 ng.h/mL versus 225 +/- 86.4 ng.h/mL, respectively; both P = .002) and increased intestinal clearances (2400 +/- 1560 mL/min versus 5500 +/- 4610 mL/min [P = .003] and 76.6 +/- 113 mL/min versus 316 +/- 457 mL/min [P = .010], respectively) and nearly abolished sterol-lowering effects.	Rifampin	83-91	ATP binding cassette subfamily C member 2	Homo sapiens	43-47
16513445-7	2006	RESULTS: Up-regulation of intestinal P-gp, MRP2, and UGT1A1 (but not of NPC1L1) by rifampin was associated with markedly decreased areas under the curve of ezetimibe and its glucuronide (116 +/- 78.1 ng.h/mL versus 49.9 +/- 31.0 ng.h/mL and 635 +/- 302 ng.h/mL versus 225 +/- 86.4 ng.h/mL, respectively; both P = .002) and increased intestinal clearances (2400 +/- 1560 mL/min versus 5500 +/- 4610 mL/min [P = .003] and 76.6 +/- 113 mL/min versus 316 +/- 457 mL/min [P = .010], respectively) and nearly abolished sterol-lowering effects.	Rifampin	83-91	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	53-59
16433874-0	2006	Pharmacokinetics of ruboxistaurin are significantly altered by rifampicin-mediated CYP3A4 induction.	Rifampin	63-73	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	83-89
16580901-13	2006	Conversely, the magnitude of CYP3A4 induction by rifampin is greater in persons with the MDR1 2677G allele and is inversely related to baseline CYP3A4 expression.	Rifampin	49-57	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	29-35
16580901-13	2006	Conversely, the magnitude of CYP3A4 induction by rifampin is greater in persons with the MDR1 2677G allele and is inversely related to baseline CYP3A4 expression.	Rifampin	49-57	ATP binding cassette subfamily B member 1	Homo sapiens	89-93
16580901-13	2006	Conversely, the magnitude of CYP3A4 induction by rifampin is greater in persons with the MDR1 2677G allele and is inversely related to baseline CYP3A4 expression.	Rifampin	49-57	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	144-150
16414346-8	2006	TCDD, dexamethasone, and rifampicin, which up-regulated CYP3A65 mRNA in zebrafish larvae, did not alter the CYP3C1 transcript levels suggesting regulatory differences between CYP3A and CYP3C enzymes in this species.	Rifampin	25-35	cytochrome P450, family 3, subfamily A, polypeptide 65	Danio rerio	56-63
16414346-8	2006	TCDD, dexamethasone, and rifampicin, which up-regulated CYP3A65 mRNA in zebrafish larvae, did not alter the CYP3C1 transcript levels suggesting regulatory differences between CYP3A and CYP3C enzymes in this species.	Rifampin	25-35	cytochrome P450, family 3, subfamily c, polypeptide 1	Danio rerio	56-61
16480505-0	2006	Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor.	Rifampin	9-19	nuclear receptor subfamily 1 group I member 2	Homo sapiens	101-120
16480505-3	2006	The concomitantly administered effects of rifampicin on other drugs can result in their altered metabolism or transportation that are metabolised by cytochromes P450 or transported by p-glycoprotein in the gastrointestinal tract and liver.	Rifampin	42-52	ATP binding cassette subfamily B member 1	Homo sapiens	184-198
16480505-5	2006	In general, rifampicin can act on a pattern: rifampicin activates the nuclear pregnane X receptor that in turn affects cytochromes P450, glucuronosyltransferases and p-glycoprotein activities.	Rifampin	12-22	nuclear receptor subfamily 1 group I member 2	Homo sapiens	78-97
16480505-5	2006	In general, rifampicin can act on a pattern: rifampicin activates the nuclear pregnane X receptor that in turn affects cytochromes P450, glucuronosyltransferases and p-glycoprotein activities.	Rifampin	12-22	ATP binding cassette subfamily B member 1	Homo sapiens	166-180
16480505-5	2006	In general, rifampicin can act on a pattern: rifampicin activates the nuclear pregnane X receptor that in turn affects cytochromes P450, glucuronosyltransferases and p-glycoprotein activities.	Rifampin	45-55	nuclear receptor subfamily 1 group I member 2	Homo sapiens	78-97
16480505-5	2006	In general, rifampicin can act on a pattern: rifampicin activates the nuclear pregnane X receptor that in turn affects cytochromes P450, glucuronosyltransferases and p-glycoprotein activities.	Rifampin	45-55	ATP binding cassette subfamily B member 1	Homo sapiens	166-180
16433874-13	2006	CONCLUSIONS: The effect of rifampicin co-administration on the exposure of ruboxistaurin is consistent with ruboxistaurin being a substrate of CYP3A4.	Rifampin	27-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	143-149
16489682-6	2006	RESULTS: The treatment of rats with INH+RIF (50 mg/kg per day each) induced hepatotoxicity in all the treated animals as judged by elevated serum ALT, AST, and bilirubin levels, presence of focal hepatocytic necrosis (6/8) and portal triaditis (8/8).	Rifampin	40-43	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	151-154
16547390-1	2006	The mRNA levels of human cytochrome P450 (CYP)2Cs and CYP3As in primary cultures of freshly isolated human hepatocytes were assessed after exposure to NO-1886 and rifampicin, a typical inducer of CYP3As.	Rifampin	163-173	peptidylprolyl isomerase F	Homo sapiens	54-58
16482631-7	2006	Partial protection was observed with NAC against RMP-induced changes in liver, which was evidenced from the prevention of increase in lipid peroxidation and the reduction in SOD and catalase enzyme levels.	Rifampin	49-52	catalase	Rattus norvegicus	182-190
16390353-11	2006	CONCLUSIONS: Rifampicin caused a substantial decrease in the plasma concentration of pioglitazone, probably by induction of CYP2C8.	Rifampin	13-23	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	124-130
17181373-5	2006	For example, protease inhibitors often must be avoided if the potent CYP inducer rifampicin is co-administered.	Rifampin	81-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72
16288819-0	2006	Successful treatment of severe unconjugated hyperbilirubinemia via induction of UGT1A1 by rifampicin.	Rifampin	90-100	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	80-86
16219912-3	2006	PXR activates cytochrome P450 3A4 gene expression upon binding to rifampicin (Rif) and clotrimazole (CTZ) by recruiting transcriptional coactivators.	Rifampin	66-76	nuclear receptor subfamily 1 group I member 2	Homo sapiens	0-3
16219912-3	2006	PXR activates cytochrome P450 3A4 gene expression upon binding to rifampicin (Rif) and clotrimazole (CTZ) by recruiting transcriptional coactivators.	Rifampin	78-81	nuclear receptor subfamily 1 group I member 2	Homo sapiens	0-3
16129589-10	2006	Uptake can be inhibited completely by the addition of the known OATP1B3-inhibitor rifampicin proving that Fluo-3 is transported by OATP1B3.	Rifampin	82-92	solute carrier organic anion transporter family member 1B3	Homo sapiens	64-71
16129589-10	2006	Uptake can be inhibited completely by the addition of the known OATP1B3-inhibitor rifampicin proving that Fluo-3 is transported by OATP1B3.	Rifampin	82-92	solute carrier organic anion transporter family member 1B3	Homo sapiens	131-138
16615094-3	2006	The purpose of this study was (1) to determine the temporal kinetics of drug-induced changes in canine CYP1A, CYP2B, and CYP3A mRNA and enzymatic activity, and (2) to characterize concentration-response relationships for CYP1A2, CYP2B11, and CYP3A12 using primary cultures of canine hepatocytes treated with beta-naphthoflavone (BNF), phenobarbital (PB), and rifampin (RIF), respectively.	Rifampin	359-367	cytochrome P450 family 1 subfamily A member 2	Canis lupus familiaris	221-227
16615094-3	2006	The purpose of this study was (1) to determine the temporal kinetics of drug-induced changes in canine CYP1A, CYP2B, and CYP3A mRNA and enzymatic activity, and (2) to characterize concentration-response relationships for CYP1A2, CYP2B11, and CYP3A12 using primary cultures of canine hepatocytes treated with beta-naphthoflavone (BNF), phenobarbital (PB), and rifampin (RIF), respectively.	Rifampin	369-372	cytochrome P450 family 1 subfamily A member 2	Canis lupus familiaris	221-227
16615094-6	2006	CYP3A12 and CYP3A26 mRNA levels were increased maximally after 72 h of treatment with PB and RIF (CYP3A12, 35-fold and 18-fold, and CYP3A26, 72-fold and 22-fold with PB and RIF treatment, respectively).	Rifampin	93-96	cytochrome P450 3A12	Canis lupus familiaris	0-7
16615094-6	2006	CYP3A12 and CYP3A26 mRNA levels were increased maximally after 72 h of treatment with PB and RIF (CYP3A12, 35-fold and 18-fold, and CYP3A26, 72-fold and 22-fold with PB and RIF treatment, respectively).	Rifampin	93-96	cytochrome P450 3A26	Canis lupus familiaris	12-19
16615094-6	2006	CYP3A12 and CYP3A26 mRNA levels were increased maximally after 72 h of treatment with PB and RIF (CYP3A12, 35-fold and 18-fold, and CYP3A26, 72-fold and 22-fold with PB and RIF treatment, respectively).	Rifampin	93-96	cytochrome P450 3A12	Canis lupus familiaris	98-105
16615094-6	2006	CYP3A12 and CYP3A26 mRNA levels were increased maximally after 72 h of treatment with PB and RIF (CYP3A12, 35-fold and 18-fold, and CYP3A26, 72-fold and 22-fold with PB and RIF treatment, respectively).	Rifampin	173-176	cytochrome P450 3A12	Canis lupus familiaris	0-7
16615094-6	2006	CYP3A12 and CYP3A26 mRNA levels were increased maximally after 72 h of treatment with PB and RIF (CYP3A12, 35-fold and 18-fold, and CYP3A26, 72-fold and 22-fold with PB and RIF treatment, respectively).	Rifampin	173-176	cytochrome P450 3A26	Canis lupus familiaris	12-19
17065468-6	2006	In hok/sok-carrying cells, anti Sok PNAs were more bactericidal than rifampicin.	Rifampin	69-79	modulator of post-segregation killing protein	Escherichia coli	3-6
16135659-7	2005	All 23 single assays were validated by assessing the effects (induction or repression) of known inducers (ethanol, 3-methylcholanthrene, rifampicin, dexamethasone, phenobarbital) on P450 expression in human primary hepatocytes.	Rifampin	137-147	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	182-186
16304167-7	2005	In agreement with the published fMLP-like activity of rifampin, the inhibitory effect of rifampin was significantly greater for fMLP (IC50 of 5.6 mg/liter) than for PMA (IC50 of 58 mg/liter) stimulation.	Rifampin	54-62	formyl peptide receptor 1	Homo sapiens	32-36
16304167-7	2005	In agreement with the published fMLP-like activity of rifampin, the inhibitory effect of rifampin was significantly greater for fMLP (IC50 of 5.6 mg/liter) than for PMA (IC50 of 58 mg/liter) stimulation.	Rifampin	89-97	formyl peptide receptor 1	Homo sapiens	32-36
16304167-7	2005	In agreement with the published fMLP-like activity of rifampin, the inhibitory effect of rifampin was significantly greater for fMLP (IC50 of 5.6 mg/liter) than for PMA (IC50 of 58 mg/liter) stimulation.	Rifampin	89-97	formyl peptide receptor 1	Homo sapiens	128-132
16120810-3	2005	We have now detected a low basal level of UGT1A5 expression in cultured human hepatocytes, and treatment with rifampicin or 3-methylcholanthrene increased the level of UGT1A5 mRNA.	Rifampin	110-120	UDP glucuronosyltransferase family 1 member A5	Homo sapiens	42-48
16120810-3	2005	We have now detected a low basal level of UGT1A5 expression in cultured human hepatocytes, and treatment with rifampicin or 3-methylcholanthrene increased the level of UGT1A5 mRNA.	Rifampin	110-120	UDP glucuronosyltransferase family 1 member A5	Homo sapiens	168-174
16120810-6	2005	Full-length UGT1A5 cDNA was isolated from Caco-2 cells that had been transfected with the pregnane X receptor and treated with rifampicin.	Rifampin	127-137	UDP glucuronosyltransferase 1 family, polypeptide A5	Mus musculus	12-18
16176562-8	2005	Rifampicin inhibited CYP2C8 (Ki 30.2 microM), CYP3A4 (Ki 18.5 microM) and repaglinide metabolism (IC50 13.7 microM).	Rifampin	0-10	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	21-27
15885729-5	2005	The hPXR activation at the top concentrations tested (10 microM) relative to the positive control 10 microM rifampicin ranged from 1.3% (trans-resveratrol) to 152% (ICI 182780).	Rifampin	108-118	nuclear receptor subfamily 1 group I member 2	Homo sapiens	4-8
16324277-1	2005	OBJECTIVE: To study the combined effect of isoniazid and rifampicin on the activities of CYP1A2 and 3A4 in primary hepatocytes from healthy human adults.	Rifampin	57-67	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	89-95
16324277-10	2005	The activity of CYP1A2 of groups with two kinds of different concentrations of isoniazid and rifampicin combined groups was (3.27 +/- 0.96), (3.97 +/- 0.25) mAU.min respectively, which had significant difference compared with that in the negative control group (P &lt; 0.05).	Rifampin	93-103	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	16-22
16324277-12	2005	The activity of CYP3A4 in rifampicin groups with concentrations of 12.5 micromol/L and 25 micromol/L was (165.17 +/- 11.47), (120.20 +/- 15.73) mAU.min respectively, which had significant difference compared with that in the negative control group (P &lt; 0.01).	Rifampin	26-36	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	16-22
16324277-13	2005	The activity of CYP3A4 in the three isoniazid and rifampicin combined groups with three kinds of different concentrations was (118.37 +/- 8.90), (77.53 +/- 6.91), (68.73 +/- 4.72) mAU.min respectively, which had significant difference compared with that in the negative control group (P &lt; 0.01), but they were lower than those in rifampicin groups with corresponding concentrations (P &lt; 0.05).	Rifampin	50-60	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	16-22
16324277-13	2005	The activity of CYP3A4 in the three isoniazid and rifampicin combined groups with three kinds of different concentrations was (118.37 +/- 8.90), (77.53 +/- 6.91), (68.73 +/- 4.72) mAU.min respectively, which had significant difference compared with that in the negative control group (P &lt; 0.01), but they were lower than those in rifampicin groups with corresponding concentrations (P &lt; 0.05).	Rifampin	333-343	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	16-22
16324277-15	2005	Isoniazid in the range of maximum clinical blood concentration can inhibit the activity of CYP3A4, while rifampicin can induce the activity of CYP3A4; the combined effect of isoniazid and rifampicin being the induction of CYP3A4 activity, but the inducing effect was less than that of rifampicin alone with the same concentration.	Rifampin	105-115	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	143-149
16324277-15	2005	Isoniazid in the range of maximum clinical blood concentration can inhibit the activity of CYP3A4, while rifampicin can induce the activity of CYP3A4; the combined effect of isoniazid and rifampicin being the induction of CYP3A4 activity, but the inducing effect was less than that of rifampicin alone with the same concentration.	Rifampin	105-115	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	143-149
16324277-15	2005	Isoniazid in the range of maximum clinical blood concentration can inhibit the activity of CYP3A4, while rifampicin can induce the activity of CYP3A4; the combined effect of isoniazid and rifampicin being the induction of CYP3A4 activity, but the inducing effect was less than that of rifampicin alone with the same concentration.	Rifampin	188-198	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	91-97
16324277-15	2005	Isoniazid in the range of maximum clinical blood concentration can inhibit the activity of CYP3A4, while rifampicin can induce the activity of CYP3A4; the combined effect of isoniazid and rifampicin being the induction of CYP3A4 activity, but the inducing effect was less than that of rifampicin alone with the same concentration.	Rifampin	188-198	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	143-149
16324277-15	2005	Isoniazid in the range of maximum clinical blood concentration can inhibit the activity of CYP3A4, while rifampicin can induce the activity of CYP3A4; the combined effect of isoniazid and rifampicin being the induction of CYP3A4 activity, but the inducing effect was less than that of rifampicin alone with the same concentration.	Rifampin	188-198	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	143-149
16324277-15	2005	Isoniazid in the range of maximum clinical blood concentration can inhibit the activity of CYP3A4, while rifampicin can induce the activity of CYP3A4; the combined effect of isoniazid and rifampicin being the induction of CYP3A4 activity, but the inducing effect was less than that of rifampicin alone with the same concentration.	Rifampin	188-198	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	91-97
16324277-15	2005	Isoniazid in the range of maximum clinical blood concentration can inhibit the activity of CYP3A4, while rifampicin can induce the activity of CYP3A4; the combined effect of isoniazid and rifampicin being the induction of CYP3A4 activity, but the inducing effect was less than that of rifampicin alone with the same concentration.	Rifampin	188-198	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	143-149
16324277-15	2005	Isoniazid in the range of maximum clinical blood concentration can inhibit the activity of CYP3A4, while rifampicin can induce the activity of CYP3A4; the combined effect of isoniazid and rifampicin being the induction of CYP3A4 activity, but the inducing effect was less than that of rifampicin alone with the same concentration.	Rifampin	188-198	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	143-149
16176562-8	2005	Rifampicin inhibited CYP2C8 (Ki 30.2 microM), CYP3A4 (Ki 18.5 microM) and repaglinide metabolism (IC50 13.7 microM).	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	46-52
16176562-11	2005	Rifampicin competitively inhibits both CYP2C8 and CYP3A4, which can counteract its inducing effect in humans.	Rifampin	0-10	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	39-45
16176562-11	2005	Rifampicin competitively inhibits both CYP2C8 and CYP3A4, which can counteract its inducing effect in humans.	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	50-56
16041547-2	2005	We investigated whether changes in mRNA expression for CYP1A2,CYP2C19, CYP2D6 and CYP3A4 in peripheral blood lymphocytes (PBLs) may serve as surrogate markers for changes in CYP enzyme activity following the administration of rifampin.	Rifampin	226-234	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	71-77
16143978-7	2005	However, this study shows contrasting actions with the antibiotic rifampicin and magnesium addition leading to a decrease of the alpha-synuclein-herbicide interaction even if other metals are present in the bulk solvent.	Rifampin	66-76	synuclein alpha	Homo sapiens	129-144
16041547-2	2005	We investigated whether changes in mRNA expression for CYP1A2,CYP2C19, CYP2D6 and CYP3A4 in peripheral blood lymphocytes (PBLs) may serve as surrogate markers for changes in CYP enzyme activity following the administration of rifampin.	Rifampin	226-234	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	82-88
15933212-6	2005	We initially identified a distal PXR/CAR-binding site in the CYP2C8 promoter that confers inducibility of CYP2C8 via the PXR agonist/ligand rifampicin and the CAR agonist/ligand CITCO [6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime].	Rifampin	140-150	nuclear receptor subfamily 1 group I member 2	Homo sapiens	33-36
15919766-2	2005	Recent studies in our laboratory have shown that the nuclear receptor pregnane X receptor (PXR) is important in the transcriptional activation of the CYP2C9 promoter by drugs such as rifampicin and that the essential element is a constitutive androstane receptor (CAR)/PXR site -1839 bp upstream of the translation start site.	Rifampin	183-193	nuclear receptor subfamily 1 group I member 2	Homo sapiens	70-89
15919766-2	2005	Recent studies in our laboratory have shown that the nuclear receptor pregnane X receptor (PXR) is important in the transcriptional activation of the CYP2C9 promoter by drugs such as rifampicin and that the essential element is a constitutive androstane receptor (CAR)/PXR site -1839 bp upstream of the translation start site.	Rifampin	183-193	nuclear receptor subfamily 1 group I member 2	Homo sapiens	91-94
15919766-2	2005	Recent studies in our laboratory have shown that the nuclear receptor pregnane X receptor (PXR) is important in the transcriptional activation of the CYP2C9 promoter by drugs such as rifampicin and that the essential element is a constitutive androstane receptor (CAR)/PXR site -1839 bp upstream of the translation start site.	Rifampin	183-193	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	150-156
15919766-2	2005	Recent studies in our laboratory have shown that the nuclear receptor pregnane X receptor (PXR) is important in the transcriptional activation of the CYP2C9 promoter by drugs such as rifampicin and that the essential element is a constitutive androstane receptor (CAR)/PXR site -1839 bp upstream of the translation start site.	Rifampin	183-193	nuclear receptor subfamily 1 group I member 3	Homo sapiens	264-267
15919766-2	2005	Recent studies in our laboratory have shown that the nuclear receptor pregnane X receptor (PXR) is important in the transcriptional activation of the CYP2C9 promoter by drugs such as rifampicin and that the essential element is a constitutive androstane receptor (CAR)/PXR site -1839 bp upstream of the translation start site.	Rifampin	183-193	nuclear receptor subfamily 1 group I member 2	Homo sapiens	269-272
15919766-6	2005	HNF4alpha synergizes with CAR and with PXR in HepG2 cells treated with rifampicin.	Rifampin	71-81	hepatocyte nuclear factor 4 alpha	Homo sapiens	0-9
15919766-6	2005	HNF4alpha synergizes with CAR and with PXR in HepG2 cells treated with rifampicin.	Rifampin	71-81	nuclear receptor subfamily 1 group I member 2	Homo sapiens	39-42
15919766-8	2005	Mutation of the two HNF4alpha binding sites differentially prevented up-regulation of CYP2C9 promoter by both CAR as well as HNF4alpha, synergy between the two receptors, and essentially abolished induction by rifampicin in HepG2 cells transfected with PXR.	Rifampin	210-220	hepatocyte nuclear factor 4 alpha	Homo sapiens	20-29
15919766-8	2005	Mutation of the two HNF4alpha binding sites differentially prevented up-regulation of CYP2C9 promoter by both CAR as well as HNF4alpha, synergy between the two receptors, and essentially abolished induction by rifampicin in HepG2 cells transfected with PXR.	Rifampin	210-220	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	86-92
15919766-8	2005	Mutation of the two HNF4alpha binding sites differentially prevented up-regulation of CYP2C9 promoter by both CAR as well as HNF4alpha, synergy between the two receptors, and essentially abolished induction by rifampicin in HepG2 cells transfected with PXR.	Rifampin	210-220	nuclear receptor subfamily 1 group I member 3	Homo sapiens	110-113
15919766-8	2005	Mutation of the two HNF4alpha binding sites differentially prevented up-regulation of CYP2C9 promoter by both CAR as well as HNF4alpha, synergy between the two receptors, and essentially abolished induction by rifampicin in HepG2 cells transfected with PXR.	Rifampin	210-220	nuclear receptor subfamily 1 group I member 2	Homo sapiens	253-256
16099622-0	2005	The occurrence of rare rpoB mutations in rifampicin-resistant clinical Mycobacterium tuberculosis isolates from Kuwait.	Rifampin	41-51	DNA-directed RNA polymerase subunit beta	Mycobacterium tuberculosis H37Rv	23-27
16099622-1	2005	Mutations associated with rifampicin (RIF) resistance in two regions of the rpoB gene were studied by line probe (INNO-LiPA Rif.	Rifampin	26-36	DNA-directed RNA polymerase subunit beta	Mycobacterium tuberculosis H37Rv	76-80
16099622-1	2005	Mutations associated with rifampicin (RIF) resistance in two regions of the rpoB gene were studied by line probe (INNO-LiPA Rif.	Rifampin	38-41	DNA-directed RNA polymerase subunit beta	Mycobacterium tuberculosis H37Rv	76-80
15933212-6	2005	We initially identified a distal PXR/CAR-binding site in the CYP2C8 promoter that confers inducibility of CYP2C8 via the PXR agonist/ligand rifampicin and the CAR agonist/ligand CITCO [6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime].	Rifampin	140-150	nuclear receptor subfamily 1 group I member 3	Homo sapiens	37-40
15933212-6	2005	We initially identified a distal PXR/CAR-binding site in the CYP2C8 promoter that confers inducibility of CYP2C8 via the PXR agonist/ligand rifampicin and the CAR agonist/ligand CITCO [6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime].	Rifampin	140-150	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	61-67
15933212-6	2005	We initially identified a distal PXR/CAR-binding site in the CYP2C8 promoter that confers inducibility of CYP2C8 via the PXR agonist/ligand rifampicin and the CAR agonist/ligand CITCO [6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime].	Rifampin	140-150	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	106-112
15933212-6	2005	We initially identified a distal PXR/CAR-binding site in the CYP2C8 promoter that confers inducibility of CYP2C8 via the PXR agonist/ligand rifampicin and the CAR agonist/ligand CITCO [6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime].	Rifampin	140-150	nuclear receptor subfamily 1 group I member 2	Homo sapiens	121-124
16193213-8	2005	At 3 days, explanted rifampin-soaked grafts exhibited no MRSA growth (4 of 4 grafts) and a &gt; or =97% mean log reduction of MRSA CFUs from the adjacent aorta and perigraft fluid (PGF).	Rifampin	21-29	placental growth factor	Canis lupus familiaris	181-184
16193213-10	2005	The 7-day rifampin group had an average log reduction in MRSA CFU of 72% (graft), 58% (PGF), 75% (aorta).	Rifampin	10-18	placental growth factor	Canis lupus familiaris	87-90
16193213-11	2005	Quantitative cultures of 14-day rifampin grafted demonstrated continued bacterial growth suppression with mean MRSA CFU log reductions of 82%, graft; 72%, PGF; 89%, aorta.	Rifampin	32-40	placental growth factor	Canis lupus familiaris	155-158
16084850-15	2005	It is advisable to increase the dosage of atorvastatin and preferable to administer it in the evening to guarantee adequate concentrations during the nighttime rapid cholesterol synthesis when rifampin or other potent inducers of cytochrome P450 3A4 are coadministered.	Rifampin	193-201	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	230-249
16308281-3	2005	The present study examined the in vivo induction potency of human CYP3A in chimeric mice with humanized liver, recently established in Japan, by a specific inducer of human CYP3A enzyme activity in this experimental condition, rifabutin, which is an analogue of rifampicin.	Rifampin	262-272	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	66-71
16028152-8	2005	Low serum concentrations of rifampin were found in both HIV-infected and non-HIV-infected patients, and such patients were less likely to have &gt;4 weeks of symptoms, more likely to have lymphadenopathy, and more likely to have low serum albumin levels (P&lt;.05 for all).	Rifampin	28-36	albumin	Homo sapiens	239-246
16003296-1	2005	The tuberculostatic compound rifampin (INN, rifampicin) induces the expression of a number of drug metabolism-related genes involved in multidrug resistance (P-glycoprotein and multidrug resistance proteins 1 and 2), cytochromes (cytochrome P450 [CYP] 3A4), uridine diphosphate-glucuronosyltransferases, monoamine oxidases, and glutathione S -transferases.	Rifampin	29-37	ATP binding cassette subfamily B member 1	Homo sapiens	158-214
16083704-7	2005	RESULTS: RIFA enhanced bile acid detoxification as well as bilirubin conjugation and excretion as reflected by enhanced expression of CYP3A4, UGT1A1, and MRP2.	Rifampin	9-13	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	134-140
16083704-7	2005	RESULTS: RIFA enhanced bile acid detoxification as well as bilirubin conjugation and excretion as reflected by enhanced expression of CYP3A4, UGT1A1, and MRP2.	Rifampin	9-13	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	142-148
16083704-7	2005	RESULTS: RIFA enhanced bile acid detoxification as well as bilirubin conjugation and excretion as reflected by enhanced expression of CYP3A4, UGT1A1, and MRP2.	Rifampin	9-13	ATP binding cassette subfamily C member 2	Homo sapiens	154-158
15833926-8	2005	Treatment with arsenite in the presence of CYP3A4 inducers, rifampicin (Rif) or phenobarbital, caused major decreases in CYP3A4 mRNA, protein, and activity.	Rifampin	60-70	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	43-49
15833926-8	2005	Treatment with arsenite in the presence of CYP3A4 inducers, rifampicin (Rif) or phenobarbital, caused major decreases in CYP3A4 mRNA, protein, and activity.	Rifampin	60-70	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	121-127
15833926-8	2005	Treatment with arsenite in the presence of CYP3A4 inducers, rifampicin (Rif) or phenobarbital, caused major decreases in CYP3A4 mRNA, protein, and activity.	Rifampin	72-75	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	43-49
15833926-8	2005	Treatment with arsenite in the presence of CYP3A4 inducers, rifampicin (Rif) or phenobarbital, caused major decreases in CYP3A4 mRNA, protein, and activity.	Rifampin	72-75	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	121-127
15833926-11	2005	We found that arsenite failed to affect expression of PXR or the transcription factor Sp1, yet caused a significant decrease in PXR responsiveness to Rif.	Rifampin	150-153	nuclear receptor subfamily 1 group I member 2	Homo sapiens	128-131
16003296-1	2005	The tuberculostatic compound rifampin (INN, rifampicin) induces the expression of a number of drug metabolism-related genes involved in multidrug resistance (P-glycoprotein and multidrug resistance proteins 1 and 2), cytochromes (cytochrome P450 [CYP] 3A4), uridine diphosphate-glucuronosyltransferases, monoamine oxidases, and glutathione S -transferases.	Rifampin	29-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	230-255
16003296-1	2005	The tuberculostatic compound rifampin (INN, rifampicin) induces the expression of a number of drug metabolism-related genes involved in multidrug resistance (P-glycoprotein and multidrug resistance proteins 1 and 2), cytochromes (cytochrome P450 [CYP] 3A4), uridine diphosphate-glucuronosyltransferases, monoamine oxidases, and glutathione S -transferases.	Rifampin	44-54	ATP binding cassette subfamily B member 1	Homo sapiens	158-214
16003296-1	2005	The tuberculostatic compound rifampin (INN, rifampicin) induces the expression of a number of drug metabolism-related genes involved in multidrug resistance (P-glycoprotein and multidrug resistance proteins 1 and 2), cytochromes (cytochrome P450 [CYP] 3A4), uridine diphosphate-glucuronosyltransferases, monoamine oxidases, and glutathione S -transferases.	Rifampin	44-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	230-255
15907539-5	2005	When harboring traA mutants, rifampin-sensitive hosts exhibited constitutive clumping, whereas rifampin-resistant hosts did not-despite the fact that the latter host exhibited a normal pheromone-inducible clumping response when harboring a wild-type plasmid.	Rifampin	29-37	pheromone-binding protein	Enterococcus faecalis	15-19
15883047-8	2005	The expression of ABCA1 and SR-BI was inhibited by the PXR activators rifampicin and lithocholic acid (LCA) in HepG2 cells and pregnenolone 16alpha-carbonitrile (PCN) in primary rat hepatocytes.	Rifampin	70-80	ATP binding cassette subfamily A member 1	Homo sapiens	18-23
15883047-8	2005	The expression of ABCA1 and SR-BI was inhibited by the PXR activators rifampicin and lithocholic acid (LCA) in HepG2 cells and pregnenolone 16alpha-carbonitrile (PCN) in primary rat hepatocytes.	Rifampin	70-80	scavenger receptor class B member 1	Homo sapiens	28-33
15883047-8	2005	The expression of ABCA1 and SR-BI was inhibited by the PXR activators rifampicin and lithocholic acid (LCA) in HepG2 cells and pregnenolone 16alpha-carbonitrile (PCN) in primary rat hepatocytes.	Rifampin	70-80	nuclear receptor subfamily 1 group I member 2	Homo sapiens	55-58
15769886-5	2005	The expression levels of human CYP3A4 mRNA and CYP3A4 protein and dexamethasone 6-hydroxylase activity, specific for human CYP3A4, were increased 8- to 22-, 3- to 10-, and 5- to 12-fold, respectively, by treatment with rifampicin.	Rifampin	219-229	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-37
15922010-5	2005	Like the human CYP3A genes, CYP3A65 transcription in the foregut region was enhanced by treatment of the zebrafish larvae with the steroid dexamethasone and the macrocyclic antibiotic rifampicin.	Rifampin	184-194	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	15-20
15922010-5	2005	Like the human CYP3A genes, CYP3A65 transcription in the foregut region was enhanced by treatment of the zebrafish larvae with the steroid dexamethasone and the macrocyclic antibiotic rifampicin.	Rifampin	184-194	cytochrome P450, family 3, subfamily A, polypeptide 65	Danio rerio	28-35
15769886-5	2005	The expression levels of human CYP3A4 mRNA and CYP3A4 protein and dexamethasone 6-hydroxylase activity, specific for human CYP3A4, were increased 8- to 22-, 3- to 10-, and 5- to 12-fold, respectively, by treatment with rifampicin.	Rifampin	219-229	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	47-53
15769886-5	2005	The expression levels of human CYP3A4 mRNA and CYP3A4 protein and dexamethasone 6-hydroxylase activity, specific for human CYP3A4, were increased 8- to 22-, 3- to 10-, and 5- to 12-fold, respectively, by treatment with rifampicin.	Rifampin	219-229	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	47-53
15883178-10	2005	In particular, rifampicin and the fluoroquinolones were the most active compounds, both in extracellular medium and in THP-1 cells.	Rifampin	15-25	GLI family zinc finger 2	Homo sapiens	119-124
15705662-0	2005	Structural disorder in the complex of human pregnane X receptor and the macrolide antibiotic rifampicin.	Rifampin	93-103	nuclear receptor subfamily 1 group I member 2	Homo sapiens	44-63
15705662-2	2005	The macrolide antibiotic rifampicin, a front-line treatment for tuberculosis, is an established PXR agonist and, at 823 Da, is one of the largest known ligands for the receptor.	Rifampin	25-35	nuclear receptor subfamily 1 group I member 2	Homo sapiens	96-99
15705662-3	2005	We present the 2.8 A crystal structure of the ligand-binding domain of human PXR in complex with rifampicin.	Rifampin	97-107	nuclear receptor subfamily 1 group I member 2	Homo sapiens	77-80
15864135-6	2005	CYP3A4-luciferase reporter assays revealed that the Q158K variant gave rise to much lower levels of CYP3A4 promoter activity in LS174T and HepG2 cells exposed to the PXR ligands, rifampin and paclitaxel, than did wild-type PXR.	Rifampin	179-187	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
15864135-6	2005	CYP3A4-luciferase reporter assays revealed that the Q158K variant gave rise to much lower levels of CYP3A4 promoter activity in LS174T and HepG2 cells exposed to the PXR ligands, rifampin and paclitaxel, than did wild-type PXR.	Rifampin	179-187	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	100-106
15864135-6	2005	CYP3A4-luciferase reporter assays revealed that the Q158K variant gave rise to much lower levels of CYP3A4 promoter activity in LS174T and HepG2 cells exposed to the PXR ligands, rifampin and paclitaxel, than did wild-type PXR.	Rifampin	179-187	nuclear receptor subfamily 1 group I member 2	Homo sapiens	223-226
15855724-3	2005	beta-naphthoflavone (beta-NF) and rifampicin (Rif) were used as typical cytochrome P450 (CYP) inducers for CYP1A2 and CYP3A4, respectively.	Rifampin	34-44	cytochrome P450, family 1, subfamily a, polypeptide 2	Mus musculus	107-113
15855724-3	2005	beta-naphthoflavone (beta-NF) and rifampicin (Rif) were used as typical cytochrome P450 (CYP) inducers for CYP1A2 and CYP3A4, respectively.	Rifampin	34-44	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	118-124
15855724-3	2005	beta-naphthoflavone (beta-NF) and rifampicin (Rif) were used as typical cytochrome P450 (CYP) inducers for CYP1A2 and CYP3A4, respectively.	Rifampin	46-49	cytochrome P450, family 1, subfamily a, polypeptide 2	Mus musculus	107-113
15778422-1	2005	This study investigated 2 hypotheses about genotype-phenotype relationships for the efflux transporter, P-glycoprotein: (1) the presence of a synonymous C3435T variant in exon 26 of the MDR1 gene correlates to higher plasma concentrations of a P-glycoprotein substrate, dicloxacillin, and (2) the effects of genotypic differences decrease under conditions of P-glycoprotein induction by rifampin.	Rifampin	387-395	ATP binding cassette subfamily B member 1	Homo sapiens	186-190
16146350-5	2005	CYP3A4 enzyme activity in noninduced and rifampicin-induced DPX-2 cells was also assessed using Vivid fluorogenic substrates.	Rifampin	41-51	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
16146350-6	2005	Significantly elevated CYP3A4 activity levels (2.8-fold +/- 0.2-fold above DMSO-treated cells) were found in DPX-2 cells after 48 hours of exposure to rifampicin, but were undetectable in parental HepG2 cells.	Rifampin	151-161	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	23-29
16146350-7	2005	Rifampicin-induced activity levels were found to be suitable for assessing the inhibitory potential of new chemical entities in downstream CYP3A4 inhibition assays.	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	139-145
15832810-6	2005	Similarly, the steroid family of orphan nuclear receptors, the constitutive androstane receptor (CAR) and pregnane X receptor (PXR), both heterodimerize with the retinoid X receptor (RXR), are shown to transcriptionally activate the promoters of CYP2B and CYP3A gene expression by xenobiotics such as phenobarbital-like compounds (CAR) and dexamethasone and rifampin-type of agents (PXR).	Rifampin	358-366	nuclear receptor subfamily 1 group I member 3	Homo sapiens	63-95
15832810-6	2005	Similarly, the steroid family of orphan nuclear receptors, the constitutive androstane receptor (CAR) and pregnane X receptor (PXR), both heterodimerize with the retinoid X receptor (RXR), are shown to transcriptionally activate the promoters of CYP2B and CYP3A gene expression by xenobiotics such as phenobarbital-like compounds (CAR) and dexamethasone and rifampin-type of agents (PXR).	Rifampin	358-366	nuclear receptor subfamily 1 group I member 3	Homo sapiens	97-100
15832810-6	2005	Similarly, the steroid family of orphan nuclear receptors, the constitutive androstane receptor (CAR) and pregnane X receptor (PXR), both heterodimerize with the retinoid X receptor (RXR), are shown to transcriptionally activate the promoters of CYP2B and CYP3A gene expression by xenobiotics such as phenobarbital-like compounds (CAR) and dexamethasone and rifampin-type of agents (PXR).	Rifampin	358-366	nuclear receptor subfamily 1 group I member 2	Homo sapiens	106-125
15832810-6	2005	Similarly, the steroid family of orphan nuclear receptors, the constitutive androstane receptor (CAR) and pregnane X receptor (PXR), both heterodimerize with the retinoid X receptor (RXR), are shown to transcriptionally activate the promoters of CYP2B and CYP3A gene expression by xenobiotics such as phenobarbital-like compounds (CAR) and dexamethasone and rifampin-type of agents (PXR).	Rifampin	358-366	nuclear receptor subfamily 1 group I member 2	Homo sapiens	127-130
15832810-6	2005	Similarly, the steroid family of orphan nuclear receptors, the constitutive androstane receptor (CAR) and pregnane X receptor (PXR), both heterodimerize with the retinoid X receptor (RXR), are shown to transcriptionally activate the promoters of CYP2B and CYP3A gene expression by xenobiotics such as phenobarbital-like compounds (CAR) and dexamethasone and rifampin-type of agents (PXR).	Rifampin	358-366	retinoid X receptor alpha	Homo sapiens	162-181
15832810-6	2005	Similarly, the steroid family of orphan nuclear receptors, the constitutive androstane receptor (CAR) and pregnane X receptor (PXR), both heterodimerize with the retinoid X receptor (RXR), are shown to transcriptionally activate the promoters of CYP2B and CYP3A gene expression by xenobiotics such as phenobarbital-like compounds (CAR) and dexamethasone and rifampin-type of agents (PXR).	Rifampin	358-366	retinoid X receptor alpha	Homo sapiens	183-186
15832810-6	2005	Similarly, the steroid family of orphan nuclear receptors, the constitutive androstane receptor (CAR) and pregnane X receptor (PXR), both heterodimerize with the retinoid X receptor (RXR), are shown to transcriptionally activate the promoters of CYP2B and CYP3A gene expression by xenobiotics such as phenobarbital-like compounds (CAR) and dexamethasone and rifampin-type of agents (PXR).	Rifampin	358-366	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	256-261
15832810-6	2005	Similarly, the steroid family of orphan nuclear receptors, the constitutive androstane receptor (CAR) and pregnane X receptor (PXR), both heterodimerize with the retinoid X receptor (RXR), are shown to transcriptionally activate the promoters of CYP2B and CYP3A gene expression by xenobiotics such as phenobarbital-like compounds (CAR) and dexamethasone and rifampin-type of agents (PXR).	Rifampin	358-366	nuclear receptor subfamily 1 group I member 3	Homo sapiens	331-334
15832810-6	2005	Similarly, the steroid family of orphan nuclear receptors, the constitutive androstane receptor (CAR) and pregnane X receptor (PXR), both heterodimerize with the retinoid X receptor (RXR), are shown to transcriptionally activate the promoters of CYP2B and CYP3A gene expression by xenobiotics such as phenobarbital-like compounds (CAR) and dexamethasone and rifampin-type of agents (PXR).	Rifampin	358-366	nuclear receptor subfamily 1 group I member 2	Homo sapiens	383-386
15635047-4	2005	We found that GBS exposed to rifampin or clindamycin (versus beta-lactam antibiotics) stimulated less TNF secretion and inducible nitric oxide synthase (iNOS) protein accumulation in RAW 264.7 cells.	Rifampin	29-37	tumor necrosis factor	Mus musculus	102-105
15855724-3	2005	beta-naphthoflavone (beta-NF) and rifampicin (Rif) were used as typical cytochrome P450 (CYP) inducers for CYP1A2 and CYP3A4, respectively.	Rifampin	46-49	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	118-124
15726657-9	2005	In contrast, administration of rifampicin markedly induced CYP3A metabolism, resulting in abolished budesonide plasma levels and high urinary excretion of 6beta-hydroxycortisol.	Rifampin	31-41	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	59-64
15635047-4	2005	We found that GBS exposed to rifampin or clindamycin (versus beta-lactam antibiotics) stimulated less TNF secretion and inducible nitric oxide synthase (iNOS) protein accumulation in RAW 264.7 cells.	Rifampin	29-37	nitric oxide synthase 2, inducible	Mus musculus	120-151
15843291-4	2005	Rifampin is known to induce the metabolism of cytochrome P450 3A4 substrates and thus plays a role in several drug-drug interactions.	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	46-65
15635047-4	2005	We found that GBS exposed to rifampin or clindamycin (versus beta-lactam antibiotics) stimulated less TNF secretion and inducible nitric oxide synthase (iNOS) protein accumulation in RAW 264.7 cells.	Rifampin	29-37	nitric oxide synthase 2, inducible	Mus musculus	153-157
15670600-1	2005	The nuclear receptor pregnane X receptor (PXR) acts as a sensor for a broad variety of natural and synthetic lipophilic compounds, such as bile acids and rifampicin, and regulates the expression of proteins that are involved in the metabolism and transport of these compounds.	Rifampin	154-164	nuclear receptor subfamily 1 group I member 2	Homo sapiens	21-40
15670600-1	2005	The nuclear receptor pregnane X receptor (PXR) acts as a sensor for a broad variety of natural and synthetic lipophilic compounds, such as bile acids and rifampicin, and regulates the expression of proteins that are involved in the metabolism and transport of these compounds.	Rifampin	154-164	nuclear receptor subfamily 1 group I member 2	Homo sapiens	42-45
15670600-8	2005	Induction of OATP2 and SHP1 mRNA expression by rifampicin confirmed that both genes are primary human PXR responding genes.	Rifampin	47-57	solute carrier organic anion transporter family member 1B1	Homo sapiens	13-18
15670600-8	2005	Induction of OATP2 and SHP1 mRNA expression by rifampicin confirmed that both genes are primary human PXR responding genes.	Rifampin	47-57	nuclear receptor subfamily 0 group B member 2	Homo sapiens	23-27
15670600-8	2005	Induction of OATP2 and SHP1 mRNA expression by rifampicin confirmed that both genes are primary human PXR responding genes.	Rifampin	47-57	nuclear receptor subfamily 1 group I member 2	Homo sapiens	102-105
15710403-4	2005	Rifampicin, which inhibits hIAPP-induced membrane permeabilisation in functional studies, prevents membrane insertion.	Rifampin	0-10	islet amyloid polypeptide	Homo sapiens	27-32
15652233-9	2005	By employing this cellular model we were able to demonstrate for the first time that OATP1B1 together with MRP2 mediates the trans-cellular transport of rifampicin.	Rifampin	153-163	solute carrier organic anion transporter family member 1B1	Homo sapiens	85-92
15652233-9	2005	By employing this cellular model we were able to demonstrate for the first time that OATP1B1 together with MRP2 mediates the trans-cellular transport of rifampicin.	Rifampin	153-163	ATP binding cassette subfamily C member 2	Sus scrofa	107-111
15489503-5	2005	This unusual structural feature explains the known promiscuity of Tlc for various ligands, with chemical structures ranging from lipids and retinoids to the macrocyclic antibiotic rifampin and even to microbial siderophores.	Rifampin	180-188	lipocalin 1	Homo sapiens	66-69
15676042-1	2005	AIMS: To investigate the potential induction by rifampicin of intestinal CYP2C8, CYP2C9, CYP2D6 and CYP3A4 using preparations of human enterocytes.	Rifampin	48-58	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	73-79
15676042-1	2005	AIMS: To investigate the potential induction by rifampicin of intestinal CYP2C8, CYP2C9, CYP2D6 and CYP3A4 using preparations of human enterocytes.	Rifampin	48-58	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	81-87
15676042-1	2005	AIMS: To investigate the potential induction by rifampicin of intestinal CYP2C8, CYP2C9, CYP2D6 and CYP3A4 using preparations of human enterocytes.	Rifampin	48-58	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	89-95
15676042-1	2005	AIMS: To investigate the potential induction by rifampicin of intestinal CYP2C8, CYP2C9, CYP2D6 and CYP3A4 using preparations of human enterocytes.	Rifampin	48-58	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	100-106
15676042-8	2005	Rifampicin administration also resulted in a significant induction of CYP3A4 protein (34.1 +/- 10.7 vs. 113.9 +/- 31.1 pmol mg(-1) protein (P &lt; 0.001, 95% CI: 51.8-107.6)).	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	70-76
15676042-11	2005	Induction of intestinal CYP2C8 and CYP2C9 might contribute in part to rifampicin - mediated drug interactions, in addition to their hepatic counterparts and intestinal and hepatic CYP3A4.	Rifampin	70-80	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	24-30
15676042-11	2005	Induction of intestinal CYP2C8 and CYP2C9 might contribute in part to rifampicin - mediated drug interactions, in addition to their hepatic counterparts and intestinal and hepatic CYP3A4.	Rifampin	70-80	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	35-41
15523048-5	2005	Transcriptome profiles before and after exposure to the CYP3A transcriptional activators rifampicin, dexamethasone, pregnane-16alpha-carbonitrile, and phenobarbital were subsequently examined.	Rifampin	89-99	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	56-61
15331348-0	2005	Mechanism of rifampicin and pregnane X receptor inhibition of human cholesterol 7 alpha-hydroxylase gene transcription.	Rifampin	13-23	cytochrome P450 family 7 subfamily A member 1	Homo sapiens	68-99
15331348-2	2005	Rifampicin, a human PXR agonist, inhibits bile acid synthesis and has been used to treat cholestatic diseases.	Rifampin	0-10	nuclear receptor subfamily 1 group I member 2	Homo sapiens	20-23
15331348-5	2005	Rifampicin reduced CYP7A1 and small heterodimer partner (SHP; NR02B) mRNA expression suggesting that SHP was not involved in PXR inhibition of CYP7A1.	Rifampin	0-10	cytochrome P450 family 7 subfamily A member 1	Homo sapiens	19-25
15331348-5	2005	Rifampicin reduced CYP7A1 and small heterodimer partner (SHP; NR02B) mRNA expression suggesting that SHP was not involved in PXR inhibition of CYP7A1.	Rifampin	0-10	nuclear receptor subfamily 0 group B member 2	Homo sapiens	30-55
15331348-5	2005	Rifampicin reduced CYP7A1 and small heterodimer partner (SHP; NR02B) mRNA expression suggesting that SHP was not involved in PXR inhibition of CYP7A1.	Rifampin	0-10	nuclear receptor subfamily 0 group B member 2	Homo sapiens	57-60
15331348-6	2005	Rifampicin inhibited CYP7A1 reporter activity and a PXR binding site was localized to the bile acid response element-I.	Rifampin	0-10	cytochrome P450 family 7 subfamily A member 1	Homo sapiens	21-27
15331348-7	2005	Mammalian two-hybrid assays revealed that PXR interacted with hepatic nuclear factor 4 alpha (HNF4 alpha, NR2A1) and rifampicin was required.	Rifampin	117-127	nuclear receptor subfamily 1 group I member 2	Homo sapiens	42-45
15331348-10	2005	Rifampicin enhanced PXR interaction with HNF4 alpha and reduced PGC-1 alpha interaction with HNF4 alpha.	Rifampin	0-10	nuclear receptor subfamily 1 group I member 2	Homo sapiens	20-23
15331348-10	2005	Rifampicin enhanced PXR interaction with HNF4 alpha and reduced PGC-1 alpha interaction with HNF4 alpha.	Rifampin	0-10	hepatocyte nuclear factor 4 alpha	Homo sapiens	41-51
15331348-10	2005	Rifampicin enhanced PXR interaction with HNF4 alpha and reduced PGC-1 alpha interaction with HNF4 alpha.	Rifampin	0-10	PPARG coactivator 1 alpha	Homo sapiens	64-75
15331348-10	2005	Rifampicin enhanced PXR interaction with HNF4 alpha and reduced PGC-1 alpha interaction with HNF4 alpha.	Rifampin	0-10	hepatocyte nuclear factor 4 alpha	Homo sapiens	93-103
15331348-11	2005	Chromatin immunoprecipitation assay showed that PXR, HNF4 alpha, and PGC-1 alpha bound to CYP7A1 chromatin, and rifampicin dissociated PGC-1 alpha from chromatin.	Rifampin	112-122	PPARG coactivator 1 alpha	Homo sapiens	135-146
15331348-12	2005	These results suggest that activation of PXR by rifampicin promotes PXR interaction with HNF4 alpha and blocks PGC-1 alpha activation with HNF4 alpha and results in inhibition of CYP7A1 gene transcription.	Rifampin	48-58	nuclear receptor subfamily 1 group I member 2	Homo sapiens	41-44
15331348-12	2005	These results suggest that activation of PXR by rifampicin promotes PXR interaction with HNF4 alpha and blocks PGC-1 alpha activation with HNF4 alpha and results in inhibition of CYP7A1 gene transcription.	Rifampin	48-58	nuclear receptor subfamily 1 group I member 2	Homo sapiens	68-71
15331348-12	2005	These results suggest that activation of PXR by rifampicin promotes PXR interaction with HNF4 alpha and blocks PGC-1 alpha activation with HNF4 alpha and results in inhibition of CYP7A1 gene transcription.	Rifampin	48-58	hepatocyte nuclear factor 4 alpha	Homo sapiens	89-99
15331348-12	2005	These results suggest that activation of PXR by rifampicin promotes PXR interaction with HNF4 alpha and blocks PGC-1 alpha activation with HNF4 alpha and results in inhibition of CYP7A1 gene transcription.	Rifampin	48-58	PPARG coactivator 1 alpha	Homo sapiens	111-122
15331348-12	2005	These results suggest that activation of PXR by rifampicin promotes PXR interaction with HNF4 alpha and blocks PGC-1 alpha activation with HNF4 alpha and results in inhibition of CYP7A1 gene transcription.	Rifampin	48-58	hepatocyte nuclear factor 4 alpha	Homo sapiens	139-149
15331348-12	2005	These results suggest that activation of PXR by rifampicin promotes PXR interaction with HNF4 alpha and blocks PGC-1 alpha activation with HNF4 alpha and results in inhibition of CYP7A1 gene transcription.	Rifampin	48-58	cytochrome P450 family 7 subfamily A member 1	Homo sapiens	179-185
16292757-6	2005	Through promoter-reporter gene assays, we found that rifampicin showed multiple-folds activation of a 1.23-kb UGDH promoter construct, the region likely to respond to rifampicin treatment is located within the range -632 to -1,050.	Rifampin	53-63	UDP-glucose 6-dehydrogenase	Homo sapiens	110-114
15966756-11	2005	RESULTS: Compared with controls, CYP3A induction (or inhibition) decreased (or increased) plasma LAAM concentrations and mean area under the plasma concentration-time curve from time zero to infinity (AUC(infinity) 199 +/- 91 [control] versus 11.3 +/- 4.0 [rifampicin] and 731 +/- 229 ng .	Rifampin	257-267	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	33-38
15849716-3	2005	Concentration-dependent changes in UGT1A1 response were evaluated in hepatocyte cultures after treatment with 3-methylchloranthrene, beta-napthoflavone, rifampicin, or phenobarbital.	Rifampin	153-163	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	35-41
15849716-7	2005	UGT1A1 was most responsive to the pregnane-X-receptor-agonists rifampicin, ritonavir, and clotrimazole at the mRNA level and, to a lesser extent, the constitutive androstane receptor-activators, phenobarbital and phenytoin.	Rifampin	63-73	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	0-6
15849716-7	2005	UGT1A1 was most responsive to the pregnane-X-receptor-agonists rifampicin, ritonavir, and clotrimazole at the mRNA level and, to a lesser extent, the constitutive androstane receptor-activators, phenobarbital and phenytoin.	Rifampin	63-73	nuclear receptor subfamily 1 group I member 2	Homo sapiens	34-53
16292757-9	2005	Cotransfection with the PPARalpha and retinoid X receptor-alpha expression vectors and subsequent treatment with the PPARalpha agonist led to the suppression of the UGDH promoter activity either in the presence or absence of rifampicin.	Rifampin	225-235	UDP-glucose 6-dehydrogenase	Homo sapiens	165-169
16292757-10	2005	Our study, for the first time, shows the UGDH gene to be under xenobiotic regulation and delineates a motif responsible for rifampicin response and transcriptional repression of the UGDH gene.	Rifampin	124-134	UDP-glucose 6-dehydrogenase	Homo sapiens	41-45
16292757-6	2005	Through promoter-reporter gene assays, we found that rifampicin showed multiple-folds activation of a 1.23-kb UGDH promoter construct, the region likely to respond to rifampicin treatment is located within the range -632 to -1,050.	Rifampin	167-177	UDP-glucose 6-dehydrogenase	Homo sapiens	110-114
16292757-8	2005	A mutation at the predicted PPAR recognizing motif eliminated normal suppression as well as the rifampicin activation effect on the UGDH promoter activity.	Rifampin	96-106	UDP-glucose 6-dehydrogenase	Homo sapiens	132-136
15630458-6	2005	CYP24 mRNA is upregulated in vivo in mice by pregnenolone 16alpha-carbonitrile and dexamethasone, 2 murine PXR agonists, and in vitro in human hepatocytes by rifampicin and hyperforin, 2 human PXR agonists.	Rifampin	158-168	cytochrome P450, family 24, subfamily a, polypeptide 1	Mus musculus	0-5
15630458-8	2005	Transfection of PXR in human embryonic kidney cells resulted in rifampicin-mediated induction of CYP24 mRNA.	Rifampin	64-74	nuclear receptor subfamily 1 group I member 2	Homo sapiens	16-19
15630458-8	2005	Transfection of PXR in human embryonic kidney cells resulted in rifampicin-mediated induction of CYP24 mRNA.	Rifampin	64-74	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	97-102
15448116-10	2004	The inducibility of CYP2C19 by agents (e.g., rifampicin) often taken concurrently with nelfinavir, together with this P450"s known polymorphic nature, may thus be important determinants of nelfinavir"s antiviral potency.	Rifampin	45-55	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	20-27
15771232-7	2005	Significant increases (3- to 6-fold) in amodiaquine N-deethylase (a functional probe for CYP2C8 activity) also were observed with clofibric acid, fenofibric acid, and rifampin, in agreement with the mRNA finding.	Rifampin	167-175	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	89-95
15771234-6	2005	RESULTS: Rifampin inhibited the P-gp-mediated efflux of [3H]-verapamil, regardless of delivery route (Imax = 62 +/- 6%).	Rifampin	9-17	phosphoglycolate phosphatase	Mus musculus	32-36
15548381-2	2004	After selection for neomycin resistance, one clone, displaying high luciferase activity in response to rifampicin (RIF), was isolated and the stable expression of hPXR was confirmed by reverse transcription polymerase chain reaction (RT-PCR).	Rifampin	103-113	nuclear receptor subfamily 1 group I member 2	Homo sapiens	163-167
15548381-2	2004	After selection for neomycin resistance, one clone, displaying high luciferase activity in response to rifampicin (RIF), was isolated and the stable expression of hPXR was confirmed by reverse transcription polymerase chain reaction (RT-PCR).	Rifampin	115-118	nuclear receptor subfamily 1 group I member 2	Homo sapiens	163-167
15322103-3	2004	Consistent with these studies, the antibiotic rifampicin, a ligand for human PXR, reduces hepatic bile acid levels in cholestasis patients.	Rifampin	46-56	nuclear receptor subfamily 1 group I member 2	Homo sapiens	77-80
15681896-5	2004	CYP3A4 and CYP3A5 mRNA levels after exposure to 50 microM rifampicin (positive control for CYP3As) were significantly increased by 5.8 (p&lt;0.01) and 2.0 times (p&lt;0.01), respectively, compared with untreated controls.	Rifampin	58-68	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
15681896-5	2004	CYP3A4 and CYP3A5 mRNA levels after exposure to 50 microM rifampicin (positive control for CYP3As) were significantly increased by 5.8 (p&lt;0.01) and 2.0 times (p&lt;0.01), respectively, compared with untreated controls.	Rifampin	58-68	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	11-17
15555995-3	2004	provide strong evidence that rifampicin interacts with alpha-synuclein and inhibits its fibrillization.	Rifampin	29-39	synuclein alpha	Homo sapiens	55-70
15556002-0	2004	Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils.	Rifampin	0-10	synuclein alpha	Homo sapiens	20-35
15556002-2	2004	We show that the antibiotic rifampicin inhibited alpha-synuclein fibrillation and disaggregated existing fibrils in a concentration-dependent manner.	Rifampin	28-38	synuclein alpha	Homo sapiens	49-64
15556002-3	2004	Size-exclusion chromatography data indicated that rifampicin stabilized alpha-synuclein as both a monomer and soluble oligomers comprised of partially folded alpha-synuclein.	Rifampin	50-60	synuclein alpha	Homo sapiens	72-87
15556002-3	2004	Size-exclusion chromatography data indicated that rifampicin stabilized alpha-synuclein as both a monomer and soluble oligomers comprised of partially folded alpha-synuclein.	Rifampin	50-60	synuclein alpha	Homo sapiens	158-173
15556002-5	2004	These results indicate that rifampicin-mediated inhibition of alpha-synuclein fibrillation and disaggregation of fibrils involves preferential stabilization of monomeric and soluble oligomeric forms, and that rifampicin potentially may have therapeutic application for Parkinson"s disease.	Rifampin	28-38	synuclein alpha	Homo sapiens	62-77
15531725-7	2004	We identified defective steroid receptor co-activator 1 (SRC1) recruitment to the GR AF-2 in COR L103 cells, although SRC1 was successfully recruited to the steroid X receptor with rifampicin, suggesting a defect in the GR.	Rifampin	181-191	nuclear receptor coactivator 1	Homo sapiens	118-122
15322103-6	2004	The coactivator PGC-1 enhanced transcriptional activity of HNF-4, and this enhancement was suppressed by rifampicin-activated PXR.	Rifampin	105-115	hepatocyte nuclear factor 4 alpha	Homo sapiens	59-64
15322103-6	2004	The coactivator PGC-1 enhanced transcriptional activity of HNF-4, and this enhancement was suppressed by rifampicin-activated PXR.	Rifampin	105-115	nuclear receptor subfamily 1 group I member 2	Homo sapiens	126-129
15322103-8	2004	Rifampicin-dependent interaction of PXR with PGC-1 was shown in cells by coimmunoprecipitation, and intranuclear localization studies using confocal microscopy provided further evidence for this interaction.	Rifampin	0-10	nuclear receptor subfamily 1 group I member 2	Sus scrofa	36-39
15322103-8	2004	Rifampicin-dependent interaction of PXR with PGC-1 was shown in cells by coimmunoprecipitation, and intranuclear localization studies using confocal microscopy provided further evidence for this interaction.	Rifampin	0-10	PPARG coactivator 1 alpha	Sus scrofa	45-50
15309450-4	2004	Carotenoids and retinol revealed a 5-6 fold reporter gene activity in HepG2 cells in comparison to a 7-fold induction by the well-known PXR agonist rifampicin, whereas apo-carotenals and lycopene exerted less or no activation potential.	Rifampin	148-158	nuclear receptor subfamily 1 group I member 2	Homo sapiens	136-139
15309450-6	2004	In addition, carotenoid- or retinol-mediated gene expression of PXR-responsive genes like CYP3A4/CYP3A7, CYP3A5, MDR-1 and MRP-2 has been determined in HepG2 cells by RT-PCR with up-regulative properties of beta-carotene or retinol being comparable to or even higher than that of rifampicin.	Rifampin	280-290	nuclear receptor subfamily 1 group I member 2	Homo sapiens	64-67
15309450-6	2004	In addition, carotenoid- or retinol-mediated gene expression of PXR-responsive genes like CYP3A4/CYP3A7, CYP3A5, MDR-1 and MRP-2 has been determined in HepG2 cells by RT-PCR with up-regulative properties of beta-carotene or retinol being comparable to or even higher than that of rifampicin.	Rifampin	280-290	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	90-96
15309450-6	2004	In addition, carotenoid- or retinol-mediated gene expression of PXR-responsive genes like CYP3A4/CYP3A7, CYP3A5, MDR-1 and MRP-2 has been determined in HepG2 cells by RT-PCR with up-regulative properties of beta-carotene or retinol being comparable to or even higher than that of rifampicin.	Rifampin	280-290	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	105-111
15309450-6	2004	In addition, carotenoid- or retinol-mediated gene expression of PXR-responsive genes like CYP3A4/CYP3A7, CYP3A5, MDR-1 and MRP-2 has been determined in HepG2 cells by RT-PCR with up-regulative properties of beta-carotene or retinol being comparable to or even higher than that of rifampicin.	Rifampin	280-290	ATP binding cassette subfamily B member 1	Homo sapiens	113-118
15322103-9	2004	In chromatin immunoprecipitation studies, rifampicin treatment did not inhibit HNF-4 binding to the native promoters of CYP7A1 and CYP8B1 but resulted in dissociation of PGC-1 and concomitant gene repression.	Rifampin	42-52	PPARG coactivator 1 alpha	Homo sapiens	170-175
15322103-10	2004	Most interestingly, these rifampicin effects were also observed in the phosphoenolpyruvate carboxykinase gene that contains a functional HNF-4-binding site and is central to hepatic gluconeogenesis.	Rifampin	26-36	hepatocyte nuclear factor 4 alpha	Homo sapiens	137-142
15322103-5	2004	Treatment with rifampicin resulted in repression of endogenous human CYP7A1 expression in HepG2 cells that was reversed by PXR small interfering RNA.	Rifampin	15-25	cytochrome P450 family 7 subfamily A member 1	Homo sapiens	69-75
15322103-5	2004	Treatment with rifampicin resulted in repression of endogenous human CYP7A1 expression in HepG2 cells that was reversed by PXR small interfering RNA.	Rifampin	15-25	nuclear receptor subfamily 1 group I member 2	Homo sapiens	123-126
15322103-6	2004	The coactivator PGC-1 enhanced transcriptional activity of HNF-4, and this enhancement was suppressed by rifampicin-activated PXR.	Rifampin	105-115	PPARG coactivator 1 alpha	Homo sapiens	16-21
15342613-3	2004	In part II, 8 different subjects were administered a single dose of 60 mg etoricoxib alone and following daily doses of 600 mg rifampin, a known strong inducer of CYP3A.	Rifampin	127-135	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	163-168
15364537-8	2004	Primary cultures of hepatocytes were treated with beta-naphthoflavone, an inducer of CYP1A2, phenobarbital or rifampin, both of which induce CYP2B6, CYP2C9, CYP2C19, and CYP3A4, albeit it to different extents.	Rifampin	110-118	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	141-147
15364537-8	2004	Primary cultures of hepatocytes were treated with beta-naphthoflavone, an inducer of CYP1A2, phenobarbital or rifampin, both of which induce CYP2B6, CYP2C9, CYP2C19, and CYP3A4, albeit it to different extents.	Rifampin	110-118	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	149-155
15364537-8	2004	Primary cultures of hepatocytes were treated with beta-naphthoflavone, an inducer of CYP1A2, phenobarbital or rifampin, both of which induce CYP2B6, CYP2C9, CYP2C19, and CYP3A4, albeit it to different extents.	Rifampin	110-118	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	157-164
15364537-8	2004	Primary cultures of hepatocytes were treated with beta-naphthoflavone, an inducer of CYP1A2, phenobarbital or rifampin, both of which induce CYP2B6, CYP2C9, CYP2C19, and CYP3A4, albeit it to different extents.	Rifampin	110-118	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	170-176
15364542-9	2004	Further studies revealed that hPXR-D163G did respond to rifampicin, but required approximately 40-fold higher concentrations than wild-type receptor, suggesting that the ligand-binding domain D163G variant has impaired ligand-binding activity.	Rifampin	56-66	nuclear receptor subfamily 1 group I member 2	Homo sapiens	30-34
15252010-3	2004	We report the induction of CYP3A5 mRNA in 13 of 16 hepatocyte preparations exposed to rifampin.	Rifampin	86-94	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	27-33
15554232-2	2004	Upon application of this method to patients receiving different kinds of drug therapy, Herbert Remmer was the first to describe that total human hepatic cytochrome P450 was markedly elevated by the new anti-tuberculosis drug rifampicin.	Rifampin	225-235	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	153-168
15554232-4	2004	In 1975, Herbert Remmer"s group described the unique species difference that induction of cytochrome P450 by rifampicin did not occur in the rat.	Rifampin	109-119	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	90-105
15554232-9	2004	The inducibility of CYP3A4 by barbiturates and rifampicin explains the effects of inducers to enhance the clearance of ethynylestradiol and thereby to reduce the effectiveness of oral contraceptives, rifampicin being one of the most potent inducers of human CYP3A4 gene expression.	Rifampin	47-57	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	20-26
15554232-9	2004	The inducibility of CYP3A4 by barbiturates and rifampicin explains the effects of inducers to enhance the clearance of ethynylestradiol and thereby to reduce the effectiveness of oral contraceptives, rifampicin being one of the most potent inducers of human CYP3A4 gene expression.	Rifampin	47-57	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	258-264
15554232-9	2004	The inducibility of CYP3A4 by barbiturates and rifampicin explains the effects of inducers to enhance the clearance of ethynylestradiol and thereby to reduce the effectiveness of oral contraceptives, rifampicin being one of the most potent inducers of human CYP3A4 gene expression.	Rifampin	200-210	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	20-26
15554232-9	2004	The inducibility of CYP3A4 by barbiturates and rifampicin explains the effects of inducers to enhance the clearance of ethynylestradiol and thereby to reduce the effectiveness of oral contraceptives, rifampicin being one of the most potent inducers of human CYP3A4 gene expression.	Rifampin	200-210	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	258-264
15554232-12	2004	It now appears that PXR is a key mediator of complex induction processes of xenobiotic processing enzymes, which are triggered by rifampicin and other inducers.	Rifampin	130-140	nuclear receptor subfamily 1 group I member 2	Homo sapiens	20-23
15554232-13	2004	Studies of the structure and substrate affinities of PXR have provided the rational explanation of the unique species difference of rifampicin induction between humans and rats that was first described by Herbert Remmer.	Rifampin	132-142	nuclear receptor subfamily 1 group I member 2	Homo sapiens	53-56
15371985-0	2004	Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone.	Rifampin	28-36	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	68-87
15331414-9	2004	The mRNAs for hCYP3A4 and hCYP1A1/2 were induced in the liver in a CYP type-specific manner when the mice were treated with rifampicin and 3-methylcholanthrene, respectively.	Rifampin	124-134	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	14-21
15331414-9	2004	The mRNAs for hCYP3A4 and hCYP1A1/2 were induced in the liver in a CYP type-specific manner when the mice were treated with rifampicin and 3-methylcholanthrene, respectively.	Rifampin	124-134	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	26-35
15371985-2	2004	Rifampin (INN, rifampicin) is a potent inducer of several CYP enzymes, and in vitro studies have suggested that it also induces CYP2C8.	Rifampin	0-8	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	128-134
15371985-3	2004	OBJECTIVE: Our aims were to investigate possible effects of trimethoprim and rifampin on CYP2C8 activity by use of rosiglitazone, a thiazolidinedione antidiabetic drug metabolized primarily by CYP2C8, as an in vivo probe.	Rifampin	77-85	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	89-95
15371985-3	2004	OBJECTIVE: Our aims were to investigate possible effects of trimethoprim and rifampin on CYP2C8 activity by use of rosiglitazone, a thiazolidinedione antidiabetic drug metabolized primarily by CYP2C8, as an in vivo probe.	Rifampin	77-85	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	193-199
15371985-16	2004	CONCLUSIONS: Trimethoprim raises and rifampin reduces the plasma concentrations of rosiglitazone by inhibiting and inducing, respectively, the CYP2C8-catalyzed biotransformation of rosiglitazone.	Rifampin	37-45	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	143-149
16026006-8	2004	Addition of verapamil, an inhibitor for P-glycoprotein (Pgp), multidrug resistance associated protein-2 (MRP-2), and other related transporters, increased absorption of rifampicin in jejunum and ileum by 2-3-fold and decreased secretion by almost 4-fold.	Rifampin	169-179	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	56-59
15319341-8	2004	Real-time polymerase chain reaction and Western blot analysis revealed significantly increased CYP3A4 mRNA and protein levels in hepatocytes treated with 10 microM rifampicin compared with untreated cells, but only modest effects of rifampicin on CYP3A5 induction.	Rifampin	164-174	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	95-101
15319341-8	2004	Real-time polymerase chain reaction and Western blot analysis revealed significantly increased CYP3A4 mRNA and protein levels in hepatocytes treated with 10 microM rifampicin compared with untreated cells, but only modest effects of rifampicin on CYP3A5 induction.	Rifampin	164-174	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	247-253
15319343-5	2004	In intestine, rifampin and SJW induced P-gp expression 3.7- and 1.6-fold and CYP3A 3.5- and 2.4-fold, respectively, whereas dexamethasone and PCN induced CYP3A only.	Rifampin	14-22	phosphoglycolate phosphatase	Mus musculus	39-43
15319343-5	2004	In intestine, rifampin and SJW induced P-gp expression 3.7- and 1.6-fold and CYP3A 3.5- and 2.4-fold, respectively, whereas dexamethasone and PCN induced CYP3A only.	Rifampin	14-22	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	77-82
15319343-5	2004	In intestine, rifampin and SJW induced P-gp expression 3.7- and 1.6-fold and CYP3A 3.5- and 2.4-fold, respectively, whereas dexamethasone and PCN induced CYP3A only.	Rifampin	14-22	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	154-159
16026006-8	2004	Addition of verapamil, an inhibitor for P-glycoprotein (Pgp), multidrug resistance associated protein-2 (MRP-2), and other related transporters, increased absorption of rifampicin in jejunum and ileum by 2-3-fold and decreased secretion by almost 4-fold.	Rifampin	169-179	ATP binding cassette subfamily C member 2	Rattus norvegicus	105-110
16026006-13	2004	As Pgp varies from person to person to an extent of 2-8-fold, it can be one direct reason for the interindividual variable bioavailability shown by rifampicin.	Rifampin	148-158	phosphoglycolate phosphatase	Homo sapiens	3-6
15332711-3	2004	Secretion of IL-1beta and TNF-a were significantly inhibited (P&lt;0.002) whereas secretion of IL-6 and IL-10 were significantly increased (P&lt;0.003) by rifampicin treated mononuclear cells.	Rifampin	155-165	interleukin 6	Homo sapiens	95-99
15276086-8	2004	Rifampicin, shown to cause clinical drug interactions via a PXR-mediated increase in PGP expression, exhibited a very similar time-course and extent of induction.	Rifampin	0-10	nuclear receptor subfamily 1 group I member 2	Homo sapiens	60-63
15276086-8	2004	Rifampicin, shown to cause clinical drug interactions via a PXR-mediated increase in PGP expression, exhibited a very similar time-course and extent of induction.	Rifampin	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	85-88
15332711-3	2004	Secretion of IL-1beta and TNF-a were significantly inhibited (P&lt;0.002) whereas secretion of IL-6 and IL-10 were significantly increased (P&lt;0.003) by rifampicin treated mononuclear cells.	Rifampin	155-165	interleukin 10	Homo sapiens	104-109
15183191-6	2004	LPS also represses the upregulation of CYP3A11 mRNA levels and erythromycin N-demethylase (ERND) catalytic activity in mice pretreated with PXR ligands dexamethasone, rifampicin, mifepristone, and phenobarbital.	Rifampin	167-177	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	39-46
15183191-6	2004	LPS also represses the upregulation of CYP3A11 mRNA levels and erythromycin N-demethylase (ERND) catalytic activity in mice pretreated with PXR ligands dexamethasone, rifampicin, mifepristone, and phenobarbital.	Rifampin	167-177	nuclear receptor subfamily 1, group I, member 2	Mus musculus	140-143
15128731-1	2004	Poly (DL-lactide-co-glycolide) (PLG) nanoparticles encapsulating three front-line antitubercular drugs, i.e. rifampicin, isoniazid and pyrazinamide, were prepared by the multiple emulsion technique and administered subcutaneously to mice for pharmacokinetic/chemotherapeutic study.	Rifampin	109-119	plasminogen	Mus musculus	32-35
15273801-6	2004	After treatment with rifampicina, isoniazida, and pirazinamida, only the levels of IFN-gamma increased significantly (p &lt; 0.01).	Rifampin	21-32	interferon gamma	Homo sapiens	83-92
15222722-1	2004	OBJECTIVE: It has been demonstrated in preliminary studies that rifampin, a semisynthetic antibiotic and known inducer of hepatic cytochrome P450 3A4, reduces serum concentrations of total bile acids only in individuals with liver disease and elevated serum bile acid levels.	Rifampin	64-72	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	130-149
15196345-11	2004	90% (63/70) rifampicin-resistant strains had rpoB gene mutation.	Rifampin	12-22	DNA-directed RNA polymerase subunit beta	Mycobacterium tuberculosis H37Rv	45-49
15196345-16	2004	CONCLUSION: Gene array might become a rapid, simple, and accurate method for detecting rpoB mutations in most of the rifampicin-resistant Mycobacterium tuberculosis.	Rifampin	117-127	DNA-directed RNA polymerase subunit beta	Mycobacterium tuberculosis H37Rv	87-91
15180306-1	2004	The expression of CYP3A4 gene is induced by a variety of structurally unrelated xenobiotics including the antibiotic rifampicin, pregnenolone 16-carbonitrile (PCN), and endogenous hormones, that might mediate through steroid and xenobiotic receptor (SXR) system.	Rifampin	117-127	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	18-24
15180306-1	2004	The expression of CYP3A4 gene is induced by a variety of structurally unrelated xenobiotics including the antibiotic rifampicin, pregnenolone 16-carbonitrile (PCN), and endogenous hormones, that might mediate through steroid and xenobiotic receptor (SXR) system.	Rifampin	117-127	nuclear receptor subfamily 1 group I member 2	Homo sapiens	217-248
15180306-1	2004	The expression of CYP3A4 gene is induced by a variety of structurally unrelated xenobiotics including the antibiotic rifampicin, pregnenolone 16-carbonitrile (PCN), and endogenous hormones, that might mediate through steroid and xenobiotic receptor (SXR) system.	Rifampin	117-127	nuclear receptor subfamily 1 group I member 2	Homo sapiens	250-253
15180306-6	2004	In HepG2 cells, CYP3A4 inducers, such as rifampicin, PCN and RU486 showed minimal stimulation of CYP3A4 proximal promoter activity in the absence of SXR and histone deacetylase (HDAC) inhibitors.	Rifampin	41-51	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	16-22
15180306-6	2004	In HepG2 cells, CYP3A4 inducers, such as rifampicin, PCN and RU486 showed minimal stimulation of CYP3A4 proximal promoter activity in the absence of SXR and histone deacetylase (HDAC) inhibitors.	Rifampin	41-51	histone deacetylase 9	Homo sapiens	178-182
15180306-8	2004	The results of this study demonstrated that both HDAC inhibitors and SXR are essential to increase of CYP3A4 proximal promoter activity by CYP3A4 inducers such as PCN, rifampicin, and RU486.	Rifampin	168-178	histone deacetylase 9	Homo sapiens	49-53
15180306-8	2004	The results of this study demonstrated that both HDAC inhibitors and SXR are essential to increase of CYP3A4 proximal promoter activity by CYP3A4 inducers such as PCN, rifampicin, and RU486.	Rifampin	168-178	nuclear receptor subfamily 1 group I member 2	Homo sapiens	69-72
15180306-8	2004	The results of this study demonstrated that both HDAC inhibitors and SXR are essential to increase of CYP3A4 proximal promoter activity by CYP3A4 inducers such as PCN, rifampicin, and RU486.	Rifampin	168-178	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	102-108
15180306-8	2004	The results of this study demonstrated that both HDAC inhibitors and SXR are essential to increase of CYP3A4 proximal promoter activity by CYP3A4 inducers such as PCN, rifampicin, and RU486.	Rifampin	168-178	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	139-145
15180307-8	2004	Taken together, these results indicated that the inhibition of histone deacetylation was required to SXR-mediated increase in CYP3A4 proximal promoter region when rifampicin, or PCN was treated.	Rifampin	163-173	nuclear receptor subfamily 1 group I member 2	Homo sapiens	101-104
15180307-8	2004	Taken together, these results indicated that the inhibition of histone deacetylation was required to SXR-mediated increase in CYP3A4 proximal promoter region when rifampicin, or PCN was treated.	Rifampin	163-173	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	126-132
14989258-4	2004	In an in vitro system, both vitamin E and rifampicin, a known stimulator of xenobiotic metabolism, activated the pregnane X receptor (PXR), an orphan nuclear receptor.	Rifampin	42-52	nuclear receptor subfamily 1 group I member 2	Homo sapiens	113-132
15100175-8	2004	Finally, the role of these sites was examined in activation of CYP3A4 expression by rifampicin, metyrapone, clotrimazole, and phenobarbital.	Rifampin	84-94	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	63-69
15499176-4	2004	Although overexpression of retinoid X receptor alpha (RXRalpha) had no clear effect for both CYP3A reporters, co-expression of apolipoprotein AI regulatory protein-1 (ARP-1) with hPXR resulted in the rifampicin-induced transactivation of the CYP3A1 reporter.	Rifampin	200-210	nuclear receptor subfamily 2 group F member 2	Homo sapiens	127-165
15499176-4	2004	Although overexpression of retinoid X receptor alpha (RXRalpha) had no clear effect for both CYP3A reporters, co-expression of apolipoprotein AI regulatory protein-1 (ARP-1) with hPXR resulted in the rifampicin-induced transactivation of the CYP3A1 reporter.	Rifampin	200-210	nuclear receptor subfamily 2 group F member 2	Homo sapiens	167-172
15499176-4	2004	Although overexpression of retinoid X receptor alpha (RXRalpha) had no clear effect for both CYP3A reporters, co-expression of apolipoprotein AI regulatory protein-1 (ARP-1) with hPXR resulted in the rifampicin-induced transactivation of the CYP3A1 reporter.	Rifampin	200-210	nuclear receptor subfamily 1 group I member 2	Homo sapiens	179-183
15499176-5	2004	A truncated CYP3A4 reporter retaining the both motifs showed the rifampicin-induced transactivation by overexpression of hPXR and ARP-1, while the transactivation in hPXR-overexpressed cells was not observed.	Rifampin	65-75	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	12-18
15499176-5	2004	A truncated CYP3A4 reporter retaining the both motifs showed the rifampicin-induced transactivation by overexpression of hPXR and ARP-1, while the transactivation in hPXR-overexpressed cells was not observed.	Rifampin	65-75	nuclear receptor subfamily 1 group I member 2	Homo sapiens	121-125
15499176-5	2004	A truncated CYP3A4 reporter retaining the both motifs showed the rifampicin-induced transactivation by overexpression of hPXR and ARP-1, while the transactivation in hPXR-overexpressed cells was not observed.	Rifampin	65-75	nuclear receptor subfamily 2 group F member 2	Homo sapiens	130-135
15499176-5	2004	A truncated CYP3A4 reporter retaining the both motifs showed the rifampicin-induced transactivation by overexpression of hPXR and ARP-1, while the transactivation in hPXR-overexpressed cells was not observed.	Rifampin	65-75	nuclear receptor subfamily 1 group I member 2	Homo sapiens	166-170
14722322-9	2004	Treatment with 10 microM rifampin resulted in increases in CYP3A4 mRNA (17-fold) and activity (6-beta-hydroxytestoterone formation, 9-fold); and in CYP2C9 mRNA (4-fold) and activity (4"-hydroxydiclofenac formation, 2-fold).	Rifampin	25-33	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	59-65
14722322-9	2004	Treatment with 10 microM rifampin resulted in increases in CYP3A4 mRNA (17-fold) and activity (6-beta-hydroxytestoterone formation, 9-fold); and in CYP2C9 mRNA (4-fold) and activity (4"-hydroxydiclofenac formation, 2-fold).	Rifampin	25-33	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	148-154
14722322-11	2004	UGT1A mRNA was induced by beta-naphthoflavone (2-fold), and MDR1 (P-glycoprotein) mRNA was induced by rifampin (3-fold).	Rifampin	102-110	ATP binding cassette subfamily B member 1	Homo sapiens	60-64
14722322-11	2004	UGT1A mRNA was induced by beta-naphthoflavone (2-fold), and MDR1 (P-glycoprotein) mRNA was induced by rifampin (3-fold).	Rifampin	102-110	ATP binding cassette subfamily B member 1	Homo sapiens	66-80
15211874-1	2004	OBJECTIVES: To examine the incidence rate by age and gender of leukopenia caused by chemotherapy including rifampicin (RFP) and isoniazid (INH), and to study the relationships between the leukopenia and the hepatic side effect or other haematological disorders such as thrombocytopenia.	Rifampin	107-117	tripartite motif containing 27	Homo sapiens	119-122
14989258-4	2004	In an in vitro system, both vitamin E and rifampicin, a known stimulator of xenobiotic metabolism, activated the pregnane X receptor (PXR), an orphan nuclear receptor.	Rifampin	42-52	nuclear receptor subfamily 1 group I member 2	Homo sapiens	134-137
15104253-2	2004	Chrysin- and rifampicin-response activities were traced to the same element as a 290-bp distal enhancer module (-3483/-3194), in which the reporter activities were enhanced by activators of nuclear receptors [constitutive androstane receptor (CAR) and pregnane X receptor (PXR)] and transcription factor [aryl hydrocarbon receptor (AhR)].	Rifampin	13-23	nuclear receptor subfamily 1 group I member 3	Homo sapiens	209-241
15104253-2	2004	Chrysin- and rifampicin-response activities were traced to the same element as a 290-bp distal enhancer module (-3483/-3194), in which the reporter activities were enhanced by activators of nuclear receptors [constitutive androstane receptor (CAR) and pregnane X receptor (PXR)] and transcription factor [aryl hydrocarbon receptor (AhR)].	Rifampin	13-23	nuclear receptor subfamily 1 group I member 3	Homo sapiens	243-246
15104253-2	2004	Chrysin- and rifampicin-response activities were traced to the same element as a 290-bp distal enhancer module (-3483/-3194), in which the reporter activities were enhanced by activators of nuclear receptors [constitutive androstane receptor (CAR) and pregnane X receptor (PXR)] and transcription factor [aryl hydrocarbon receptor (AhR)].	Rifampin	13-23	nuclear receptor subfamily 1 group I member 2	Homo sapiens	252-271
15104253-2	2004	Chrysin- and rifampicin-response activities were traced to the same element as a 290-bp distal enhancer module (-3483/-3194), in which the reporter activities were enhanced by activators of nuclear receptors [constitutive androstane receptor (CAR) and pregnane X receptor (PXR)] and transcription factor [aryl hydrocarbon receptor (AhR)].	Rifampin	13-23	nuclear receptor subfamily 1 group I member 2	Homo sapiens	273-276
15104253-2	2004	Chrysin- and rifampicin-response activities were traced to the same element as a 290-bp distal enhancer module (-3483/-3194), in which the reporter activities were enhanced by activators of nuclear receptors [constitutive androstane receptor (CAR) and pregnane X receptor (PXR)] and transcription factor [aryl hydrocarbon receptor (AhR)].	Rifampin	13-23	aryl hydrocarbon receptor	Homo sapiens	305-330
15104253-2	2004	Chrysin- and rifampicin-response activities were traced to the same element as a 290-bp distal enhancer module (-3483/-3194), in which the reporter activities were enhanced by activators of nuclear receptors [constitutive androstane receptor (CAR) and pregnane X receptor (PXR)] and transcription factor [aryl hydrocarbon receptor (AhR)].	Rifampin	13-23	aryl hydrocarbon receptor	Homo sapiens	332-335
15104253-6	2004	Chrysin and rifampicin induced the activation of the wild-type reporter gene and T-3263G-mutated gene to a similar extent in HepG2 cells cotransfected with expression vectors of CAR and PXR.	Rifampin	12-22	nuclear receptor subfamily 1 group I member 3	Homo sapiens	178-181
15104253-6	2004	Chrysin and rifampicin induced the activation of the wild-type reporter gene and T-3263G-mutated gene to a similar extent in HepG2 cells cotransfected with expression vectors of CAR and PXR.	Rifampin	12-22	nuclear receptor subfamily 1 group I member 2	Homo sapiens	186-189
15001973-11	2004	Furthermore, we measured the disposition of long-term oral carvedilol after comedication of the pregnane X receptor ligand rifampin (INN, rifampicin) (600 mg, 9 days), which up-regulates both P-glycoprotein and MRP2 but not CYP2D6.	Rifampin	123-131	ATP binding cassette subfamily B member 1	Homo sapiens	192-206
14977870-7	2004	EC50 values for CYP2B6 and CYP3A4 induction by clotrimazole, phenobarbital, phenytoin, and rifampin were strongly correlated (r2 = 0.99) and were statistically indistinguishable for clotrimazole, phenytoin, and rifampin.	Rifampin	91-99	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	16-22
14977870-7	2004	EC50 values for CYP2B6 and CYP3A4 induction by clotrimazole, phenobarbital, phenytoin, and rifampin were strongly correlated (r2 = 0.99) and were statistically indistinguishable for clotrimazole, phenytoin, and rifampin.	Rifampin	91-99	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	27-33
14977870-7	2004	EC50 values for CYP2B6 and CYP3A4 induction by clotrimazole, phenobarbital, phenytoin, and rifampin were strongly correlated (r2 = 0.99) and were statistically indistinguishable for clotrimazole, phenytoin, and rifampin.	Rifampin	211-219	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	16-22
14977870-7	2004	EC50 values for CYP2B6 and CYP3A4 induction by clotrimazole, phenobarbital, phenytoin, and rifampin were strongly correlated (r2 = 0.99) and were statistically indistinguishable for clotrimazole, phenytoin, and rifampin.	Rifampin	211-219	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	27-33
14977870-8	2004	Kinetic constants governing time-dependent induction by phenobarbital and rifampin were also similar between CYP2B6 and CYP3A4.	Rifampin	74-82	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	109-115
15001973-11	2004	Furthermore, we measured the disposition of long-term oral carvedilol after comedication of the pregnane X receptor ligand rifampin (INN, rifampicin) (600 mg, 9 days), which up-regulates both P-glycoprotein and MRP2 but not CYP2D6.	Rifampin	123-131	ATP binding cassette subfamily C member 2	Homo sapiens	211-215
15001973-11	2004	Furthermore, we measured the disposition of long-term oral carvedilol after comedication of the pregnane X receptor ligand rifampin (INN, rifampicin) (600 mg, 9 days), which up-regulates both P-glycoprotein and MRP2 but not CYP2D6.	Rifampin	123-131	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	224-230
15001973-11	2004	Furthermore, we measured the disposition of long-term oral carvedilol after comedication of the pregnane X receptor ligand rifampin (INN, rifampicin) (600 mg, 9 days), which up-regulates both P-glycoprotein and MRP2 but not CYP2D6.	Rifampin	138-148	ATP binding cassette subfamily B member 1	Homo sapiens	192-206
14634033-9	2004	It is concluded that rifampicin limits the hepatic entrance of digoxin and reduced the hepatic exposure of digoxin to CYP3A by inhibiting the basolateral Oatp2 uptake transport, whereas quinidine increased the hepatic exposure of digoxin to CYP3A by inhibiting the canalicular P-gp transport.	Rifampin	21-31	solute carrier organic anion transporter family, member 1a4	Rattus norvegicus	154-159
14634033-1	2004	The disposition of digoxin and the influence of the organic anion transporting polypeptide (Oatp)2 inhibitor rifampicin and the P-glycoprotein (P-gp) inhibitor quinidine on its hepatic disposition were examined in the isolated perfused rat liver.	Rifampin	109-119	solute carrier organic anion transporter family, member 1a4	Rattus norvegicus	92-98
14634033-9	2004	It is concluded that rifampicin limits the hepatic entrance of digoxin and reduced the hepatic exposure of digoxin to CYP3A by inhibiting the basolateral Oatp2 uptake transport, whereas quinidine increased the hepatic exposure of digoxin to CYP3A by inhibiting the canalicular P-gp transport.	Rifampin	21-31	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	277-281
14748817-1	2004	AIMS: Previous work has shown that rifampicin, a potent inducer of several cytochrome P450 (CYP) enzymes and transporters, decreased the plasma concentrations of simvastatin acid by more than 90%.	Rifampin	35-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-90
14605865-1	2004	OBJECTIVE: This study was carried out to investigate the influence of CYP3A induction with rifampicin on imatinib (Gleevec) exposure.	Rifampin	91-101	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	70-75
14748817-1	2004	AIMS: Previous work has shown that rifampicin, a potent inducer of several cytochrome P450 (CYP) enzymes and transporters, decreased the plasma concentrations of simvastatin acid by more than 90%.	Rifampin	35-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-95
14709631-7	2004	UGT1A9-mediated propofol glucuronidation was induced by phenobarbital (up to 2.2-fold) and rifampicin (up to 1.7-fold).	Rifampin	91-101	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	0-6
14600250-0	2004	Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor.	Rifampin	29-39	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	19-25
14600250-0	2004	Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor.	Rifampin	29-39	nuclear receptor subfamily 1 group I member 2	Homo sapiens	90-109
14600250-2	2004	Several studies have reported that certain drugs such as rifampicin and phenobarbital induce CYP2C9, but the molecular basis for this induction remains unknown.	Rifampin	57-67	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	93-99
14600250-3	2004	In the present study, we demonstrate that the human pregnane X receptor (hPXR) mediates induction of CYP2C9 by the prototype drugs rifampicin, hyperforin (found in St. John"s Wart), and phenobarbital.	Rifampin	131-141	nuclear receptor subfamily 1 group I member 2	Homo sapiens	52-71
14600250-3	2004	In the present study, we demonstrate that the human pregnane X receptor (hPXR) mediates induction of CYP2C9 by the prototype drugs rifampicin, hyperforin (found in St. John"s Wart), and phenobarbital.	Rifampin	131-141	nuclear receptor subfamily 1 group I member 2	Homo sapiens	73-77
14600250-3	2004	In the present study, we demonstrate that the human pregnane X receptor (hPXR) mediates induction of CYP2C9 by the prototype drugs rifampicin, hyperforin (found in St. John"s Wart), and phenobarbital.	Rifampin	131-141	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	101-107
14600250-4	2004	Deletion and mutagenesis studies with luciferase reporter constructs showed that a functional PXR-responsive element located -1839/-1824 base pairs upstream from the translation start site was the primary binding site mediating the rifampicin induction of CYP2C9.	Rifampin	232-242	nuclear receptor subfamily 1 group I member 2	Homo sapiens	94-97
14600250-4	2004	Deletion and mutagenesis studies with luciferase reporter constructs showed that a functional PXR-responsive element located -1839/-1824 base pairs upstream from the translation start site was the primary binding site mediating the rifampicin induction of CYP2C9.	Rifampin	232-242	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	256-262
14600250-6	2004	Mutational analysis of 3- and 12-kilobase CYP2C9 promoter fragments indicated that this proximal binding site was essential for rifampicin inducibility, although a cooperative effect could be attributed to a second CAR-RE located at -2899/-2883.	Rifampin	128-138	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	42-48
14600250-7	2004	In summary, we have demonstrated rifampicin induction of CYP2C9 promoter constructs that is consistent with the magnitude of induction of CYP2C9 protein and mRNA reported in vivo and in primary human hepatocytes, and we have identified the cis-element essential for this response.	Rifampin	33-43	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	57-63
14600250-7	2004	In summary, we have demonstrated rifampicin induction of CYP2C9 promoter constructs that is consistent with the magnitude of induction of CYP2C9 protein and mRNA reported in vivo and in primary human hepatocytes, and we have identified the cis-element essential for this response.	Rifampin	33-43	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	138-144
14600250-8	2004	This is the first report to demonstrate that the nuclear receptor PXR mediates induction of CYP2C9 with rifampicin, phenobarbital, and hyperforin.	Rifampin	104-114	nuclear receptor subfamily 1 group I member 2	Homo sapiens	66-69
14600250-8	2004	This is the first report to demonstrate that the nuclear receptor PXR mediates induction of CYP2C9 with rifampicin, phenobarbital, and hyperforin.	Rifampin	104-114	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	92-98
14707025-6	2004	Individual platelet aggregation was studied in 10 healthy volunteers after the coadministration of clopidogrel and rifampin (a CYP3A4 inducer).	Rifampin	115-123	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	127-133
14709618-0	2004	The pregnane X receptor binds to response elements in a genomic context-dependent manner, and PXR activator rifampicin selectively alters the binding among target genes.	Rifampin	108-118	nuclear receptor subfamily 1 group I member 2	Homo sapiens	94-97
14709618-10	2004	However, such abundant interactions were markedly diminished when cells were treated with PXR activator rifampicin.	Rifampin	104-114	nuclear receptor subfamily 1 group I member 2	Homo sapiens	90-93
14614579-14	2004	CONCLUSION: Rifampicin pretreatment reduces plasma celiprolol concentrations, possibly by induction of the efflux transporter P-glycoprotein, particularly in the intestinal wall, which leads to decreased absorption of celiprolol.	Rifampin	12-22	ATP binding cassette subfamily B member 1	Homo sapiens	126-140
15001966-12	2004	CONCLUSION: This study showed that rifampin affected the disposition of rosiglitazone in humans, probably by the induction of cytochrome P450 (CYP) 2C8 and, to a lesser extent, CYP2C9.	Rifampin	35-43	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	126-151
15001966-12	2004	CONCLUSION: This study showed that rifampin affected the disposition of rosiglitazone in humans, probably by the induction of cytochrome P450 (CYP) 2C8 and, to a lesser extent, CYP2C9.	Rifampin	35-43	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	177-183
14722235-2	2004	Interestingly, certain PXR ligands such as rifampin have been shown to readily induce human and rabbit but not rodent members of the cytochrome P450 3A.	Rifampin	43-51	nuclear receptor subfamily 1 group I member 2	Homo sapiens	23-26
14722235-8	2004	Rifampin, paclitaxel, and hyperforin sensitivity was conferred to rat PXR when Phe305 was converted to leucine, whereas attenuation of sensitivity was observed when Leu308 of human PXR was replaced with phenylalanine.	Rifampin	0-8	nuclear receptor subfamily 1, group I, member 2	Rattus norvegicus	70-73
14636322-10	2003	Comparatively, rifampicin (10 microM) effected 14.5-, 25.3-, and a 20.3-fold increase in CYP3A4 activity, immunoreactive protein levels, and mRNA levels, respectively.	Rifampin	15-25	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	89-95
14586385-0	2003	Cytochrome p450 3A4 messenger ribonucleic acid induction by rifampin in human peripheral blood mononuclear cells: correlation with alprazolam pharmacokinetics.	Rifampin	60-68	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-19
12920130-7	2003	The known SXR activators rifampicin and hyperforin induced this panel of bone markers to an extent similar to vitamin K2.	Rifampin	25-35	nuclear receptor subfamily 1, group I, member 2	Mus musculus	10-13
14709322-0	2004	Induction of proteins involved in multidrug resistance (P-glycoprotein, MRP1, MRP2, LRP) and of CYP 3A4 by rifampicin in LLC-PK1 cells.	Rifampin	107-117	LOW QUALITY PROTEIN: multidrug resistance-associated protein 6	Sus scrofa	72-76
14709322-2	2004	In the LLC-PK(1) tubular renal cell line, a 15-day treatment with 25 microM rifampicin significantly increased the mRNA levels of P-glycoprotein, MRP1, MRP2, LRP and cytochrome P450 3A4 (CYP 3A4).	Rifampin	76-86	LOW QUALITY PROTEIN: multidrug resistance-associated protein 6	Sus scrofa	146-150
14709322-2	2004	In the LLC-PK(1) tubular renal cell line, a 15-day treatment with 25 microM rifampicin significantly increased the mRNA levels of P-glycoprotein, MRP1, MRP2, LRP and cytochrome P450 3A4 (CYP 3A4).	Rifampin	76-86	ATP binding cassette subfamily C member 2	Sus scrofa	152-156
14705863-6	2003	This explains the risk for drug interactions that is inherent to pharmacotherapy with PXR ligands such as rifampin, phenobarbital, statins, and St. John"s wort.	Rifampin	106-114	nuclear receptor subfamily 1 group I member 2	Homo sapiens	86-89
14586385-8	2003	Leukocyte CYP3A4 mRNA was detectable in all samples with a median of 28 molecules per 1 ng total ribonucleic acid before (range, 10-128 molecules per 1 ng total ribonucleic acid) and 50 molecules per 1 ng total ribonucleic acid after (range, 9-484 molecules per 1 ng total ribonucleic acid) rifampin treatment (P &lt;.001).	Rifampin	291-299	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	10-16
12814912-4	2003	The PrP(82-146) WT- and PrP(82-146) (127-146) SC-formed cation channels with fast kinetics are Cu2+ sensitive and rifampicin (RIF) insensitive, whereas the time-dependent inactivating channels formed by these same peptides are both Cu2+ and RIF insensitive.	Rifampin	114-124	prion protein	Homo sapiens	4-7
14534520-8	2003	CONCLUSION: The effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide suggests that rifampin affects the disposition of gliclazide in humans, possibly by the induction of cytochrome P450 2C9.	Rifampin	108-116	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	195-214
12966371-1	2003	BACKGROUND: The relative susceptibility of intestinal and hepatic cytochrome P450 (CYP) 3A to induction by rifampin (INN, rifampicin), as a function of age and sex, was investigated with the CYP3A substrate midazolam.	Rifampin	107-115	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	66-90
12966371-1	2003	BACKGROUND: The relative susceptibility of intestinal and hepatic cytochrome P450 (CYP) 3A to induction by rifampin (INN, rifampicin), as a function of age and sex, was investigated with the CYP3A substrate midazolam.	Rifampin	107-115	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	191-196
12966371-1	2003	BACKGROUND: The relative susceptibility of intestinal and hepatic cytochrome P450 (CYP) 3A to induction by rifampin (INN, rifampicin), as a function of age and sex, was investigated with the CYP3A substrate midazolam.	Rifampin	122-132	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	66-90
12966371-16	2003	CONCLUSION: Sex-related differences exist in the extent of intestinal and hepatic CYP3A induction by rifampin.	Rifampin	101-109	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	82-87
12948020-4	2003	Additional experiments were performed to assess the potential for enhancing brain uptake by inhibiting P-gp with intranasal rifampin.	Rifampin	124-132	phosphoglycolate phosphatase	Mus musculus	103-107
12948020-7	2003	Co-administration of rifampin enhanced brain uptake of relevant substrates, and resulted in complete elimination of P-gp-mediated transport for 3H- verapamil.	Rifampin	21-29	phosphoglycolate phosphatase	Mus musculus	116-120
12843640-10	2003	Exposure to rifampicin reduced CYP3A4 mRNA levels for all donors at 0.5% and 2.5% DMSO.	Rifampin	12-22	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-37
12843640-11	2003	Exposure to rifampicin also reduced CYP3A5 and CYP3A7 mRNA levels for donors 1 and 3 at 0.5% and 2.5% DMSO.	Rifampin	12-22	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	36-42
12843640-11	2003	Exposure to rifampicin also reduced CYP3A5 and CYP3A7 mRNA levels for donors 1 and 3 at 0.5% and 2.5% DMSO.	Rifampin	12-22	cytochrome P450 family 3 subfamily A member 7	Homo sapiens	47-53
12814963-4	2003	A range of PXR activation was observed, 0 to 150% of the activation of the known human CYP3A inducer rifampicin.	Rifampin	101-111	nuclear receptor subfamily 1 group I member 2	Homo sapiens	11-14
12814963-4	2003	A range of PXR activation was observed, 0 to 150% of the activation of the known human CYP3A inducer rifampicin.	Rifampin	101-111	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	87-92
14599235-10	2003	Similarly, treatment of cryopreserved human hepatocytes with rifampicin (25 microM) for 3 d increased testosterone 6 beta-hydroxylase activity (CYP3A4) by five- to eightfold over untreated cultures and increased CYP3A4 mRNA expression by four- to eightfold.	Rifampin	61-71	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	144-150
14599235-10	2003	Similarly, treatment of cryopreserved human hepatocytes with rifampicin (25 microM) for 3 d increased testosterone 6 beta-hydroxylase activity (CYP3A4) by five- to eightfold over untreated cultures and increased CYP3A4 mRNA expression by four- to eightfold.	Rifampin	61-71	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	212-218
14604466-2	2003	The possibility of cytochrome p450 (CYP) induction by bupropion (10 microM) was evaluated in-vitro by comparing catalytic activity, immunoreactive protein and CYP mRNA levels from human hepatocytes in primary culture versus cells treated with vehicle (0.5% methanol) and with rifampicin (rifampin) as a positive control.	Rifampin	276-286	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-34
14604466-2	2003	The possibility of cytochrome p450 (CYP) induction by bupropion (10 microM) was evaluated in-vitro by comparing catalytic activity, immunoreactive protein and CYP mRNA levels from human hepatocytes in primary culture versus cells treated with vehicle (0.5% methanol) and with rifampicin (rifampin) as a positive control.	Rifampin	276-286	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
14604466-2	2003	The possibility of cytochrome p450 (CYP) induction by bupropion (10 microM) was evaluated in-vitro by comparing catalytic activity, immunoreactive protein and CYP mRNA levels from human hepatocytes in primary culture versus cells treated with vehicle (0.5% methanol) and with rifampicin (rifampin) as a positive control.	Rifampin	288-296	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-34
14604466-2	2003	The possibility of cytochrome p450 (CYP) induction by bupropion (10 microM) was evaluated in-vitro by comparing catalytic activity, immunoreactive protein and CYP mRNA levels from human hepatocytes in primary culture versus cells treated with vehicle (0.5% methanol) and with rifampicin (rifampin) as a positive control.	Rifampin	288-296	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
14604466-4	2003	CYP2B6 activity, protein and mRNA levels were increased by 2.5, 1.5 and 2.1 fold, respectively, by 20 microM rifampicin.	Rifampin	109-119	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	0-6
14604466-7	2003	Rifampicin (20 microM) increased CYP2E1 protein by 2.1 fold, while 10 microM bupropion minimally altered CYP2E1 protein (1.2 fold).	Rifampin	0-10	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	33-39
12721332-2	2003	Potential P-gp inducers (rifampin and morphine) were administered subchorionically to P-gp-competent [mdr1a(+/+)] mice to induce P-gp expression in brain; the impact of rifampin pretreatment on brain penetration of verapamil also was evaluated with an in situ brain perfusion technique.	Rifampin	25-33	phosphoglycolate phosphatase	Mus musculus	10-14
12721332-3	2003	In addition, the effect of single-dose rifampin on P-gp BBB transport activity was assessed with brain perfusion using verapamil and quinidine as model P-gp substrates.	Rifampin	39-47	phosphoglycolate phosphatase	Mus musculus	51-55
12721332-4	2003	Chronic exposure to rifampin or morphine induced P-gp expression in mouse brain to a modest extent.	Rifampin	20-28	phosphoglycolate phosphatase	Mus musculus	49-53
12721332-5	2003	However, single-dose rifampin treatment increased the brain uptake of verapamil and quinidine in mdr1a(+/+) mice in a dose- and concentration-dependent manner, consistent with P-gp inhibition.	Rifampin	21-29	phosphoglycolate phosphatase	Mus musculus	176-180
12721332-6	2003	Maximum inhibition of P-gp-mediated efflux of verapamil by rifampin pretreatment in vivo (150 mg/kg) was approximately 55%, whereas there was only approximately 12% inhibition of P-gp-mediated efflux of quinidine at that rifampin dose.	Rifampin	59-67	phosphoglycolate phosphatase	Mus musculus	22-26
12721332-6	2003	Maximum inhibition of P-gp-mediated efflux of verapamil by rifampin pretreatment in vivo (150 mg/kg) was approximately 55%, whereas there was only approximately 12% inhibition of P-gp-mediated efflux of quinidine at that rifampin dose.	Rifampin	221-229	phosphoglycolate phosphatase	Mus musculus	22-26
12721332-7	2003	Coperfusion of rifampin at a concentration of 500 microM abolished P-gp-mediated efflux of verapamil at the BBB.	Rifampin	15-23	phosphoglycolate phosphatase	Mus musculus	67-71
12721332-8	2003	However, only approximately 40% inhibition of P-gp-mediated efflux of quinidine was observed with coperfusion of rifampin, even at a 2-fold higher rifampin concentration (1000 microM).	Rifampin	113-121	phosphoglycolate phosphatase	Mus musculus	46-50
12721332-8	2003	However, only approximately 40% inhibition of P-gp-mediated efflux of quinidine was observed with coperfusion of rifampin, even at a 2-fold higher rifampin concentration (1000 microM).	Rifampin	147-155	phosphoglycolate phosphatase	Mus musculus	46-50
12721332-9	2003	The present studies demonstrate that P-gp function at the BBB can be modulated by rifampin in a dose- and concentration-dependent manner.	Rifampin	82-90	phosphoglycolate phosphatase	Mus musculus	37-41
12721332-10	2003	The degree to which rifampin inhibits P-gp-mediated transport is dependent on the substrate molecule.	Rifampin	20-28	phosphoglycolate phosphatase	Mus musculus	38-42
12814912-4	2003	The PrP(82-146) WT- and PrP(82-146) (127-146) SC-formed cation channels with fast kinetics are Cu2+ sensitive and rifampicin (RIF) insensitive, whereas the time-dependent inactivating channels formed by these same peptides are both Cu2+ and RIF insensitive.	Rifampin	114-124	prion protein	Homo sapiens	24-27
12814912-4	2003	The PrP(82-146) WT- and PrP(82-146) (127-146) SC-formed cation channels with fast kinetics are Cu2+ sensitive and rifampicin (RIF) insensitive, whereas the time-dependent inactivating channels formed by these same peptides are both Cu2+ and RIF insensitive.	Rifampin	126-129	prion protein	Homo sapiens	4-7
12814912-4	2003	The PrP(82-146) WT- and PrP(82-146) (127-146) SC-formed cation channels with fast kinetics are Cu2+ sensitive and rifampicin (RIF) insensitive, whereas the time-dependent inactivating channels formed by these same peptides are both Cu2+ and RIF insensitive.	Rifampin	126-129	prion protein	Homo sapiens	24-27
12781341-4	2003	Since this heterodimer then binds to xenobiotic response elements to activate transcription of CYP3A4, we examined a 13kb promoter region of CYP3A4 for responsiveness to dexamethasone and rifampicin.	Rifampin	188-198	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	141-147
12869636-2	2003	Previous studies show that compounds such as rifampicin and dexamethasone induce CYP2C19 both in vivo in humans and in vitro in human hepatocytes.	Rifampin	45-55	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	81-88
12869636-9	2003	Rifampicin produced a modest increase in promoter activity in cells cotransfected with hPXR.	Rifampin	0-10	nuclear receptor subfamily 1 group I member 2	Homo sapiens	87-91
12815172-4	2003	Colchicine (COL) decreased both basal and rifampicin- and phenobarbital-inducible expression of CYP2B6, CYP2C8/9, and CYP3A4.	Rifampin	42-52	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	96-102
12815172-4	2003	Colchicine (COL) decreased both basal and rifampicin- and phenobarbital-inducible expression of CYP2B6, CYP2C8/9, and CYP3A4.	Rifampin	42-52	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	104-110
12815172-4	2003	Colchicine (COL) decreased both basal and rifampicin- and phenobarbital-inducible expression of CYP2B6, CYP2C8/9, and CYP3A4.	Rifampin	42-52	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	118-124
12781341-8	2003	Co-injection with a human PXR expression vector resulted in a dramatic increase in rifampicin-induced activity and a smaller increase of dexamethasone-induced activity.	Rifampin	83-93	nuclear receptor subfamily 1 group I member 2	Homo sapiens	26-29
12781341-9	2003	Co-injection of an antisense murine PXR construct with the CYP3A4-luc reduced both the dexamethasone- and rifampicin-induced responses, thus demonstrating that the murine PXR receptor can participate in the regulation of the human CYP3A4 promoter in mice.	Rifampin	106-116	nuclear receptor subfamily 1, group I, member 2	Mus musculus	36-39
12781341-9	2003	Co-injection of an antisense murine PXR construct with the CYP3A4-luc reduced both the dexamethasone- and rifampicin-induced responses, thus demonstrating that the murine PXR receptor can participate in the regulation of the human CYP3A4 promoter in mice.	Rifampin	106-116	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	59-65
12781341-9	2003	Co-injection of an antisense murine PXR construct with the CYP3A4-luc reduced both the dexamethasone- and rifampicin-induced responses, thus demonstrating that the murine PXR receptor can participate in the regulation of the human CYP3A4 promoter in mice.	Rifampin	106-116	nuclear receptor subfamily 1, group I, member 2	Mus musculus	171-174
12781341-9	2003	Co-injection of an antisense murine PXR construct with the CYP3A4-luc reduced both the dexamethasone- and rifampicin-induced responses, thus demonstrating that the murine PXR receptor can participate in the regulation of the human CYP3A4 promoter in mice.	Rifampin	106-116	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	231-237
12695351-4	2003	In contrast, treatment with 0.1 microM DEX enhanced CYP2B6 induction by different pregnane X receptor (PXR) activators, including rifampin, phenytoin, clotrimazole, and phenobarbital.	Rifampin	130-138	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	52-58
12695351-4	2003	In contrast, treatment with 0.1 microM DEX enhanced CYP2B6 induction by different pregnane X receptor (PXR) activators, including rifampin, phenytoin, clotrimazole, and phenobarbital.	Rifampin	130-138	nuclear receptor subfamily 1 group I member 2	Homo sapiens	82-101
12695351-4	2003	In contrast, treatment with 0.1 microM DEX enhanced CYP2B6 induction by different pregnane X receptor (PXR) activators, including rifampin, phenytoin, clotrimazole, and phenobarbital.	Rifampin	130-138	nuclear receptor subfamily 1 group I member 2	Homo sapiens	103-106
12673034-3	2003	In this study, we demonstrated the inductive effects of phenobarbital, rifampicin, carbamazepine, phenytoin, prednisolone, ciclosporin and clotrimazole on CYP3A4, CYP3A5 and CYP3A7 mRNA expression, and established the relationship between the expression of human glucocorticoid receptor alpha (hGR) mRNA and the induction of CYP3A4 mRNA in cultured HepG2 cells by reverse transcription polymerase chain reaction (RT-PCR).	Rifampin	71-81	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	155-161
12673034-3	2003	In this study, we demonstrated the inductive effects of phenobarbital, rifampicin, carbamazepine, phenytoin, prednisolone, ciclosporin and clotrimazole on CYP3A4, CYP3A5 and CYP3A7 mRNA expression, and established the relationship between the expression of human glucocorticoid receptor alpha (hGR) mRNA and the induction of CYP3A4 mRNA in cultured HepG2 cells by reverse transcription polymerase chain reaction (RT-PCR).	Rifampin	71-81	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	163-169
12673034-4	2003	Treatment with prednisolone, rifampicin and carbamazepine rapidly induced the level of CYP3A4 mRNA expression by 3- to 6-fold.	Rifampin	29-39	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	87-93
12673034-3	2003	In this study, we demonstrated the inductive effects of phenobarbital, rifampicin, carbamazepine, phenytoin, prednisolone, ciclosporin and clotrimazole on CYP3A4, CYP3A5 and CYP3A7 mRNA expression, and established the relationship between the expression of human glucocorticoid receptor alpha (hGR) mRNA and the induction of CYP3A4 mRNA in cultured HepG2 cells by reverse transcription polymerase chain reaction (RT-PCR).	Rifampin	71-81	cytochrome P450 family 3 subfamily A member 7	Homo sapiens	174-180
12673034-7	2003	Treatment with phenytoin, rifampicin, carbamazepine and ciclosporin induced approximately 2-fold increases in the expression of CYP3A5 mRNA, although prednisolone, phenytoin and clotrimazole had no effect.	Rifampin	26-36	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	128-134
12673034-3	2003	In this study, we demonstrated the inductive effects of phenobarbital, rifampicin, carbamazepine, phenytoin, prednisolone, ciclosporin and clotrimazole on CYP3A4, CYP3A5 and CYP3A7 mRNA expression, and established the relationship between the expression of human glucocorticoid receptor alpha (hGR) mRNA and the induction of CYP3A4 mRNA in cultured HepG2 cells by reverse transcription polymerase chain reaction (RT-PCR).	Rifampin	71-81	nuclear receptor subfamily 3 group C member 1	Homo sapiens	263-286
12673034-3	2003	In this study, we demonstrated the inductive effects of phenobarbital, rifampicin, carbamazepine, phenytoin, prednisolone, ciclosporin and clotrimazole on CYP3A4, CYP3A5 and CYP3A7 mRNA expression, and established the relationship between the expression of human glucocorticoid receptor alpha (hGR) mRNA and the induction of CYP3A4 mRNA in cultured HepG2 cells by reverse transcription polymerase chain reaction (RT-PCR).	Rifampin	71-81	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	325-331
12673034-8	2003	Treatment with rifampicin, phenytoin, clotrimazole and ciclosporin resulted in approximately a 2-fold induction of the CYP3A7 mRNA level.	Rifampin	15-25	cytochrome P450 family 3 subfamily A member 7	Homo sapiens	119-125
12721102-9	2003	promazine metabolism in a primary culture of human hepatocytes treated with specific inducers (rifampicin-CYP3A4, CYP2B6 and CYP2C inducer, 2,3,7,8-tetrachlordibenzeno-p-dioxin (TCDD)-CYP1A1/1A2 inducer).	Rifampin	95-105	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	106-112
12689656-0	2003	Rifampicin and dexamethasone have similar effects on macrophage phagocytosis of zymosan, but differ in their effects on nitrite and TNF-alpha production.	Rifampin	0-10	tumor necrosis factor	Homo sapiens	132-141
12689656-6	2003	At high doses, rifampicin moderately suppressed TNF-alpha while dexamethasone inhibited it in a dose-dependent manner, which was ameliorated by the presence of RU486.	Rifampin	15-25	tumor necrosis factor	Homo sapiens	48-57
12682816-0	2003	Rifampin-impregnated silicone catheters: a potential tool for prevention and treatment of CSF shunt infections.	Rifampin	0-8	colony stimulating factor 2	Homo sapiens	90-93
12721102-19	2003	In a primary culture of human hepatocytes, TCDD (a CYP1A subfamily inducer), as well as rifampicin (mainly a CYP3A4 inducer) induced the formation of promazine 5-sulphoxide and N-desmethylpromazine.	Rifampin	88-98	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	109-115
12908606-0	2003	Modulation of taurine on CYP3A4 induction by rifampicin in a HepG2 cell line.	Rifampin	45-55	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	25-31
12601364-4	2003	The CYP3A4 messenger RNA (mRNA) expression level 48 hours after rifampicin treatment in the RBF was approximately 100 times higher than that in a monolayer culture.	Rifampin	64-74	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	4-10
12601364-6	2003	When testosterone, a substrate for CYP3A4, was added to the rifampicin-treated cell culture, 6 beta-hydroxy testosterone as a metabolite was formed.	Rifampin	60-70	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	35-41
12601364-7	2003	Electrophoretic mobility shift assay (EMSA) with a CYP3A4 ER6 probe demonstrated that relatively high molecular weight complex containing pregnane X receptor (PXR)/retinoid X receptor alpha(RXR alpha), compared with that in the monolayer culture, is possibly generated in the RFB culture of FLC-5 treated with rifampicin.	Rifampin	310-320	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	51-57
12601364-7	2003	Electrophoretic mobility shift assay (EMSA) with a CYP3A4 ER6 probe demonstrated that relatively high molecular weight complex containing pregnane X receptor (PXR)/retinoid X receptor alpha(RXR alpha), compared with that in the monolayer culture, is possibly generated in the RFB culture of FLC-5 treated with rifampicin.	Rifampin	310-320	nuclear receptor subfamily 1 group I member 2	Homo sapiens	138-157
12601364-7	2003	Electrophoretic mobility shift assay (EMSA) with a CYP3A4 ER6 probe demonstrated that relatively high molecular weight complex containing pregnane X receptor (PXR)/retinoid X receptor alpha(RXR alpha), compared with that in the monolayer culture, is possibly generated in the RFB culture of FLC-5 treated with rifampicin.	Rifampin	310-320	nuclear receptor subfamily 1 group I member 2	Homo sapiens	159-162
12601364-7	2003	Electrophoretic mobility shift assay (EMSA) with a CYP3A4 ER6 probe demonstrated that relatively high molecular weight complex containing pregnane X receptor (PXR)/retinoid X receptor alpha(RXR alpha), compared with that in the monolayer culture, is possibly generated in the RFB culture of FLC-5 treated with rifampicin.	Rifampin	310-320	retinoid X receptor alpha	Homo sapiens	164-189
12601364-7	2003	Electrophoretic mobility shift assay (EMSA) with a CYP3A4 ER6 probe demonstrated that relatively high molecular weight complex containing pregnane X receptor (PXR)/retinoid X receptor alpha(RXR alpha), compared with that in the monolayer culture, is possibly generated in the RFB culture of FLC-5 treated with rifampicin.	Rifampin	310-320	retinoid X receptor alpha	Homo sapiens	190-199
12504802-4	2003	In HepG2 cells transfected with the human PXR and the chloramphenicol acetyl transferase (CAT) gene linked to two PXR responsive elements, CAT activity was most strongly induced by alpha- and gamma-tocotrienol followed by rifampicin, delta-, alpha- and gamma-tocopherol.	Rifampin	222-232	nuclear receptor subfamily 1 group I member 2	Homo sapiens	42-45
12504802-4	2003	In HepG2 cells transfected with the human PXR and the chloramphenicol acetyl transferase (CAT) gene linked to two PXR responsive elements, CAT activity was most strongly induced by alpha- and gamma-tocotrienol followed by rifampicin, delta-, alpha- and gamma-tocopherol.	Rifampin	222-232	nuclear receptor subfamily 1 group I member 2	Homo sapiens	114-117
12504802-6	2003	Up-regulation of endogenous CYP3A4 and CYP3A5 mRNA was obtained by gamma-tocotrienol, the most potent activator of PXR, with the same efficacy as with rifampicin.	Rifampin	151-161	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	28-34
12504802-6	2003	Up-regulation of endogenous CYP3A4 and CYP3A5 mRNA was obtained by gamma-tocotrienol, the most potent activator of PXR, with the same efficacy as with rifampicin.	Rifampin	151-161	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	39-45
12504802-6	2003	Up-regulation of endogenous CYP3A4 and CYP3A5 mRNA was obtained by gamma-tocotrienol, the most potent activator of PXR, with the same efficacy as with rifampicin.	Rifampin	151-161	nuclear receptor subfamily 1 group I member 2	Homo sapiens	115-118
12882588-1	2003	The antituberculosis drug rifampicin (rifampin) induces a number of drug-metabolising enzymes, having the greatest effects on the expression of cytochrome P450 (CYP) 3A4 in the liver and in the small intestine.	Rifampin	26-36	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	144-169
13677133-0	2003	[Formation of virulent antigen-modified mutants (Fra-, Fra-Tox-) of plague bacteria resistant to rifampicin and quinolones].	Rifampin	97-107	rabaptin, RAB GTPase binding effector protein 2	Mus musculus	49-52
13677133-0	2003	[Formation of virulent antigen-modified mutants (Fra-, Fra-Tox-) of plague bacteria resistant to rifampicin and quinolones].	Rifampin	97-107	rabaptin, RAB GTPase binding effector protein 2	Mus musculus	55-58
13677133-0	2003	[Formation of virulent antigen-modified mutants (Fra-, Fra-Tox-) of plague bacteria resistant to rifampicin and quinolones].	Rifampin	97-107	thymocyte selection-associated high mobility group box	Mus musculus	59-62
12882588-1	2003	The antituberculosis drug rifampicin (rifampin) induces a number of drug-metabolising enzymes, having the greatest effects on the expression of cytochrome P450 (CYP) 3A4 in the liver and in the small intestine.	Rifampin	38-46	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	144-169
12882588-2	2003	In addition, rifampicin induces some drug transporter proteins, such as intestinal and hepatic P-glycoprotein.	Rifampin	13-23	ATP binding cassette subfamily B member 1	Homo sapiens	95-109
12882588-4	2003	Rifampicin has its greatest effects on the pharmacokinetics of orally administered drugs that are metabolised by CYP3A4 and/or are transported by P-glycoprotein.	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	113-119
12882588-4	2003	Rifampicin has its greatest effects on the pharmacokinetics of orally administered drugs that are metabolised by CYP3A4 and/or are transported by P-glycoprotein.	Rifampin	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	146-160
12882588-10	2003	Rifampicin also induces CYP2C-mediated metabolism and thus reduces the plasma concentrations of, for example, the CYP2C9 substrate (S)-warfarin and the sulfonylurea antidiabetic drugs.	Rifampin	0-10	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	114-120
12882588-11	2003	In addition, rifampicin can reduce the plasma concentrations of drugs that are not metabolised (e.g. digoxin) by inducing drug transporters such as P-glycoprotein.	Rifampin	13-23	ATP binding cassette subfamily B member 1	Homo sapiens	148-162
12645856-0	2003	Molecular basis of rifampicin-induced inhibition of anti-CD95-induced apoptosis of peripheral blood T lymphocytes: the role of CD95 ligand and FLIPs.	Rifampin	19-29	Fas cell surface death receptor	Homo sapiens	57-61
12486675-0	2003	Unexpected lack of effect of the rifampin-induced P-glycoprotein on the oral bioavailability of its substrate, talinolol, in humans: implication in phenotyping.	Rifampin	33-41	ATP binding cassette subfamily B member 1	Homo sapiens	50-64
12490595-1	2003	Rifampin, a member of the rifamycin class of antibiotics, is well known for its ability to induce drug-metabolizing enzymes and transporters, through activation of the pregnane X receptor.	Rifampin	0-8	nuclear receptor subfamily 1 group I member 2	Homo sapiens	168-187
12490595-5	2003	Indeed, both OATP-C and OATP8 seemed capable of mediating rifampin uptake into HeLa cells.	Rifampin	58-66	solute carrier organic anion transporter family member 1B1	Homo sapiens	13-19
12490595-5	2003	Indeed, both OATP-C and OATP8 seemed capable of mediating rifampin uptake into HeLa cells.	Rifampin	58-66	solute carrier organic anion transporter family member 1B3	Homo sapiens	24-29
12490595-8	2003	In cell-based, transactivation assays, OATP-C expression was associated with increased cellular rifampin retention as well as potentiation of PXR reporter gene activity.	Rifampin	96-104	solute carrier organic anion transporter family member 1B1	Homo sapiens	39-45
12431788-0	2002	Taurine modulates induction of cytochrome P450 3A4 mRNA by rifampicin in the HepG2 cell line.	Rifampin	59-69	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-50
12492608-1	2002	AIMS: A noncoding single nucleotide polymorphism (SNP) in exon 26 3435C &gt; T of the highly polymorphic MDR1 gene has been demonstrated to alter digoxin absorption after induction of the MDR1 gene product P-glycoprotein by rifampicin or after multiple oral dosing.	Rifampin	224-234	ATP binding cassette subfamily B member 1	Homo sapiens	105-109
12492608-1	2002	AIMS: A noncoding single nucleotide polymorphism (SNP) in exon 26 3435C &gt; T of the highly polymorphic MDR1 gene has been demonstrated to alter digoxin absorption after induction of the MDR1 gene product P-glycoprotein by rifampicin or after multiple oral dosing.	Rifampin	224-234	ATP binding cassette subfamily B member 1	Homo sapiens	188-192
12492608-1	2002	AIMS: A noncoding single nucleotide polymorphism (SNP) in exon 26 3435C &gt; T of the highly polymorphic MDR1 gene has been demonstrated to alter digoxin absorption after induction of the MDR1 gene product P-glycoprotein by rifampicin or after multiple oral dosing.	Rifampin	224-234	ATP binding cassette subfamily B member 1	Homo sapiens	206-220
12645856-0	2003	Molecular basis of rifampicin-induced inhibition of anti-CD95-induced apoptosis of peripheral blood T lymphocytes: the role of CD95 ligand and FLIPs.	Rifampin	19-29	Fas cell surface death receptor	Homo sapiens	127-131
12645856-4	2003	Therefore, we examined the effect of rifampicin on signaling pathway of anti-CD95-induced apoptosis in peripheral blood lymphocytes.	Rifampin	37-47	Fas cell surface death receptor	Homo sapiens	77-81
12645856-5	2003	Rifampicin, in a concentration-dependent manner, inhibited anti-CD95-induced apoptosis in both CD4+ and CD8+ T cells, which was associated with the inhibition of activation of both caspase-3 and caspase-8.	Rifampin	0-10	Fas cell surface death receptor	Homo sapiens	64-68
12645856-5	2003	Rifampicin, in a concentration-dependent manner, inhibited anti-CD95-induced apoptosis in both CD4+ and CD8+ T cells, which was associated with the inhibition of activation of both caspase-3 and caspase-8.	Rifampin	0-10	caspase 3	Homo sapiens	181-190
12645856-5	2003	Rifampicin, in a concentration-dependent manner, inhibited anti-CD95-induced apoptosis in both CD4+ and CD8+ T cells, which was associated with the inhibition of activation of both caspase-3 and caspase-8.	Rifampin	0-10	caspase 8	Homo sapiens	195-204
12645856-6	2003	In addition, rifampicin down-regulated the expression of CD95L and Bax.	Rifampin	13-23	Fas ligand	Homo sapiens	57-62
12645856-6	2003	In addition, rifampicin down-regulated the expression of CD95L and Bax.	Rifampin	13-23	BCL2 associated X, apoptosis regulator	Homo sapiens	67-70
17535057-9	2003	CONCLUSIONS: The increase in rifampicin levels on administration of a PGP/CYP3A4 blocker suggests a pivotal role for PGP/CYP3A4 in the absorption of rifampicin in patients with TB, which may be responsible for lower or variable levels of rifampicin.	Rifampin	29-39	ATP binding cassette subfamily B member 1	Homo sapiens	70-73
12645856-7	2003	The inhibitory effects of rifampicin on apoptosis and caspase activation as well as its effect on the expression of CD95L and FLIPs were reversed by RU486, an antagonist of glucocorticoid receptor.	Rifampin	26-36	Fas ligand	Homo sapiens	116-121
12645856-7	2003	The inhibitory effects of rifampicin on apoptosis and caspase activation as well as its effect on the expression of CD95L and FLIPs were reversed by RU486, an antagonist of glucocorticoid receptor.	Rifampin	26-36	nuclear receptor subfamily 3 group C member 1	Homo sapiens	173-196
17535057-9	2003	CONCLUSIONS: The increase in rifampicin levels on administration of a PGP/CYP3A4 blocker suggests a pivotal role for PGP/CYP3A4 in the absorption of rifampicin in patients with TB, which may be responsible for lower or variable levels of rifampicin.	Rifampin	29-39	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	74-80
17535057-9	2003	CONCLUSIONS: The increase in rifampicin levels on administration of a PGP/CYP3A4 blocker suggests a pivotal role for PGP/CYP3A4 in the absorption of rifampicin in patients with TB, which may be responsible for lower or variable levels of rifampicin.	Rifampin	29-39	ATP binding cassette subfamily B member 1	Homo sapiens	117-120
12645856-8	2003	These data suggest that rifampicin inhibits anti-CD95-mediated apoptosis in lymphocytes by modulating the expression of certain proteins that regulate apoptosis, at least in part, via glucocorticoid receptors.	Rifampin	24-34	Fas cell surface death receptor	Homo sapiens	49-53
17535057-9	2003	CONCLUSIONS: The increase in rifampicin levels on administration of a PGP/CYP3A4 blocker suggests a pivotal role for PGP/CYP3A4 in the absorption of rifampicin in patients with TB, which may be responsible for lower or variable levels of rifampicin.	Rifampin	29-39	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	121-127
12426514-3	2002	Rifampin (INN, rifampicin), a potent enzyme inducer of CYP-mediated metabolism (especially CYP2C9, CYP2C19, and CYP3A4), is known to markedly decrease plasma concentrations and effects of a number coadministered drugs.	Rifampin	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-58
17535057-9	2003	CONCLUSIONS: The increase in rifampicin levels on administration of a PGP/CYP3A4 blocker suggests a pivotal role for PGP/CYP3A4 in the absorption of rifampicin in patients with TB, which may be responsible for lower or variable levels of rifampicin.	Rifampin	149-159	ATP binding cassette subfamily B member 1	Homo sapiens	70-73
17535057-9	2003	CONCLUSIONS: The increase in rifampicin levels on administration of a PGP/CYP3A4 blocker suggests a pivotal role for PGP/CYP3A4 in the absorption of rifampicin in patients with TB, which may be responsible for lower or variable levels of rifampicin.	Rifampin	149-159	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	74-80
17535057-9	2003	CONCLUSIONS: The increase in rifampicin levels on administration of a PGP/CYP3A4 blocker suggests a pivotal role for PGP/CYP3A4 in the absorption of rifampicin in patients with TB, which may be responsible for lower or variable levels of rifampicin.	Rifampin	149-159	ATP binding cassette subfamily B member 1	Homo sapiens	117-120
17535057-9	2003	CONCLUSIONS: The increase in rifampicin levels on administration of a PGP/CYP3A4 blocker suggests a pivotal role for PGP/CYP3A4 in the absorption of rifampicin in patients with TB, which may be responsible for lower or variable levels of rifampicin.	Rifampin	149-159	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	121-127
17535057-9	2003	CONCLUSIONS: The increase in rifampicin levels on administration of a PGP/CYP3A4 blocker suggests a pivotal role for PGP/CYP3A4 in the absorption of rifampicin in patients with TB, which may be responsible for lower or variable levels of rifampicin.	Rifampin	149-159	ATP binding cassette subfamily B member 1	Homo sapiens	70-73
17535057-9	2003	CONCLUSIONS: The increase in rifampicin levels on administration of a PGP/CYP3A4 blocker suggests a pivotal role for PGP/CYP3A4 in the absorption of rifampicin in patients with TB, which may be responsible for lower or variable levels of rifampicin.	Rifampin	149-159	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	74-80
17535057-9	2003	CONCLUSIONS: The increase in rifampicin levels on administration of a PGP/CYP3A4 blocker suggests a pivotal role for PGP/CYP3A4 in the absorption of rifampicin in patients with TB, which may be responsible for lower or variable levels of rifampicin.	Rifampin	149-159	ATP binding cassette subfamily B member 1	Homo sapiens	117-120
17535057-9	2003	CONCLUSIONS: The increase in rifampicin levels on administration of a PGP/CYP3A4 blocker suggests a pivotal role for PGP/CYP3A4 in the absorption of rifampicin in patients with TB, which may be responsible for lower or variable levels of rifampicin.	Rifampin	149-159	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	121-127
12426516-13	2002	The erythromycin-rifampin interaction cannot be attributed to CYP3A4 induction alone and probably also reflected intestinal P-glycoprotein induction.	Rifampin	17-25	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	62-68
12426516-13	2002	The erythromycin-rifampin interaction cannot be attributed to CYP3A4 induction alone and probably also reflected intestinal P-glycoprotein induction.	Rifampin	17-25	ATP binding cassette subfamily B member 1	Homo sapiens	124-138
12426514-3	2002	Rifampin (INN, rifampicin), a potent enzyme inducer of CYP-mediated metabolism (especially CYP2C9, CYP2C19, and CYP3A4), is known to markedly decrease plasma concentrations and effects of a number coadministered drugs.	Rifampin	0-8	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	91-97
12426514-3	2002	Rifampin (INN, rifampicin), a potent enzyme inducer of CYP-mediated metabolism (especially CYP2C9, CYP2C19, and CYP3A4), is known to markedly decrease plasma concentrations and effects of a number coadministered drugs.	Rifampin	0-8	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	99-106
12426514-3	2002	Rifampin (INN, rifampicin), a potent enzyme inducer of CYP-mediated metabolism (especially CYP2C9, CYP2C19, and CYP3A4), is known to markedly decrease plasma concentrations and effects of a number coadministered drugs.	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	112-118
12426514-3	2002	Rifampin (INN, rifampicin), a potent enzyme inducer of CYP-mediated metabolism (especially CYP2C9, CYP2C19, and CYP3A4), is known to markedly decrease plasma concentrations and effects of a number coadministered drugs.	Rifampin	15-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-58
12426514-3	2002	Rifampin (INN, rifampicin), a potent enzyme inducer of CYP-mediated metabolism (especially CYP2C9, CYP2C19, and CYP3A4), is known to markedly decrease plasma concentrations and effects of a number coadministered drugs.	Rifampin	15-25	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	91-97
12426514-3	2002	Rifampin (INN, rifampicin), a potent enzyme inducer of CYP-mediated metabolism (especially CYP2C9, CYP2C19, and CYP3A4), is known to markedly decrease plasma concentrations and effects of a number coadministered drugs.	Rifampin	15-25	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	99-106
12426514-3	2002	Rifampin (INN, rifampicin), a potent enzyme inducer of CYP-mediated metabolism (especially CYP2C9, CYP2C19, and CYP3A4), is known to markedly decrease plasma concentrations and effects of a number coadministered drugs.	Rifampin	15-25	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	112-118
12426516-0	2002	Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin.	Rifampin	108-116	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-19
12426516-0	2002	Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin.	Rifampin	108-116	ATP binding cassette subfamily B member 1	Homo sapiens	24-38
12386126-7	2002	Rifampin caused a 13-fold induction of testosterone 6beta-hydroxylase (CYP3A12) activity in vitro and up to a 4.5-fold increase in vivo.	Rifampin	0-8	cytochrome P450 3A12	Canis lupus familiaris	71-78
12404239-10	2002	Cyclosporin A, rifampicin, and glibenclamide were proved to be competitive inhibitors of BSEP taurocholate transport, with inhibition constant values of 9.5 micromol/L, 31 micromol/L, and 27.5 micromol/L, respectively.	Rifampin	15-25	ATP binding cassette subfamily B member 11	Homo sapiens	89-93
12369894-10	2002	Similarly, the steroid family of orphan receptors, the constitutive androstane receptor (CAR) and pregnane X receptors (PXR), heterodimerize with the retinoid X receptor (RXR), transcriptionally activate the promoters of CYP2B and CYP3A gene expression by xenobiotics such as phenobarbital-like compounds (CAR) and dexamethasone and rifampin-type of agents (PXR).	Rifampin	333-341	nuclear receptor subfamily 1 group I member 3	Homo sapiens	55-87
12369894-10	2002	Similarly, the steroid family of orphan receptors, the constitutive androstane receptor (CAR) and pregnane X receptors (PXR), heterodimerize with the retinoid X receptor (RXR), transcriptionally activate the promoters of CYP2B and CYP3A gene expression by xenobiotics such as phenobarbital-like compounds (CAR) and dexamethasone and rifampin-type of agents (PXR).	Rifampin	333-341	nuclear receptor subfamily 1 group I member 3	Homo sapiens	89-92
12369894-10	2002	Similarly, the steroid family of orphan receptors, the constitutive androstane receptor (CAR) and pregnane X receptors (PXR), heterodimerize with the retinoid X receptor (RXR), transcriptionally activate the promoters of CYP2B and CYP3A gene expression by xenobiotics such as phenobarbital-like compounds (CAR) and dexamethasone and rifampin-type of agents (PXR).	Rifampin	333-341	nuclear receptor subfamily 1 group I member 2	Homo sapiens	98-118
12369894-10	2002	Similarly, the steroid family of orphan receptors, the constitutive androstane receptor (CAR) and pregnane X receptors (PXR), heterodimerize with the retinoid X receptor (RXR), transcriptionally activate the promoters of CYP2B and CYP3A gene expression by xenobiotics such as phenobarbital-like compounds (CAR) and dexamethasone and rifampin-type of agents (PXR).	Rifampin	333-341	nuclear receptor subfamily 1 group I member 2	Homo sapiens	120-123
12369894-10	2002	Similarly, the steroid family of orphan receptors, the constitutive androstane receptor (CAR) and pregnane X receptors (PXR), heterodimerize with the retinoid X receptor (RXR), transcriptionally activate the promoters of CYP2B and CYP3A gene expression by xenobiotics such as phenobarbital-like compounds (CAR) and dexamethasone and rifampin-type of agents (PXR).	Rifampin	333-341	retinoid X receptor alpha	Homo sapiens	150-169
12369894-10	2002	Similarly, the steroid family of orphan receptors, the constitutive androstane receptor (CAR) and pregnane X receptors (PXR), heterodimerize with the retinoid X receptor (RXR), transcriptionally activate the promoters of CYP2B and CYP3A gene expression by xenobiotics such as phenobarbital-like compounds (CAR) and dexamethasone and rifampin-type of agents (PXR).	Rifampin	333-341	retinoid X receptor alpha	Homo sapiens	171-174
12369894-10	2002	Similarly, the steroid family of orphan receptors, the constitutive androstane receptor (CAR) and pregnane X receptors (PXR), heterodimerize with the retinoid X receptor (RXR), transcriptionally activate the promoters of CYP2B and CYP3A gene expression by xenobiotics such as phenobarbital-like compounds (CAR) and dexamethasone and rifampin-type of agents (PXR).	Rifampin	333-341	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	231-236
12369894-10	2002	Similarly, the steroid family of orphan receptors, the constitutive androstane receptor (CAR) and pregnane X receptors (PXR), heterodimerize with the retinoid X receptor (RXR), transcriptionally activate the promoters of CYP2B and CYP3A gene expression by xenobiotics such as phenobarbital-like compounds (CAR) and dexamethasone and rifampin-type of agents (PXR).	Rifampin	333-341	nuclear receptor subfamily 1 group I member 3	Homo sapiens	306-309
12369894-10	2002	Similarly, the steroid family of orphan receptors, the constitutive androstane receptor (CAR) and pregnane X receptors (PXR), heterodimerize with the retinoid X receptor (RXR), transcriptionally activate the promoters of CYP2B and CYP3A gene expression by xenobiotics such as phenobarbital-like compounds (CAR) and dexamethasone and rifampin-type of agents (PXR).	Rifampin	333-341	nuclear receptor subfamily 1 group I member 2	Homo sapiens	358-361
12169622-5	2002	The S487L change is the predominant change found in rpoB mutations sequenced from rifampin-resistant clinical isolates of Mycobacterium tuberculosis.	Rifampin	82-90	RNA polymerase (beta subunit)	Bacillus subtilis subsp. subtilis str. 168	52-56
12395981-3	2002	However, an important issue associated with a rifampicin-containing FDC is its quality.	Rifampin	46-56	CMD1B	Homo sapiens	68-71
12235278-8	2002	Treatment of transformants with various concentrations of rifampicin produced a dose-response curve with maximal induction at 10 microM (5.6 +/- 0.18- and 2.1 +/- 0.3-fold above dimethyl sulfoxide (DMSO)-treated cells in transformants with and without PXR, respectively).	Rifampin	58-68	nuclear receptor subfamily 1 group I member 2	Homo sapiens	252-255
12395192-2	2002	We have found that certain rifampicin-resistant ( rif) mutants isolated from either relA or relC strains regain the ability to produce actinorhodin at the same level as the wild-type strain, although their capacity to synthesize ppGpp is unchanged.	Rifampin	27-37	RELA proto-oncogene, NF-kB subunit	Homo sapiens	84-88
12167558-6	2002	hPXR"s capability of binding to extremely large ligands, such as rifampicin, implies that its binding cavity may be able to expand further through the flexibility of a surface loop.	Rifampin	65-75	nuclear receptor subfamily 1 group I member 2	Homo sapiens	0-4
12072427-2	2002	Many inducers of human CYP3A4, such as rifampicin, bind to the orphan nuclear receptor SXR (steroid and xenobiotic receptor) as ligands and stimulate transcription on xenobiotic response elements located in the CYP3A4 promoter.	Rifampin	39-49	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	23-29
12072427-2	2002	Many inducers of human CYP3A4, such as rifampicin, bind to the orphan nuclear receptor SXR (steroid and xenobiotic receptor) as ligands and stimulate transcription on xenobiotic response elements located in the CYP3A4 promoter.	Rifampin	39-49	nuclear receptor subfamily 1 group I member 2	Homo sapiens	87-90
12072427-2	2002	Many inducers of human CYP3A4, such as rifampicin, bind to the orphan nuclear receptor SXR (steroid and xenobiotic receptor) as ligands and stimulate transcription on xenobiotic response elements located in the CYP3A4 promoter.	Rifampin	39-49	nuclear receptor subfamily 1 group I member 2	Homo sapiens	92-123
12072427-2	2002	Many inducers of human CYP3A4, such as rifampicin, bind to the orphan nuclear receptor SXR (steroid and xenobiotic receptor) as ligands and stimulate transcription on xenobiotic response elements located in the CYP3A4 promoter.	Rifampin	39-49	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	211-217
12072427-5	2002	Cotransfection of SMRT, but not NCoR, inhibited not only basal but also rifampicin-induced transcriptional activity of SXR on the CYP3A4 promoter through specific SMRT-SXR interaction in HepG2 cells.	Rifampin	72-82	nuclear receptor corepressor 2	Homo sapiens	18-22
12072427-5	2002	Cotransfection of SMRT, but not NCoR, inhibited not only basal but also rifampicin-induced transcriptional activity of SXR on the CYP3A4 promoter through specific SMRT-SXR interaction in HepG2 cells.	Rifampin	72-82	nuclear receptor subfamily 1 group I member 2	Homo sapiens	119-122
12072427-5	2002	Cotransfection of SMRT, but not NCoR, inhibited not only basal but also rifampicin-induced transcriptional activity of SXR on the CYP3A4 promoter through specific SMRT-SXR interaction in HepG2 cells.	Rifampin	72-82	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	130-136
12072427-5	2002	Cotransfection of SMRT, but not NCoR, inhibited not only basal but also rifampicin-induced transcriptional activity of SXR on the CYP3A4 promoter through specific SMRT-SXR interaction in HepG2 cells.	Rifampin	72-82	nuclear receptor corepressor 2	Homo sapiens	163-167
12072427-5	2002	Cotransfection of SMRT, but not NCoR, inhibited not only basal but also rifampicin-induced transcriptional activity of SXR on the CYP3A4 promoter through specific SMRT-SXR interaction in HepG2 cells.	Rifampin	72-82	nuclear receptor subfamily 1 group I member 2	Homo sapiens	168-171
12072427-6	2002	Interestingly, rifampicin also increased the interaction of SXR with SMRT as well as with coactivator SRC-1.	Rifampin	15-25	nuclear receptor subfamily 1 group I member 2	Homo sapiens	60-63
12072427-6	2002	Interestingly, rifampicin also increased the interaction of SXR with SMRT as well as with coactivator SRC-1.	Rifampin	15-25	nuclear receptor corepressor 2	Homo sapiens	69-73
12072427-6	2002	Interestingly, rifampicin also increased the interaction of SXR with SMRT as well as with coactivator SRC-1.	Rifampin	15-25	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	102-107
11991950-3	2002	Full VDR response of various CYP3A4 heterologous/homologous promoter-reporter constructs requires both the proximal ER6 and the distal DR3 motifs, as observed previously with rifampicin-activated PXR.	Rifampin	175-185	vitamin D receptor	Homo sapiens	5-8
12567899-4	2002	RESULTS: The concentration of rifampicin was linear with ln(F0/F) when concentration was in the range of 10-170 micrograms/mL-1.	Rifampin	30-40	L1 cell adhesion molecule	Mus musculus	123-127
12130704-2	2002	We used primary cultures of human hepatocytes from 15 subjects to assess the inducibility of CYP2C enzyme expression by prototypical inducer agents, including rifampicin, dexamethasone, and phenobarbital.	Rifampin	159-169	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	93-98
12130704-5	2002	Parallel increases in CYP2C mRNAs, measured by Northern blotting and/or RNase protection, were found in rifampicin-treated hepatocytes, with CYP2C8, CYP2C9, and CYP2C19 transcripts exhibiting increases of 688 +/- 635, 207 +/- 49, and 230 +/- 60%, respectively, versus an 8.8-fold enhancement of CYP3A4 mRNA levels.	Rifampin	104-114	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	22-27
12130704-5	2002	Parallel increases in CYP2C mRNAs, measured by Northern blotting and/or RNase protection, were found in rifampicin-treated hepatocytes, with CYP2C8, CYP2C9, and CYP2C19 transcripts exhibiting increases of 688 +/- 635, 207 +/- 49, and 230 +/- 60%, respectively, versus an 8.8-fold enhancement of CYP3A4 mRNA levels.	Rifampin	104-114	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	141-147
12130704-5	2002	Parallel increases in CYP2C mRNAs, measured by Northern blotting and/or RNase protection, were found in rifampicin-treated hepatocytes, with CYP2C8, CYP2C9, and CYP2C19 transcripts exhibiting increases of 688 +/- 635, 207 +/- 49, and 230 +/- 60%, respectively, versus an 8.8-fold enhancement of CYP3A4 mRNA levels.	Rifampin	104-114	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	149-155
12130704-5	2002	Parallel increases in CYP2C mRNAs, measured by Northern blotting and/or RNase protection, were found in rifampicin-treated hepatocytes, with CYP2C8, CYP2C9, and CYP2C19 transcripts exhibiting increases of 688 +/- 635, 207 +/- 49, and 230 +/- 60%, respectively, versus an 8.8-fold enhancement of CYP3A4 mRNA levels.	Rifampin	104-114	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	161-168
12130704-5	2002	Parallel increases in CYP2C mRNAs, measured by Northern blotting and/or RNase protection, were found in rifampicin-treated hepatocytes, with CYP2C8, CYP2C9, and CYP2C19 transcripts exhibiting increases of 688 +/- 635, 207 +/- 49, and 230 +/- 60%, respectively, versus an 8.8-fold enhancement of CYP3A4 mRNA levels.	Rifampin	104-114	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	295-301
12130704-8	2002	Our results show that CYP2C enzyme expression in human hepatocytes is highly inducible by rifampicin, dexamethasone, and phenobarbital.	Rifampin	90-100	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	22-27
12167569-8	2002	This mutation disrupts induction of a reporter gene construct by the glucocorticoids dexamethasone and hydrocortisone; yet induction by the potent PXR ligand rifampicin is unaffected.	Rifampin	158-168	nuclear receptor subfamily 1 group I member 2	Homo sapiens	147-150
11991950-3	2002	Full VDR response of various CYP3A4 heterologous/homologous promoter-reporter constructs requires both the proximal ER6 and the distal DR3 motifs, as observed previously with rifampicin-activated PXR.	Rifampin	175-185	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	29-35
11991950-3	2002	Full VDR response of various CYP3A4 heterologous/homologous promoter-reporter constructs requires both the proximal ER6 and the distal DR3 motifs, as observed previously with rifampicin-activated PXR.	Rifampin	175-185	TNF receptor superfamily member 25	Homo sapiens	135-138
11991950-3	2002	Full VDR response of various CYP3A4 heterologous/homologous promoter-reporter constructs requires both the proximal ER6 and the distal DR3 motifs, as observed previously with rifampicin-activated PXR.	Rifampin	175-185	nuclear receptor subfamily 1 group I member 2	Homo sapiens	196-199
12135489-7	2002	Bsep promoter activity was reduced by rifampin and beta-estradiol.	Rifampin	38-46	ATP binding cassette subfamily B member 11	Rattus norvegicus	0-4
12065438-7	2002	Clotrimazole, phenobarbital, rifampin, and sulfinpyrazone highly activated PXR and increased CYP3A4 activity; carbamazepine, dexamethasone, dexamethasone-t-butylacetate, phenytoin, sulfadimidine, and taxol weakly activated PXR and induced CYP3A4 activity, and methotrexate and probenecid showed no marked activation in either system.	Rifampin	29-37	nuclear receptor subfamily 1 group I member 2	Homo sapiens	75-78
12065438-7	2002	Clotrimazole, phenobarbital, rifampin, and sulfinpyrazone highly activated PXR and increased CYP3A4 activity; carbamazepine, dexamethasone, dexamethasone-t-butylacetate, phenytoin, sulfadimidine, and taxol weakly activated PXR and induced CYP3A4 activity, and methotrexate and probenecid showed no marked activation in either system.	Rifampin	29-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	93-99
12065438-7	2002	Clotrimazole, phenobarbital, rifampin, and sulfinpyrazone highly activated PXR and increased CYP3A4 activity; carbamazepine, dexamethasone, dexamethasone-t-butylacetate, phenytoin, sulfadimidine, and taxol weakly activated PXR and induced CYP3A4 activity, and methotrexate and probenecid showed no marked activation in either system.	Rifampin	29-37	nuclear receptor subfamily 1 group I member 2	Homo sapiens	223-226
12065438-7	2002	Clotrimazole, phenobarbital, rifampin, and sulfinpyrazone highly activated PXR and increased CYP3A4 activity; carbamazepine, dexamethasone, dexamethasone-t-butylacetate, phenytoin, sulfadimidine, and taxol weakly activated PXR and induced CYP3A4 activity, and methotrexate and probenecid showed no marked activation in either system.	Rifampin	29-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	239-245
12085361-2	2002	In rats, rifamycin SV and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides Oatp1 and Oatp2.	Rifampin	26-36	solute carrier organic anion transporter family, member 1a1	Rattus norvegicus	156-161
12085361-2	2002	In rats, rifamycin SV and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides Oatp1 and Oatp2.	Rifampin	26-36	solute carrier organic anion transporter family, member 1a4	Rattus norvegicus	166-171
12085361-7	2002	Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%.	Rifampin	0-10	solute carrier organic anion transporter family member 1B3	Homo sapiens	37-42
12085361-8	2002	100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively.	Rifampin	15-25	solute carrier organic anion transporter family member 1B1	Homo sapiens	36-42
12085361-8	2002	100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively.	Rifampin	15-25	solute carrier organic anion transporter family member 1B3	Homo sapiens	48-53
12085361-8	2002	100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively.	Rifampin	15-25	solute carrier organic anion transporter family member 2B1	Homo sapiens	56-62
12085361-8	2002	100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively.	Rifampin	15-25	solute carrier organic anion transporter family member 1A2	Homo sapiens	68-74
12085361-10	2002	Direct transport of rifampicin could be shown for OATP-C (apparent K(m) value 13 micromol/L) and OATP8 (2.3 micromol/L).	Rifampin	20-30	solute carrier organic anion transporter family member 1B1	Homo sapiens	50-56
12085361-10	2002	Direct transport of rifampicin could be shown for OATP-C (apparent K(m) value 13 micromol/L) and OATP8 (2.3 micromol/L).	Rifampin	20-30	solute carrier organic anion transporter family member 1B3	Homo sapiens	97-102
12051692-4	2002	Phenobarbital induced CYP2B and rifampicin induced CYP3A, respectively, in addition to NADPH-cytochrome P450 reductase.	Rifampin	32-42	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	51-56
11978200-11	2002	CYP2A6 activity was markedly inhibited (&gt; 50 %) by pilocarpine, diethyldithio carbamic (DDC), and rifampicin, the IC50 was 5.31 micromol/L, 156.35 micromol/L, and 38.81 micromol/L, respectively.	Rifampin	101-111	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	0-6
11978200-15	2002	Not only pilocarpine, CYP2A6 specific inhibitor, but also rifampicin and DDC inhibited CYP2A6 activity selectively.	Rifampin	58-68	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	87-93
11950795-12	2002	The efficacy of tamoxifen and 4-hydroxytamoxifen relative to rifampicin for hPXR activation was approximately 30 and 60%, respectively.	Rifampin	61-71	nuclear receptor subfamily 1 group I member 2	Homo sapiens	76-80
12040753-6	2002	The levels of CYP1A1, CYP2B6, CYP2C8, CYP3A4, CYP3A5, ADH3, and ABCG1 mRNA in human hepatocytes increased after exposure to rifampicin.	Rifampin	124-134	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	14-20
12040753-6	2002	The levels of CYP1A1, CYP2B6, CYP2C8, CYP3A4, CYP3A5, ADH3, and ABCG1 mRNA in human hepatocytes increased after exposure to rifampicin.	Rifampin	124-134	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	22-28
12040753-6	2002	The levels of CYP1A1, CYP2B6, CYP2C8, CYP3A4, CYP3A5, ADH3, and ABCG1 mRNA in human hepatocytes increased after exposure to rifampicin.	Rifampin	124-134	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	30-36
12040753-6	2002	The levels of CYP1A1, CYP2B6, CYP2C8, CYP3A4, CYP3A5, ADH3, and ABCG1 mRNA in human hepatocytes increased after exposure to rifampicin.	Rifampin	124-134	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	38-44
12040753-6	2002	The levels of CYP1A1, CYP2B6, CYP2C8, CYP3A4, CYP3A5, ADH3, and ABCG1 mRNA in human hepatocytes increased after exposure to rifampicin.	Rifampin	124-134	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	46-52
12040753-6	2002	The levels of CYP1A1, CYP2B6, CYP2C8, CYP3A4, CYP3A5, ADH3, and ABCG1 mRNA in human hepatocytes increased after exposure to rifampicin.	Rifampin	124-134	alcohol dehydrogenase 1C (class I), gamma polypeptide	Homo sapiens	54-58
12040753-6	2002	The levels of CYP1A1, CYP2B6, CYP2C8, CYP3A4, CYP3A5, ADH3, and ABCG1 mRNA in human hepatocytes increased after exposure to rifampicin.	Rifampin	124-134	ATP binding cassette subfamily G member 1	Homo sapiens	64-69
12040753-7	2002	The levels of CYP1A1, CYP2B6, CYP3A4, CYP3A5, and ABCG1 mRNA recovered after a change to media without rifampicin.	Rifampin	103-113	ATP binding cassette subfamily G member 1	Homo sapiens	50-55
11744607-0	2002	Induction of multidrug resistance-1 and cytochrome P450 mRNAs in human mononuclear cells by rifampin.	Rifampin	92-100	ATP binding cassette subfamily B member 1	Homo sapiens	13-35
11893771-4	2002	Interestingly, both the antibiotic rifampicin and the herbal antidepressant St. John"s wort activate PXR and have anticholestatic properties, which suggests that more potent, selective PXR agonists may be useful in the treatment of biliary cholestasis or other diseases characterized by the accumulation of bile acids or other toxins in the liver.	Rifampin	35-45	nuclear receptor subfamily 1 group I member 2	Homo sapiens	101-104
11893771-4	2002	Interestingly, both the antibiotic rifampicin and the herbal antidepressant St. John"s wort activate PXR and have anticholestatic properties, which suggests that more potent, selective PXR agonists may be useful in the treatment of biliary cholestasis or other diseases characterized by the accumulation of bile acids or other toxins in the liver.	Rifampin	35-45	nuclear receptor subfamily 1 group I member 2	Homo sapiens	185-188
11883641-5	2002	whereas digoxin, quinine, and rifampicin preferentially inhibited Oatp2 at low concentrations.	Rifampin	30-40	solute carrier organic anion transporter family, member 1a4	Rattus norvegicus	66-71
11679585-3	2002	In previous work, we have shown that CYP2C9 is inducible in primary human hepatocytes by xenobiotics including dexamethasone, rifampicin, and phenobarbital.	Rifampin	126-136	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	37-43
11679585-8	2002	Identification of these functional elements provides rational mechanistic basis for CYP2C9 induction by dexamethasone (submicromolar concentrations), and by phenobarbital and rifampicin, respectively.	Rifampin	175-185	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	84-90
11836020-1	2002	In the present study, we investigated the inducibility of the drug conjugate transporter genes MRP1 and MRP2 by redox-active compounds such as tertiary butylated hydroquinone (tBHQ) and quercetin and by chemicals known to activate the pregnane X receptor (PXR) such as rifampicin and clotrimazol and by the metalloid compound arsenite.	Rifampin	269-279	ATP binding cassette subfamily C member 1	Homo sapiens	95-99
11836020-1	2002	In the present study, we investigated the inducibility of the drug conjugate transporter genes MRP1 and MRP2 by redox-active compounds such as tertiary butylated hydroquinone (tBHQ) and quercetin and by chemicals known to activate the pregnane X receptor (PXR) such as rifampicin and clotrimazol and by the metalloid compound arsenite.	Rifampin	269-279	synaptonemal complex central element protein 1 like	Homo sapiens	104-108
11836020-2	2002	The human MRP2 gene was found to be inducible in HepG2 cells by rifampicin, clotrimazol, arsenite and tBHQ.	Rifampin	64-74	synaptonemal complex central element protein 1 like	Homo sapiens	10-14
11829457-4	2002	Marked induction was detected in the cases of dexamethasone, clofibrate, and rifampicin treatments for 96 h both in enzyme activity (178, 176, and 168%) and in UGT1A1 protein level (362, 328, and 250%).	Rifampin	77-87	UDP glucuronosyltransferase family 1 member A1	Rattus norvegicus	160-166
12206135-3	2002	In addition, MRP2 levels are altered in hepatocytes in response to hormones such as glucocorticoids and to structurally unrelated drugs such as rifampicin, phenobarbital, ritonavir, and cisplatin.	Rifampin	144-154	ATP binding cassette subfamily C member 2	Homo sapiens	13-17
11744607-0	2002	Induction of multidrug resistance-1 and cytochrome P450 mRNAs in human mononuclear cells by rifampin.	Rifampin	92-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-55
11744607-5	2002	A significant (P &lt; 0.05; n = 37) increase in the expression of MDR1 mRNA from 176,900 +/- 122,000 to 248,500 +/- 162,300 molecules/microg of RNA was observed following rifampin administration in the human lymphocytes.	Rifampin	171-179	ATP binding cassette subfamily B member 1	Homo sapiens	66-70
11744607-11	2002	The mRNA of CYP2E1, CYP3A5, CYP3A7, CYP4A11, and CYP4B1 genes were variably expressed at baseline and following rifampin treatment.	Rifampin	112-120	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	12-18
11744607-11	2002	The mRNA of CYP2E1, CYP3A5, CYP3A7, CYP4A11, and CYP4B1 genes were variably expressed at baseline and following rifampin treatment.	Rifampin	112-120	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	20-26
11744607-11	2002	The mRNA of CYP2E1, CYP3A5, CYP3A7, CYP4A11, and CYP4B1 genes were variably expressed at baseline and following rifampin treatment.	Rifampin	112-120	cytochrome P450 family 3 subfamily A member 7	Homo sapiens	28-34
11744607-11	2002	The mRNA of CYP2E1, CYP3A5, CYP3A7, CYP4A11, and CYP4B1 genes were variably expressed at baseline and following rifampin treatment.	Rifampin	112-120	cytochrome P450 family 4 subfamily A member 11	Homo sapiens	36-43
11744607-11	2002	The mRNA of CYP2E1, CYP3A5, CYP3A7, CYP4A11, and CYP4B1 genes were variably expressed at baseline and following rifampin treatment.	Rifampin	112-120	cytochrome P450 family 4 subfamily B member 1	Homo sapiens	49-55
11744607-12	2002	In contrast, CYP2C9 and CYP3A4 mRNAs were undetectable in lymphocytes both before and after rifampin dosing.	Rifampin	92-100	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	24-30
11389115-2	2001	In this study, Poly (DL-lactide-co-glycolide) (PLG) microparticles containing a combination of isoniazid and rifampicin were developed as sustained release carrier systems.	Rifampin	109-119	plasminogen	Mus musculus	47-50
11958592-0	2002	Rifampicin inhibits CD95-mediated apoptosis of Jurkat T cells via glucocorticoid receptors by modifying the expression of molecules regulating apoptosis.	Rifampin	0-10	Fas cell surface death receptor	Homo sapiens	20-24
11958592-5	2002	Rifampicin, in a concentration-dependent manner, inhibited anti-CD95-induced apoptosis.	Rifampin	0-10	Fas cell surface death receptor	Homo sapiens	64-68
11958592-6	2002	Furthermore, rifampicin down-regulated the expression of Bax and CD95L and up-regulated the expression of Bcl-2, Bcl-xL, and Flice-inhibitory protein-L (FLIPL); however, rifampicin had no effect on CD95 or XIAP expression.	Rifampin	13-23	BCL2 associated X, apoptosis regulator	Homo sapiens	57-60
11958592-6	2002	Furthermore, rifampicin down-regulated the expression of Bax and CD95L and up-regulated the expression of Bcl-2, Bcl-xL, and Flice-inhibitory protein-L (FLIPL); however, rifampicin had no effect on CD95 or XIAP expression.	Rifampin	13-23	Fas ligand	Homo sapiens	65-70
11958592-6	2002	Furthermore, rifampicin down-regulated the expression of Bax and CD95L and up-regulated the expression of Bcl-2, Bcl-xL, and Flice-inhibitory protein-L (FLIPL); however, rifampicin had no effect on CD95 or XIAP expression.	Rifampin	13-23	BCL2 apoptosis regulator	Homo sapiens	106-111
11958592-6	2002	Furthermore, rifampicin down-regulated the expression of Bax and CD95L and up-regulated the expression of Bcl-2, Bcl-xL, and Flice-inhibitory protein-L (FLIPL); however, rifampicin had no effect on CD95 or XIAP expression.	Rifampin	13-23	BCL2 like 1	Homo sapiens	113-119
11958592-6	2002	Furthermore, rifampicin down-regulated the expression of Bax and CD95L and up-regulated the expression of Bcl-2, Bcl-xL, and Flice-inhibitory protein-L (FLIPL); however, rifampicin had no effect on CD95 or XIAP expression.	Rifampin	13-23	Fas cell surface death receptor	Homo sapiens	65-69
11958592-6	2002	Furthermore, rifampicin down-regulated the expression of Bax and CD95L and up-regulated the expression of Bcl-2, Bcl-xL, and Flice-inhibitory protein-L (FLIPL); however, rifampicin had no effect on CD95 or XIAP expression.	Rifampin	13-23	X-linked inhibitor of apoptosis	Homo sapiens	206-210
11958592-10	2002	Taken together, these findings suggest that rifampicin inhibits anti-CD95-induced apoptosis in Jurkat T cells by modulating the expression of various molecules regulating apoptosis and its effect appears to be mediated via GR and at least in part through NF-kappaB signaling pathway.	Rifampin	44-54	Fas cell surface death receptor	Homo sapiens	69-73
11714868-5	2001	The oligonucleotide-based array made it possible to detect different levels of induction within the CYP2C family, with rifampin causing a 6.5-fold increase in expression of CYP2C8 and a 3.7-fold increase in CYP2C9 while having no effect on the level of CYP2C18 mRNA.	Rifampin	119-127	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	173-179
11714868-5	2001	The oligonucleotide-based array made it possible to detect different levels of induction within the CYP2C family, with rifampin causing a 6.5-fold increase in expression of CYP2C8 and a 3.7-fold increase in CYP2C9 while having no effect on the level of CYP2C18 mRNA.	Rifampin	119-127	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	207-213
11714868-5	2001	The oligonucleotide-based array made it possible to detect different levels of induction within the CYP2C family, with rifampin causing a 6.5-fold increase in expression of CYP2C8 and a 3.7-fold increase in CYP2C9 while having no effect on the level of CYP2C18 mRNA.	Rifampin	119-127	cytochrome P450 family 2 subfamily C member 18	Homo sapiens	253-260
11714868-6	2001	Rifampin also induced other CYP enzymes including CYP2B6 and all three members of the CYP3A family, with CYP3A4 showing the highest level of induction at 55.1-fold.	Rifampin	0-8	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	50-56
11714868-6	2001	Rifampin also induced other CYP enzymes including CYP2B6 and all three members of the CYP3A family, with CYP3A4 showing the highest level of induction at 55.1-fold.	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	105-111
11668216-12	2001	The relevance of each of the 38 PXR SNPs identified in DNA of individuals whose CYP3A basal and rifampin-inducible CYP3A4 expression was determined in vivo and/or in vitro was demonstrated by univariate statistical analysis.	Rifampin	96-104	nuclear receptor subfamily 1 group I member 2	Homo sapiens	32-35
11668216-12	2001	The relevance of each of the 38 PXR SNPs identified in DNA of individuals whose CYP3A basal and rifampin-inducible CYP3A4 expression was determined in vivo and/or in vitro was demonstrated by univariate statistical analysis.	Rifampin	96-104	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	115-121
11502872-4	2001	In primary cultures of human hepatocytes, CYP2B6 was highly inducible by a number of compounds known to be human PXR ligands, including rifampicin and hyperforin.	Rifampin	136-146	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	42-48
11502872-4	2001	In primary cultures of human hepatocytes, CYP2B6 was highly inducible by a number of compounds known to be human PXR ligands, including rifampicin and hyperforin.	Rifampin	136-146	nuclear receptor subfamily 1 group I member 2	Homo sapiens	113-116
11503007-3	2001	The aim of this study was to investigate modulation of the CYP-mediated metabolism of ifosfamide with ketoconazole, a potent inhibitor of CYP3A4, and rifampin (INN, rifampicin), an inducer of CYP3A4/CYP2B6.	Rifampin	150-158	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	199-205
11471773-5	2001	METHODS: Pharmacokinetic parameters of midazolam and 6beta-OH cortisol urinary ratio were evaluated in 8 volunteers before and after 6 days treatment with rifampin, a potent inducer of CYP3A, and after cessation of rifampin treatment.	Rifampin	155-163	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	185-190
12405865-13	2002	Rifampicin (rifampin), phenobarbital, phenytoin, carbamazepine, nevirapine, and efavirenz decrease methadone blood concentrations, probably by induction of CYP3A4 activity, which can result in severe withdrawal symptoms.	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	156-162
12405865-13	2002	Rifampicin (rifampin), phenobarbital, phenytoin, carbamazepine, nevirapine, and efavirenz decrease methadone blood concentrations, probably by induction of CYP3A4 activity, which can result in severe withdrawal symptoms.	Rifampin	12-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	156-162
11965845-2	2002	In view of the worldwide re-emergency of tuberculosis (TB) and the rise of pulmonary TB (TBP) resistant to the two main first line drugs, namely isoniazid (H) and rifampin (R), so called multidrug resistant TBP (MDR-TBP), it was considered necessary to carry out a national, non randomized, multicenter, prospective pilot survey to determine the rates of resistant Mycobacterium tuberculosis (MTB) in patients with no previous antituberculous treatment (primary resistance).	Rifampin	163-171	TATA-box binding protein	Homo sapiens	89-92
11965845-2	2002	In view of the worldwide re-emergency of tuberculosis (TB) and the rise of pulmonary TB (TBP) resistant to the two main first line drugs, namely isoniazid (H) and rifampin (R), so called multidrug resistant TBP (MDR-TBP), it was considered necessary to carry out a national, non randomized, multicenter, prospective pilot survey to determine the rates of resistant Mycobacterium tuberculosis (MTB) in patients with no previous antituberculous treatment (primary resistance).	Rifampin	163-171	TATA-box binding protein	Homo sapiens	207-210
11965845-2	2002	In view of the worldwide re-emergency of tuberculosis (TB) and the rise of pulmonary TB (TBP) resistant to the two main first line drugs, namely isoniazid (H) and rifampin (R), so called multidrug resistant TBP (MDR-TBP), it was considered necessary to carry out a national, non randomized, multicenter, prospective pilot survey to determine the rates of resistant Mycobacterium tuberculosis (MTB) in patients with no previous antituberculous treatment (primary resistance).	Rifampin	163-171	TATA-box binding protein	Homo sapiens	207-210
11868391-6	2002	For human CYP3A4 genes, pregnane X receptor (PXR) binds to the xenobiotic-responsive enhancer module (XREM) and upon induction by rifampicin, a PXR:RXR heterodimer could transactivate XREM.	Rifampin	130-140	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	10-16
11868391-6	2002	For human CYP3A4 genes, pregnane X receptor (PXR) binds to the xenobiotic-responsive enhancer module (XREM) and upon induction by rifampicin, a PXR:RXR heterodimer could transactivate XREM.	Rifampin	130-140	nuclear receptor subfamily 1 group I member 2	Homo sapiens	24-43
11868391-6	2002	For human CYP3A4 genes, pregnane X receptor (PXR) binds to the xenobiotic-responsive enhancer module (XREM) and upon induction by rifampicin, a PXR:RXR heterodimer could transactivate XREM.	Rifampin	130-140	nuclear receptor subfamily 1 group I member 2	Homo sapiens	45-48
11868391-6	2002	For human CYP3A4 genes, pregnane X receptor (PXR) binds to the xenobiotic-responsive enhancer module (XREM) and upon induction by rifampicin, a PXR:RXR heterodimer could transactivate XREM.	Rifampin	130-140	nuclear receptor subfamily 1 group I member 2	Homo sapiens	144-147
11868391-6	2002	For human CYP3A4 genes, pregnane X receptor (PXR) binds to the xenobiotic-responsive enhancer module (XREM) and upon induction by rifampicin, a PXR:RXR heterodimer could transactivate XREM.	Rifampin	130-140	retinoid X receptor alpha	Homo sapiens	148-151
11602520-6	2001	Known ligands for pregnane X receptor (PXR) (rifampin, dexamethasone, and dexamethasone t-butyl acetate) markedly induced CYP3A4 expression in human hepatocytes.	Rifampin	45-53	nuclear receptor subfamily 1 group I member 2	Homo sapiens	18-37
11602520-6	2001	Known ligands for pregnane X receptor (PXR) (rifampin, dexamethasone, and dexamethasone t-butyl acetate) markedly induced CYP3A4 expression in human hepatocytes.	Rifampin	45-53	nuclear receptor subfamily 1 group I member 2	Homo sapiens	39-42
11602520-6	2001	Known ligands for pregnane X receptor (PXR) (rifampin, dexamethasone, and dexamethasone t-butyl acetate) markedly induced CYP3A4 expression in human hepatocytes.	Rifampin	45-53	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	122-128
11601668-5	2001	However, potent inducers of CYP, such as rifampin, may decrease rofecoxib concentrations because of induction of general hepatic metabolic activity.	Rifampin	41-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-31
11503007-3	2001	The aim of this study was to investigate modulation of the CYP-mediated metabolism of ifosfamide with ketoconazole, a potent inhibitor of CYP3A4, and rifampin (INN, rifampicin), an inducer of CYP3A4/CYP2B6.	Rifampin	150-158	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	192-198
11389115-3	2001	A single dose of PLG microparticles exhibited a sustained release of isoniazid and rifampicin in vivo up to 7 and 6 weeks, respectively.	Rifampin	83-93	plasminogen	Mus musculus	17-20
11336975-1	2001	Induction of P450 isoforms 1A (CYP1A) and 3A (CYP3A) by model inducers dexamethasone, omeprazole and rifampin was evaluated in primary cultured hepatocytes from man and laboratory animals.	Rifampin	101-109	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	46-51
11336975-3	2001	Results with human hepatocytes from six human donors consistently show that both rifampin and dexamethasone were inducers of CYP3A activity (measured as testosterone 6beta-hydroxylase activity), with rifampin being more potent.	Rifampin	81-89	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	125-130
11336976-5	2001	Pregnenolone 16alpha-carbonitrile, a known CYP3A inducer in rodents, is a very efficacious activator of mouse and rat PXR, whereas rifampicin, a known inducer of CYP3A in humans and rabbits, is a very efficacious activator of human and rabbit PXR.	Rifampin	131-141	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	162-167
11336977-5	2001	The activity of intestinal 6beta-OHT in both control and Rif-treated dogs was specifically inhibited by anti-CYP3A12 antiserum.	Rifampin	57-60	cytochrome P450 3A12	Canis lupus familiaris	109-116
11336977-10	2001	These results demonstrate that Rif induces not only hepatic CYP3A12 but also intestinal CYP3A in dogs.	Rifampin	31-34	cytochrome P450 3A12	Canis lupus familiaris	60-67
11745918-8	2001	Rifampin increased CYP3A6 activity by 2- to 3-fold in hepatic microsomes compared to vehicle.	Rifampin	0-8	cytochrome P450 3A6	Oryctolagus cuniculus	19-25
11297522-4	2001	So far, the mechanisms by which rifampin induces MDR1 expression are poorly understood.	Rifampin	32-40	ATP binding cassette subfamily B member 1	Homo sapiens	49-53
11297522-7	2001	The human colon carcinoma cell line LS174T was used as an intestinal model to study induction because in these cells the endogenous MDR1 gene is highly inducible by rifampin.	Rifampin	165-173	ATP binding cassette subfamily B member 1	Homo sapiens	132-136
11491386-9	2001	Since CYP3A6 is mainly induced by rifampicin in rabbit-cultured hepatocytes, the data suggest that this isoform is involved in the biotransformation of MDEA to 3OH-MDEA.	Rifampin	34-44	cytochrome P450 3A6	Oryctolagus cuniculus	6-12
11745918-3	2001	The rabbit isoform CYP3A6 and the human isoform CYP3A4 have similar P-450 predominance and substrate specificity and are both induced by rifampin.	Rifampin	137-145	cytochrome P450 3A6	Oryctolagus cuniculus	19-25
11745918-3	2001	The rabbit isoform CYP3A6 and the human isoform CYP3A4 have similar P-450 predominance and substrate specificity and are both induced by rifampin.	Rifampin	137-145	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	48-54
11745918-5	2001	We determined the in vivo and ex vivo CYP3A6 induction by 4 days of treatment with rifabutin (100 mg/kg), rifampin (100 mg/kg), or vehicle (DMSO) in the rabbit.	Rifampin	106-114	cytochrome P450 3A6	Oryctolagus cuniculus	38-44
11322768-7	2001	Of the MRP inhibitors including probenecid, ofloxacin, erythromycin, and rifampicin used in this study, only probenecid showed a marked chemosensitizing effect in AML-2/DX100 but not in HL-60/Adr, suggesting that the chemosensitizing effects of the MRP inhibitors vary according to the type of resistant cells.	Rifampin	73-83	RUNX family transcription factor 3	Homo sapiens	163-168
11323161-4	2001	Furthermore, the antibiotic rifampicin was identified as MRP2 inducer in HepG2 cells.	Rifampin	28-38	ATP binding cassette subfamily C member 2	Homo sapiens	57-61
11296180-9	2001	Treatment with clarithromycin combined with two or three other antibiotics, including ethambutol, rifampicin, ofloxacin, or ciprofloxacin, for at least 6 months resulted in a significant fall in plasma HBD-2 concentrations in responders, but not in nonresponders.	Rifampin	98-108	defensin beta 4A	Homo sapiens	202-207
11323161-6	2001	However, MRP3 and 5 mRNAs were detected in addition to MRP2 and their expression was found to be increased by 2-AAF, cisplatin and rifampicin.	Rifampin	131-141	ATP binding cassette subfamily C member 3	Homo sapiens	9-19
11323161-6	2001	However, MRP3 and 5 mRNAs were detected in addition to MRP2 and their expression was found to be increased by 2-AAF, cisplatin and rifampicin.	Rifampin	131-141	ATP binding cassette subfamily C member 2	Homo sapiens	55-59
11181490-4	2001	Compounds known to activate the pregnane X receptor (PXR) such as rifampicin, or the constitutively activated receptor (CAR) such as phenobarbital, induced CYP2C8, CYP2C9, and to a lesser extent CYP2C19 mRNAs and proteins.	Rifampin	66-76	nuclear receptor subfamily 1 group I member 2	Homo sapiens	32-51
11257517-5	2001	Treatment with phenobarbitone caused CYP2B, CYP2C-2 and CYP3A21 levels to increase, rifampicin caused increases in CYP2B and CYP2C-1 and a decrease in CYP3A21 levels, whereas dioxin caused CYP1A1 and CYP1A2 levels to increase and CYP2E1 levels to decrease.	Rifampin	84-94	cytochrome P450 3A21	Callithrix jacchus	151-158
11257517-5	2001	Treatment with phenobarbitone caused CYP2B, CYP2C-2 and CYP3A21 levels to increase, rifampicin caused increases in CYP2B and CYP2C-1 and a decrease in CYP3A21 levels, whereas dioxin caused CYP1A1 and CYP1A2 levels to increase and CYP2E1 levels to decrease.	Rifampin	84-94	cytochrome P450 family 1 subfamily A member 1	Callithrix jacchus	189-195
11257517-5	2001	Treatment with phenobarbitone caused CYP2B, CYP2C-2 and CYP3A21 levels to increase, rifampicin caused increases in CYP2B and CYP2C-1 and a decrease in CYP3A21 levels, whereas dioxin caused CYP1A1 and CYP1A2 levels to increase and CYP2E1 levels to decrease.	Rifampin	84-94	cytochrome P450 1A2	Callithrix jacchus	200-206
11257517-5	2001	Treatment with phenobarbitone caused CYP2B, CYP2C-2 and CYP3A21 levels to increase, rifampicin caused increases in CYP2B and CYP2C-1 and a decrease in CYP3A21 levels, whereas dioxin caused CYP1A1 and CYP1A2 levels to increase and CYP2E1 levels to decrease.	Rifampin	84-94	cytochrome P450 2E1	Callithrix jacchus	230-236
11257517-7	2001	P450 enzyme activities were assessed using 8 different substrates and increases were found after treatment with phenobarbitone, rifampicin, and dioxin.	Rifampin	128-138	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	0-4
11181490-4	2001	Compounds known to activate the pregnane X receptor (PXR) such as rifampicin, or the constitutively activated receptor (CAR) such as phenobarbital, induced CYP2C8, CYP2C9, and to a lesser extent CYP2C19 mRNAs and proteins.	Rifampin	66-76	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	156-162
11181490-4	2001	Compounds known to activate the pregnane X receptor (PXR) such as rifampicin, or the constitutively activated receptor (CAR) such as phenobarbital, induced CYP2C8, CYP2C9, and to a lesser extent CYP2C19 mRNAs and proteins.	Rifampin	66-76	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	164-170
11181490-4	2001	Compounds known to activate the pregnane X receptor (PXR) such as rifampicin, or the constitutively activated receptor (CAR) such as phenobarbital, induced CYP2C8, CYP2C9, and to a lesser extent CYP2C19 mRNAs and proteins.	Rifampin	66-76	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	195-202
11181490-6	2001	The concentration dependence of CYP2C8 and CYP2C9 mRNAs in response to rifampicin and phenobarbital paralleled that of CYP3A4 and CYP2B6, the maximum accumulation being reached with 10 microM rifampicin and 100 microM phenobarbital.	Rifampin	71-81	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	32-38
11181490-6	2001	The concentration dependence of CYP2C8 and CYP2C9 mRNAs in response to rifampicin and phenobarbital paralleled that of CYP3A4 and CYP2B6, the maximum accumulation being reached with 10 microM rifampicin and 100 microM phenobarbital.	Rifampin	71-81	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	43-49
11181490-6	2001	The concentration dependence of CYP2C8 and CYP2C9 mRNAs in response to rifampicin and phenobarbital paralleled that of CYP3A4 and CYP2B6, the maximum accumulation being reached with 10 microM rifampicin and 100 microM phenobarbital.	Rifampin	71-81	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	130-136
11181490-6	2001	The concentration dependence of CYP2C8 and CYP2C9 mRNAs in response to rifampicin and phenobarbital paralleled that of CYP3A4 and CYP2B6, the maximum accumulation being reached with 10 microM rifampicin and 100 microM phenobarbital.	Rifampin	192-202	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	32-38
11181490-6	2001	The concentration dependence of CYP2C8 and CYP2C9 mRNAs in response to rifampicin and phenobarbital paralleled that of CYP3A4 and CYP2B6, the maximum accumulation being reached with 10 microM rifampicin and 100 microM phenobarbital.	Rifampin	192-202	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	43-49
11181490-6	2001	The concentration dependence of CYP2C8 and CYP2C9 mRNAs in response to rifampicin and phenobarbital paralleled that of CYP3A4 and CYP2B6, the maximum accumulation being reached with 10 microM rifampicin and 100 microM phenobarbital.	Rifampin	192-202	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	130-136
11181490-9	2001	Furthermore, dexamethasone, which has been recently shown to up-regulate PXR and CAR expression through the glucocorticoid receptor, potentiated CYP2C8 and CYP2C9 mRNA induction in response to rifampicin and phenobarbital.	Rifampin	193-203	nuclear receptor subfamily 1 group I member 2	Homo sapiens	73-76
11181490-9	2001	Furthermore, dexamethasone, which has been recently shown to up-regulate PXR and CAR expression through the glucocorticoid receptor, potentiated CYP2C8 and CYP2C9 mRNA induction in response to rifampicin and phenobarbital.	Rifampin	193-203	nuclear receptor subfamily 1 group I member 3	Homo sapiens	81-84
11181490-9	2001	Furthermore, dexamethasone, which has been recently shown to up-regulate PXR and CAR expression through the glucocorticoid receptor, potentiated CYP2C8 and CYP2C9 mRNA induction in response to rifampicin and phenobarbital.	Rifampin	193-203	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	145-151
11181490-9	2001	Furthermore, dexamethasone, which has been recently shown to up-regulate PXR and CAR expression through the glucocorticoid receptor, potentiated CYP2C8 and CYP2C9 mRNA induction in response to rifampicin and phenobarbital.	Rifampin	193-203	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	156-162
11266076-8	2001	CYP3A43 is also expressed in several other tissues including liver, where it can be induced by rifampicin.	Rifampin	95-105	cytochrome P450 family 3 subfamily A member 43	Homo sapiens	0-7
11327199-6	2001	Concomitant use of CYP inducers, such as rifampicin (rifampin), rifabutin, phenytoin, phenobarbital or carbamazepine, should be avoided since delavirdine plasma concentrations are significantly lowered.	Rifampin	41-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-22
11327199-6	2001	Concomitant use of CYP inducers, such as rifampicin (rifampin), rifabutin, phenytoin, phenobarbital or carbamazepine, should be avoided since delavirdine plasma concentrations are significantly lowered.	Rifampin	53-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	19-22
11432536-4	2001	The relative potency of the rifamycins as CYP3A inducers is rifampin &gt; rifapentine &gt; rifabutin; rifabutin is also a CYP3A substrate.	Rifampin	60-68	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	42-47
11432536-4	2001	The relative potency of the rifamycins as CYP3A inducers is rifampin &gt; rifapentine &gt; rifabutin; rifabutin is also a CYP3A substrate.	Rifampin	60-68	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	122-127
11406737-12	2001	The mechanism underlying the interaction between rifampin and glyburide is probably induction of either CYP2C9 or P-glycoprotein or both.	Rifampin	49-57	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	104-110
11406737-12	2001	The mechanism underlying the interaction between rifampin and glyburide is probably induction of either CYP2C9 or P-glycoprotein or both.	Rifampin	49-57	ATP binding cassette subfamily B member 1	Homo sapiens	114-128
11735605-5	2001	On the other hand, rifampicin is a nonspecific inducer of CYP-mediated metabolism (especially of CYP2C9, CYP2C19 and CYP3A4) and may therefore cause therapeutic failure of other coadministered drugs by increasing their clearance.	Rifampin	19-29	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	97-103
11735605-5	2001	On the other hand, rifampicin is a nonspecific inducer of CYP-mediated metabolism (especially of CYP2C9, CYP2C19 and CYP3A4) and may therefore cause therapeutic failure of other coadministered drugs by increasing their clearance.	Rifampin	19-29	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	105-112
11735605-5	2001	On the other hand, rifampicin is a nonspecific inducer of CYP-mediated metabolism (especially of CYP2C9, CYP2C19 and CYP3A4) and may therefore cause therapeutic failure of other coadministered drugs by increasing their clearance.	Rifampin	19-29	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	117-123
11460875-8	2001	However, such an interaction effect was masked following administration at 22.00 h. The time-dependent influence of rifampicin on the pharmacokinetics of zidovudine may be due to time-dependent changes in absorption and elimination of rifampicin, thus modifying its induction effect on the levels of UDP glucuronyl transferase and cytochrome P-450 content in liver which are responsible for metabolism of zidovudine.	Rifampin	116-126	cytochrome P-450	Oryctolagus cuniculus	331-347
11181490-4	2001	Compounds known to activate the pregnane X receptor (PXR) such as rifampicin, or the constitutively activated receptor (CAR) such as phenobarbital, induced CYP2C8, CYP2C9, and to a lesser extent CYP2C19 mRNAs and proteins.	Rifampin	66-76	nuclear receptor subfamily 1 group I member 2	Homo sapiens	53-56
11136298-7	2000	CONCLUSIONS: The effects of rifampicin on the pharmacokinetics of glimepiride suggest that rifampicin induced the CYP2C9-mediated metabolism of glimepiride and thereby slightly increased its systemic clearance.	Rifampin	28-38	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	114-120
11136298-7	2000	CONCLUSIONS: The effects of rifampicin on the pharmacokinetics of glimepiride suggest that rifampicin induced the CYP2C9-mediated metabolism of glimepiride and thereby slightly increased its systemic clearance.	Rifampin	91-101	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	114-120
11180018-1	2000	BACKGROUND: Rifampin (rifampicin) is a potent inducer of several cytochrome P450 (CYP) enzymes, including CYP3A4.	Rifampin	12-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-80
11147822-12	2000	Simultaneous expression of the H and L ferritin genes in Escherichia coli grown in a deficient medium with minimal iron and with the addition of rifampicin resulted in the production of a range of recombinant human apoferritin heteromers that could be separated based on their subunit composition.	Rifampin	145-155	ferritin heavy chain 1	Homo sapiens	215-226
11180018-1	2000	BACKGROUND: Rifampin (rifampicin) is a potent inducer of several cytochrome P450 (CYP) enzymes, including CYP3A4.	Rifampin	12-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-85
11180018-1	2000	BACKGROUND: Rifampin (rifampicin) is a potent inducer of several cytochrome P450 (CYP) enzymes, including CYP3A4.	Rifampin	12-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	106-112
11180018-1	2000	BACKGROUND: Rifampin (rifampicin) is a potent inducer of several cytochrome P450 (CYP) enzymes, including CYP3A4.	Rifampin	22-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-80
11180018-1	2000	BACKGROUND: Rifampin (rifampicin) is a potent inducer of several cytochrome P450 (CYP) enzymes, including CYP3A4.	Rifampin	22-32	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-85
11180018-1	2000	BACKGROUND: Rifampin (rifampicin) is a potent inducer of several cytochrome P450 (CYP) enzymes, including CYP3A4.	Rifampin	22-32	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	106-112
11180018-11	2000	Because the elimination half-life of simvastatin was not affected by rifampin, induction of the CYP3A4-mediated first-pass metabolism of simvastatin in the intestine and the liver probably explains this interaction.	Rifampin	69-77	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	96-102
11082432-8	2000	The induction of CYP3A by rifampicin enhanced the metabolism, and the induction of all-trans-RA metabolism was also observed after preincubation of the cells with all-trans-RA.	Rifampin	26-36	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	17-22
11061580-0	2000	In vivo modulation of CYP enzymes by quinidine and rifampin.	Rifampin	51-59	peptidylprolyl isomerase G	Homo sapiens	22-25
11090943-8	2000	And finally, PXRs from different species are differentially activated by certain compounds such as rifampicin and pregnenolone 16alpha-carbonitrile (PCN) in a manner that correlates with species-specific induction of CYP3A gene expression.	Rifampin	99-109	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	217-222
11073816-0	2000	The effect of rifampin treatment on intestinal expression of human MRP transporters.	Rifampin	14-22	ATP binding cassette subfamily C member 1	Homo sapiens	67-70
11073816-2	2000	For example, induction of intestinal P-glycoprotein by rifampin appears to be the underlying mechanism of decreased plasma concentrations of P-glycoprotein substrates such as digoxin with concomitant rifampin therapy.	Rifampin	55-63	ATP binding cassette subfamily B member 1	Homo sapiens	37-51
11073816-2	2000	For example, induction of intestinal P-glycoprotein by rifampin appears to be the underlying mechanism of decreased plasma concentrations of P-glycoprotein substrates such as digoxin with concomitant rifampin therapy.	Rifampin	55-63	ATP binding cassette subfamily B member 1	Homo sapiens	141-155
11073816-4	2000	Therefore, we tested in this study the hypothesis whether the conjugate export pump MRP2 (cMOAT), which is another member of the ABC transporter family, is inducible by rifampin in humans.	Rifampin	169-177	ATP binding cassette subfamily C member 2	Homo sapiens	84-88
11073816-4	2000	Therefore, we tested in this study the hypothesis whether the conjugate export pump MRP2 (cMOAT), which is another member of the ABC transporter family, is inducible by rifampin in humans.	Rifampin	169-177	ATP binding cassette subfamily C member 2	Homo sapiens	90-95
11073816-7	2000	Rifampin induced duodenal MRP2 mRNA in 14 out of 16 individuals.	Rifampin	0-8	ATP binding cassette subfamily C member 2	Homo sapiens	26-30
11073816-8	2000	Moreover, MRP2 protein, which was expressed in the apical membrane of enterocytes, was significantly induced by rifampin in 10 out of 16 subjects.	Rifampin	112-120	ATP binding cassette subfamily C member 2	Homo sapiens	10-14
11073816-9	2000	In summary, rifampin induces MRP2 mRNA and protein in human duodenum.	Rifampin	12-20	ATP binding cassette subfamily C member 2	Homo sapiens	29-33
11073816-10	2000	Increased elimination of MRP2 substrates (eg, drug conjugates) into the lumen of the gastrointestinal tract during treatment with rifampin could be a new mechanism of drug interactions.	Rifampin	130-138	ATP binding cassette subfamily C member 2	Homo sapiens	25-29
11061574-2	2000	It has been demonstrated that rifampin (INN, rifampicin) induces P-glycoprotein, particularly in the gut wall.	Rifampin	30-38	ATP binding cassette subfamily B member 1	Homo sapiens	65-79
11061574-2	2000	It has been demonstrated that rifampin (INN, rifampicin) induces P-glycoprotein, particularly in the gut wall.	Rifampin	45-55	ATP binding cassette subfamily B member 1	Homo sapiens	65-79
11061574-3	2000	We therefore hypothesized that rifampin affects pharmacokinetics of the P-glycoprotein substrate talinolol, a beta1-blocker without appreciable metabolic disposition but intense intestinal secretion in human beings.	Rifampin	31-39	ATP binding cassette subfamily B member 1	Homo sapiens	72-86
11061574-6	2000	Treatment with rifampin resulted in a significantly increased expression of duodenal P-glycoprotein content 4.2-fold (2.9, 6.51) (Western blot) and messenger RNA was increased in six of the eight volunteers.	Rifampin	15-23	ATP binding cassette subfamily B member 1	Homo sapiens	85-99
11144420-5	2000	The overall frequency of drug resistance traits among the 1,749 MRSA strains was high (over 70% and up to and over 90% of the strains) to ciprofloxacin, erythromycin, clindamycin, gentamicin, and tetracycline, and was somewhat less frequent to sulfamethoxazole-trimethoprim (45%), chloramphenicol (30%), and rifampin (38%).	Rifampin	308-316	solute carrier family 9 member A6	Homo sapiens	64-68
11129093-1	2000	It has recently been shown that P-glycoprotein (P-gp) is inducible by rifampicin in the human gut as shown in intestinal biopsies.	Rifampin	70-80	ATP binding cassette subfamily B member 1	Homo sapiens	32-46
11129093-1	2000	It has recently been shown that P-glycoprotein (P-gp) is inducible by rifampicin in the human gut as shown in intestinal biopsies.	Rifampin	70-80	ATP binding cassette subfamily B member 1	Homo sapiens	48-52
11129093-8	2000	Cytochrome P4503A4 (CYP3A4) inducibility was measured by comparing the urinary metabolic ratio of 6beta-hydroxycortisol/cortisol on day 14 and 19, Lymphocyte P-gp expression and activity was not induced by rifampicin, while it increased CYP3A4 activity from 5.0 +/- 4.0 to 22.9 +/- 16.6 (P &lt; 0.001).	Rifampin	206-216	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-18
11129093-8	2000	Cytochrome P4503A4 (CYP3A4) inducibility was measured by comparing the urinary metabolic ratio of 6beta-hydroxycortisol/cortisol on day 14 and 19, Lymphocyte P-gp expression and activity was not induced by rifampicin, while it increased CYP3A4 activity from 5.0 +/- 4.0 to 22.9 +/- 16.6 (P &lt; 0.001).	Rifampin	206-216	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	20-26
10975612-0	2000	Quantitative RT-PCR for CYP3A4 mRNA in human peripheral lymphocytes: induction of CYP3A4 in lymphocytes and in liver by rifampicin.	Rifampin	120-130	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	82-88
10859152-9	2000	Under identical experimental conditions, rifampicin and lansoprazole significantly elevated CYP3A4 mRNA expression (P &lt;.05), whereas 3-methylcholanthrene, omeprazole, and dimethyl sulfoxide were without significant effect.	Rifampin	41-51	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	92-98
10924340-4	2000	In parallel, IL-6 decreases both rifampicin- and phenobarbital-mediated induction of CYP2B6, CYP2C8, CYP2C9, and CYP3A4.	Rifampin	33-43	interleukin 6	Homo sapiens	13-17
10924340-4	2000	In parallel, IL-6 decreases both rifampicin- and phenobarbital-mediated induction of CYP2B6, CYP2C8, CYP2C9, and CYP3A4.	Rifampin	33-43	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	85-91
10924340-4	2000	In parallel, IL-6 decreases both rifampicin- and phenobarbital-mediated induction of CYP2B6, CYP2C8, CYP2C9, and CYP3A4.	Rifampin	33-43	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	93-99
10924340-4	2000	In parallel, IL-6 decreases both rifampicin- and phenobarbital-mediated induction of CYP2B6, CYP2C8, CYP2C9, and CYP3A4.	Rifampin	33-43	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	101-107
10924340-4	2000	In parallel, IL-6 decreases both rifampicin- and phenobarbital-mediated induction of CYP2B6, CYP2C8, CYP2C9, and CYP3A4.	Rifampin	33-43	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	113-119
10908304-3	2000	We report that dexamethasone increases both retinoid X receptor-alpha (RXRalpha) and PXR mRNA expression in cultured human hepatocytes, whereas PXR activators such as rifampicin and clotrimazole do not.	Rifampin	167-177	nuclear receptor subfamily 1 group I member 2	Homo sapiens	144-147
10869292-0	2000	Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2.	Rifampin	17-27	solute carrier organic anion transporter family, member 1a1	Rattus norvegicus	120-125
10869292-0	2000	Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2.	Rifampin	17-27	solute carrier organic anion transporter family, member 1a4	Rattus norvegicus	130-135
10869292-6	2000	Rifampicin potently inhibited Oatp2-mediated taurocholate uptake, but did not interfere with Oatp1-mediated taurocholate uptake.	Rifampin	0-10	solute carrier organic anion transporter family, member 1a4	Rattus norvegicus	30-35
10869292-7	2000	Similar effects of rifamycin SV and rifampicin were found for Oatp1- and Oatp2-mediated estradiol-17beta-glucuronide transport.	Rifampin	36-46	solute carrier organic anion transporter family, member 1a1	Rattus norvegicus	62-67
10869292-7	2000	Similar effects of rifamycin SV and rifampicin were found for Oatp1- and Oatp2-mediated estradiol-17beta-glucuronide transport.	Rifampin	36-46	solute carrier organic anion transporter family, member 1a4	Rattus norvegicus	73-78
11061580-8	2000	The quinidine/rifampin combination resulted in selective CYP2D6 inhibition and induction of all other enzymes evaluated over this time period, suggesting that predictable complex interactions occur with the drug combination.	Rifampin	14-22	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	57-63
10873607-4	2000	Model inducers like rifampicin, phenobarbital, or 3-methylcholanthrene and beta-naphtoflavone were able to induce CYP1A or CYP3A4 as well as EROD or T6H activities for up to 30 days.	Rifampin	20-30	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	123-129
10869292-9	2000	These results demonstrate that rifamycin SV and rifampicin exhibit differential inhibition on Oatp1 and Oatp2, and identify rifampicin as a selective Oatp2 inhibitor.	Rifampin	48-58	solute carrier organic anion transporter family, member 1a1	Rattus norvegicus	94-99
10869292-9	2000	These results demonstrate that rifamycin SV and rifampicin exhibit differential inhibition on Oatp1 and Oatp2, and identify rifampicin as a selective Oatp2 inhibitor.	Rifampin	48-58	solute carrier organic anion transporter family, member 1a4	Rattus norvegicus	104-109
10869292-9	2000	These results demonstrate that rifamycin SV and rifampicin exhibit differential inhibition on Oatp1 and Oatp2, and identify rifampicin as a selective Oatp2 inhibitor.	Rifampin	124-134	solute carrier organic anion transporter family, member 1a4	Rattus norvegicus	150-155
10903421-4	2000	The goal of these investigations was to evaluate the effect of altering culture conditions on rifampin-mediated induction of CYP3A isoforms in cultured porcine hepatocytes.	Rifampin	94-102	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	125-130
10824630-3	2000	METHODS: Six extensive metabolizers of CYP2D6 (age, 70.5 +/- 3.5 years) ingested 600 mg rifampin once daily for 9 consecutive days.	Rifampin	88-96	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	39-45
10620362-12	2000	Finally, in both chicken embryo liver and chicken hepatoma cells (LMH), CYP3A37 mRNA was increased after treatment with typical CYP3A inducers, such as metyrapone, phenobarbital, dexamethasone, and pregnenolone 16alpha-carbonitrile, but not rifampicin.	Rifampin	241-251	cytochrome P450 family 3 subfamily A member 5	Gallus gallus	72-79
10772626-6	2000	Although the responses to dexamethasone and rifampicin were both increased by both receptors, dexamethasone activation of CYP3A4 was similar for both the hGR and the hPXR, whereas rifampicin-dependent activation favored the hPXR.	Rifampin	180-190	nuclear receptor subfamily 1 group I member 2	Homo sapiens	224-228
10727519-2	2000	Recently, rifampicin has been reported to activate the glucocorticoid receptor (GR) in human hepatocytes.	Rifampin	10-20	nuclear receptor subfamily 3 group C member 1	Homo sapiens	55-78
10727519-2	2000	Recently, rifampicin has been reported to activate the glucocorticoid receptor (GR) in human hepatocytes.	Rifampin	10-20	nuclear receptor subfamily 3 group C member 1	Homo sapiens	80-82
10727519-3	2000	Because there is evidence that increased levels of glucocorticoids may induce cognitive impairment, sometimes culminating in depression, the side effects of rifampicin may result from GR activation in central nerve cells.	Rifampin	157-167	nuclear receptor subfamily 3 group C member 1	Homo sapiens	184-186
10727519-6	2000	Rifampicin was also inactive in the same HepG2 cell line that was originally used to demonstrate the effect of rifampicin on GR.	Rifampin	111-121	nuclear receptor subfamily 3 group C member 1	Homo sapiens	125-127
10706865-4	2000	Finally, in the MAIPA assay, the rifampicin-dependent antibody almost completely cross-blocked the binding of the anti-GPIX mAb (SZ1) to platelets.	Rifampin	33-43	glycoprotein IX platelet	Homo sapiens	119-123
10706865-6	2000	This finding not only confirms that the epitope of the rifampicin-dependent antibody is on GPIX but it is also identical to or located in close proximity to that of the quinine-dependent antibody and SZ1.	Rifampin	55-65	glycoprotein IX platelet	Homo sapiens	91-95
10751073-0	2000	Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity.	Rifampin	75-85	N-acetyltransferase 2	Homo sapiens	5-26
10751073-2	2000	OBJECTIVE: To elucidate the relationship between N-acetyltransferase 2 (NAT2) genotype and the incidence of isoniazid + rifampicin-induced hepatotoxicity.	Rifampin	120-130	N-acetyltransferase 2	Homo sapiens	49-70
10751073-2	2000	OBJECTIVE: To elucidate the relationship between N-acetyltransferase 2 (NAT2) genotype and the incidence of isoniazid + rifampicin-induced hepatotoxicity.	Rifampin	120-130	N-acetyltransferase 2	Homo sapiens	72-76
10648470-6	2000	Cyclosporin A, rifamycin SV, rifampicin, and glibenclamide cis-inhibited Bsep-mediated bile salt transport to similar extents as ATP-dependent taurocholate transport in cLPM vesicles.	Rifampin	29-39	ATP binding cassette subfamily B member 11	Homo sapiens	73-77
10673364-4	2000	Using an RT-competitive PCR (RT-cPCR) with beta-actin as the standard in this study, the constitutive and rifampicin (RFP)-induced expression of CYP3A4, CYP2C9, CYP2E1, and CYP1A2 mRNA in the HepG2 cells could be quantitatively and reproducibly determined.	Rifampin	106-116	POTE ankyrin domain family member F	Homo sapiens	43-53
10673364-4	2000	Using an RT-competitive PCR (RT-cPCR) with beta-actin as the standard in this study, the constitutive and rifampicin (RFP)-induced expression of CYP3A4, CYP2C9, CYP2E1, and CYP1A2 mRNA in the HepG2 cells could be quantitatively and reproducibly determined.	Rifampin	106-116	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	145-151
10673364-4	2000	Using an RT-competitive PCR (RT-cPCR) with beta-actin as the standard in this study, the constitutive and rifampicin (RFP)-induced expression of CYP3A4, CYP2C9, CYP2E1, and CYP1A2 mRNA in the HepG2 cells could be quantitatively and reproducibly determined.	Rifampin	106-116	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	153-159
10673364-4	2000	Using an RT-competitive PCR (RT-cPCR) with beta-actin as the standard in this study, the constitutive and rifampicin (RFP)-induced expression of CYP3A4, CYP2C9, CYP2E1, and CYP1A2 mRNA in the HepG2 cells could be quantitatively and reproducibly determined.	Rifampin	106-116	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	161-167
10673364-4	2000	Using an RT-competitive PCR (RT-cPCR) with beta-actin as the standard in this study, the constitutive and rifampicin (RFP)-induced expression of CYP3A4, CYP2C9, CYP2E1, and CYP1A2 mRNA in the HepG2 cells could be quantitatively and reproducibly determined.	Rifampin	106-116	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	173-179
10772631-0	2000	Rabbit pregnane X receptor is activated by rifampicin.	Rifampin	43-53	nuclear receptor subfamily 1, group I, member 2	Mus musculus	7-26
10772631-7	2000	Rifampicin treatment of CV-1 cells cotransfected with a rabbit PXR expression plasmid and a luciferase reporter construct containing two copies of the DR3 enhancer from CYP3A23 produced a 6-fold induction of luciferase activity.	Rifampin	0-10	nuclear receptor subfamily 1 group I member 2	Oryctolagus cuniculus	63-66
10803787-0	2000	Rifampicin suppresses hepatic CYP2E1 expression and minimizes DNA injury caused by carbon tetrachloride in perivenular hepatocytes of mice.	Rifampin	0-10	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	30-36
10803787-1	2000	BACKGROUND: Rifampicin has been shown to increase during activities of serum transaminases and to decrease in cytochrome P-450-mediated monooxygenase activities in livers of mice treated with carbon tetrachloride (CCl4).	Rifampin	12-22	chemokine (C-C motif) ligand 4	Mus musculus	214-218
10803787-2	2000	Although these findings suggest that rifampicin prevents hepatocyte damage caused by CCl4, detailed information on the protective effects is not available.	Rifampin	37-47	chemokine (C-C motif) ligand 4	Mus musculus	85-89
10803787-6	2000	RESULTS: Rifampicin prevented the denaturation and fragmentation of DNA caused by CCl4 in perivenular hepatocytes except for those located within two or three cell layers surrounding the central venule.	Rifampin	9-19	chemokine (C-C motif) ligand 4	Mus musculus	82-86
10803787-7	2000	Furthermore, CYP2E1 decreased in liver homogenates or microsomes from rifampicin-treated animals.	Rifampin	70-80	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	13-19
10803787-8	2000	It is therefore likely that rifampicin suppresses expression of CYP2E1 and protects CCl4-mediated DNA damage of hepatocytes by inhibiting formation of free radicals.	Rifampin	28-38	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	64-70
10803787-8	2000	It is therefore likely that rifampicin suppresses expression of CYP2E1 and protects CCl4-mediated DNA damage of hepatocytes by inhibiting formation of free radicals.	Rifampin	28-38	chemokine (C-C motif) ligand 4	Mus musculus	84-88
10803787-9	2000	In addition, perivenular hepatocytes except for those surrounding the venule showed negative immunoreaction for p53 and bcl2 in rifampicin+CCl4-treated animals.	Rifampin	128-138	B cell leukemia/lymphoma 2	Mus musculus	120-124
10729196-12	2000	Upon incubation with phenobarbital and rifampin (rifampicin), human hepatocytes increased CYP 2B6, 3A4, and 3A5 among others.	Rifampin	39-47	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	90-97
10729196-12	2000	Upon incubation with phenobarbital and rifampin (rifampicin), human hepatocytes increased CYP 2B6, 3A4, and 3A5 among others.	Rifampin	49-59	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	90-97
10681370-1	2000	Cytochrome P-4503A, CYP2B, and P-450 reductase are induced by glucocorticoids, antiglucocorticoids such as pregnenolone 16alpha-carbonitrile, and drugs such as rifampin and phenobarbital.	Rifampin	160-168	cytochrome P450, family 2, subfamily b, polypeptide 10	Mus musculus	20-25
10681370-8	2000	Similarly, rifampin induced CYP3A in either wild-type or glucocorticoid receptor-null mice.	Rifampin	11-19	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	28-33
10681370-8	2000	Similarly, rifampin induced CYP3A in either wild-type or glucocorticoid receptor-null mice.	Rifampin	11-19	nuclear receptor subfamily 3, group C, member 1	Mus musculus	57-80
10681370-9	2000	Despite reports that rifampin is a nonsteroidal ligand for the human glucocorticoid receptor, rifampin failed to induce tyrosine aminotransferase in mice regardless of glucocorticoid receptor genotype, and rifampin did not compete for ligand binding to either mouse or human glucocorticoid receptor.	Rifampin	21-29	nuclear receptor subfamily 3 group C member 1	Homo sapiens	69-92
10752642-8	2000	The capacity of troglitazone to induce CYP3A4 was between that of rifampin (EC50 = 0.8 microM) and dexamethasone (40-50 microM).	Rifampin	66-74	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	39-45
10706193-9	2000	Moreover, induction of intestinal P-glycoprotein by rifampin has now been identified as the major underlying mechanism of reduced digoxin plasma concentrations during concomitant rifampin therapy.	Rifampin	52-60	ATP binding cassette subfamily B member 1	Homo sapiens	34-48
10620362-12	2000	Finally, in both chicken embryo liver and chicken hepatoma cells (LMH), CYP3A37 mRNA was increased after treatment with typical CYP3A inducers, such as metyrapone, phenobarbital, dexamethasone, and pregnenolone 16alpha-carbonitrile, but not rifampicin.	Rifampin	241-251	cytochrome P450 family 3 subfamily A member 5	Gallus gallus	72-77
10611146-5	2000	The pregnane X receptor (PXR), which has recently been shown to mediate the transcriptional induction of CYP3A4 expression in response to rifampicin, was activated by metyrapone in CV-1 cells transiently cotransfected with an expression vector encoding the human PXR and a reporter construct containing the everted repeat sequence that confers CYP3A4 induction responsiveness to inducers within its promoter.	Rifampin	138-148	nuclear receptor subfamily 1 group I member 2	Homo sapiens	25-28
10611140-5	2000	The amplitude of the increase in CYP3A4 protein and activity by 25 microM eletriptan was significantly lower, with a mean of 19 (P =.0015) and 26% (P =.0002), respectively, of that observed in response to 25 microM rifampicin.	Rifampin	215-225	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	33-39
10611140-6	2000	CYP2A6, a protein with minor pharmacological implication, also was induced by eletriptan and rifampicin in two cultures but was not detected in the others.	Rifampin	93-103	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	0-6
10611146-5	2000	The pregnane X receptor (PXR), which has recently been shown to mediate the transcriptional induction of CYP3A4 expression in response to rifampicin, was activated by metyrapone in CV-1 cells transiently cotransfected with an expression vector encoding the human PXR and a reporter construct containing the everted repeat sequence that confers CYP3A4 induction responsiveness to inducers within its promoter.	Rifampin	138-148	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	105-111
10654647-3	2000	Mutations in the rpoB gene identified by LiPA that confer resistance to rifampicin (RMP) were confirmed by DNA sequencing, while susceptibilities were confirmed by the proportion method and BACTEC.	Rifampin	72-82	lipase A, lysosomal acid type	Homo sapiens	41-45
10654647-3	2000	Mutations in the rpoB gene identified by LiPA that confer resistance to rifampicin (RMP) were confirmed by DNA sequencing, while susceptibilities were confirmed by the proportion method and BACTEC.	Rifampin	84-87	lipase A, lysosomal acid type	Homo sapiens	41-45
10570062-0	1999	The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module.	Rifampin	90-100	nuclear receptor subfamily 1 group I member 2	Homo sapiens	17-36
10628745-8	2000	For example, the macrolide antibiotic rifampicin, the antidiabetic drug troglitazone, and the hypocholesterolemic drug SR12813 are efficacious activators of the human and rabbit PXR but have little activity on the rat and mouse PXR.	Rifampin	38-48	nuclear receptor subfamily 1 group I member 2	Oryctolagus cuniculus	178-181
10628745-8	2000	For example, the macrolide antibiotic rifampicin, the antidiabetic drug troglitazone, and the hypocholesterolemic drug SR12813 are efficacious activators of the human and rabbit PXR but have little activity on the rat and mouse PXR.	Rifampin	38-48	nuclear receptor subfamily 1, group I, member 2	Mus musculus	228-231
10570062-0	1999	The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module.	Rifampin	90-100	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	80-86
10570062-1	1999	Cytochrome P-450 3A4 (CYP3A4), the predominant cytochrome P-450 expressed in adult human liver, is subject to transcriptional induction by a variety of structurally unrelated xenobiotics, including the antibiotic rifampicin.	Rifampin	213-223	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-20
10570062-1	1999	Cytochrome P-450 3A4 (CYP3A4), the predominant cytochrome P-450 expressed in adult human liver, is subject to transcriptional induction by a variety of structurally unrelated xenobiotics, including the antibiotic rifampicin.	Rifampin	213-223	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	22-28
10570062-4	1999	Rifampicin-inducible transcription of the reporter gene was observed only with the longest construct, which encompassed bases -13000 to +53 of CYP3A4 (3-fold induction).	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	143-149
10570062-5	1999	The responsive region was functional regardless of its position or orientation relative to the proximal promoter of CYP3A4 and was capable of conferring rifampicin-inducible expression on a heterologous promoter.	Rifampin	153-163	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	116-122
10570062-9	1999	Cotransfection of responsive constructs with a hPXR expression vector substantially increased the rifampicin-inducibility to approximately 50-fold.	Rifampin	98-108	nuclear receptor subfamily 1 group I member 2	Homo sapiens	47-51
10628900-9	1999	The results indicate that the inductive effect of rifampicin is likely to be of clinical relevance particularly when used concomitantly with drugs metabolized by CYP3A4.	Rifampin	50-60	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	162-168
10634135-4	1999	Four received ALP after a 2-day pretreatment with ketoconazole, an inhibitor of CYP3A4, and four normal volunteers received ALP after 4 days of rifampin, an inducer of CYP3A4.	Rifampin	144-152	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	168-174
10563691-1	1999	Rifampicin has been successfully used as an adjunct to vancomycin therapy in several clinical conditions of MRSA infections such as endocarditis, ventriculoperitoneal shunts and septicaemia.	Rifampin	0-10	solute carrier family 9 member A6	Homo sapiens	108-112
10545214-7	1999	The expression of CYP2A15 mRNA was slightly induced by treatment with either rifampicin or 3-methylcholanthrene.	Rifampin	77-87	cytochrome P450 2A15	Cricetulus griseus	18-25
10563691-3	1999	The present prospective study was conducted to evaluate the efficacy of rifampicin as an adjunct therapy in burn cases with MRSA septicaemia not responding well to vancomycin.	Rifampin	72-82	solute carrier family 9 member A6	Homo sapiens	124-128
10563691-11	1999	Institution of rifampicin, as an adjunct to vancomycin therapy to which the MRSA isolates were susceptible, showed a dramatic clinical response and survival of grafts.	Rifampin	15-25	solute carrier family 9 member A6	Homo sapiens	76-80
10563691-13	1999	The present study thus confirms the efficacy of clinical use of rifampicin as an adjunct in vancomycin nonresponding cases of MRSA septicaemia in burns.	Rifampin	64-74	solute carrier family 9 member A6	Homo sapiens	126-130
10486655-9	1999	Following explanation can be hypothesis: several antihypertensive drugs are liver-metabolised by microsomal cytochrome P450 3A4 isoform that could explain a significantly decreased half-life in association with enzymatic inducers, such as rifampicine or antiepileptic drugs (phenobarbital, phenytoin or carbamazepine).	Rifampin	239-250	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	108-127
10506631-2	1999	RIF treatment with combined pentoxifylline (PTX) and tocopherol (Vit E) was prompted by recent advances in cellular and molecular biology that have improved researchers" understanding of radiation-induced late-injury mechanisms and by the excellent results from our previous human and animal studies.	Rifampin	0-3	vitrin	Homo sapiens	65-68
10591535-16	1999	Thus, induction of both phase I pathways (CYP3A4/1A2) and phase II pathways (glucuronidation, sulfation) of propafenone by rifampicin resulted in a clinically relevant metabolic drug interaction which was more pronounced in extensive metabolizers than in poor metabolizers with regard to percentage decrease in bioavailability of propafenone.	Rifampin	123-133	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	42-52
10462436-3	1999	Roles for three "orphan" nuclear receptor superfamily members, designated CAR, PXR, and PPAR, in respectively mediating the induction of hepatic P450s belonging to families CYP2, CYP3, and CYP4 in response to the prototypical inducers phenobarbital (CAR), pregnenolone 16alpha-carbonitrile and rifampicin (PXR), and clofibric acid (PPAR) have now been established.	Rifampin	294-304	CXADR pseudogene 1	Homo sapiens	74-77
10462436-3	1999	Roles for three "orphan" nuclear receptor superfamily members, designated CAR, PXR, and PPAR, in respectively mediating the induction of hepatic P450s belonging to families CYP2, CYP3, and CYP4 in response to the prototypical inducers phenobarbital (CAR), pregnenolone 16alpha-carbonitrile and rifampicin (PXR), and clofibric acid (PPAR) have now been established.	Rifampin	294-304	nuclear receptor subfamily 1 group I member 2	Homo sapiens	79-82
10462436-3	1999	Roles for three "orphan" nuclear receptor superfamily members, designated CAR, PXR, and PPAR, in respectively mediating the induction of hepatic P450s belonging to families CYP2, CYP3, and CYP4 in response to the prototypical inducers phenobarbital (CAR), pregnenolone 16alpha-carbonitrile and rifampicin (PXR), and clofibric acid (PPAR) have now been established.	Rifampin	294-304	peroxisome proliferator activated receptor alpha	Homo sapiens	88-92
10462436-3	1999	Roles for three "orphan" nuclear receptor superfamily members, designated CAR, PXR, and PPAR, in respectively mediating the induction of hepatic P450s belonging to families CYP2, CYP3, and CYP4 in response to the prototypical inducers phenobarbital (CAR), pregnenolone 16alpha-carbonitrile and rifampicin (PXR), and clofibric acid (PPAR) have now been established.	Rifampin	294-304	peptidylprolyl isomerase F	Homo sapiens	179-183
10462436-3	1999	Roles for three "orphan" nuclear receptor superfamily members, designated CAR, PXR, and PPAR, in respectively mediating the induction of hepatic P450s belonging to families CYP2, CYP3, and CYP4 in response to the prototypical inducers phenobarbital (CAR), pregnenolone 16alpha-carbonitrile and rifampicin (PXR), and clofibric acid (PPAR) have now been established.	Rifampin	294-304	CXADR pseudogene 1	Homo sapiens	250-253
10462436-3	1999	Roles for three "orphan" nuclear receptor superfamily members, designated CAR, PXR, and PPAR, in respectively mediating the induction of hepatic P450s belonging to families CYP2, CYP3, and CYP4 in response to the prototypical inducers phenobarbital (CAR), pregnenolone 16alpha-carbonitrile and rifampicin (PXR), and clofibric acid (PPAR) have now been established.	Rifampin	294-304	nuclear receptor subfamily 1 group I member 2	Homo sapiens	306-309
10462436-3	1999	Roles for three "orphan" nuclear receptor superfamily members, designated CAR, PXR, and PPAR, in respectively mediating the induction of hepatic P450s belonging to families CYP2, CYP3, and CYP4 in response to the prototypical inducers phenobarbital (CAR), pregnenolone 16alpha-carbonitrile and rifampicin (PXR), and clofibric acid (PPAR) have now been established.	Rifampin	294-304	peroxisome proliferator activated receptor alpha	Homo sapiens	332-336
10470557-2	1999	Penicillins, certain cephalosporins, carbapenems, fluoroquinolones, vancomycin, and rifampin provide the highest ratios of CSF levels to the MBC for common infecting organisms.	Rifampin	84-92	colony stimulating factor 2	Homo sapiens	123-126
10421615-5	1999	The maximal CYP3A activity detected after treatment with Taxol or rifampicin was similar in six separate human hepatocyte cultures, suggesting that the cultures have achieved a limit of maximally inducible CYP3A.	Rifampin	66-76	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	12-17
10704137-2	1999	The resolution of ternary mixtures of rifampicin, isoniazid and pyrazinamide has been accomplished by using partial least squares (PLS-1) regression analysis.	Rifampin	38-48	plastin 1	Homo sapiens	131-136
10403778-5	1999	Using electrophoretic mobility shift assays and cotransfection experiments we show that this element is able to bind the PXR:RXR complex and transactivates the expression of a down stream promoter in response to rifampicin, clotrimazole, and RU-486, three compounds known to specifically activate the human PXR.	Rifampin	212-222	nuclear receptor subfamily 1 group I member 2	Homo sapiens	121-124
10403778-5	1999	Using electrophoretic mobility shift assays and cotransfection experiments we show that this element is able to bind the PXR:RXR complex and transactivates the expression of a down stream promoter in response to rifampicin, clotrimazole, and RU-486, three compounds known to specifically activate the human PXR.	Rifampin	212-222	retinoid X receptor alpha	Homo sapiens	125-128
10403778-5	1999	Using electrophoretic mobility shift assays and cotransfection experiments we show that this element is able to bind the PXR:RXR complex and transactivates the expression of a down stream promoter in response to rifampicin, clotrimazole, and RU-486, three compounds known to specifically activate the human PXR.	Rifampin	212-222	nuclear receptor subfamily 1 group I member 2	Homo sapiens	307-310
10493554-3	1999	We describe a case of rifampicin-associated acute renal failure, with biopsy findings of tubulointerstitial nephritis; inflammatory cells were characterized by immunohistochemistry, which showed immunoreactivity for CD3 and CD5 (T lymphocytes) and for CD68 (macrophages).	Rifampin	22-32	CD5 molecule	Homo sapiens	224-227
10493554-3	1999	We describe a case of rifampicin-associated acute renal failure, with biopsy findings of tubulointerstitial nephritis; inflammatory cells were characterized by immunohistochemistry, which showed immunoreactivity for CD3 and CD5 (T lymphocytes) and for CD68 (macrophages).	Rifampin	22-32	CD68 molecule	Homo sapiens	252-256
10411543-0	1999	The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.	Rifampin	72-80	ATP binding cassette subfamily B member 1	Homo sapiens	23-37
10411543-2	1999	On the basis of clinical observations of patients in whom digoxin levels decreased considerably when treated with rifampin, we hypothesized that concomitant rifampin therapy may affect digoxin disposition in humans by induction of P-gp.	Rifampin	114-122	ATP binding cassette subfamily B member 1	Homo sapiens	231-235
10411543-2	1999	On the basis of clinical observations of patients in whom digoxin levels decreased considerably when treated with rifampin, we hypothesized that concomitant rifampin therapy may affect digoxin disposition in humans by induction of P-gp.	Rifampin	157-165	ATP binding cassette subfamily B member 1	Homo sapiens	231-235
10381771-5	1999	Oatp1-mediated gadoxetate uptake (100 microM) could be inhibited by 10 microM bromosulfophthalein (45%), 200 microM taurocholate (92%), 100 microM rifamycin SV (97%), and 100 microM rifampicin (51%).	Rifampin	182-192	solute carrier organic anion transporter family, member 1a1	Rattus norvegicus	0-5
10348770-2	1999	Here it is shown that the Escherichia coli msbB mutant, which elaborates defective, penta-acylated lipid A, is practically as resistant to a representative set of hydrophobic solutes (rifampin, fusidic acid, erythromycin, clindamycin, and azithromycin) as the parent-type control strain.	Rifampin	184-192	lipid A biosynthesis (KDO)2-(lauroyl)-lipid IVA acyltransferase	Escherichia coli	43-47
10463384-3	1999	We examined the 6beta-OHF/F ratio in urine of common marmosets administered with rifampicin, a potent inducer of CYP3A, to evaluate the usefulness of common marmosets for the prediction of CYP3A induction.	Rifampin	81-91	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	113-118
10354960-9	1999	The identification of CYP3A4 as a low-affinity nortriptyline E-10-hydroxylase explains the ability of poor metabolizers of debrisoquin to hydroxylate nortriptyline, as well as the increased in vivo clearance via this pathway caused by CYP3A4-inducing drugs such as pentobarbital, carbamazepine, and rifampin.	Rifampin	299-307	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	22-28
10354960-9	1999	The identification of CYP3A4 as a low-affinity nortriptyline E-10-hydroxylase explains the ability of poor metabolizers of debrisoquin to hydroxylate nortriptyline, as well as the increased in vivo clearance via this pathway caused by CYP3A4-inducing drugs such as pentobarbital, carbamazepine, and rifampin.	Rifampin	299-307	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	235-241
10220562-1	1999	It has recently been reported that rifampicin activates the glucocorticoid receptor and acts as an immunosuppressive drug.	Rifampin	35-45	nuclear receptor subfamily 3 group C member 1	Homo sapiens	60-83
10591535-0	1999	Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6.	Rifampin	16-26	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	102-108
10591535-3	1999	However, non-CYP2D6-dependent pathways may be induced as a case report described dramatically lowered plasma concentrations of propafenone with loss of dysrhythmia control associated with rifampicin treatment.	Rifampin	188-198	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	13-19
10591535-4	1999	Therefore, this study aimed to investigate induction properties of rifampicin on propafenone disposition in extensive metabolizers and poor metabolizers of CYP2D6.	Rifampin	67-77	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	156-162
10408915-0	1999	Inhibition of multidrug resistance-associated protein (MRP) activity by rifampicin in human multidrug-resistant lung tumor cells.	Rifampin	72-82	ATP binding cassette subfamily C member 3	Homo sapiens	14-53
10408915-0	1999	Inhibition of multidrug resistance-associated protein (MRP) activity by rifampicin in human multidrug-resistant lung tumor cells.	Rifampin	72-82	ATP binding cassette subfamily C member 3	Homo sapiens	55-58
10408915-2	1999	In order to look for compounds that can lead to reversal of such a resistance, the antituberculosis compound rifampicin, belonging to the chemical class of rifamycins, was examined for its effect on MRP activity in human multidrug resistant lung cancer GLC4/ADR cells.	Rifampin	109-119	ATP binding cassette subfamily C member 3	Homo sapiens	199-202
10408915-3	1999	Rifampicin was shown to increase accumulation of the MRP substrate calcein in GLC4/ADR cells in a dose-dependent manner by inhibiting its MRP-mediated efflux from the cells; it also enhanced intracellular retention of another substrate of MRP such as the anticancer drug vincristine in the resistant cells.	Rifampin	0-10	ATP binding cassette subfamily C member 3	Homo sapiens	53-56
10408915-3	1999	Rifampicin was shown to increase accumulation of the MRP substrate calcein in GLC4/ADR cells in a dose-dependent manner by inhibiting its MRP-mediated efflux from the cells; it also enhanced intracellular retention of another substrate of MRP such as the anticancer drug vincristine in the resistant cells.	Rifampin	0-10	ATP binding cassette subfamily C member 3	Homo sapiens	138-141
10408915-3	1999	Rifampicin was shown to increase accumulation of the MRP substrate calcein in GLC4/ADR cells in a dose-dependent manner by inhibiting its MRP-mediated efflux from the cells; it also enhanced intracellular retention of another substrate of MRP such as the anticancer drug vincristine in the resistant cells.	Rifampin	0-10	ATP binding cassette subfamily C member 3	Homo sapiens	138-141
10408915-6	1999	These results therefore indicate that rifamycins, including rifampicin, probably constitute a new chemical class of modulators down-regulating MRP-mediated drug transport.	Rifampin	60-70	ATP binding cassette subfamily C member 3	Homo sapiens	143-146
10220562-3	1999	We have used reporter gene assays to measure the trans-activating and trans-repressing capacity of the glucocorticoid receptor after treating A549 human alveolar cells with rifampicin.	Rifampin	173-183	nuclear receptor subfamily 3 group C member 1	Homo sapiens	103-126
10379985-8	1999	Rifampicin induced (2-3-fold) cortisol 6beta-hydroxylase, S-mephenytoin 4"-hydroxylase, S-mephenytoin N-demethylase and tolbutamide hydroxylase activities, the O-dealkylations of methoxy-, ethoxy- and propoxyresorufin and CYP2C- and CYP3A-immunorelated proteins in monkey.	Rifampin	0-10	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	58-86
10943389-7	1999	In this temperature-sensitive strain, the recovery of active aldehyde dehydrogenase, in the presence of rifampicin but not of chloramphenicol, when cells grown at 37 degrees C were shifted to 30 degrees C indicated that this mutation affected the folding process of the protein at the restrictive temperature.	Rifampin	104-114	Aldehyde dehydrogenase	Escherichia coli	61-83
10223773-2	1999	Rifampin (INN, rifampicin) is a potent inducer of CYP3A4 and some other CYP enzymes.	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	50-56
10223773-2	1999	Rifampin (INN, rifampicin) is a potent inducer of CYP3A4 and some other CYP enzymes.	Rifampin	15-25	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	50-56
10223773-14	1999	Concomitant use of rifampin or other potent inducers of CYP3A4 with ondansetron may result in a reduced antiemetic effect, particularly after oral administration of ondansetron.	Rifampin	19-27	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	56-62
10037683-5	1999	In addition to PBREM, CAR also transactivates the steroid/rifampicin-response element of the human CYP3A4 gene in HepG2 cells.	Rifampin	58-68	CXADR pseudogene 1	Homo sapiens	22-25
10037683-5	1999	In addition to PBREM, CAR also transactivates the steroid/rifampicin-response element of the human CYP3A4 gene in HepG2 cells.	Rifampin	58-68	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	99-105
10339711-3	1999	He became asymptomatic on treatment with tetracycline, rifampicin and streptomycin with significant CSF response.	Rifampin	55-65	colony stimulating factor 2	Homo sapiens	100-103
9987705-3	1999	A pharmacokinetic interaction with rifampin, an antituberculosis agent and potent inducer of CYP3A4 and P-glycoprotein, and tacrolimus was evaluated in six healthy male volunteers.	Rifampin	35-43	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	93-99
10219967-9	1999	Induction of CYP3A4-dependent reporter gene expression and enhancement of the induction by the glucocorticoid receptor was also observed with pregnenolone-16alpha-carbonitrile (PCN), rifampicin, phenytoin, carbamazepine, phenylbutazone and phenobarbitone, all known in vivo inducers of CYP3A4 in man.	Rifampin	183-193	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	13-19
10219967-9	1999	Induction of CYP3A4-dependent reporter gene expression and enhancement of the induction by the glucocorticoid receptor was also observed with pregnenolone-16alpha-carbonitrile (PCN), rifampicin, phenytoin, carbamazepine, phenylbutazone and phenobarbitone, all known in vivo inducers of CYP3A4 in man.	Rifampin	183-193	nuclear receptor subfamily 3 group C member 1	Homo sapiens	95-118
9987705-3	1999	A pharmacokinetic interaction with rifampin, an antituberculosis agent and potent inducer of CYP3A4 and P-glycoprotein, and tacrolimus was evaluated in six healthy male volunteers.	Rifampin	35-43	ATP binding cassette subfamily B member 1	Homo sapiens	104-118
9987705-7	1999	Rifampin appears to induce both intestinal and hepatic metabolism of tacrolimus, most likely through induction of CYP3A and P-glycoprotein in the liver and small bowel.	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	114-119
9987705-7	1999	Rifampin appears to induce both intestinal and hepatic metabolism of tacrolimus, most likely through induction of CYP3A and P-glycoprotein in the liver and small bowel.	Rifampin	0-8	ATP binding cassette subfamily B member 1	Homo sapiens	124-138
10069527-10	1999	Neither in PMNs nor in lymphocytes, induction of CYP 3A protein expression was observed after rifampicin treatment despite overall induction of CYP 3A activity assessed by the urinary excretion of 6beta-hydroxycortisol.	Rifampin	94-104	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	49-55
10803271-3	1999	The strongest immunosuppression effect was demonstrated using rifampicin (39 ng/ml IFN-gamma) (Control: 123 +/- 29 ng/ml IFN-gamma, p &lt; 0.05).	Rifampin	62-72	interferon gamma	Mus musculus	83-92
10803271-3	1999	The strongest immunosuppression effect was demonstrated using rifampicin (39 ng/ml IFN-gamma) (Control: 123 +/- 29 ng/ml IFN-gamma, p &lt; 0.05).	Rifampin	62-72	interferon gamma	Mus musculus	121-130
10803271-6	1999	Our results suggest that rifampicin, ticarcillin, cephalosporins and aminoglycosides act as inhibitors of production IFN-gamma.	Rifampin	25-35	interferon gamma	Mus musculus	117-126
10548883-11	1999	Many of the PXR activators are widely used drugs such as dexamethasone, lovastatin, and rifampicin, whose induction of CYP3A levels causes them to promote the metabolism of other drugs, often with adverse consequences.	Rifampin	88-98	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	119-124
9825726-1	1998	Cultured rabbit hepatocytes were used to compare the relative activities of cytokines to inhibit the constitutive or rifampicin (RIF)-induced expression of the cytochrome P450 3A6 gene (CYP3A6).	Rifampin	117-127	cytochrome P450 3A6	Oryctolagus cuniculus	160-179
9862241-1	1998	AIMS: The N-deethylation of lignocaine to monoethylglycinexylidide (MEGX) is partially catalysed by the rifampicin inducible P-450 isoenzyme CYP3A4.	Rifampin	104-114	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	141-147
9862241-13	1998	CONCLUSION: An insignificant increase of MEGX plasma concentrations was found in 10 volunteers after induction of CYP3A4 activity by rifampicin.	Rifampin	133-143	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	114-120
9883615-2	1998	0.3-0.5 g).rifampicin (RFP.	Rifampin	11-21	tripartite motif containing 27	Homo sapiens	23-26
9950072-0	1998	Induction of hepatic mrp2 (cmrp/cmoat) gene expression in nonhuman primates treated with rifampicin or tamoxifen.	Rifampin	89-99	ATP binding cassette subfamily C member 2	Macaca mulatta	21-25
9950072-3	1998	Based on previous observations in rat hepatocytes, the inducibility of mrp2 gene expression in primate liver was investigated in rhesus monkeys treated with tamoxifen or rifampicin.	Rifampin	170-180	ATP binding cassette subfamily C member 2	Rattus norvegicus	71-75
9950072-4	1998	It was found that treatment with tamoxifen (25 mg/kg per day; over 7 days) or rifampicin (15 mg/kg per day; over 7 days) leading to an induction of cytochrome P450 3A4, resulted in a strong increase in mrp2 mRNA in the liver of male and female rhesus monkeys.	Rifampin	78-88	ATP binding cassette subfamily C member 2	Macaca mulatta	202-206
9871429-1	1998	BACKGROUND: Rifampin (INN, rifampicin) is a potent inducer of cytochrome P450 (CYP) enzymes involved in drug metabolism and therefore causes many drug interactions.	Rifampin	12-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-77
9871429-1	1998	BACKGROUND: Rifampin (INN, rifampicin) is a potent inducer of cytochrome P450 (CYP) enzymes involved in drug metabolism and therefore causes many drug interactions.	Rifampin	12-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-82
9871429-1	1998	BACKGROUND: Rifampin (INN, rifampicin) is a potent inducer of cytochrome P450 (CYP) enzymes involved in drug metabolism and therefore causes many drug interactions.	Rifampin	27-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-77
9871429-1	1998	BACKGROUND: Rifampin (INN, rifampicin) is a potent inducer of cytochrome P450 (CYP) enzymes involved in drug metabolism and therefore causes many drug interactions.	Rifampin	27-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	79-82
9871429-9	1998	CONCLUSIONS: Rifampin markedly reduces the plasma concentrations of tamoxifen and toremifene by inducing their CYP3A4-mediated metabolism.	Rifampin	13-21	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	111-117
9871429-10	1998	Concomitant use of rifampin or other potent inducers of CYP3A4 with tamoxifen and toremifene may reduce the efficacy of these antiestrogens.	Rifampin	19-27	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	56-62
9825726-1	1998	Cultured rabbit hepatocytes were used to compare the relative activities of cytokines to inhibit the constitutive or rifampicin (RIF)-induced expression of the cytochrome P450 3A6 gene (CYP3A6).	Rifampin	117-127	cytochrome P450 3A6	Oryctolagus cuniculus	186-192
9825726-1	1998	Cultured rabbit hepatocytes were used to compare the relative activities of cytokines to inhibit the constitutive or rifampicin (RIF)-induced expression of the cytochrome P450 3A6 gene (CYP3A6).	Rifampin	129-132	cytochrome P450 3A6	Oryctolagus cuniculus	160-179
9825726-1	1998	Cultured rabbit hepatocytes were used to compare the relative activities of cytokines to inhibit the constitutive or rifampicin (RIF)-induced expression of the cytochrome P450 3A6 gene (CYP3A6).	Rifampin	129-132	cytochrome P450 3A6	Oryctolagus cuniculus	186-192
9812178-19	1998	Rifampicin (rifampin), a potent CYP3A inducer, decreased the AUC of ritonavir by only 35%.	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	32-37
9770465-3	1998	hPAR was found to be efficiently activated by pregnanes and by clinically used drugs including rifampicin, an antibiotic known to selectively induce human but not murine CYP3A expression.	Rifampin	95-105	nuclear receptor subfamily 1 group I member 2	Homo sapiens	0-4
9770465-3	1998	hPAR was found to be efficiently activated by pregnanes and by clinically used drugs including rifampicin, an antibiotic known to selectively induce human but not murine CYP3A expression.	Rifampin	95-105	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	170-175
9812178-19	1998	Rifampicin (rifampin), a potent CYP3A inducer, decreased the AUC of ritonavir by only 35%.	Rifampin	12-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	32-37
9784933-16	1998	Inducers of cytochrome P450 (CYP) 3A4, e.g. rifampicin (rifampin) and phenytoin should not be combined with nisoldipine CC, as they may reduce its bioavailability and result in a loss of efficacy.	Rifampin	44-54	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	12-37
9806107-7	1998	Hyperuricaemia, which was reported only during the intensive phase, elevated ALT and AST levels and neutropenia were the most common treatment-related adverse events reported in patients receiving rifapentine- or rifampicin-containing regimens for tuberculosis in 1 Western study.	Rifampin	213-223	solute carrier family 17 member 5	Homo sapiens	85-88
9732934-0	1998	Unexpected clinical remission of cholestasis after rifampicin therapy in patients with normal or slightly increased levels of gamma-glutamyl transpeptidase.	Rifampin	51-61	inactive glutathione hydrolase 2	Homo sapiens	126-155
9732934-12	1998	CONCLUSION: Rifampicin may induce clinical remission, and perhaps prevent clinical relapses of intrahepatic cholestasis with normal or slightly increased levels of gamma-glutamyl transpeptidase.	Rifampin	12-22	inactive glutathione hydrolase 2	Homo sapiens	164-193
9784933-16	1998	Inducers of cytochrome P450 (CYP) 3A4, e.g. rifampicin (rifampin) and phenytoin should not be combined with nisoldipine CC, as they may reduce its bioavailability and result in a loss of efficacy.	Rifampin	56-64	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	12-37
9650537-5	1998	Rifampin induced CYP3A, reflected in a mean percent (+/- standard deviation) increase in EBT values of 86 +/- 30%.	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	17-22
9753209-3	1998	Known inducers of CYP3A, such as rifampin, phenytoin, carbamazepine, and phenobarbital, increase the urinary excretion of 6beta-hydroxycortisol and the ratio of 6beta-hydroxycortisol to cortisol.	Rifampin	33-41	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	18-23
9675018-6	1998	Taxol was almost as effective as rifampicin in inducing CYP3A in two of the cultures, but less effective than rifampicin in two other cultures.	Rifampin	33-43	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	56-61
9661035-1	1998	The contributions of 23 insertion, deletion, or missense mutations within an 81-bp fragment of rpoB, the gene encoding the beta-subunit of the DNA-dependent RNA polymerase of Mycobacterium tuberculosis, to the development of resistance to rifamycins (rifampin, rifabutin, rifapentine, and KRM-1648) in 29 rifampin-resistant clinical isolates were defined.	Rifampin	251-259	DNA-directed RNA polymerase subunit beta	Mycobacterium tuberculosis H37Rv	95-99
9661035-1	1998	The contributions of 23 insertion, deletion, or missense mutations within an 81-bp fragment of rpoB, the gene encoding the beta-subunit of the DNA-dependent RNA polymerase of Mycobacterium tuberculosis, to the development of resistance to rifamycins (rifampin, rifabutin, rifapentine, and KRM-1648) in 29 rifampin-resistant clinical isolates were defined.	Rifampin	305-313	DNA-directed RNA polymerase subunit beta	Mycobacterium tuberculosis H37Rv	95-99
9661035-2	1998	Specific mutant rpoB alleles led to the development of cross-resistance to all rifamycins tested, while a subset of mutations were associated with resistance to rifampin and rifapentine but not to KRM-1648 or rifabutin.	Rifampin	161-169	DNA-directed RNA polymerase subunit beta	Mycobacterium tuberculosis H37Rv	16-20
9663807-3	1998	CYP2C9 activity in vivo is inducible by rifampicin.	Rifampin	40-50	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	0-6
9677642-3	1998	CASE REPORT: Three patients developed a pruritic rash 1 hour after the first dose of isoniazide, rifampicine, pyrazinamide and ethambutol given simultaneously.	Rifampin	97-108	HRas proto-oncogene, GTPase	Homo sapiens	49-55
9667078-0	1998	Characterization of cytochrome P450 (CYP3A12) induction by rifampicin in dog liver.	Rifampin	59-69	cytochrome P450 3A12	Canis lupus familiaris	37-44
9667078-2	1998	Effects of rifampicin (Rif) on the contents of cytochrome P450 (P450) enzymes (CYP1A1/2, 2B11, 2C21 and 3A12) assessed by enzyme-linked immunosorbent assay and catalytic activities (ethoxyresorufin O-deethylase, and testosterone 6 beta-, 16 alpha- and 16 beta-hydroxylase; 6 beta-, 16 alpha- and 16 beta-OHT) in dog liver microsomes were compared between liver lobes of both the male and female dogs.	Rifampin	11-21	Cytochrome P450 1A1	Canis lupus familiaris	79-93
9667078-13	1998	These results indicate that Rif treatment induces the expression of CYP3A12 protein, and correlates well with the elevation of its catalytic activity (6 beta- and 16 beta-OHT), and that the female dog is more responsive to Rif treatment as compared with the male.	Rifampin	28-31	cytochrome P450 3A12	Canis lupus familiaris	68-75
9625027-3	1998	Other medications, e.g., rifampin and phenobarbital, which also induce p450 3A activity, have been reported to significantly decrease cyclosporine (CsA) concentrations.	Rifampin	25-33	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	148-151
9556634-8	1998	Nicked DNA was significantly generated, and the frequency of mutations resistant to rifampicin was increased by 30-fold, depending upon the expression of Bax.	Rifampin	84-94	BCL2 associated X, apoptosis regulator	Homo sapiens	154-157
9578186-8	1998	CONCLUSIONS: The strong interaction between rifampicin and buspirone is probably mostly due to enhanced CYP3A4-mediated first-pass metabolism of buspirone.	Rifampin	44-54	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	104-110
9489590-0	1998	The induction effect of rifampicin on activity of mephenytoin 4"-hydroxylase related to M1 mutation of CYP2C19 and gene dose.	Rifampin	24-34	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	50-76
9514072-4	1998	In male rats, western blot analyses showed that rifampicin and dexamethasone caused 50% and 5-fold increases in Pgp levels, respectively.	Rifampin	48-58	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	112-115
9514072-5	1998	RNase protection assays using gene-specific probes for the three Pgp isoforms revealed a 3-fold increase in mdr2 mRNA levels after dexamethasone administration and a 2-fold increase following rifampicin treatment.	Rifampin	192-202	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	65-68
9454825-5	1998	When hepatocytes were treated with inducers, marked increases in the specific activities of CYP1A1/2 by 3-methylcholanthrene and CYP3A4 by rifampicin were observed, and these inductive effects were greatly reduced in the presence of HGF.	Rifampin	139-149	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	92-98
9454825-5	1998	When hepatocytes were treated with inducers, marked increases in the specific activities of CYP1A1/2 by 3-methylcholanthrene and CYP3A4 by rifampicin were observed, and these inductive effects were greatly reduced in the presence of HGF.	Rifampin	139-149	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	129-135
9454825-7	1998	The observed changes in the activity and protein levels of CYP1A2 and CYP3A4 correlated with a reduction in the specific messenger RNA levels both in control, 3-methylcholanthrene-treated (for CYP1A2) and rifampicin-treated (for CYP3A4) hepatocytes, which thus suggested that HGF could down-regulate CYP expression at a pretranslational level.	Rifampin	205-215	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	59-65
9454825-7	1998	The observed changes in the activity and protein levels of CYP1A2 and CYP3A4 correlated with a reduction in the specific messenger RNA levels both in control, 3-methylcholanthrene-treated (for CYP1A2) and rifampicin-treated (for CYP3A4) hepatocytes, which thus suggested that HGF could down-regulate CYP expression at a pretranslational level.	Rifampin	205-215	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	70-76
9454825-7	1998	The observed changes in the activity and protein levels of CYP1A2 and CYP3A4 correlated with a reduction in the specific messenger RNA levels both in control, 3-methylcholanthrene-treated (for CYP1A2) and rifampicin-treated (for CYP3A4) hepatocytes, which thus suggested that HGF could down-regulate CYP expression at a pretranslational level.	Rifampin	205-215	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	229-235
9454825-7	1998	The observed changes in the activity and protein levels of CYP1A2 and CYP3A4 correlated with a reduction in the specific messenger RNA levels both in control, 3-methylcholanthrene-treated (for CYP1A2) and rifampicin-treated (for CYP3A4) hepatocytes, which thus suggested that HGF could down-regulate CYP expression at a pretranslational level.	Rifampin	205-215	hepatocyte growth factor	Homo sapiens	276-279
9454825-7	1998	The observed changes in the activity and protein levels of CYP1A2 and CYP3A4 correlated with a reduction in the specific messenger RNA levels both in control, 3-methylcholanthrene-treated (for CYP1A2) and rifampicin-treated (for CYP3A4) hepatocytes, which thus suggested that HGF could down-regulate CYP expression at a pretranslational level.	Rifampin	205-215	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-62
9489590-0	1998	The induction effect of rifampicin on activity of mephenytoin 4"-hydroxylase related to M1 mutation of CYP2C19 and gene dose.	Rifampin	24-34	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	103-110
9402948-5	1997	In addition, the expression and inducibility of CYP proteins of the CYP1, CYP2 and CYP3 families in response to their prototypical inducers including 2,3,7,8-tetrachlorodibenzo(p)dioxin and rifampicin, have been evaluated by immunoblot analysis of microsomes or cell lysates.	Rifampin	190-200	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	68-72
9427613-0	1998	The antibiotic rifampicin is a nonsteroidal ligand and activator of the human glucocorticoid receptor.	Rifampin	15-25	nuclear receptor subfamily 3 group C member 1	Homo sapiens	78-101
9385296-1	1997	Rifampin is a potent inducer of cytochrome P-450 oxidative enzymes.	Rifampin	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-48
9402947-2	1997	Our study here represents the first reported study that directly compares the cytochrome P450 isozyme 3A (CYP3A) induction potential of three antimicrobials derived from rifamycin B, namely, rifampin, rifapentine and rifabutin.	Rifampin	191-199	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	78-104
9402947-4	1997	Results obtained with hepatocytes from four different human donors show consistently that rifampin and rifapentine are potent inducers of CYP3A, while a significantly lower induction potential is observed for rifabutin.	Rifampin	90-98	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	138-143
9402948-5	1997	In addition, the expression and inducibility of CYP proteins of the CYP1, CYP2 and CYP3 families in response to their prototypical inducers including 2,3,7,8-tetrachlorodibenzo(p)dioxin and rifampicin, have been evaluated by immunoblot analysis of microsomes or cell lysates.	Rifampin	190-200	peptidylprolyl isomerase F	Homo sapiens	83-87
9402949-9	1997	Likewise, Cyp3A and Cyp2A6 mRNAs can be shown to be induced in primary human hepatocytes cultured on collagen-coated plates and treated with rifampin for 72 h. By contrast, mRNA levels for Cyp1A1 and Cyp2E1 were not increased by rifampin treatment.	Rifampin	141-149	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	10-15
9402949-9	1997	Likewise, Cyp3A and Cyp2A6 mRNAs can be shown to be induced in primary human hepatocytes cultured on collagen-coated plates and treated with rifampin for 72 h. By contrast, mRNA levels for Cyp1A1 and Cyp2E1 were not increased by rifampin treatment.	Rifampin	141-149	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	20-26
9402949-9	1997	Likewise, Cyp3A and Cyp2A6 mRNAs can be shown to be induced in primary human hepatocytes cultured on collagen-coated plates and treated with rifampin for 72 h. By contrast, mRNA levels for Cyp1A1 and Cyp2E1 were not increased by rifampin treatment.	Rifampin	141-149	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	189-195
9402949-9	1997	Likewise, Cyp3A and Cyp2A6 mRNAs can be shown to be induced in primary human hepatocytes cultured on collagen-coated plates and treated with rifampin for 72 h. By contrast, mRNA levels for Cyp1A1 and Cyp2E1 were not increased by rifampin treatment.	Rifampin	141-149	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	200-206
9402949-9	1997	Likewise, Cyp3A and Cyp2A6 mRNAs can be shown to be induced in primary human hepatocytes cultured on collagen-coated plates and treated with rifampin for 72 h. By contrast, mRNA levels for Cyp1A1 and Cyp2E1 were not increased by rifampin treatment.	Rifampin	229-237	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	10-15
9402949-9	1997	Likewise, Cyp3A and Cyp2A6 mRNAs can be shown to be induced in primary human hepatocytes cultured on collagen-coated plates and treated with rifampin for 72 h. By contrast, mRNA levels for Cyp1A1 and Cyp2E1 were not increased by rifampin treatment.	Rifampin	229-237	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	20-26
9402949-9	1997	Likewise, Cyp3A and Cyp2A6 mRNAs can be shown to be induced in primary human hepatocytes cultured on collagen-coated plates and treated with rifampin for 72 h. By contrast, mRNA levels for Cyp1A1 and Cyp2E1 were not increased by rifampin treatment.	Rifampin	229-237	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	189-195
9413920-7	1997	Compared with control (dimethyl sulphoxide only treated) liver slice microsomes, rifampicin increased levels of CYP3A4 but had no effect on CYP1A2.	Rifampin	81-91	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	112-118
9413920-9	1997	These results demonstrate that rifampicin induces CYP3A isoforms, but not CYP1A2, in cultured human liver slices.	Rifampin	31-41	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	50-55
9353130-11	1997	Rifampicin treatment (50 micromol/L) for 7 days resulted in a 3.7-fold induction of CYP 3A4 at day 9 in culture.	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	84-91
9353130-14	1997	These results demonstrate that rat and human hepatocytes preserve the major forms of CYP isozymes and phase II activities and respond to inducing drugs such as rifampicin.	Rifampin	160-170	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88
9391787-0	1997	Relationship between cytochrome P-450 induction by rifampicin, hepatic volume and portal blood flow in man.	Rifampin	51-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-37
9391787-10	1997	CONCLUSION: A fourfold increase of urinary 6-beta-hydroxycortisol output after induction of cytochrome P-450 by rifampicin is associated with a significant but less than 10% increase in human liver volume.	Rifampin	112-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-108
9350037-9	1997	Whereas ATA caused increased stability of PR isoforms, Rifampicin induced a upshift in the mobility of PR in SDS gels-a phenomenon associated with hyperphosphorylation of steroid receptors (SRs).	Rifampin	55-65	progesterone receptor	Homo sapiens	103-105
9350037-12	1997	We propose that the inhibition of T47D cell proliferation by phenanthroline, Rifampicin and ATA results from a number of cellular changes that include regulation of p53 and PR.	Rifampin	77-87	tumor protein p53	Homo sapiens	165-168
9350037-12	1997	We propose that the inhibition of T47D cell proliferation by phenanthroline, Rifampicin and ATA results from a number of cellular changes that include regulation of p53 and PR.	Rifampin	77-87	progesterone receptor	Homo sapiens	173-175
9596814-1	1996	OBJECTIVE: To evaluate rpoB gene mutation in rifampin-resistant Mycobacterium tuberculosis and its relationship with rifampin resistance.	Rifampin	45-53	ER membrane protein complex subunit 3	Rattus norvegicus	23-27
9298257-8	1997	Rifampin induction of CYP3A, a known effect of rifampin in vivo, was also reproduced in primary human hepatocytes.	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	22-27
9298257-11	1997	To demonstrate that the rifampin-induction of testosterone 6 beta-hydroxylation could be generalized to other CYP3A4 substrates, we evaluated the metabolism of another known substrate of CYP3A4, lidocaine.	Rifampin	24-32	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	187-193
9157990-5	1997	Rifampin (1 microM, 96-h exposure) was a particularly potent inducer of ifosfamide and cyclophosphamide 4-hydroxylation, as well as of CYP3A protein levels and CYP3A-dependent testosterone 6beta-hydroxylation.	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	135-140
9157990-5	1997	Rifampin (1 microM, 96-h exposure) was a particularly potent inducer of ifosfamide and cyclophosphamide 4-hydroxylation, as well as of CYP3A protein levels and CYP3A-dependent testosterone 6beta-hydroxylation.	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	160-165
9141435-3	1997	In the absence of EGF, the accumulation of CYP3A4 and CYP1A2 messenger RNAs (mRNAs) in response to their respective inducers (rifampicin and dioxin) was dramatically decreased in subconfluent culture with respect to confluent cultures.	Rifampin	126-136	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	43-49
9141435-3	1997	In the absence of EGF, the accumulation of CYP3A4 and CYP1A2 messenger RNAs (mRNAs) in response to their respective inducers (rifampicin and dioxin) was dramatically decreased in subconfluent culture with respect to confluent cultures.	Rifampin	126-136	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	54-60
9084959-20	1997	Recognised enzyme inducers of CYP3A, which are likely to be prescribed for patients with HIV disease, include rifampicin (rifampin) [treatment of pulmonary tuberculosis], rifabutin (treatment and prophylaxis of Mycobacterium avium complex), phenobarbital (phenobarbitone), phenytoin and carbamazepine (treatment of seizures secondary to cerebral toxoplasmosis or cerebral lymphoma).	Rifampin	110-120	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	30-35
9084959-20	1997	Recognised enzyme inducers of CYP3A, which are likely to be prescribed for patients with HIV disease, include rifampicin (rifampin) [treatment of pulmonary tuberculosis], rifabutin (treatment and prophylaxis of Mycobacterium avium complex), phenobarbital (phenobarbitone), phenytoin and carbamazepine (treatment of seizures secondary to cerebral toxoplasmosis or cerebral lymphoma).	Rifampin	122-130	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	30-35
9187114-8	1997	By the introduction of recombinant hMMH, the rate of mutation, the formation of rifampicin-resistant revertants, was reduced by 4-7 fold.	Rifampin	80-90	8-oxoguanine DNA glycosylase	Homo sapiens	35-39
9157990-7	1997	In one human hepatocyte culture that contained the polymorphically expressed CYP3A5 in addition to the more widely expressed CYP3A4, only CYP3A4 was induced by cyclophosphamide, ifosfamide, and rifampin.	Rifampin	194-202	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	77-83
9157990-7	1997	In one human hepatocyte culture that contained the polymorphically expressed CYP3A5 in addition to the more widely expressed CYP3A4, only CYP3A4 was induced by cyclophosphamide, ifosfamide, and rifampin.	Rifampin	194-202	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	138-144
9145822-0	1997	Effect of combination therapy of rifampicin and azithromycin on TNF levels during a rat model of chronic osteomyelitis.	Rifampin	33-43	tumor necrosis factor	Rattus norvegicus	64-67
9178371-4	1997	Seven different possible metabolites were identified in the microsomal preparations from rats treated with rifampin or dexamethasone whereas the microsomes from the control rats failed to produce the mono-demethylated and monohydroxylated metabolite of TAC (TAC+2, m/z = 805.5).	Rifampin	107-115	tachykinin precursor 3	Rattus norvegicus	253-256
9148761-1	1997	Rifampicin and its analogues, p-benzoquinone and hydroquinone, inhibited the toxicity of preformed aggregates of human islet amyloid polypeptide, amylin, to rat pheochromocytoma PC12 cells, when preincubated with the aggregated peptide before addition to cell cultures.	Rifampin	0-10	islet amyloid polypeptide	Homo sapiens	146-152
9024169-2	1997	Rifampin (rifampicin) is a potent inducer of CYP3A4 and it is known to markedly reduce plasma concentrations and effects of drugs such as midazolam.	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	45-51
9024169-2	1997	Rifampin (rifampicin) is a potent inducer of CYP3A4 and it is known to markedly reduce plasma concentrations and effects of drugs such as midazolam.	Rifampin	10-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	45-51
9024169-12	1997	This is most likely due to increased metabolism of triazolam after induction of CYP3A4 in the gut wall and liver by rifampin.	Rifampin	116-124	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	80-86
9010637-5	1997	The inducers of CYP3A and/or CYP2C9 (e.g. rifampicin and phenytoin) are likely to alter the disposition of seratrodast.	Rifampin	42-52	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	16-21
9010637-5	1997	The inducers of CYP3A and/or CYP2C9 (e.g. rifampicin and phenytoin) are likely to alter the disposition of seratrodast.	Rifampin	42-52	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	29-35
9131486-5	1996	CYP3A activity can also be readily modulated by inducers like rifampicin and several anticonvulsant agents, and many potent inhibitors exist such as azole antifungal agents and macrolide antibiotics.	Rifampin	62-72	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-5
8855178-2	1996	CYP3A4 for example is present and inducible by rifampin in epithelial cells of the gastrointestinal tract.	Rifampin	47-55	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
8883230-14	1996	Prophylactic ciprofloxacin and rifampin is a well-tolerated and highly effective combination that effectively decreases the risk of both gram-positive and gram-negative bacterial infection following HDC/ASCR.	Rifampin	31-39	prion protein	Homo sapiens	203-207
8843295-13	1996	A comparison of equal doses of rifampin and rifabutin administered to healthy volunteers for 2 weeks indicates that induction of CYP1A2, as measured by theophylline clearance, is significantly less following rifabutin treatment than it is following rifampin treatment.	Rifampin	31-39	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	129-135
8753820-0	1996	The fetal specific gene CYP3A7 is inducible by rifampicin in adult human hepatocytes in primary culture.	Rifampin	47-57	cytochrome P450 family 3 subfamily A member 7	Homo sapiens	24-30
8753820-5	1996	However, when the cells were treated for 48 hours with 25 microM rifampicin, both CYP3A4 and CYP3A7 mRNAs were strongly induced in the 3 and in 2 of 3 cultures examined, respectively.	Rifampin	65-75	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	82-88
8753820-5	1996	However, when the cells were treated for 48 hours with 25 microM rifampicin, both CYP3A4 and CYP3A7 mRNAs were strongly induced in the 3 and in 2 of 3 cultures examined, respectively.	Rifampin	65-75	cytochrome P450 family 3 subfamily A member 7	Homo sapiens	93-99
8753820-8	1996	These results show for the first time that CYP3A7 and CYP3A4 mRNAs, but not the proteins, are co-inducible by rifampicin in adult human hepatocytes in culture.	Rifampin	110-120	cytochrome P450 family 3 subfamily A member 7	Homo sapiens	43-49
8753820-8	1996	These results show for the first time that CYP3A7 and CYP3A4 mRNAs, but not the proteins, are co-inducible by rifampicin in adult human hepatocytes in culture.	Rifampin	110-120	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	54-60
8843295-3	1996	This study, involving 12 adult male volunteers, compared the effects of 14-day courses of rifampin and rifabutin on clearance of theophylline, a substrate for the hepatic microsomal enzyme CYP1A2.	Rifampin	90-98	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	189-195
8819303-7	1996	The oral treatment of male dogs with phenobarbital (PB), rifampicin (Rif) or beta-naphthoflavone (beta-NF) induced significant increases in the contents of CYP1A1/2 (12-fold by beta-NF), 2B11 (16-fold by PB), 2C21 (2-fold by PB) and 3A12 (5-fold by PB and Rif), resulting in marked proportional alterations of the P450 enzymes in dog liver microsomes.	Rifampin	57-67	Cytochrome P450 1A1	Canis lupus familiaris	156-162
8670846-6	1996	Expression of CDG or TDG in Escherichia coli causes 4- to 100-fold increases in the yield of rifampicin-resistant mutants.	Rifampin	93-103	thymine DNA glycosylase	Homo sapiens	21-24
8700101-1	1996	Interindividual variation in the spontaneous and in the glucocorticoid-or rifampicin-inducible expression of the CYP3A cytochromes P450, the dominant froms of this supergene family that catalyze the oxidation of numerous drugs and environmental chemicals in human liver, remains largely unexplained, due in part to the lack of a validated animal model.	Rifampin	74-84	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	113-118
8819303-7	1996	The oral treatment of male dogs with phenobarbital (PB), rifampicin (Rif) or beta-naphthoflavone (beta-NF) induced significant increases in the contents of CYP1A1/2 (12-fold by beta-NF), 2B11 (16-fold by PB), 2C21 (2-fold by PB) and 3A12 (5-fold by PB and Rif), resulting in marked proportional alterations of the P450 enzymes in dog liver microsomes.	Rifampin	69-72	Cytochrome P450 1A1	Canis lupus familiaris	156-162
8819303-7	1996	The oral treatment of male dogs with phenobarbital (PB), rifampicin (Rif) or beta-naphthoflavone (beta-NF) induced significant increases in the contents of CYP1A1/2 (12-fold by beta-NF), 2B11 (16-fold by PB), 2C21 (2-fold by PB) and 3A12 (5-fold by PB and Rif), resulting in marked proportional alterations of the P450 enzymes in dog liver microsomes.	Rifampin	256-259	Cytochrome P450 1A1	Canis lupus familiaris	156-162
8690981-3	1996	This was the motive behind the state of Sao Paulo"s Health Department"s decision to carry out a study that would evaluate not only the incidence rate of adverse effects of rifampin in relation to kidney function but also in relation to the use of WHO/MDT in general.	Rifampin	172-180	solute carrier family 4 member 1 (Diego blood group)	Homo sapiens	40-43
8621783-8	1996	During normal Na diet, RIF PGE2 and cGMP increased in response to angiotensin II.	Rifampin	23-26	angiotensinogen	Rattus norvegicus	66-80
8836814-0	1996	Inducing properties of rifampicin and rifabutin for selected enzyme activities of the cytochrome P-450 and UDP-glucuronosyltransferase superfamilies in female rat liver.	Rifampin	23-33	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	86-102
8836814-0	1996	Inducing properties of rifampicin and rifabutin for selected enzyme activities of the cytochrome P-450 and UDP-glucuronosyltransferase superfamilies in female rat liver.	Rifampin	23-33	UDP glycosyltransferase 2 family, polypeptide B	Rattus norvegicus	107-134
8836814-3	1996	In the present study a strong induction of cytochrome P-450 3A-dependent enzyme activities was observed in female rat liver microsomes after high dose treatment (&gt; or = 250 mg/kg/day for 9 days) with rifampicin, resulting in an up to 30-fold enhanced hydroxylation rate of testosterone in the 2 beta-, 6 beta- and 15 beta-position in vitro.	Rifampin	203-213	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	43-59
8836814-5	1996	A steep increase in cytochrome P-450 3A activity on a moderate elevation of the dose administered, together with the previously observed lack of efficient induction with doses below 200 mg/kg/day demonstrated that there is a threshold in enzyme induction by rifampicin.	Rifampin	258-268	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	20-36
8836814-7	1996	Induction by rifabutin showed an isoenzyme-selectivity profile similar to that produced by rifampicin, but the maximally achievable induction of cytochrome P-450 3A by rifabutin was about two-fold lower compared with rifampicin.	Rifampin	217-227	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	145-161
8619627-5	1996	A putative CYP3A protein is expressed in PLHC-1 cells but its content was not altered by exposure of cultures to the prototypical mammalian CYP3A inducers dexamethasone (DEX), pregnenolone-16 alpha-carbonitrile (PCN), or rifampicin (RIF).	Rifampin	221-231	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	11-16
8619627-5	1996	A putative CYP3A protein is expressed in PLHC-1 cells but its content was not altered by exposure of cultures to the prototypical mammalian CYP3A inducers dexamethasone (DEX), pregnenolone-16 alpha-carbonitrile (PCN), or rifampicin (RIF).	Rifampin	233-236	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	11-16
8619627-11	1996	Two other glucocorticoid receptor (GR) agonists, cortisol and prednisone, also produced a strong potentiation of CYP1A induction, but other mammalian CYP3A inducers that are not GR agonists, such as the anti-glucocorticoid PCN, the anti-mineralocorticoid spironolactone, or the macrolide antibiotics RIF and troleandomycin, did not potentiate the CYP1A induction in PLHC-1 cells.	Rifampin	300-303	nuclear receptor subfamily 3 group C member 1	Homo sapiens	10-33
8619627-11	1996	Two other glucocorticoid receptor (GR) agonists, cortisol and prednisone, also produced a strong potentiation of CYP1A induction, but other mammalian CYP3A inducers that are not GR agonists, such as the anti-glucocorticoid PCN, the anti-mineralocorticoid spironolactone, or the macrolide antibiotics RIF and troleandomycin, did not potentiate the CYP1A induction in PLHC-1 cells.	Rifampin	300-303	nuclear receptor subfamily 3 group C member 1	Homo sapiens	35-37
8633005-0	1996	P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans.	Rifampin	39-49	phosphoglycolate phosphatase	Mus musculus	0-14
8633005-0	1996	P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans.	Rifampin	39-49	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	74-80
8633005-3	1996	The magnitude of CYP3A induction by rifampicin was compared in the human parental colon carcinoma cell line LS 180/WT (wild type) and in two derivative clones overexpressing the human multidrug resistance gene MDR1 (also designated PGY1) because of either drug selection (LS 180/ADR) or transfection with MDRI cDNA (LS 180/MDR).	Rifampin	36-46	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	17-22
8633005-4	1996	In both MDR1 cDNA-overexpressing clones, rifampicin induction of CYP3A mRNA and protein was decreased and required greater rifampicin concentrations compared with parental cells.	Rifampin	41-51	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	8-12
8633005-4	1996	In both MDR1 cDNA-overexpressing clones, rifampicin induction of CYP3A mRNA and protein was decreased and required greater rifampicin concentrations compared with parental cells.	Rifampin	41-51	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	65-70
8633005-4	1996	In both MDR1 cDNA-overexpressing clones, rifampicin induction of CYP3A mRNA and protein was decreased and required greater rifampicin concentrations compared with parental cells.	Rifampin	123-133	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	65-70
8633005-6	1996	Oral treatment with increasing doses of rifampicin resulted in elevated drug levels in the livers of mdr1a (-/-) mice compared with mdr1a (+/+) mice at all doses.	Rifampin	40-50	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	101-106
8633005-6	1996	Oral treatment with increasing doses of rifampicin resulted in elevated drug levels in the livers of mdr1a (-/-) mice compared with mdr1a (+/+) mice at all doses.	Rifampin	40-50	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	132-137
8633005-7	1996	Consistent with the enhanced accumulation of rifampicin in mdr1a (-/-) mice, lower doses of rifampicin were required for induction of CYP3A proteins, and the magnitude of CYP3A induction was greater at all doses of rifampicin in mdr1a (-/-) mice compared with mdr1a (+/+) mice.	Rifampin	45-55	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	59-64
8633005-7	1996	Consistent with the enhanced accumulation of rifampicin in mdr1a (-/-) mice, lower doses of rifampicin were required for induction of CYP3A proteins, and the magnitude of CYP3A induction was greater at all doses of rifampicin in mdr1a (-/-) mice compared with mdr1a (+/+) mice.	Rifampin	92-102	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	134-139
8633005-7	1996	Consistent with the enhanced accumulation of rifampicin in mdr1a (-/-) mice, lower doses of rifampicin were required for induction of CYP3A proteins, and the magnitude of CYP3A induction was greater at all doses of rifampicin in mdr1a (-/-) mice compared with mdr1a (+/+) mice.	Rifampin	92-102	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	229-234
8633005-7	1996	Consistent with the enhanced accumulation of rifampicin in mdr1a (-/-) mice, lower doses of rifampicin were required for induction of CYP3A proteins, and the magnitude of CYP3A induction was greater at all doses of rifampicin in mdr1a (-/-) mice compared with mdr1a (+/+) mice.	Rifampin	92-102	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	229-234
8633005-7	1996	Consistent with the enhanced accumulation of rifampicin in mdr1a (-/-) mice, lower doses of rifampicin were required for induction of CYP3A proteins, and the magnitude of CYP3A induction was greater at all doses of rifampicin in mdr1a (-/-) mice compared with mdr1a (+/+) mice.	Rifampin	92-102	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	134-139
8633005-7	1996	Consistent with the enhanced accumulation of rifampicin in mdr1a (-/-) mice, lower doses of rifampicin were required for induction of CYP3A proteins, and the magnitude of CYP3A induction was greater at all doses of rifampicin in mdr1a (-/-) mice compared with mdr1a (+/+) mice.	Rifampin	92-102	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	229-234
8633005-7	1996	Consistent with the enhanced accumulation of rifampicin in mdr1a (-/-) mice, lower doses of rifampicin were required for induction of CYP3A proteins, and the magnitude of CYP3A induction was greater at all doses of rifampicin in mdr1a (-/-) mice compared with mdr1a (+/+) mice.	Rifampin	92-102	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	229-234
8636108-6	1996	These results suggest that at least one mechanism of rifampicin-mediated inhibition of A beta aggregation and neurotoxicity involves scavenging of free radicals and that rifampicin and/or appropriate hydroxyl radical scavengers may have therapeutic potential for Alzheimer"s disease.	Rifampin	53-63	amyloid beta precursor protein	Rattus norvegicus	87-93
8549036-2	1996	Rifampin is a potent enzyme inducer that may seriously interact with some substrates of CYP3A4.	Rifampin	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	88-94
8640817-8	1996	Docetaxel metabolism was induced in vitro in human hepatocytes by dexamethasone and rifampicin, both classical CYP3A inducers.	Rifampin	84-94	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	111-116
8632764-3	1996	P-glycoprotein and CYP3A4 were constitutively expressed in both LS180/AD50 and LS180/WT cells, and both proteins were up-regulated after treatment with many drugs, including rifampicin, phenobarbital, clotrimazole, reserpine, and isosafrole.	Rifampin	174-184	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
8632764-3	1996	P-glycoprotein and CYP3A4 were constitutively expressed in both LS180/AD50 and LS180/WT cells, and both proteins were up-regulated after treatment with many drugs, including rifampicin, phenobarbital, clotrimazole, reserpine, and isosafrole.	Rifampin	174-184	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	19-25
8549036-10	1996	CONCLUSIONS: The observed substantial decrease in plasma concentrations and effects of midazolam most likely results from induction of CYP3A4 by rifampin in both the gut wall and the liver.	Rifampin	145-153	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	135-141
7585637-5	1995	Pretreatment of the cells with 3-methylcholanthrene or rifampicin, inducers of CYP1A2 and CYP3A4, respectively, caused a significant increase in AFB1 metabolism.	Rifampin	55-65	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	79-85
7585637-5	1995	Pretreatment of the cells with 3-methylcholanthrene or rifampicin, inducers of CYP1A2 and CYP3A4, respectively, caused a significant increase in AFB1 metabolism.	Rifampin	55-65	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	90-96
8786635-1	1995	Rifampicin conferred significant protection against carbon tetrachloride (CCl4)-induced liver injury.	Rifampin	0-10	chemokine (C-C motif) ligand 4	Mus musculus	74-78
8786635-2	1995	Serum alanine transaminase (ALT) and aspartate transaminase (AST) activities were not markedly altered and only hepatocellular fatty degeneration was found in mice pretreated with rifampicin (200 mg/kg), whereas severe centrilobular necrosis was observed and serum ALT and AST activities were as high as 281 and 271 I.U./l, respectively, in the control group following administration of CCl4 (400 microliters/kg).	Rifampin	180-190	glutamic pyruvic transaminase, soluble	Mus musculus	28-31
8786635-2	1995	Serum alanine transaminase (ALT) and aspartate transaminase (AST) activities were not markedly altered and only hepatocellular fatty degeneration was found in mice pretreated with rifampicin (200 mg/kg), whereas severe centrilobular necrosis was observed and serum ALT and AST activities were as high as 281 and 271 I.U./l, respectively, in the control group following administration of CCl4 (400 microliters/kg).	Rifampin	180-190	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	61-64
8786635-2	1995	Serum alanine transaminase (ALT) and aspartate transaminase (AST) activities were not markedly altered and only hepatocellular fatty degeneration was found in mice pretreated with rifampicin (200 mg/kg), whereas severe centrilobular necrosis was observed and serum ALT and AST activities were as high as 281 and 271 I.U./l, respectively, in the control group following administration of CCl4 (400 microliters/kg).	Rifampin	180-190	glutamic pyruvic transaminase, soluble	Mus musculus	265-268
8786635-2	1995	Serum alanine transaminase (ALT) and aspartate transaminase (AST) activities were not markedly altered and only hepatocellular fatty degeneration was found in mice pretreated with rifampicin (200 mg/kg), whereas severe centrilobular necrosis was observed and serum ALT and AST activities were as high as 281 and 271 I.U./l, respectively, in the control group following administration of CCl4 (400 microliters/kg).	Rifampin	180-190	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	273-276
8786635-2	1995	Serum alanine transaminase (ALT) and aspartate transaminase (AST) activities were not markedly altered and only hepatocellular fatty degeneration was found in mice pretreated with rifampicin (200 mg/kg), whereas severe centrilobular necrosis was observed and serum ALT and AST activities were as high as 281 and 271 I.U./l, respectively, in the control group following administration of CCl4 (400 microliters/kg).	Rifampin	180-190	chemokine (C-C motif) ligand 4	Mus musculus	387-391
8786635-4	1995	CCl4-mediated malondialdehyde (MDA) formation was increased in rifampicin-treated liver microsomes, demonstrating that rifampicin was capable of increasing the NADPH-dependent metabolism of CCl4 catalyzed by P-450 2E1 to produce free radicals.	Rifampin	63-73	chemokine (C-C motif) ligand 4	Mus musculus	0-4
8786635-4	1995	CCl4-mediated malondialdehyde (MDA) formation was increased in rifampicin-treated liver microsomes, demonstrating that rifampicin was capable of increasing the NADPH-dependent metabolism of CCl4 catalyzed by P-450 2E1 to produce free radicals.	Rifampin	63-73	chemokine (C-C motif) ligand 4	Mus musculus	190-194
8786635-4	1995	CCl4-mediated malondialdehyde (MDA) formation was increased in rifampicin-treated liver microsomes, demonstrating that rifampicin was capable of increasing the NADPH-dependent metabolism of CCl4 catalyzed by P-450 2E1 to produce free radicals.	Rifampin	119-129	chemokine (C-C motif) ligand 4	Mus musculus	0-4
8786635-4	1995	CCl4-mediated malondialdehyde (MDA) formation was increased in rifampicin-treated liver microsomes, demonstrating that rifampicin was capable of increasing the NADPH-dependent metabolism of CCl4 catalyzed by P-450 2E1 to produce free radicals.	Rifampin	119-129	chemokine (C-C motif) ligand 4	Mus musculus	190-194
8786635-5	1995	However, MDA formation was obviously depressed by rifampicin at varying concentrations from 2 to 32 x 10(-6) M in an in vitro cytochrome P-450 (P-450) enzyme system.	Rifampin	50-60	cytochrome P450, family 21, subfamily a, polypeptide 1	Mus musculus	126-142
8786635-7	1995	Therefore, the protective effect of rifampicin against CCl4 hepatotoxicity appeared to result from the direct inhibition of lipid peroxidation generated by CCl4-derived free radicals.	Rifampin	36-46	chemokine (C-C motif) ligand 4	Mus musculus	55-59
8786635-7	1995	Therefore, the protective effect of rifampicin against CCl4 hepatotoxicity appeared to result from the direct inhibition of lipid peroxidation generated by CCl4-derived free radicals.	Rifampin	36-46	chemokine (C-C motif) ligand 4	Mus musculus	156-160
8591727-9	1995	Treatment of cells with inducers of CYP1A (beta-naphthoflavone) and CYP3A (rifampicin and phenobarbital) greatly increased the rate of production of this metabolite.	Rifampin	75-85	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	68-73
7646562-4	1995	This activity was specifically increased four-fold upon addition of beta-naphthoflavone into culture medium but not by rifampicine or clofibrate and was related to a biosynthesis of UDP-glucuronosyltransferase 1*6 (UGT1*6).	Rifampin	119-130	UDP glucuronosyltransferase family 1 member A6	Homo sapiens	182-213
7574728-7	1995	In all three cultures, the increases in CYP3A after treatment with ethanol were less than those observed after treatment with rifampicin, a highly effective inducer of CYP3A in human hepatocytes.	Rifampin	126-136	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	168-173
7574728-10	1995	In this latter culture, the steady-state levels of CYP3A3/4 mRNA increased by 0.1 mM isopentanol and 1 microM rifampicin were similar.	Rifampin	110-120	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	51-57
7557864-6	1995	When cells were treated with the CYP inducer alone, large increases in the expression of CYP1A1 and CYP1A2 by beta-naphthoflavone and of CYP3A4 by rifampicin were observed at messenger RNA (mRNA) and protein levels, by ribonuclease protection and immunoblotting, respectively.	Rifampin	147-157	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	89-95
7557864-6	1995	When cells were treated with the CYP inducer alone, large increases in the expression of CYP1A1 and CYP1A2 by beta-naphthoflavone and of CYP3A4 by rifampicin were observed at messenger RNA (mRNA) and protein levels, by ribonuclease protection and immunoblotting, respectively.	Rifampin	147-157	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	100-106
7557864-6	1995	When cells were treated with the CYP inducer alone, large increases in the expression of CYP1A1 and CYP1A2 by beta-naphthoflavone and of CYP3A4 by rifampicin were observed at messenger RNA (mRNA) and protein levels, by ribonuclease protection and immunoblotting, respectively.	Rifampin	147-157	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	137-143
7557864-10	1995	In cells preinduced with beta-naphthoflavone or rifampicin, the decay with time of the levels of the CYP1A2 or CYP3A4 proteins, after the removal of the inducer, was not affected by cytokines.	Rifampin	48-58	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	101-107
7557864-10	1995	In cells preinduced with beta-naphthoflavone or rifampicin, the decay with time of the levels of the CYP1A2 or CYP3A4 proteins, after the removal of the inducer, was not affected by cytokines.	Rifampin	48-58	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	111-117
7763306-1	1995	Rifampicin, a semi-synthetic antibiotic used in the treatment of tuberculosis and belonging to the chemical class of rifamycins, was examined for its effect on anti-cancer drug accumulation and activity in multidrug resistant cells overexpressing P-glycoprotein (P-gp).	Rifampin	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	247-261
7614688-7	1995	Treatment of cynomolgus monkeys with rifampicin induced hepatic cytochromes P450 related to human CYP3A4 and CYP2C9/10 without inducing CYP1A1 or CYP1A2.	Rifampin	37-47	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	98-104
7614688-7	1995	Treatment of cynomolgus monkeys with rifampicin induced hepatic cytochromes P450 related to human CYP3A4 and CYP2C9/10 without inducing CYP1A1 or CYP1A2.	Rifampin	37-47	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	109-115
7614688-12	1995	Since cytochromes P4503A and/or P4502C are constitutively expressed in cynomolgus monkey hepatic microsomes, and upon induction with rifampicin are associated with an increased metabolic activation of IQ but not MeIQx, it appears that CYP3A and/or CYP2C are the isoform(s) showing the selective substrate specificity in the metabolic activation of IQ over MeIQx.	Rifampin	133-143	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	235-240
7614688-12	1995	Since cytochromes P4503A and/or P4502C are constitutively expressed in cynomolgus monkey hepatic microsomes, and upon induction with rifampicin are associated with an increased metabolic activation of IQ but not MeIQx, it appears that CYP3A and/or CYP2C are the isoform(s) showing the selective substrate specificity in the metabolic activation of IQ over MeIQx.	Rifampin	133-143	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	248-253
7636727-2	1995	We report the effect of a known cytochrome P450 (CYP) inducer, rifampicin, on the metabolism of lidocaine by primary human hepatocytes.	Rifampin	63-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	32-47
7636727-2	1995	We report the effect of a known cytochrome P450 (CYP) inducer, rifampicin, on the metabolism of lidocaine by primary human hepatocytes.	Rifampin	63-73	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-52
7636727-3	1995	Rifampicin has been shown to induce CYP3A4, a major human hepatic CYP isozyme that is known to metabolize lidocaine to its primary metabolite, monoethylglycinexylidide.	Rifampin	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	36-42
7636727-3	1995	Rifampicin has been shown to induce CYP3A4, a major human hepatic CYP isozyme that is known to metabolize lidocaine to its primary metabolite, monoethylglycinexylidide.	Rifampin	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
7745704-4	1995	p32 was associated with vaccinia virus membranes at all stages of virion assembly, starting with the viral crescents, as well as with the membranes which accumulated during the inhibition of assembly by rifampin.	Rifampin	203-211	complement C1q binding protein	Homo sapiens	0-3
7548905-4	1995	RESULTS: With therapy of TB (with isoniazid [INH], rifampin [RIF], ethambutol and/or pyrazinamide), TBG increased above control values and T3RU decreased (P &lt; 0.001).	Rifampin	51-59	serpin family A member 7	Homo sapiens	100-103
7548905-4	1995	RESULTS: With therapy of TB (with isoniazid [INH], rifampin [RIF], ethambutol and/or pyrazinamide), TBG increased above control values and T3RU decreased (P &lt; 0.001).	Rifampin	61-64	serpin family A member 7	Homo sapiens	100-103
7763306-1	1995	Rifampicin, a semi-synthetic antibiotic used in the treatment of tuberculosis and belonging to the chemical class of rifamycins, was examined for its effect on anti-cancer drug accumulation and activity in multidrug resistant cells overexpressing P-glycoprotein (P-gp).	Rifampin	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	263-267
7763306-6	1995	Rifampicin was also demonstrated to inhibit P-gp radiolabeling by the photoactivable P-gp ligand azidopine, thereby suggesting that the antituberculosis compound can interfere directly with P-gp drug binding sites.	Rifampin	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	44-48
7763306-6	1995	Rifampicin was also demonstrated to inhibit P-gp radiolabeling by the photoactivable P-gp ligand azidopine, thereby suggesting that the antituberculosis compound can interfere directly with P-gp drug binding sites.	Rifampin	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	85-89
7763306-6	1995	Rifampicin was also demonstrated to inhibit P-gp radiolabeling by the photoactivable P-gp ligand azidopine, thereby suggesting that the antituberculosis compound can interfere directly with P-gp drug binding sites.	Rifampin	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	85-89
7763306-7	1995	These results thus indicate that rifampicin was able to down-modulate P-gp-associated resistance through inhibition of P-gp function.	Rifampin	33-43	ATP binding cassette subfamily B member 1	Homo sapiens	70-74
7763306-7	1995	These results thus indicate that rifampicin was able to down-modulate P-gp-associated resistance through inhibition of P-gp function.	Rifampin	33-43	ATP binding cassette subfamily B member 1	Homo sapiens	119-123
8068867-5	1994	An increase to 72 +/- 25 mL min-1 in the CLH of cortisol to 6 beta-hydroxycortisol was calculated following rifampicin treatment.	Rifampin	108-118	CD59 molecule (CD59 blood group)	Homo sapiens	28-33
7628309-1	1995	We previously demonstrated that induction of hepatic cytochrome P4503A (CYP3A) immunoreactive protein is a response in rats, but not rabbits, treated with the antiglucocorticoid, pregnenolone 16 alpha-carbonitrile and in rabbits, but not rats, treated with rifampicin.	Rifampin	257-267	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	53-59
7628309-1	1995	We previously demonstrated that induction of hepatic cytochrome P4503A (CYP3A) immunoreactive protein is a response in rats, but not rabbits, treated with the antiglucocorticoid, pregnenolone 16 alpha-carbonitrile and in rabbits, but not rats, treated with rifampicin.	Rifampin	257-267	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	72-77
7628309-4	1995	As expected from their effects in vivo, incubations of cultures with medium containing pregnenolone 16 alpha-carbonitrile or rifampicin induced CYP3A mRNA to high levels exclusively in rat hepatocytes or rabbit hepatocytes, respectively.	Rifampin	125-135	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	144-149
7628309-5	1995	Pregnenolone 16 alpha-carbonitrile treatment also did not induce CYP3A immunoreactive protein in rabbit hepatocytes, although rifampicin treatment did increase CYP3A immunoreactive protein levels in rat hepatocyte cultures.	Rifampin	126-136	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	160-165
8844805-8	1995	In addition, Rifampicin-induced rabbit liver microsomes which are enriched for CYP3A6, show enhanced activation of MeIQ in the presence of alpha-napthoflavone.	Rifampin	13-23	cytochrome P450 3A6	Oryctolagus cuniculus	79-85
7853151-1	1994	The suppositories of rifampicin (RFP) containing sodium para-aminosalicylate dihydrate (PAS-Na) were prepared in order to enhance the rectal absorption of RFP.	Rifampin	21-31	calcium voltage-gated channel subunit alpha1 D	Homo sapiens	88-94
8169844-5	1994	Omeprazole, omeprazole sulfone and lansoprazole induced CYP3A in approximately 50% of tested cultures, whereas 100% of tested cultures responded to omeprazole and to rifampicin in terms of CYP1A and CYP3A induction, respectively.	Rifampin	166-176	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	199-204
8347575-2	1993	Addition of rifampicin to inhibit the E. coli RNA polymerase after induction of the T7 RNA polymerase gene resulted in about 30% of newly synthesized protein being alpha 1-antitrypsin.	Rifampin	12-22	serpin family A member 1	Homo sapiens	164-183
8049635-2	1994	Debrisoquine metabolism is controlled by a cytochrome P-450 isozyme encoded at the CYP2D6 locus, which is inducible by antipyrine and rifampicin.	Rifampin	134-144	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
8049635-2	1994	Debrisoquine metabolism is controlled by a cytochrome P-450 isozyme encoded at the CYP2D6 locus, which is inducible by antipyrine and rifampicin.	Rifampin	134-144	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	83-89
8126890-3	1994	Antibiotics, such as macrolides, new quinolones and rifampicin, are very active against Legionella spp.	Rifampin	52-62	histocompatibility minor 13	Homo sapiens	99-102
8119047-8	1993	By contrast, rifampicin (rifampin) and rifabutin induce several cytochromes P450, including CYP3A4, and hence can enhance the metabolism of many other drugs.	Rifampin	13-23	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	92-98
8119047-8	1993	By contrast, rifampicin (rifampin) and rifabutin induce several cytochromes P450, including CYP3A4, and hence can enhance the metabolism of many other drugs.	Rifampin	25-33	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	92-98
8091338-11	1993	Some P450 (3A, 1A, 2E, ...) are inducible by compounds such as phenobarbital, rifampicin, aromatic hydrocarbon, ethanol, or omeprazole.	Rifampin	78-88	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	5-9
8325897-12	1993	However, when neonatal rabbits were treated with either dexamethasone or rifampicin, UGT2B13 mRNA levels were induced.	Rifampin	73-83	UDP-glucuronosyltransferase 2B13	Oryctolagus cuniculus	85-92
8161275-2	1993	The rifampicin MIC with respect to 50 strains of the plague microbe of different origin in the tests on the Hottinger agar ranged from 1.6 to 6.4 micrograms/ml.	Rifampin	4-14	microphthalmia Japan	Mus musculus	15-18
1460703-1	1992	The objective of the present study was to assess renal damage, if any, by non-invasive technique, viz NAG activity in urine and GFR in patients on continuous and intermittent rifampicin therapy.	Rifampin	175-185	N-acetyl-alpha-glucosaminidase	Homo sapiens	102-105
8335500-1	1993	Rifampicin is used to treat neurosurgical shunt infections because of its excellent in-vitro activity against staphylococci and its adequate penetration into the CSF.	Rifampin	0-10	colony stimulating factor 2	Rattus norvegicus	162-165
8503179-5	1993	Temperature-sensitive mutants C6, C17, and C43 were found to be rifampicin hypersensitive.	Rifampin	64-74	cytokine like 1	Homo sapiens	34-37
8503179-9	1993	Further, the finding that the hypersensitive mutants C6 and C17 contain a wild-type D13L ORF suggests a possible role of other viral functions in the interaction of rifampicin with vaccinia virus.	Rifampin	165-175	cytokine like 1	Homo sapiens	60-63
8508626-0	1993	Increased insulin requirement in a patient with type 1 diabetes on rifampicin.	Rifampin	67-77	insulin	Homo sapiens	10-17
1430211-0	1992	Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes.	Rifampin	18-26	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	48-54
1430211-6	1992	Rifampin treatment resulted in a five- or eightfold mean increase (P &lt; 0.05) in the biopsy concentration of P450IIIA4 mRNA when normalized for content of sucrase isomaltase or intestinal fatty acid binding protein mRNAs, respectively.	Rifampin	0-8	sucrase-isomaltase	Homo sapiens	157-175
1546459-1	1992	Specific missense mutations of the vaccinia virus D13L gene confer resistance to the effects of rifampicin on virion morphogenesis.	Rifampin	96-106	rifampicin target	Vaccinia virus	50-54
1454750-1	1992	A previous study has demonstrated that the urinary level of 6 beta-hydroxycortisol is a marker of liver CYP3A content after induction by rifampicin.	Rifampin	137-147	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	104-109
1418078-0	1992	Fibrinogen and antithrombin III blood levels fluctuations during isoniazid or isoniazid plus rifampicin administration.	Rifampin	93-103	fibrinogen beta chain	Homo sapiens	0-10
1418078-0	1992	Fibrinogen and antithrombin III blood levels fluctuations during isoniazid or isoniazid plus rifampicin administration.	Rifampin	93-103	serpin family C member 1	Homo sapiens	15-31
1495829-3	1992	EF4 bacteria were susceptible to aminopenicillins, carboxypenicillins, ureidopenicillins, third-generation cephalosporins, fluoroquinolones, rifampicin, and trimethoprime-sulfamethoxazole.	Rifampin	141-151	GTP binding elongation factor GUF1	Homo sapiens	0-3
1768567-8	1991	In contrast, rifampicin treatment produced a larger and a differential increase in the oral clearance of R-(-) hexobarbitone in young and elderly subjects; an 89 fold change in the young (15.6 +/- 16.4 to 1146.7 +/- 1478.0 ml min-1 kg-1) and a 19 fold change (10.3 +/- 3.0 to 199.9 +/- 98.1 ml min-1 kg-1) in the elderly.	Rifampin	13-23	CD59 molecule (CD59 blood group)	Homo sapiens	226-236
1768567-8	1991	In contrast, rifampicin treatment produced a larger and a differential increase in the oral clearance of R-(-) hexobarbitone in young and elderly subjects; an 89 fold change in the young (15.6 +/- 16.4 to 1146.7 +/- 1478.0 ml min-1 kg-1) and a 19 fold change (10.3 +/- 3.0 to 199.9 +/- 98.1 ml min-1 kg-1) in the elderly.	Rifampin	13-23	CD59 molecule (CD59 blood group)	Homo sapiens	294-304